<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>Enbrel, INN-etanercept</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="author" content="CHMP"/>
<meta name="keywords" content="Enbrel, INN-etanercept"/>
<meta name="date" content="2023-08-14T13:30:12+00:00"/>
<meta name="subject" content="EPAR"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:12px;font-family:PZJVUM+Arial;color:#000000;}
	.ft11{font-size:17px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page1-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft10">1</p>
<p style="position:absolute;top:544px;left:412px;white-space:nowrap" class="ft11"><b>ANNEX I</b></p>
<p style="position:absolute;top:582px;left:264px;white-space:nowrap" class="ft11"><b>SUMMARY OF PRODUCT CHARACTERISTICS</b></p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft22{font-size:17px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
	.ft23{font-size:17px;line-height:19px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
	.ft24{font-size:17px;line-height:18px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft20">2</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft21"><b>1.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft21"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft22">Enbrel&#160;25&#160;mg&#160;powder for solution for injection</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft21"><b>2.</b></p>
<p style="position:absolute;top:203px;left:146px;white-space:nowrap" class="ft21"><b>QUALITATIVE AND QUANTITATIVE&#160;COMPOSITION</b></p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft22">Each vial contains&#160;25&#160;mg&#160;of etanercept.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft23">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant&#160;<br/>DNA technology in a Chinese hamster ovary (CHO) mammalian expression system.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft22">For&#160;the&#160;full list of excipients, see section 6.1.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft21"><b>3.</b></p>
<p style="position:absolute;top:392px;left:146px;white-space:nowrap" class="ft21"><b>PHARMACEUTICAL FORM</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft22">Powder for solution for injection&#160;(powder for injection).</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft22">The powder is white.&#160;</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft21"><b>4.</b></p>
<p style="position:absolute;top:525px;left:146px;white-space:nowrap" class="ft21"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft21"><b>4.1</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft21"><b>Therapeutic indications</b></p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft22">Rheumatoid arthritis</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft23">Enbrel in combination with methotrexate is&#160;indicated for the treatment of moderate to severe active&#160;<br/>rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including&#160;<br/>methotrexate (unless contraindicated), has been inadequate.</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft24">Enbrel can be given as monotherapy in&#160;case of intolerance to methotrexate or when continued&#160;<br/>treatment with methotrexate is inappropriate.</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft24">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults&#160;<br/>not previously treated with methotrexate.</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft24">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression&#160;<br/>of joint damage as measured by X-ray and to improve physical function.</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft22">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft23">Treatment of&#160;polyarthritis (rheumatoid factor positive or&#160;negative)&#160;and extended oligoarthritis&#160;in&#160;<br/>children and adolescents from the age of 2&#160;years who have had an inadequate response to, or who have&#160;<br/>proved intolerant of, methotrexate.&#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft24">Treatment of&#160;psoriatic arthritis in adolescents from the age of 12&#160;years&#160;who have had an inadequate&#160;<br/>response to, or who have proved intolerant of, methotrexate.</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft24">Treatment of enthesitis-related arthritis in&#160;adolescents from the age of 12&#160;years who have had an&#160;<br/>inadequate response to, or who have proved intolerant of, conventional therapy.</p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft35{font-size:17px;font-family:PZJVUM+TimesNewRoman,Italic;color:#000000;}
	.ft36{font-size:17px;line-height:19px;font-family:PZJVUM+TimesNewRoman,Italic;color:#000000;}
	.ft37{font-size:17px;line-height:18px;font-family:PZJVUM+TimesNewRoman,Italic;color:#000000;}
	.ft38{font-size:17px;line-height:20px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
	.ft39{font-size:17px;line-height:21px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page3-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft30">3</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft32">Psoriatic arthritis</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft33">Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-<br/>modifying antirheumatic drug therapy has been inadequate.&#160;Enbrel has been shown to improve&#160;<br/>physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral<br/>joint damage as measured by X-ray in patients with&#160;polyarticular&#160;symmetrical subtypes of the disease.</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft32">Axial spondyloarthritis</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft33"><i>Ankylosing spondylitis&#160;(AS)<br/></i>Treatment of adults&#160;with severe active ankylosing spondylitis who have had an inadequate response to&#160;<br/>conventional therapy.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft34"><i>Non-radiographic axial spondyloarthritis<br/></i>Treatment of adults with severe non-radiographic axial spondyloarthritis&#160;with objective signs of&#160;<br/>inflammation as indicated by elevated&#160;C-reactive protein (CRP)&#160;and/or&#160;magnetic resonance imaging&#160;<br/>(MRI)&#160;evidence, who have had an inadequate response&#160;to&#160;nonsteroidal anti-inflammatory drugs<br/>(NSAIDs).</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft32">Plaque psoriasis</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft33">Treatment of&#160;adults with moderate to severe plaque psoriasis who failed to respond to, or who have a&#160;<br/>contraindication to, or are intolerant to other systemic therapy,&#160;including ciclosporin, methotrexate or&#160;<br/>psoralen and ultraviolet-A light (PUVA) (see section 5.1).</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft32">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft33">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6&#160;years who&#160;<br/>are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft31"><b>4.2</b></p>
<p style="position:absolute;top:679px;left:149px;white-space:nowrap" class="ft31"><b>Posology and method of&#160;administration</b></p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft33">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the&#160;<br/>diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,&#160;<br/>ankylosing spondylitis,&#160;non-radiographic axial spondyloarthritis,&#160;plaque psoriasis or paediatric plaque&#160;<br/>psoriasis. Patients treated with Enbrel should be given the Patient Card.</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft32">Enbrel is available in strengths of&#160;10,&#160;25 and 50&#160;mg.&#160;</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft32">Posology</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft33"><i>Rheumatoid arthritis<br/></i>25&#160;mg Enbrel administered twice&#160;weekly is the recommended dose. Alternatively, 50&#160;mg administered&#160;<br/>once weekly has been shown to be safe and effective (see section 5.1).</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft34"><i>Psoriatic arthritis,&#160;ankylosing spondylitis&#160;and non-radiographic axial spondyloarthritis<br/></i>The recommended dose is 25&#160;mg&#160;Enbrel administered twice weekly, or 50&#160;mg administered once&#160;<br/>weekly. &#160;</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft39">For all of the above indications, available data suggest that a clinical response is usually achieved&#160;<br/>within 12 weeks of treatment. Continued therapy should be carefully reconsidered&#160;in a patient not&#160;<br/>responding within this time period.</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page4-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft40">4</p>
<p style="position:absolute;top:108px;left:107px;white-space:nowrap" class="ft45"><i>Plaque psoriasis</i></p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft43">The recommended dose of Enbrel is 25&#160;mg administered twice weekly or 50&#160;mg administered once&#160;<br/>weekly. Alternatively, 50&#160;mg given twice weekly may be used for up to 12&#160;weeks followed, if&#160;<br/>necessary, by a dose of 25&#160;mg twice weekly or 50&#160;mg&#160;once weekly. Treatment with Enbrel should&#160;<br/>continue until remission is achieved, for up to 24&#160;weeks.&#160;Continuous therapy beyond 24&#160;weeks may be&#160;<br/>appropriate for some adult patients (see section 5.1).&#160;Treatment should be discontinued in patients who&#160;<br/>show no response after 12&#160;weeks. If re-treatment with Enbrel is indicated, the same guidance on&#160;<br/>treatment duration should be followed. The dose should be 25&#160;mg twice weekly or 50&#160;mg once&#160;<br/>weekly.&#160;</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft42">Special populations</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft46"><i>Renal and hepatic impairment<br/></i>No dose adjustment is required.</p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft44"><i>Elderly<br/></i>No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of&#160;<br/>age.</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft47"><i>Paediatric population<br/></i>The safety and&#160;efficacy of&#160;Enbrel&#160;in children aged less than 2 years has not been established.</p>
<p style="position:absolute;top:508px;left:107px;white-space:nowrap" class="ft42">No data are available.</p>
<p style="position:absolute;top:547px;left:107px;white-space:nowrap" class="ft45"><i>Juvenile idiopathic arthritis&#160;</i></p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft44">The recommended dose is 0.4&#160;mg/kg (up to a maximum of 25&#160;mg per dose), given twice weekly as a&#160;<br/>subcutaneous injection with an interval of&#160;3-4&#160;days between doses&#160;or 0.8&#160;mg/kg (up to a maximum of&#160;<br/>50&#160;mg per dose) given once weekly.&#160;Discontinuation of treatment should be considered in patients&#160;<br/>who show no response after 4 months.</p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft44">The 10&#160;mg&#160;vial strength may be more appropriate for administration to children with JIA below the&#160;<br/>weight of 25&#160;kg.</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft44">No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety&#160;<br/>data from a patient registry suggest that the safety profile in children from 2 to 3&#160;years of age is similar&#160;<br/>to that seen in adults and children aged 4 years and older, when dosed every week with 0.8&#160;mg/kg&#160;<br/>subcutaneously (see section 5.1).</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft43">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile&#160;<br/>idiopathic arthritis.</p>
<p style="position:absolute;top:870px;left:107px;white-space:nowrap" class="ft42">Paediatric plaque psoriasis (age 6 years and above)</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft44">The recommended dose is 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly for up to&#160;<br/>24&#160;weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft44">If&#160;re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed.&#160;<br/>The dose should be 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly.</p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft43">There is generally no applicable use of Enbrel in children aged below 6 years&#160;in the indication plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:1060px;left:106px;white-space:nowrap" class="ft42">Method of administration</p>
<p style="position:absolute;top:1098px;left:106px;white-space:nowrap" class="ft43">Enbrel is administered by subcutaneous injection.&#160;Enbrel powder for solution must be reconstituted in&#160;<br/>1&#160;ml of solvent before use&#160;(see section 6.6).</p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page5-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft50">5</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft53">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are&#160;<br/>given in the package leaflet, section 7, &#34;Instructions for preparation and giving an injection of Enbrel.&#34;<br/>Detailed instructions on unintentional dosing or scheduling variations, including missed&#160;doses, are&#160;<br/>provided in section 3 of the package leaflet.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft51"><b>4.3</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft51"><b>Contraindications</b></p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft52">Hypersensitivity to the active substance or to any of the excipients&#160;listed in section 6.1.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft52">Sepsis or risk of sepsis.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft54">Treatment with Enbrel should not be initiated in&#160;patients with active infections,&#160;including chronic or&#160;<br/>localised infections.</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft51"><b>4.4</b></p>
<p style="position:absolute;top:373px;left:149px;white-space:nowrap" class="ft51"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft54">In order to improve the traceability of biological medicinal products, the&#160;brand name&#160;and batch&#160;<br/>number of the administered product should be clearly recorded (or stated) in the patient file.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft52">Infections</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft53">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into&#160;<br/>consideration that the mean elimination half-life of etanercept is approximately&#160;70&#160;hours (range 7 to&#160;<br/>300&#160;hours).</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft54">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal&#160;<br/>infections,&#160;listeriosis and legionellosis,&#160;have been reported with the use of Enbrel (see section 4.8).&#160;<br/>These infections were due to bacteria, mycobacteria, fungi,&#160;viruses&#160;and parasites (including protozoa).&#160;<br/>In some cases, particular fungal&#160;and other opportunistic infections have not been recognised, resulting&#160;<br/>in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the&#160;<br/>patient’s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be&#160;<br/>considered.&#160;</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft54">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored&#160;<br/>closely. Administration of Enbrel should be discontinued if a patient develops a serious infection.&#160;The&#160;<br/>safety and efficacy of Enbrel&#160;in patients with chronic infections have not been evaluated.&#160;Physicians&#160;<br/>should exercise caution when considering the use of Enbrel in patients with a history of recurring or&#160;<br/>chronic infections or with underlying conditions that may predispose patients to&#160;infections,&#160;such as&#160;<br/>advanced or poorly controlled diabetes.</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft52">Tuberculosis</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft54">Cases of active tuberculosis,&#160;including miliary tuberculosis and tuberculosis with extra-pulmonary&#160;<br/>location,&#160;have been reported in patients treated with Enbrel.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft53">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive&#160;<br/>(‘latent’) tuberculosis. This evaluation should include a detailed medical history with personal history&#160;<br/>of tuberculosis or possible previous contact with tuberculosis and previous and/or current&#160;<br/>immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray,&#160;<br/>should be performed in all patients (local recommendations may apply). It is recommended that the&#160;<br/>conduct of these tests should be recorded in the&#160;Patient&#160;Card. Prescribers are reminded of the risk of&#160;<br/>false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.</p>
<p style="position:absolute;top:1133px;left:106px;white-space:nowrap" class="ft53">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (‘latent’)&#160;<br/>tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis&#160;</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page6-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft60">6</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft64">therapy before the initiation of Enbrel, and in accordance with local recommendations. In this&#160;<br/>situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft64">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis&#160;<br/>(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft62">Hepatitis B reactivation</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft63">Reactivation of hepatitis B in patients who&#160;were previously infected with the&#160;hepatitis B virus (HBV)&#160;<br/>and had received concomitant&#160;TNF-antagonists,&#160;including Enbrel,&#160;has been reported.&#160;This&#160;includes&#160;<br/>reports of reactivation of&#160;hepatitis B&#160;in patients who were anti-HBc positive but HBsAg negative.<br/>Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who&#160;<br/>test positive for HBV infection, consultation with a physician with expertise in the treatment of&#160;<br/>hepatitis B is recommended.&#160;Caution should be exercised when administering Enbrel&#160;in&#160;patients&#160;<br/>previously infected with&#160;HBV.&#160;These&#160;patients should be monitored for signs and symptoms of active&#160;<br/>HBV infection&#160;throughout therapy and for several&#160;weeks following termination of therapy.&#160;Adequate&#160;<br/>data from treating patients infected with&#160;HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be&#160;<br/>stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft62">Worsening of hepatitis C</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft63">There have been reports of worsening of hepatitis C in patients receiving Enbrel.&#160;Enbrel should be&#160;<br/>used with caution in patients with a history of hepatitis C.</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft62">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft63">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious&#160;<br/>infections and neutropenia compared&#160;to Enbrel alone. This combination has not demonstrated&#160;<br/>increased clinical benefit. Thus,&#160;the combined use of Enbrel and anakinra is not recommended (see&#160;<br/>sections 4.5 and 4.8).</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft62">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft64">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see&#160;section 4.5).</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft62">Allergic reactions</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft63">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic&#160;<br/>reactions have included angioedema and urticaria; serious reactions have occurred. If any serious&#160;<br/>allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and<br/>appropriate therapy initiated.</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft62">Immunosuppression</p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft63">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections&#160;<br/>and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a&#160;<br/>study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector cell populations.</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft64">Two juvenile idiopathic&#160;arthritis patients developed varicella infection and signs and symptoms of&#160;<br/>aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella&#160;</p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page7-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft70">7</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft74">virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with&#160;<br/>Varicella Zoster Immune Globulin.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft72">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft72">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft74"><i>Solid and haematopoietic malignancies (excluding skin&#160;cancers)<br/></i>Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been&#160;<br/>received in the postmarketing period (see section 4.8).&#160;</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft74">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been&#160;<br/>observed among patients receiving a TNF-antagonist compared with control patients. However, the&#160;<br/>occurrence was rare, and the&#160;follow-up period of placebo patients was shorter than for patients&#160;<br/>receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported&#160;<br/>in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and&#160;<br/>leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates&#160;risk estimation.</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft74">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other&#160;<br/>haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded.&#160;<br/>Caution should be exercised when considering TNF-antagonist therapy for patients with a history of&#160;<br/>malignancy or when considering continuing treatment in patients who develop a malignancy.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft74">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤ 18 years of age), including&#160;<br/>Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases&#160;<br/>represented a variety of different malignancies and included rare malignancies typically associated&#160;<br/>with immunosuppression. A risk for the development of malignancies in children and adolescents&#160;<br/>treated with TNF-antagonists cannot be excluded.</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft73"><i>Skin cancers<br/></i>Melanoma and non-melanoma skin cancer (NMSC) have been reported in&#160;patients treated with&#160;<br/>TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported&#160;<br/>very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all&#160;<br/>patients, particularly those with&#160;risk factors for skin cancer.</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft73">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients&#160;<br/>receiving Enbrel compared with control patients, particularly in patients with psoriasis.</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft72">Vaccinations</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft74">Live vaccines should&#160;not be given concurrently with Enbrel. No data are available on the secondary&#160;<br/>transmission of infection by live vaccines in patients receiving Enbrel. In a double-blind,&#160;<br/>placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also&#160;<br/>received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic&#160;<br/>arthritis patients receiving Enbrel were able to mount effective B-cell immune response to&#160;<br/>pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients&#160;<br/>had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this&#160;<br/>is unknown.</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft72">Autoantibody formation</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft72">Treatment with Enbrel may result in the formation of&#160;autoimmune antibodies (see section 4.8).</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page8-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft80">8</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft82">Haematologic reactions</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft83">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have&#160;<br/>been reported in patients treated with Enbrel. Caution should be exercised in patients being&#160;treated&#160;<br/>with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers&#160;<br/>should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or&#160;<br/>infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they&#160;<br/>should seek immediate medical advice. Such patients should be investigated urgently, including full&#160;<br/>blood count; if blood dyscrasias are confirmed,&#160;Enbrel should be discontinued.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft82">Neurological disorders</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft83">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see&#160;<br/>section 4.8). Additionally, there have been&#160;rare reports&#160;of peripheral demyelinating polyneuropathies&#160;<br/>(including Guillain-Barré syndrome, chronic inflammatory&#160;demyelinating polyneuropathy,&#160;<br/>demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have&#160;<br/>been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other&#160;<br/>TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful&#160;<br/>risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel&#160;<br/>to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered&#160;<br/>to have an increased risk of developing demyelinating disease.</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft82">Combination therapy</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft84">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of&#160;<br/>Enbrel and methotrexate did not result in&#160;unexpected safety findings, and the safety profile of Enbrel&#160;<br/>when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel&#160;<br/>and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The&#160;<br/>long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs&#160;<br/>(DMARD) has not been established.</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft84">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of&#160;<br/>psoriasis has not been&#160;studied.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft82">Renal and hepatic impairment</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft84">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal&#160;<br/>or hepatic impairment; clinical experience in such patients is limited.</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft82">Congestive heart failure&#160;(Cardiac failure&#160;congestive)</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft83">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF).&#160;<br/>There have been postmarketing reports of worsening of CHF, with and without identifiable&#160;<br/>precipitating factors, in patients taking Enbrel.&#160;There have also been rare (&lt;&#160;0.1%) reports of new&#160;<br/>onset CHF, including CHF in patients without known pre-existing cardiovascular disease.&#160;Some of&#160;<br/>these patients have been under 50&#160;years of age.&#160;Two large clinical trials evaluating the use of Enbrel in&#160;<br/>the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data&#160;<br/>from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned&#160;<br/>to Enbrel treatment.&#160;</p>
<p style="position:absolute;top:1060px;left:106px;white-space:nowrap" class="ft82">Alcoholic hepatitis</p>
<p style="position:absolute;top:1098px;left:106px;white-space:nowrap" class="ft84">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or&#160;<br/>placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in&#160;<br/>patients treated with Enbrel was significantly higher after 6&#160;months.&#160;Consequently, Enbrel should not&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page9-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:443px;white-space:nowrap" class="ft90">9</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft94">be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using&#160;<br/>Enbrel in patients who also have moderate to severe alcoholic hepatitis.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft92">Wegener's granulomatosis</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft93">A placebo-controlled&#160;trial, in which 89 adult patients were treated with Enbrel in addition to standard&#160;<br/>therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of&#160;<br/>25&#160;months, has not shown Enbrel to be an effective treatment for Wegener’s granulomatosis. The&#160;<br/>incidence of non-cutaneous malignancies of various types was significantly higher in patients treated&#160;<br/>with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft92">Hypoglycaemia in patients treated for diabetes</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft93">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving&#160;<br/>medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft92">Special populations</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft94"><i>Elderly<br/></i>In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall&#160;<br/>differences in adverse events, serious adverse events, and serious infections in patients age 65 or older&#160;<br/>who received Enbrel were observed compared with younger patients. However, caution should be&#160;<br/>exercised when treating the elderly and particular attention paid with respect to occurrence of&#160;<br/>infections.</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft95"><i>Paediatric population</i></p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft94"><i>Vaccinations<br/></i>It&#160;is recommended that paediatric patients, if possible,&#160;be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Enbrel therapy&#160;(see Vaccinations,&#160;<br/>above).</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft91"><b>4.5</b></p>
<p style="position:absolute;top:734px;left:149px;white-space:nowrap" class="ft91"><b>Interaction with other medicinal products and other forms of interaction</b></p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft92">Concurrent treatment&#160;with anakinra&#160;</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft93">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft94">In addition, in a double-blind, placebo-controlled trial in adult patients receiving background&#160;<br/>methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The&#160;<br/>combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not&#160;<br/>recommended.</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft92">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft93">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see section 4.4).&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft92">Concurrent treatment with sulfasalazine&#160;</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft93">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which&#160;<br/>Enbrel was added, patients in the combination group experienced a statistically significant decrease in&#160;</p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page10-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft100">10</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft104">mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The&#160;<br/>clinical significance of this interaction is unknown.&#160;Physicians should use caution when considering&#160;<br/>combination therapy with sulfasalazine.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft102">Non-interactions</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft103">In clinical trials, no interactions have been observed when Enbrel was administered with&#160;<br/>glucocorticoids,&#160;salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs),&#160;<br/>analgesics, or methotrexate. See section 4.4 for vaccination advice.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft104">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with&#160;<br/>methotrexate,&#160;digoxin or warfarin.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft101"><b>4.6</b></p>
<p style="position:absolute;top:355px;left:149px;white-space:nowrap" class="ft101"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft102">Women of childbearing potential</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft103">Women of childbearing potential should&#160;consider the&#160;use&#160;of&#160;appropriate contraception to avoid&#160;<br/>becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft102">Pregnancy&#160;</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft103">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the&#160;<br/>foetus or neonatal rat due to etanercept.&#160;The effects of&#160;etanercept&#160;on pregnancy outcomes have been&#160;<br/>investigated in two observational cohort studies.&#160;A&#160;higher rate of major birth defects was observed in&#160;<br/>one&#160;observational study comparing pregnancies exposed to etanercept&#160;(n=370)&#160;during the first&#160;<br/>trimester with pregnancies not exposed to etanercept or other TNF-antagonists&#160;(n=164)&#160;(adjusted odds&#160;<br/>ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most&#160;<br/>commonly reported in the general population and no particular pattern of abnormalities was identified.&#160;<br/>No change in the rate of&#160;spontaneous abortion, stillbirth, or minor malformations was observed.&#160;In&#160;<br/>another observational multi-country registry study comparing the risk of adverse pregnancy outcomes&#160;<br/>in women exposed to etanercept&#160;during the first 90&#160;days of pregnancy (n=425)&#160;to those exposed to&#160;<br/>non-biologic drugs&#160;(n=3497), there was no observed increased risk of major birth defects (crude odds&#160;<br/>ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for&#160;<br/>country, maternal disease, parity, maternal&#160;age and smoking in early pregnancy).&#160;This study also&#160;<br/>showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year&#160;<br/>of life&#160;for infants born to women exposed to etanercept during pregnancy.&#160;Enbrel should only be used&#160;<br/>during&#160;pregnancy&#160;if&#160;clearly needed.</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft103">Etanercept crosses the placenta and has been detected in the serum of&#160;infants born to female patients&#160;<br/>treated with&#160;Enbrel&#160;during pregnancy. The clinical impact of this is unknown, however, infants may be&#160;<br/>at increased risk of infection. Administration of live vaccines to infants for 16&#160;weeks after the&#160;<br/>mother’s last dose of&#160;Enbrel&#160;is generally not recommended.</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft102">Breast-feeding</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft103">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and&#160;<br/>detected in the serum of pups.&#160;Limited information from the published literature indicates etanercept&#160;<br/>has been detected at low levels in human milk.&#160;Etanercept could be considered for use during&#160;<br/>breast-feeding taking into account the benefit of breast-feeding for the child&#160;and the benefit of therapy&#160;<br/>for the woman.</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft104">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely&#160;<br/>degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant&#160;<br/>are&#160;available. Therefore, the administration of live vaccines&#160;(e.g., BCG)&#160;to a breastfed infant when the&#160;</p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1110{font-size:14px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
	.ft1111{font-size:14px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
	.ft1112{font-size:14px;line-height:15px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
	.ft1113{font-size:14px;line-height:15px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page11-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft110">11</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft114">mother is receiving etanercept&#160;could be considered 16 weeks after stopping breast-feeding&#160;(or at an&#160;<br/>earlier timepoint&#160;if the infant etanercept serum levels are undetectable).&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft112">Fertility</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft114">Preclinical data about peri-&#160;and postnatal toxicity of etanercept and of effects of etanercept on fertility&#160;<br/>and general reproductive performance are not available.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft111"><b>4.7</b></p>
<p style="position:absolute;top:260px;left:149px;white-space:nowrap" class="ft111"><b>Effects on ability to drive and use machines</b></p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft112">Enbrel&#160;has no or negligible influence on the ability to drive&#160;and&#160;use machines.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft111"><b>4.8</b></p>
<p style="position:absolute;top:335px;left:149px;white-space:nowrap" class="ft111"><b>Undesirable effects</b></p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft112">Summary of the safety profile</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft114">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling,&#160;<br/>itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections,&#160;<br/>bronchitis, bladder infections and skin infections),&#160;headache,&#160;allergic reactions, development of&#160;<br/>autoantibodies, itching, and fever.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft113">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect&#160;<br/>the immune system and their use may affect the body’s defenses against infection and cancer. Serious&#160;<br/>infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal&#160;and&#160;<br/>life-threatening infections and sepsis. Various malignancies have also been reported with use of&#160;<br/>Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma). &#160;</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft113">Serious haematological, neurological&#160;and autoimmune reactions have also been reported. These&#160;<br/>include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral&#160;<br/>demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There&#160;have&#160;<br/>been rare reports of lupus, lupus-related conditions, and vasculitis.</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft112">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:753px;left:106px;white-space:nowrap" class="ft113">The following list of adverse reactions is based on experience from clinical trials and on&#160;<br/>postmarketing experience.</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft113">Within the organ system&#160;classes, adverse reactions are listed under headings of frequency (number of&#160;<br/>patients expected to experience the reaction), using the following categories: very common (≥&#160;1/10);&#160;<br/>common (≥&#160;1/100 to &lt;&#160;1/10); uncommon (≥&#160;1/1,000 to &lt;&#160;1/100); rare (≥&#160;1/10,000&#160;to &lt;&#160;1/1,000); very&#160;<br/>rare (&lt;&#160;1/10,000); not known (cannot be estimated from the available data).</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft1112"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:906px;left:211px;white-space:nowrap" class="ft1112"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:906px;left:286px;white-space:nowrap" class="ft1112"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:906px;left:375px;white-space:nowrap" class="ft1112"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:906px;left:498px;white-space:nowrap" class="ft1112"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:906px;left:626px;white-space:nowrap" class="ft1112"><b>Very&#160;<br/>Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:906px;left:701px;white-space:nowrap" class="ft1112"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from&#160;<br/>Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft1113">Infections and&#160;<br/>infestations</p>
<p style="position:absolute;top:1000px;left:211px;white-space:nowrap" class="ft1113">Infection&#160;<br/>(including&#160;<br/>upper&#160;<br/>respiratory&#160;<br/>tract&#160;<br/>infection,&#160;<br/>bronchitis,&#160;<br/>cystitis,&#160;<br/>skin&#160;<br/>infection)*</p>
<p style="position:absolute;top:1000px;left:375px;white-space:nowrap" class="ft1113">Serious infections&#160;<br/>(including&#160;<br/>pneumonia,&#160;<br/>cellulitis, arthritis&#160;<br/>bacterial, sepsis<br/>and parasitic&#160;<br/>infection)*</p>
<p style="position:absolute;top:1000px;left:498px;white-space:nowrap" class="ft1113">Tuberculosis,&#160;<br/>opportunistic&#160;<br/>infection&#160;(including&#160;<br/>invasive fungal,&#160;<br/>protozoal, bacterial,&#160;<br/>atypical&#160;<br/>mycobacterial, viral&#160;<br/>infections,&#160;and&#160;<br/>Legionella)*</p>
<p style="position:absolute;top:1000px;left:701px;white-space:nowrap" class="ft1113">Hepatitis B&#160;<br/>reactivation,&#160;<br/>listeria</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page12-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft120">12</p>
<p style="position:absolute;top:109px;left:106px;white-space:nowrap" class="ft1212"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:211px;white-space:nowrap" class="ft1212"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:286px;white-space:nowrap" class="ft1212"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:375px;white-space:nowrap" class="ft1212"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:498px;white-space:nowrap" class="ft1212"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:626px;white-space:nowrap" class="ft1212"><b>Very&#160;<br/>Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:701px;white-space:nowrap" class="ft1212"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from&#160;<br/>Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft1213">Neoplasms&#160;<br/>benign,&#160;<br/>malignant&#160;and&#160;<br/>unspecified&#160;<br/>(including cysts&#160;<br/>and polyps)</p>
<p style="position:absolute;top:202px;left:375px;white-space:nowrap" class="ft1213">Non-melanoma&#160;<br/>skin cancers* (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:202px;left:498px;white-space:nowrap" class="ft1213">Malignant&#160;<br/>melanoma (see&#160;<br/>section 4.4),&#160;<br/>lymphoma,&#160;<br/>leukaemia&#160;</p>
<p style="position:absolute;top:202px;left:701px;white-space:nowrap" class="ft1213">Merkel cell&#160;<br/>carcinoma (see&#160;<br/>section 4.4),&#160;<br/>Kaposi’s&#160;<br/>sarcoma</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft1213">Blood and&#160;<br/>lymphatic&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:296px;left:375px;white-space:nowrap" class="ft1213">Thrombocytopenia,&#160;<br/>anaemia,&#160;<br/>leukopenia,&#160;<br/>neutropenia</p>
<p style="position:absolute;top:296px;left:498px;white-space:nowrap" class="ft1211">Pancytopenia*</p>
<p style="position:absolute;top:296px;left:626px;white-space:nowrap" class="ft1213">Aplastic&#160;<br/>anaemia*</p>
<p style="position:absolute;top:296px;left:701px;white-space:nowrap" class="ft1213">Histiocytosis&#160;<br/>haematophagic&#160;<br/>(macrophage&#160;<br/>activation&#160;<br/>syndrome)*</p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft1213">Immune system&#160;<br/>disorders</p>
<p style="position:absolute;top:375px;left:286px;white-space:nowrap" class="ft1213">Allergic&#160;<br/>reactions&#160;<br/>(see Skin and&#160;<br/>subcutaneous&#160;<br/>tissue&#160;<br/>disorders),&#160;<br/>autoantibody&#160;<br/>formation*</p>
<p style="position:absolute;top:375px;left:375px;white-space:nowrap" class="ft1213">Vasculitis&#160;<br/>(including&#160;anti-<br/>neutrophilic&#160;<br/>cytoplasmic&#160;<br/>antibody positive&#160;<br/>vasculitis)</p>
<p style="position:absolute;top:375px;left:498px;white-space:nowrap" class="ft1213">Serious&#160;<br/>allergic/anaphylactic&#160;<br/>reactions (including&#160;<br/>angioedema,&#160;<br/>bronchospasm),&#160;<br/>sarcoidosis</p>
<p style="position:absolute;top:375px;left:701px;white-space:nowrap" class="ft1213">Worsening of&#160;<br/>symptoms of&#160;<br/>dermatomyositis</p>
<p style="position:absolute;top:499px;left:106px;white-space:nowrap" class="ft1213">Nervous system&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:499px;left:211px;white-space:nowrap" class="ft1211">Headache</p>
<p style="position:absolute;top:499px;left:498px;white-space:nowrap" class="ft1213">CNS demyelinating&#160;<br/>events suggestive of&#160;<br/>multiple sclerosis or&#160;<br/>localised&#160;<br/>demyelinating&#160;<br/>conditions, such as&#160;<br/>optic neuritis and&#160;<br/>transverse myelitis&#160;<br/>(see section 4.4),&#160;<br/>peripheral&#160;<br/>demyelinating&#160;<br/>events, including&#160;<br/>Guillain-Barré&#160;<br/>syndrome, chronic&#160;<br/>inflammatory&#160;<br/>demyelinating&#160;<br/>polyneuropathy,&#160;<br/>demyelinating&#160;<br/>polyneuropathy, and&#160;<br/>multifocal motor&#160;<br/>neuropathy (see&#160;<br/>section 4.4), seizure</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1211">Eye disorders&#160;</p>
<p style="position:absolute;top:842px;left:375px;white-space:nowrap" class="ft1211">Uveitis, scleritis</p>
<p style="position:absolute;top:858px;left:106px;white-space:nowrap" class="ft1213">Cardiac&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:858px;left:375px;white-space:nowrap" class="ft1213">Worsening of&#160;<br/>cardiac failure&#160;<br/>congestive (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:858px;left:498px;white-space:nowrap" class="ft1213">New onset cardiac&#160;<br/>failure congestive&#160;<br/>(see section 4.4)</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1213">Respiratory,&#160;<br/>thoracic, and&#160;<br/>mediastinal&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:921px;left:498px;white-space:nowrap" class="ft1213">Interstitial lung&#160;<br/>disease (including&#160;<br/>pneumonitis and&#160;<br/>pulmonary&#160;<br/>fibrosis)*</p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft1213">Gastrointestinal&#160;<br/>disorders</p>
<p style="position:absolute;top:999px;left:375px;white-space:nowrap" class="ft1213">Inflammatory&#160;<br/>bowel disease</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft1213">Hepatobiliary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:1031px;left:375px;white-space:nowrap" class="ft1213">Elevated liver&#160;<br/>enzymes*</p>
<p style="position:absolute;top:1031px;left:498px;white-space:nowrap" class="ft1213">Autoimmune&#160;<br/>hepatitis*</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page13-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft130">13</p>
<p style="position:absolute;top:109px;left:106px;white-space:nowrap" class="ft1312"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:211px;white-space:nowrap" class="ft1312"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:286px;white-space:nowrap" class="ft1312"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:375px;white-space:nowrap" class="ft1312"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:498px;white-space:nowrap" class="ft1312"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:626px;white-space:nowrap" class="ft1312"><b>Very&#160;<br/>Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:701px;white-space:nowrap" class="ft1312"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from&#160;<br/>Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft1313">Skin and&#160;<br/>subcutaneous&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:202px;left:286px;white-space:nowrap" class="ft1311">Pruritus, rash</p>
<p style="position:absolute;top:202px;left:375px;white-space:nowrap" class="ft1313">Angioedema,&#160;<br/>psoriasis (including&#160;<br/>new onset or&#160;<br/>worsening and&#160;<br/>pustular, primarily&#160;<br/>palms and soles),&#160;<br/>urticaria,&#160;<br/>psoriasiform rash</p>
<p style="position:absolute;top:202px;left:498px;white-space:nowrap" class="ft1313">Stevens-Johnson&#160;<br/>syndrome,&#160;<br/>cutaneous vasculitis&#160;<br/>(including&#160;<br/>hypersensitivity&#160;<br/>vasculitis), erythema&#160;<br/>multiforme,&#160;<br/>lichenoid reactions</p>
<p style="position:absolute;top:202px;left:626px;white-space:nowrap" class="ft1313">Toxic&#160;<br/>epidermal&#160;<br/>necrolysis</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft1313">Musculoskeletal&#160;<br/>and connective&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:327px;left:498px;white-space:nowrap" class="ft1313">Cutaneous lupus&#160;<br/>erythematosus,&#160;<br/>subacute cutaneous&#160;<br/>lupus&#160;<br/>erythematosus,&#160;<br/>lupus-like syndrome</p>
<p style="position:absolute;top:421px;left:106px;white-space:nowrap" class="ft1313">General&#160;<br/>disorders and&#160;<br/>administration&#160;<br/>site conditions&#160;</p>
<p style="position:absolute;top:421px;left:211px;white-space:nowrap" class="ft1313">Injection&#160;<br/>site&#160;<br/>reactions&#160;<br/>(including&#160;<br/>bleeding,&#160;<br/>bruising,&#160;<br/>erythema,&#160;<br/>itching,&#160;<br/>pain,&#160;<br/>swelling)*</p>
<p style="position:absolute;top:421px;left:286px;white-space:nowrap" class="ft1311">Pyrexia</p>
<p style="position:absolute;top:577px;left:106px;white-space:nowrap" class="ft1311">*see Description of selected adverse reactions, below.</p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft132">Description of selected adverse reactions</p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft134"><i>Malignancies and lymphoproliferative disorders<br/></i>One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114&#160;<br/>rheumatoid arthritis patients treated in clinical trials with Enbrel for up&#160;to approximately 6&#160;years,&#160;<br/>including 231&#160;patients treated with Enbrel in combination with methotrexate in the 2-year&#160;<br/>active-controlled study. The observed rates and incidences in these clinical trials were similar to those&#160;<br/>expected for the population studied. A total of 2 malignancies were reported in clinical studies of&#160;<br/>approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical&#160;<br/>studies conducted for more than 2&#160;years with 351 ankylosing spondylitis patients, 6&#160;malignancies were&#160;<br/>reported in Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in&#160;<br/>double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin&#160;<br/>cancers were reported.</p>
<p style="position:absolute;top:878px;left:106px;white-space:nowrap" class="ft134">In a group of 7,416&#160;patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing&#160;<br/>spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft133">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also&#160;been&#160;<br/>received in the postmarketing period (see section 4.4).</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft133"><i>Injection site reactions<br/></i>Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher&#160;<br/>incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first&#160;<br/>month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of&#160;<br/>injection site reactions in the Enbrel treatment groups, and the majority of patients who were given&#160;<br/>treatment received topical preparations, such as corticosteroids, or oral antihistamines. Additionally,&#160;<br/>some patients developed recall injection site reactions characterised by a skin reaction at the most&#160;<br/>recent site of injection, along with the simultaneous appearance of injection site reactions at previous&#160;<br/>injection sites. These reactions were generally transient and did not recur with treatment.</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1414{font-size:17px;font-family:PZJVUM+Symbol;color:#000000;}
-->
</style>
<div id="page14-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft140">14</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft143">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with&#160;<br/>Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the&#160;<br/>first 12 weeks of treatment.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft144"><i>Serious infections<br/></i>In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or&#160;<br/>requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3%&#160;<br/>of rheumatoid arthritis patients treated with Enbrel for up to 48&#160;months. These included abscess (at&#160;<br/>various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis,&#160;<br/>endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection,&#160;<br/>osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin&#160;<br/>infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year&#160;<br/>active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or&#160;<br/>Enbrel in combination with methotrexate, the rates of serious infections were similar among the&#160;<br/>treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate&#160;<br/>could be associated with an increase in the rate of infections.</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft143">There were no differences in rates of infection among patients treated with Enbrel and those treated&#160;<br/>with placebo for plaque psoriasis&#160;in placebo-controlled trials of up to 24 weeks duration. Serious&#160;<br/>infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia,&#160;<br/>cholecystitis, osteomyelitis, gastritis, appendicitis,&#160;<i>Streptococcal&#160;</i>fasciitis, myositis, septic shock,&#160;<br/>diverticulitis&#160;and abscess. In the double-blind and open-label psoriatic arthritis trials, 1&#160;patient reported&#160;<br/>a serious infection (pneumonia).</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft144">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include&#160;<br/>bacteria, mycobacteria (including&#160;tuberculosis), viruses and fungi. Some have occurred within a few&#160;<br/>weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes,&#160;<br/>congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis&#160;<br/>(see section&#160;4.4). Enbrel treatment may increase mortality in patients with established sepsis.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft144">Opportunistic infections have been reported in association with Enbrel, including invasive fungal,&#160;<br/>parasitic (including&#160;protozoal),&#160;viral (including herpes zoster),&#160;bacterial (including&#160;<i>Listeria&#160;</i>and&#160;<br/><i>Legionella</i>), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall&#160;<br/>incidence of opportunistic infections was 0.09% for the 15,402&#160;subjects who received Enbrel. The&#160;<br/>exposure-adjusted rate was 0.06&#160;events per 100&#160;patient-years. In postmarketing experience,&#160;<br/>approximately half of all of&#160;the case reports of opportunistic infections worldwide were invasive&#160;<br/>fungal infections.&#160;The most commonly reported invasive fungal infections&#160;included&#160;<i>Candida,<br/>Pneumocystis,&#160;Aspergillus,&#160;</i>and&#160;<i>Histoplasma</i>. Invasive fungal infections accounted for more than&#160;half&#160;<br/>of the fatalities amongst patients who developed opportunistic infections. The majority of the reports&#160;<br/>with a fatal outcome were in patients with&#160;<i>Pneumocystis&#160;</i>pneumonia, unspecified systemic fungal&#160;<br/>infections, and aspergillosis (see section 4.4).</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft148"><i>Autoantibodies<br/></i>Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid&#160;<br/>arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed&#160;<br/>new positive ANA (</p>
<p style="position:absolute;top:981px;left:240px;white-space:nowrap" class="ft1414">1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated&#160;</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft144">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA&#160;<br/>antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel&#160;compared to 4%&#160;<br/>of placebo-treated patients) and by&#160;<i>Crithidia luciliae&#160;</i>assay (3% of patients treated with Enbrel&#160;<br/>compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who&#160;<br/>developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.&#160;<br/>The impact of long-term treatment with Enbrel on the development of autoimmune diseases is&#160;<br/>unknown.</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1515{font-size:10px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page15-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft150">15</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft154">There have been rare reports of patients, including rheumatoid factor positive patients, who have&#160;<br/>developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are&#160;<br/>compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft154"><i>Pancytopenia and aplastic anaemia<br/></i>There have been postmarketing reports&#160;of pancytopenia and aplastic anaemia, some of which had fatal&#160;<br/>outcomes (see section 4.4).</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft154"><i>Interstitial lung disease<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47%&#160;<br/>(frequency uncommon).&#160;There have been postmarketing reports of interstitial lung disease (including&#160;<br/>pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft158"><i>Concurrent treatment with anakinra&#160;<br/></i>In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of&#160;<br/>serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed&#160;<br/>neutropenia (absolute neutrophil count&#160;</p>
<p style="position:absolute;top:469px;left:366px;white-space:nowrap" class="ft1514">&#160;1000/mm3). While neutropenic, one patient developed&#160;</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft152">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft153"><i>Elevated liver enzymes<br/></i>In&#160;the&#160;double-blind&#160;periods of&#160;controlled clinical trials of etanercept across all indications, the&#160;<br/>frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving&#160;<br/>etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In&#160;the double-blind&#160;<br/>periods of controlled clinical trials&#160;that allowed&#160;concomitant treatment with etanercept and&#160;<br/>methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was&#160;<br/>4.18% (frequency common).</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft154"><i>Autoimmune hepatitis<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24%&#160;<br/>(frequency uncommon).</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft152">Paediatric population</p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft154"><i>Undesirable effects in paediatric patients with juvenile idiopathic arthritis<br/></i>In general, the adverse events in paediatric patients with juvenile idiopathic&#160;arthritis were similar in&#160;<br/>frequency and type to those seen in adult patients. Differences from adults and other special&#160;<br/>considerations are discussed in the following paragraphs.</p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft154">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18 years&#160;<br/>were generally mild to moderate and consistent with those commonly seen in outpatient paediatric&#160;<br/>populations. Severe adverse events reported included varicella with signs and symptoms of aseptic&#160;<br/>meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis,&#160;<br/>depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic&#160;<br/>shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</p>
<p style="position:absolute;top:1080px;left:106px;white-space:nowrap" class="ft154">In one study in children with juvenile idiopathic arthritis aged 4 to 17 years, 43 of 69 (62%) children&#160;<br/>experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and&#160;<br/>the frequency and severity of infections was similar in 58 patients completing 12 months of open-label&#160;<br/>extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients&#160;<br/>were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and&#160;the&#160;</p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1616{font-size:17px;font-family:PZJVUM+TimesNewRoman;color:#0000fe;}
-->
</style>
<div id="page16-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft160">16</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft164">majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic&#160;<br/>arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients.&#160;<br/>These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per&#160;<br/>patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per&#160;<br/>patient year).</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft162">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft163"><i>Undesirable effects in paediatric patients with plaque psoriasis<br/></i>In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse&#160;<br/>events reported were similar to those seen in previous studies in adults with plaque psoriasis.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft162">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft164">Reporting suspected adverse reactions after authorisation&#160;of the medicinal product is important. It&#160;<br/>allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare&#160;<br/>professionals are asked to report any suspected adverse reactions&#160;via&#160;the national reporting system&#160;<br/>listed in&#160;<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V</a>.</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft161"><b>4.9</b></p>
<p style="position:absolute;top:469px;left:149px;white-space:nowrap" class="ft161"><b>Overdose</b></p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft163">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The&#160;<br/>highest dose level evaluated has been an intravenous loading dose of 32&#160;mg/m2&#160;followed by&#160;<br/>subcutaneous doses of 16&#160;mg/m2&#160;administered twice weekly. One rheumatoid arthritis patient&#160;<br/>mistakenly self-administered 62&#160;mg Enbrel subcutaneously twice weekly for 3 weeks without&#160;<br/>experiencing undesirable effects. There is no known antidote to Enbrel.</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft161"><b>5.</b></p>
<p style="position:absolute;top:639px;left:146px;white-space:nowrap" class="ft161"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft161"><b>5.1</b></p>
<p style="position:absolute;top:677px;left:149px;white-space:nowrap" class="ft161"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft164">Pharmacotherapeutic group: Immunosuppressants,&#160;Tumour Necrosis Factor alpha (TNF-α) inhibitors,&#160;<br/>ATC code:&#160;L04AB01</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft164">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid&#160;<br/>arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with&#160;<br/>psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque&#160;<br/>psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in&#160;<br/>psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of&#160;<br/>TNF binding to&#160;its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and&#160;<br/>lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the&#160;<br/>55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs&#160;<br/>exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF&#160;<br/>biological activity.</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft163">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on&#160;<br/>cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher&#160;<br/>affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of&#160;<br/>TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion&#160;<br/>element in the construction of a dimeric receptor imparts a longer serum half-life.</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft162">Mechanism of action</p>
<p style="position:absolute;top:1133px;left:106px;white-space:nowrap" class="ft163">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in&#160;<br/>plaque psoriasis&#160;is mediated by pro-inflammatory molecules that are linked in a network controlled by&#160;</p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page17-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft170">17</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft174">TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF&#160;<br/>binding to cell surface TNFR, preventing TNF-mediated cellular responses by&#160;rendering TNF&#160;<br/>biologically inactive. Etanercept may also modulate biologic responses controlled by additional&#160;<br/>downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or&#160;<br/>regulated by TNF.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft172">Clinical&#160;efficacy and safety</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft174">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis,&#160;<br/>one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis,&#160;two&#160;studies<br/>in adults with non-radiographic axial spondyloarthritis,&#160;four studies in adults with plaque psoriasis,&#160;<br/>three&#160;studies&#160;in juvenile idiopathic arthritis and&#160;one study in paediatric patients with plaque psoriasis.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft174"><i>Adult patients with rheumatoid arthritis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The&#160;<br/>study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least&#160;<br/>one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel or placebo were administered subcutaneously twice a week for 6&#160;consecutive months.&#160;<br/>The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis&#160;<br/>using American College of Rheumatology (ACR) response criteria.&#160;</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft174">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6&#160;months than in&#160;<br/>patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and&#160;<br/>6&#160;months, respectively: ACR&#160;50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6,&#160;<br/>respectively; p&lt;0.01 Enbrel vs. placebo at all timepoints for both ACR 20 and ACR 50 responses).&#160;</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft173">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month&#160;3 and&#160;<br/>month&#160;6&#160;compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel,&#160;<br/>the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly&#160;<br/>always occurred by 3 months. A dose response was seen; results with 10&#160;mg were intermediate&#160;<br/>between placebo and 25&#160;mg. Enbrel was significantly better than placebo in all components of the&#160;<br/>ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the&#160;<br/>ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which&#160;<br/>included disability, vitality, mental health, general health status, and arthritis-associated health status&#160;<br/>subdomains, was administered every 3&#160;months during the trial. All subdomains&#160;of the HAQ were&#160;<br/>improved in patients treated with Enbrel compared to controls at 3 and 6&#160;months.&#160;</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft174">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month.&#160;<br/>Re-introduction of treatment with Enbrel after discontinuation of&#160;up to 24 months resulted in the same&#160;<br/>magnitudes of responses as patients who received Enbrel without interruption of therapy based on&#160;<br/>results of open-label studies. Continued durable responses have been seen for up to&#160;10&#160;years&#160;in&#160;<br/>open-label extension treatment trials when patients received Enbrel without interruption.&#160;</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft174">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with&#160;<br/>blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid&#160;<br/>arthritis (&lt;3 years duration) who had never received treatment with methotrexate. Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel were administered subcutaneously (SC) twice a week for up to 24 months. Methotrexate&#160;<br/>doses were escalated from 7.5&#160;mg/week to a maximum&#160;of 20&#160;mg/week over the first 8&#160;weeks of the&#160;<br/>trial and continued for up to 24&#160;months. Clinical improvement, including onset of action within&#160;<br/>2&#160;weeks with Enbrel 25&#160;mg, was similar to that seen in the previous trials and was maintained for up to&#160;<br/>24&#160;months.&#160;At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to&#160;<br/>1.5. Treatment with Enbrel 25&#160;mg resulted in substantial improvement at 12&#160;months, with about 44%&#160;<br/>of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year&#160;2 of&#160;<br/>this study.</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1817{font-size:15px;font-family:PZJVUM+Arial;color:#000000;-moz-transform: matrix(         0,         -1,          1,          0, 0, 0);-webkit-transform: matrix(         0,         -1,          1,          0, 0, 0);-o-transform: matrix(         0,         -1,          1,          0, 0, 0);-ms-transform: matrix(         0,         -1,          1,          0, 0, 0);-moz-transform-origin: left 75%;-webkit-transform-origin: left 75%;-o-transform-origin: left 75%;-ms-transform-origin: left 75%;}
	.ft1818{font-size:10px;font-family:PZJVUM+Arial,Bold;color:#000000;}
	.ft1819{font-size:13px;font-family:PZJVUM+Arial,Bold;color:#000000;}
	.ft1820{font-size:15px;font-family:PZJVUM+Arial,Bold;color:#000000;}
	.ft1821{font-size:10px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
	.ft1822{font-size:10px;font-family:PZJVUM+Symbol;color:#000000;}
	.ft1823{font-size:17px;line-height:18px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
	.ft1824{font-size:17px;line-height:19px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page18-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft180">18</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft184">In this study, structural joint damage was assessed radiographically and expressed as change in Total&#160;<br/>Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score.&#160;<br/>Radiographs of&#160;hands/wrists and feet were read at baseline and 6, 12, and 24&#160;months. The 10&#160;mg&#160;<br/>Enbrel dose had consistently less effect on structural damage than the 25&#160;mg dose. Enbrel 25&#160;mg was&#160;<br/>significantly superior to methotrexate for erosion scores at both 12 and 24&#160;months. The differences in&#160;<br/>TSS and JSN were not statistically significant between methotrexate and Enbrel 25&#160;mg. The results are&#160;<br/>shown in the figure below.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1823"><b>Radiographic&#160;&#160;Progression:&#160;&#160;Comparison&#160;&#160;of&#160;&#160;Enbrel&#160;&#160;vs.&#160;&#160;Methotrexate&#160;&#160;in&#160;&#160;Patients&#160;&#160;with&#160;&#160;RA&#160;&#160;of&#160;<br/>&lt;3&#160;Years Duration</b></p>
<p style="position:absolute;top:477px;left:132px;white-space:nowrap" class="ft1817">C</p>
<p style="position:absolute;top:466px;left:132px;white-space:nowrap" class="ft1817">ha</p>
<p style="position:absolute;top:450px;left:132px;white-space:nowrap" class="ft1817">ng</p>
<p style="position:absolute;top:434px;left:132px;white-space:nowrap" class="ft1817">e&#160;</p>
<p style="position:absolute;top:422px;left:132px;white-space:nowrap" class="ft1817">fr</p>
<p style="position:absolute;top:412px;left:132px;white-space:nowrap" class="ft1817">om</p>
<p style="position:absolute;top:392px;left:132px;white-space:nowrap" class="ft1817">&#160;B</p>
<p style="position:absolute;top:377px;left:132px;white-space:nowrap" class="ft1817">as</p>
<p style="position:absolute;top:362px;left:132px;white-space:nowrap" class="ft1817">e</p>
<p style="position:absolute;top:354px;left:132px;white-space:nowrap" class="ft1817">lin</p>
<p style="position:absolute;top:339px;left:132px;white-space:nowrap" class="ft1817">e</p>
<p style="position:absolute;top:513px;left:145px;white-space:nowrap" class="ft1818"><b>0.0</b></p>
<p style="position:absolute;top:476px;left:145px;white-space:nowrap" class="ft1818"><b>0.5</b></p>
<p style="position:absolute;top:439px;left:145px;white-space:nowrap" class="ft1818"><b>1.0</b></p>
<p style="position:absolute;top:401px;left:145px;white-space:nowrap" class="ft1818"><b>1.5</b></p>
<p style="position:absolute;top:364px;left:145px;white-space:nowrap" class="ft1818"><b>2.0</b></p>
<p style="position:absolute;top:327px;left:145px;white-space:nowrap" class="ft1818"><b>2.5</b></p>
<p style="position:absolute;top:514px;left:483px;white-space:nowrap" class="ft1818"><b>0.0</b></p>
<p style="position:absolute;top:477px;left:483px;white-space:nowrap" class="ft1818"><b>0.5</b></p>
<p style="position:absolute;top:440px;left:483px;white-space:nowrap" class="ft1818"><b>1.0</b></p>
<p style="position:absolute;top:403px;left:483px;white-space:nowrap" class="ft1818"><b>1.5</b></p>
<p style="position:absolute;top:365px;left:483px;white-space:nowrap" class="ft1818"><b>2.0</b></p>
<p style="position:absolute;top:328px;left:483px;white-space:nowrap" class="ft1818"><b>2.5</b></p>
<p style="position:absolute;top:560px;left:433px;white-space:nowrap" class="ft1819"><b>MTX</b></p>
<p style="position:absolute;top:574px;left:433px;white-space:nowrap" class="ft1819"><b>Enbrel 25 mg</b></p>
<p style="position:absolute;top:321px;left:251px;white-space:nowrap" class="ft1819"><b>12 Months</b></p>
<p style="position:absolute;top:321px;left:597px;white-space:nowrap" class="ft1819"><b>24 Months</b></p>
<p style="position:absolute;top:532px;left:221px;white-space:nowrap" class="ft1820"><b>TSS</b></p>
<p style="position:absolute;top:532px;left:269px;white-space:nowrap" class="ft1820"><b>Erosions</b></p>
<p style="position:absolute;top:533px;left:351px;white-space:nowrap" class="ft1820"><b>JSN</b></p>
<p style="position:absolute;top:534px;left:553px;white-space:nowrap" class="ft1820"><b>TSS</b></p>
<p style="position:absolute;top:534px;left:607px;white-space:nowrap" class="ft1820"><b>Erosions</b></p>
<p style="position:absolute;top:534px;left:687px;white-space:nowrap" class="ft1820"><b>JSN</b></p>
<p style="position:absolute;top:402px;left:208px;white-space:nowrap" class="ft1819"><b>1.3</b></p>
<p style="position:absolute;top:440px;left:232px;white-space:nowrap" class="ft1819"><b>0.8</b></p>
<p style="position:absolute;top:432px;left:276px;white-space:nowrap" class="ft1819"><b>0.9</b></p>
<p style="position:absolute;top:470px;left:300px;white-space:nowrap" class="ft1819"><b>0.4*</b></p>
<p style="position:absolute;top:470px;left:343px;white-space:nowrap" class="ft1819"><b>0.4&#160;0.4</b></p>
<p style="position:absolute;top:335px;left:547px;white-space:nowrap" class="ft1819"><b>2.2</b></p>
<p style="position:absolute;top:410px;left:571px;white-space:nowrap" class="ft1819"><b>1.2</b></p>
<p style="position:absolute;top:402px;left:614px;white-space:nowrap" class="ft1819"><b>1.3</b></p>
<p style="position:absolute;top:455px;left:637px;white-space:nowrap" class="ft1819"><b>0.6*</b></p>
<p style="position:absolute;top:432px;left:680px;white-space:nowrap" class="ft1819"><b>0.9</b></p>
<p style="position:absolute;top:455px;left:704px;white-space:nowrap" class="ft1819"><b>0.6</b></p>
<p style="position:absolute;top:602px;left:419px;white-space:nowrap" class="ft1819"><b>*p &lt; 0.05</b></p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft184">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and&#160;<br/>radiographic progression in RA patients treated with Enbrel alone (25&#160;mg twice weekly), methotrexate&#160;<br/>alone (7.5 to 20&#160;mg&#160;weekly, median dose 20&#160;mg), and the combination of Enbrel and methotrexate&#160;<br/>initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6&#160;months&#160;<br/>to 20&#160;years duration (median 5&#160;years) who had a less than satisfactory response to at least 1 disease-<br/>modifying antirheumatic drug (DMARD) other than methotrexate.</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft184">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher&#160;<br/>ACR&#160;20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and&#160;<br/>52&#160;weeks than patients in either of the single therapy groups (results shown in table below).&#160;<br/>Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed&#160;after 24&#160;months.</p>
<p style="position:absolute;top:881px;left:104px;white-space:nowrap" class="ft1824"><b>Clinical Efficacy Results at 12&#160;Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel&#160;<br/>in Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration</b></p>
<p style="position:absolute;top:939px;left:102px;white-space:nowrap" class="ft181"><b>Endpoint</b></p>
<p style="position:absolute;top:939px;left:328px;white-space:nowrap" class="ft182">Methotrexate</p>
<p style="position:absolute;top:958px;left:337px;white-space:nowrap" class="ft182">(n =&#160;228)</p>
<p style="position:absolute;top:939px;left:494px;white-space:nowrap" class="ft182">Enbrel</p>
<p style="position:absolute;top:958px;left:481px;white-space:nowrap" class="ft182">(n = 223)</p>
<p style="position:absolute;top:920px;left:639px;white-space:nowrap" class="ft182">Enbrel +</p>
<p style="position:absolute;top:939px;left:620px;white-space:nowrap" class="ft182">Methotrexate</p>
<p style="position:absolute;top:958px;left:633px;white-space:nowrap" class="ft182">(n = 231)</p>
<p style="position:absolute;top:997px;left:102px;white-space:nowrap" class="ft181"><b>ACR Responses</b>a</p>
<p style="position:absolute;top:1016px;left:131px;white-space:nowrap" class="ft182">ACR 20</p>
<p style="position:absolute;top:1016px;left:350px;white-space:nowrap" class="ft182">58.8%</p>
<p style="position:absolute;top:1016px;left:494px;white-space:nowrap" class="ft182">65.5%</p>
<p style="position:absolute;top:1017px;left:638px;white-space:nowrap" class="ft182">74.5%&#160;<b>†,</b></p>
<p style="position:absolute;top:1036px;left:131px;white-space:nowrap" class="ft182">ACR 50</p>
<p style="position:absolute;top:1037px;left:350px;white-space:nowrap" class="ft182">36.4%</p>
<p style="position:absolute;top:1037px;left:494px;white-space:nowrap" class="ft182">43.0%</p>
<p style="position:absolute;top:1037px;left:638px;white-space:nowrap" class="ft182">63.2%&#160;<b>†,</b></p>
<p style="position:absolute;top:1056px;left:131px;white-space:nowrap" class="ft182">ACR 70</p>
<p style="position:absolute;top:1057px;left:350px;white-space:nowrap" class="ft182">16.7%</p>
<p style="position:absolute;top:1057px;left:494px;white-space:nowrap" class="ft182">22.0%</p>
<p style="position:absolute;top:1057px;left:638px;white-space:nowrap" class="ft182">39.8%&#160;<b>†,</b></p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1925{font-size:14px;font-family:PZJVUM+Arial;color:#000000;-moz-transform: matrix(         0,         -1,          1,          0, 0, 0);-webkit-transform: matrix(         0,         -1,          1,          0, 0, 0);-o-transform: matrix(         0,         -1,          1,          0, 0, 0);-ms-transform: matrix(         0,         -1,          1,          0, 0, 0);-moz-transform-origin: left 75%;-webkit-transform-origin: left 75%;-o-transform-origin: left 75%;-ms-transform-origin: left 75%;}
	.ft1926{font-size:12px;font-family:PZJVUM+Arial,Bold;color:#000000;}
	.ft1927{font-size:17px;font-family:PZJVUM+Arial,Bold;color:#000000;}
-->
</style>
<div id="page19-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft190">19</p>
<p style="position:absolute;top:108px;left:104px;white-space:nowrap" class="ft1923"><b>Clinical Efficacy Results at 12&#160;Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel&#160;<br/>in Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration</b></p>
<p style="position:absolute;top:165px;left:102px;white-space:nowrap" class="ft191"><b>Endpoint</b></p>
<p style="position:absolute;top:165px;left:328px;white-space:nowrap" class="ft192">Methotrexate</p>
<p style="position:absolute;top:184px;left:337px;white-space:nowrap" class="ft192">(n =&#160;228)</p>
<p style="position:absolute;top:165px;left:494px;white-space:nowrap" class="ft192">Enbrel</p>
<p style="position:absolute;top:184px;left:481px;white-space:nowrap" class="ft192">(n = 223)</p>
<p style="position:absolute;top:146px;left:639px;white-space:nowrap" class="ft192">Enbrel +</p>
<p style="position:absolute;top:165px;left:620px;white-space:nowrap" class="ft192">Methotrexate</p>
<p style="position:absolute;top:184px;left:633px;white-space:nowrap" class="ft192">(n = 231)</p>
<p style="position:absolute;top:203px;left:102px;white-space:nowrap" class="ft191"><b>DAS</b></p>
<p style="position:absolute;top:222px;left:131px;white-space:nowrap" class="ft192">Baseline scoreb</p>
<p style="position:absolute;top:222px;left:361px;white-space:nowrap" class="ft192">5.5</p>
<p style="position:absolute;top:222px;left:505px;white-space:nowrap" class="ft192">5.7</p>
<p style="position:absolute;top:222px;left:658px;white-space:nowrap" class="ft192">5.5</p>
<p style="position:absolute;top:241px;left:131px;white-space:nowrap" class="ft192">Week 52 scoreb</p>
<p style="position:absolute;top:241px;left:361px;white-space:nowrap" class="ft192">3.0</p>
<p style="position:absolute;top:241px;left:505px;white-space:nowrap" class="ft192">3.0</p>
<p style="position:absolute;top:243px;left:651px;white-space:nowrap" class="ft192">2.3<b>†,</b></p>
<p style="position:absolute;top:261px;left:131px;white-space:nowrap" class="ft192">Remissionc</p>
<p style="position:absolute;top:261px;left:357px;white-space:nowrap" class="ft192">14%</p>
<p style="position:absolute;top:261px;left:501px;white-space:nowrap" class="ft192">18%</p>
<p style="position:absolute;top:263px;left:646px;white-space:nowrap" class="ft192">37%<b>†,</b></p>
<p style="position:absolute;top:301px;left:102px;white-space:nowrap" class="ft191"><b>HAQ</b></p>
<p style="position:absolute;top:320px;left:129px;white-space:nowrap" class="ft192">Baseline</p>
<p style="position:absolute;top:320px;left:361px;white-space:nowrap" class="ft192">1.7</p>
<p style="position:absolute;top:320px;left:505px;white-space:nowrap" class="ft192">1.7</p>
<p style="position:absolute;top:320px;left:658px;white-space:nowrap" class="ft192">1.8</p>
<p style="position:absolute;top:339px;left:129px;white-space:nowrap" class="ft192">Week 52</p>
<p style="position:absolute;top:339px;left:361px;white-space:nowrap" class="ft192">1.1</p>
<p style="position:absolute;top:339px;left:505px;white-space:nowrap" class="ft192">1.0</p>
<p style="position:absolute;top:340px;left:651px;white-space:nowrap" class="ft192">0.8<b>†,</b></p>
<p style="position:absolute;top:360px;left:153px;white-space:nowrap" class="ft198">a: Patients who did not complete 12 months in the study were considered to be non-responders.<br/>b: Values for Disease Activity Score (DAS) are means.<br/>c: Remission is defined as DAS &lt;1.6.<br/>Pairwise comparison p-values:&#160;†&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs.&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:435px;left:271px;white-space:nowrap" class="ft1914">&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. Enbrel.</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft194">Radiographic progression at 12&#160;months was significantly less in the Enbrel group than in the&#160;<br/>methotrexate group,&#160;while the combination was significantly better than either monotherapy at&#160;<br/>slowing radiographic progression (see figure below).</p>
<p style="position:absolute;top:551px;left:106px;white-space:nowrap" class="ft1923"><b>Radiographic Progression: Comparison of Enbrel vs. Methotrexate vs. Enbrel in Combination&#160;<br/>with Methotrexate in Patients with RA&#160;of&#160;6&#160;Months To 20&#160;Years Duration (12&#160;Month Results)</b></p>
<p style="position:absolute;top:978px;left:233px;white-space:nowrap" class="ft198">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs.&#160;<br/>methotrexate, † = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs.&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:1015px;left:351px;white-space:nowrap" class="ft1914">&#160;= p&#160;&lt;&#160;0.05 for comparisons of Enbrel&#160;+ methotrexate vs.&#160;</p>
<p style="position:absolute;top:1036px;left:233px;white-space:nowrap" class="ft192">Enbrel.</p>
<p style="position:absolute;top:1074px;left:106px;white-space:nowrap" class="ft193">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months. Similarly, the&#160;<br/>significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also&#160;<br/>observed after 24&#160;months.</p>
<p style="position:absolute;top:830px;left:206px;white-space:nowrap" class="ft1925">C</p>
<p style="position:absolute;top:819px;left:206px;white-space:nowrap" class="ft1925">ha</p>
<p style="position:absolute;top:804px;left:206px;white-space:nowrap" class="ft1925">ng</p>
<p style="position:absolute;top:788px;left:206px;white-space:nowrap" class="ft1925">e&#160;</p>
<p style="position:absolute;top:776px;left:206px;white-space:nowrap" class="ft1925">fr</p>
<p style="position:absolute;top:767px;left:206px;white-space:nowrap" class="ft1925">om</p>
<p style="position:absolute;top:747px;left:206px;white-space:nowrap" class="ft1925">&#160;B</p>
<p style="position:absolute;top:734px;left:206px;white-space:nowrap" class="ft1925">as</p>
<p style="position:absolute;top:719px;left:206px;white-space:nowrap" class="ft1925">el</p>
<p style="position:absolute;top:708px;left:206px;white-space:nowrap" class="ft1925">in</p>
<p style="position:absolute;top:696px;left:206px;white-space:nowrap" class="ft1925">e</p>
<p style="position:absolute;top:916px;left:232px;white-space:nowrap" class="ft190">-1.0</p>
<p style="position:absolute;top:878px;left:232px;white-space:nowrap" class="ft190">-0.5</p>
<p style="position:absolute;top:841px;left:236px;white-space:nowrap" class="ft190">0.0</p>
<p style="position:absolute;top:803px;left:236px;white-space:nowrap" class="ft190">0.5</p>
<p style="position:absolute;top:766px;left:236px;white-space:nowrap" class="ft190">1.0</p>
<p style="position:absolute;top:728px;left:236px;white-space:nowrap" class="ft190">1.5</p>
<p style="position:absolute;top:691px;left:236px;white-space:nowrap" class="ft190">2.0</p>
<p style="position:absolute;top:653px;left:236px;white-space:nowrap" class="ft190">2.5</p>
<p style="position:absolute;top:616px;left:236px;white-space:nowrap" class="ft190">3.0</p>
<p style="position:absolute;top:629px;left:552px;white-space:nowrap" class="ft1926"><b>Methotrexate</b></p>
<p style="position:absolute;top:644px;left:551px;white-space:nowrap" class="ft1926"><b>Enbrel&#160;</b></p>
<p style="position:absolute;top:659px;left:552px;white-space:nowrap" class="ft1926"><b>Enbrel + Methotrexate</b></p>
<p style="position:absolute;top:619px;left:334px;white-space:nowrap" class="ft1926"><b>2.80</b></p>
<p style="position:absolute;top:790px;left:361px;white-space:nowrap" class="ft1926"><b>0.52*</b></p>
<p style="position:absolute;top:893px;left:380px;white-space:nowrap" class="ft1926"><b>-0.54†</b>,</p>
<p style="position:absolute;top:703px;left:443px;white-space:nowrap" class="ft1926"><b>1.68</b></p>
<p style="position:absolute;top:813px;left:469px;white-space:nowrap" class="ft1926"><b>0.21*</b></p>
<p style="position:absolute;top:876px;left:489px;white-space:nowrap" class="ft1926"><b>-0.30†</b></p>
<p style="position:absolute;top:745px;left:551px;white-space:nowrap" class="ft1926"><b>1.12</b></p>
<p style="position:absolute;top:805px;left:577px;white-space:nowrap" class="ft1926"><b>0.32</b></p>
<p style="position:absolute;top:869px;left:599px;white-space:nowrap" class="ft1926"><b>-0.23†</b>,</p>
<p style="position:absolute;top:925px;left:352px;white-space:nowrap" class="ft1927"><b>TSS</b></p>
<p style="position:absolute;top:924px;left:442px;white-space:nowrap" class="ft1927"><b>Erosions</b></p>
<p style="position:absolute;top:924px;left:571px;white-space:nowrap" class="ft1927"><b>JSN</b></p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page20-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft200">20</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft204">In an analysis in which all patients who dropped out of the study for any reason were considered to&#160;<br/>have progressed, the percentage of patients without progression (TSS change&#160;≤ 0.5) at 24&#160;months was&#160;<br/>higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and&#160;<br/>methotrexate alone groups&#160;(62%, 50%, and 36%, respectively; p&lt;0.05). The difference between&#160;<br/>Enbrel alone and methotrexate alone was also significant (p&lt;0.05). Among patients who completed a&#160;<br/>full 24&#160;months of therapy in the study, the non-progression rates were 78%, 70%, and 61%,&#160;<br/>respectively.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft203">The safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered once weekly were&#160;<br/>evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53&#160;<br/>patients received placebo, 214 patients received 50&#160;mg&#160;Enbrel once weekly and 153 patients received&#160;<br/>25&#160;mg Enbrel twice weekly. The safety and efficacy profiles&#160;of the two Enbrel treatment regimens&#160;<br/>were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16&#160;did not show&#160;<br/>comparability (non-inferiority) between the two regimens.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft208"><i>Adult patients with psoriatic arthritis<br/></i>The efficacy of&#160;Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205&#160;<br/>patients with psoriatic arthritis. Patients were between 18 and 70&#160;years of age and had active psoriatic&#160;<br/>arthritis (</p>
<p style="position:absolute;top:449px;left:167px;white-space:nowrap" class="ft2014">&#160;3 swollen joints and&#160;&#160;3 tender joints) in at least one&#160;of the following forms: (1)&#160;distal&#160;</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft208">interphalangeal (DIP) involvement; (2)&#160;polyarticular arthritis (absence of rheumatoid nodules and&#160;<br/>presence of psoriasis); (3)&#160;arthritis mutilans; (4)&#160;asymmetric psoriatic arthritis; or (5)&#160;spondylitis-like&#160;<br/>ankylosis. Patients also had plaque psoriasis with a qualifying target lesion&#160;</p>
<p style="position:absolute;top:507px;left:604px;white-space:nowrap" class="ft2014">&#160;2&#160;cm in diameter.&#160;</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft208">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids&#160;<br/>(24%). Patients currently on methotrexate therapy (stable for&#160;</p>
<p style="position:absolute;top:547px;left:512px;white-space:nowrap" class="ft2014">&#160;2 months) could continue at a stable&#160;</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft202">dose of&#160;</p>
<p style="position:absolute;top:567px;left:159px;white-space:nowrap" class="ft2014">&#160;25&#160;mg/week methotrexate. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in&#160;</p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft204">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6&#160;months. At the&#160;<br/>end of the double-blind study, patients could enter a long-term open-label extension study for a total&#160;<br/>duration of up to 2&#160;years.</p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft203">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70&#160;<br/>response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results&#160;<br/>are summarised in the table below.</p>
<p style="position:absolute;top:739px;left:239px;white-space:nowrap" class="ft201"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:758px;left:389px;white-space:nowrap" class="ft201"><b>Controlled Trial</b></p>
<p style="position:absolute;top:778px;left:495px;white-space:nowrap" class="ft202">Percent of Patients</p>
<p style="position:absolute;top:797px;left:473px;white-space:nowrap" class="ft202">Placebo</p>
<p style="position:absolute;top:797px;left:586px;white-space:nowrap" class="ft202">Enbrela</p>
<p style="position:absolute;top:816px;left:226px;white-space:nowrap" class="ft202">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:816px;left:474px;white-space:nowrap" class="ft202">n = 104</p>
<p style="position:absolute;top:816px;left:585px;white-space:nowrap" class="ft202">n = 101</p>
<p style="position:absolute;top:855px;left:226px;white-space:nowrap" class="ft2024"><b>&#160;&#160;ACR 20<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:874px;left:491px;white-space:nowrap" class="ft202">15</p>
<p style="position:absolute;top:874px;left:600px;white-space:nowrap" class="ft202">59b</p>
<p style="position:absolute;top:893px;left:226px;white-space:nowrap" class="ft202">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:893px;left:491px;white-space:nowrap" class="ft202">13</p>
<p style="position:absolute;top:893px;left:600px;white-space:nowrap" class="ft202">50b</p>
<p style="position:absolute;top:931px;left:226px;white-space:nowrap" class="ft2023"><b>&#160;&#160;ACR 50<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:950px;left:495px;white-space:nowrap" class="ft202">4</p>
<p style="position:absolute;top:950px;left:600px;white-space:nowrap" class="ft202">38b</p>
<p style="position:absolute;top:969px;left:226px;white-space:nowrap" class="ft202">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:969px;left:495px;white-space:nowrap" class="ft202">4</p>
<p style="position:absolute;top:969px;left:600px;white-space:nowrap" class="ft202">37b</p>
<p style="position:absolute;top:1007px;left:226px;white-space:nowrap" class="ft2023"><b>&#160;&#160;ACR 70<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:1026px;left:495px;white-space:nowrap" class="ft202">0</p>
<p style="position:absolute;top:1026px;left:600px;white-space:nowrap" class="ft202">11b</p>
<p style="position:absolute;top:1045px;left:226px;white-space:nowrap" class="ft202">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:1045px;left:495px;white-space:nowrap" class="ft202">1</p>
<p style="position:absolute;top:1045px;left:604px;white-space:nowrap" class="ft202">9c</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page21-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft210">21</p>
<p style="position:absolute;top:108px;left:239px;white-space:nowrap" class="ft211"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:127px;left:389px;white-space:nowrap" class="ft211"><b>Controlled Trial</b></p>
<p style="position:absolute;top:146px;left:495px;white-space:nowrap" class="ft212">Percent of Patients</p>
<p style="position:absolute;top:165px;left:473px;white-space:nowrap" class="ft212">Placebo</p>
<p style="position:absolute;top:165px;left:586px;white-space:nowrap" class="ft212">Enbrela</p>
<p style="position:absolute;top:184px;left:226px;white-space:nowrap" class="ft212">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:184px;left:474px;white-space:nowrap" class="ft212">n = 104</p>
<p style="position:absolute;top:184px;left:585px;white-space:nowrap" class="ft212">n = 101</p>
<p style="position:absolute;top:203px;left:226px;white-space:nowrap" class="ft2123"><b>&#160;&#160;PsARC<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:222px;left:491px;white-space:nowrap" class="ft212">31</p>
<p style="position:absolute;top:222px;left:600px;white-space:nowrap" class="ft212">72b</p>
<p style="position:absolute;top:241px;left:226px;white-space:nowrap" class="ft212">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:241px;left:491px;white-space:nowrap" class="ft212">23</p>
<p style="position:absolute;top:241px;left:600px;white-space:nowrap" class="ft212">70b</p>
<p style="position:absolute;top:261px;left:236px;white-space:nowrap" class="ft214">a: 25&#160;mg Enbrel SC twice weekly<br/>b: p&#160;&lt; 0.001, Enbrel vs. placebo<br/>c: p &lt; 0.01, Enbrel vs. placebo</p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft214">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at&#160;<br/>the time of the first visit (4&#160;weeks) and were maintained through 6&#160;months of therapy. Enbrel was&#160;<br/>significantly better than placebo in all measures of disease activity (p &lt; 0.001), and responses were&#160;<br/>similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis&#160;<br/>patients was assessed at every timepoint using the disability index of the HAQ. The disability index&#160;<br/>score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel,&#160;<br/>relative to placebo (p&#160;&lt;&#160;0.001).&#160;</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft213">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists&#160;<br/>were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in&#160;<br/>the table below. In an analysis in which all patients who dropped out of the study for any reason were&#160;<br/>considered to have progressed, the percentage of patients without progression (TSS&#160;change&#160;≤ 0.5) at&#160;<br/>12&#160;months was higher in the Enbrel group compared with the placebo group (73% vs. 47%,&#160;<br/>respectively, p&#160;≤&#160;0.001). The effect of Enbrel on radiographic progression was maintained in patients&#160;<br/>who continued on treatment during the second year.&#160;The slowing of peripheral joint damage was&#160;<br/>observed in patients with polyarticular symmetrical joint involvement. &#160;</p>
<p style="position:absolute;top:664px;left:238px;white-space:nowrap" class="ft211"><b>Mean (SE) Annualized Change from Baseline in Total Sharp Score</b></p>
<p style="position:absolute;top:693px;left:469px;white-space:nowrap" class="ft212">Placebo</p>
<p style="position:absolute;top:693px;left:684px;white-space:nowrap" class="ft212">Etanercept</p>
<p style="position:absolute;top:721px;left:232px;white-space:nowrap" class="ft212">Time</p>
<p style="position:absolute;top:721px;left:464px;white-space:nowrap" class="ft212">(n = 104)</p>
<p style="position:absolute;top:721px;left:688px;white-space:nowrap" class="ft212">(n = 101)</p>
<p style="position:absolute;top:750px;left:217px;white-space:nowrap" class="ft212">Month 12</p>
<p style="position:absolute;top:750px;left:458px;white-space:nowrap" class="ft212">1.00 (0.29)</p>
<p style="position:absolute;top:750px;left:677px;white-space:nowrap" class="ft212">-0.03&#160;(0.09)a</p>
<p style="position:absolute;top:769px;left:123px;white-space:nowrap" class="ft213">SE = standard error. &#160;<br/>a. p = 0.0001. &#160;</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft213">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this&#160;<br/>benefit was maintained during the longer-term exposure of up to 2&#160;years.</p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft214">There is insufficient&#160;evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and&#160;<br/>arthritis mutilans&#160;psoriatic arthropathies due to the small number of patients studied.<br/>No study has been performed in patients with psoriatic arthritis using the 50&#160;mg once-weekly dosing&#160;<br/>regimen. Evidence of efficacy for the once-weekly dosing regimen in this patient population has been&#160;<br/>based on data from the study in patients with ankylosing spondylitis.</p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft218"><i>Adult patients with ankylosing spondylitis<br/></i>The efficacy of Enbrel in&#160;ankylosing spondylitis was assessed in 3 randomised, double-blind studies&#160;<br/>comparing twice-weekly administration of 25&#160;mg Enbrel with placebo. A total of 401 patients were&#160;<br/>enrolled, from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled&#160;<br/>patients who were between 18 and 70&#160;years of age and had active ankylosing spondylitis defined as&#160;<br/>visual analog scale (VAS) scores of&#160;</p>
<p style="position:absolute;top:1086px;left:347px;white-space:nowrap" class="ft2114">&#160;30 for average of duration and intensity of morning stiffness&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft212">plus VAS scores of&#160;</p>
<p style="position:absolute;top:1106px;left:239px;white-space:nowrap" class="ft2114">&#160;30 for at least 2 of the&#160;following 3 parameters: patient global assessment;&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft214">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the&#160;<br/>Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or&#160;</p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page22-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft220">22</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft223">corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine&#160;<br/>were not included in the study. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in patients&#160;<br/>with rheumatoid arthritis) or placebo were administered subcutaneously&#160;twice a week for 6&#160;months in&#160;<br/>138&#160;patients.</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft222">The primary measure of efficacy (ASAS 20) was a&#160;</p>
<p style="position:absolute;top:202px;left:446px;white-space:nowrap" class="ft2214">20% improvement in at least 3 of the 4&#160;</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft223">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain,&#160;<br/>BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70&#160;<br/>responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft224">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20,&#160;<br/>ASAS&#160;50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</p>
<p style="position:absolute;top:356px;left:255px;white-space:nowrap" class="ft221"><b>Responses of Patients with Ankylosing Spondylitis in a&#160;</b></p>
<p style="position:absolute;top:375px;left:361px;white-space:nowrap" class="ft221"><b>Placebo-controlled Trial</b></p>
<p style="position:absolute;top:395px;left:482px;white-space:nowrap" class="ft222">Percent of Patients</p>
<p style="position:absolute;top:416px;left:242px;white-space:nowrap" class="ft222">&#160;&#160;Ankylosing Spondylitis&#160;</p>
<p style="position:absolute;top:434px;left:249px;white-space:nowrap" class="ft222">Response</p>
<p style="position:absolute;top:416px;left:464px;white-space:nowrap" class="ft222">Placebo</p>
<p style="position:absolute;top:434px;left:462px;white-space:nowrap" class="ft222">N = 139</p>
<p style="position:absolute;top:416px;left:576px;white-space:nowrap" class="ft222">Enbrel</p>
<p style="position:absolute;top:434px;left:570px;white-space:nowrap" class="ft222">N = 138</p>
<p style="position:absolute;top:455px;left:241px;white-space:nowrap" class="ft222">&#160;&#160;ASAS 20&#160;</p>
<p style="position:absolute;top:475px;left:259px;white-space:nowrap" class="ft222">2&#160;weeks</p>
<p style="position:absolute;top:475px;left:481px;white-space:nowrap" class="ft222">22</p>
<p style="position:absolute;top:475px;left:587px;white-space:nowrap" class="ft222">46a</p>
<p style="position:absolute;top:495px;left:259px;white-space:nowrap" class="ft222">3 months</p>
<p style="position:absolute;top:495px;left:481px;white-space:nowrap" class="ft222">27</p>
<p style="position:absolute;top:495px;left:587px;white-space:nowrap" class="ft222">60a</p>
<p style="position:absolute;top:515px;left:259px;white-space:nowrap" class="ft222">6&#160;months</p>
<p style="position:absolute;top:515px;left:481px;white-space:nowrap" class="ft222">23</p>
<p style="position:absolute;top:515px;left:587px;white-space:nowrap" class="ft222">58a</p>
<p style="position:absolute;top:544px;left:241px;white-space:nowrap" class="ft222">&#160;&#160;ASAS 50&#160;</p>
<p style="position:absolute;top:564px;left:259px;white-space:nowrap" class="ft222">2 weeks</p>
<p style="position:absolute;top:564px;left:485px;white-space:nowrap" class="ft222">7</p>
<p style="position:absolute;top:564px;left:587px;white-space:nowrap" class="ft222">24a</p>
<p style="position:absolute;top:584px;left:259px;white-space:nowrap" class="ft222">3 months</p>
<p style="position:absolute;top:584px;left:481px;white-space:nowrap" class="ft222">13</p>
<p style="position:absolute;top:584px;left:587px;white-space:nowrap" class="ft222">45a</p>
<p style="position:absolute;top:604px;left:259px;white-space:nowrap" class="ft222">6&#160;months</p>
<p style="position:absolute;top:604px;left:481px;white-space:nowrap" class="ft222">10</p>
<p style="position:absolute;top:604px;left:587px;white-space:nowrap" class="ft222">42a</p>
<p style="position:absolute;top:633px;left:241px;white-space:nowrap" class="ft222">&#160;&#160;ASAS 70</p>
<p style="position:absolute;top:654px;left:259px;white-space:nowrap" class="ft222">2 weeks</p>
<p style="position:absolute;top:654px;left:485px;white-space:nowrap" class="ft222">2</p>
<p style="position:absolute;top:654px;left:586px;white-space:nowrap" class="ft222">12b</p>
<p style="position:absolute;top:674px;left:259px;white-space:nowrap" class="ft222">3 months</p>
<p style="position:absolute;top:674px;left:485px;white-space:nowrap" class="ft222">7</p>
<p style="position:absolute;top:674px;left:586px;white-space:nowrap" class="ft222">29b</p>
<p style="position:absolute;top:694px;left:259px;white-space:nowrap" class="ft222">6&#160;months&#160;</p>
<p style="position:absolute;top:694px;left:485px;white-space:nowrap" class="ft222">5</p>
<p style="position:absolute;top:694px;left:586px;white-space:nowrap" class="ft222">28b</p>
<p style="position:absolute;top:723px;left:246px;white-space:nowrap" class="ft223">a: p&#160;&lt;0.001, Enbrel vs. placebo<br/>b: p = 0.002, Enbrel vs. placebo</p>
<p style="position:absolute;top:782px;left:106px;white-space:nowrap" class="ft224">Among&#160;patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent&#160;<br/>at the time of the first visit (2&#160;weeks) and were maintained through 6&#160;months of therapy. Responses&#160;<br/>were similar in patients who were or were not receiving concomitant therapies at baseline.</p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft222">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft224">In a fourth study, the safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered&#160;<br/>once weekly vs. 25&#160;mg Enbrel administered twice&#160;weekly were evaluated in a double-blind,&#160;<br/>placebo-controlled study of 356&#160;patients with active ankylosing spondylitis. The safety and efficacy&#160;<br/>profiles of the 50&#160;mg once-weekly and 25&#160;mg twice-weekly regimens were similar.</p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft225"><i>Adult patients with&#160;non-radiographic axial spondyloarthritis</i></p>
<p style="position:absolute;top:1029px;left:106px;white-space:nowrap" class="ft223"><i>Study 1<br/></i>The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was&#160;<br/>assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated&#160;<br/>215&#160;adult patients&#160;(modified intent-to-treat population)&#160;with active nr-AxSpa (18 to 49 years of age),<br/>defined as those patients meeting the ASAS&#160;classification criteria of&#160;axial&#160;spondyloarthritis but did not&#160;<br/>meet the modified New York criteria for AS.&#160;Patients were also&#160;required to have an&#160;inadequate&#160;<br/>response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel&#160;</p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page23-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft230">23</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft233">50&#160;mg weekly or placebo for 12&#160;weeks. The primary measure of efficacy (ASAS 40) was a 40%&#160;<br/>improvement in at least three of the four ASAS domains and absence of deterioration in the remaining&#160;<br/>domain.&#160;The double-blind period was followed by an open-label period during which all patients&#160;<br/>receive&#160;Enbrel 50 mg weekly for up to an additional 92 weeks.&#160;MRIs of the sacroiliac joint and&#160;spine&#160;<br/>were obtained to assess inflammation at baseline and at weeks&#160;12 and 104.</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft234">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the&#160;<br/>ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial&#160;<br/>remission and BASDAI 50.&#160;Week 12&#160;results are shown in the table below.</p>
<p style="position:absolute;top:301px;left:135px;white-space:nowrap" class="ft231"><b>Efficacy Response&#160;in Placebo-Controlled nr-AxSpa Study:&#160;Percent of Patients Achieving&#160;</b></p>
<p style="position:absolute;top:320px;left:410px;white-space:nowrap" class="ft231"><b>Endpoints</b></p>
<p style="position:absolute;top:339px;left:141px;white-space:nowrap" class="ft233">Double-Blind Clinical<br/>Responses at Week 12&#160;</p>
<p style="position:absolute;top:339px;left:481px;white-space:nowrap" class="ft232">Placebo</p>
<p style="position:absolute;top:358px;left:457px;white-space:nowrap" class="ft232">N=106 to 109*</p>
<p style="position:absolute;top:339px;left:661px;white-space:nowrap" class="ft232">Enbrel</p>
<p style="position:absolute;top:358px;left:633px;white-space:nowrap" class="ft232">N=103 to 105*</p>
<p style="position:absolute;top:378px;left:141px;white-space:nowrap" class="ft232">ASAS** 40</p>
<p style="position:absolute;top:378px;left:493px;white-space:nowrap" class="ft232">15.7</p>
<p style="position:absolute;top:378px;left:666px;white-space:nowrap" class="ft232">32.4b</p>
<p style="position:absolute;top:398px;left:141px;white-space:nowrap" class="ft232">ASAS 20</p>
<p style="position:absolute;top:398px;left:493px;white-space:nowrap" class="ft232">36.1</p>
<p style="position:absolute;top:398px;left:666px;white-space:nowrap" class="ft232">52.4c</p>
<p style="position:absolute;top:417px;left:141px;white-space:nowrap" class="ft232">ASAS 5/6</p>
<p style="position:absolute;top:417px;left:493px;white-space:nowrap" class="ft232">10.4</p>
<p style="position:absolute;top:417px;left:666px;white-space:nowrap" class="ft232">33.0a</p>
<p style="position:absolute;top:437px;left:141px;white-space:nowrap" class="ft232">ASAS partial remission</p>
<p style="position:absolute;top:437px;left:493px;white-space:nowrap" class="ft232">11.9</p>
<p style="position:absolute;top:437px;left:666px;white-space:nowrap" class="ft232">24.8c</p>
<p style="position:absolute;top:457px;left:141px;white-space:nowrap" class="ft232">BASDAI***50</p>
<p style="position:absolute;top:457px;left:493px;white-space:nowrap" class="ft232">23.9</p>
<p style="position:absolute;top:457px;left:666px;white-space:nowrap" class="ft232">43.8b</p>
<p style="position:absolute;top:477px;left:149px;white-space:nowrap" class="ft234">*Some patients did not provide complete data for each endpoint<br/>**ASAS=Assessments in Spondyloarthritis International Society<br/>***Bath Ankylosing Spondylitis Disease Activity Index<br/>a: p&#160;&lt;0.001,&#160;b:&lt;0.01 and&#160;c:&lt;0.05,&#160;respectively between&#160;Enbrel and placebo</p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft234">At week&#160;12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis&#160;<br/>Research Consortium of Canada) score&#160;for the sacroiliac joint&#160;(SIJ)&#160;as measured by MRI for patients<br/>receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8&#160;<br/>for placebo treated (n=105) patients (p&lt;0.001).&#160;At week&#160;104, the mean change from baseline in the&#160;<br/>SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and&#160;<br/>1.40&#160;the spine (n=154).</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft234">Enbrel showed statistically significantly greater improvement&#160;from baseline to week 12 compared to&#160;<br/>placebo&#160;in&#160;most health-related quality of life and physical function assessments, including&#160;BASFI<br/>(Bath Ankylosing Spondylitis Functional Index),&#160;EuroQol 5D&#160;Overall Health State Score and SF-36&#160;<br/>Physical Component Score.</p>
<p style="position:absolute;top:799px;left:106px;white-space:nowrap" class="ft234">Clinical responses among&#160;nr-AxSpa&#160;patients who received Enbrel were apparent at the time of the first&#160;<br/>visit (2&#160;weeks) and were maintained through&#160;2&#160;years&#160;of therapy.&#160;Improvements in health-related&#160;<br/>quality of life and physical function&#160;were also maintained through 2&#160;years of therapy. The 2&#160;year data&#160;<br/>did not reveal any new safety findings.&#160;At week&#160;104, 8&#160;subjects had progressed to a score of bilateral&#160;<br/>Grade&#160;2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial&#160;<br/>spondyloarthropathy.</p>
<p style="position:absolute;top:932px;left:106px;white-space:nowrap" class="ft234"><i>Study 2<br/></i>This multi-center, open-label,&#160;phase 4,&#160;3-period study evaluated the withdrawal and retreatment of&#160;<br/>Enbrel&#160;in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined&#160;<br/>as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive&#160;protein (CRP) less than 1.3)&#160;<br/>following 24&#160;weeks of treatment.&#160;</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft233">209&#160;adult patients with active nr-AxSpa (18 to 49&#160;years of age), defined as those patients meeting the&#160;<br/>Assessment of SpondyloArthritis&#160;International Society (ASAS) classification criteria of axial&#160;<br/>spondyloarthritis (but not meeting the modified New York criteria for AS), having&#160;positive&#160;MRI&#160;<br/>findings (active inflammation on MRI highly suggestive of&#160;sacroiliitis&#160;associated with SpA) and/or&#160;<br/>positive hsCRP (defined as high sensitivity C-reactive protein&#160;[hsCRP]&#160;&gt;&#160;3&#160;mg/l), and&#160;active&#160;<br/>symptoms defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received&#160;<br/>open-label Enbrel 50&#160;mg weekly&#160;plus stable background NSAID at the optimal tolerated&#160;</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page24-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft240">24</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft244">anti-inflammatory dosage&#160;for 24&#160;weeks in Period 1. Patients were also required to have an inadequate&#160;<br/>response or intolerance to two or more NSAIDs. At week&#160;24, 119 (57%) patients achieved inactive&#160;<br/>disease and entered into the Period&#160;2&#160;40-week withdrawal phase&#160;where subjects discontinued&#160;<br/>etanercept, yet maintained the background NSAID. The&#160;primary measure of efficacy was the&#160;<br/>occurrence of flare (defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal&#160;<br/>to 2.1) within 40&#160;weeks following withdrawal of Enbrel. Patients who flared were retreated with&#160;<br/>Enbrel 50&#160;mg weekly for 12&#160;weeks (Period 3).</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft243">In Period&#160;2, the proportion of patients experiencing&#160;≥1 flare increased from 22% (25/112) at week 4 to&#160;<br/>67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within&#160;<br/>40&#160;weeks following withdrawal of Enbrel.&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft244">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and&#160;<br/>additionally&#160;compare&#160;the time to flare to&#160;patients from Study 1 who met the Study&#160;2&#160;withdrawal phase&#160;<br/>entry requirements and continued Enbrel therapy.&#160;</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft243">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24&#160;weeks).&#160;Less&#160;<br/>than 25% of patients in Study&#160;1 who did not have treatment withdrawn experienced a flare&#160;over the&#160;<br/>equivalent&#160;40-weeks&#160;as in&#160;Period 2&#160;Study 2. The time to flare was statistically significantly shorter in&#160;<br/>subjects who discontinued&#160;Enbrel&#160;treatment (Study 2) compared to subjects who received continuous&#160;<br/>etanercept treatment (Study 1), p&lt;0.0001.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft244">Of the 87&#160;patients who entered Period 3 and were retreated with Enbrel 50&#160;mg weekly for 12&#160;weeks,&#160;<br/>62% (54/87) reachieved inactive disease,&#160;with 50%&#160;of them&#160;reachieving&#160;it&#160;within 5&#160;weeks (95% CI:&#160;<br/>4-8&#160;weeks).</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft243"><i>Adult patients with plaque psoriasis<br/></i>Enbrel is recommended for use in patients as defined in section 4.1. Patients who “failed to respond&#160;<br/>to” in the target population is defined by insufficient response (PASI&lt;50 or PGA less than good), or&#160;<br/>worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long&#160;<br/>duration to assess response with at least&#160;one&#160;of the three major systemic therapies as available.</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft243">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis&#160;<br/>(responsive to&#160;other systemic therapies) has not been evaluated in studies directly comparing Enbrel&#160;<br/>with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four&#160;<br/>randomised, double-blind, placebo-controlled studies. The primary efficacy&#160;endpoint in all four studies&#160;<br/>was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75%&#160;<br/>improvement in the Psoriasis Area and Severity Index score from baseline) at 12&#160;weeks.</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft248">Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving&#160;<br/>&#160;10% of the body surface area who were&#160;&#160;18 years old. One hundred and twelve (112) patients were&#160;<br/>randomised to receive a dose of 25&#160;mg of Enbrel (n=57) or placebo (n=55) twice a week for&#160;24&#160;weeks.</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft244">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study&#160;<br/>1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel&#160;<br/>was administered at doses of 25&#160;mg once&#160;a week, 25&#160;mg twice a week or 50&#160;mg twice a week for&#160;<br/>6&#160;consecutive months. During the first 12 weeks of the double-blind treatment period, patients&#160;<br/>received placebo or one of the above three Enbrel doses. After 12&#160;weeks of treatment, patients in the&#160;<br/>placebo group began treatment with blinded Enbrel (25&#160;mg twice a week); patients in the active&#160;<br/>treatment groups continued to week&#160;24 on the dose to which they were originally randomised.</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft244">Study&#160;3 evaluated 583 patients and had the same inclusion criteria as study&#160;2. Patients in this study&#160;<br/>received a dose of 25&#160;mg or 50&#160;mg Enbrel, or placebo twice a week for 12&#160;weeks and then all patients&#160;<br/>received open-label 25&#160;mg&#160;Enbrel twice weekly for an additional 24&#160;weeks.</p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page25-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft250">25</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft254">Study&#160;4 evaluated 142 patients and had similar inclusion criteria to studies&#160;2 and 3. Patients in this&#160;<br/>study received a dose of 50&#160;mg Enbrel or placebo once weekly for 12&#160;weeks and then all patients&#160;<br/>received open-label 50&#160;mg&#160;Enbrel once weekly for an additional 12&#160;weeks.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft254">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75&#160;<br/>response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;0.0001). At 24 weeks,&#160;<br/>56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of&#160;<br/>placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</p>
<p style="position:absolute;top:278px;left:262px;white-space:nowrap" class="ft251"><b>Responses of Patients with Psoriasis in Studies 2, 3 and 4</b></p>
<p style="position:absolute;top:416px;left:118px;white-space:nowrap" class="ft252">Respons</p>
<p style="position:absolute;top:435px;left:127px;white-space:nowrap" class="ft252">e (%)</p>
<p style="position:absolute;top:299px;left:273px;white-space:nowrap" class="ft252">Study 2</p>
<p style="position:absolute;top:299px;left:489px;white-space:nowrap" class="ft252">Study 3</p>
<p style="position:absolute;top:299px;left:691px;white-space:nowrap" class="ft252">Study 4</p>
<p style="position:absolute;top:357px;left:191px;white-space:nowrap" class="ft252">Placebo</p>
<p style="position:absolute;top:320px;left:262px;white-space:nowrap" class="ft252">----------Enbrel---------</p>
<p style="position:absolute;top:357px;left:421px;white-space:nowrap" class="ft252">Placebo</p>
<p style="position:absolute;top:320px;left:488px;white-space:nowrap" class="ft252">--------Enbrel-------</p>
<p style="position:absolute;top:357px;left:623px;white-space:nowrap" class="ft252">Placebo</p>
<p style="position:absolute;top:320px;left:696px;white-space:nowrap" class="ft252">-------Enbrel------</p>
<p style="position:absolute;top:339px;left:270px;white-space:nowrap" class="ft252">25&#160;mg&#160;</p>
<p style="position:absolute;top:357px;left:275px;white-space:nowrap" class="ft252">BIW</p>
<p style="position:absolute;top:339px;left:351px;white-space:nowrap" class="ft252">50&#160;mg&#160;</p>
<p style="position:absolute;top:357px;left:356px;white-space:nowrap" class="ft252">BIW</p>
<p style="position:absolute;top:339px;left:493px;white-space:nowrap" class="ft252">25&#160;mg</p>
<p style="position:absolute;top:357px;left:497px;white-space:nowrap" class="ft252">BIW</p>
<p style="position:absolute;top:339px;left:561px;white-space:nowrap" class="ft252">50&#160;mg</p>
<p style="position:absolute;top:357px;left:565px;white-space:nowrap" class="ft252">BIW</p>
<p style="position:absolute;top:339px;left:696px;white-space:nowrap" class="ft252">50&#160;mg&#160;</p>
<p style="position:absolute;top:357px;left:702px;white-space:nowrap" class="ft252">QW</p>
<p style="position:absolute;top:339px;left:763px;white-space:nowrap" class="ft252">50&#160;mg</p>
<p style="position:absolute;top:357px;left:769px;white-space:nowrap" class="ft252">QW</p>
<p style="position:absolute;top:377px;left:192px;white-space:nowrap" class="ft252">n = 166</p>
<p style="position:absolute;top:395px;left:196px;white-space:nowrap" class="ft252">wk 12</p>
<p style="position:absolute;top:377px;left:260px;white-space:nowrap" class="ft252">n =&#160;</p>
<p style="position:absolute;top:395px;left:258px;white-space:nowrap" class="ft252">162</p>
<p style="position:absolute;top:414px;left:260px;white-space:nowrap" class="ft252">wk&#160;</p>
<p style="position:absolute;top:433px;left:262px;white-space:nowrap" class="ft252">12</p>
<p style="position:absolute;top:377px;left:300px;white-space:nowrap" class="ft252">n =&#160;</p>
<p style="position:absolute;top:395px;left:298px;white-space:nowrap" class="ft252">162</p>
<p style="position:absolute;top:414px;left:301px;white-space:nowrap" class="ft254">wk&#160;<br/>24a</p>
<p style="position:absolute;top:377px;left:341px;white-space:nowrap" class="ft252">n =&#160;</p>
<p style="position:absolute;top:395px;left:339px;white-space:nowrap" class="ft252">164</p>
<p style="position:absolute;top:414px;left:341px;white-space:nowrap" class="ft252">wk&#160;</p>
<p style="position:absolute;top:433px;left:343px;white-space:nowrap" class="ft252">12</p>
<p style="position:absolute;top:377px;left:381px;white-space:nowrap" class="ft252">n =&#160;</p>
<p style="position:absolute;top:395px;left:379px;white-space:nowrap" class="ft252">164</p>
<p style="position:absolute;top:414px;left:382px;white-space:nowrap" class="ft254">wk&#160;<br/>24a</p>
<p style="position:absolute;top:377px;left:422px;white-space:nowrap" class="ft252">n = 193</p>
<p style="position:absolute;top:395px;left:426px;white-space:nowrap" class="ft252">wk 12</p>
<p style="position:absolute;top:377px;left:489px;white-space:nowrap" class="ft252">n = 196</p>
<p style="position:absolute;top:395px;left:493px;white-space:nowrap" class="ft252">wk 12</p>
<p style="position:absolute;top:377px;left:557px;white-space:nowrap" class="ft252">n = 196</p>
<p style="position:absolute;top:395px;left:561px;white-space:nowrap" class="ft252">wk 12</p>
<p style="position:absolute;top:377px;left:628px;white-space:nowrap" class="ft252">n = 46</p>
<p style="position:absolute;top:395px;left:628px;white-space:nowrap" class="ft252">wk 12</p>
<p style="position:absolute;top:377px;left:695px;white-space:nowrap" class="ft252">n = 96</p>
<p style="position:absolute;top:395px;left:696px;white-space:nowrap" class="ft252">wk 12</p>
<p style="position:absolute;top:377px;left:763px;white-space:nowrap" class="ft252">n = 90</p>
<p style="position:absolute;top:395px;left:761px;white-space:nowrap" class="ft252">wk 24a</p>
<p style="position:absolute;top:455px;left:114px;white-space:nowrap" class="ft252">PASI 50</p>
<p style="position:absolute;top:455px;left:208px;white-space:nowrap" class="ft252">14</p>
<p style="position:absolute;top:455px;left:258px;white-space:nowrap" class="ft252">58*</p>
<p style="position:absolute;top:455px;left:302px;white-space:nowrap" class="ft252">70</p>
<p style="position:absolute;top:455px;left:339px;white-space:nowrap" class="ft252">74*</p>
<p style="position:absolute;top:455px;left:383px;white-space:nowrap" class="ft252">77</p>
<p style="position:absolute;top:455px;left:441px;white-space:nowrap" class="ft252">9</p>
<p style="position:absolute;top:455px;left:501px;white-space:nowrap" class="ft252">64*</p>
<p style="position:absolute;top:455px;left:568px;white-space:nowrap" class="ft252">77*</p>
<p style="position:absolute;top:455px;left:644px;white-space:nowrap" class="ft252">9</p>
<p style="position:absolute;top:455px;left:703px;white-space:nowrap" class="ft252">69*</p>
<p style="position:absolute;top:455px;left:775px;white-space:nowrap" class="ft252">83</p>
<p style="position:absolute;top:476px;left:114px;white-space:nowrap" class="ft252">PASI 75</p>
<p style="position:absolute;top:476px;left:212px;white-space:nowrap" class="ft252">4</p>
<p style="position:absolute;top:476px;left:258px;white-space:nowrap" class="ft252">34*</p>
<p style="position:absolute;top:476px;left:302px;white-space:nowrap" class="ft252">44</p>
<p style="position:absolute;top:476px;left:339px;white-space:nowrap" class="ft252">49*</p>
<p style="position:absolute;top:476px;left:383px;white-space:nowrap" class="ft252">59</p>
<p style="position:absolute;top:476px;left:441px;white-space:nowrap" class="ft252">3</p>
<p style="position:absolute;top:476px;left:501px;white-space:nowrap" class="ft252">34*</p>
<p style="position:absolute;top:476px;left:568px;white-space:nowrap" class="ft252">49*</p>
<p style="position:absolute;top:476px;left:644px;white-space:nowrap" class="ft252">2</p>
<p style="position:absolute;top:476px;left:703px;white-space:nowrap" class="ft252">38*</p>
<p style="position:absolute;top:476px;left:775px;white-space:nowrap" class="ft252">71</p>
<p style="position:absolute;top:501px;left:114px;white-space:nowrap" class="ft254">DSGAb,&#160;<br/>clear or&#160;<br/>almost&#160;<br/>clear</p>
<p style="position:absolute;top:558px;left:212px;white-space:nowrap" class="ft252">5</p>
<p style="position:absolute;top:558px;left:258px;white-space:nowrap" class="ft252">34*</p>
<p style="position:absolute;top:558px;left:302px;white-space:nowrap" class="ft252">39</p>
<p style="position:absolute;top:558px;left:339px;white-space:nowrap" class="ft252">49*</p>
<p style="position:absolute;top:558px;left:383px;white-space:nowrap" class="ft252">55</p>
<p style="position:absolute;top:558px;left:441px;white-space:nowrap" class="ft252">4</p>
<p style="position:absolute;top:558px;left:501px;white-space:nowrap" class="ft252">39*</p>
<p style="position:absolute;top:558px;left:568px;white-space:nowrap" class="ft252">57*</p>
<p style="position:absolute;top:558px;left:644px;white-space:nowrap" class="ft252">4</p>
<p style="position:absolute;top:558px;left:703px;white-space:nowrap" class="ft252">39*</p>
<p style="position:absolute;top:558px;left:775px;white-space:nowrap" class="ft252">64</p>
<p style="position:absolute;top:579px;left:114px;white-space:nowrap" class="ft252">*p&#160;</p>
<p style="position:absolute;top:577px;left:135px;white-space:nowrap" class="ft2514">&#160;0.0001 compared with placebo</p>
<p style="position:absolute;top:598px;left:114px;white-space:nowrap" class="ft254">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4&#160;because the original&#160;<br/>placebo group began receiving Enbrel 25&#160;mg BIW or 50&#160;mg once weekly from week 13 to week 24.<br/>b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft254">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo&#160;<br/>were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft258">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement&#160;<br/>of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the&#160;<br/>occurrence of rebound (PASI&#160;</p>
<p style="position:absolute;top:768px;left:304px;white-space:nowrap" class="ft2514">150% of baseline) and for the time to relapse (defined as a loss of at&#160;</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft254">least half of the improvement achieved between baseline and week 24). During the withdrawal period,&#160;<br/>symptoms of psoriasis gradually returned, with a median time to disease relapse of 3 months. No&#160;<br/>rebound flare of disease and no psoriasis-related serious adverse events were observed. There was&#160;<br/>some evidence to&#160;support a benefit of re-treatment with Enbrel in patients initially responding to&#160;<br/>treatment.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft254">In study 3, the majority of patients (77%) who were initially randomised to 50&#160;mg twice weekly and&#160;<br/>had their Enbrel dose decreased at week 12 to 25&#160;mg twice weekly maintained their PASI 75 response&#160;<br/>through week 36. For patients who received 25&#160;mg twice weekly throughout the study, the PASI 75&#160;<br/>response continued to improve between weeks 12 and 36.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft254">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12&#160;<br/>(38%) compared to the placebo-treated group (2%) (p&lt;&#160;0.0001). For patients who received 50&#160;mg once&#160;<br/>weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI&#160;<br/>75 at week 24.</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft254">In long-term&#160;(up to 34&#160;months) open-label studies where Enbrel was given without interruption,&#160;<br/>clinical responses were sustained and safety was comparable to shorter-term studies.</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page26-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft260">26</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft263">An analysis of clinical trial data&#160;did not reveal any&#160;baseline disease characteristics&#160;that would assist&#160;<br/>clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently,&#160;<br/>the choice of intermittent or continuous therapy should be based upon physician judgment and&#160;<br/>individual patient needs.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft263"><i>Antibodies to Enbrel<br/></i>Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept.&#160;<br/>These antibodies have all been non-neutralising and are generally transient. There appears to be no&#160;<br/>correlation between antibody development and clinical response or adverse events.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft264">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative&#160;<br/>rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5%&#160;<br/>of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with&#160;<br/>psoriasis, 9.7% of subjects with paediatric psoriasis, and&#160;4.8% of subjects with juvenile idiopathic&#160;<br/>arthritis.&#160;</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft264">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to&#160;<br/>3.5&#160;years) increases over time, as expected. However, due to their transient nature, the incidence of&#160;<br/>antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis&#160;<br/>subjects and psoriasis subjects.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft264">In a long-term psoriasis study in which patients received 50&#160;mg twice weekly for 96&#160;weeks, the&#160;<br/>incidence of antibodies observed at each assessment point was up to approximately 9%.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft262">Paediatric population</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft268"><i>Paediatric patients with juvenile&#160;idiopathic arthritis<br/></i>The safety and efficacy of Enbrel were assessed in a two-part study in&#160;69 children with&#160;<br/>polyarticular-course&#160;juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset&#160;<br/>types&#160;(polyarthritis, pauciarthritis, systemic onset).&#160;Patients aged 4 to 17&#160;years with moderately to&#160;<br/>severely active polyarticular-course&#160;juvenile idiopathic arthritis refractory to, or intolerant of,&#160;<br/>methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal&#160;<br/>anti-inflammatory drug and/or prednisone (&lt;&#160;0.2&#160;mg/kg/day or 10&#160;mg maximum). In part 1, all patients&#160;<br/>received 0.4&#160;mg/kg (maximum 25&#160;mg per dose) Enbrel subcutaneously twice weekly. In part 2,&#160;<br/>patients with a clinical response at day 90 were randomised to remain&#160;on Enbrel or receive placebo for&#160;<br/>four months and assessed for disease flare. Responses were measured using the&#160;ACR Pedi 30&#160;, defined&#160;<br/>as&#160;</p>
<p style="position:absolute;top:792px;left:124px;white-space:nowrap" class="ft2614">&#160;30% improvement in at least three of six and&#160;&#160;30% worsening in no more than one of six JRA&#160;</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft268">core set criteria, including active joint count, limitation of motion, physician and patient/parent global&#160;<br/>assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was&#160;<br/>defined as a&#160;</p>
<p style="position:absolute;top:850px;left:189px;white-space:nowrap" class="ft2614">&#160;30% worsening in three of six JRA core set criteria and&#160;&#160;30% improvement in not&#160;</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft262">more than one of the six JRA core set criteria and a minimum of two active joints.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft264">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In&#160;<br/>part 2, 6&#160;of 25 (24%) patients remaining on Enbrel&#160;experienced a disease flare compared to 20 of&#160;<br/>26&#160;(77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was&#160;</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft263">&#160;116&#160;days for patients who received Enbrel and 28 days for patients who received placebo. Of&#160;<br/>patients who&#160;demonstrated a clinical response at 90 days and entered part 2 of the study, some of the&#160;<br/>patients remaining on Enbrel continued to improve from month 3 through month 7, while those who&#160;<br/>received placebo did not improve.</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft264">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of&#160;<br/>4&#160;years at time of enrollment) continued to receive Enbrel for up to 10 years.&#160;Rates of serious adverse&#160;<br/>events and serious infections did not increase with long-term&#160;exposure.</p>
<p style="position:absolute;top:1138px;left:106px;white-space:nowrap" class="ft264">Long-term&#160;safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate&#160;<br/>monotherapy (n=197) were assessed for up to 3&#160;years in a registry of 594 children aged 2 to 18&#160;years&#160;</p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page27-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft270">27</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft274">with juvenile idiopathic arthritis, 39 of whom were 2 to 3&#160;years of&#160;age. Overall, infections were more&#160;<br/>commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus&#160;<br/>2%), and the infections associated with etanercept use were of a more severe nature.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft274">In another open-label&#160;single-arm&#160;study&#160;(n=127),&#160;60&#160;patients with extended oligoarthritis&#160;(EO)&#160;<br/>(15&#160;patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged&#160;12 to 17 years old),&#160;38 patients&#160;<br/>with&#160;enthesitis-related arthritis (12 to 17 years old),&#160;and 29 patients with&#160;psoriatic&#160;arthritis (12 to&#160;<br/>17&#160;years old) were treated with Enbrel at a dose of 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose)&#160;<br/>administered weekly for 12&#160;weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi&#160;<br/>30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender&#160;<br/>joints and physician global assessment. The safety profile was consistent with that observed in other&#160;<br/>JIA studies.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft273">Of the 127&#160;patients in the parent study, 109 participated in the open-label extension study and were&#160;<br/>followed for&#160;an additional&#160;8 years&#160;for a total of up to 10 years.&#160;At the end of the extension study,&#160;<br/>84/109 (77%) patients had completed the study; 27 (25%) while actively taking&#160;Enbrel, 7 (6%) had&#160;<br/>withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started&#160;Enbrel&#160;following an&#160;<br/>earlier withdrawal from treatment; and 45 (41%) had stopped&#160;Enbrel&#160;(but remained under&#160;<br/>observation);&#160;25/109 (23%) patients&#160;permanently discontinued from the&#160;study.&#160;Improvements in&#160;<br/>clinical status achieved in the parent study were generally maintained for all efficacy endpoints during&#160;<br/>the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-<br/>retreatment period once during the extension study based on investigator’s judgement of clinical&#160;<br/>response. 30&#160;patients entered the withdrawal period. 17&#160;patients were reported to have a flare (defined&#160;<br/>as&#160;≥&#160;30% worsening in at least 3 of the 6 ACR Pedi components with&#160;≥&#160;30% improvement in not more&#160;<br/>than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after&#160;<br/>Enbrel withdrawal was 190&#160;days. 13&#160;patients were&#160;re-treated and the median time to re-treatment from&#160;<br/>withdrawal was estimated as 274&#160;days. Due to the small number of data points, these&#160;results should be&#160;<br/>interpreted with caution.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft272">The safety profile was consistent with that observed in&#160;the parent study.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft274">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of&#160;<br/>continued Enbrel therapy in patients&#160;who do not respond within 3 months of initiating Enbrel therapy.&#160;<br/>Additionally, studies have not been conducted to assess&#160;the effects of&#160;reducing the recommended dose&#160;<br/>of Enbrel following its long-term&#160;use in patients with JIA.</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft273"><i>Paediatric patients with plaque psoriasis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211&#160;<br/>paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA&#160;<br/>score&#160;≥&#160;3, involving&#160;≥&#160;10% of the BSA, and PASI&#160;≥&#160;12). Eligible patients had a history of receiving&#160;<br/>phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft273">Patients received Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) or placebo once weekly for 12 weeks. At week 12,&#160;<br/>more patients randomised to Enbrel had positive efficacy responses (e.g., PASI 75) than those&#160;<br/>randomised to placebo.</p>
<p style="position:absolute;top:995px;left:261px;white-space:nowrap" class="ft271"><b>Paediatric Plaque Psoriasis Outcomes at 12 Weeks</b></p>
<p style="position:absolute;top:1023px;left:495px;white-space:nowrap" class="ft271"><b>Enbrel</b></p>
<p style="position:absolute;top:1043px;left:465px;white-space:nowrap" class="ft271"><b>0.8&#160;mg/kg Once&#160;</b></p>
<p style="position:absolute;top:1061px;left:493px;white-space:nowrap" class="ft271"><b>Weekly</b></p>
<p style="position:absolute;top:1080px;left:487px;white-space:nowrap" class="ft271"><b>(N = 106)</b></p>
<p style="position:absolute;top:1061px;left:647px;white-space:nowrap" class="ft271"><b>Placebo</b></p>
<p style="position:absolute;top:1080px;left:642px;white-space:nowrap" class="ft271"><b>(N = 105)</b></p>
<p style="position:absolute;top:1100px;left:136px;white-space:nowrap" class="ft272">PASI 75, n (%)</p>
<p style="position:absolute;top:1100px;left:486px;white-space:nowrap" class="ft272">60 (57%)a</p>
<p style="position:absolute;top:1100px;left:644px;white-space:nowrap" class="ft272">12 (11%)</p>
<p style="position:absolute;top:1119px;left:136px;white-space:nowrap" class="ft272">PASI&#160;50, n (%)</p>
<p style="position:absolute;top:1119px;left:486px;white-space:nowrap" class="ft272">79 (75%)a</p>
<p style="position:absolute;top:1119px;left:644px;white-space:nowrap" class="ft272">24 (23%)</p>
<p style="position:absolute;top:1151px;left:136px;white-space:nowrap" class="ft272">sPGA “clear” or “minimal”, n (%)</p>
<p style="position:absolute;top:1151px;left:486px;white-space:nowrap" class="ft272">56&#160;(53%)a</p>
<p style="position:absolute;top:1151px;left:644px;white-space:nowrap" class="ft272">14 (13%)</p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page28-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft280">28</p>
<p style="position:absolute;top:108px;left:136px;white-space:nowrap" class="ft284">Abbreviation: sPGA-static Physician Global Assessment<br/>a.&#160;p &lt; 0.0001 compared with placebo</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft283">After the 12-week double-blind treatment period, all patients received Enbrel&#160;0.8&#160;mg/kg (up to 50&#160;mg)&#160;<br/>once weekly for additional 24 weeks. Responses observed during the open-label period were similar to&#160;<br/>those observed in the double-blind period.</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft284">During a randomised withdrawal period, significantly more patients re-randomised to&#160;placebo&#160;<br/>experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to&#160;<br/>Enbrel. With continued therapy, responses were maintained up to 48 weeks.</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft284">The long-term safety and effectiveness of Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) once&#160;weekly was assessed&#160;<br/>in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years&#160;<br/>beyond the 48 week study discussed above. Long-term experience with Enbrel was generally&#160;<br/>comparable to the original 48-week study and did not reveal any new safety findings.&#160;</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft281"><b>5.2</b></p>
<p style="position:absolute;top:414px;left:149px;white-space:nowrap" class="ft281"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:452px;left:106px;white-space:nowrap" class="ft284">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA)&#160;<br/>method, which may detect ELISA-reactive degradation products, as well as the parent compound.</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft282">Absorption</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft288">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum&#160;<br/>concentration approximately 48&#160;hours after a single dose. The absolute bioavailability is 76%. With&#160;<br/>twice-weekly doses, it is anticipated that steady-state&#160;concentrations are approximately twice as high&#160;<br/>as those observed after single doses. After a single subcutaneous dose of 25&#160;mg Enbrel, the average&#160;<br/>maximum serum concentration observed in healthy volunteers was 1.65&#160;</p>
<p style="position:absolute;top:622px;left:585px;white-space:nowrap" class="ft2814">&#160;0.66&#160;g/ml, and the area&#160;</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft282">under the curve was 235</p>
<p style="position:absolute;top:642px;left:272px;white-space:nowrap" class="ft2814">&#160;96.6&#160;ghr/ml.&#160;</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft284">Mean serum concentration profiles at steady state in treated RA patients were Cmax&#160;of 2.4&#160;mg/l vs.&#160;<br/>2.6&#160;mg/l, Cmin&#160;of 1.2&#160;mg/l vs. 1.4&#160;mg/l, and partial AUC of 297&#160;mgh/l vs. 316&#160;mgh/l for 50&#160;mg Enbrel&#160;<br/>once weekly (n=21) vs.&#160;25&#160;mg Enbrel twice weekly (n=16), respectively. In an open-label, single-<br/>dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single&#160;<br/>50&#160;mg/ml injection was found to be bioequivalent to two simultaneous injections of 25&#160;mg/ml.</p>
<p style="position:absolute;top:796px;left:106px;white-space:nowrap" class="ft288">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady&#160;<br/>state AUCs were 466</p>
<p style="position:absolute;top:814px;left:251px;white-space:nowrap" class="ft2814">ghr/ml and 474&#160;ghr/ml for 50&#160;mg Enbrel once weekly (N= 154) and 25&#160;mg&#160;</p>
<p style="position:absolute;top:835px;left:106px;white-space:nowrap" class="ft282">twice weekly (N = 148), respectively.</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft282">Distribution</p>
<p style="position:absolute;top:911px;left:106px;white-space:nowrap" class="ft283">A&#160;biexponential curve is required to describe the concentration time curve of etanercept. The central&#160;<br/>volume of distribution of etanercept is 7.6&#160;l, while the volume of distribution at steady-state is 10.4&#160;l.</p>
<p style="position:absolute;top:968px;left:106px;white-space:nowrap" class="ft282">Elimination</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft284">Etanercept is cleared slowly from the body. The half-life is long, approximately 70&#160;hours. Clearance is&#160;<br/>approximately 0.066&#160;l/hr in patients with rheumatoid arthritis, somewhat lower than the value of&#160;<br/>0.11&#160;l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in&#160;rheumatoid&#160;<br/>arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</p>
<p style="position:absolute;top:1101px;left:106px;white-space:nowrap" class="ft282">There is no apparent pharmacokinetic difference between males and females.</p>
<p style="position:absolute;top:1139px;left:106px;white-space:nowrap" class="ft282">Linearity</p>
</div>
<!-- Page 29 -->
<a name="29"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page29-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft290">29</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft294">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance&#160;<br/>across the dosing range.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft292">Special populations</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft293"><i>Renal impairment<br/></i>Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept&#160;<br/>to patients and volunteers, increased etanercept&#160;concentrations were not observed in patients with&#160;<br/>acute renal failure. The presence of renal impairment should not require a change in dosage.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft294"><i>Hepatic impairment<br/></i>Increased etanercept concentrations were not observed in patients with acute hepatic failure.&#160;The&#160;<br/>presence of hepatic impairment should not require a change in dosage.</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft294"><i>Elderly<br/></i>The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept&#160;<br/>serum concentrations. Clearance and volume estimates in patients aged 65 to&#160;87 years were similar to&#160;<br/>estimates in patients less than 65 years of age.</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft292">Paediatric population</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft293"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>In a polyarticular-course&#160;juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged&#160;4 to 17&#160;years)&#160;<br/>were administered 0.4&#160;mg&#160;Enbrel/kg twice weekly for three months. Serum concentration profiles&#160;<br/>were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age)&#160;<br/>had reduced clearance (increased clearance when&#160;normalised by weight) compared with older children&#160;<br/>(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of&#160;<br/>age) will have serum levels close to those seen in adults, younger children will have appreciably lower<br/>levels.</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft294"><i>Paediatric patients with plaque psoriasis<br/></i>Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8&#160;mg/kg (up to a&#160;<br/>maximum dose of 50&#160;mg per week) of etanercept once weekly for up to 48 weeks. The mean serum&#160;<br/>steady-state trough concentrations ranged from 1.6&#160;to 2.1&#160;mcg/ml at weeks 12, 24, and 48. These mean&#160;<br/>concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed&#160;<br/>in patients with&#160;juvenile idiopathic arthritis&#160;(treated with 0.4&#160;mg/kg etanercept twice weekly, up to&#160;<br/>maximum dose of 50&#160;mg per week). These mean concentrations were similar to those seen in adult&#160;<br/>patients with plaque psoriasis treated with 25&#160;mg etanercept twice-weekly.</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft291"><b>5.3</b></p>
<p style="position:absolute;top:850px;left:149px;white-space:nowrap" class="ft291"><b>Preclinical safety data</b></p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft294">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel&#160;<br/>was considered to be non-genotoxic from a battery of&#160;<i>in vitro&#160;</i>and&#160;<i>in vivo&#160;</i>studies. Carcinogenicity&#160;<br/>studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel&#160;<br/>due to the development of neutralising antibodies in rodents.</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft294">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single&#160;<br/>subcutaneous dose of 2000&#160;mg/kg or a single intravenous dose of&#160;1000&#160;mg/kg. Enbrel did not elicit&#160;<br/>dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous&#160;<br/>administration for 4 or 26&#160;consecutive weeks at a dose (15&#160;mg/kg) that resulted in AUC-based serum&#160;<br/>drug concentrations that were over 27-fold higher than that obtained in humans at the recommended&#160;<br/>dose of 25&#160;mg.</p>
</div>
<!-- Page 30 -->
<a name="30"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page30-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft300">30</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft301"><b>6.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft301"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft301"><b>6.1</b></p>
<p style="position:absolute;top:146px;left:149px;white-space:nowrap" class="ft301"><b>List of excipients</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft302">Powder</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft303">Mannitol&#160;(E421)<br/>Sucrose<br/>Trometamol</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft301"><b>6.2</b></p>
<p style="position:absolute;top:297px;left:149px;white-space:nowrap" class="ft301"><b>Incompatibilities</b></p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft303">In the absence of compatibility studies, this&#160;medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft301"><b>6.3</b></p>
<p style="position:absolute;top:392px;left:149px;white-space:nowrap" class="ft301"><b>Shelf life</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft302">4&#160;years.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft308">Chemical and physical in-use stability has been demonstrated for 6&#160;hours at temperatures of up to&#160;<br/>25</p>
<p style="position:absolute;top:487px;left:123px;white-space:nowrap" class="ft3014">C after reconstitution. From a microbiological point of view, the reconstituted medicinal product&#160;</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft308">should be used immediately. If not used immediately, storage times and conditions prior to use are the&#160;<br/>responsibility of the user and would normally not be longer than 6&#160;hours at temperatures of up to&#160;<br/>25</p>
<p style="position:absolute;top:545px;left:123px;white-space:nowrap" class="ft3014">C, unless reconstitution has taken place in controlled and validated aseptic conditions.</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft301"><b>6.4</b></p>
<p style="position:absolute;top:585px;left:149px;white-space:nowrap" class="ft301"><b>Special precautions for storage</b></p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft302">Store in a refrigerator (2</p>
<p style="position:absolute;top:622px;left:267px;white-space:nowrap" class="ft3014">C&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft302">Enbrel may be stored at temperatures up to a maximum of 25</p>
<p style="position:absolute;top:661px;left:511px;white-space:nowrap" class="ft3014">C for a single period of up to&#160;four&#160;</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft303">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within&#160;<br/>four weeks of removal from refrigeration.</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft302">For storage conditions of the reconstituted medicinal product,&#160;see section 6.3.</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft301"><b>6.5</b></p>
<p style="position:absolute;top:777px;left:149px;white-space:nowrap" class="ft301"><b>Nature and contents&#160;of&#160;container</b></p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft303">Clear glass vial (2&#160;ml, type I glass) with rubber stoppers, aluminium seals, and flip-off plastic caps.&#160;<br/>Cartons contain 4 vials of Enbrel with 8 alcohol swabs.</p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft301"><b>6.6</b></p>
<p style="position:absolute;top:872px;left:149px;white-space:nowrap" class="ft301"><b>Special precautions for disposal and other handling</b></p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft302">Instructions for use and&#160;handling</p>
<p style="position:absolute;top:948px;left:106px;white-space:nowrap" class="ft304">Enbrel is reconstituted with 1&#160;ml water for injections before use and administered by subcutaneous&#160;<br/>injection. Enbrel contains no antibacterial preservative, and therefore, solutions prepared with water&#160;<br/>for injections should be administered as soon as possible and within 6&#160;hours following reconstitution.&#160;<br/>The solution should be clear and colourless to pale yellow&#160;or pale brown, with no lumps, flakes or&#160;<br/>particles. Some white foam may remain in the vial&#160;–&#160;this is normal. Enbrel should not be used if&#160;all the&#160;<br/>powder in the vial is not dissolved within 10 minutes. If this is the case, start again with another vial.</p>
<p style="position:absolute;top:1081px;left:106px;white-space:nowrap" class="ft304">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are&#160;<br/>given in the package leaflet, section&#160;7,&#160;“Instructions for preparation and giving an injection of Enbrel”.</p>
<p style="position:absolute;top:1138px;left:106px;white-space:nowrap" class="ft304">Any unused&#160;medicinal&#160;product or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
</div>
<!-- Page 31 -->
<a name="31"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page31-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft310">31</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft311"><b>7.</b></p>
<p style="position:absolute;top:146px;left:146px;white-space:nowrap" class="ft311"><b>MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft314">Pfizer Europe MA EEIG<br/>Boulevard de la&#160;Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft311"><b>8.</b></p>
<p style="position:absolute;top:297px;left:146px;white-space:nowrap" class="ft311"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft312">EU/1/99/126/002</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft311"><b>9.</b></p>
<p style="position:absolute;top:392px;left:146px;white-space:nowrap" class="ft311"><b>DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft313">Date of first authorisation:&#160;03 February 2000<br/>Date of last renewal:&#160;26&#160;November&#160;2009</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft311"><b>10.</b></p>
<p style="position:absolute;top:506px;left:146px;white-space:nowrap" class="ft311"><b>DATE OF REVISION OF THE TEXT</b></p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft314">Detailed information on this&#160;medicinal&#160;product is available on the website of the European Medicines&#160;<br/>Agency&#160;<a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</p>
</div>
<!-- Page 32 -->
<a name="32"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page32-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft320">32</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft321"><b>1.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft321"><b>NAME&#160;OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft322">Enbrel 25&#160;mg powder and&#160;solvent for solution for injection</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft321"><b>2.</b></p>
<p style="position:absolute;top:203px;left:146px;white-space:nowrap" class="ft321"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION</b></p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft322">Each vial contains 25&#160;mg of etanercept.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft323">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant&#160;<br/>DNA technology in a Chinese hamster ovary (CHO) mammalian expression system.&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft322">For&#160;the&#160;full list of excipients, see section 6.1.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft321"><b>3.</b></p>
<p style="position:absolute;top:392px;left:146px;white-space:nowrap" class="ft321"><b>PHARMACEUTICAL FORM</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft322">Powder and solvent for solution for injection (powder for injection).</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft322">The powder is white. The solvent is a clear, colourless liquid.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft321"><b>4.</b></p>
<p style="position:absolute;top:525px;left:146px;white-space:nowrap" class="ft321"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft321"><b>4.1</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft321"><b>Therapeutic indications</b></p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft322">Rheumatoid arthritis</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft323">Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active&#160;<br/>rheumatoid arthritis in adults when the response to disease-modifying&#160;antirheumatic drugs, including&#160;<br/>methotrexate (unless contraindicated), has been inadequate.</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft324">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued&#160;<br/>treatment with methotrexate is inappropriate.</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft324">Enbrel is also indicated&#160;in the treatment of severe, active and progressive rheumatoid arthritis in adults&#160;<br/>not previously treated with methotrexate.</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft324">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression&#160;<br/>of joint damage as measured by&#160;X-ray and to improve physical function.</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft322">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft323">Treatment of&#160;polyarthritis (rheumatoid factor positive or negative)&#160;and extended oligoarthritis&#160;in&#160;<br/>children and adolescents from the age of 2&#160;years who have had an inadequate response to, or who have&#160;<br/>proved intolerant of, methotrexate.&#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft324">Treatment of&#160;psoriatic arthritis in adolescents from the age of 12&#160;years who have had an inadequate&#160;<br/>response to, or who have proved intolerant of, methotrexate.</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft324">Treatment of enthesitis-related arthritis in adolescents from the age of 12&#160;years who have had an&#160;<br/>inadequate response to, or who have proved intolerant of, conventional therapy.</p>
</div>
<!-- Page 33 -->
<a name="33"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page33-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft330">33</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft332">Psoriatic arthritis</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft333">Treatment of active and progressive psoriatic arthritis in adults when the response to previous&#160;<br/>disease-modifying antirheumatic drug therapy has been inadequate.&#160;Enbrel has been shown to improve&#160;<br/>physical function in patients with psoriatic arthritis, and to reduce&#160;the rate of progression of peripheral<br/>joint damage as measured by X-ray in patients with&#160;polyarticular&#160;symmetrical subtypes of the disease.</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft332">Axial spondyloarthritis</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft333"><i>Ankylosing spondylitis&#160;(AS)<br/></i>Treatment of adults with severe active ankylosing spondylitis&#160;who have had an inadequate response to&#160;<br/>conventional therapy.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft334"><i>Non-radiographic axial spondyloarthritis<br/></i>Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of&#160;<br/>inflammation as indicated by elevated&#160;C-reactive&#160;protein (CRP)&#160;and/or&#160;magnetic resonance&#160;imaging&#160;<br/>(MRI)&#160;evidence, who have had an inadequate response&#160;to&#160;nonsteroidal anti-inflammatory drugs<br/>(NSAIDs).</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft332">Plaque psoriasis</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft333">Treatment of adults with moderate to severe plaque psoriasis who failed to respond to,&#160;or who have a&#160;<br/>contraindication to, or are intolerant to other systemic therapy,&#160;including ciclosporin, methotrexate or&#160;<br/>psoralen and ultraviolet-A light (PUVA) (see section 5.1).</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft332">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft333">Treatment of chronic severe plaque psoriasis in&#160;children and adolescents from the age of 6&#160;years who&#160;<br/>are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft331"><b>4.2</b></p>
<p style="position:absolute;top:679px;left:149px;white-space:nowrap" class="ft331"><b>Posology and method of administration</b></p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft333">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the&#160;<br/>diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,&#160;<br/>ankylosing spondylitis,&#160;non-radiographic axial spondyloarthritis,&#160;plaque psoriasis or paediatric plaque&#160;<br/>psoriasis. Patients treated with Enbrel should be given the Patient Card.</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft332">Enbrel is available in strengths of 10, 25 and 50&#160;mg.</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft332">Posology</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft333"><i>Rheumatoid arthritis<br/></i>25&#160;mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50&#160;mg administered&#160;<br/>once weekly&#160;has been shown to be safe and effective (see section 5.1).</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft334"><i>Psoriatic arthritis,&#160;ankylosing spondylitis&#160;and non-radiographic axial spondyloarthritis<br/></i>The recommended dose is 25&#160;mg Enbrel administered twice weekly, or 50&#160;mg administered once&#160;<br/>weekly.</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft339">For all&#160;of the above indications, available data suggest that a clinical response is usually achieved&#160;<br/>within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not&#160;<br/>responding within this time period.</p>
</div>
<!-- Page 34 -->
<a name="34"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page34-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft340">34</p>
<p style="position:absolute;top:108px;left:107px;white-space:nowrap" class="ft345"><i>Plaque psoriasis</i></p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft343">The recommended dose of Enbrel is 25&#160;mg administered twice weekly or 50&#160;mg administered once&#160;<br/>weekly. Alternatively, 50&#160;mg given twice weekly may be used for up to 12&#160;weeks followed, if&#160;<br/>necessary, by a dose of 25&#160;mg twice weekly or 50&#160;mg&#160;once weekly. Treatment with&#160;Enbrel should&#160;<br/>continue until remission is achieved, for up to 24&#160;weeks.&#160;Continuous therapy beyond 24&#160;weeks may be&#160;<br/>appropriate for some adult patients (see section 5.1).&#160;Treatment should be discontinued in patients who&#160;<br/>show no response after 12&#160;weeks. If re-treatment with Enbrel is indicated, the same guidance on&#160;<br/>treatment duration should be followed. The dose should be 25&#160;mg twice weekly or 50&#160;mg once&#160;<br/>weekly.&#160;</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft342">Special populations</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft346"><i>Renal and hepatic impairment<br/></i>No dose adjustment is required.</p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft344"><i>Elderly<br/></i>No&#160;dose adjustment is required. Posology and administration are the same as for adults 18-64 years of&#160;<br/>age.</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft347"><i>Paediatric population<br/></i>The safety and efficacy of&#160;Enbrel&#160;in children aged less than 2&#160;years has not been established.</p>
<p style="position:absolute;top:508px;left:107px;white-space:nowrap" class="ft342">No data are available.</p>
<p style="position:absolute;top:547px;left:107px;white-space:nowrap" class="ft345"><i>Juvenile&#160;idiopathic arthritis&#160;</i></p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft344">The recommended dose is 0.4&#160;mg/kg (up to a maximum of 25&#160;mg per dose), given twice weekly as a&#160;<br/>subcutaneous injection with an interval of 3-4&#160;days between doses&#160;or 0.8&#160;mg/kg (up to a maximum of&#160;<br/>50&#160;mg per dose) given once weekly.&#160;Discontinuation of treatment should be considered in patients&#160;<br/>who show no response after 4 months.</p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft344">The 10&#160;mg&#160;vial strength may be more appropriate for administration to children with JIA below the&#160;<br/>weight of 25&#160;kg.</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft344">No formal clinical trials have been conducted&#160;in children aged 2 to 3 years. However, limited safety&#160;<br/>data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar&#160;<br/>to that seen in adults and children aged 4 years and older, when dosed every week with 0.8&#160;mg/kg&#160;<br/>subcutaneously (see section 5.1).</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft343">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile&#160;<br/>idiopathic arthritis.</p>
<p style="position:absolute;top:870px;left:107px;white-space:nowrap" class="ft342">Paediatric plaque psoriasis (age 6 years and above)</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft344">The recommended dose is 0.8&#160;mg/kg&#160;(up to a maximum of 50&#160;mg per dose) once weekly for up to&#160;<br/>24&#160;weeks. Treatment should be discontinued in patients who show no response after 12&#160;weeks.</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft344">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed.&#160;<br/>The dose should be 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly.</p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft343">There is generally no applicable use of Enbrel in children aged below 6&#160;years in the indication plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:1060px;left:106px;white-space:nowrap" class="ft342">Method of administration</p>
<p style="position:absolute;top:1098px;left:106px;white-space:nowrap" class="ft343">Enbrel is administered by subcutaneous&#160;injection.&#160;Enbrel powder for solution must be reconstituted in&#160;<br/>1&#160;ml of solvent before use&#160;(see section 6.6).</p>
</div>
<!-- Page 35 -->
<a name="35"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page35-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft350">35</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft353">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are&#160;<br/>given in the package leaflet, section 7, &#34;Instructions for preparation and giving an injection of Enbrel.&#34;<br/>Detailed instructions on unintentional dosing or scheduling variations, including missed doses, are&#160;<br/>provided in section 3 of the package leaflet.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft351"><b>4.3</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft351"><b>Contraindications</b></p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft352">Hypersensitivity to&#160;the active substance or to any of the excipients&#160;listed in section 6.1.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft352">Sepsis or risk of sepsis.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft354">Treatment with Enbrel should not be initiated in patients with active infections,&#160;including chronic or&#160;<br/>localised infections.</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft351"><b>4.4</b></p>
<p style="position:absolute;top:373px;left:149px;white-space:nowrap" class="ft351"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft354">In order to improve the traceability of biological medicinal products, the&#160;brand name&#160;and batch&#160;<br/>number of the administered product should be clearly recorded (or stated) in the patient file.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft352">Infections</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft353">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into&#160;<br/>consideration that the mean elimination half-life of etanercept is approximately 70&#160;hours (range 7 to&#160;<br/>300&#160;hours).</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft354">Serious infections, sepsis, tuberculosis, and opportunistic infections,&#160;including invasive fungal&#160;<br/>infections,&#160;listeriosis and legionellosis,&#160;have been reported with the use of Enbrel (see section 4.8).&#160;<br/>These infections were due to bacteria, mycobacteria, fungi,&#160;viruses&#160;and parasites (including protozoa).&#160;<br/>In some cases, particular fungal and other opportunistic infections have not been recognised, resulting&#160;<br/>in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the&#160;<br/>patient’s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be&#160;<br/>considered.&#160;</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft354">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored&#160;<br/>closely. Administration of Enbrel should be discontinued if a patient develops a serious infection.&#160;The&#160;<br/>safety and efficacy&#160;of Enbrel in patients with chronic infections have not been evaluated.&#160;Physicians&#160;<br/>should exercise caution when considering the use of Enbrel in patients with a history of recurring or&#160;<br/>chronic infections or with underlying conditions that may predispose&#160;patients to infections,&#160;such as&#160;<br/>advanced or poorly controlled diabetes.</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft352">Tuberculosis</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft354">Cases of active tuberculosis,&#160;including miliary tuberculosis and tuberculosis with extra-pulmonary&#160;<br/>location,&#160;have been reported in patients treated with Enbrel.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft353">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive&#160;<br/>(‘latent’) tuberculosis. This evaluation should include a detailed medical history with personal history&#160;<br/>of tuberculosis or possible previous contact with tuberculosis and previous and/or current&#160;<br/>immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray,&#160;<br/>should be performed in all patients (local recommendations may apply). It is recommended that the&#160;<br/>conduct of these tests should be recorded in the&#160;Patient&#160;Card. Prescribers are reminded of the risk of&#160;<br/>false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.</p>
<p style="position:absolute;top:1133px;left:106px;white-space:nowrap" class="ft353">If active tuberculosis is diagnosed, Enbrel therapy must not&#160;be initiated. If inactive (‘latent’)&#160;<br/>tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis&#160;</p>
</div>
<!-- Page 36 -->
<a name="36"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page36-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft360">36</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft364">therapy before the initiation of Enbrel, and in accordance with local recommendations. In this&#160;<br/>situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft364">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis&#160;<br/>(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft362">Hepatitis B reactivation</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft363">Reactivation of hepatitis B in patients who&#160;were previously infected with the&#160;hepatitis B virus (HBV)&#160;<br/>and had received concomitant&#160;TNF-antagonists,&#160;including Enbrel,&#160;has been reported.&#160;This&#160;includes&#160;<br/>reports of reactivation of&#160;hepatitis B&#160;in patients who were anti-HBc positive but HBsAg negative.<br/>Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who&#160;<br/>test positive for HBV infection, consultation with a physician with expertise in the treatment of&#160;<br/>hepatitis B is recommended.&#160;Caution should be exercised when administering Enbrel&#160;in&#160;patients&#160;<br/>previously infected with&#160;HBV.&#160;These&#160;patients should be monitored for signs and symptoms of active&#160;<br/>HBV infection&#160;throughout therapy and for several weeks following termination of therapy.&#160;Adequate&#160;<br/>data from treating patients infected with&#160;HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy are not available. In patients who develop HBV infection,&#160;Enbrel should be&#160;<br/>stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft362">Worsening of hepatitis C</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft363">There have been reports of worsening of hepatitis C in patients receiving Enbrel.&#160;Enbrel should be&#160;<br/>used with caution in patients with a history of hepatitis C.</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft362">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft363">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious&#160;<br/>infections and neutropenia compared&#160;to Enbrel alone. This combination has not demonstrated&#160;<br/>increased clinical benefit. Thus,&#160;the combined use of Enbrel and anakinra is not recommended (see&#160;<br/>sections 4.5 and 4.8).</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft362">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft364">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see&#160;section 4.5).</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft362">Allergic reactions</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft363">Allergic reactions associated&#160;with Enbrel administration have been reported commonly. Allergic&#160;<br/>reactions have included angioedema and urticaria; serious reactions have occurred. If any serious&#160;<br/>allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and&#160;<br/>appropriate therapy initiated.</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft364">The rubber tip cap (closure) of the diluent syringe contains latex (dry natural rubber) that may cause&#160;<br/>hypersensitivity reactions when handled by, or when Enbrel is administered to, persons with known or&#160;<br/>possible latex sensitivity.</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft362">Immunosuppression</p>
<p style="position:absolute;top:1078px;left:106px;white-space:nowrap" class="ft363">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections&#160;<br/>and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a&#160;<br/>study of 49 adult&#160;patients with rheumatoid arthritis treated with Enbrel, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector cell populations.</p>
</div>
<!-- Page 37 -->
<a name="37"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page37-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft370">37</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft374">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of&#160;<br/>aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella&#160;<br/>virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with&#160;<br/>Varicella Zoster Immune Globulin.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft372">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft372">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft374"><i>Solid and haematopoietic malignancies (excluding skin cancers)<br/></i>Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been&#160;<br/>received in the postmarketing period (see section 4.8).&#160;</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft373">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been&#160;<br/>observed&#160;among patients receiving a TNF-antagonist compared with control patients. However, the&#160;<br/>occurrence was rare, and the follow-up period of placebo patients was shorter than for patients&#160;<br/>receiving TNF-antagonist therapy. In the postmarketing setting, cases of&#160;leukaemia have been reported&#160;<br/>in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and&#160;<br/>leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates risk estimation.</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft373">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other&#160;<br/>haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded.&#160;<br/>Caution should be exercised when considering TNF-antagonist therapy for patients with a history of&#160;<br/>malignancy or when considering continuing treatment in patients who develop a malignancy.</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft373">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤&#160;18&#160;years of age), including&#160;<br/>Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases&#160;<br/>represented a variety of different malignancies and included rare malignancies typically associated&#160;<br/>with immunosuppression. A risk for the development of malignancies in children and adolescents&#160;<br/>treated with TNF-antagonists cannot be excluded.</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft373"><i>Skin cancers<br/></i>Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients&#160;treated with&#160;<br/>TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported&#160;<br/>very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all&#160;<br/>patients, particularly those with risk factors for skin cancer.</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft374">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients&#160;<br/>receiving Enbrel compared with control patients, particularly in patients with psoriasis.</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft372">Vaccinations</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft373">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary&#160;<br/>transmission of infection by live vaccines in patients receiving Enbrel. In a double-blind,&#160;<br/>placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also&#160;<br/>received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic&#160;<br/>arthritis patients receiving Enbrel were able to mount effective B-cell immune response to&#160;<br/>pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients&#160;<br/>had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this&#160;<br/>is unknown.</p>
</div>
<!-- Page 38 -->
<a name="38"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page38-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft380">38</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft382">Autoantibody formation</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft382">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft382">Haematologic reactions</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft384">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have&#160;<br/>been reported in patients treated with Enbrel. Caution should be exercised in patients being treated&#160;<br/>with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers&#160;<br/>should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or&#160;<br/>infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they&#160;<br/>should seek immediate medical advice. Such patients should be investigated urgently, including full&#160;<br/>blood count; if blood dyscrasias are confirmed,&#160;Enbrel should be discontinued.</p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft382">Neurological disorders</p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft384">There have been rare reports of CNS demyelinating disorders in&#160;patients treated with Enbrel (see&#160;<br/>section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies&#160;<br/>(including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy,&#160;<br/>demyelinating polyneuropathy, and&#160;multifocal motor neuropathy). Although no clinical trials have&#160;<br/>been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other&#160;<br/>TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful&#160;<br/>risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel&#160;<br/>to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered&#160;<br/>to have an increased risk of developing&#160;demyelinating disease.</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft382">Combination therapy</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft383">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of&#160;<br/>Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel&#160;<br/>when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel&#160;<br/>and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The&#160;<br/>long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs&#160;<br/>(DMARD) has not been established.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft384">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of&#160;<br/>psoriasis has not been studied.</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft382">Renal and hepatic impairment</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft383">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal&#160;<br/>or hepatic impairment; clinical experience in such patients is limited.</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft382">Congestive heart failure&#160;(Cardiac failure congestive)</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft384">Physicians should use caution when using Enbrel in&#160;patients who have congestive heart failure (CHF).&#160;<br/>There have been postmarketing reports of worsening of CHF, with and without identifiable&#160;<br/>precipitating factors, in patients taking Enbrel.&#160;There have also been rare (&lt;&#160;0.1%) reports of new&#160;<br/>onset CHF, including CHF in patients without known pre-existing cardiovascular disease.&#160;Some of&#160;<br/>these patients have been under 50&#160;years of age.&#160;Two large clinical trials evaluating the use of Enbrel in&#160;<br/>the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data&#160;<br/>from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned<br/>to Enbrel treatment.&#160;</p>
</div>
<!-- Page 39 -->
<a name="39"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page39-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft390">39</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft392">Alcoholic hepatitis</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft394">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or&#160;<br/>placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in&#160;<br/>patients treated with Enbrel was significantly higher after 6&#160;months. Consequently, Enbrel should not&#160;<br/>be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using&#160;<br/>Enbrel in patients who also have moderate to severe&#160;alcoholic hepatitis.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft392">Wegener's granulomatosis</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft393">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard&#160;<br/>therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of&#160;<br/>25&#160;months, has not shown Enbrel to be an effective treatment for Wegener’s granulomatosis. The&#160;<br/>incidence of non-cutaneous malignancies of various types was significantly higher in patients treated&#160;<br/>with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft392">Hypoglycaemia in patients treated for diabetes</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft393">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving&#160;<br/>medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft392">Special populations</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft394"><i>Elderly<br/></i>In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall&#160;<br/>differences in adverse events, serious adverse events, and serious&#160;infections in patients age 65 or older&#160;<br/>who received Enbrel were observed compared with younger patients. However, caution should be&#160;<br/>exercised when treating the elderly and particular attention paid with respect to occurrence of&#160;<br/>infections.</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft395"><i>Paediatric population</i></p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft394"><i>Vaccinations<br/></i>It&#160;is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Enbrel therapy&#160;(see Vaccinations,&#160;<br/>above).</p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft391"><b>4.5</b></p>
<p style="position:absolute;top:830px;left:149px;white-space:nowrap" class="ft391"><b>Interaction with&#160;other medicinal products and other forms of interaction</b></p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft392">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft393">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infection when compared with patients treated with either Enbrel&#160;or anakinra alone (historical data).</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft394">In addition, in a double-blind, placebo-controlled trial in adult patients receiving background&#160;<br/>methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infections (7%) and&#160;neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The&#160;<br/>combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not&#160;<br/>recommended.</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft392">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft393">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see section 4.4).&#160;</p>
</div>
<!-- Page 40 -->
<a name="40"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page40-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft400">40</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft402">Concurrent treatment with sulfasalazine&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft404">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which&#160;<br/>Enbrel was added, patients in the combination group experienced a statistically significant decrease in&#160;<br/>mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The&#160;<br/>clinical significance of this interaction is unknown.&#160;Physicians should use caution when considering&#160;<br/>combination therapy with sulfasalazine.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft402">Non-interactions</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft403">In clinical trials, no interactions&#160;have been observed when Enbrel was administered with&#160;<br/>glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs),&#160;<br/>analgesics, or methotrexate. See section 4.4 for vaccination advice.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft404">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with&#160;<br/>methotrexate,&#160;digoxin or warfarin.</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft401"><b>4.6</b></p>
<p style="position:absolute;top:450px;left:149px;white-space:nowrap" class="ft401"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft402">Women of childbearing potential</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft403">Women of childbearing potential should&#160;consider the&#160;use&#160;of&#160;appropriate contraception to avoid&#160;<br/>becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft402">Pregnancy&#160;</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft403">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the&#160;<br/>foetus or neonatal rat due to etanercept.&#160;The effects of etanercept on pregnancy outcomes have been&#160;<br/>investigated in two observational cohort studies. A&#160;higher rate of major birth defects was observed in&#160;<br/>one observational study comparing pregnancies exposed to etanercept (n=370) during the first&#160;<br/>trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds&#160;<br/>ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most&#160;<br/>commonly reported in the general population and no particular pattern of abnormalities was identified.&#160;<br/>No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed.&#160;In&#160;<br/>another observational multi-country registry study comparing the risk of adverse pregnancy outcomes&#160;<br/>in women exposed to etanercept&#160;during the first 90&#160;days of pregnancy (n=425)&#160;to those exposed to&#160;<br/>non-biologic drugs&#160;(n=3497), there was no observed increased risk of major birth defects (crude odds&#160;<br/>ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for&#160;<br/>country, maternal disease, parity, maternal age and smoking in early pregnancy).&#160;This study&#160;also&#160;<br/>showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year&#160;<br/>of life&#160;for infants born to women exposed to etanercept during pregnancy.&#160;Enbrel should only be used&#160;<br/>during&#160;pregnancy&#160;if&#160;clearly needed.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft403">Etanercept crosses the placenta and has been detected in the serum of infants born to female patients&#160;<br/>treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be&#160;<br/>at increased risk of infection. Administration of&#160;live vaccines to infants for 16&#160;weeks after the&#160;<br/>mother’s last dose of Enbrel is generally not recommended.</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft402">Breast-feeding</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft403">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and&#160;<br/>detected in the serum of pups.&#160;Limited information from the published literature indicates etanercept&#160;<br/>has been detected at low levels in human milk.&#160;Etanercept could be considered for use during&#160;<br/>breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy&#160;<br/>for the woman.</p>
</div>
<!-- Page 41 -->
<a name="41"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page41-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft410">41</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft413">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely&#160;<br/>degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant&#160;<br/>are&#160;available. Therefore, the administration of live&#160;vaccines&#160;(e.g., BCG)&#160;to a breastfed infant when the&#160;<br/>mother is receiving etanercept&#160;could be considered 16 weeks after stopping breast-feeding (or at an&#160;<br/>earlier timepoint if the infant etanercept serum levels are undetectable).&#160;</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft412">Fertility</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft413">Preclinical data&#160;about peri-&#160;and postnatal toxicity of etanercept and of effects of etanercept on fertility&#160;<br/>and general reproductive performance are not available.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft411"><b>4.7</b></p>
<p style="position:absolute;top:335px;left:149px;white-space:nowrap" class="ft411"><b>Effects on ability to drive and use machines</b></p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft412">Enbrel&#160;has no or negligible influence on the ability to drive&#160;and&#160;use machines.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft411"><b>4.8</b></p>
<p style="position:absolute;top:411px;left:149px;white-space:nowrap" class="ft411"><b>Undesirable effects</b></p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft412">Summary of the safety profile</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft413">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling,&#160;<br/>itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections,&#160;<br/>bronchitis, bladder infections and skin infections),&#160;headache,&#160;allergic reactions, development of&#160;<br/>autoantibodies, itching, and fever.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft414">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect&#160;<br/>the immune system and their use may affect the body’s defenses against infection and cancer. Serious&#160;<br/>infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and&#160;<br/>life-threatening infections and sepsis. Various malignancies have also been reported with use of&#160;<br/>Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma). &#160;</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft414">Serious haematological, neurological and autoimmune reactions have also been reported. These&#160;<br/>include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral&#160;<br/>demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have&#160;<br/>been rare reports of lupus, lupus-related conditions, and vasculitis.</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft412">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft414">The following list of adverse reactions is based on experience from clinical trials and on&#160;<br/>postmarketing experience.</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft414">Within the organ system classes, adverse reactions are listed under headings of frequency (number of&#160;<br/>patients&#160;expected to experience the reaction), using the following categories: very common (≥&#160;1/10);&#160;<br/>common (≥&#160;1/100 to &lt;&#160;1/10); uncommon (≥&#160;1/1,000 to &lt;&#160;1/100); rare (≥&#160;1/10,000 to &lt;&#160;1/1,000); very&#160;<br/>rare (&lt;&#160;1/10,000); not known (cannot be estimated from the&#160;available data).</p>
<p style="position:absolute;top:982px;left:104px;white-space:nowrap" class="ft4112"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:982px;left:206px;white-space:nowrap" class="ft4112"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:982px;left:285px;white-space:nowrap" class="ft4112"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:982px;left:380px;white-space:nowrap" class="ft4112"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:982px;left:485px;white-space:nowrap" class="ft4112"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:982px;left:619px;white-space:nowrap" class="ft4112"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:982px;left:700px;white-space:nowrap" class="ft4112"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:1061px;left:104px;white-space:nowrap" class="ft4113">Infections and&#160;<br/>infestations</p>
<p style="position:absolute;top:1061px;left:206px;white-space:nowrap" class="ft4113">Infection<br/>(including&#160;<br/>upper&#160;<br/>respiratory&#160;<br/>tract&#160;<br/>infection,&#160;<br/>bronchitis,&#160;</p>
<p style="position:absolute;top:1061px;left:380px;white-space:nowrap" class="ft4113">Serious&#160;<br/>infections&#160;<br/>(including&#160;<br/>pneumonia,&#160;<br/>cellulitis,&#160;<br/>arthritis&#160;<br/>bacterial, sepsis</p>
<p style="position:absolute;top:1061px;left:485px;white-space:nowrap" class="ft4113">Tuberculosis,&#160;<br/>opportunistic&#160;<br/>infection&#160;(including&#160;<br/>invasive fungal,&#160;<br/>protozoal, bacterial,&#160;<br/>atypical&#160;<br/>mycobacterial, viral&#160;</p>
<p style="position:absolute;top:1061px;left:700px;white-space:nowrap" class="ft4113">Hepatitis B&#160;<br/>reactivation,&#160;<br/>listeria</p>
</div>
<!-- Page 42 -->
<a name="42"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page42-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft420">42</p>
<p style="position:absolute;top:109px;left:104px;white-space:nowrap" class="ft4212"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:206px;white-space:nowrap" class="ft4212"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:285px;white-space:nowrap" class="ft4212"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:380px;white-space:nowrap" class="ft4212"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:485px;white-space:nowrap" class="ft4212"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:619px;white-space:nowrap" class="ft4212"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:700px;white-space:nowrap" class="ft4212"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:187px;left:206px;white-space:nowrap" class="ft4213">cystitis,&#160;<br/>skin&#160;<br/>infection)*</p>
<p style="position:absolute;top:187px;left:380px;white-space:nowrap" class="ft4213">and parasitic&#160;<br/>infection)*</p>
<p style="position:absolute;top:187px;left:485px;white-space:nowrap" class="ft4213">infections,&#160;and&#160;<br/>Legionella)*</p>
<p style="position:absolute;top:234px;left:104px;white-space:nowrap" class="ft4213">Neoplasms&#160;<br/>benign,&#160;<br/>malignant and&#160;<br/>unspecified&#160;<br/>(including&#160;<br/>cysts and&#160;<br/>polyps)</p>
<p style="position:absolute;top:234px;left:380px;white-space:nowrap" class="ft4213">Non-melanoma&#160;<br/>skin cancers*&#160;<br/>(see section 4.4)</p>
<p style="position:absolute;top:234px;left:485px;white-space:nowrap" class="ft4213">Malignant melanoma&#160;<br/>(see section 4.4),&#160;<br/>lymphoma,&#160;<br/>leukaemia&#160;</p>
<p style="position:absolute;top:234px;left:700px;white-space:nowrap" class="ft4213">Merkel cell&#160;<br/>carcinoma (see&#160;<br/>section 4.4),&#160;<br/>Kaposi’s&#160;<br/>sarcoma</p>
<p style="position:absolute;top:344px;left:104px;white-space:nowrap" class="ft4213">Blood and&#160;<br/>lymphatic&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:344px;left:380px;white-space:nowrap" class="ft4213">Thrombocytope<br/>nia, anaemia,&#160;<br/>leukopenia,&#160;<br/>neutropenia</p>
<p style="position:absolute;top:344px;left:485px;white-space:nowrap" class="ft4211">Pancytopenia*</p>
<p style="position:absolute;top:344px;left:619px;white-space:nowrap" class="ft4213">Aplastic&#160;<br/>anaemia*</p>
<p style="position:absolute;top:344px;left:700px;white-space:nowrap" class="ft4213">Histiocytosis&#160;<br/>haematophagic&#160;<br/>(macrophage&#160;<br/>activation&#160;<br/>syndrome)*</p>
<p style="position:absolute;top:422px;left:104px;white-space:nowrap" class="ft4213">Immune&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:422px;left:285px;white-space:nowrap" class="ft4213">Allergic&#160;<br/>reactions (see&#160;<br/>Skin and&#160;<br/>subcutaneous&#160;<br/>tissue&#160;<br/>disorders),&#160;<br/>autoantibody&#160;<br/>formation*</p>
<p style="position:absolute;top:422px;left:380px;white-space:nowrap" class="ft4213">Vasculitis&#160;<br/>(including&#160;anti-<br/>neutrophilic&#160;<br/>cytoplasmic&#160;<br/>antibody positive&#160;<br/>vasculitis)</p>
<p style="position:absolute;top:422px;left:485px;white-space:nowrap" class="ft4213">Serious&#160;<br/>allergic/anaphylactic&#160;<br/>reactions (including&#160;<br/>angioedema,&#160;<br/>bronchospasm),&#160;<br/>sarcoidosis</p>
<p style="position:absolute;top:422px;left:700px;white-space:nowrap" class="ft4213">Worsening of&#160;<br/>symptoms of&#160;<br/>dermatomyositis</p>
<p style="position:absolute;top:547px;left:104px;white-space:nowrap" class="ft4213">Nervous&#160;<br/>system&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:547px;left:206px;white-space:nowrap" class="ft4211">Headache</p>
<p style="position:absolute;top:547px;left:485px;white-space:nowrap" class="ft4213">CNS demyelinating&#160;<br/>events suggestive of&#160;<br/>multiple sclerosis or&#160;<br/>localised<br/>demyelinating&#160;<br/>conditions, such as&#160;<br/>optic neuritis and&#160;<br/>transverse myelitis&#160;<br/>(see section 4.4),&#160;<br/>peripheral&#160;<br/>demyelinating&#160;<br/>events, including&#160;<br/>Guillain-Barré&#160;<br/>syndrome, chronic&#160;<br/>inflammatory&#160;<br/>demyelinating&#160;<br/>polyneuropathy,&#160;<br/>demyelinating&#160;<br/>polyneuropathy, and&#160;<br/>multifocal&#160;motor&#160;<br/>neuropathy (see&#160;<br/>section 4.4), seizure</p>
<p style="position:absolute;top:889px;left:104px;white-space:nowrap" class="ft4211">Eye disorders&#160;</p>
<p style="position:absolute;top:889px;left:380px;white-space:nowrap" class="ft4211">Uveitis, scleritis</p>
<p style="position:absolute;top:905px;left:104px;white-space:nowrap" class="ft4213">Cardiac&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:905px;left:380px;white-space:nowrap" class="ft4213">Worsening of&#160;<br/>cardiac failure&#160;<br/>congestive (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:905px;left:485px;white-space:nowrap" class="ft4213">New onset cardiac&#160;<br/>failure congestive&#160;<br/>(see section 4.4)</p>
<p style="position:absolute;top:968px;left:104px;white-space:nowrap" class="ft4213">Respiratory,&#160;<br/>thoracic, and&#160;<br/>mediastinal&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:968px;left:485px;white-space:nowrap" class="ft4213">Interstitial lung&#160;<br/>disease (including&#160;<br/>pneumonitis and&#160;<br/>pulmonary fibrosis)*</p>
<p style="position:absolute;top:1031px;left:104px;white-space:nowrap" class="ft4213">Gastrointestinal&#160;<br/>disorders</p>
<p style="position:absolute;top:1031px;left:380px;white-space:nowrap" class="ft4213">Inflammatory&#160;<br/>bowel disease</p>
<p style="position:absolute;top:1063px;left:104px;white-space:nowrap" class="ft4213">Hepatobiliary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:1063px;left:380px;white-space:nowrap" class="ft4213">Elevated liver&#160;<br/>enzymes*</p>
<p style="position:absolute;top:1063px;left:485px;white-space:nowrap" class="ft4213">Autoimmune&#160;<br/>hepatitis*</p>
</div>
<!-- Page 43 -->
<a name="43"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page43-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft430">43</p>
<p style="position:absolute;top:109px;left:104px;white-space:nowrap" class="ft4312"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:206px;white-space:nowrap" class="ft4312"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:285px;white-space:nowrap" class="ft4312"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:380px;white-space:nowrap" class="ft4312"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:485px;white-space:nowrap" class="ft4312"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:619px;white-space:nowrap" class="ft4312"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:700px;white-space:nowrap" class="ft4312"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:187px;left:104px;white-space:nowrap" class="ft4313">Skin and&#160;<br/>subcutaneous&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:187px;left:285px;white-space:nowrap" class="ft4311">Pruritus, rash</p>
<p style="position:absolute;top:187px;left:380px;white-space:nowrap" class="ft4313">Angioedema,&#160;<br/>psoriasis&#160;<br/>(including new&#160;<br/>onset or&#160;<br/>worsening and&#160;<br/>pustular,&#160;<br/>primarily palms&#160;<br/>and soles),&#160;<br/>urticaria,&#160;<br/>psoriasiform&#160;<br/>rash</p>
<p style="position:absolute;top:187px;left:485px;white-space:nowrap" class="ft4313">Stevens-Johnson&#160;<br/>syndrome, cutaneous&#160;<br/>vasculitis (including&#160;<br/>hypersensitivity&#160;<br/>vasculitis), erythema&#160;<br/>multiforme,&#160;<br/>lichenoid reactions</p>
<p style="position:absolute;top:187px;left:619px;white-space:nowrap" class="ft4313">Toxic&#160;<br/>epidermal&#160;<br/>necrolysis</p>
<p style="position:absolute;top:358px;left:104px;white-space:nowrap" class="ft4313">Musculoskeleta<br/>l and&#160;<br/>connective&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:358px;left:485px;white-space:nowrap" class="ft4313">Cutaneous lupus&#160;<br/>erythematosus,&#160;<br/>subacute cutaneous&#160;<br/>lupus erythematosus,&#160;<br/>lupus-like syndrome</p>
<p style="position:absolute;top:437px;left:104px;white-space:nowrap" class="ft4313">General&#160;<br/>disorders and&#160;<br/>administration&#160;<br/>site conditions&#160;</p>
<p style="position:absolute;top:437px;left:206px;white-space:nowrap" class="ft4313">Injection&#160;<br/>site&#160;<br/>reactions&#160;<br/>(including&#160;<br/>bleeding,&#160;<br/>bruising,&#160;<br/>erythema,&#160;<br/>itching,&#160;<br/>pain,&#160;<br/>swelling)*</p>
<p style="position:absolute;top:437px;left:285px;white-space:nowrap" class="ft4311">Pyrexia</p>
<p style="position:absolute;top:593px;left:104px;white-space:nowrap" class="ft4311">*see Description of selected adverse reactions, below.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft432">Description of selected adverse&#160;reactions</p>
<p style="position:absolute;top:666px;left:106px;white-space:nowrap" class="ft434"><i>Malignancies and lymphoproliferative disorders<br/></i>One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114&#160;<br/>rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6&#160;years,&#160;<br/>including 231&#160;patients treated with Enbrel in combination with methotrexate in the 2-year&#160;<br/>active-controlled study. The observed rates and incidences in these clinical trials were similar to those&#160;<br/>expected for the population studied. A total of 2 malignancies were reported in clinical studies of&#160;<br/>approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical&#160;<br/>studies conducted for more than 2&#160;years with 351 ankylosing spondylitis patients, 6&#160;malignancies were&#160;<br/>reported in&#160;Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in&#160;<br/>double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin&#160;<br/>cancers were reported.</p>
<p style="position:absolute;top:894px;left:106px;white-space:nowrap" class="ft433">In a group of 7,416&#160;patients treated with&#160;Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing&#160;<br/>spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</p>
<p style="position:absolute;top:951px;left:106px;white-space:nowrap" class="ft433">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been&#160;<br/>received in the postmarketing period (see section 4.4).</p>
<p style="position:absolute;top:1008px;left:106px;white-space:nowrap" class="ft434"><i>Injection site reactions<br/></i>Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher&#160;<br/>incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first&#160;<br/>month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of&#160;<br/>injection site reactions in the Enbrel treatment groups, and the majority of patients who were given&#160;<br/>treatment received topical preparations, such as corticosteroids, or oral antihistamines. Additionally,&#160;<br/>some&#160;patients developed recall injection site reactions characterised by a skin reaction at the most&#160;</p>
</div>
<!-- Page 44 -->
<a name="44"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page44-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft440">44</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft444">recent site of injection, along with the simultaneous appearance of injection site reactions at previous&#160;<br/>injection sites. These reactions were generally transient and did not recur with treatment.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft443">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with&#160;<br/>Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the&#160;<br/>first 12 weeks of treatment.</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft443"><i>Serious infections<br/></i>In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or&#160;<br/>requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3%&#160;<br/>of rheumatoid arthritis patients treated with Enbrel for up to 48&#160;months. These included abscess (at&#160;<br/>various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis,&#160;<br/>endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection,&#160;<br/>osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin&#160;<br/>infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year&#160;<br/>active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or&#160;<br/>Enbrel in combination with methotrexate, the rates of serious infections were similar among the&#160;<br/>treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate&#160;<br/>could be associated with an increase in the rate of infections.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft443">There were no differences in rates of infection among patients treated with Enbrel and those treated&#160;<br/>with placebo for plaque psoriasis&#160;in placebo-controlled trials of up&#160;to 24 weeks duration. Serious&#160;<br/>infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia,&#160;<br/>cholecystitis, osteomyelitis, gastritis, appendicitis,&#160;<i>Streptococcal&#160;</i>fasciitis, myositis, septic shock,&#160;<br/>diverticulitis&#160;and abscess. In the double-blind and open-label psoriatic arthritis trials, 1&#160;patient reported&#160;<br/>a serious infection (pneumonia).</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft444">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include&#160;<br/>bacteria, mycobacteria (including&#160;tuberculosis), viruses and fungi. Some have occurred within a few&#160;<br/>weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes,&#160;<br/>congestive heart failure, history of active or chronic infections) in addition to their&#160;rheumatoid arthritis&#160;<br/>(see section&#160;4.4). Enbrel treatment may increase mortality in patients with established sepsis.</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft444">Opportunistic infections have been reported in association with Enbrel, including invasive fungal,&#160;<br/>parasitic (including&#160;protozoal),&#160;viral&#160;(including herpes zoster),&#160;bacterial (including&#160;<i>Listeria&#160;</i>and&#160;<br/><i>Legionella</i>), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall&#160;<br/>incidence of opportunistic infections was 0.09% for the 15,402&#160;subjects who received&#160;Enbrel. The&#160;<br/>exposure-adjusted rate was 0.06&#160;events per 100&#160;patient-years. In postmarketing experience,&#160;<br/>approximately half of all of the case reports of opportunistic infections worldwide were invasive&#160;<br/>fungal infections.&#160;The most commonly reported invasive&#160;fungal infections&#160;included&#160;<i>Candida,<br/>Pneumocystis,&#160;Aspergillus,&#160;</i>and&#160;<i>Histoplasma</i>. Invasive fungal infections accounted for more than half&#160;<br/>of the fatalities amongst patients who developed opportunistic infections. The majority of the reports&#160;<br/>with a fatal outcome were in patients with&#160;<i>Pneumocystis&#160;</i>pneumonia, unspecified systemic fungal&#160;<br/>infections, and aspergillosis (see section 4.4).</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft448"><i>Autoantibodies<br/></i>Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid&#160;<br/>arthritis&#160;patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed&#160;<br/>new positive ANA (</p>
<p style="position:absolute;top:1019px;left:240px;white-space:nowrap" class="ft4414">1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated&#160;</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft443">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA&#160;<br/>antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4%&#160;<br/>of placebo-treated patients) and by&#160;<i>Crithidia luciliae&#160;</i>assay (3% of patients treated with Enbrel&#160;<br/>compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who&#160;<br/>developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.&#160;<br/>The impact of long-term treatment with Enbrel on the development of autoimmune diseases is&#160;<br/>unknown.</p>
</div>
<!-- Page 45 -->
<a name="45"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page45-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft450">45</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft453">There have been rare reports of patients, including rheumatoid factor positive patients, who have&#160;<br/>developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are&#160;<br/>compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft454"><i>Pancytopenia and aplastic anaemia<br/></i>There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal&#160;<br/>outcomes (see section 4.4).</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft453"><i>Interstitial lung disease<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47%&#160;<br/>(frequency uncommon).&#160;There have been postmarketing reports of interstitial lung disease (including&#160;<br/>pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft458"><i>Concurrent treatment with anakinra&#160;<br/></i>In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of&#160;<br/>serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed&#160;<br/>neutropenia (absolute neutrophil count&#160;</p>
<p style="position:absolute;top:488px;left:366px;white-space:nowrap" class="ft4514">&#160;1000/mm3). While&#160;neutropenic, one patient developed&#160;</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft452">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft454"><i>Elevated liver enzymes<br/></i>In&#160;the&#160;double-blind&#160;periods of&#160;controlled clinical trials of etanercept across all indications, the&#160;<br/>frequency (incidence&#160;proportion) of adverse events of elevated liver enzymes in patients receiving&#160;<br/>etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In&#160;the double-blind&#160;<br/>periods&#160;of controlled clinical trials&#160;that allowed&#160;concomitant treatment with etanercept and&#160;<br/>methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was&#160;<br/>4.18% (frequency common).</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft453"><i>Autoimmune hepatitis<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24%&#160;<br/>(frequency uncommon).</p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft452">Paediatric population</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft454"><i>Undesirable effects in paediatric patients with juvenile idiopathic arthritis<br/></i>In general, the adverse events in paediatric patients with juvenile idiopathic arthritis&#160;were similar in&#160;<br/>frequency and type to those seen in adult patients. Differences from adults and other special&#160;<br/>considerations are discussed in the following paragraphs.</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft454">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18&#160;years&#160;<br/>were generally mild to moderate and consistent with those commonly seen in outpatient paediatric&#160;<br/>populations. Severe adverse events reported included varicella with signs and symptoms of aseptic&#160;<br/>meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis,&#160;<br/>depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic&#160;<br/>shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft454">In one&#160;study in children with juvenile idiopathic arthritis aged 4 to 17&#160;years, 43 of 69 (62%) children&#160;<br/>experienced an infection while receiving Enbrel during 3&#160;months of the study (part 1, open-label), and&#160;<br/>the frequency and severity of infections was similar in&#160;58 patients completing 12&#160;months of open-label&#160;<br/>extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients&#160;</p>
</div>
<!-- Page 46 -->
<a name="46"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page46-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft460">46</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft463">were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the&#160;<br/>majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic&#160;<br/>arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients.&#160;<br/>These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per&#160;<br/>patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per&#160;<br/>patient year).</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft462">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft464"><i>Undesirable effects in paediatric patients with plaque psoriasis<br/></i>In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse&#160;<br/>events reported were similar to those seen in previous studies in adults with plaque psoriasis.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft462">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft463">Reporting suspected adverse reactions after authorisation&#160;of the medicinal product is important. It&#160;<br/>allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare&#160;<br/>professionals are asked to report any suspected adverse&#160;reactions&#160;via&#160;the national reporting system&#160;<br/>listed in&#160;<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V</a>.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft461"><b>4.9</b></p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft461"><b>Overdose</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft464">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The&#160;<br/>highest dose level&#160;evaluated has been an intravenous loading dose of 32&#160;mg/m2&#160;followed by&#160;<br/>subcutaneous doses of 16&#160;mg/m2&#160;administered twice weekly. One rheumatoid arthritis patient&#160;<br/>mistakenly self-administered 62&#160;mg Enbrel subcutaneously twice weekly for 3&#160;weeks without&#160;<br/>experiencing undesirable effects. There is no known antidote to Enbrel.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft461"><b>5.</b></p>
<p style="position:absolute;top:658px;left:146px;white-space:nowrap" class="ft461"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft461"><b>5.1</b></p>
<p style="position:absolute;top:696px;left:149px;white-space:nowrap" class="ft461"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft464">Pharmacotherapeutic group: Immunosuppressants,&#160;Tumour Necrosis Factor alpha (TNF-α) inhibitors,&#160;<br/>ATC code:&#160;L04AB01</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft463">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid&#160;<br/>arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with&#160;<br/>psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque&#160;<br/>psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in&#160;<br/>psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of&#160;<br/>TNF binding to its&#160;cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and&#160;<br/>lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the&#160;<br/>55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs&#160;<br/>exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF&#160;<br/>biological activity.</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft464">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on&#160;<br/>cross-linking of&#160;cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher&#160;<br/>affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of&#160;<br/>TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion&#160;<br/>element in the construction of a dimeric receptor imparts a longer serum half-life.</p>
</div>
<!-- Page 47 -->
<a name="47"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page47-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft470">47</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft472">Mechanism of action</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft473">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in&#160;<br/>plaque psoriasis is&#160;mediated by pro-inflammatory molecules that are linked in a network controlled by&#160;<br/>TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF&#160;<br/>binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF&#160;<br/>biologically inactive. Etanercept may also modulate biologic responses controlled by additional&#160;<br/>downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or&#160;<br/>regulated by TNF.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft472">Clinical&#160;efficacy and safety</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft473">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis,&#160;<br/>one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis,&#160;two&#160;studies<br/>in adults with non-radiographic axial&#160;spondyloarthritis,&#160;four studies in adults with plaque psoriasis,&#160;<br/>three&#160;studies&#160;in juvenile idiopathic arthritis and&#160;one study in paediatric patients with plaque psoriasis.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft473"><i>Adult patients with rheumatoid arthritis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The&#160;<br/>study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least&#160;<br/>one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel or placebo were administered subcutaneously twice a week for 6&#160;consecutive months.&#160;<br/>The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis&#160;<br/>using American College of Rheumatology (ACR) response criteria.&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft473">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6&#160;months than in&#160;<br/>patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and&#160;<br/>6&#160;months, respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5%&#160;at months 3 and 6,&#160;<br/>respectively; p&#160;&lt;&#160;0.01 Enbrel vs. placebo at all timepoints for both ACR 20 and ACR 50 responses).&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft474">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month&#160;3 and&#160;<br/>month&#160;6&#160;compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel,&#160;<br/>the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly&#160;<br/>always occurred by 3 months. A dose response was seen; results with 10&#160;mg were intermediate&#160;<br/>between&#160;placebo and 25&#160;mg. Enbrel was significantly better than placebo in all components of the&#160;<br/>ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the&#160;<br/>ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which&#160;<br/>included disability, vitality, mental health, general health status, and arthritis-associated health status&#160;<br/>subdomains, was administered every 3&#160;months during the trial. All subdomains of the HAQ were&#160;<br/>improved in patients treated with Enbrel compared to controls at 3 and 6&#160;months.&#160;</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft473">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month.&#160;<br/>Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same&#160;<br/>magnitudes of responses as patients who received Enbrel without interruption of therapy based on&#160;<br/>results of open-label studies. Continued durable responses have been seen for up to&#160;10&#160;years&#160;in&#160;<br/>open-label extension treatment trials when patients received Enbrel without interruption.&#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft473">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with&#160;<br/>blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid&#160;<br/>arthritis (&lt;&#160;3&#160;years duration) who had never received treatment with methotrexate. Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel were administered subcutaneously (SC) twice a week for up to 24 months. Methotrexate&#160;<br/>doses were escalated from 7.5&#160;mg/week to a maximum of 20&#160;mg/week over the first 8&#160;weeks of the&#160;<br/>trial and continued for up to 24&#160;months. Clinical improvement, including onset of action within&#160;<br/>2&#160;weeks with Enbrel 25&#160;mg, was similar to that seen in the previous trials and was maintained for up to&#160;<br/>24&#160;months. At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to&#160;<br/>1.5. Treatment with Enbrel 25&#160;mg resulted in substantial improvement at 12&#160;months, with about 44%&#160;</p>
</div>
<!-- Page 48 -->
<a name="48"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page48-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft480">48</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft484">of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year&#160;2 of&#160;<br/>this study.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft484">In this study, structural joint damage was assessed radiographically and expressed as change in Total&#160;<br/>Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score.&#160;<br/>Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24&#160;months. The 10&#160;mg&#160;<br/>Enbrel dose had consistently less effect on structural damage than the 25&#160;mg dose. Enbrel 25&#160;mg was&#160;<br/>significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in&#160;<br/>TSS and JSN&#160;were not statistically significant between methotrexate and Enbrel 25&#160;mg. The results are&#160;<br/>shown in the figure below.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft4823"><b>Radiographic&#160;&#160;Progression:&#160;&#160;Comparison&#160;&#160;of&#160;&#160;Enbrel&#160;&#160;vs.&#160;&#160;Methotrexate&#160;&#160;in&#160;&#160;Patients&#160;&#160;with&#160;&#160;RA&#160;&#160;of&#160;<br/>&lt;3&#160;Years Duration</b></p>
<p style="position:absolute;top:533px;left:132px;white-space:nowrap" class="ft4817">C</p>
<p style="position:absolute;top:522px;left:132px;white-space:nowrap" class="ft4817">ha</p>
<p style="position:absolute;top:506px;left:132px;white-space:nowrap" class="ft4817">ng</p>
<p style="position:absolute;top:490px;left:132px;white-space:nowrap" class="ft4817">e&#160;</p>
<p style="position:absolute;top:478px;left:132px;white-space:nowrap" class="ft4817">fr</p>
<p style="position:absolute;top:469px;left:132px;white-space:nowrap" class="ft4817">o</p>
<p style="position:absolute;top:460px;left:132px;white-space:nowrap" class="ft4817">m</p>
<p style="position:absolute;top:448px;left:132px;white-space:nowrap" class="ft4817">&#160;B</p>
<p style="position:absolute;top:434px;left:132px;white-space:nowrap" class="ft4817">as</p>
<p style="position:absolute;top:419px;left:132px;white-space:nowrap" class="ft4817">e</p>
<p style="position:absolute;top:410px;left:132px;white-space:nowrap" class="ft4817">lin</p>
<p style="position:absolute;top:396px;left:132px;white-space:nowrap" class="ft4817">e</p>
<p style="position:absolute;top:569px;left:145px;white-space:nowrap" class="ft4818"><b>0.0</b></p>
<p style="position:absolute;top:532px;left:145px;white-space:nowrap" class="ft4818"><b>0.5</b></p>
<p style="position:absolute;top:495px;left:145px;white-space:nowrap" class="ft4818"><b>1.0</b></p>
<p style="position:absolute;top:457px;left:145px;white-space:nowrap" class="ft4818"><b>1.5</b></p>
<p style="position:absolute;top:420px;left:145px;white-space:nowrap" class="ft4818"><b>2.0</b></p>
<p style="position:absolute;top:383px;left:145px;white-space:nowrap" class="ft4818"><b>2.5</b></p>
<p style="position:absolute;top:570px;left:484px;white-space:nowrap" class="ft4818"><b>0.0</b></p>
<p style="position:absolute;top:533px;left:484px;white-space:nowrap" class="ft4818"><b>0.5</b></p>
<p style="position:absolute;top:496px;left:484px;white-space:nowrap" class="ft4818"><b>1.0</b></p>
<p style="position:absolute;top:459px;left:484px;white-space:nowrap" class="ft4818"><b>1.5</b></p>
<p style="position:absolute;top:422px;left:484px;white-space:nowrap" class="ft4818"><b>2.0</b></p>
<p style="position:absolute;top:385px;left:484px;white-space:nowrap" class="ft4818"><b>2.5</b></p>
<p style="position:absolute;top:615px;left:433px;white-space:nowrap" class="ft4819"><b>MTX</b></p>
<p style="position:absolute;top:629px;left:434px;white-space:nowrap" class="ft4819"><b>Enbrel&#160;25 mg</b></p>
<p style="position:absolute;top:378px;left:251px;white-space:nowrap" class="ft4819"><b>12 Months</b></p>
<p style="position:absolute;top:378px;left:598px;white-space:nowrap" class="ft4819"><b>24 Months</b></p>
<p style="position:absolute;top:587px;left:221px;white-space:nowrap" class="ft4820"><b>TSS</b></p>
<p style="position:absolute;top:587px;left:269px;white-space:nowrap" class="ft4820"><b>Erosions</b></p>
<p style="position:absolute;top:588px;left:351px;white-space:nowrap" class="ft4820"><b>JSN</b></p>
<p style="position:absolute;top:590px;left:554px;white-space:nowrap" class="ft4820"><b>TSS</b></p>
<p style="position:absolute;top:590px;left:608px;white-space:nowrap" class="ft4820"><b>Erosions</b></p>
<p style="position:absolute;top:590px;left:688px;white-space:nowrap" class="ft4820"><b>JSN</b></p>
<p style="position:absolute;top:458px;left:208px;white-space:nowrap" class="ft4819"><b>1.3</b></p>
<p style="position:absolute;top:496px;left:233px;white-space:nowrap" class="ft4819"><b>0.8</b></p>
<p style="position:absolute;top:488px;left:276px;white-space:nowrap" class="ft4819"><b>0.9</b></p>
<p style="position:absolute;top:526px;left:301px;white-space:nowrap" class="ft4819"><b>0.4*</b></p>
<p style="position:absolute;top:526px;left:344px;white-space:nowrap" class="ft4819"><b>0.4&#160;0.4</b></p>
<p style="position:absolute;top:391px;left:547px;white-space:nowrap" class="ft4819"><b>2.2</b></p>
<p style="position:absolute;top:466px;left:571px;white-space:nowrap" class="ft4819"><b>1.2</b></p>
<p style="position:absolute;top:458px;left:615px;white-space:nowrap" class="ft4819"><b>1.3</b></p>
<p style="position:absolute;top:510px;left:638px;white-space:nowrap" class="ft4819"><b>0.6*</b></p>
<p style="position:absolute;top:488px;left:681px;white-space:nowrap" class="ft4819"><b>0.9</b></p>
<p style="position:absolute;top:510px;left:705px;white-space:nowrap" class="ft4819"><b>0.6</b></p>
<p style="position:absolute;top:657px;left:420px;white-space:nowrap" class="ft4819"><b>*p &lt; 0.05</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft483">In&#160;another active-controlled, double-blind, randomised study, clinical efficacy, safety, and&#160;<br/>radiographic progression in RA patients treated with Enbrel alone (25&#160;mg twice weekly), methotrexate&#160;<br/>alone (7.5 to 20&#160;mg&#160;weekly, median dose 20&#160;mg), and the combination of Enbrel and methotrexate&#160;<br/>initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6&#160;months&#160;<br/>to 20&#160;years duration (median 5&#160;years) who had a less than satisfactory response to at least 1&#160;<br/>disease-modifying antirheumatic drug (DMARD) other than methotrexate.</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft484">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher&#160;<br/>ACR&#160;20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and&#160;<br/>52&#160;weeks than patients in either of the single therapy groups (results shown in table below).&#160;<br/>Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months.</p>
<p style="position:absolute;top:936px;left:99px;white-space:nowrap" class="ft481"><b>Clinical Efficacy Results&#160;at 12&#160;Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel&#160;</b></p>
<p style="position:absolute;top:955px;left:100px;white-space:nowrap" class="ft481"><b>in Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration</b></p>
<p style="position:absolute;top:994px;left:93px;white-space:nowrap" class="ft481"><b>Endpoint</b></p>
<p style="position:absolute;top:994px;left:336px;white-space:nowrap" class="ft482">Methotrexate</p>
<p style="position:absolute;top:1013px;left:345px;white-space:nowrap" class="ft482">(n =&#160;228)</p>
<p style="position:absolute;top:994px;left:502px;white-space:nowrap" class="ft482">Enbrel</p>
<p style="position:absolute;top:1013px;left:489px;white-space:nowrap" class="ft482">(n = 223)</p>
<p style="position:absolute;top:975px;left:643px;white-space:nowrap" class="ft482">Enbrel +</p>
<p style="position:absolute;top:994px;left:624px;white-space:nowrap" class="ft482">Methotrexate</p>
<p style="position:absolute;top:1013px;left:637px;white-space:nowrap" class="ft482">(n = 231)</p>
<p style="position:absolute;top:1052px;left:93px;white-space:nowrap" class="ft481"><b>ACR Responses</b>a</p>
<p style="position:absolute;top:1071px;left:122px;white-space:nowrap" class="ft482">ACR 20</p>
<p style="position:absolute;top:1071px;left:359px;white-space:nowrap" class="ft482">58.8%</p>
<p style="position:absolute;top:1071px;left:503px;white-space:nowrap" class="ft482">65.5%</p>
<p style="position:absolute;top:1072px;left:642px;white-space:nowrap" class="ft482">74.5%&#160;<b>†,</b></p>
<p style="position:absolute;top:1091px;left:122px;white-space:nowrap" class="ft482">ACR 50</p>
<p style="position:absolute;top:1091px;left:359px;white-space:nowrap" class="ft482">36.4%</p>
<p style="position:absolute;top:1091px;left:503px;white-space:nowrap" class="ft482">43.0%</p>
<p style="position:absolute;top:1092px;left:642px;white-space:nowrap" class="ft482">63.2%&#160;<b>†,</b></p>
<p style="position:absolute;top:1111px;left:122px;white-space:nowrap" class="ft482">ACR 70</p>
<p style="position:absolute;top:1112px;left:359px;white-space:nowrap" class="ft482">16.7%</p>
<p style="position:absolute;top:1112px;left:503px;white-space:nowrap" class="ft482">22.0%</p>
<p style="position:absolute;top:1112px;left:642px;white-space:nowrap" class="ft482">39.8%&#160;<b>†,</b></p>
</div>
<!-- Page 49 -->
<a name="49"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page49-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft490">49</p>
<p style="position:absolute;top:108px;left:99px;white-space:nowrap" class="ft491"><b>Clinical Efficacy Results&#160;at 12&#160;Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel&#160;</b></p>
<p style="position:absolute;top:127px;left:100px;white-space:nowrap" class="ft491"><b>in Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration</b></p>
<p style="position:absolute;top:165px;left:93px;white-space:nowrap" class="ft491"><b>Endpoint</b></p>
<p style="position:absolute;top:165px;left:336px;white-space:nowrap" class="ft492">Methotrexate</p>
<p style="position:absolute;top:184px;left:345px;white-space:nowrap" class="ft492">(n =&#160;228)</p>
<p style="position:absolute;top:165px;left:502px;white-space:nowrap" class="ft492">Enbrel</p>
<p style="position:absolute;top:184px;left:489px;white-space:nowrap" class="ft492">(n = 223)</p>
<p style="position:absolute;top:146px;left:643px;white-space:nowrap" class="ft492">Enbrel +</p>
<p style="position:absolute;top:165px;left:624px;white-space:nowrap" class="ft492">Methotrexate</p>
<p style="position:absolute;top:184px;left:637px;white-space:nowrap" class="ft492">(n = 231)</p>
<p style="position:absolute;top:203px;left:93px;white-space:nowrap" class="ft491"><b>DAS</b></p>
<p style="position:absolute;top:222px;left:122px;white-space:nowrap" class="ft492">Baseline scoreb</p>
<p style="position:absolute;top:222px;left:370px;white-space:nowrap" class="ft492">5.5</p>
<p style="position:absolute;top:222px;left:514px;white-space:nowrap" class="ft492">5.7</p>
<p style="position:absolute;top:222px;left:662px;white-space:nowrap" class="ft492">5.5</p>
<p style="position:absolute;top:241px;left:122px;white-space:nowrap" class="ft492">Week 52 scoreb</p>
<p style="position:absolute;top:241px;left:370px;white-space:nowrap" class="ft492">3.0</p>
<p style="position:absolute;top:241px;left:514px;white-space:nowrap" class="ft492">3.0</p>
<p style="position:absolute;top:243px;left:655px;white-space:nowrap" class="ft492">2.3<b>†,</b></p>
<p style="position:absolute;top:261px;left:122px;white-space:nowrap" class="ft492">Remissionc</p>
<p style="position:absolute;top:261px;left:365px;white-space:nowrap" class="ft492">14%</p>
<p style="position:absolute;top:261px;left:509px;white-space:nowrap" class="ft492">18%</p>
<p style="position:absolute;top:263px;left:650px;white-space:nowrap" class="ft492">37%<b>†,</b></p>
<p style="position:absolute;top:301px;left:93px;white-space:nowrap" class="ft491"><b>HAQ</b></p>
<p style="position:absolute;top:320px;left:121px;white-space:nowrap" class="ft492">Baseline</p>
<p style="position:absolute;top:320px;left:370px;white-space:nowrap" class="ft492">1.7</p>
<p style="position:absolute;top:320px;left:514px;white-space:nowrap" class="ft492">1.7</p>
<p style="position:absolute;top:320px;left:662px;white-space:nowrap" class="ft492">1.8</p>
<p style="position:absolute;top:339px;left:121px;white-space:nowrap" class="ft492">Week 52</p>
<p style="position:absolute;top:339px;left:370px;white-space:nowrap" class="ft492">1.1</p>
<p style="position:absolute;top:339px;left:514px;white-space:nowrap" class="ft492">1.0</p>
<p style="position:absolute;top:340px;left:655px;white-space:nowrap" class="ft492">0.8<b>†,</b></p>
<p style="position:absolute;top:360px;left:154px;white-space:nowrap" class="ft498">a:&#160;Patients who did not complete 12 months in the study were considered to be non-responders.<br/>b: Values for Disease Activity Score (DAS) are means.<br/>c: Remission is defined as DAS &lt;1.6.<br/>Pairwise comparison p-values:&#160;†&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs.&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:435px;left:273px;white-space:nowrap" class="ft4914">&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. Enbrel.</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft494">Radiographic progression at 12&#160;months was significantly less in the Enbrel group than in the&#160;<br/>methotrexate group, while the combination was significantly&#160;better than either monotherapy at&#160;<br/>slowing radiographic progression (see figure below).</p>
<p style="position:absolute;top:551px;left:106px;white-space:nowrap" class="ft4923"><b>Radiographic Progression: Comparison of Enbrel vs. Methotrexate vs. Enbrel in Combination&#160;<br/>with Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration&#160;(12&#160;Month Results)</b></p>
<p style="position:absolute;top:978px;left:233px;white-space:nowrap" class="ft498">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs.&#160;<br/>methotrexate, † = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs.&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:1015px;left:351px;white-space:nowrap" class="ft4914">&#160;= p&#160;&lt;&#160;0.05 for comparisons of Enbrel + methotrexate vs.&#160;</p>
<p style="position:absolute;top:1036px;left:233px;white-space:nowrap" class="ft492">Enbrel.</p>
<p style="position:absolute;top:1074px;left:106px;white-space:nowrap" class="ft493">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months. Similarly, the&#160;<br/>significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also&#160;<br/>observed after 24&#160;months.</p>
<p style="position:absolute;top:830px;left:206px;white-space:nowrap" class="ft4925">C</p>
<p style="position:absolute;top:819px;left:206px;white-space:nowrap" class="ft4925">ha</p>
<p style="position:absolute;top:804px;left:206px;white-space:nowrap" class="ft4925">ng</p>
<p style="position:absolute;top:788px;left:206px;white-space:nowrap" class="ft4925">e&#160;</p>
<p style="position:absolute;top:776px;left:206px;white-space:nowrap" class="ft4925">fr</p>
<p style="position:absolute;top:767px;left:206px;white-space:nowrap" class="ft4925">om</p>
<p style="position:absolute;top:747px;left:206px;white-space:nowrap" class="ft4925">&#160;B</p>
<p style="position:absolute;top:734px;left:206px;white-space:nowrap" class="ft4925">as</p>
<p style="position:absolute;top:719px;left:206px;white-space:nowrap" class="ft4925">el</p>
<p style="position:absolute;top:708px;left:206px;white-space:nowrap" class="ft4925">in</p>
<p style="position:absolute;top:696px;left:206px;white-space:nowrap" class="ft4925">e</p>
<p style="position:absolute;top:916px;left:232px;white-space:nowrap" class="ft490">-1.0</p>
<p style="position:absolute;top:878px;left:232px;white-space:nowrap" class="ft490">-0.5</p>
<p style="position:absolute;top:841px;left:236px;white-space:nowrap" class="ft490">0.0</p>
<p style="position:absolute;top:803px;left:236px;white-space:nowrap" class="ft490">0.5</p>
<p style="position:absolute;top:766px;left:236px;white-space:nowrap" class="ft490">1.0</p>
<p style="position:absolute;top:728px;left:236px;white-space:nowrap" class="ft490">1.5</p>
<p style="position:absolute;top:691px;left:236px;white-space:nowrap" class="ft490">2.0</p>
<p style="position:absolute;top:653px;left:236px;white-space:nowrap" class="ft490">2.5</p>
<p style="position:absolute;top:616px;left:236px;white-space:nowrap" class="ft490">3.0</p>
<p style="position:absolute;top:629px;left:552px;white-space:nowrap" class="ft4926"><b>Methotrexate</b></p>
<p style="position:absolute;top:644px;left:551px;white-space:nowrap" class="ft4926"><b>Enbrel&#160;</b></p>
<p style="position:absolute;top:659px;left:552px;white-space:nowrap" class="ft4926"><b>Enbrel + Methotrexate</b></p>
<p style="position:absolute;top:619px;left:334px;white-space:nowrap" class="ft4926"><b>2.80</b></p>
<p style="position:absolute;top:790px;left:361px;white-space:nowrap" class="ft4926"><b>0.52*</b></p>
<p style="position:absolute;top:893px;left:380px;white-space:nowrap" class="ft4926"><b>-0.54†</b>,</p>
<p style="position:absolute;top:703px;left:443px;white-space:nowrap" class="ft4926"><b>1.68</b></p>
<p style="position:absolute;top:813px;left:469px;white-space:nowrap" class="ft4926"><b>0.21*</b></p>
<p style="position:absolute;top:876px;left:489px;white-space:nowrap" class="ft4926"><b>-0.30†</b></p>
<p style="position:absolute;top:745px;left:551px;white-space:nowrap" class="ft4926"><b>1.12</b></p>
<p style="position:absolute;top:805px;left:577px;white-space:nowrap" class="ft4926"><b>0.32</b></p>
<p style="position:absolute;top:869px;left:599px;white-space:nowrap" class="ft4926"><b>-0.23†</b>,</p>
<p style="position:absolute;top:925px;left:352px;white-space:nowrap" class="ft4927"><b>TSS</b></p>
<p style="position:absolute;top:924px;left:442px;white-space:nowrap" class="ft4927"><b>Erosions</b></p>
<p style="position:absolute;top:924px;left:571px;white-space:nowrap" class="ft4927"><b>JSN</b></p>
</div>
<!-- Page 50 -->
<a name="50"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page50-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft500">50</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft504">In an analysis in which all patients who dropped out of the study for any reason were considered to&#160;<br/>have progressed, the percentage of patients without progression (TSS change&#160;≤&#160;0.5) at 24&#160;months was&#160;<br/>higher in the&#160;Enbrel in combination with methotrexate group compared with the Enbrel alone and&#160;<br/>methotrexate alone groups&#160;(62%, 50%, and 36%, respectively; p&#160;&lt;&#160;0.05). The difference between&#160;<br/>Enbrel alone and methotrexate alone was also significant (p&#160;&lt;&#160;0.05). Among patients who completed a&#160;<br/>full 24&#160;months of therapy in the study, the non-progression rates were 78%, 70%, and 61%,&#160;<br/>respectively.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft503">The safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered once weekly were&#160;<br/>evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53&#160;<br/>patients received placebo, 214 patients received 50&#160;mg&#160;Enbrel once weekly and 153 patients received&#160;<br/>25&#160;mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment&#160;regimens&#160;<br/>were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16&#160;did not show&#160;<br/>comparability (non-inferiority) between the two regimens.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft508"><i>Adult patients with psoriatic arthritis<br/></i>The efficacy of Enbrel was assessed in a&#160;randomised, double-blind, placebo-controlled study in 205&#160;<br/>patients with psoriatic arthritis. Patients were between 18 and 70&#160;years of age and had active psoriatic&#160;<br/>arthritis (</p>
<p style="position:absolute;top:449px;left:167px;white-space:nowrap" class="ft5014">&#160;3 swollen joints and&#160;&#160;3 tender joints) in at least one of the following forms:&#160;(1)&#160;distal&#160;</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft508">interphalangeal (DIP) involvement; (2)&#160;polyarticular arthritis (absence of rheumatoid nodules and&#160;<br/>presence of psoriasis); (3)&#160;arthritis mutilans; (4)&#160;asymmetric psoriatic arthritis; or (5)&#160;spondylitis-like&#160;<br/>ankylosis. Patients also had plaque psoriasis with a qualifying target lesion&#160;</p>
<p style="position:absolute;top:507px;left:604px;white-space:nowrap" class="ft5014">&#160;2&#160;cm in diameter.&#160;</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft508">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids&#160;<br/>(24%). Patients currently on methotrexate therapy (stable for&#160;</p>
<p style="position:absolute;top:547px;left:512px;white-space:nowrap" class="ft5014">&#160;2 months) could continue at a stable&#160;</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft502">dose of&#160;</p>
<p style="position:absolute;top:567px;left:159px;white-space:nowrap" class="ft5014">&#160;25&#160;mg/week methotrexate. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in&#160;</p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft504">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6&#160;months. At the&#160;<br/>end of the double-blind study, patients could enter a long-term open-label extension study for a total&#160;<br/>duration of up to 2&#160;years.</p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft503">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70&#160;<br/>response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results&#160;<br/>are summarised in the table below.</p>
<p style="position:absolute;top:739px;left:239px;white-space:nowrap" class="ft501"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:758px;left:389px;white-space:nowrap" class="ft501"><b>Controlled Trial</b></p>
<p style="position:absolute;top:778px;left:495px;white-space:nowrap" class="ft502">Percent of Patients</p>
<p style="position:absolute;top:797px;left:473px;white-space:nowrap" class="ft502">Placebo</p>
<p style="position:absolute;top:797px;left:586px;white-space:nowrap" class="ft502">Enbrela</p>
<p style="position:absolute;top:816px;left:226px;white-space:nowrap" class="ft502">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:816px;left:474px;white-space:nowrap" class="ft502">n = 104</p>
<p style="position:absolute;top:816px;left:585px;white-space:nowrap" class="ft502">n = 101</p>
<p style="position:absolute;top:855px;left:226px;white-space:nowrap" class="ft5024"><b>&#160;&#160;ACR 20<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:874px;left:491px;white-space:nowrap" class="ft502">15</p>
<p style="position:absolute;top:874px;left:600px;white-space:nowrap" class="ft502">59b</p>
<p style="position:absolute;top:893px;left:226px;white-space:nowrap" class="ft502">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:893px;left:491px;white-space:nowrap" class="ft502">13</p>
<p style="position:absolute;top:893px;left:600px;white-space:nowrap" class="ft502">50b</p>
<p style="position:absolute;top:931px;left:226px;white-space:nowrap" class="ft5023"><b>&#160;&#160;ACR 50<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:950px;left:495px;white-space:nowrap" class="ft502">4</p>
<p style="position:absolute;top:950px;left:600px;white-space:nowrap" class="ft502">38b</p>
<p style="position:absolute;top:969px;left:226px;white-space:nowrap" class="ft502">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:969px;left:495px;white-space:nowrap" class="ft502">4</p>
<p style="position:absolute;top:969px;left:600px;white-space:nowrap" class="ft502">37b</p>
<p style="position:absolute;top:1007px;left:226px;white-space:nowrap" class="ft5023"><b>&#160;&#160;ACR 70<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:1026px;left:495px;white-space:nowrap" class="ft502">0</p>
<p style="position:absolute;top:1026px;left:600px;white-space:nowrap" class="ft502">11b</p>
<p style="position:absolute;top:1045px;left:226px;white-space:nowrap" class="ft502">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:1045px;left:495px;white-space:nowrap" class="ft502">1</p>
<p style="position:absolute;top:1045px;left:604px;white-space:nowrap" class="ft502">9c</p>
</div>
<!-- Page 51 -->
<a name="51"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page51-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft510">51</p>
<p style="position:absolute;top:108px;left:239px;white-space:nowrap" class="ft511"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:127px;left:389px;white-space:nowrap" class="ft511"><b>Controlled Trial</b></p>
<p style="position:absolute;top:146px;left:495px;white-space:nowrap" class="ft512">Percent of Patients</p>
<p style="position:absolute;top:165px;left:473px;white-space:nowrap" class="ft512">Placebo</p>
<p style="position:absolute;top:165px;left:586px;white-space:nowrap" class="ft512">Enbrela</p>
<p style="position:absolute;top:184px;left:226px;white-space:nowrap" class="ft512">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:184px;left:474px;white-space:nowrap" class="ft512">n = 104</p>
<p style="position:absolute;top:184px;left:585px;white-space:nowrap" class="ft512">n = 101</p>
<p style="position:absolute;top:203px;left:226px;white-space:nowrap" class="ft5123"><b>&#160;&#160;PsARC<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:222px;left:491px;white-space:nowrap" class="ft512">31</p>
<p style="position:absolute;top:222px;left:600px;white-space:nowrap" class="ft512">72b</p>
<p style="position:absolute;top:241px;left:226px;white-space:nowrap" class="ft512">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:241px;left:491px;white-space:nowrap" class="ft512">23</p>
<p style="position:absolute;top:241px;left:600px;white-space:nowrap" class="ft512">70b</p>
<p style="position:absolute;top:261px;left:236px;white-space:nowrap" class="ft514">a: 25&#160;mg Enbrel SC twice weekly<br/>b: p &lt; 0.001, Enbrel vs. placebo<br/>c: p &lt; 0.01,&#160;Enbrel vs. placebo</p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft514">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at&#160;<br/>the time of the first visit (4&#160;weeks) and were maintained through 6&#160;months of therapy. Enbrel was&#160;<br/>significantly better than placebo in&#160;all measures of disease activity (p&#160;&lt;&#160;0.001), and responses were&#160;<br/>similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis&#160;<br/>patients was assessed at every timepoint using the disability index of the HAQ. The disability index&#160;<br/>score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel,&#160;<br/>relative to placebo (p&#160;&lt;&#160;0.001).&#160;</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft513">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists&#160;<br/>were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in&#160;<br/>the table below. In an analysis in which all patients who dropped out of the study for any reason were&#160;<br/>considered to have progressed, the percentage of patients without progression (TSS change&#160;≤&#160;0.5) at&#160;<br/>12&#160;months was higher in the Enbrel group compared with the placebo group (73% vs. 47%,&#160;<br/>respectively, p&#160;≤&#160;0.001). The effect of Enbrel on radiographic progression was maintained in patients&#160;<br/>who continued on treatment during the second year. The slowing of peripheral joint damage was&#160;<br/>observed in patients with polyarticular symmetrical joint involvement. &#160;</p>
<p style="position:absolute;top:664px;left:238px;white-space:nowrap" class="ft511"><b>Mean (SE) Annualized Change from Baseline in Total Sharp Score</b></p>
<p style="position:absolute;top:693px;left:469px;white-space:nowrap" class="ft512">Placebo</p>
<p style="position:absolute;top:693px;left:684px;white-space:nowrap" class="ft512">Etanercept</p>
<p style="position:absolute;top:721px;left:232px;white-space:nowrap" class="ft512">Time</p>
<p style="position:absolute;top:721px;left:464px;white-space:nowrap" class="ft512">(n = 104)</p>
<p style="position:absolute;top:721px;left:688px;white-space:nowrap" class="ft512">(n = 101)</p>
<p style="position:absolute;top:750px;left:217px;white-space:nowrap" class="ft512">Month&#160;12</p>
<p style="position:absolute;top:750px;left:458px;white-space:nowrap" class="ft512">1.00 (0.29)</p>
<p style="position:absolute;top:750px;left:677px;white-space:nowrap" class="ft512">-0.03 (0.09)a</p>
<p style="position:absolute;top:769px;left:123px;white-space:nowrap" class="ft513">SE = standard error. &#160;<br/>a. p = 0.0001. &#160;</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft513">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this&#160;<br/>benefit was maintained during the longer-term exposure of up to 2&#160;years.</p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft513">There&#160;is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and&#160;<br/>arthritis mutilans&#160;psoriatic arthropathies due to the small number of patients studied.</p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft513">No study has been performed in patients with psoriatic arthritis using the 50&#160;mg once-weekly dosing&#160;<br/>regimen. Evidence of efficacy for the once-weekly dosing regimen in this patient population has been&#160;<br/>based on data from the study in patients with ankylosing spondylitis.</p>
<p style="position:absolute;top:1010px;left:106px;white-space:nowrap" class="ft518"><i>Adult patients with ankylosing spondylitis<br/></i>The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies&#160;<br/>comparing twice-weekly administration of 25&#160;mg Enbrel with placebo. A total of 401 patients were&#160;<br/>enrolled, from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled&#160;<br/>patients who were between 18 and 70&#160;years of age and had active ankylosing spondylitis defined as&#160;<br/>visual analog scale (VAS) scores of&#160;</p>
<p style="position:absolute;top:1105px;left:347px;white-space:nowrap" class="ft5114">&#160;30 for average of duration and intensity of morning stiffness&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft512">plus VAS scores of&#160;</p>
<p style="position:absolute;top:1125px;left:239px;white-space:nowrap" class="ft5114">&#160;30 for&#160;at least 2 of the following 3 parameters: patient global assessment;&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft512">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the&#160;</p>
</div>
<!-- Page 52 -->
<a name="52"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page52-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft520">52</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft524">Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS,&#160;or&#160;<br/>corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine&#160;<br/>were not included in the study. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in patients&#160;<br/>with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6&#160;months in&#160;<br/>138&#160;patients.</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft522">The primary measure of efficacy (ASAS 20) was a&#160;</p>
<p style="position:absolute;top:221px;left:446px;white-space:nowrap" class="ft5214">20% improvement in at least 3 of the 4&#160;</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft524">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain,&#160;<br/>BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70&#160;<br/>responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft524">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20,&#160;<br/>ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</p>
<p style="position:absolute;top:375px;left:255px;white-space:nowrap" class="ft521"><b>Responses of Patients with Ankylosing Spondylitis in a&#160;</b></p>
<p style="position:absolute;top:394px;left:361px;white-space:nowrap" class="ft521"><b>Placebo-controlled Trial</b></p>
<p style="position:absolute;top:414px;left:482px;white-space:nowrap" class="ft522">Percent of Patients</p>
<p style="position:absolute;top:434px;left:242px;white-space:nowrap" class="ft522">&#160;&#160;Ankylosing Spondylitis&#160;</p>
<p style="position:absolute;top:453px;left:249px;white-space:nowrap" class="ft522">Response</p>
<p style="position:absolute;top:434px;left:464px;white-space:nowrap" class="ft522">Placebo</p>
<p style="position:absolute;top:453px;left:462px;white-space:nowrap" class="ft522">N = 139</p>
<p style="position:absolute;top:434px;left:576px;white-space:nowrap" class="ft522">Enbrel</p>
<p style="position:absolute;top:453px;left:570px;white-space:nowrap" class="ft522">N = 138</p>
<p style="position:absolute;top:474px;left:241px;white-space:nowrap" class="ft522">&#160;&#160;ASAS 20&#160;</p>
<p style="position:absolute;top:494px;left:259px;white-space:nowrap" class="ft522">2 weeks</p>
<p style="position:absolute;top:494px;left:481px;white-space:nowrap" class="ft522">22</p>
<p style="position:absolute;top:494px;left:587px;white-space:nowrap" class="ft522">46a</p>
<p style="position:absolute;top:514px;left:259px;white-space:nowrap" class="ft522">3 months</p>
<p style="position:absolute;top:514px;left:481px;white-space:nowrap" class="ft522">27</p>
<p style="position:absolute;top:514px;left:587px;white-space:nowrap" class="ft522">60a</p>
<p style="position:absolute;top:534px;left:259px;white-space:nowrap" class="ft522">6&#160;months</p>
<p style="position:absolute;top:534px;left:481px;white-space:nowrap" class="ft522">23</p>
<p style="position:absolute;top:534px;left:587px;white-space:nowrap" class="ft522">58a</p>
<p style="position:absolute;top:563px;left:241px;white-space:nowrap" class="ft522">&#160;&#160;ASAS 50&#160;</p>
<p style="position:absolute;top:583px;left:259px;white-space:nowrap" class="ft522">2 weeks</p>
<p style="position:absolute;top:583px;left:485px;white-space:nowrap" class="ft522">7</p>
<p style="position:absolute;top:583px;left:587px;white-space:nowrap" class="ft522">24a</p>
<p style="position:absolute;top:603px;left:259px;white-space:nowrap" class="ft522">3 months</p>
<p style="position:absolute;top:603px;left:481px;white-space:nowrap" class="ft522">13</p>
<p style="position:absolute;top:603px;left:587px;white-space:nowrap" class="ft522">45a</p>
<p style="position:absolute;top:623px;left:259px;white-space:nowrap" class="ft522">6&#160;months</p>
<p style="position:absolute;top:623px;left:481px;white-space:nowrap" class="ft522">10</p>
<p style="position:absolute;top:623px;left:587px;white-space:nowrap" class="ft522">42a</p>
<p style="position:absolute;top:652px;left:241px;white-space:nowrap" class="ft522">&#160;&#160;ASAS 70</p>
<p style="position:absolute;top:672px;left:259px;white-space:nowrap" class="ft522">2 weeks</p>
<p style="position:absolute;top:672px;left:485px;white-space:nowrap" class="ft522">2</p>
<p style="position:absolute;top:672px;left:586px;white-space:nowrap" class="ft522">12b</p>
<p style="position:absolute;top:693px;left:259px;white-space:nowrap" class="ft522">3 months</p>
<p style="position:absolute;top:693px;left:485px;white-space:nowrap" class="ft522">7</p>
<p style="position:absolute;top:693px;left:586px;white-space:nowrap" class="ft522">29b</p>
<p style="position:absolute;top:713px;left:259px;white-space:nowrap" class="ft522">6&#160;months&#160;</p>
<p style="position:absolute;top:713px;left:485px;white-space:nowrap" class="ft522">5</p>
<p style="position:absolute;top:713px;left:586px;white-space:nowrap" class="ft522">28b</p>
<p style="position:absolute;top:742px;left:246px;white-space:nowrap" class="ft528">a: p&lt;0.001, Enbrel vs. placebo<br/>b: p = 0.002, Enbrel vs. placebo</p>
<p style="position:absolute;top:801px;left:106px;white-space:nowrap" class="ft524">Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent&#160;<br/>at the time of the first visit (2&#160;weeks) and were maintained through 6&#160;months of therapy. Responses&#160;<br/>were similar in patients who were or were not receiving concomitant therapies at baseline.</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft522">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft524">In a fourth study, the safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered&#160;<br/>once weekly vs. 25&#160;mg Enbrel administered twice weekly were evaluated in a double-blind,&#160;<br/>placebo-controlled study of 356&#160;patients with active ankylosing spondylitis. The safety and efficacy&#160;<br/>profiles of the 50&#160;mg once-weekly and 25&#160;mg twice-weekly regimens were similar.</p>
<p style="position:absolute;top:1010px;left:106px;white-space:nowrap" class="ft525"><i>Adult patients with&#160;non-radiographic axial spondyloarthritis</i></p>
<p style="position:absolute;top:1048px;left:106px;white-space:nowrap" class="ft523"><i>Study 1<br/></i>The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was&#160;<br/>assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated&#160;<br/>215&#160;adult patients&#160;(modified intent-to-treat population)&#160;with active nr-AxSpa (18 to 49 years of age),<br/>defined as those patients meeting the ASAS&#160;classification criteria of&#160;axial&#160;spondyloarthritis but did not&#160;<br/>meet the modified New York criteria for AS.&#160;Patients were also required to have an&#160;inadequate&#160;</p>
</div>
<!-- Page 53 -->
<a name="53"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page53-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft530">53</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft533">response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel&#160;<br/>50&#160;mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40%&#160;<br/>improvement in at least three of the four ASAS domains and absence of deterioration in the remaining&#160;<br/>domain.&#160;The double-blind period was followed by an open-label period during which all patients&#160;<br/>receive&#160;Enbrel 50&#160;mg weekly for up to an additional 92 weeks.&#160;MRIs of the sacroiliac joint and spine&#160;<br/>were obtained to assess inflammation at baseline and at weeks&#160;12&#160;and 104.</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft533">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the&#160;<br/>ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial&#160;<br/>remission and BASDAI 50.&#160;Week 12&#160;results are shown in the table below.</p>
<p style="position:absolute;top:320px;left:135px;white-space:nowrap" class="ft531"><b>Efficacy Response&#160;in Placebo-Controlled nr-AxSpa Study:&#160;Percent of Patients Achieving&#160;</b></p>
<p style="position:absolute;top:339px;left:410px;white-space:nowrap" class="ft531"><b>Endpoints</b></p>
<p style="position:absolute;top:359px;left:141px;white-space:nowrap" class="ft534">Double-Blind Clinical<br/>Responses at Week 12&#160;</p>
<p style="position:absolute;top:359px;left:481px;white-space:nowrap" class="ft532">Placebo</p>
<p style="position:absolute;top:378px;left:457px;white-space:nowrap" class="ft532">N=106 to 109*</p>
<p style="position:absolute;top:359px;left:661px;white-space:nowrap" class="ft532">Enbrel</p>
<p style="position:absolute;top:378px;left:633px;white-space:nowrap" class="ft532">N=103 to 105*</p>
<p style="position:absolute;top:397px;left:141px;white-space:nowrap" class="ft532">ASAS** 40</p>
<p style="position:absolute;top:397px;left:493px;white-space:nowrap" class="ft532">15.7</p>
<p style="position:absolute;top:397px;left:666px;white-space:nowrap" class="ft532">32.4b</p>
<p style="position:absolute;top:417px;left:141px;white-space:nowrap" class="ft532">ASAS 20</p>
<p style="position:absolute;top:417px;left:493px;white-space:nowrap" class="ft532">36.1</p>
<p style="position:absolute;top:417px;left:666px;white-space:nowrap" class="ft532">52.4c</p>
<p style="position:absolute;top:437px;left:141px;white-space:nowrap" class="ft532">ASAS 5/6</p>
<p style="position:absolute;top:437px;left:493px;white-space:nowrap" class="ft532">10.4</p>
<p style="position:absolute;top:437px;left:666px;white-space:nowrap" class="ft532">33.0a</p>
<p style="position:absolute;top:457px;left:141px;white-space:nowrap" class="ft532">ASAS partial remission</p>
<p style="position:absolute;top:457px;left:493px;white-space:nowrap" class="ft532">11.9</p>
<p style="position:absolute;top:457px;left:666px;white-space:nowrap" class="ft532">24.8c</p>
<p style="position:absolute;top:476px;left:141px;white-space:nowrap" class="ft532">BASDAI***50</p>
<p style="position:absolute;top:476px;left:493px;white-space:nowrap" class="ft532">23.9</p>
<p style="position:absolute;top:476px;left:666px;white-space:nowrap" class="ft532">43.8b</p>
<p style="position:absolute;top:496px;left:149px;white-space:nowrap" class="ft533">*Some patients did not provide complete data for each endpoint<br/>**ASAS=Assessments in Spondyloarthritis International Society<br/>***Bath Ankylosing Spondylitis Disease Activity Index<br/>a: p&#160;&lt;0.001,&#160;b:&lt;0.01 and&#160;c:&lt;0.05,&#160;respectively between&#160;Enbrel and&#160;placebo</p>
<p style="position:absolute;top:591px;left:106px;white-space:nowrap" class="ft534">At week 12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis&#160;<br/>Research Consortium of Canada) score&#160;for the sacroiliac joint&#160;(SIJ)&#160;as measured by MRI for patients&#160;<br/>receiving Enbrel. Adjusted mean change from baseline&#160;was 3.8 for Enbrel treated (n=95) versus 0.8&#160;<br/>for placebo treated (n=105) patients (p&lt;0.001).&#160;At week&#160;104, the mean change from baseline in the&#160;<br/>SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and&#160;<br/>1.40&#160;the spine (n=154).</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft534">Enbrel showed statistically significantly greater improvement&#160;from baseline to week 12 compared to&#160;<br/>placebo&#160;in&#160;most health-related quality of life and physical function assessments, including&#160;BASFI<br/>(Bath Ankylosing Spondylitis Functional Index),&#160;EuroQol 5D&#160;Overall Health State Score and SF-36&#160;<br/>Physical Component Score.</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft534">Clinical responses among&#160;nr-AxSpa&#160;patients who received Enbrel were apparent at the time of the first&#160;<br/>visit (2&#160;weeks) and were maintained through&#160;2&#160;years&#160;of therapy.&#160;Improvements in health-related&#160;<br/>quality of life and physical function&#160;were also maintained through 2&#160;years of therapy. The 2&#160;year data&#160;<br/>did not reveal any new safety findings.&#160;At week&#160;104, 8&#160;subjects had progressed to a score of bilateral&#160;<br/>Grade&#160;2 on spinal X-ray according to&#160;the modified New York Radiological Grade, indicative of axial&#160;<br/>spondyloarthropathy.</p>
<p style="position:absolute;top:951px;left:106px;white-space:nowrap" class="ft533"><i>Study 2<br/></i>This multi-center, open-label,&#160;phase 4,&#160;3-period study evaluated the withdrawal and retreatment of&#160;<br/>Enbrel&#160;in patients with active nr-AxSpa who achieved an adequate&#160;response (inactive disease defined&#160;<br/>as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3)&#160;<br/>following 24&#160;weeks of treatment.&#160;</p>
<p style="position:absolute;top:1065px;left:106px;white-space:nowrap" class="ft534">209&#160;adult patients with active nr-AxSpa (18 to 49&#160;years of age), defined as those patients meeting the&#160;<br/>Assessment of SpondyloArthritis&#160;International Society (ASAS) classification criteria of axial&#160;<br/>spondyloarthritis (but not meeting the modified New York criteria for AS), having&#160;positive&#160;MRI&#160;<br/>findings (active inflammation on MRI highly suggestive of&#160;sacroiliitis&#160;associated with SpA) and/or&#160;<br/>positive hsCRP (defined as high sensitivity C-reactive protein&#160;[hsCRP]&#160;&gt;3&#160;mg/l), and&#160;active symptoms&#160;</p>
</div>
<!-- Page 54 -->
<a name="54"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page54-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft540">54</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft543">defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received open-label&#160;<br/>Enbrel 50&#160;mg weekly&#160;plus stable background NSAID at the optimal tolerated anti-inflammatory&#160;<br/>dosage&#160;for 24&#160;weeks in Period 1. Patients were also required to have&#160;an inadequate response or&#160;<br/>intolerance to two or more NSAIDs. At week&#160;24, 119 (57%) patients achieved inactive disease and&#160;<br/>entered into the Period&#160;2&#160;40-week withdrawal phase&#160;where subjects discontinued etanercept, yet&#160;<br/>maintained the background NSAID. The&#160;primary measure of efficacy was the occurrence of flare&#160;<br/>(defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal to 2.1) within&#160;<br/>40&#160;weeks following withdrawal of Enbrel. Patients who flared were retreated with&#160;Enbrel 50&#160;mg&#160;<br/>weekly for 12&#160;weeks (Period 3).</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft544">In Period&#160;2, the proportion of patients experiencing&#160;≥1 flare increased from 22% (25/112) at week 4 to&#160;<br/>67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within&#160;<br/>40&#160;weeks following withdrawal of Enbrel.&#160;</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft544">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and&#160;<br/>additionally&#160;compare&#160;the time to flare to&#160;patients from Study 1 who met the Study&#160;2 withdrawal phase&#160;<br/>entry requirements and continued Enbrel&#160;therapy.&#160;</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft543">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24&#160;weeks).&#160;Less&#160;<br/>than 25% of patients in Study&#160;1 who did not have treatment withdrawn experienced a flare&#160;over the&#160;<br/>equivalent&#160;40-weeks&#160;as in&#160;Period 2&#160;Study 2. The time to flare was statistically significantly shorter in&#160;<br/>subjects who discontinued&#160;Enbrel&#160;treatment (Study 2) compared to subjects who received continuous&#160;<br/>etanercept treatment (Study 1), p&#160;&lt;&#160;0.0001.</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft544">Of the 87&#160;patients who entered Period 3 and were retreated with Enbrel 50&#160;mg weekly for 12&#160;weeks,&#160;<br/>62% (54/87) reachieved inactive disease,&#160;with 50% of&#160;them&#160;reachieving&#160;it&#160;within 5&#160;weeks (95% CI:&#160;<br/>4-8&#160;weeks).</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft543"><i>Adult patients with plaque psoriasis<br/></i>Enbrel is recommended for use in patients as defined in section 4.1. Patients who “failed to respond&#160;<br/>to” in the target population is defined by insufficient response (PASI&lt;50 or PGA less than good), or&#160;<br/>worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long&#160;<br/>duration to assess response with at least&#160;one&#160;of the three major systemic therapies as available.</p>
<p style="position:absolute;top:753px;left:106px;white-space:nowrap" class="ft544">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis&#160;<br/>(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel&#160;<br/>with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four&#160;<br/>randomised, double-blind, placebo-controlled studies. The primary&#160;efficacy endpoint in all four studies&#160;<br/>was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75%&#160;<br/>improvement in the Psoriasis Area and Severity Index score from baseline) at 12&#160;weeks.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft542">Study 1 was a Phase 2 study&#160;in patients with active, but clinically stable, plaque psoriasis involving&#160;</p>
<p style="position:absolute;top:885px;left:766px;white-space:nowrap" class="ft5414"></p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft542">10% of the body surface area who were&#160;</p>
<p style="position:absolute;top:906px;left:372px;white-space:nowrap" class="ft5414">&#160;18 years old. One hundred and twelve (112) patients were&#160;</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft542">randomised to receive a dose of 25&#160;mg of Enbrel (n=57) or placebo (n=55) twice a week for 24&#160;weeks.</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft544">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study&#160;<br/>1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel&#160;<br/>was administered at doses of 25&#160;mg once a week, 25&#160;mg twice a week or 50&#160;mg twice a week for&#160;<br/>6&#160;consecutive months. During the first 12 weeks of the double-blind treatment period, patients&#160;<br/>received placebo or one of the above three Enbrel doses. After 12&#160;weeks of treatment, patients in the&#160;<br/>placebo group began treatment with blinded Enbrel (25&#160;mg twice a week); patients in the active&#160;<br/>treatment groups continued to week&#160;24 on the dose to which they were originally randomised.</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft543">Study&#160;3 evaluated 583 patients and had the same inclusion criteria&#160;as study&#160;2. Patients in this study&#160;<br/>received a dose of 25&#160;mg or 50&#160;mg Enbrel, or placebo twice a week for 12&#160;weeks and then all patients&#160;<br/>received open-label 25&#160;mg&#160;Enbrel twice weekly for an additional 24&#160;weeks.</p>
</div>
<!-- Page 55 -->
<a name="55"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page55-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft550">55</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft553">Study&#160;4 evaluated 142 patients and had similar inclusion criteria to studies&#160;2 and 3. Patients in this&#160;<br/>study received a dose of 50&#160;mg Enbrel or placebo once weekly for 12&#160;weeks and then all patients&#160;<br/>received open-label 50&#160;mg&#160;Enbrel once weekly for an additional 12&#160;weeks.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft553">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75&#160;<br/>response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;0.0001). At 24 weeks,&#160;<br/>56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of&#160;<br/>placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</p>
<p style="position:absolute;top:297px;left:262px;white-space:nowrap" class="ft551"><b>Responses of Patients with Psoriasis in Studies 2, 3 and 4</b></p>
<p style="position:absolute;top:435px;left:118px;white-space:nowrap" class="ft552">Respons</p>
<p style="position:absolute;top:454px;left:127px;white-space:nowrap" class="ft552">e (%)</p>
<p style="position:absolute;top:318px;left:273px;white-space:nowrap" class="ft552">Study 2</p>
<p style="position:absolute;top:318px;left:489px;white-space:nowrap" class="ft552">Study 3</p>
<p style="position:absolute;top:318px;left:691px;white-space:nowrap" class="ft552">Study 4</p>
<p style="position:absolute;top:377px;left:191px;white-space:nowrap" class="ft552">Placebo</p>
<p style="position:absolute;top:339px;left:262px;white-space:nowrap" class="ft552">----------Enbrel---------</p>
<p style="position:absolute;top:377px;left:421px;white-space:nowrap" class="ft552">Placebo</p>
<p style="position:absolute;top:339px;left:488px;white-space:nowrap" class="ft552">--------Enbrel-------</p>
<p style="position:absolute;top:377px;left:623px;white-space:nowrap" class="ft552">Placebo</p>
<p style="position:absolute;top:339px;left:696px;white-space:nowrap" class="ft552">-------Enbrel------</p>
<p style="position:absolute;top:357px;left:270px;white-space:nowrap" class="ft552">25&#160;mg&#160;</p>
<p style="position:absolute;top:377px;left:275px;white-space:nowrap" class="ft552">BIW</p>
<p style="position:absolute;top:357px;left:351px;white-space:nowrap" class="ft552">50&#160;mg&#160;</p>
<p style="position:absolute;top:377px;left:356px;white-space:nowrap" class="ft552">BIW</p>
<p style="position:absolute;top:357px;left:493px;white-space:nowrap" class="ft552">25&#160;mg</p>
<p style="position:absolute;top:377px;left:497px;white-space:nowrap" class="ft552">BIW</p>
<p style="position:absolute;top:357px;left:561px;white-space:nowrap" class="ft552">50&#160;mg</p>
<p style="position:absolute;top:377px;left:565px;white-space:nowrap" class="ft552">BIW</p>
<p style="position:absolute;top:357px;left:696px;white-space:nowrap" class="ft552">50&#160;mg&#160;</p>
<p style="position:absolute;top:377px;left:702px;white-space:nowrap" class="ft552">QW</p>
<p style="position:absolute;top:357px;left:763px;white-space:nowrap" class="ft552">50&#160;mg</p>
<p style="position:absolute;top:377px;left:769px;white-space:nowrap" class="ft552">QW</p>
<p style="position:absolute;top:395px;left:192px;white-space:nowrap" class="ft552">n = 166</p>
<p style="position:absolute;top:414px;left:196px;white-space:nowrap" class="ft552">wk 12</p>
<p style="position:absolute;top:395px;left:260px;white-space:nowrap" class="ft552">n =&#160;</p>
<p style="position:absolute;top:414px;left:258px;white-space:nowrap" class="ft552">162</p>
<p style="position:absolute;top:433px;left:260px;white-space:nowrap" class="ft552">wk&#160;</p>
<p style="position:absolute;top:452px;left:262px;white-space:nowrap" class="ft552">12</p>
<p style="position:absolute;top:395px;left:300px;white-space:nowrap" class="ft552">n =&#160;</p>
<p style="position:absolute;top:414px;left:298px;white-space:nowrap" class="ft552">162</p>
<p style="position:absolute;top:433px;left:301px;white-space:nowrap" class="ft554">wk&#160;<br/>24a</p>
<p style="position:absolute;top:395px;left:341px;white-space:nowrap" class="ft552">n =&#160;</p>
<p style="position:absolute;top:414px;left:339px;white-space:nowrap" class="ft552">164</p>
<p style="position:absolute;top:433px;left:341px;white-space:nowrap" class="ft552">wk&#160;</p>
<p style="position:absolute;top:452px;left:343px;white-space:nowrap" class="ft552">12</p>
<p style="position:absolute;top:395px;left:381px;white-space:nowrap" class="ft552">n =&#160;</p>
<p style="position:absolute;top:414px;left:379px;white-space:nowrap" class="ft552">164</p>
<p style="position:absolute;top:433px;left:382px;white-space:nowrap" class="ft554">wk&#160;<br/>24a</p>
<p style="position:absolute;top:395px;left:422px;white-space:nowrap" class="ft552">n = 193</p>
<p style="position:absolute;top:414px;left:426px;white-space:nowrap" class="ft552">wk 12</p>
<p style="position:absolute;top:395px;left:489px;white-space:nowrap" class="ft552">n = 196</p>
<p style="position:absolute;top:414px;left:493px;white-space:nowrap" class="ft552">wk 12</p>
<p style="position:absolute;top:395px;left:557px;white-space:nowrap" class="ft552">n = 196</p>
<p style="position:absolute;top:414px;left:561px;white-space:nowrap" class="ft552">wk 12</p>
<p style="position:absolute;top:395px;left:628px;white-space:nowrap" class="ft552">n = 46</p>
<p style="position:absolute;top:414px;left:628px;white-space:nowrap" class="ft552">wk 12</p>
<p style="position:absolute;top:395px;left:695px;white-space:nowrap" class="ft552">n = 96</p>
<p style="position:absolute;top:414px;left:696px;white-space:nowrap" class="ft552">wk 12</p>
<p style="position:absolute;top:395px;left:763px;white-space:nowrap" class="ft552">n = 90</p>
<p style="position:absolute;top:414px;left:761px;white-space:nowrap" class="ft552">wk 24a</p>
<p style="position:absolute;top:474px;left:114px;white-space:nowrap" class="ft552">PASI 50</p>
<p style="position:absolute;top:474px;left:208px;white-space:nowrap" class="ft552">14</p>
<p style="position:absolute;top:474px;left:258px;white-space:nowrap" class="ft552">58*</p>
<p style="position:absolute;top:474px;left:302px;white-space:nowrap" class="ft552">70</p>
<p style="position:absolute;top:474px;left:339px;white-space:nowrap" class="ft552">74*</p>
<p style="position:absolute;top:474px;left:383px;white-space:nowrap" class="ft552">77</p>
<p style="position:absolute;top:474px;left:441px;white-space:nowrap" class="ft552">9</p>
<p style="position:absolute;top:474px;left:501px;white-space:nowrap" class="ft552">64*</p>
<p style="position:absolute;top:474px;left:568px;white-space:nowrap" class="ft552">77*</p>
<p style="position:absolute;top:474px;left:644px;white-space:nowrap" class="ft552">9</p>
<p style="position:absolute;top:474px;left:703px;white-space:nowrap" class="ft552">69*</p>
<p style="position:absolute;top:474px;left:775px;white-space:nowrap" class="ft552">83</p>
<p style="position:absolute;top:495px;left:114px;white-space:nowrap" class="ft552">PASI 75</p>
<p style="position:absolute;top:495px;left:212px;white-space:nowrap" class="ft552">4</p>
<p style="position:absolute;top:495px;left:258px;white-space:nowrap" class="ft552">34*</p>
<p style="position:absolute;top:495px;left:302px;white-space:nowrap" class="ft552">44</p>
<p style="position:absolute;top:495px;left:339px;white-space:nowrap" class="ft552">49*</p>
<p style="position:absolute;top:495px;left:383px;white-space:nowrap" class="ft552">59</p>
<p style="position:absolute;top:495px;left:441px;white-space:nowrap" class="ft552">3</p>
<p style="position:absolute;top:495px;left:501px;white-space:nowrap" class="ft552">34*</p>
<p style="position:absolute;top:495px;left:568px;white-space:nowrap" class="ft552">49*</p>
<p style="position:absolute;top:495px;left:644px;white-space:nowrap" class="ft552">2</p>
<p style="position:absolute;top:495px;left:703px;white-space:nowrap" class="ft552">38*</p>
<p style="position:absolute;top:495px;left:775px;white-space:nowrap" class="ft552">71</p>
<p style="position:absolute;top:520px;left:114px;white-space:nowrap" class="ft553">DSGAb,&#160;<br/>clear or&#160;<br/>almost&#160;<br/>clear</p>
<p style="position:absolute;top:577px;left:212px;white-space:nowrap" class="ft552">5</p>
<p style="position:absolute;top:577px;left:258px;white-space:nowrap" class="ft552">34*</p>
<p style="position:absolute;top:577px;left:302px;white-space:nowrap" class="ft552">39</p>
<p style="position:absolute;top:577px;left:339px;white-space:nowrap" class="ft552">49*</p>
<p style="position:absolute;top:577px;left:383px;white-space:nowrap" class="ft552">55</p>
<p style="position:absolute;top:577px;left:441px;white-space:nowrap" class="ft552">4</p>
<p style="position:absolute;top:577px;left:501px;white-space:nowrap" class="ft552">39*</p>
<p style="position:absolute;top:577px;left:568px;white-space:nowrap" class="ft552">57*</p>
<p style="position:absolute;top:577px;left:644px;white-space:nowrap" class="ft552">4</p>
<p style="position:absolute;top:577px;left:703px;white-space:nowrap" class="ft552">39*</p>
<p style="position:absolute;top:577px;left:775px;white-space:nowrap" class="ft552">64</p>
<p style="position:absolute;top:598px;left:114px;white-space:nowrap" class="ft552">*p&#160;</p>
<p style="position:absolute;top:596px;left:135px;white-space:nowrap" class="ft5514">&#160;0.0001 compared with placebo</p>
<p style="position:absolute;top:617px;left:114px;white-space:nowrap" class="ft553">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4&#160;because the original&#160;<br/>placebo group began receiving Enbrel 25&#160;mg BIW or 50&#160;mg once weekly from week 13 to week 24.<br/>b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft553">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo&#160;<br/>were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft558">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement&#160;<br/>of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the&#160;<br/>occurrence of rebound (PASI&#160;</p>
<p style="position:absolute;top:787px;left:304px;white-space:nowrap" class="ft5514">150% of baseline) and for the time to relapse (defined as a loss of at&#160;</p>
<p style="position:absolute;top:808px;left:106px;white-space:nowrap" class="ft554">least half of the improvement achieved between baseline and week 24). During the withdrawal period,&#160;<br/>symptoms of psoriasis gradually returned, with a median time to disease relapse of 3 months. No&#160;<br/>rebound flare of disease and no psoriasis-related serious adverse events were observed. There was&#160;<br/>some evidence to&#160;support a benefit of re-treatment with Enbrel in patients initially responding to&#160;<br/>treatment.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft554">In study 3, the majority of patients (77%) who were initially randomised to 50&#160;mg twice weekly and&#160;<br/>had their Enbrel dose decreased at week 12 to 25&#160;mg twice weekly maintained their PASI 75 response&#160;<br/>through week 36. For patients who received 25&#160;mg twice weekly throughout the study, the PASI 75&#160;<br/>response continued to improve between weeks 12 and 36.</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft554">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12&#160;<br/>(38%) compared to the placebo-treated group (2%) (p&lt;0.0001). For patients who received 50&#160;mg once&#160;<br/>weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI&#160;<br/>75 at week 24.</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft553">In long-term&#160;(up to 34 months) open-label studies where Enbrel was given without interruption,&#160;<br/>clinical responses were sustained and safety was comparable to shorter-term studies.</p>
</div>
<!-- Page 56 -->
<a name="56"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page56-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft560">56</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft563">An analysis of clinical trial data&#160;did not reveal any&#160;baseline disease characteristics&#160;that would assist&#160;<br/>clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently,&#160;<br/>the choice of intermittent or continuous therapy should be based upon physician judgment and&#160;<br/>individual patient needs.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft563"><i>Antibodies to Enbrel<br/></i>Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept.&#160;<br/>These antibodies have all been non-neutralising and are generally transient. There appears to be no&#160;<br/>correlation between antibody development and clinical response or adverse events.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft564">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative&#160;<br/>rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5%&#160;<br/>of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with&#160;<br/>psoriasis, 9.7% of subjects with paediatric psoriasis, and&#160;4.8&#160;% of subjects with juvenile idiopathic&#160;<br/>arthritis.&#160;</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft564">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to&#160;<br/>3.5&#160;years) increases over time, as expected. However, due to their transient nature, the incidence of&#160;<br/>antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis&#160;<br/>subjects and psoriasis subjects.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft564">In a long-term psoriasis study in which patients received 50&#160;mg twice weekly for 96&#160;weeks, the&#160;<br/>incidence of antibodies observed at each assessment point was up to approximately 9%.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft562">Paediatric population</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft568"><i>Paediatric patients with juvenile&#160;idiopathic arthritis<br/></i>The safety and efficacy of Enbrel were assessed in a two-part study in&#160;69 children with polyarticular-<br/>course&#160;juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types<br/>(polyarthritis, pauciarthritis,&#160;systemic onset). Patients aged 4 to 17 years with moderately to severely&#160;<br/>active polyarticular-course&#160;juvenile idiopathic arthritis refractory to, or intolerant of, methotrexate&#160;<br/>were enrolled; patients remained on a stable dose of a single nonsteroidal anti-inflammatory drug&#160;<br/>and/or prednisone (&lt; 0.2&#160;mg/kg/day or 10&#160;mg maximum). In part 1, all patients received 0.4&#160;mg/kg&#160;<br/>(maximum 25&#160;mg per dose) Enbrel subcutaneously twice weekly. In part 2, patients with a clinical&#160;<br/>response at day 90 were randomised to remain on Enbrel or receive placebo for four months and&#160;<br/>assessed for disease flare. Responses were measured using&#160;ACR Pedi 30&#160;, defined as&#160;</p>
<p style="position:absolute;top:773px;left:669px;white-space:nowrap" class="ft5614">&#160;30%&#160;</p>
<p style="position:absolute;top:795px;left:106px;white-space:nowrap" class="ft562">improvement in at least three of six and&#160;</p>
<p style="position:absolute;top:793px;left:372px;white-space:nowrap" class="ft5614">&#160;30% worsening in no more than one of six JRA core set&#160;</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft568">criteria, including&#160;active joint count, limitation of motion, physician and patient/parent global&#160;<br/>assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was&#160;<br/>defined as a&#160;</p>
<p style="position:absolute;top:852px;left:189px;white-space:nowrap" class="ft5614">&#160;30% worsening in three of six JRA core set criteria and&#160;&#160;30% improvement in not&#160;</p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft562">more than one of the six JRA core set criteria and a minimum of two active joints.</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft563">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In&#160;<br/>part 2, 6&#160;of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of&#160;<br/>26&#160;(77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was&#160;</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft564">&#160;116&#160;days for patients who received Enbrel and 28 days for patients who received placebo. Of&#160;<br/>patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the&#160;<br/>patients remaining on Enbrel continued to improve from month 3 through month 7, while those who&#160;<br/>received placebo did not improve.</p>
<p style="position:absolute;top:1063px;left:106px;white-space:nowrap" class="ft564">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of&#160;<br/>4&#160;years at time of enrollment) continued to receive&#160;Enbrel for up to 10 years.&#160;Rates of serious adverse&#160;<br/>events and serious infections did not increase with long-term&#160;exposure.</p>
<p style="position:absolute;top:1139px;left:106px;white-space:nowrap" class="ft564">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate&#160;<br/>monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18&#160;years&#160;</p>
</div>
<!-- Page 57 -->
<a name="57"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page57-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft570">57</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft574">with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age.&#160;Overall, infections were more&#160;<br/>commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus&#160;<br/>2%), and the infections associated with etanercept use were of a more severe nature.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft574">In another open-label&#160;single-arm&#160;study&#160;(n=127),&#160;60&#160;patients with extended oligoarthritis&#160;(EO)<br/>(15&#160;patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged&#160;12 to 17 years old),&#160;38 patients&#160;<br/>with&#160;enthesitis-related arthritis (12 to 17 years old),&#160;and 29 patients with&#160;psoriatic arthritis (12 to&#160;<br/>17&#160;years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose)&#160;<br/>administered weekly for 12&#160;weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi&#160;<br/>30 criteria and demonstrated clinical improvement in&#160;secondary endpoints such as number of tender&#160;<br/>joints and physician global assessment. The safety profile was consistent with that observed in other&#160;<br/>JIA studies.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft573">Of the 127&#160;patients in the parent study, 109 participated in the open-label extension study and were&#160;<br/>followed for&#160;an additional&#160;8 years&#160;for a total of up to 10 years.&#160;At the end of the extension study,&#160;<br/>84/109 (77%) patients had completed the study; 27 (25%) while actively taking&#160;Enbrel, 7 (6%) had&#160;<br/>withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started&#160;Enbrel&#160;following an&#160;<br/>earlier withdrawal from treatment; and 45 (41%) had stopped&#160;Enbrel&#160;(but remained under&#160;<br/>observation);&#160;25/109 (23%) patients&#160;permanently discontinued from the&#160;study.&#160;Improvements in&#160;<br/>clinical status achieved in the parent study were generally maintained for all efficacy endpoints during&#160;<br/>the entire follow-up period. Patients actively taking&#160;Enbrel could enter an optional withdrawal-<br/>retreatment period once during the extension study based on investigator’s judgement of clinical&#160;<br/>response. 30&#160;patients entered the withdrawal period. 17&#160;patients were reported to have a flare (defined&#160;<br/>as&#160;≥&#160;30% worsening in at least 3 of the 6 ACR Pedi components with&#160;≥&#160;30% improvement in not more&#160;<br/>than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after&#160;<br/>Enbrel withdrawal was 190&#160;days. 13&#160;patients were&#160;re-treated and the median time to re-treatment from&#160;<br/>withdrawal was estimated as 274&#160;days. Due to the small number of data points, these results should be&#160;<br/>interpreted with caution.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft572">The safety profile was consistent with that observed in&#160;the parent study.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft574">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of&#160;<br/>continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy.&#160;<br/>Additionally, studies have not been conducted to assess&#160;the effects of&#160;reducing&#160;the recommended dose&#160;<br/>of Enbrel following its long-term&#160;use in patients with JIA.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft573"><i>Paediatric patients with plaque psoriasis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211&#160;<br/>paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA&#160;<br/>score&#160;≥&#160;3, involving&#160;≥&#160;10% of the BSA, and PASI&#160;≥&#160;12).&#160;Eligible patients had a history of receiving&#160;<br/>phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft573">Patients received Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) or placebo once weekly for 12 weeks. At week 12,&#160;<br/>more patients randomised&#160;to Enbrel had positive efficacy responses (e.g., PASI 75) than those&#160;<br/>randomised to placebo.</p>
<p style="position:absolute;top:995px;left:263px;white-space:nowrap" class="ft571"><b>Paediatric Plaque Psoriasis Outcomes at 12 Weeks</b></p>
<p style="position:absolute;top:1024px;left:495px;white-space:nowrap" class="ft571"><b>Enbrel</b></p>
<p style="position:absolute;top:1043px;left:465px;white-space:nowrap" class="ft571"><b>0.8&#160;mg/kg Once&#160;</b></p>
<p style="position:absolute;top:1062px;left:493px;white-space:nowrap" class="ft571"><b>Weekly</b></p>
<p style="position:absolute;top:1081px;left:487px;white-space:nowrap" class="ft571"><b>(N = 106)</b></p>
<p style="position:absolute;top:1062px;left:647px;white-space:nowrap" class="ft571"><b>Placebo</b></p>
<p style="position:absolute;top:1081px;left:642px;white-space:nowrap" class="ft571"><b>(N = 105)</b></p>
<p style="position:absolute;top:1101px;left:136px;white-space:nowrap" class="ft572">PASI 75, n (%)</p>
<p style="position:absolute;top:1101px;left:486px;white-space:nowrap" class="ft572">60 (57%)a</p>
<p style="position:absolute;top:1101px;left:644px;white-space:nowrap" class="ft572">12 (11%)</p>
<p style="position:absolute;top:1120px;left:136px;white-space:nowrap" class="ft572">PASI 50, n (%)</p>
<p style="position:absolute;top:1120px;left:486px;white-space:nowrap" class="ft572">79&#160;(75%)a</p>
<p style="position:absolute;top:1120px;left:644px;white-space:nowrap" class="ft572">24 (23%)</p>
<p style="position:absolute;top:1151px;left:136px;white-space:nowrap" class="ft572">sPGA “clear” or “minimal”, n (%)</p>
<p style="position:absolute;top:1151px;left:486px;white-space:nowrap" class="ft572">56&#160;(53%)a</p>
<p style="position:absolute;top:1151px;left:644px;white-space:nowrap" class="ft572">14 (13%)</p>
</div>
<!-- Page 58 -->
<a name="58"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page58-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft580">58</p>
<p style="position:absolute;top:108px;left:136px;white-space:nowrap" class="ft584">Abbreviation: sPGA-static Physician Global Assessment<br/>a.&#160;p &lt; 0.0001 compared with placebo</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft583">After the 12-week double-blind treatment period, all patients received Enbrel 0.8&#160;mg/kg (up to&#160;50&#160;mg)&#160;<br/>once weekly for additional 24 weeks. Responses observed during the open-label period were similar to&#160;<br/>those observed in the double-blind period.</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft584">During a randomised withdrawal period, significantly more patients re-randomised to placebo&#160;<br/>experienced&#160;disease relapse (loss of PASI 75 response) compared with patients re-randomised to&#160;<br/>Enbrel. With continued therapy, responses were maintained up to 48 weeks.</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft584">The long-term safety and effectiveness of Enbrel 0.8 mg/kg (up to 50 mg) once weekly was&#160;assessed&#160;<br/>in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2&#160;years&#160;<br/>beyond the 48 week study discussed above. Long-term experience with Enbrel was generally&#160;<br/>comparable to the original 48-week study and did not reveal any new safety findings.&#160;</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft581"><b>5.2</b></p>
<p style="position:absolute;top:414px;left:149px;white-space:nowrap" class="ft581"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:452px;left:106px;white-space:nowrap" class="ft584">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA)&#160;<br/>method, which may detect ELISA-reactive degradation products, as well as the parent compound.</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft582">Absorption</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft588">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum&#160;<br/>concentration approximately 48&#160;hours after a single dose. The absolute bioavailability is 76%. With&#160;<br/>twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high&#160;<br/>as those observed after single doses. After a single subcutaneous dose of 25&#160;mg Enbrel, the average&#160;<br/>maximum serum concentration observed in healthy volunteers was 1.65&#160;</p>
<p style="position:absolute;top:622px;left:585px;white-space:nowrap" class="ft5814">&#160;0.66&#160;g/ml, and the area&#160;</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft582">under the curve was 235</p>
<p style="position:absolute;top:642px;left:272px;white-space:nowrap" class="ft5814">&#160;96.6&#160;ghr/ml.</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft584">Mean serum concentration profiles at steady state in treated RA patients were Cmax&#160;of 2.4&#160;mg/l vs.&#160;<br/>2.6&#160;mg/l, Cmin&#160;of 1.2&#160;mg/l vs. 1.4&#160;mg/l, and partial AUC of 297&#160;mgh/l vs. 316&#160;mgh/l for 50&#160;mg Enbrel&#160;<br/>once weekly (n=21) vs. 25&#160;mg Enbrel&#160;twice weekly (n=16), respectively. In an open-label, single-<br/>dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single&#160;<br/>50&#160;mg/ml injection was found to be bioequivalent to two simultaneous injections of 25&#160;mg/ml.</p>
<p style="position:absolute;top:796px;left:106px;white-space:nowrap" class="ft588">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady&#160;<br/>state AUCs were 466</p>
<p style="position:absolute;top:814px;left:251px;white-space:nowrap" class="ft5814">ghr/ml and 474&#160;ghr/ml for 50&#160;mg Enbrel once weekly (N= 154) and 25&#160;mg&#160;</p>
<p style="position:absolute;top:835px;left:106px;white-space:nowrap" class="ft582">twice weekly (N = 148), respectively.</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft582">Distribution</p>
<p style="position:absolute;top:911px;left:106px;white-space:nowrap" class="ft583">A biexponential&#160;curve is required to describe the concentration time curve of etanercept. The central&#160;<br/>volume of distribution of etanercept is 7.6&#160;l, while the volume of distribution at steady-state is 10.4&#160;l.</p>
<p style="position:absolute;top:968px;left:106px;white-space:nowrap" class="ft582">Elimination</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft584">Etanercept is cleared slowly from the body. The&#160;half-life is long, approximately 70&#160;hours. Clearance is&#160;<br/>approximately 0.066&#160;l/hr in patients with rheumatoid arthritis, somewhat lower than the value of&#160;<br/>0.11&#160;l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid&#160;<br/>arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</p>
<p style="position:absolute;top:1101px;left:106px;white-space:nowrap" class="ft582">There is no apparent pharmacokinetic difference between males and females.</p>
</div>
<!-- Page 59 -->
<a name="59"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page59-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft590">59</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft592">Linearity</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft593">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance&#160;<br/>across the dosing range.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft592">Special populations</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft593"><i>Renal impairment<br/></i>Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept&#160;<br/>to patients and volunteers, increased etanercept concentrations were&#160;not observed in patients with&#160;<br/>acute renal failure. The presence of renal impairment should not require a change in dosage.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft594"><i>Hepatic impairment<br/></i>Increased etanercept concentrations were not observed in patients with acute hepatic failure. The&#160;<br/>presence of&#160;hepatic impairment should not require a change in dosage.</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft594"><i>Elderly<br/></i>The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept&#160;<br/>serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to&#160;<br/>estimates in patients less than 65 years of age.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft592">Paediatric population</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft594"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>In a polyarticular-course&#160;juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged&#160;4 to 17&#160;years)&#160;<br/>were administered 0.4&#160;mg&#160;Enbrel/kg twice weekly for three months. Serum concentration profiles&#160;<br/>were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age)&#160;<br/>had reduced clearance (increased clearance when normalised by weight) compared with older children&#160;<br/>(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of&#160;<br/>age) will have serum levels close to those seen in adults, younger children will have appreciably lower&#160;<br/>levels.</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft594"><i>Paediatric patients with plaque psoriasis<br/></i>Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8&#160;mg/kg (up to a&#160;<br/>maximum dose of 50&#160;mg per week) of etanercept once weekly for up to 48 weeks. The mean serum&#160;<br/>steady-state trough&#160;concentrations ranged from 1.6&#160;to 2.1&#160;mcg/ml at weeks 12, 24, and 48. These mean&#160;<br/>concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed&#160;<br/>in patients with&#160;juvenile idiopathic arthritis&#160;(treated with 0.4&#160;mg/kg&#160;etanercept twice weekly, up to&#160;<br/>maximum dose of 50&#160;mg per week). These mean concentrations were similar to those seen in adult&#160;<br/>patients with plaque psoriasis treated with 25&#160;mg etanercept twice-weekly.</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft591"><b>5.3</b></p>
<p style="position:absolute;top:888px;left:149px;white-space:nowrap" class="ft591"><b>Preclinical safety data</b></p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft594">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel&#160;<br/>was considered to be non-genotoxic from a battery of&#160;<i>in vitro&#160;</i>and&#160;<i>in vivo&#160;</i>studies. Carcinogenicity&#160;<br/>studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel&#160;<br/>due to the development of neutralising antibodies in rodents.</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft593">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single&#160;<br/>subcutaneous dose of 2000&#160;mg/kg or a single intravenous dose of 1000&#160;mg/kg. Enbrel did not elicit&#160;<br/>dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous&#160;<br/>administration for 4 or 26&#160;consecutive weeks at a dose (15&#160;mg/kg) that resulted in AUC-based serum&#160;<br/>drug concentrations that were over&#160;27-fold higher than that obtained in humans at the recommended&#160;<br/>dose of 25&#160;mg.</p>
</div>
<!-- Page 60 -->
<a name="60"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page60-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft600">60</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft601"><b>6.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft601"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft601"><b>6.1</b></p>
<p style="position:absolute;top:146px;left:149px;white-space:nowrap" class="ft601"><b>List of excipients</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft602">Powder</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft603">Mannitol (E421)<br/>Sucrose<br/>Trometamol</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft602">Solvent</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft602">Water for injections</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft601"><b>6.2</b></p>
<p style="position:absolute;top:373px;left:149px;white-space:nowrap" class="ft601"><b>Incompatibilities</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft604">In the absence of&#160;compatibility studies, this medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft601"><b>6.3</b></p>
<p style="position:absolute;top:468px;left:149px;white-space:nowrap" class="ft601"><b>Shelf life</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft602">4&#160;years.</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft608">Chemical and physical in-use stability has been demonstrated for 6&#160;hours at temperatures of up to&#160;<br/>25</p>
<p style="position:absolute;top:562px;left:123px;white-space:nowrap" class="ft6014">C after reconstitution. From a&#160;microbiological point of view, the reconstituted medicinal product&#160;</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft608">should be used immediately. If not used immediately, storage times and conditions prior to use are the&#160;<br/>responsibility of the user and would normally not be longer than 6&#160;hours at temperatures of up to&#160;<br/>25</p>
<p style="position:absolute;top:621px;left:123px;white-space:nowrap" class="ft6014">C, unless reconstitution has taken place in controlled and validated aseptic conditions.</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft601"><b>6.4</b></p>
<p style="position:absolute;top:660px;left:149px;white-space:nowrap" class="ft601"><b>Special precautions for storage</b></p>
<p style="position:absolute;top:700px;left:106px;white-space:nowrap" class="ft602">Store in a refrigerator (2</p>
<p style="position:absolute;top:698px;left:267px;white-space:nowrap" class="ft6014">C&#160;-&#160;8C).&#160;Do not freeze.</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft602">Enbrel may be stored at temperatures up to a maximum of 25</p>
<p style="position:absolute;top:737px;left:511px;white-space:nowrap" class="ft6014">C&#160;for a single period of up to four&#160;</p>
<p style="position:absolute;top:758px;left:106px;white-space:nowrap" class="ft604">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within&#160;<br/>four weeks of removal from refrigeration.</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft602">For storage conditions of the reconstituted medicinal product, see section 6.3.</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft601"><b>6.5</b></p>
<p style="position:absolute;top:853px;left:149px;white-space:nowrap" class="ft601"><b>Nature and contents of container</b></p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft604">Clear glass vial (2&#160;ml, type I glass) with rubber stoppers, aluminium seals, and flip-off plastic caps.&#160;<br/>Enbrel is supplied with pre-filled syringes containing water for injection. The syringes are type I glass.<br/>The syringe cover contains dry natural rubber (latex) (see section 4.4).&#160;Cartons contain 4, 8 or 24 vials&#160;<br/>of Enbrel with 4, 8 or 24 pre-filled solvent syringes, 4, 8 or 24 needles,&#160;4, 8 or 24 vial adaptors and 8,&#160;<br/>16&#160;or 48 alcohol swabs. Not all pack sizes&#160;may be marketed.</p>
<p style="position:absolute;top:1004px;left:106px;white-space:nowrap" class="ft601"><b>6.6</b></p>
<p style="position:absolute;top:1004px;left:149px;white-space:nowrap" class="ft601"><b>Special precautions for disposal and other handling</b></p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft602">Instructions for use and handling</p>
<p style="position:absolute;top:1081px;left:106px;white-space:nowrap" class="ft604">Enbrel is reconstituted with 1&#160;ml water for injections before use, and administered by subcutaneous&#160;<br/>injection. Enbrel contains no antibacterial preservative, and therefore, solutions prepared with water&#160;<br/>for injections should be administered as soon as possible and within 6&#160;hours following reconstitution.&#160;<br/>The solution should be clear and colourless to pale yellow&#160;or pale brown, with no lumps, flakes&#160;or&#160;</p>
</div>
<!-- Page 61 -->
<a name="61"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page61-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft610">61</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft614">particles. Some white foam may remain in the vial&#160;–&#160;this is normal. Enbrel should not be used if all the&#160;<br/>powder in the vial is not dissolved within 10 minutes. If this is the case, start again with another vial.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft614">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are&#160;<br/>given in the package leaflet, section 7,&#160;“Instructions for preparation and giving an injection of Enbrel”.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft614">Any unused&#160;medicinal&#160;product or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft611"><b>7.</b></p>
<p style="position:absolute;top:297px;left:146px;white-space:nowrap" class="ft611"><b>MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft613">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft611"><b>8.</b></p>
<p style="position:absolute;top:449px;left:146px;white-space:nowrap" class="ft611"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft613">EU/1/99/126/003&#160;<br/>EU/1/99/126/004&#160;<br/>EU/1/99/126/005&#160;</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft611"><b>9.</b></p>
<p style="position:absolute;top:582px;left:146px;white-space:nowrap" class="ft611"><b>DATE OF FIRST&#160;AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft614">Date of first authorisation:&#160;03 February 2000<br/>Date of last renewal:&#160;26&#160;November&#160;2009</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft611"><b>10.</b></p>
<p style="position:absolute;top:696px;left:146px;white-space:nowrap" class="ft611"><b>DATE OF REVISION OF THE TEXT</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft614">Detailed information on this&#160;medicinal&#160;product is available on the website of the European Medicines&#160;<br/>Agency&#160;<a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</p>
</div>
<!-- Page 62 -->
<a name="62"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page62-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft620">62</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft621"><b>1.</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft621"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft623">Enbrel&#160;25&#160;mg&#160;solution for injection in pre-filled syringe<br/>Enbrel 50&#160;mg solution for&#160;injection in pre-filled syringe</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft621"><b>2.</b></p>
<p style="position:absolute;top:222px;left:146px;white-space:nowrap" class="ft621"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION</b></p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft622">Enbrel 25&#160;mg solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft622">Each pre-filled syringe contains&#160;25&#160;mg&#160;of etanercept.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft622">Enbrel 50&#160;mg solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft622">Each&#160;pre-filled syringe contains 50&#160;mg of etanercept.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft624">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant&#160;<br/>DNA technology in a Chinese hamster ovary (CHO) mammalian expression system.&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft622">For&#160;the&#160;full list of excipients, see section 6.1.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft621"><b>3.</b></p>
<p style="position:absolute;top:525px;left:146px;white-space:nowrap" class="ft621"><b>PHARMACEUTICAL FORM</b></p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft622">Solution for injection.</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft622">The solution is clear, and colourless&#160;to&#160;pale yellow&#160;or pale brown.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft621"><b>4.</b></p>
<p style="position:absolute;top:658px;left:146px;white-space:nowrap" class="ft621"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft621"><b>4.1</b></p>
<p style="position:absolute;top:696px;left:149px;white-space:nowrap" class="ft621"><b>Therapeutic indications</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft622">Rheumatoid arthritis</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft623">Enbrel in combination with&#160;methotrexate is indicated for the treatment of moderate to severe active&#160;<br/>rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including&#160;<br/>methotrexate (unless contraindicated), has been inadequate.</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft623">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued&#160;<br/>treatment with methotrexate is inappropriate.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft624">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults&#160;<br/>not previously treated with methotrexate.</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft624">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression&#160;<br/>of joint damage as measured by X-ray and to improve physical function.</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft622">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft623">Treatment of&#160;polyarthritis (rheumatoid factor positive or negative)&#160;and extended oligoarthritis&#160;in&#160;<br/>children and adolescents from the age of 2&#160;years who have had an inadequate response to, or who have&#160;<br/>proved intolerant of, methotrexate.</p>
<p style="position:absolute;top:1133px;left:106px;white-space:nowrap" class="ft623">Treatment of&#160;psoriatic arthritis in adolescents from the&#160;age of 12&#160;years who have had an inadequate&#160;<br/>response to, or who have proved intolerant of, methotrexate.</p>
</div>
<!-- Page 63 -->
<a name="63"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page63-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft630">63</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft634">Treatment of enthesitis-related arthritis in adolescents from the age of 12&#160;years who have had an&#160;<br/>inadequate response to, or who have proved intolerant&#160;of, conventional therapy.&#160;</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft632">Psoriatic arthritis</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft634">Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-<br/>modifying antirheumatic drug therapy has been inadequate.&#160;Enbrel has been shown to improve&#160;<br/>physical&#160;function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral<br/>joint damage as measured by X-ray in patients with&#160;polyarticular&#160;symmetrical subtypes of the disease.</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft632">Axial spondyloarthritis</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft633"><i>Ankylosing spondylitis&#160;(AS)<br/></i>Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to&#160;<br/>conventional therapy.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft634"><i>Non-radiographic axial spondyloarthritis<br/></i>Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of&#160;<br/>inflammation as indicated by elevated&#160;C-reactive protein (CRP)&#160;and/or&#160;magnetic resonance imaging&#160;<br/>(MRI)&#160;evidence, who have had an inadequate response&#160;to&#160;nonsteroidal anti-inflammatory drugs<br/>(NSAIDs).</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft632">Plaque psoriasis</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft634">Treatment of adults with&#160;moderate to severe plaque psoriasis who failed to respond to, or who have a&#160;<br/>contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or&#160;<br/>psoralen and ultraviolet-A light (PUVA) (see section 5.1).</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft632">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft634">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6&#160;years who&#160;<br/>are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft631"><b>4.2</b></p>
<p style="position:absolute;top:755px;left:149px;white-space:nowrap" class="ft631"><b>Posology and method of administration</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft634">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the&#160;<br/>diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,&#160;<br/>ankylosing spondylitis,&#160;non-radiographic axial spondyloarthritis,&#160;plaque psoriasis or paediatric plaque&#160;<br/>psoriasis. Patients treated with Enbrel should be given the Patient Card.</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft632">Enbrel is available in strengths of&#160;10,&#160;25 and 50&#160;mg.&#160;</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft632">Posology</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft634"><i>Rheumatoid arthritis<br/></i>25&#160;mg Enbrel administered twice weekly is the&#160;recommended dose. Alternatively, 50&#160;mg administered&#160;<br/>once weekly has been shown to be safe and effective (see section 5.1).</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft633"><i>Psoriatic arthritis,&#160;ankylosing spondylitis&#160;and non-radiographic axial spondyloarthritis<br/></i>The recommended dose is 25&#160;mg Enbrel administered twice weekly, or 50&#160;mg administered once&#160;<br/>weekly. &#160;</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft633">For all of the above indications, available data suggest that a clinical response is usually achieved&#160;<br/>within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not&#160;<br/>responding within this time period.</p>
</div>
<!-- Page 64 -->
<a name="64"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page64-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft640">64</p>
<p style="position:absolute;top:128px;left:107px;white-space:nowrap" class="ft645"><i>Plaque psoriasis</i></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft644">The recommended dose of Enbrel is 25&#160;mg administered twice weekly or 50&#160;mg administered once&#160;<br/>weekly. Alternatively, 50&#160;mg given twice weekly may be used for up to 12&#160;weeks followed, if&#160;<br/>necessary, by&#160;a dose of 25&#160;mg twice weekly or 50&#160;mg&#160;once weekly. Treatment with Enbrel should&#160;<br/>continue until remission is achieved, for up to 24&#160;weeks.&#160;Continuous therapy beyond 24&#160;weeks may be&#160;<br/>appropriate for some adult patients (see section 5.1).&#160;Treatment should be discontinued in patients who&#160;<br/>show no response after 12&#160;weeks. If re-treatment with Enbrel is indicated, the same guidance on&#160;<br/>treatment duration should be followed. The dose should be 25&#160;mg twice weekly or 50&#160;mg once&#160;<br/>weekly.&#160;</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft642">Special populations</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft646"><i>Renal and&#160;hepatic impairment<br/></i>No dose adjustment is required.</p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft643"><i>Elderly<br/></i>No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of&#160;<br/>age.</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft645"><i>Paediatric population</i></p>
<p style="position:absolute;top:509px;left:107px;white-space:nowrap" class="ft643">The&#160;dosage&#160;of&#160;Enbrel&#160;is&#160;based&#160;on&#160;body&#160;weight&#160;for&#160;paediatric&#160;patients.&#160;Patients&#160;weighing&#160;less&#160;than&#160;62.5&#160;kg&#160;<br/>should&#160;be&#160;accurately&#160;dosed&#160;on&#160;a&#160;mg/kg&#160;basis&#160;using&#160;the&#160;powder&#160;and&#160;solvent&#160;for&#160;solution&#160;for&#160;injection&#160;<br/>presentations&#160;or&#160;the&#160;powder&#160;for&#160;solution&#160;for&#160;injection&#160;presentations&#160;(see&#160;below&#160;for&#160;dosing&#160;for&#160;specific&#160;<br/>indications). Patients weighing 62.5&#160;kg&#160;or&#160;more,&#160;may&#160;be dosed using a fixed-dose pre-filled syringe or&#160;<br/>pre-filled pen.&#160;</p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft642">The safety and&#160;efficacy of&#160;Enbrel&#160;in children aged less than 2 years has not been established.</p>
<p style="position:absolute;top:644px;left:107px;white-space:nowrap" class="ft642">No data are available.</p>
<p style="position:absolute;top:683px;left:107px;white-space:nowrap" class="ft645"><i>Juvenile idiopathic arthritis&#160;</i></p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft643">The recommended dose is 0.4&#160;mg/kg (up to a maximum of 25&#160;mg per dose) given twice weekly as a&#160;<br/>subcutaneous injection with an interval of 3-4&#160;days between doses&#160;or 0.8&#160;mg/kg (up to a maximum of&#160;<br/>50&#160;mg per dose) given once weekly.&#160;Discontinuation of treatment should be considered in patients&#160;<br/>who show no response after 4 months.</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft643">The 10&#160;mg&#160;vial strength may be more appropriate for administration to children with JIA below the&#160;<br/>weight of 25 kg.</p>
<p style="position:absolute;top:854px;left:106px;white-space:nowrap" class="ft643">No formal clinical trials have been&#160;conducted in children aged 2 to 3 years. However, limited safety&#160;<br/>data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar&#160;<br/>to that seen in adults and children aged 4 years and older, when dosed every week&#160;with 0.8&#160;mg/kg&#160;<br/>subcutaneously (see section 5.1).</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft644">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile&#160;<br/>idiopathic arthritis.</p>
<p style="position:absolute;top:1006px;left:107px;white-space:nowrap" class="ft642">Paediatric plaque psoriasis (age 6 years and above)</p>
<p style="position:absolute;top:1025px;left:106px;white-space:nowrap" class="ft643">The recommended dose is 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly for up to&#160;<br/>24&#160;weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</p>
<p style="position:absolute;top:1082px;left:106px;white-space:nowrap" class="ft643">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be&#160;followed.&#160;<br/>The dose should be 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly.</p>
<p style="position:absolute;top:1139px;left:106px;white-space:nowrap" class="ft644">There is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque&#160;<br/>psoriasis.</p>
</div>
<!-- Page 65 -->
<a name="65"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page65-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft650">65</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft652">Method of administration</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft652">Enbrel is administered by&#160;subcutaneous injection&#160;(see section 6.6).</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft654">Comprehensive instructions for administration are given in the package leaflet, section 7, &#34;Instructions&#160;<br/>for preparation and giving an injection of Enbrel.&#34;&#160;Detailed instructions on unintentional dosing or&#160;<br/>scheduling variations, including missed doses, are provided in section 3 of the package leaflet.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft651"><b>4.3</b></p>
<p style="position:absolute;top:279px;left:149px;white-space:nowrap" class="ft651"><b>Contraindications</b></p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft652">Hypersensitivity to the active substance or to any of the excipients&#160;listed in section 6.1.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft652">Sepsis or risk of sepsis.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft654">Treatment with Enbrel should not be initiated in patients with active infections, including chronic or&#160;<br/>localised infections.</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft651"><b>4.4</b></p>
<p style="position:absolute;top:450px;left:149px;white-space:nowrap" class="ft651"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft654">In order to improve the traceability of biological medicinal products, the&#160;brand name&#160;and batch&#160;<br/>number of the administered product should be clearly recorded (or stated) in the patient file.</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft652">Infections</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft654">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking&#160;into&#160;<br/>consideration that the mean elimination half-life of etanercept is approximately 70&#160;hours (range 7 to&#160;<br/>300&#160;hours).</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft653">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal&#160;<br/>infections,&#160;listeriosis and legionellosis,&#160;have been reported with the use of Enbrel (see section 4.8).&#160;<br/>These infections were due to bacteria, mycobacteria, fungi,&#160;viruses&#160;and parasites (including protozoa).&#160;<br/>In some cases, particular fungal and other opportunistic infections have not been recognised, resulting&#160;<br/>in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the&#160;<br/>patient’s risk for relevant opportunistic infections&#160;(e.g., exposure to endemic mycoses) should be&#160;<br/>considered.&#160;</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft653">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored&#160;<br/>closely. Administration of Enbrel should be discontinued if a patient develops a serious infection.&#160;The&#160;<br/>safety and efficacy of Enbrel in patients with chronic infections have not been evaluated.&#160;Physicians&#160;<br/>should exercise caution when considering the use of Enbrel in patients with a history of recurring or&#160;<br/>chronic infections or with underlying conditions that may predispose patients to infections, such as&#160;<br/>advanced or poorly controlled diabetes.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft652">Tuberculosis</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft654">Cases of active tuberculosis, including miliary tuberculosis and tuberculosis with extra-pulmonary&#160;<br/>location, have been reported in patients treated&#160;with Enbrel.</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft654">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive&#160;<br/>(‘latent’) tuberculosis. This evaluation should include a detailed medical history with personal history&#160;<br/>of tuberculosis or possible previous&#160;contact with tuberculosis and previous and/or current&#160;<br/>immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray,&#160;<br/>should be performed in all patients (local recommendations may apply). It is recommended that the&#160;<br/>conduct of these tests should be recorded in the&#160;Patient&#160;Card. Prescribers are reminded of the risk of&#160;</p>
</div>
<!-- Page 66 -->
<a name="66"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page66-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft660">66</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft664">false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft664">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (‘latent’)&#160;<br/>tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis&#160;<br/>therapy before the initiation of Enbrel, and in accordance with local recommendations. In this&#160;<br/>situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft664">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis&#160;<br/>(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft662">Hepatitis B reactivation</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft663">Reactivation of hepatitis B in patients who&#160;were previously infected with the&#160;hepatitis B virus (HBV)&#160;<br/>and had received concomitant&#160;TNF-antagonists, including Enbrel, has been reported.&#160;This&#160;includes&#160;<br/>reports of reactivation of&#160;hepatitis B&#160;in patients who were anti-HBc positive but HBsAg negative.<br/>Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who&#160;<br/>test positive for HBV infection, consultation with a physician with expertise in the treatment of&#160;<br/>hepatitis B is recommended.&#160;Caution should be exercised when administering Enbrel&#160;in&#160;patients&#160;<br/>previously infected with&#160;HBV.&#160;These&#160;patients should be monitored for signs and symptoms of active&#160;<br/>HBV infection&#160;throughout therapy and for several weeks following termination of therapy.&#160;Adequate&#160;<br/>data from treating patients infected with&#160;HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy are not available. In patients who develop HBV infection,&#160;Enbrel should be&#160;<br/>stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft662">Worsening of hepatitis C</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft663">There have been reports of worsening of hepatitis C in patients receiving Enbrel.&#160;Enbrel should be&#160;<br/>used with caution in patients with a history of hepatitis C.</p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft662">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft663">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious&#160;<br/>infections and neutropenia compared to Enbrel alone. This&#160;combination has not demonstrated&#160;<br/>increased clinical benefit. Thus, the combined use of Enbrel and anakinra is not recommended (see&#160;<br/>sections 4.5 and 4.8).</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft662">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft664">In clinical studies, concurrent administration of abatacept and&#160;Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see&#160;section 4.5).</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft662">Allergic reactions</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft663">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic&#160;<br/>reactions have included angioedema and urticaria; serious reactions have occurred. If any serious&#160;<br/>allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and&#160;<br/>appropriate therapy initiated.</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft664">The needle cover of the pre-filled syringe contains latex (dry natural rubber) that may cause&#160;<br/>hypersensitivity reactions when handled by, or when Enbrel is administered to, persons with known or&#160;<br/>possible latex sensitivity.</p>
</div>
<!-- Page 67 -->
<a name="67"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page67-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft670">67</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft672">Immunosuppression</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft674">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections&#160;<br/>and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a&#160;<br/>study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector cell populations.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft674">Two juvenile&#160;idiopathic arthritis patients developed varicella infection and signs and symptoms of&#160;<br/>aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella&#160;<br/>virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with&#160;<br/>Varicella Zoster Immune Globulin.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft672">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft672">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft674"><i>Solid and haematopoietic malignancies&#160;(excluding skin cancers)<br/></i>Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been&#160;<br/>received in the postmarketing period (see section 4.8).&#160;</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft674">In the controlled portions of clinical trials of TNF-antagonists, more cases of&#160;lymphoma have been&#160;<br/>observed among patients receiving a TNF-antagonist compared with control patients. However, the&#160;<br/>occurrence was rare, and the follow-up period of placebo patients was shorter than for patients&#160;<br/>receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported&#160;<br/>in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and&#160;<br/>leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates risk estimation.</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft674">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other&#160;<br/>haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded.&#160;<br/>Caution should be exercised when considering TNF-antagonist therapy for patients with a history of&#160;<br/>malignancy or when considering continuing treatment in patients who develop a malignancy.</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft674">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤ 18 years of age), including&#160;<br/>Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases&#160;<br/>represented a variety of different malignancies and included rare malignancies typically associated&#160;<br/>with immunosuppression. A risk for the development of malignancies in children and adolescents&#160;<br/>treated with TNF-antagonists cannot be excluded.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft673"><i>Skin cancers<br/></i>Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with&#160;<br/>TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported&#160;<br/>very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all&#160;<br/>patients, particularly those with risk factors for skin cancer.</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft673">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients&#160;<br/>receiving Enbrel compared with control patients, particularly in patients with psoriasis.</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft672">Vaccinations</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft673">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary&#160;<br/>transmission of infection by live vaccines in patients receiving Enbrel. In a double-blind,&#160;<br/>placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also&#160;<br/>received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic&#160;</p>
</div>
<!-- Page 68 -->
<a name="68"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page68-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft680">68</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft683">arthritis patients receiving Enbrel were able to mount effective B-cell immune response to&#160;<br/>pneumococcal polysaccharide&#160;vaccine, but titres in aggregate were moderately lower, and few patients&#160;<br/>had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this&#160;<br/>is unknown.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft682">Autoantibody formation</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft682">Treatment with Enbrel may result in the&#160;formation of autoimmune antibodies (see section 4.8).</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft682">Haematologic reactions</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft684">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have&#160;<br/>been reported in patients treated with Enbrel. Caution should be exercised in patients being treated&#160;<br/>with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers&#160;<br/>should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or&#160;<br/>infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they&#160;<br/>should seek immediate medical advice. Such patients should be investigated urgently, including full&#160;<br/>blood count; if blood dyscrasias are confirmed,&#160;Enbrel should be discontinued.</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft682">Neurological disorders</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft684">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see&#160;<br/>section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies&#160;<br/>(including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy,&#160;<br/>demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have&#160;<br/>been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other&#160;<br/>TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful&#160;<br/>risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel&#160;<br/>to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered&#160;<br/>to have an increased risk of developing demyelinating disease.</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft682">Combination therapy</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft683">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of&#160;<br/>Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel&#160;<br/>when&#160;given in combination with methotrexate was similar to the profiles reported in studies of Enbrel&#160;<br/>and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The&#160;<br/>long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs&#160;<br/>(DMARD) has not been established.</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft684">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of&#160;<br/>psoriasis has not been studied.</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft682">Renal and hepatic impairment</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft684">Based on pharmacokinetic&#160;data (see section 5.2), no dose adjustment is needed in patients with renal&#160;<br/>or hepatic impairment; clinical experience in such patients is limited.</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft682">Congestive heart failure&#160;(Cardiac failure congestive)</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft683">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF).&#160;<br/>There have been postmarketing reports of worsening of CHF, with and without identifiable&#160;<br/>precipitating factors, in patients taking Enbrel.&#160;There have also been rare (&lt;&#160;0.1%) reports of new&#160;<br/>onset CHF, including CHF in patients without known pre-existing cardiovascular disease.&#160;Some of&#160;<br/>these patients have been under 50&#160;years of age.&#160;Two large clinical trials evaluating the use of Enbrel in&#160;<br/>the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data&#160;</p>
</div>
<!-- Page 69 -->
<a name="69"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page69-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft690">69</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft694">from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned<br/>to Enbrel treatment.&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft692">Alcoholic hepatitis</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft694">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or&#160;<br/>placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in&#160;<br/>patients treated with Enbrel was significantly higher after 6&#160;months. Consequently, Enbrel should not&#160;<br/>be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using&#160;<br/>Enbrel in patients who also have moderate to severe alcoholic hepatitis.</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft692">Wegener's granulomatosis</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft693">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard&#160;<br/>therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of&#160;<br/>25&#160;months, has not shown Enbrel to be an effective treatment for Wegener’s granulomatosis. The&#160;<br/>incidence of non-cutaneous malignancies of various types was significantly higher in patients treated&#160;<br/>with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft692">Hypoglycaemia in patients treated for diabetes</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft693">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving&#160;<br/>medication for diabetes, necessitating a reduction in anti-diabetic&#160;medication in some of these patients.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft692">Special populations</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft694"><i>Elderly<br/></i>In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall&#160;<br/>differences in adverse events, serious adverse events, and serious infections in&#160;patients age 65 or older&#160;<br/>who received Enbrel were observed compared with younger patients. However, caution should be&#160;<br/>exercised when treating the elderly and particular attention paid with respect to occurrence of&#160;<br/>infections.</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft695"><i>Paediatric population</i></p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft694"><i>Vaccinations<br/></i>It&#160;is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Enbrel therapy&#160;(see Vaccinations,&#160;<br/>above).</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft692">Sodium&#160;content</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft694">This medicinal&#160;product contains less than 1&#160;mmol sodium (23&#160;mg) per dosage unit. Patients on low&#160;<br/>sodium diets can be informed that this medicinal product is essentially ‘sodium-free’.</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft691"><b>4.5</b></p>
<p style="position:absolute;top:982px;left:149px;white-space:nowrap" class="ft691"><b>Interaction with other medicinal products and other forms of interaction</b></p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft692">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft694">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft693">In addition, in a&#160;double-blind, placebo-controlled trial in adult patients receiving background&#160;<br/>methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The&#160;</p>
</div>
<!-- Page 70 -->
<a name="70"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page70-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft700">70</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft704">combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not&#160;<br/>recommended.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft702">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft704">In clinical studies, concurrent administration of abatacept and Enbrel resulted&#160;in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see section 4.4).&#160;</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft702">Concurrent treatment with sulfasalazine&#160;</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft703">In a clinical study of adult patients who were&#160;receiving established doses of sulfasalazine, to which&#160;<br/>Enbrel was added, patients in the combination group experienced a statistically significant decrease in&#160;<br/>mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone.&#160;The&#160;<br/>clinical significance of this interaction is unknown.&#160;Physicians should use caution when considering&#160;<br/>combination therapy with sulfasalazine.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft702">Non-interactions</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft703">In clinical trials, no interactions have been observed when Enbrel was administered with&#160;<br/>glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs),&#160;<br/>analgesics, or methotrexate. See section 4.4 for vaccination advice.</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft704">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with&#160;<br/>methotrexate,&#160;digoxin or warfarin.</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft701"><b>4.6</b></p>
<p style="position:absolute;top:603px;left:149px;white-space:nowrap" class="ft701"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft702">Women of childbearing potential</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft704">Women of childbearing potential should&#160;consider&#160;the&#160;use&#160;of&#160;appropriate contraception to avoid&#160;<br/>becoming pregnant during Enbrel therapy and&#160;for three weeks after discontinuation of therapy.</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft702">Pregnancy&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft703">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the&#160;<br/>foetus or neonatal rat due to etanercept.&#160;The effects of etanercept on pregnancy outcomes have been&#160;<br/>investigated in two observational cohort studies. A&#160;higher rate of major birth defects was observed in&#160;<br/>one observational study comparing pregnancies exposed to etanercept (n=370) during the first&#160;<br/>trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds&#160;<br/>ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most&#160;<br/>commonly reported in the general population and no particular pattern of abnormalities was identified.&#160;<br/>No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed.&#160;In&#160;<br/>another observational multi-country registry study comparing the risk of adverse pregnancy outcomes&#160;<br/>in women exposed&#160;to etanercept&#160;during the first 90&#160;days of pregnancy (n=425)&#160;to those exposed to&#160;<br/>non-biologic drugs&#160;(n=3497), there was no observed increased risk of major birth defects (crude odds&#160;<br/>ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60&#160;after adjusting for&#160;<br/>country, maternal disease, parity, maternal age and smoking in early pregnancy).&#160;This study also&#160;<br/>showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year&#160;<br/>of life&#160;for infants born to women exposed to etanercept during pregnancy.&#160;Enbrel should only be used&#160;<br/>during&#160;pregnancy&#160;if&#160;clearly needed.</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft703">Etanercept crosses the placenta and has been detected in the serum of&#160;infants born to female patients&#160;<br/>treated with&#160;Enbrel&#160;during pregnancy. The clinical impact of this is unknown, however, infants may be&#160;<br/>at increased risk of infection. Administration of live vaccines to infants for 16&#160;weeks after the&#160;<br/>mother’s last dose of&#160;Enbrel&#160;is generally not recommended.</p>
</div>
<!-- Page 71 -->
<a name="71"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page71-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft710">71</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft712">Breast-feeding</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft714">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and&#160;<br/>detected in the serum of pups.&#160;Limited information from the published literature indicates etanercept&#160;<br/>has been detected at low levels in human milk.&#160;Etanercept could be considered for use during&#160;<br/>breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of&#160;therapy&#160;<br/>for the woman.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft713">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely&#160;<br/>degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant&#160;<br/>are&#160;available. Therefore, the&#160;administration of live vaccines&#160;(e.g., BCG)&#160;to a breastfed infant when the&#160;<br/>mother is receiving etanercept&#160;could be considered 16 weeks after stopping breast-feeding (or at an&#160;<br/>earlier timepoint if the infant etanercept serum levels are undetectable).&#160;</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft712">Fertility</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft713">Preclinical data about peri-&#160;and postnatal toxicity of etanercept and of effects of etanercept on fertility&#160;<br/>and general reproductive performance are not available.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft711"><b>4.7</b></p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft711"><b>Effects on ability to drive and use machines</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft712">Enbrel&#160;has no or negligible influence on the ability to drive&#160;and&#160;use machines.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft711"><b>4.8</b></p>
<p style="position:absolute;top:564px;left:149px;white-space:nowrap" class="ft711"><b>Undesirable effects</b></p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft712">Summary of the safety profile</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft714">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling,&#160;<br/>itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections,&#160;<br/>bronchitis, bladder infections and skin infections),&#160;headache,&#160;allergic reactions, development of&#160;<br/>autoantibodies, itching, and fever.</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft714">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect&#160;<br/>the immune system and their use may affect the body’s defenses against&#160;infection and cancer. Serious&#160;<br/>infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and&#160;<br/>life-threatening infections and sepsis. Various malignancies have also been reported with use of&#160;<br/>Enbrel, including cancers of&#160;the breast, lung, skin and lymph glands (lymphoma). &#160;</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft713">Serious haematological, neurological and autoimmune reactions have also been reported. These&#160;<br/>include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral&#160;<br/>demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have&#160;<br/>been rare reports of lupus, lupus-related conditions, and vasculitis.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft712">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft713">The following list of adverse reactions is based on&#160;experience from clinical trials and on&#160;<br/>postmarketing experience.</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft713">Within the organ system classes, adverse reactions are listed under headings of frequency (number of&#160;<br/>patients expected to experience the reaction), using the following categories: very common (≥&#160;1/10);&#160;<br/>common (≥&#160;1/100 to &lt;&#160;1/10); uncommon (≥&#160;1/1,000 to &lt;&#160;1/100); rare (≥&#160;1/10,000 to &lt;&#160;1/1,000); very&#160;<br/>rare (&lt;&#160;1/10,000); not known (cannot be estimated from the available data).</p>
</div>
<!-- Page 72 -->
<a name="72"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page72-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft720">72</p>
<p style="position:absolute;top:109px;left:100px;white-space:nowrap" class="ft7212"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:202px;white-space:nowrap" class="ft7212"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:282px;white-space:nowrap" class="ft7212"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:377px;white-space:nowrap" class="ft7212"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:482px;white-space:nowrap" class="ft7212"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:615px;white-space:nowrap" class="ft7212"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:696px;white-space:nowrap" class="ft7212"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated from&#160;<br/>Available Data)</b></p>
<p style="position:absolute;top:171px;left:100px;white-space:nowrap" class="ft7213">Infections and&#160;<br/>infestations</p>
<p style="position:absolute;top:171px;left:202px;white-space:nowrap" class="ft7213">Infection&#160;<br/>(including&#160;<br/>upper&#160;<br/>respiratory&#160;<br/>tract&#160;<br/>infection,&#160;<br/>bronchitis,&#160;<br/>cystitis,&#160;<br/>skin&#160;<br/>infection)*</p>
<p style="position:absolute;top:171px;left:377px;white-space:nowrap" class="ft7213">Serious&#160;<br/>infections&#160;<br/>(including&#160;<br/>pneumonia,&#160;<br/>cellulitis,&#160;<br/>arthritis&#160;<br/>bacterial, sepsis<br/>and parasitic&#160;<br/>infection)*</p>
<p style="position:absolute;top:171px;left:482px;white-space:nowrap" class="ft7213">Tuberculosis,&#160;<br/>opportunistic&#160;<br/>infection&#160;(including&#160;<br/>invasive fungal,&#160;<br/>protozoal, bacterial,&#160;<br/>atypical&#160;<br/>mycobacterial, viral&#160;<br/>infections,&#160;and&#160;<br/>Legionella)*</p>
<p style="position:absolute;top:171px;left:696px;white-space:nowrap" class="ft7213">Hepatitis B&#160;<br/>reactivation,&#160;<br/>listeria</p>
<p style="position:absolute;top:327px;left:100px;white-space:nowrap" class="ft7213">Neoplasms&#160;<br/>benign,&#160;<br/>malignant and&#160;<br/>unspecified&#160;<br/>(including&#160;<br/>cysts and&#160;<br/>polyps)</p>
<p style="position:absolute;top:327px;left:377px;white-space:nowrap" class="ft7213">Non-melanoma&#160;<br/>skin cancers*&#160;<br/>(see section 4.4)</p>
<p style="position:absolute;top:327px;left:482px;white-space:nowrap" class="ft7213">Malignant melanoma&#160;<br/>(see section 4.4),&#160;<br/>lymphoma,&#160;<br/>leukaemia&#160;</p>
<p style="position:absolute;top:327px;left:696px;white-space:nowrap" class="ft7213">Merkel cell&#160;<br/>carcinoma&#160;(see&#160;<br/>section 4.4),&#160;<br/>Kaposi’s sarcoma</p>
<p style="position:absolute;top:437px;left:100px;white-space:nowrap" class="ft7213">Blood and&#160;<br/>lymphatic&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:437px;left:377px;white-space:nowrap" class="ft7213">Thrombocytope<br/>nia, anaemia,&#160;<br/>leukopenia,&#160;<br/>neutropenia</p>
<p style="position:absolute;top:437px;left:482px;white-space:nowrap" class="ft7211">Pancytopenia*</p>
<p style="position:absolute;top:437px;left:615px;white-space:nowrap" class="ft7213">Aplastic&#160;<br/>anaemia*</p>
<p style="position:absolute;top:437px;left:696px;white-space:nowrap" class="ft7213">Histiocytosis&#160;<br/>haematophagic&#160;<br/>(macrophage&#160;<br/>activation&#160;<br/>syndrome)*</p>
<p style="position:absolute;top:515px;left:100px;white-space:nowrap" class="ft7213">Immune&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:515px;left:282px;white-space:nowrap" class="ft7213">Allergic<br/>reactions (see&#160;<br/>Skin and&#160;<br/>subcutaneous&#160;<br/>tissue&#160;<br/>disorders),&#160;<br/>autoantibody&#160;<br/>formation*</p>
<p style="position:absolute;top:515px;left:377px;white-space:nowrap" class="ft7213">Vasculitis&#160;<br/>(including&#160;anti-<br/>neutrophilic&#160;<br/>cytoplasmic&#160;<br/>antibody positive&#160;<br/>vasculitis)</p>
<p style="position:absolute;top:515px;left:482px;white-space:nowrap" class="ft7213">Serious&#160;<br/>allergic/anaphylactic&#160;<br/>reactions (including&#160;<br/>angioedema,&#160;<br/>bronchospasm),&#160;<br/>sarcoidosis</p>
<p style="position:absolute;top:515px;left:696px;white-space:nowrap" class="ft7213">Worsening of&#160;<br/>symptoms of&#160;<br/>dermatomyositis</p>
<p style="position:absolute;top:640px;left:100px;white-space:nowrap" class="ft7213">Nervous&#160;<br/>system&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:640px;left:202px;white-space:nowrap" class="ft7211">Headache</p>
<p style="position:absolute;top:640px;left:482px;white-space:nowrap" class="ft7213">CNS demyelinating&#160;<br/>events suggestive of&#160;<br/>multiple sclerosis or&#160;<br/>localised&#160;<br/>demyelinating&#160;<br/>conditions, such as&#160;<br/>optic neuritis and&#160;<br/>transverse myelitis&#160;<br/>(see section 4.4),&#160;<br/>peripheral&#160;<br/>demyelinating&#160;<br/>events, including&#160;<br/>Guillain-Barré&#160;<br/>syndrome, chronic&#160;<br/>inflammatory&#160;<br/>demyelinating&#160;<br/>polyneuropathy,&#160;<br/>demyelinating&#160;<br/>polyneuropathy, and&#160;<br/>multifocal motor&#160;<br/>neuropathy (see&#160;<br/>section 4.4), seizure</p>
<p style="position:absolute;top:982px;left:100px;white-space:nowrap" class="ft7211">Eye disorders&#160;</p>
<p style="position:absolute;top:982px;left:377px;white-space:nowrap" class="ft7211">Uveitis, scleritis</p>
<p style="position:absolute;top:999px;left:100px;white-space:nowrap" class="ft7213">Cardiac&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:999px;left:377px;white-space:nowrap" class="ft7213">Worsening of&#160;<br/>cardiac failure&#160;<br/>congestive (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:999px;left:482px;white-space:nowrap" class="ft7213">New onset cardiac&#160;<br/>failure congestive&#160;<br/>(see section 4.4)</p>
<p style="position:absolute;top:1061px;left:100px;white-space:nowrap" class="ft7213">Respiratory,&#160;<br/>thoracic, and&#160;<br/>mediastinal&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:1061px;left:482px;white-space:nowrap" class="ft7213">Interstitial lung&#160;<br/>disease (including&#160;<br/>pneumonitis and&#160;<br/>pulmonary fibrosis)*</p>
<p style="position:absolute;top:1124px;left:100px;white-space:nowrap" class="ft7213">Gastrointestinal&#160;<br/>disorders</p>
<p style="position:absolute;top:1124px;left:377px;white-space:nowrap" class="ft7213">Inflammatory&#160;<br/>bowel disease</p>
</div>
<!-- Page 73 -->
<a name="73"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page73-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft730">73</p>
<p style="position:absolute;top:109px;left:100px;white-space:nowrap" class="ft7312"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:202px;white-space:nowrap" class="ft7312"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:282px;white-space:nowrap" class="ft7312"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:377px;white-space:nowrap" class="ft7312"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:482px;white-space:nowrap" class="ft7312"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:615px;white-space:nowrap" class="ft7312"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:696px;white-space:nowrap" class="ft7312"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated from&#160;<br/>Available Data)</b></p>
<p style="position:absolute;top:171px;left:100px;white-space:nowrap" class="ft7313">Hepatobiliary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:171px;left:377px;white-space:nowrap" class="ft7313">Elevated liver&#160;<br/>enzymes*</p>
<p style="position:absolute;top:171px;left:482px;white-space:nowrap" class="ft7313">Autoimmune&#160;<br/>hepatitis*</p>
<p style="position:absolute;top:203px;left:100px;white-space:nowrap" class="ft7313">Skin and&#160;<br/>subcutaneous&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:203px;left:282px;white-space:nowrap" class="ft7311">Pruritus, rash</p>
<p style="position:absolute;top:203px;left:377px;white-space:nowrap" class="ft7313">Angioedema,&#160;<br/>psoriasis&#160;<br/>(including new&#160;<br/>onset or&#160;<br/>worsening and&#160;<br/>pustular,&#160;<br/>primarily palms&#160;<br/>and soles),&#160;<br/>urticaria,&#160;<br/>psoriasiform&#160;<br/>rash</p>
<p style="position:absolute;top:203px;left:482px;white-space:nowrap" class="ft7313">Stevens-Johnson&#160;<br/>syndrome, cutaneous&#160;<br/>vasculitis (including&#160;<br/>hypersensitivity&#160;<br/>vasculitis), erythema&#160;<br/>multiforme,&#160;<br/>lichenoid reactions</p>
<p style="position:absolute;top:203px;left:615px;white-space:nowrap" class="ft7313">Toxic&#160;<br/>epidermal&#160;<br/>necrolysis</p>
<p style="position:absolute;top:375px;left:100px;white-space:nowrap" class="ft7313">Musculoskeleta<br/>l and&#160;<br/>connective&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:375px;left:482px;white-space:nowrap" class="ft7313">Cutaneous lupus&#160;<br/>erythematosus,&#160;<br/>subacute cutaneous&#160;<br/>lupus erythematosus,&#160;<br/>lupus-like syndrome</p>
<p style="position:absolute;top:453px;left:100px;white-space:nowrap" class="ft7313">General&#160;<br/>disorders and&#160;<br/>administration&#160;<br/>site conditions&#160;</p>
<p style="position:absolute;top:453px;left:202px;white-space:nowrap" class="ft7313">Injection&#160;<br/>site&#160;<br/>reactions&#160;<br/>(including&#160;<br/>bleeding,&#160;<br/>bruising,&#160;<br/>erythema,&#160;<br/>itching,&#160;<br/>pain,&#160;<br/>swelling)*</p>
<p style="position:absolute;top:453px;left:282px;white-space:nowrap" class="ft7311">Pyrexia</p>
<p style="position:absolute;top:609px;left:100px;white-space:nowrap" class="ft7311">*see Description of selected adverse reactions, below.</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft732">Description of selected adverse reactions</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft733"><i>Malignancies and lymphoproliferative disorders<br/></i>One hundred and twenty-nine&#160;(129) new malignancies of various types were observed in 4,114&#160;<br/>rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6&#160;years,&#160;<br/>including 231&#160;patients treated with Enbrel in combination with methotrexate in the 2-year&#160;<br/>active-controlled study. The observed rates and incidences in these clinical trials were similar to those&#160;<br/>expected for the population studied. A total of 2 malignancies were reported in clinical studies of&#160;<br/>approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical&#160;<br/>studies conducted for more than 2&#160;years with 351 ankylosing spondylitis patients, 6&#160;malignancies were&#160;<br/>reported in Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel&#160;in&#160;<br/>double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin&#160;<br/>cancers were reported.</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft734">In a group of 7,416&#160;patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing&#160;<br/>spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft734">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been&#160;<br/>received in the postmarketing period (see section 4.4).</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft734"><i>Injection site reactions<br/></i>Compared to placebo, patients&#160;with rheumatic diseases treated with Enbrel had a significantly higher&#160;<br/>incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first&#160;<br/>month. Mean duration was approximately 3 to 5 days. No treatment was given for&#160;the majority of&#160;<br/>injection site reactions in the Enbrel treatment groups, and the majority of patients who were given&#160;<br/>treatment received topical preparations, such as corticosteroids, or oral antihistamines. Additionally,&#160;<br/>some patients developed recall injection site reactions characterised by a skin reaction at the most&#160;</p>
</div>
<!-- Page 74 -->
<a name="74"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page74-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft740">74</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft744">recent site of injection, along with the simultaneous appearance of injection site reactions at previous&#160;<br/>injection sites. These reactions were generally transient and did not recur with treatment.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft743">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with&#160;<br/>Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the&#160;<br/>first 12 weeks of treatment.</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft743"><i>Serious infections<br/></i>In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or&#160;<br/>requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3%&#160;<br/>of rheumatoid arthritis patients treated with Enbrel for up to 48&#160;months. These included abscess (at&#160;<br/>various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis,&#160;<br/>endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection,&#160;<br/>osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin&#160;<br/>infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year&#160;<br/>active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or&#160;<br/>Enbrel in combination with methotrexate, the rates of serious infections were similar among the&#160;<br/>treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate&#160;<br/>could be&#160;associated with an increase in the rate of infections.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft743">There were no differences in rates of infection among patients treated with Enbrel and those treated&#160;<br/>with placebo for plaque psoriasis&#160;in placebo-controlled trials of up to 24 weeks duration. Serious<br/>infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia,&#160;<br/>cholecystitis, osteomyelitis, gastritis, appendicitis,&#160;<i>Streptococcal&#160;</i>fasciitis, myositis, septic shock,&#160;<br/>diverticulitis&#160;and abscess. In the double-blind and&#160;open-label psoriatic arthritis trials, 1&#160;patient reported&#160;<br/>a serious infection (pneumonia).</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft744">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include&#160;<br/>bacteria, mycobacteria (including&#160;tuberculosis), viruses and fungi.&#160;Some have occurred within a few&#160;<br/>weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes,&#160;<br/>congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis&#160;<br/>(see section&#160;4.4). Enbrel treatment may increase mortality in patients with established sepsis.</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft744">Opportunistic infections have been reported in association with Enbrel, including invasive fungal,&#160;<br/>parasitic (including&#160;protozoal),&#160;viral (including herpes zoster),&#160;bacterial (including&#160;<i>Listeria&#160;</i>and&#160;<br/><i>Legionella</i>), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall&#160;<br/>incidence of opportunistic infections was 0.09% for the 15,402&#160;subjects who received Enbrel. The&#160;<br/>exposure-adjusted rate&#160;was 0.06&#160;events per 100&#160;patient-years. In postmarketing experience,&#160;<br/>approximately half of all of the case reports of opportunistic infections worldwide were invasive&#160;<br/>fungal infections.&#160;The most commonly reported invasive fungal infections&#160;included&#160;<i>Candida,<br/>Pneumocystis,&#160;Aspergillus,&#160;</i>and&#160;<i>Histoplasma</i>. Invasive fungal infections accounted for more than half&#160;<br/>of the fatalities amongst patients who developed opportunistic infections. The majority of the reports&#160;<br/>with a fatal outcome were in patients with&#160;<i>Pneumocystis&#160;</i>pneumonia, unspecified systemic fungal&#160;<br/>infections, and aspergillosis (see section 4.4).</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft748"><i>Autoantibodies<br/></i>Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid&#160;<br/>arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed&#160;<br/>new positive ANA (</p>
<p style="position:absolute;top:1019px;left:240px;white-space:nowrap" class="ft7414">1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated&#160;</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft743">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA&#160;<br/>antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4%&#160;<br/>of placebo-treated patients) and by&#160;<i>Crithidia luciliae&#160;</i>assay (3% of patients treated with Enbrel&#160;<br/>compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who&#160;<br/>developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.&#160;<br/>The impact of long-term treatment with Enbrel on the development of autoimmune diseases is&#160;<br/>unknown.</p>
</div>
<!-- Page 75 -->
<a name="75"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page75-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft750">75</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft753">There have been&#160;rare reports of patients, including rheumatoid factor positive patients, who have&#160;<br/>developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are&#160;<br/>compatible with subacute cutaneous lupus or discoid lupus by clinical presentation&#160;and biopsy.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft754"><i>Pancytopenia and aplastic anaemia<br/></i>There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal&#160;<br/>outcomes (see section 4.4).</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft753"><i>Interstitial lung disease<br/></i>In controlled clinical trials of etanercept across&#160;all indications, the frequency (incidence proportion) of&#160;<br/>interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47%&#160;<br/>(frequency uncommon).&#160;There have been postmarketing reports of interstitial lung disease (including&#160;<br/>pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft758"><i>Concurrent treatment with anakinra&#160;<br/></i>In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of&#160;<br/>serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed&#160;<br/>neutropenia (absolute neutrophil count&#160;</p>
<p style="position:absolute;top:488px;left:366px;white-space:nowrap" class="ft7514">&#160;1000/mm3). While neutropenic, one patient developed&#160;</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft752">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft754"><i>Elevated liver enzymes<br/></i>In&#160;the&#160;double-blind&#160;periods of&#160;controlled clinical trials of etanercept across all indications, the&#160;<br/>frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving&#160;<br/>etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In&#160;the double-blind&#160;<br/>periods&#160;of controlled clinical trials&#160;that allowed&#160;concomitant treatment with etanercept and&#160;<br/>methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was&#160;<br/>4.18% (frequency common).</p>
<p style="position:absolute;top:700px;left:106px;white-space:nowrap" class="ft753"><i>Autoimmune hepatitis<br/></i>In controlled clinical&#160;trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24%&#160;<br/>(frequency uncommon).</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft752">Paediatric population</p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft754"><i>Undesirable effects in paediatric patients with juvenile idiopathic arthritis<br/></i>In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in&#160;<br/>frequency and type to those seen in adult patients. Differences from adults and other special&#160;<br/>considerations are discussed in the following paragraphs.</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft754">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18&#160;years&#160;<br/>were generally mild to moderate and consistent with those commonly seen in outpatient paediatric&#160;<br/>populations. Severe adverse events reported included varicella with signs and symptoms of aseptic&#160;<br/>meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis,&#160;<br/>depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic&#160;<br/>shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</p>
<p style="position:absolute;top:1100px;left:106px;white-space:nowrap" class="ft754">In one study in children with juvenile idiopathic arthritis aged 4 to 17&#160;years, 43 of 69 (62%) children&#160;<br/>experienced an infection while receiving Enbrel during 3 months of the study (part&#160;1, open-label), and&#160;<br/>the frequency and severity of infections was similar in 58 patients completing 12 months of open-label&#160;<br/>extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients&#160;</p>
</div>
<!-- Page 76 -->
<a name="76"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page76-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft760">76</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft763">were similar to those seen in&#160;trials of Enbrel in adult patients with rheumatoid arthritis, and the&#160;<br/>majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic&#160;<br/>arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients.&#160;<br/>These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per&#160;<br/>patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per&#160;<br/>patient year).</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft762">There were 4 reports of&#160;macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft764"><i>Undesirable effects in paediatric patients with plaque psoriasis<br/></i>In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse&#160;<br/>events&#160;reported were similar to those seen in previous studies in adults with plaque psoriasis.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft762">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft763">Reporting suspected adverse reactions after authorisation&#160;of the medicinal product is important. It&#160;<br/>allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare&#160;<br/>professionals are asked to report any suspected adverse&#160;reactions&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft761"><b>4.9</b></p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft761"><b>Overdose</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft764">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The&#160;<br/>highest dose level evaluated has been an intravenous loading dose of 32&#160;mg/m2&#160;followed by&#160;<br/>subcutaneous doses of 16&#160;mg/m2&#160;administered twice weekly. One rheumatoid arthritis patient&#160;<br/>mistakenly self-administered 62&#160;mg Enbrel subcutaneously twice weekly for 3 weeks without&#160;<br/>experiencing undesirable effects. There is no known antidote to Enbrel.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft761"><b>5.</b></p>
<p style="position:absolute;top:658px;left:146px;white-space:nowrap" class="ft761"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft761"><b>5.1</b></p>
<p style="position:absolute;top:696px;left:149px;white-space:nowrap" class="ft761"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft764">Pharmacotherapeutic group: Immunosuppressants,&#160;Tumour Necrosis Factor alpha (TNF-α) inhibitors,&#160;<br/>ATC code:&#160;L04AB01</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft763">Tumour necrosis&#160;factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid&#160;<br/>arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with&#160;<br/>psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque&#160;<br/>psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in&#160;<br/>psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of&#160;<br/>TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and&#160;<br/>lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the&#160;<br/>55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs&#160;<br/>exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF&#160;<br/>biological activity.</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft764">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on&#160;<br/>cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher&#160;<br/>affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of&#160;<br/>TNF binding to its cellular receptors. In addition, use of an immunoglobulin&#160;Fc region as a fusion&#160;<br/>element in the construction of a dimeric receptor imparts a longer serum half-life.</p>
</div>
<!-- Page 77 -->
<a name="77"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page77-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft770">77</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft772">Mechanism of action</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft773">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in&#160;<br/>plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by&#160;<br/>TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF&#160;<br/>binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF&#160;<br/>biologically inactive. Etanercept may also modulate biologic responses controlled by additional&#160;<br/>downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or&#160;<br/>regulated by TNF.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft772">Clinical&#160;efficacy and safety</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft773">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis,&#160;<br/>one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis,&#160;two&#160;studies<br/>in adults with non-radiographic axial spondyloarthritis,&#160;four studies in adults with plaque psoriasis,&#160;<br/>three&#160;studies&#160;in juvenile idiopathic arthritis and&#160;one study in paediatric patients with plaque psoriasis.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft773"><i>Adult patients with rheumatoid arthritis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The&#160;<br/>study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least&#160;<br/>one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel or placebo were administered subcutaneously twice a week for 6&#160;consecutive months.&#160;<br/>The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis&#160;<br/>using American College of Rheumatology (ACR) response criteria.&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft773">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6&#160;months than in&#160;<br/>patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and&#160;<br/>6&#160;months, respectively: ACR&#160;50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6,&#160;<br/>respectively; p&lt;0.01 Enbrel vs. placebo at all timepoints for both ACR 20 and ACR 50 responses).&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft774">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month&#160;3 and&#160;<br/>month&#160;6&#160;compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel,&#160;<br/>the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly&#160;<br/>always occurred by 3 months. A dose response was seen; results with 10&#160;mg were intermediate&#160;<br/>between placebo and 25&#160;mg. Enbrel was significantly better than placebo in all components of the&#160;<br/>ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the&#160;<br/>ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which&#160;<br/>included disability, vitality, mental health, general health status, and arthritis-associated health status&#160;<br/>subdomains, was administered every 3&#160;months during the trial. All subdomains&#160;of the HAQ were&#160;<br/>improved in patients treated with Enbrel compared to controls at 3 and 6&#160;months.&#160;</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft773">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month.&#160;<br/>Re-introduction of treatment with Enbrel after discontinuation of&#160;up to 24 months resulted in the same&#160;<br/>magnitudes of responses as patients who received Enbrel without interruption of therapy based on&#160;<br/>results of open-label studies. Continued durable responses have been seen for up to&#160;10&#160;years&#160;in&#160;<br/>open-label extension treatment trials when patients received Enbrel without interruption.&#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft773">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with&#160;<br/>blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid&#160;<br/>arthritis (&lt;3 years duration) who had never received treatment with methotrexate. Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel were administered subcutaneously (SC) twice a week for up to 24 months. Methotrexate&#160;<br/>doses were escalated from 7.5&#160;mg/week to a maximum&#160;of 20&#160;mg/week over the first 8&#160;weeks of the&#160;<br/>trial and continued for up to 24&#160;months. Clinical improvement, including onset of action within&#160;<br/>2&#160;weeks with Enbrel 25&#160;mg, was similar to that seen in the previous trials and was maintained for up to&#160;<br/>24&#160;months.&#160;At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to&#160;<br/>1.5. Treatment with Enbrel 25&#160;mg resulted in substantial improvement at 12&#160;months, with about 44%&#160;</p>
</div>
<!-- Page 78 -->
<a name="78"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page78-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft780">78</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft784">of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year&#160;2 of&#160;<br/>this study.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft784">In this study, structural joint damage was assessed radiographically and expressed as change in Total&#160;<br/>Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score.&#160;<br/>Radiographs of&#160;hands/wrists and feet were read at baseline and 6, 12, and 24&#160;months. The 10&#160;mg&#160;<br/>Enbrel dose had consistently less effect on structural damage than the 25&#160;mg dose. Enbrel 25&#160;mg was&#160;<br/>significantly superior to methotrexate for erosion scores at both 12 and 24&#160;months. The differences in&#160;<br/>TSS and JSN were not statistically significant between methotrexate and Enbrel 25&#160;mg. The results are&#160;<br/>shown in the figure below.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft7823"><b>Radiographic Progression: Comparison of Enbrel vs. Methotrexate in Patients with RA of&#160;<br/>&lt;3&#160;Years Duration</b></p>
<p style="position:absolute;top:533px;left:132px;white-space:nowrap" class="ft7817">C</p>
<p style="position:absolute;top:522px;left:132px;white-space:nowrap" class="ft7817">ha</p>
<p style="position:absolute;top:506px;left:132px;white-space:nowrap" class="ft7817">ng</p>
<p style="position:absolute;top:490px;left:132px;white-space:nowrap" class="ft7817">e&#160;</p>
<p style="position:absolute;top:478px;left:132px;white-space:nowrap" class="ft7817">fr</p>
<p style="position:absolute;top:469px;left:132px;white-space:nowrap" class="ft7817">o</p>
<p style="position:absolute;top:460px;left:132px;white-space:nowrap" class="ft7817">m</p>
<p style="position:absolute;top:448px;left:132px;white-space:nowrap" class="ft7817">&#160;B</p>
<p style="position:absolute;top:434px;left:132px;white-space:nowrap" class="ft7817">as</p>
<p style="position:absolute;top:419px;left:132px;white-space:nowrap" class="ft7817">e</p>
<p style="position:absolute;top:410px;left:132px;white-space:nowrap" class="ft7817">lin</p>
<p style="position:absolute;top:396px;left:132px;white-space:nowrap" class="ft7817">e</p>
<p style="position:absolute;top:569px;left:145px;white-space:nowrap" class="ft7818"><b>0.0</b></p>
<p style="position:absolute;top:532px;left:145px;white-space:nowrap" class="ft7818"><b>0.5</b></p>
<p style="position:absolute;top:495px;left:145px;white-space:nowrap" class="ft7818"><b>1.0</b></p>
<p style="position:absolute;top:457px;left:145px;white-space:nowrap" class="ft7818"><b>1.5</b></p>
<p style="position:absolute;top:420px;left:145px;white-space:nowrap" class="ft7818"><b>2.0</b></p>
<p style="position:absolute;top:383px;left:145px;white-space:nowrap" class="ft7818"><b>2.5</b></p>
<p style="position:absolute;top:570px;left:484px;white-space:nowrap" class="ft7818"><b>0.0</b></p>
<p style="position:absolute;top:533px;left:484px;white-space:nowrap" class="ft7818"><b>0.5</b></p>
<p style="position:absolute;top:496px;left:484px;white-space:nowrap" class="ft7818"><b>1.0</b></p>
<p style="position:absolute;top:459px;left:484px;white-space:nowrap" class="ft7818"><b>1.5</b></p>
<p style="position:absolute;top:422px;left:484px;white-space:nowrap" class="ft7818"><b>2.0</b></p>
<p style="position:absolute;top:385px;left:484px;white-space:nowrap" class="ft7818"><b>2.5</b></p>
<p style="position:absolute;top:615px;left:433px;white-space:nowrap" class="ft7819"><b>MTX</b></p>
<p style="position:absolute;top:629px;left:434px;white-space:nowrap" class="ft7819"><b>Enbrel&#160;25 mg</b></p>
<p style="position:absolute;top:378px;left:251px;white-space:nowrap" class="ft7819"><b>12 Months</b></p>
<p style="position:absolute;top:378px;left:598px;white-space:nowrap" class="ft7819"><b>24 Months</b></p>
<p style="position:absolute;top:587px;left:221px;white-space:nowrap" class="ft7820"><b>TSS</b></p>
<p style="position:absolute;top:587px;left:269px;white-space:nowrap" class="ft7820"><b>Erosions</b></p>
<p style="position:absolute;top:588px;left:351px;white-space:nowrap" class="ft7820"><b>JSN</b></p>
<p style="position:absolute;top:590px;left:554px;white-space:nowrap" class="ft7820"><b>TSS</b></p>
<p style="position:absolute;top:590px;left:608px;white-space:nowrap" class="ft7820"><b>Erosions</b></p>
<p style="position:absolute;top:590px;left:688px;white-space:nowrap" class="ft7820"><b>JSN</b></p>
<p style="position:absolute;top:458px;left:208px;white-space:nowrap" class="ft7819"><b>1.3</b></p>
<p style="position:absolute;top:496px;left:233px;white-space:nowrap" class="ft7819"><b>0.8</b></p>
<p style="position:absolute;top:488px;left:276px;white-space:nowrap" class="ft7819"><b>0.9</b></p>
<p style="position:absolute;top:526px;left:301px;white-space:nowrap" class="ft7819"><b>0.4*</b></p>
<p style="position:absolute;top:526px;left:344px;white-space:nowrap" class="ft7819"><b>0.4&#160;0.4</b></p>
<p style="position:absolute;top:391px;left:547px;white-space:nowrap" class="ft7819"><b>2.2</b></p>
<p style="position:absolute;top:466px;left:571px;white-space:nowrap" class="ft7819"><b>1.2</b></p>
<p style="position:absolute;top:458px;left:615px;white-space:nowrap" class="ft7819"><b>1.3</b></p>
<p style="position:absolute;top:510px;left:638px;white-space:nowrap" class="ft7819"><b>0.6*</b></p>
<p style="position:absolute;top:488px;left:681px;white-space:nowrap" class="ft7819"><b>0.9</b></p>
<p style="position:absolute;top:510px;left:705px;white-space:nowrap" class="ft7819"><b>0.6</b></p>
<p style="position:absolute;top:657px;left:420px;white-space:nowrap" class="ft7819"><b>*p &lt; 0.05</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft783">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and&#160;<br/>radiographic progression in RA patients treated with Enbrel alone (25&#160;mg twice weekly), methotrexate&#160;<br/>alone (7.5 to 20&#160;mg&#160;weekly, median dose 20&#160;mg), and the combination of Enbrel and methotrexate&#160;<br/>initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6&#160;months&#160;<br/>to 20&#160;years duration (median 5&#160;years) who had a less than satisfactory response to&#160;at least 1&#160;<br/>disease-modifying antirheumatic drug (DMARD) other than methotrexate.</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft784">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher&#160;<br/>ACR&#160;20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both&#160;24 and&#160;<br/>52&#160;weeks than patients in either of the single therapy groups (results shown in table below).&#160;<br/>Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after&#160;24&#160;months.</p>
<p style="position:absolute;top:936px;left:126px;white-space:nowrap" class="ft781"><b>Clinical Efficacy Results at 12&#160;Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel&#160;</b></p>
<p style="position:absolute;top:955px;left:126px;white-space:nowrap" class="ft781"><b>in Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration</b></p>
<p style="position:absolute;top:994px;left:120px;white-space:nowrap" class="ft781"><b>Endpoint</b></p>
<p style="position:absolute;top:994px;left:281px;white-space:nowrap" class="ft782">Methotrexate</p>
<p style="position:absolute;top:1013px;left:291px;white-space:nowrap" class="ft782">(n =&#160;228)</p>
<p style="position:absolute;top:994px;left:447px;white-space:nowrap" class="ft782">Enbrel</p>
<p style="position:absolute;top:1013px;left:435px;white-space:nowrap" class="ft782">(n = 223)</p>
<p style="position:absolute;top:975px;left:629px;white-space:nowrap" class="ft782">Enbrel +</p>
<p style="position:absolute;top:994px;left:610px;white-space:nowrap" class="ft782">Methotrexate</p>
<p style="position:absolute;top:1013px;left:623px;white-space:nowrap" class="ft782">(n = 231)</p>
<p style="position:absolute;top:1052px;left:120px;white-space:nowrap" class="ft781"><b>ACR Responses</b>a</p>
<p style="position:absolute;top:1071px;left:149px;white-space:nowrap" class="ft782">ACR 20</p>
<p style="position:absolute;top:1071px;left:304px;white-space:nowrap" class="ft782">58.8%</p>
<p style="position:absolute;top:1071px;left:448px;white-space:nowrap" class="ft782">65.5%</p>
<p style="position:absolute;top:1072px;left:628px;white-space:nowrap" class="ft782">74.5%&#160;<b>†,</b></p>
<p style="position:absolute;top:1091px;left:149px;white-space:nowrap" class="ft782">ACR 50</p>
<p style="position:absolute;top:1091px;left:304px;white-space:nowrap" class="ft782">36.4%</p>
<p style="position:absolute;top:1091px;left:448px;white-space:nowrap" class="ft782">43.0%</p>
<p style="position:absolute;top:1092px;left:628px;white-space:nowrap" class="ft782">63.2%&#160;<b>†,</b></p>
<p style="position:absolute;top:1111px;left:149px;white-space:nowrap" class="ft782">ACR 70</p>
<p style="position:absolute;top:1112px;left:304px;white-space:nowrap" class="ft782">16.7%</p>
<p style="position:absolute;top:1112px;left:448px;white-space:nowrap" class="ft782">22.0%</p>
<p style="position:absolute;top:1112px;left:628px;white-space:nowrap" class="ft782">39.8%&#160;<b>†,</b></p>
</div>
<!-- Page 79 -->
<a name="79"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft7928{font-size:13px;font-family:PZJVUM+Arial;color:#000000;-moz-transform: matrix(         0,         -1,          1,          0, 0, 0);-webkit-transform: matrix(         0,         -1,          1,          0, 0, 0);-o-transform: matrix(         0,         -1,          1,          0, 0, 0);-ms-transform: matrix(         0,         -1,          1,          0, 0, 0);-moz-transform-origin: left 75%;-webkit-transform-origin: left 75%;-o-transform-origin: left 75%;-ms-transform-origin: left 75%;}
	.ft7929{font-size:11px;font-family:PZJVUM+Arial;color:#000000;}
	.ft7930{font-size:11px;font-family:PZJVUM+Arial,Bold;color:#000000;}
	.ft7931{font-size:9px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
	.ft7932{font-size:9px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
	.ft7933{font-size:9px;font-family:PZJVUM+Symbol;color:#000000;}
	.ft7934{font-size:16px;font-family:PZJVUM+Arial,Bold;color:#000000;}
-->
</style>
<div id="page79-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft790">79</p>
<p style="position:absolute;top:108px;left:126px;white-space:nowrap" class="ft791"><b>Clinical Efficacy Results at 12&#160;Months: Comparison of Enbrel vs. Methotrexate vs. Enbrel&#160;</b></p>
<p style="position:absolute;top:127px;left:126px;white-space:nowrap" class="ft791"><b>in Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration</b></p>
<p style="position:absolute;top:165px;left:120px;white-space:nowrap" class="ft791"><b>Endpoint</b></p>
<p style="position:absolute;top:165px;left:281px;white-space:nowrap" class="ft792">Methotrexate</p>
<p style="position:absolute;top:184px;left:291px;white-space:nowrap" class="ft792">(n =&#160;228)</p>
<p style="position:absolute;top:165px;left:447px;white-space:nowrap" class="ft792">Enbrel</p>
<p style="position:absolute;top:184px;left:435px;white-space:nowrap" class="ft792">(n = 223)</p>
<p style="position:absolute;top:146px;left:629px;white-space:nowrap" class="ft792">Enbrel +</p>
<p style="position:absolute;top:165px;left:610px;white-space:nowrap" class="ft792">Methotrexate</p>
<p style="position:absolute;top:184px;left:623px;white-space:nowrap" class="ft792">(n = 231)</p>
<p style="position:absolute;top:203px;left:120px;white-space:nowrap" class="ft791"><b>DAS</b></p>
<p style="position:absolute;top:222px;left:149px;white-space:nowrap" class="ft792">Baseline&#160;</p>
<p style="position:absolute;top:241px;left:120px;white-space:nowrap" class="ft792">scoreb</p>
<p style="position:absolute;top:222px;left:315px;white-space:nowrap" class="ft792">5.5</p>
<p style="position:absolute;top:222px;left:459px;white-space:nowrap" class="ft792">5.7</p>
<p style="position:absolute;top:222px;left:648px;white-space:nowrap" class="ft792">5.5</p>
<p style="position:absolute;top:260px;left:149px;white-space:nowrap" class="ft792">Week 52&#160;</p>
<p style="position:absolute;top:279px;left:120px;white-space:nowrap" class="ft792">scoreb</p>
<p style="position:absolute;top:260px;left:315px;white-space:nowrap" class="ft792">3.0</p>
<p style="position:absolute;top:260px;left:459px;white-space:nowrap" class="ft792">3.0</p>
<p style="position:absolute;top:261px;left:641px;white-space:nowrap" class="ft792">2.3<b>†,</b></p>
<p style="position:absolute;top:298px;left:149px;white-space:nowrap" class="ft792">Remissionc</p>
<p style="position:absolute;top:298px;left:310px;white-space:nowrap" class="ft792">14%</p>
<p style="position:absolute;top:298px;left:454px;white-space:nowrap" class="ft792">18%</p>
<p style="position:absolute;top:299px;left:636px;white-space:nowrap" class="ft792">37%<b>†,</b></p>
<p style="position:absolute;top:337px;left:120px;white-space:nowrap" class="ft791"><b>HAQ</b></p>
<p style="position:absolute;top:356px;left:147px;white-space:nowrap" class="ft792">Baseline</p>
<p style="position:absolute;top:356px;left:315px;white-space:nowrap" class="ft792">1.7</p>
<p style="position:absolute;top:356px;left:459px;white-space:nowrap" class="ft792">1.7</p>
<p style="position:absolute;top:356px;left:648px;white-space:nowrap" class="ft792">1.8</p>
<p style="position:absolute;top:375px;left:147px;white-space:nowrap" class="ft792">Week 52</p>
<p style="position:absolute;top:375px;left:315px;white-space:nowrap" class="ft792">1.1</p>
<p style="position:absolute;top:375px;left:459px;white-space:nowrap" class="ft792">1.0</p>
<p style="position:absolute;top:377px;left:641px;white-space:nowrap" class="ft792">0.8<b>†,</b></p>
<p style="position:absolute;top:396px;left:127px;white-space:nowrap" class="ft798">a: Patients who did not complete 12 months in the study were considered to be non-responders.<br/>b: Values for Disease Activity Score (DAS) are means.<br/>c: Remission is defined as DAS &lt;1.6.<br/>Pairwise comparison p-values:&#160;†&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs.&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:471px;left:245px;white-space:nowrap" class="ft7914">&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. Enbrel.</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft794">Radiographic progression at 12&#160;months was significantly less in the Enbrel group than in the&#160;<br/>methotrexate group, while the combination was significantly better than either monotherapy at&#160;<br/>slowing radiographic progression (see figure below).</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft7923"><b>Radiographic Progression: Comparison of Enbrel vs. Methotrexate vs. Enbrel in Combination&#160;<br/>with Methotrexate in Patients with RA of&#160;6&#160;Months To 20&#160;Years Duration (12&#160;Month Results)</b></p>
<p style="position:absolute;top:976px;left:233px;white-space:nowrap" class="ft798">Pairwise comparison p-values: * = p &lt;&#160;0.05 for comparisons of Enbrel vs.&#160;<br/>methotrexate, † = p &lt;&#160;0.05 for comparisons of Enbrel + methotrexate vs.&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:1013px;left:351px;white-space:nowrap" class="ft7914">&#160;= p&#160;&lt;&#160;0.05 for comparisons of Enbrel +&#160;methotrexate vs.&#160;</p>
<p style="position:absolute;top:1034px;left:233px;white-space:nowrap" class="ft792">Enbrel.</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft793">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months. Similarly, the&#160;<br/>significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also&#160;<br/>observed after 24&#160;months.</p>
<p style="position:absolute;top:835px;left:217px;white-space:nowrap" class="ft7928">C</p>
<p style="position:absolute;top:825px;left:217px;white-space:nowrap" class="ft7928">ha</p>
<p style="position:absolute;top:810px;left:217px;white-space:nowrap" class="ft7928">ng</p>
<p style="position:absolute;top:795px;left:217px;white-space:nowrap" class="ft7928">e&#160;</p>
<p style="position:absolute;top:784px;left:217px;white-space:nowrap" class="ft7928">fr</p>
<p style="position:absolute;top:775px;left:217px;white-space:nowrap" class="ft7928">om</p>
<p style="position:absolute;top:757px;left:217px;white-space:nowrap" class="ft7928">&#160;B</p>
<p style="position:absolute;top:744px;left:217px;white-space:nowrap" class="ft7928">as</p>
<p style="position:absolute;top:730px;left:217px;white-space:nowrap" class="ft7928">el</p>
<p style="position:absolute;top:719px;left:217px;white-space:nowrap" class="ft7928">in</p>
<p style="position:absolute;top:709px;left:217px;white-space:nowrap" class="ft7928">e</p>
<p style="position:absolute;top:916px;left:242px;white-space:nowrap" class="ft7929">-1.0</p>
<p style="position:absolute;top:880px;left:242px;white-space:nowrap" class="ft7929">-0.5</p>
<p style="position:absolute;top:845px;left:245px;white-space:nowrap" class="ft7929">0.0</p>
<p style="position:absolute;top:810px;left:245px;white-space:nowrap" class="ft7929">0.5</p>
<p style="position:absolute;top:774px;left:245px;white-space:nowrap" class="ft7929">1.0</p>
<p style="position:absolute;top:739px;left:245px;white-space:nowrap" class="ft7929">1.5</p>
<p style="position:absolute;top:703px;left:245px;white-space:nowrap" class="ft7929">2.0</p>
<p style="position:absolute;top:668px;left:245px;white-space:nowrap" class="ft7929">2.5</p>
<p style="position:absolute;top:633px;left:245px;white-space:nowrap" class="ft7929">3.0</p>
<p style="position:absolute;top:645px;left:548px;white-space:nowrap" class="ft7930"><b>Methotrexate</b></p>
<p style="position:absolute;top:659px;left:547px;white-space:nowrap" class="ft7930"><b>Enbrel&#160;</b></p>
<p style="position:absolute;top:673px;left:548px;white-space:nowrap" class="ft7930"><b>Enbrel + Methotrexate</b></p>
<p style="position:absolute;top:636px;left:339px;white-space:nowrap" class="ft7930"><b>2.80</b></p>
<p style="position:absolute;top:797px;left:365px;white-space:nowrap" class="ft7930"><b>0.52*</b></p>
<p style="position:absolute;top:894px;left:383px;white-space:nowrap" class="ft7930"><b>-0.54†</b>,</p>
<p style="position:absolute;top:715px;left:443px;white-space:nowrap" class="ft7930"><b>1.68</b></p>
<p style="position:absolute;top:819px;left:468px;white-space:nowrap" class="ft7930"><b>0.21*</b></p>
<p style="position:absolute;top:878px;left:487px;white-space:nowrap" class="ft7930"><b>-0.30†</b></p>
<p style="position:absolute;top:755px;left:546px;white-space:nowrap" class="ft7930"><b>1.12</b></p>
<p style="position:absolute;top:811px;left:572px;white-space:nowrap" class="ft7930"><b>0.32</b></p>
<p style="position:absolute;top:872px;left:592px;white-space:nowrap" class="ft7930"><b>-0.23†</b>,</p>
<p style="position:absolute;top:924px;left:356px;white-space:nowrap" class="ft7934"><b>TSS</b></p>
<p style="position:absolute;top:924px;left:442px;white-space:nowrap" class="ft7934"><b>Erosions</b></p>
<p style="position:absolute;top:924px;left:565px;white-space:nowrap" class="ft7934"><b>JSN</b></p>
</div>
<!-- Page 80 -->
<a name="80"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page80-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft800">80</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft804">In an analysis in which all patients who dropped out of the study for any reason were considered to&#160;<br/>have progressed, the percentage of patients without progression (TSS change&#160;≤&#160;0.5)&#160;at 24&#160;months was&#160;<br/>higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and&#160;<br/>methotrexate alone groups&#160;(62%, 50%, and 36%, respectively; p&lt;&#160;0.05). The difference between&#160;<br/>Enbrel alone and methotrexate alone was also significant (p&lt;&#160;0.05). Among patients who completed a&#160;<br/>full 24&#160;months of therapy in the study, the non-progression rates were 78%, 70%, and 61%,&#160;<br/>respectively.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft803">The safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered once weekly were&#160;<br/>evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53&#160;<br/>patients received placebo, 214 patients received 50&#160;mg&#160;Enbrel once weekly and 153 patients received&#160;<br/>25&#160;mg Enbrel twice weekly. The safety and efficacy profiles&#160;of the two Enbrel treatment regimens&#160;<br/>were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16&#160;did not show&#160;<br/>comparability (non-inferiority) between the two regimens.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft808"><i>Adult patients with psoriatic arthritis<br/></i>The efficacy of&#160;Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205&#160;<br/>patients with psoriatic arthritis. Patients were between 18 and 70&#160;years of age and had active psoriatic&#160;<br/>arthritis (</p>
<p style="position:absolute;top:449px;left:167px;white-space:nowrap" class="ft8014">&#160;3 swollen joints and&#160;&#160;3 tender joints) in at least one&#160;of the following forms: (1)&#160;distal&#160;</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft808">interphalangeal (DIP) involvement; (2)&#160;polyarticular arthritis (absence of rheumatoid nodules and&#160;<br/>presence of psoriasis); (3)&#160;arthritis mutilans; (4)&#160;asymmetric psoriatic arthritis; or (5)&#160;spondylitis-like&#160;<br/>ankylosis. Patients also had plaque psoriasis with a qualifying target lesion&#160;</p>
<p style="position:absolute;top:507px;left:604px;white-space:nowrap" class="ft8014">&#160;2&#160;cm in diameter.&#160;</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft808">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids&#160;<br/>(24%). Patients currently on methotrexate therapy (stable for&#160;</p>
<p style="position:absolute;top:547px;left:512px;white-space:nowrap" class="ft8014">&#160;2 months) could continue at a stable&#160;</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft802">dose of&#160;</p>
<p style="position:absolute;top:567px;left:159px;white-space:nowrap" class="ft8014">&#160;25&#160;mg/week methotrexate. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in&#160;</p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft804">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6&#160;months. At the&#160;<br/>end of the double-blind study, patients could enter a long-term open-label extension study for a total&#160;<br/>duration of up to 2&#160;years.</p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft803">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70&#160;<br/>response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results&#160;<br/>are summarised in the table below.</p>
<p style="position:absolute;top:739px;left:239px;white-space:nowrap" class="ft801"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:758px;left:389px;white-space:nowrap" class="ft801"><b>Controlled Trial</b></p>
<p style="position:absolute;top:778px;left:495px;white-space:nowrap" class="ft802">Percent of Patients</p>
<p style="position:absolute;top:797px;left:473px;white-space:nowrap" class="ft802">Placebo</p>
<p style="position:absolute;top:797px;left:586px;white-space:nowrap" class="ft802">Enbrela</p>
<p style="position:absolute;top:816px;left:226px;white-space:nowrap" class="ft802">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:816px;left:474px;white-space:nowrap" class="ft802">n = 104</p>
<p style="position:absolute;top:816px;left:585px;white-space:nowrap" class="ft802">n = 101</p>
<p style="position:absolute;top:855px;left:226px;white-space:nowrap" class="ft8024"><b>&#160;&#160;ACR 20<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:874px;left:491px;white-space:nowrap" class="ft802">15</p>
<p style="position:absolute;top:874px;left:600px;white-space:nowrap" class="ft802">59b</p>
<p style="position:absolute;top:893px;left:226px;white-space:nowrap" class="ft802">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:893px;left:491px;white-space:nowrap" class="ft802">13</p>
<p style="position:absolute;top:893px;left:600px;white-space:nowrap" class="ft802">50b</p>
<p style="position:absolute;top:931px;left:226px;white-space:nowrap" class="ft8023"><b>&#160;&#160;ACR 50<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:950px;left:495px;white-space:nowrap" class="ft802">4</p>
<p style="position:absolute;top:950px;left:600px;white-space:nowrap" class="ft802">38b</p>
<p style="position:absolute;top:969px;left:226px;white-space:nowrap" class="ft802">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:969px;left:495px;white-space:nowrap" class="ft802">4</p>
<p style="position:absolute;top:969px;left:600px;white-space:nowrap" class="ft802">37b</p>
<p style="position:absolute;top:1007px;left:226px;white-space:nowrap" class="ft8023"><b>&#160;&#160;ACR 70<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:1026px;left:495px;white-space:nowrap" class="ft802">0</p>
<p style="position:absolute;top:1026px;left:600px;white-space:nowrap" class="ft802">11b</p>
<p style="position:absolute;top:1045px;left:226px;white-space:nowrap" class="ft802">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:1045px;left:495px;white-space:nowrap" class="ft802">1</p>
<p style="position:absolute;top:1045px;left:604px;white-space:nowrap" class="ft802">9c</p>
<p style="position:absolute;top:1083px;left:226px;white-space:nowrap" class="ft8024"><b>&#160;&#160;PsARC<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:1102px;left:491px;white-space:nowrap" class="ft802">31</p>
<p style="position:absolute;top:1102px;left:600px;white-space:nowrap" class="ft802">72b</p>
<p style="position:absolute;top:1121px;left:226px;white-space:nowrap" class="ft802">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:1121px;left:491px;white-space:nowrap" class="ft802">23</p>
<p style="position:absolute;top:1121px;left:600px;white-space:nowrap" class="ft802">70b</p>
</div>
<!-- Page 81 -->
<a name="81"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page81-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft810">81</p>
<p style="position:absolute;top:108px;left:239px;white-space:nowrap" class="ft811"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:127px;left:389px;white-space:nowrap" class="ft811"><b>Controlled Trial</b></p>
<p style="position:absolute;top:146px;left:495px;white-space:nowrap" class="ft812">Percent of Patients</p>
<p style="position:absolute;top:165px;left:473px;white-space:nowrap" class="ft812">Placebo</p>
<p style="position:absolute;top:165px;left:586px;white-space:nowrap" class="ft812">Enbrela</p>
<p style="position:absolute;top:184px;left:226px;white-space:nowrap" class="ft812">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:184px;left:474px;white-space:nowrap" class="ft812">n = 104</p>
<p style="position:absolute;top:184px;left:585px;white-space:nowrap" class="ft812">n = 101</p>
<p style="position:absolute;top:204px;left:236px;white-space:nowrap" class="ft813">a: 25&#160;mg Enbrel SC twice weekly<br/>b: p &lt; 0.001,&#160;Enbrel vs. placebo<br/>c: p &lt; 0.01, Enbrel vs. placebo</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft814">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at&#160;<br/>the time of the first visit (4&#160;weeks) and were maintained through 6&#160;months of therapy. Enbrel was&#160;<br/>significantly better than placebo in all measures of disease activity (p &lt; 0.001), and responses were&#160;<br/>similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis&#160;<br/>patients was assessed at every timepoint using the disability index of the HAQ. The disability index&#160;<br/>score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel,&#160;<br/>relative to placebo (p&#160;&lt;&#160;0.001).&#160;</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft813">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists&#160;<br/>were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in&#160;<br/>the table below. In an analysis in which all patients who dropped out of the study for any reason were&#160;<br/>considered to have progressed, the percentage of patients without progression (TSS&#160;change&#160;≤&#160;0.5) at&#160;<br/>12&#160;months was higher in the Enbrel group compared with the placebo group (73% vs. 47%,&#160;<br/>respectively, p&#160;≤&#160;0.001). The effect of Enbrel on radiographic progression was maintained in patients&#160;<br/>who continued on treatment during the second year.&#160;The slowing of peripheral joint damage was&#160;<br/>observed in patients with polyarticular symmetrical joint involvement. &#160;</p>
<p style="position:absolute;top:621px;left:238px;white-space:nowrap" class="ft811"><b>Mean (SE) Annualized Change from Baseline in Total Sharp Score</b></p>
<p style="position:absolute;top:649px;left:469px;white-space:nowrap" class="ft812">Placebo</p>
<p style="position:absolute;top:649px;left:684px;white-space:nowrap" class="ft812">Etanercept</p>
<p style="position:absolute;top:677px;left:232px;white-space:nowrap" class="ft812">Time</p>
<p style="position:absolute;top:677px;left:464px;white-space:nowrap" class="ft812">(n = 104)</p>
<p style="position:absolute;top:677px;left:688px;white-space:nowrap" class="ft812">(n = 101)</p>
<p style="position:absolute;top:706px;left:217px;white-space:nowrap" class="ft812">Month 12</p>
<p style="position:absolute;top:706px;left:458px;white-space:nowrap" class="ft812">1.00 (0.29)</p>
<p style="position:absolute;top:706px;left:677px;white-space:nowrap" class="ft812">-0.03&#160;(0.09)a</p>
<p style="position:absolute;top:726px;left:123px;white-space:nowrap" class="ft814">SE = standard error. &#160;<br/>a. p = 0.0001. &#160;</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft813">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this&#160;<br/>benefit was maintained during the longer-term exposure of up to 2&#160;years.</p>
<p style="position:absolute;top:834px;left:106px;white-space:nowrap" class="ft813">There is insufficient&#160;evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and&#160;<br/>arthritis mutilans&#160;psoriatic arthropathies due to the small number of patients studied.</p>
<p style="position:absolute;top:890px;left:106px;white-space:nowrap" class="ft814">No study has been performed in patients with psoriatic arthritis using the 50&#160;mg once-weekly dosing&#160;<br/>regimen. Evidence of efficacy for the once-weekly dosing regimen in this patient population has been&#160;<br/>based on data from the study in patients with ankylosing spondylitis.</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft818"><i>Adult patients with ankylosing spondylitis<br/></i>The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies&#160;<br/>comparing twice-weekly administration of 25&#160;mg Enbrel with placebo. A total of 401 patients were&#160;<br/>enrolled, from which 203 were treated with Enbrel. The largest of these trials (n=&#160;277) enrolled&#160;<br/>patients who were between 18 and 70&#160;years of age and had active ankylosing spondylitis defined as&#160;<br/>visual analog scale (VAS) scores of&#160;</p>
<p style="position:absolute;top:1061px;left:347px;white-space:nowrap" class="ft8114">&#160;30 for average of duration and intensity of morning stiffness&#160;</p>
<p style="position:absolute;top:1083px;left:106px;white-space:nowrap" class="ft812">plus VAS scores of&#160;</p>
<p style="position:absolute;top:1081px;left:239px;white-space:nowrap" class="ft8114">&#160;30 for at least 2 of the following 3 parameters: patient global assessment;&#160;</p>
<p style="position:absolute;top:1102px;left:106px;white-space:nowrap" class="ft814">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the&#160;<br/>Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or&#160;<br/>corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine&#160;<br/>were not included in the study. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in patients&#160;</p>
</div>
<!-- Page 82 -->
<a name="82"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page82-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft820">82</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft824">with rheumatoid arthritis) or placebo were administered subcutaneously&#160;twice a week for 6&#160;months in&#160;<br/>138&#160;patients.</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft822">The primary measure of efficacy (ASAS 20) was a&#160;</p>
<p style="position:absolute;top:164px;left:446px;white-space:nowrap" class="ft8214">20% improvement in at least 3 of the 4&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft823">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain,&#160;<br/>BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70&#160;<br/>responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft824">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20,&#160;<br/>ASAS&#160;50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</p>
<p style="position:absolute;top:318px;left:255px;white-space:nowrap" class="ft821"><b>Responses of Patients with Ankylosing Spondylitis in a&#160;</b></p>
<p style="position:absolute;top:337px;left:361px;white-space:nowrap" class="ft821"><b>Placebo-controlled Trial</b></p>
<p style="position:absolute;top:357px;left:482px;white-space:nowrap" class="ft822">Percent of Patients</p>
<p style="position:absolute;top:378px;left:242px;white-space:nowrap" class="ft822">&#160;&#160;Ankylosing Spondylitis&#160;</p>
<p style="position:absolute;top:396px;left:249px;white-space:nowrap" class="ft822">Response</p>
<p style="position:absolute;top:378px;left:464px;white-space:nowrap" class="ft822">Placebo</p>
<p style="position:absolute;top:396px;left:462px;white-space:nowrap" class="ft822">N = 139</p>
<p style="position:absolute;top:378px;left:576px;white-space:nowrap" class="ft822">Enbrel</p>
<p style="position:absolute;top:396px;left:570px;white-space:nowrap" class="ft822">N = 138</p>
<p style="position:absolute;top:417px;left:241px;white-space:nowrap" class="ft822">&#160;&#160;ASAS 20&#160;</p>
<p style="position:absolute;top:437px;left:259px;white-space:nowrap" class="ft822">2&#160;weeks</p>
<p style="position:absolute;top:437px;left:481px;white-space:nowrap" class="ft822">22</p>
<p style="position:absolute;top:437px;left:587px;white-space:nowrap" class="ft822">46a</p>
<p style="position:absolute;top:457px;left:259px;white-space:nowrap" class="ft822">3 months</p>
<p style="position:absolute;top:457px;left:481px;white-space:nowrap" class="ft822">27</p>
<p style="position:absolute;top:457px;left:587px;white-space:nowrap" class="ft822">60a</p>
<p style="position:absolute;top:477px;left:259px;white-space:nowrap" class="ft822">6&#160;months</p>
<p style="position:absolute;top:477px;left:481px;white-space:nowrap" class="ft822">23</p>
<p style="position:absolute;top:477px;left:587px;white-space:nowrap" class="ft822">58a</p>
<p style="position:absolute;top:506px;left:241px;white-space:nowrap" class="ft822">&#160;&#160;ASAS 50&#160;</p>
<p style="position:absolute;top:526px;left:259px;white-space:nowrap" class="ft822">2 weeks</p>
<p style="position:absolute;top:526px;left:485px;white-space:nowrap" class="ft822">7</p>
<p style="position:absolute;top:526px;left:587px;white-space:nowrap" class="ft822">24a</p>
<p style="position:absolute;top:546px;left:259px;white-space:nowrap" class="ft822">3 months</p>
<p style="position:absolute;top:546px;left:481px;white-space:nowrap" class="ft822">13</p>
<p style="position:absolute;top:546px;left:587px;white-space:nowrap" class="ft822">45a</p>
<p style="position:absolute;top:566px;left:259px;white-space:nowrap" class="ft822">6&#160;months</p>
<p style="position:absolute;top:566px;left:481px;white-space:nowrap" class="ft822">10</p>
<p style="position:absolute;top:566px;left:587px;white-space:nowrap" class="ft822">42a</p>
<p style="position:absolute;top:595px;left:241px;white-space:nowrap" class="ft822">&#160;&#160;ASAS 70</p>
<p style="position:absolute;top:616px;left:259px;white-space:nowrap" class="ft822">2 weeks</p>
<p style="position:absolute;top:616px;left:485px;white-space:nowrap" class="ft822">2</p>
<p style="position:absolute;top:616px;left:586px;white-space:nowrap" class="ft822">12b</p>
<p style="position:absolute;top:636px;left:259px;white-space:nowrap" class="ft822">3 months</p>
<p style="position:absolute;top:636px;left:485px;white-space:nowrap" class="ft822">7</p>
<p style="position:absolute;top:636px;left:586px;white-space:nowrap" class="ft822">29b</p>
<p style="position:absolute;top:656px;left:259px;white-space:nowrap" class="ft822">6&#160;months&#160;</p>
<p style="position:absolute;top:656px;left:485px;white-space:nowrap" class="ft822">5</p>
<p style="position:absolute;top:656px;left:586px;white-space:nowrap" class="ft822">28b</p>
<p style="position:absolute;top:685px;left:246px;white-space:nowrap" class="ft823">a: p&#160;&lt;0.001, Enbrel vs. placebo<br/>b: p = 0.002, Enbrel vs. placebo</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft824">Among&#160;patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent&#160;<br/>at the time of the first visit (2&#160;weeks) and were maintained through 6&#160;months of therapy. Responses&#160;<br/>were similar in patients who were or were not receiving concomitant therapies at baseline.</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft822">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft824">In a fourth study, the safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered&#160;<br/>once weekly vs. 25&#160;mg Enbrel administered twice&#160;weekly were evaluated in a double-blind,&#160;<br/>placebo-controlled study of 356&#160;patients with active ankylosing spondylitis. The safety and efficacy&#160;<br/>profiles of the 50&#160;mg once-weekly and 25&#160;mg twice-weekly regimens were similar.</p>
<p style="position:absolute;top:953px;left:106px;white-space:nowrap" class="ft825"><i>Adult patients with&#160;non-radiographic axial spondyloarthritis</i></p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft823"><i>Study 1<br/></i>The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was&#160;<br/>assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated&#160;<br/>215&#160;adult patients&#160;(modified intent-to-treat population)&#160;with active nr-AxSpa (18 to 49 years of age),<br/>defined as those patients meeting the ASAS&#160;classification criteria of&#160;axial&#160;spondyloarthritis but did not&#160;<br/>meet the modified New York criteria for AS.&#160;Patients were also&#160;required to have an&#160;inadequate&#160;<br/>response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel&#160;<br/>50 mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40%&#160;<br/>improvement in at least three of the four ASAS domains and absence of deterioration in the remaining&#160;</p>
</div>
<!-- Page 83 -->
<a name="83"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page83-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft830">83</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft833">domain. The double-blind period was followed by an open-label period during which all patients&#160;<br/>receive&#160;Enbrel 50 mg weekly for up to an additional 92 weeks.&#160;MRIs of the sacroiliac joint and&#160;spine&#160;<br/>were obtained to assess inflammation at baseline and at weeks&#160;12&#160;and 104.</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft833">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the&#160;<br/>ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial&#160;<br/>remission and BASDAI 50.&#160;Week 12&#160;results are shown in the table below.</p>
<p style="position:absolute;top:262px;left:135px;white-space:nowrap" class="ft831"><b>Efficacy Response&#160;in Placebo-Controlled nr-AxSpa Study:&#160;Percent of Patients Achieving&#160;</b></p>
<p style="position:absolute;top:281px;left:410px;white-space:nowrap" class="ft831"><b>Endpoints</b></p>
<p style="position:absolute;top:300px;left:141px;white-space:nowrap" class="ft834">Double-Blind Clinical<br/>Responses at Week 12&#160;</p>
<p style="position:absolute;top:300px;left:481px;white-space:nowrap" class="ft832">Placebo</p>
<p style="position:absolute;top:319px;left:457px;white-space:nowrap" class="ft832">N=106 to 109*</p>
<p style="position:absolute;top:300px;left:661px;white-space:nowrap" class="ft832">Enbrel</p>
<p style="position:absolute;top:319px;left:633px;white-space:nowrap" class="ft832">N=103 to 105*</p>
<p style="position:absolute;top:339px;left:141px;white-space:nowrap" class="ft832">ASAS** 40</p>
<p style="position:absolute;top:339px;left:493px;white-space:nowrap" class="ft832">15.7</p>
<p style="position:absolute;top:339px;left:666px;white-space:nowrap" class="ft832">32.4b</p>
<p style="position:absolute;top:359px;left:141px;white-space:nowrap" class="ft832">ASAS 20</p>
<p style="position:absolute;top:359px;left:493px;white-space:nowrap" class="ft832">36.1</p>
<p style="position:absolute;top:359px;left:666px;white-space:nowrap" class="ft832">52.4c</p>
<p style="position:absolute;top:378px;left:141px;white-space:nowrap" class="ft832">ASAS 5/6</p>
<p style="position:absolute;top:378px;left:493px;white-space:nowrap" class="ft832">10.4</p>
<p style="position:absolute;top:378px;left:666px;white-space:nowrap" class="ft832">33.0a</p>
<p style="position:absolute;top:398px;left:141px;white-space:nowrap" class="ft832">ASAS partial remission</p>
<p style="position:absolute;top:398px;left:493px;white-space:nowrap" class="ft832">11.9</p>
<p style="position:absolute;top:398px;left:666px;white-space:nowrap" class="ft832">24.8c</p>
<p style="position:absolute;top:418px;left:141px;white-space:nowrap" class="ft832">BASDAI***50</p>
<p style="position:absolute;top:418px;left:493px;white-space:nowrap" class="ft832">23.9</p>
<p style="position:absolute;top:418px;left:666px;white-space:nowrap" class="ft832">43.8b</p>
<p style="position:absolute;top:438px;left:149px;white-space:nowrap" class="ft833">*Some patients did not provide complete data for each endpoint<br/>**ASAS=Assessments in Spondyloarthritis International Society<br/>***Bath Ankylosing Spondylitis Disease Activity Index<br/>a: p&#160;&lt;0.001,&#160;b:&lt;0.01 and&#160;c:&lt;0.05,&#160;respectively between&#160;Enbrel and placebo</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft834">At week&#160;12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis&#160;<br/>Research Consortium of Canada) score&#160;for the sacroiliac joint&#160;(SIJ)&#160;as measured by MRI for patients<br/>receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8&#160;<br/>for placebo treated (n=105) patients (p&lt;0.001).&#160;At week&#160;104, the mean change from baseline in the&#160;<br/>SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and&#160;<br/>1.40&#160;the spine (n=154).</p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft834">Enbrel showed statistically significantly greater improvement&#160;from baseline to week 12 compared to&#160;<br/>placebo&#160;in&#160;most health-related quality of life and physical function assessments, including&#160;BASFI<br/>(Bath Ankylosing Spondylitis Functional Index),&#160;EuroQol 5D&#160;Overall Health State Score and SF-36&#160;<br/>Physical Component Score.</p>
<p style="position:absolute;top:760px;left:106px;white-space:nowrap" class="ft834">Clinical responses among&#160;nr-AxSpa&#160;patients who received Enbrel were apparent at the time of the first&#160;<br/>visit (2&#160;weeks) and were maintained through&#160;2&#160;years&#160;of therapy.&#160;Improvements in health-related&#160;<br/>quality of life and physical function&#160;were also maintained through 2&#160;years of therapy. The 2&#160;year data&#160;<br/>did not reveal any new safety findings.&#160;At week&#160;104, 8&#160;subjects had progressed to a score of bilateral&#160;<br/>Grade&#160;2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial&#160;<br/>spondyloarthropathy.</p>
<p style="position:absolute;top:893px;left:106px;white-space:nowrap" class="ft833"><i>Study 2<br/></i>This multi-center, open-label,&#160;phase 4,&#160;3-period study evaluated the withdrawal and retreatment of&#160;<br/>Enbrel&#160;in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined&#160;<br/>as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3)&#160;<br/>following 24&#160;weeks of treatment.&#160;</p>
<p style="position:absolute;top:1007px;left:106px;white-space:nowrap" class="ft833">209&#160;adult patients with active nr-AxSpa (18 to 49&#160;years of age), defined as those patients meeting the&#160;<br/>Assessment of SpondyloArthritis&#160;International&#160;Society (ASAS) classification criteria of axial&#160;<br/>spondyloarthritis (but not meeting the modified New York criteria for AS), having&#160;positive&#160;MRI&#160;<br/>findings (active inflammation on MRI highly suggestive of&#160;sacroiliitis&#160;associated with SpA) and/or&#160;<br/>positive hsCRP (defined as high sensitivity C-reactive protein&#160;[hsCRP]&#160;&gt;3&#160;mg/l), and&#160;active symptoms&#160;<br/>defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received open-label&#160;<br/>Enbrel 50&#160;mg weekly&#160;plus stable background NSAID at the optimal tolerated anti-inflammatory&#160;<br/>dosage&#160;for 24&#160;weeks in Period 1. Patients were also required to have an inadequate response or&#160;<br/>intolerance to two or more NSAIDs. At week&#160;24, 119 (57%) patients achieved inactive disease and&#160;</p>
</div>
<!-- Page 84 -->
<a name="84"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page84-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft840">84</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft844">entered into the Period&#160;2&#160;40-week withdrawal phase&#160;where subjects discontinued etanercept, yet&#160;<br/>maintained the background NSAID. The&#160;primary measure of efficacy was the occurrence of flare&#160;<br/>(defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal to 2.1) within&#160;<br/>40&#160;weeks following withdrawal of Enbrel. Patients who flared were retreated with&#160;Enbrel 50&#160;mg&#160;<br/>weekly for 12&#160;weeks (Period 3).</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft843">In Period&#160;2, the proportion of patients experiencing&#160;≥1 flare increased from 22% (25/112) at week 4 to&#160;<br/>67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within&#160;<br/>40&#160;weeks following withdrawal of Enbrel.&#160;</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft844">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and&#160;<br/>additionally&#160;compare&#160;the time to flare to&#160;patients from Study 1 who met the Study&#160;2&#160;withdrawal phase&#160;<br/>entry requirements and continued Enbrel therapy.&#160;</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft843">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24&#160;weeks).&#160;Less&#160;<br/>than 25% of patients in Study&#160;1 who did not have treatment withdrawn experienced a flare&#160;over the&#160;<br/>equivalent&#160;40-weeks&#160;as in&#160;Period 2&#160;Study 2. The time to flare was statistically significantly shorter in&#160;<br/>subjects who discontinued&#160;Enbrel&#160;treatment (Study 2) compared to subjects who received continuous&#160;<br/>etanercept treatment (Study 1), p&lt;0.0001.</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft843">Of the 87&#160;patients who entered Period 3 and were retreated with Enbrel 50&#160;mg weekly for 12&#160;weeks,&#160;<br/>62% (54/87) reachieved inactive disease,&#160;with 50% of&#160;them&#160;reachieving&#160;it&#160;within 5&#160;weeks (95% CI:&#160;<br/>4-8&#160;weeks).</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft843"><i>Adult patients with plaque psoriasis<br/></i>Enbrel is recommended for use in patients as defined in section 4.1. Patients who “failed to respond&#160;<br/>to” in the target population is defined by insufficient response (PASI&lt;50 or PGA less than good), or&#160;<br/>worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long&#160;<br/>duration to assess response with at least&#160;one&#160;of the three major systemic therapies as available.</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft843">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis&#160;<br/>(responsive to&#160;other systemic therapies) has not been evaluated in studies directly comparing Enbrel&#160;<br/>with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four&#160;<br/>randomised, double-blind, placebo-controlled studies. The primary efficacy&#160;endpoint in all four studies&#160;<br/>was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75%&#160;<br/>improvement in the Psoriasis Area and Severity Index score from baseline) at 12&#160;weeks.</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft842">Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving&#160;</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft848">&#160;10% of the body surface area who were&#160;&#160;18 years old. One hundred and twelve (112) patients were&#160;<br/>randomised to receive a dose of 25&#160;mg of Enbrel (n=57) or placebo (n=55) twice a week for&#160;24&#160;weeks.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft843">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study&#160;<br/>1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel&#160;<br/>was administered at doses of 25&#160;mg once&#160;a week, 25&#160;mg twice a week or 50&#160;mg twice a week for&#160;<br/>6&#160;consecutive months. During the first 12 weeks of the double-blind treatment period, patients&#160;<br/>received placebo or one of the above three Enbrel doses. After 12&#160;weeks of treatment, patients in the&#160;<br/>placebo group began treatment with blinded Enbrel (25&#160;mg twice a week); patients in the active&#160;<br/>treatment groups continued to week&#160;24 on the dose to which they were originally randomised.</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft844">Study&#160;3 evaluated 583 patients and had the same inclusion criteria as study&#160;2. Patients in this study&#160;<br/>received a dose of 25&#160;mg or 50&#160;mg Enbrel, or placebo twice a week for 12&#160;weeks and then all patients&#160;<br/>received open-label 25&#160;mg&#160;Enbrel twice weekly for an additional 24&#160;weeks.</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft843">Study&#160;4 evaluated 142 patients and had similar&#160;inclusion criteria to studies&#160;2 and 3. Patients in this&#160;<br/>study received a dose of 50&#160;mg Enbrel or placebo once weekly for 12&#160;weeks and then all patients&#160;<br/>received open-label 50&#160;mg&#160;Enbrel once weekly for an additional 12&#160;weeks.</p>
</div>
<!-- Page 85 -->
<a name="85"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page85-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft850">85</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft854">In study 1, the Enbrel-treated&#160;group had a significantly higher proportion of patients with a PASI 75&#160;<br/>response at week 12 (30%) compared to the placebo-treated group (2%) (p&#160;&lt;&#160;0.0001). At 24 weeks,&#160;<br/>56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of&#160;<br/>placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</p>
<p style="position:absolute;top:222px;left:262px;white-space:nowrap" class="ft851"><b>Responses of Patients with Psoriasis in Studies 2, 3 and 4</b></p>
<p style="position:absolute;top:359px;left:118px;white-space:nowrap" class="ft852">Respons</p>
<p style="position:absolute;top:378px;left:127px;white-space:nowrap" class="ft852">e (%)</p>
<p style="position:absolute;top:242px;left:273px;white-space:nowrap" class="ft852">Study 2</p>
<p style="position:absolute;top:242px;left:489px;white-space:nowrap" class="ft852">Study 3</p>
<p style="position:absolute;top:242px;left:691px;white-space:nowrap" class="ft852">Study 4</p>
<p style="position:absolute;top:301px;left:191px;white-space:nowrap" class="ft852">Placebo</p>
<p style="position:absolute;top:263px;left:262px;white-space:nowrap" class="ft852">----------Enbrel---------</p>
<p style="position:absolute;top:301px;left:421px;white-space:nowrap" class="ft852">Placebo</p>
<p style="position:absolute;top:263px;left:488px;white-space:nowrap" class="ft852">--------Enbrel-------</p>
<p style="position:absolute;top:301px;left:623px;white-space:nowrap" class="ft852">Placebo</p>
<p style="position:absolute;top:263px;left:696px;white-space:nowrap" class="ft852">-------Enbrel------</p>
<p style="position:absolute;top:282px;left:270px;white-space:nowrap" class="ft852">25&#160;mg&#160;</p>
<p style="position:absolute;top:301px;left:275px;white-space:nowrap" class="ft852">BIW</p>
<p style="position:absolute;top:282px;left:351px;white-space:nowrap" class="ft852">50&#160;mg&#160;</p>
<p style="position:absolute;top:301px;left:356px;white-space:nowrap" class="ft852">BIW</p>
<p style="position:absolute;top:282px;left:493px;white-space:nowrap" class="ft852">25&#160;mg</p>
<p style="position:absolute;top:301px;left:497px;white-space:nowrap" class="ft852">BIW</p>
<p style="position:absolute;top:282px;left:561px;white-space:nowrap" class="ft852">50&#160;mg</p>
<p style="position:absolute;top:301px;left:565px;white-space:nowrap" class="ft852">BIW</p>
<p style="position:absolute;top:282px;left:696px;white-space:nowrap" class="ft852">50&#160;mg&#160;</p>
<p style="position:absolute;top:301px;left:702px;white-space:nowrap" class="ft852">QW</p>
<p style="position:absolute;top:282px;left:763px;white-space:nowrap" class="ft852">50&#160;mg</p>
<p style="position:absolute;top:301px;left:769px;white-space:nowrap" class="ft852">QW</p>
<p style="position:absolute;top:320px;left:192px;white-space:nowrap" class="ft852">n = 166</p>
<p style="position:absolute;top:339px;left:196px;white-space:nowrap" class="ft852">wk 12</p>
<p style="position:absolute;top:320px;left:260px;white-space:nowrap" class="ft852">n =&#160;</p>
<p style="position:absolute;top:339px;left:258px;white-space:nowrap" class="ft852">162</p>
<p style="position:absolute;top:357px;left:260px;white-space:nowrap" class="ft852">wk&#160;</p>
<p style="position:absolute;top:377px;left:262px;white-space:nowrap" class="ft852">12</p>
<p style="position:absolute;top:320px;left:300px;white-space:nowrap" class="ft852">n =&#160;</p>
<p style="position:absolute;top:339px;left:298px;white-space:nowrap" class="ft852">162</p>
<p style="position:absolute;top:357px;left:301px;white-space:nowrap" class="ft853">wk&#160;<br/>24a</p>
<p style="position:absolute;top:320px;left:341px;white-space:nowrap" class="ft852">n =&#160;</p>
<p style="position:absolute;top:339px;left:339px;white-space:nowrap" class="ft852">164</p>
<p style="position:absolute;top:357px;left:341px;white-space:nowrap" class="ft852">wk&#160;</p>
<p style="position:absolute;top:377px;left:343px;white-space:nowrap" class="ft852">12</p>
<p style="position:absolute;top:320px;left:381px;white-space:nowrap" class="ft852">n =&#160;</p>
<p style="position:absolute;top:339px;left:379px;white-space:nowrap" class="ft852">164</p>
<p style="position:absolute;top:357px;left:382px;white-space:nowrap" class="ft853">wk&#160;<br/>24a</p>
<p style="position:absolute;top:320px;left:422px;white-space:nowrap" class="ft852">n = 193</p>
<p style="position:absolute;top:339px;left:426px;white-space:nowrap" class="ft852">wk 12</p>
<p style="position:absolute;top:320px;left:489px;white-space:nowrap" class="ft852">n = 196</p>
<p style="position:absolute;top:339px;left:493px;white-space:nowrap" class="ft852">wk 12</p>
<p style="position:absolute;top:320px;left:557px;white-space:nowrap" class="ft852">n = 196</p>
<p style="position:absolute;top:339px;left:561px;white-space:nowrap" class="ft852">wk 12</p>
<p style="position:absolute;top:320px;left:628px;white-space:nowrap" class="ft852">n = 46</p>
<p style="position:absolute;top:339px;left:628px;white-space:nowrap" class="ft852">wk 12</p>
<p style="position:absolute;top:320px;left:695px;white-space:nowrap" class="ft852">n = 96</p>
<p style="position:absolute;top:339px;left:696px;white-space:nowrap" class="ft852">wk 12</p>
<p style="position:absolute;top:320px;left:763px;white-space:nowrap" class="ft852">n = 90</p>
<p style="position:absolute;top:339px;left:761px;white-space:nowrap" class="ft852">wk 24a</p>
<p style="position:absolute;top:398px;left:114px;white-space:nowrap" class="ft852">PASI 50</p>
<p style="position:absolute;top:398px;left:208px;white-space:nowrap" class="ft852">14</p>
<p style="position:absolute;top:398px;left:258px;white-space:nowrap" class="ft852">58*</p>
<p style="position:absolute;top:398px;left:302px;white-space:nowrap" class="ft852">70</p>
<p style="position:absolute;top:398px;left:339px;white-space:nowrap" class="ft852">74*</p>
<p style="position:absolute;top:398px;left:383px;white-space:nowrap" class="ft852">77</p>
<p style="position:absolute;top:398px;left:441px;white-space:nowrap" class="ft852">9</p>
<p style="position:absolute;top:398px;left:501px;white-space:nowrap" class="ft852">64*</p>
<p style="position:absolute;top:398px;left:568px;white-space:nowrap" class="ft852">77*</p>
<p style="position:absolute;top:398px;left:644px;white-space:nowrap" class="ft852">9</p>
<p style="position:absolute;top:398px;left:703px;white-space:nowrap" class="ft852">69*</p>
<p style="position:absolute;top:398px;left:775px;white-space:nowrap" class="ft852">83</p>
<p style="position:absolute;top:419px;left:114px;white-space:nowrap" class="ft852">PASI 75</p>
<p style="position:absolute;top:419px;left:212px;white-space:nowrap" class="ft852">4</p>
<p style="position:absolute;top:419px;left:258px;white-space:nowrap" class="ft852">34*</p>
<p style="position:absolute;top:419px;left:302px;white-space:nowrap" class="ft852">44</p>
<p style="position:absolute;top:419px;left:339px;white-space:nowrap" class="ft852">49*</p>
<p style="position:absolute;top:419px;left:383px;white-space:nowrap" class="ft852">59</p>
<p style="position:absolute;top:419px;left:441px;white-space:nowrap" class="ft852">3</p>
<p style="position:absolute;top:419px;left:501px;white-space:nowrap" class="ft852">34*</p>
<p style="position:absolute;top:419px;left:568px;white-space:nowrap" class="ft852">49*</p>
<p style="position:absolute;top:419px;left:644px;white-space:nowrap" class="ft852">2</p>
<p style="position:absolute;top:419px;left:703px;white-space:nowrap" class="ft852">38*</p>
<p style="position:absolute;top:419px;left:775px;white-space:nowrap" class="ft852">71</p>
<p style="position:absolute;top:444px;left:114px;white-space:nowrap" class="ft854">DSGAb,&#160;<br/>clear or&#160;<br/>almost&#160;<br/>clear</p>
<p style="position:absolute;top:501px;left:212px;white-space:nowrap" class="ft852">5</p>
<p style="position:absolute;top:501px;left:258px;white-space:nowrap" class="ft852">34*</p>
<p style="position:absolute;top:501px;left:302px;white-space:nowrap" class="ft852">39</p>
<p style="position:absolute;top:501px;left:339px;white-space:nowrap" class="ft852">49*</p>
<p style="position:absolute;top:501px;left:383px;white-space:nowrap" class="ft852">55</p>
<p style="position:absolute;top:501px;left:441px;white-space:nowrap" class="ft852">4</p>
<p style="position:absolute;top:501px;left:501px;white-space:nowrap" class="ft852">39*</p>
<p style="position:absolute;top:501px;left:568px;white-space:nowrap" class="ft852">57*</p>
<p style="position:absolute;top:501px;left:644px;white-space:nowrap" class="ft852">4</p>
<p style="position:absolute;top:501px;left:703px;white-space:nowrap" class="ft852">39*</p>
<p style="position:absolute;top:501px;left:775px;white-space:nowrap" class="ft852">64</p>
<p style="position:absolute;top:522px;left:114px;white-space:nowrap" class="ft852">*p</p>
<p style="position:absolute;top:520px;left:135px;white-space:nowrap" class="ft8514">&#160;0.0001 compared with placebo</p>
<p style="position:absolute;top:541px;left:114px;white-space:nowrap" class="ft854">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4&#160;because the original&#160;<br/>placebo group began receiving Enbrel 25&#160;mg BIW or 50&#160;mg once weekly from week 13 to week 24.<br/>b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft854">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo&#160;<br/>were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft858">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement&#160;<br/>of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the&#160;<br/>occurrence of rebound (PASI&#160;</p>
<p style="position:absolute;top:711px;left:304px;white-space:nowrap" class="ft8514">&#160;150% of baseline) and for the time to relapse (defined as a loss of at&#160;</p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft853">least half of the improvement achieved between baseline and week 24). During the withdrawal period,&#160;<br/>symptoms of psoriasis gradually returned, with a median time to disease relapse of 3 months. No&#160;<br/>rebound flare of disease and no psoriasis-related serious adverse events were observed. There was&#160;<br/>some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to&#160;<br/>treatment.</p>
<p style="position:absolute;top:846px;left:106px;white-space:nowrap" class="ft853">In study 3, the majority of patients (77%) who were initially randomised to 50&#160;mg twice weekly and&#160;<br/>had their Enbrel dose decreased at week 12 to 25&#160;mg twice weekly maintained their PASI 75 response&#160;<br/>through week 36. For patients who received 25&#160;mg twice weekly throughout the study, the PASI 75&#160;<br/>response continued to improve between weeks 12 and 36.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft853">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12&#160;<br/>(38%) compared to the placebo-treated group (2%) (p&lt;&#160;0.0001). For patients who received 50&#160;mg once&#160;<br/>weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI&#160;<br/>75 at week 24.</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft854">In long-term&#160;(up to 34 months) open-label studies where Enbrel was given without interruption,&#160;<br/>clinical responses were sustained and safety was comparable to shorter-term studies.</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft854">An analysis of clinical trial data&#160;did not reveal any&#160;baseline disease characteristics&#160;that would assist&#160;<br/>clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently,&#160;<br/>the choice of intermittent or continuous therapy should be based upon physician judgment and&#160;<br/>individual patient needs.</p>
</div>
<!-- Page 86 -->
<a name="86"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page86-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft860">86</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft864"><i>Antibodies to Enbrel<br/></i>Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept.&#160;<br/>These antibodies have all been non-neutralising and are generally transient. There appears to be no&#160;<br/>correlation between antibody development and clinical response or adverse events.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft863">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative&#160;<br/>rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5%&#160;<br/>of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with&#160;<br/>psoriasis, 9.7% of subjects with paediatric psoriasis, and&#160;4.8% of subjects with juvenile idiopathic&#160;<br/>arthritis.&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft863">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to&#160;<br/>3.5&#160;years) increases over time, as expected. However, due to their transient nature, the incidence of&#160;<br/>antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis&#160;<br/>subjects and psoriasis subjects.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft863">In a long-term psoriasis study in which patients received 50&#160;mg twice weekly for 96&#160;weeks, the&#160;<br/>incidence of antibodies observed at each assessment point was up to approximately 9%.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft862">Paediatric population</p>
<p style="position:absolute;top:527px;left:106px;white-space:nowrap" class="ft868"><i>Paediatric patients with juvenile&#160;idiopathic arthritis<br/></i>The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with&#160;<br/>polyarticular-course&#160;juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset&#160;<br/>types&#160;(polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17&#160;years with moderately to&#160;<br/>severely active polyarticular-course&#160;juvenile idiopathic arthritis refractory to, or intolerant of,&#160;<br/>methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal&#160;<br/>anti-inflammatory drug and/or prednisone (&lt;&#160;0.2&#160;mg/kg/day or 10&#160;mg maximum). In part 1, all patients&#160;<br/>received 0.4&#160;mg/kg (maximum 25&#160;mg per dose) Enbrel subcutaneously twice weekly. In part 2,&#160;<br/>patients with a clinical response at day 90 were randomised to remain&#160;on Enbrel or receive placebo for&#160;<br/>four months and assessed for disease flare. Responses were measured using the&#160;ACR Pedi 30, defined&#160;<br/>as&#160;</p>
<p style="position:absolute;top:716px;left:124px;white-space:nowrap" class="ft8614">&#160;30% improvement in at least three of six and&#160;&#160;30% worsening in no more than one of six JRA&#160;</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft868">core set criteria, including active joint count, limitation of motion, physician and patient/parent global&#160;<br/>assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was&#160;<br/>defined as a&#160;</p>
<p style="position:absolute;top:774px;left:189px;white-space:nowrap" class="ft8614">&#160;30% worsening in three of six JRA core set criteria and&#160;&#160;30% improvement in not&#160;</p>
<p style="position:absolute;top:795px;left:106px;white-space:nowrap" class="ft862">more than one of the six JRA core set criteria and a minimum of two active joints.</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft863">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In&#160;<br/>part 2, 6&#160;of 25 (24%) patients remaining on Enbrel&#160;experienced a disease flare compared to 20 of&#160;<br/>26&#160;(77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was&#160;<br/>&#160;116&#160;days for patients who received Enbrel and 28 days for patients who received placebo. Of&#160;<br/>patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the&#160;<br/>patients remaining on Enbrel continued to improve from month 3 through month 7, while those who&#160;<br/>received placebo did not improve.</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft863">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of&#160;<br/>4&#160;years at time of enrolment) continued to receive Enbrel for up to 10 years.&#160;Rates of serious adverse&#160;<br/>events and serious infections did not increase with long-term&#160;exposure.</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft864">Long-term&#160;safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate&#160;<br/>monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years&#160;<br/>with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of&#160;age. Overall, infections were more&#160;<br/>commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus&#160;<br/>2%), and the infections associated with etanercept use were of a more severe nature.</p>
</div>
<!-- Page 87 -->
<a name="87"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page87-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft870">87</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft874">In another open-label&#160;single-arm&#160;study&#160;(n=127),&#160;60&#160;patients with extended oligoarthritis&#160;(EO)&#160;<br/>(15&#160;patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged&#160;12 to 17 years old),&#160;38 patients&#160;<br/>with&#160;enthesitis-related arthritis (12 to 17 years old),&#160;and 29 patients with&#160;psoriatic arthritis (12 to&#160;<br/>17&#160;years old) were treated with Enbrel at a dose of 0.8 mg/kg (up to a maximum of 50 mg per dose)&#160;<br/>administered weekly for 12&#160;weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi&#160;<br/>30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender&#160;<br/>joints and physician global assessment. The safety profile was consistent with that observed in other&#160;<br/>JIA studies.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft874">Of the 127&#160;patients in the parent study, 109 participated in the open-label extension study and were&#160;<br/>followed for&#160;an additional&#160;8 years&#160;for a total of up to 10 years.&#160;At the end of the extension study,&#160;<br/>84/109 (77%) patients had completed the study; 27 (25%) while actively taking&#160;Enbrel, 7 (6%) had&#160;<br/>withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started&#160;Enbrel&#160;following an&#160;<br/>earlier withdrawal from treatment; and 45 (41%) had stopped&#160;Enbrel&#160;(but remained under&#160;<br/>observation);&#160;25/109 (23%) patients&#160;permanently discontinued from the&#160;study.&#160;Improvements in&#160;<br/>clinical status achieved in the parent study were generally maintained for all efficacy endpoints during&#160;<br/>the entire follow-up period. Patients actively taking&#160;Enbrel could enter an optional withdrawal-<br/>retreatment period once during the extension study based on investigator’s judgement of clinical&#160;<br/>response. 30&#160;patients entered the withdrawal period. 17&#160;patients were reported to have a flare (defined&#160;<br/>as&#160;≥&#160;30% worsening in at least 3 of the 6 ACR Pedi components with&#160;≥&#160;30% improvement in not more&#160;<br/>than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after&#160;<br/>Enbrel withdrawal was 190&#160;days. 13&#160;patients were&#160;re-treated and the median time to re-treatment from&#160;<br/>withdrawal was estimated as 274&#160;days. Due to the small number of data points, these results should be&#160;<br/>interpreted with caution.</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft872">The safety profile was consistent with that observed in&#160;the parent study.</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft873">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of&#160;<br/>continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy.&#160;<br/>Additionally, studies have not been conducted to assess&#160;the effects of&#160;reducing&#160;the recommended dose&#160;<br/>of Enbrel following its long-term&#160;use in patients with JIA.</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft873"><i>Paediatric patients with plaque psoriasis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211&#160;<br/>paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA&#160;<br/>score&#160;≥&#160;3, involving&#160;≥&#160;10% of the BSA, and PASI&#160;≥&#160;12).&#160;Eligible patients had a history of receiving&#160;<br/>phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft873">Patients received Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) or placebo once weekly for 12 weeks. At week 12,&#160;<br/>more patients randomised&#160;to Enbrel had positive efficacy responses (e.g., PASI 75) than those&#160;<br/>randomised to placebo.</p>
<p style="position:absolute;top:920px;left:263px;white-space:nowrap" class="ft871"><b>Paediatric Plaque Psoriasis Outcomes at 12 Weeks</b></p>
<p style="position:absolute;top:948px;left:495px;white-space:nowrap" class="ft871"><b>Enbrel</b></p>
<p style="position:absolute;top:967px;left:465px;white-space:nowrap" class="ft871"><b>0.8&#160;mg/kg Once&#160;</b></p>
<p style="position:absolute;top:986px;left:493px;white-space:nowrap" class="ft871"><b>Weekly</b></p>
<p style="position:absolute;top:1005px;left:487px;white-space:nowrap" class="ft871"><b>(N = 106)</b></p>
<p style="position:absolute;top:986px;left:647px;white-space:nowrap" class="ft871"><b>Placebo</b></p>
<p style="position:absolute;top:1005px;left:642px;white-space:nowrap" class="ft871"><b>(N = 105)</b></p>
<p style="position:absolute;top:1025px;left:136px;white-space:nowrap" class="ft872">PASI 75, n (%)</p>
<p style="position:absolute;top:1025px;left:486px;white-space:nowrap" class="ft872">60 (57%)a</p>
<p style="position:absolute;top:1025px;left:644px;white-space:nowrap" class="ft872">12 (11%)</p>
<p style="position:absolute;top:1044px;left:136px;white-space:nowrap" class="ft872">PASI 50, n (%)</p>
<p style="position:absolute;top:1044px;left:486px;white-space:nowrap" class="ft872">79&#160;(75%)a</p>
<p style="position:absolute;top:1044px;left:644px;white-space:nowrap" class="ft872">24 (23%)</p>
<p style="position:absolute;top:1075px;left:136px;white-space:nowrap" class="ft872">sPGA “clear” or “minimal”, n (%)</p>
<p style="position:absolute;top:1075px;left:486px;white-space:nowrap" class="ft872">56&#160;(53%)a</p>
<p style="position:absolute;top:1075px;left:644px;white-space:nowrap" class="ft872">14 (13%)</p>
<p style="position:absolute;top:1095px;left:136px;white-space:nowrap" class="ft874">Abbreviation: sPGA-static Physician Global Assessment<br/>a.&#160;p &lt; 0.0001 compared with placebo</p>
</div>
<!-- Page 88 -->
<a name="88"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page88-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft880">88</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft883">After the 12-week double-blind treatment period, all patients received Enbrel 0.8&#160;mg/kg (up to&#160;50&#160;mg)&#160;<br/>once weekly for additional 24 weeks. Responses observed during the open-label period were similar to&#160;<br/>those observed in the double-blind period.</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft883">During a randomised withdrawal period, significantly more patients re-randomised to placebo&#160;<br/>experienced&#160;disease relapse (loss of PASI 75 response) compared with patients re-randomised to&#160;<br/>Enbrel. With continued therapy, responses were maintained up to 48 weeks.</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft883">The&#160;long-term safety and effectiveness of Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) once weekly was assessed in&#160;<br/>an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years beyond&#160;<br/>the 48 week study discussed above. Long-term experience with Enbrel was generally comparable to the&#160;<br/>original 48-week study and did not reveal any new safety findings.&#160;</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft881"><b>5.2</b></p>
<p style="position:absolute;top:356px;left:149px;white-space:nowrap" class="ft881"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft883">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA)&#160;<br/>method, which may detect ELISA-reactive degradation products, as well as the parent compound.</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft882">Absorption</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft888">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum&#160;<br/>concentration approximately 48&#160;hours after a single dose. The absolute bioavailability is 76%. With&#160;<br/>twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high&#160;<br/>as those observed after single doses. After a single subcutaneous dose of 25&#160;mg Enbrel, the average&#160;<br/>maximum serum concentration observed in healthy volunteers was 1.65&#160;</p>
<p style="position:absolute;top:564px;left:585px;white-space:nowrap" class="ft8814">&#160;0.66&#160;g/ml, and the area&#160;</p>
<p style="position:absolute;top:586px;left:106px;white-space:nowrap" class="ft882">under the curve was 235</p>
<p style="position:absolute;top:584px;left:272px;white-space:nowrap" class="ft8814">&#160;96.6&#160;ghr/ml.</p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft883">Mean serum concentration profiles at steady state in treated RA patients were Cmax&#160;of 2.4&#160;mg/l vs.&#160;<br/>2.6&#160;mg/l, Cmin&#160;of 1.2&#160;mg/l vs. 1.4&#160;mg/l, and partial AUC of 297&#160;mgh/l vs. 316&#160;mgh/l for 50&#160;mg Enbrel&#160;<br/>once weekly (n=21) vs. 25&#160;mg Enbrel twice weekly (n=16), respectively. In an open-label,&#160;<br/>single-dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single&#160;<br/>50&#160;mg/ml injection was found to be bioequivalent to two simultaneous injections of 25&#160;mg/ml.</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft888">In a&#160;population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady&#160;<br/>state AUCs were 466</p>
<p style="position:absolute;top:756px;left:251px;white-space:nowrap" class="ft8814">ghr/ml and 474&#160;ghr/ml for 50&#160;mg Enbrel once weekly (N&#160;= 154) and 25&#160;mg&#160;</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft882">twice weekly (N = 148), respectively.</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft882">Distribution</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft884">A&#160;biexponential curve is required to describe the concentration time curve of etanercept. The central&#160;<br/>volume of distribution of etanercept is 7.6&#160;l, while the volume of distribution at steady-state is 10.4&#160;l.</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft882">Elimination</p>
<p style="position:absolute;top:948px;left:106px;white-space:nowrap" class="ft884">Etanercept is cleared slowly from the body. The half-life is long, approximately 70&#160;hours. Clearance is&#160;<br/>approximately 0.066&#160;l/hr in patients with rheumatoid arthritis, somewhat lower than the value of&#160;<br/>0.11&#160;l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in&#160;rheumatoid&#160;<br/>arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft882">There is no apparent pharmacokinetic difference between males and females.</p>
<p style="position:absolute;top:1081px;left:106px;white-space:nowrap" class="ft882">Linearity</p>
<p style="position:absolute;top:1119px;left:106px;white-space:nowrap" class="ft884">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance&#160;<br/>across the dosing range.</p>
</div>
<!-- Page 89 -->
<a name="89"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page89-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft890">89</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft892">Special populations</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft893"><i>Renal impairment<br/></i>Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept&#160;<br/>to patients and volunteers, increased etanercept concentrations were not observed in patients with&#160;<br/>acute renal failure. The presence of renal impairment should not require a change in dosage.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft894"><i>Hepatic impairment<br/></i>Increased etanercept concentrations were not observed in patients with acute hepatic failure. The&#160;<br/>presence of hepatic impairment should not require a change in dosage.</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft894"><i>Elderly<br/></i>The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept&#160;<br/>serum concentrations. Clearance and volume estimates in patients aged 65 to 87&#160;years were similar to&#160;<br/>estimates in patients less than 65 years of age.</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft892">Paediatric population</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft894"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>In a polyarticular-course&#160;juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged&#160;4 to 17 years)&#160;<br/>were administered 0.4&#160;mg&#160;Enbrel/kg twice weekly for three months. Serum concentration profiles&#160;<br/>were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age)&#160;<br/>had reduced clearance (increased clearance when normalised by weight) compared with older children&#160;<br/>(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of&#160;<br/>age) will have serum levels close to those seen in adults, younger children will have appreciably lower&#160;<br/>levels.</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft894"><i>Paediatric patients with plaque psoriasis<br/></i>Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8&#160;mg/kg (up to a&#160;<br/>maximum dose of 50&#160;mg per week) of etanercept once weekly for up to 48 weeks. The mean serum&#160;<br/>steady-state trough concentrations ranged from 1.6&#160;to 2.1&#160;mcg/ml at weeks 12, 24, and 48. These mean&#160;<br/>concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed&#160;<br/>in patients with&#160;juvenile idiopathic arthritis&#160;(treated with 0.4&#160;mg/kg etanercept twice weekly, up to&#160;<br/>maximum dose of 50&#160;mg per week). These mean concentrations were similar to those seen in adult&#160;<br/>patients with plaque psoriasis treated with 25&#160;mg etanercept twice-weekly.</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft891"><b>5.3</b></p>
<p style="position:absolute;top:793px;left:149px;white-space:nowrap" class="ft891"><b>Preclinical safety data</b></p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft893">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel&#160;<br/>was considered to be non-genotoxic from a battery of&#160;<i>in vitro&#160;</i>and&#160;<i>in vivo&#160;</i>studies. Carcinogenicity&#160;<br/>studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel&#160;<br/>due to the development of neutralising antibodies in rodents.</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft893">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single&#160;<br/>subcutaneous dose of 2000&#160;mg/kg or a single intravenous dose of 1000&#160;mg/kg. Enbrel did not elicit&#160;<br/>dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous&#160;<br/>administration for 4 or 26&#160;consecutive weeks at a dose (15&#160;mg/kg) that resulted in AUC-based serum&#160;<br/>drug concentrations that were over 27-fold higher than that obtained in humans at the recommended&#160;<br/>dose of 25&#160;mg.</p>
</div>
<!-- Page 90 -->
<a name="90"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page90-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft900">90</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft901"><b>6.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft901"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft901"><b>6.1</b></p>
<p style="position:absolute;top:146px;left:149px;white-space:nowrap" class="ft901"><b>List of excipients</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft904">Sucrose<br/>Sodium chloride<br/>L-Arginine hydrochloride<br/>Sodium phosphate monobasic dihydrate<br/>Sodium&#160;phosphate dibasic dihydrate<br/>Water for injections</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft901"><b>6.2</b></p>
<p style="position:absolute;top:316px;left:149px;white-space:nowrap" class="ft901"><b>Incompatibilities</b></p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft904">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft901"><b>6.3</b></p>
<p style="position:absolute;top:411px;left:149px;white-space:nowrap" class="ft901"><b>Shelf life</b></p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft902">30 months.</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft901"><b>6.4</b></p>
<p style="position:absolute;top:487px;left:149px;white-space:nowrap" class="ft901"><b>Special precautions for storage</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft902">Store in a refrigerator (2</p>
<p style="position:absolute;top:525px;left:267px;white-space:nowrap" class="ft9014">C&#160;-&#160;8C).&#160;</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft902">Do not freeze.</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft902">Enbrel may be stored at temperatures up to a maximum of 25</p>
<p style="position:absolute;top:583px;left:511px;white-space:nowrap" class="ft9014">C for a single period of up to four&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft904">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within&#160;<br/>four&#160;weeks of removal from refrigeration.</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft902">Keep the pre-filled syringes in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft901"><b>6.5</b></p>
<p style="position:absolute;top:698px;left:149px;white-space:nowrap" class="ft901"><b>Nature and contents of container</b></p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft902">Enbrel&#160;25&#160;mg solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft904">Clear glass syringe (type I glass) with&#160;stainless steel needle, rubber needle cover and plastic plunger.<br/>Cartons contain 4, 8, 12&#160;or 24 pre-filled syringes of Enbrel and&#160;4, 8, 12&#160;or 24&#160;alcohol swabs. The&#160;<br/>needle cover contains dry natural rubber (latex) (see section 4.4). Not all pack sizes may&#160;be marketed.</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft902">Enbrel 50&#160;mg solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft903">Clear glass syringe (type I glass) with stainless steel needle, rubber needle cover and plastic plunger.&#160;<br/>Cartons contain 2, 4 or 12 pre-filled syringes of Enbrel with 2, 4 or 12 alcohol swabs. The needle&#160;<br/>cover contains dry natural rubber (latex) (see section 4.4). Not all pack sizes may be marketed.</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft901"><b>6.6</b></p>
<p style="position:absolute;top:964px;left:149px;white-space:nowrap" class="ft901"><b>Special precautions for disposal and other handling</b></p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft904">Before injection, Enbrel single-use pre-filled syringe should be allowed to reach room temperature&#160;<br/>(approximately 15 to 30 minutes). The needle cover should not be removed while allowing the pre-<br/>filled syringe to reach room temperature. The solution should&#160;be clear&#160;to slightly opalescent,<br/>colourless&#160;to&#160;pale yellow&#160;or pale brown&#160;and&#160;may contain small translucent or white particles of&#160;<br/>protein.&#160;</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft904">Comprehensive instructions for administration are given in the package leaflet, section 7, &#34;Instructions&#160;<br/>for preparation and giving an injection of Enbrel.&#34;</p>
</div>
<!-- Page 91 -->
<a name="91"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page91-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft910">91</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft914">Any unused&#160;medicinal&#160;product or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft911"><b>7.</b></p>
<p style="position:absolute;top:184px;left:146px;white-space:nowrap" class="ft911"><b>MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft914">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft911"><b>8.</b></p>
<p style="position:absolute;top:335px;left:146px;white-space:nowrap" class="ft911"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft912">Enbrel&#160;25&#160;mg solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft914">EU/1/99/126/013<br/>EU/1/99/126/014<br/>EU/1/99/126/015<br/>EU/1/99/126/026</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft912">Enbrel 50&#160;mg solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft913">EU/1/99/126/016<br/>EU/1/99/126/017<br/>EU/1/99/126/018</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft911"><b>9.</b></p>
<p style="position:absolute;top:639px;left:146px;white-space:nowrap" class="ft911"><b>DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft914">Date of first authorisation:&#160;03 February 2000<br/>Date of last renewal:&#160;26&#160;November&#160;2009</p>
<p style="position:absolute;top:753px;left:106px;white-space:nowrap" class="ft911"><b>10.</b></p>
<p style="position:absolute;top:753px;left:146px;white-space:nowrap" class="ft911"><b>DATE OF REVISION OF THE TEXT</b></p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft913">Detailed information on this&#160;medicinal&#160;product is available on the website of the European Medicines&#160;<br/>Agency&#160;<a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</p>
</div>
<!-- Page 92 -->
<a name="92"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page92-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft920">92</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft921"><b>1.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft921"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft923">Enbrel&#160;25&#160;mg solution for injection in pre-filled&#160;pen<br/>Enbrel&#160;50&#160;mg&#160;solution for injection in pre-filled pen</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft921"><b>2.</b></p>
<p style="position:absolute;top:222px;left:146px;white-space:nowrap" class="ft921"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION</b></p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft922">Enbrel&#160;25 mg solution for injection in pre-filled pen&#160;</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft922">Each pre-filled&#160;pen&#160;contains 25&#160;mg of etanercept.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft922">Enbrel&#160;50 mg solution for injection in pre-filled pen&#160;</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft922">Each pre-filled pen contains&#160;50&#160;mg&#160;of etanercept.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft924">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant&#160;<br/>DNA technology in a Chinese hamster ovary (CHO) mammalian expression system.&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft922">For&#160;the&#160;full list of excipients, see section 6.1.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft921"><b>3.</b></p>
<p style="position:absolute;top:525px;left:146px;white-space:nowrap" class="ft921"><b>PHARMACEUTICAL FORM</b></p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft922">Solution for injection.</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft922">The solution is clear, and colourless&#160;to&#160;pale yellow&#160;or pale brown.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft921"><b>4.</b></p>
<p style="position:absolute;top:658px;left:146px;white-space:nowrap" class="ft921"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft921"><b>4.1</b></p>
<p style="position:absolute;top:696px;left:149px;white-space:nowrap" class="ft921"><b>Therapeutic indications</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft922">Rheumatoid arthritis</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft923">Enbrel in combination with&#160;methotrexate is indicated for the treatment of moderate to severe active&#160;<br/>rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including&#160;<br/>methotrexate (unless contraindicated), has been inadequate.</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft923">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued&#160;<br/>treatment with methotrexate is inappropriate.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft924">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults&#160;<br/>not previously treated with&#160;methotrexate.</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft924">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression&#160;<br/>of joint damage as measured by X-ray and to improve physical function.</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft922">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft923">Treatment of&#160;polyarthritis&#160;(rheumatoid&#160;factor positive or negative)&#160;and extended oligoarthritis&#160;in&#160;<br/>children and adolescents from the age of 2&#160;years who have had an inadequate response to, or who have&#160;<br/>proved intolerant of, methotrexate.&#160;</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft923">Treatment of&#160;psoriatic arthritis in&#160;adolescents from the age of 12&#160;years who have had an inadequate&#160;<br/>response to, or who have proved intolerant of, methotrexate.</p>
</div>
<!-- Page 93 -->
<a name="93"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page93-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft930">93</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft934">Treatment of enthesitis-related arthritis in adolescents from the age&#160;of 12&#160;years who have had an&#160;<br/>inadequate response to, or who&#160;have proved intolerant of, conventional therapy.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft932">Psoriatic arthritis</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft934">Treatment of active and progressive psoriatic arthritis in adults when the response to previous&#160;<br/>disease-modifying antirheumatic drug therapy has been inadequate.&#160;Enbrel has been shown to improve&#160;<br/>physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral<br/>joint damage as measured by X-ray in patients with&#160;polyarticular&#160;symmetrical subtypes of the disease.</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft932">Axial spondyloarthritis</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft933"><i>Ankylosing&#160;spondylitis&#160;(AS)<br/></i>Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to&#160;<br/>conventional therapy.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft934"><i>Non-radiographic axial spondyloarthritis<br/></i>Treatment of adults with severe non-radiographic axial spondyloarthritis&#160;with objective signs of&#160;<br/>inflammation as indicated by elevated&#160;C-reactive protein (CRP)&#160;and/or&#160;magnetic resonance imaging&#160;<br/>(MRI)&#160;evidence, who have had an inadequate response&#160;to&#160;nonsteroidal anti-inflammatory drugs<br/>(NSAIDs).</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft932">Plaque psoriasis</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft934">Treatment of&#160;adults with moderate to severe plaque psoriasis who failed to respond to, or who have a&#160;<br/>contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or&#160;<br/>psoralen and ultraviolet-A light (PUVA) (see section 5.1).</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft932">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft934">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6&#160;years who&#160;<br/>are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft931"><b>4.2</b></p>
<p style="position:absolute;top:755px;left:149px;white-space:nowrap" class="ft931"><b>Posology and method of&#160;administration</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft934">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the&#160;<br/>diagnosis and treatment of rheumatoid arthritis,&#160;juvenile idiopathic arthritis,&#160;psoriatic arthritis,&#160;<br/>ankylosing spondylitis,&#160;non-radiographic axial spondyloarthritis,&#160;plaque psoriasis or paediatric plaque&#160;<br/>psoriasis. Patients treated with Enbrel should be given the Patient Card.</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft934">The Enbrel pre-filled pen is available in&#160;25&#160;mg&#160;and&#160;50&#160;mg strengths. Other presentations of Enbrel are&#160;<br/>available in strengths of&#160;10&#160;mg,&#160;25&#160;mg,&#160;and 50&#160;mg.</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft932">Posology</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft933"><i>Rheumatoid arthritis<br/></i>25&#160;mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50&#160;mg administered&#160;<br/>once weekly has been shown to be safe and effective (see section 5.1).</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft934"><i>Psoriatic arthritis,&#160;ankylosing spondylitis&#160;and non-radiographic axial spondyloarthritis<br/></i>The recommended dose is 25&#160;mg Enbrel administered twice weekly, or 50&#160;mg administered once&#160;<br/>weekly.&#160;</p>
</div>
<!-- Page 94 -->
<a name="94"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page94-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft940">94</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft944">For all of the above indications, available data suggest that a clinical response is usually achieved&#160;<br/>within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not&#160;<br/>responding within this time period.</p>
<p style="position:absolute;top:184px;left:107px;white-space:nowrap" class="ft945"><i>Plaque psoriasis</i></p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft944">The recommended dose of Enbrel is 25&#160;mg administered twice weekly or 50&#160;mg administered once&#160;<br/>weekly. Alternatively, 50&#160;mg given twice weekly may be used for up to 12&#160;weeks followed, if&#160;<br/>necessary, by a dose of 25&#160;mg twice weekly or 50&#160;mg&#160;once weekly. Treatment with Enbrel should&#160;<br/>continue until remission is achieved, for up to 24&#160;weeks.&#160;Continuous therapy beyond 24&#160;weeks may be&#160;<br/>appropriate for some adult patients (see section 5.1).&#160;Treatment should be discontinued in patients who&#160;<br/>show no response after 12&#160;weeks. If re-treatment with Enbrel is indicated, the same guidance on&#160;<br/>treatment duration should be followed. The dose should be 25&#160;mg twice weekly or 50&#160;mg once&#160;<br/>weekly.&#160;</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft942">Special populations</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft946"><i>Renal and hepatic impairment<br/></i>No dose adjustment is required.</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft943"><i>Elderly<br/></i>No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of&#160;<br/>age.</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft943"><i>Paediatric population<br/></i>The dosage of Enbrel is based on body weight for paediatric patients. Patients weighing less than&#160;<br/>62.5&#160;kg should be accurately dosed on a mg/kg basis using&#160;the&#160;powder and solvent for solution&#160;for&#160;<br/>injection&#160;presentations or the powder for solution for injection presentations&#160;(see below for dosing for&#160;<br/>specific indication). Patients weighing 62.5&#160;kg or more, may be dosed using a fixed-dose pre-filled&#160;<br/>syringe or pre-filled pen.&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft942">The safety and&#160;efficacy of&#160;Enbrel&#160;in children aged less than 2 years has not been established.</p>
<p style="position:absolute;top:698px;left:107px;white-space:nowrap" class="ft942">No data are available.</p>
<p style="position:absolute;top:736px;left:107px;white-space:nowrap" class="ft945"><i>Juvenile idiopathic arthritis&#160;</i></p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft944">The recommended dose is 0.4&#160;mg/kg (up to a maximum of 25&#160;mg per dose), given twice weekly as a&#160;<br/>subcutaneous injection with an interval of 3-4&#160;days between doses or 0.8&#160;mg/kg (up to a maximum of&#160;<br/>50&#160;mg per dose) given once weekly.&#160;Discontinuation of treatment should be considered in patients&#160;<br/>who show no response after 4 months.</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft944">The 10&#160;mg&#160;vial strength may be more appropriate for administration to children with JIA below the&#160;<br/>weight of 25&#160;kg.</p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft943">No formal clinical&#160;trials have been conducted in children aged 2 to 3 years. However, limited safety&#160;<br/>data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar&#160;<br/>to that seen in adults and children aged 4 years and older, when&#160;dosed every week with 0.8&#160;mg/kg&#160;<br/>subcutaneously (see section 5.1).</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft943">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile&#160;<br/>idiopathic arthritis.</p>
<p style="position:absolute;top:1059px;left:107px;white-space:nowrap" class="ft942">Paediatric plaque psoriasis (age 6 years and above)</p>
<p style="position:absolute;top:1079px;left:106px;white-space:nowrap" class="ft944">The recommended dose is 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly for up to&#160;<br/>24&#160;weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</p>
<p style="position:absolute;top:1135px;left:106px;white-space:nowrap" class="ft943">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed.&#160;<br/>The dose should be 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly.</p>
</div>
<!-- Page 95 -->
<a name="95"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page95-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft950">95</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft954">There is generally no applicable use of Enbrel in children aged below 6&#160;years in the indication plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft952">Method of administration</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft952">Enbrel is administered by subcutaneous injection&#160;(see section 6.6).</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft953">Comprehensive instructions for administration are given in the package leaflet, section 7, “Using the&#160;<br/>MYCLIC pre-filled pen to inject Enbrel.”&#160;Detailed instructions on unintentional dosing or&#160;scheduling&#160;<br/>variations, including missed doses, are provided in section 3 of the package leaflet.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft951"><b>4.3</b></p>
<p style="position:absolute;top:335px;left:149px;white-space:nowrap" class="ft951"><b>Contraindications</b></p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft952">Hypersensitivity to the active substance or to any of the excipients&#160;listed in section 6.1.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft952">Sepsis or risk of sepsis.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft954">Treatment with&#160;Enbrel should not be initiated in patients with active infections including chronic or&#160;<br/>localised infections.</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft951"><b>4.4</b></p>
<p style="position:absolute;top:506px;left:149px;white-space:nowrap" class="ft951"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft954">In order to improve the traceability of biological medicinal products, the&#160;brand name&#160;and batch&#160;<br/>number of the administered product should be clearly recorded (or stated) in the patient file.</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft952">Infections</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft953">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into&#160;<br/>consideration that the mean elimination&#160;half-life of etanercept is approximately 70&#160;hours (range 7 to&#160;<br/>300&#160;hours).</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft954">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal&#160;<br/>infections,&#160;listeriosis and legionellosis,&#160;have been reported with the use of Enbrel (see section 4.8).&#160;<br/>These infections were due to bacteria, mycobacteria, fungi,&#160;viruses&#160;and parasites&#160;(including protozoa).&#160;<br/>In some cases, particular fungal and other opportunistic infections have not been recognised, resulting&#160;<br/>in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the&#160;<br/>patient’s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be&#160;<br/>considered.&#160;</p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft953">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored&#160;<br/>closely. Administration of Enbrel should be discontinued if a patient develops a serious infection.&#160;The&#160;<br/>safety and efficacy of Enbrel in patients with chronic infections have not been evaluated.&#160;Physicians&#160;<br/>should exercise caution when considering the use of Enbrel in patients with a history of recurring or&#160;<br/>chronic infections or with underlying conditions that may predispose patients to infections such as&#160;<br/>advanced or poorly controlled diabetes.</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft952">Tuberculosis</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft953">Cases of active tuberculosis including miliary tuberculosis and tuberculosis with extra-pulmonary&#160;<br/>location have been reported in patients treated with Enbrel.</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft953">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive&#160;<br/>(‘latent’) tuberculosis. This evaluation should include a detailed medical history with personal history&#160;<br/>of tuberculosis or possible previous contact with tuberculosis and previous and/or current&#160;<br/>immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test&#160;and chest X-ray,&#160;</p>
</div>
<!-- Page 96 -->
<a name="96"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page96-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft960">96</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft963">should be performed in all patients (local recommendations may apply). It is recommended that the&#160;<br/>conduct of these tests should be recorded in the&#160;Patient&#160;Card. Prescribers are reminded of the risk of&#160;<br/>false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft963">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (‘latent’)&#160;<br/>tuberculosis is diagnosed, treatment for latent tuberculosis must be started with&#160;anti-tuberculosis&#160;<br/>therapy before the initiation of Enbrel, and in accordance with local recommendations. In this&#160;<br/>situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft964">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis&#160;<br/>(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft962">Hepatitis B reactivation</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft963">Reactivation of hepatitis B in patients who&#160;were previously infected with the&#160;hepatitis B virus (HBV)&#160;<br/>and had received concomitant&#160;TNF-antagonists,&#160;including Enbrel,&#160;has been reported.&#160;This&#160;includes&#160;<br/>reports of reactivation of&#160;hepatitis B&#160;in patients who were anti-HBc positive but HBsAg negative.<br/>Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who&#160;<br/>test positive for HBV infection, consultation with a physician with expertise in the treatment of&#160;<br/>hepatitis B is recommended.&#160;Caution should be exercised when administering Enbrel&#160;in&#160;patients&#160;<br/>previously infected with&#160;HBV.&#160;These&#160;patients should be monitored for signs and symptoms of active&#160;<br/>HBV infection&#160;throughout therapy and for several weeks following termination of therapy.&#160;Adequate&#160;<br/>data from treating patients infected with&#160;HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be&#160;<br/>stopped and effective anti-viral therapy with appropriate supportive treatment should be&#160;initiated.</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft962">Worsening of hepatitis C</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft963">There have been reports of worsening of hepatitis C in patients receiving Enbrel.&#160;Enbrel should be&#160;<br/>used with caution in patients with a history of hepatitis C.</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft962">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft964">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious&#160;<br/>infections and neutropenia compared to Enbrel alone. This combination has not demonstrated&#160;<br/>increased clinical benefit. Thus the combined use of Enbrel and anakinra is not recommended (see&#160;<br/>sections 4.5 and 4.8).</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft962">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft963">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased&#160;clinical benefit; such use&#160;<br/>is not recommended (see&#160;section 4.5).</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft962">Allergic reactions</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft963">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic&#160;<br/>reactions have included angioedema and urticaria; serious reactions have&#160;occurred. If any serious&#160;<br/>allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and&#160;<br/>appropriate therapy initiated.</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft964">The needle cap of the pre-filled pen contains latex (dry natural rubber) that may cause hypersensitivity&#160;<br/>reactions when handled by or when Enbrel is administered to persons with known or possible latex&#160;<br/>sensitivity.&#160;</p>
</div>
<!-- Page 97 -->
<a name="97"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page97-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft970">97</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft972">Immunosuppression</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft974">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections&#160;<br/>and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a&#160;<br/>study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector cell populations.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft974">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of&#160;<br/>aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella&#160;<br/>virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with&#160;<br/>Varicella Zoster Immune Globulin.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft972">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft972">Malignancies and&#160;lymphoproliferative disorders</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft974"><i>Solid and haematopoietic malignancies (excluding skin cancers)<br/></i>Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been&#160;<br/>received in the postmarketing period (see section 4.8).&#160;</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft974">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been&#160;<br/>observed among patients receiving a TNF-antagonist compared with control patients. However, the&#160;<br/>occurrence was rare, and the follow-up period of placebo patients was shorter than for patients&#160;<br/>receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported&#160;<br/>in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and&#160;<br/>leukaemia in rheumatoid arthritis&#160;patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates risk estimation.</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft974">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other&#160;<br/>haematopoietic or solid malignancies in patients treated&#160;with a TNF-antagonist cannot be excluded.&#160;<br/>Caution should be exercised when considering TNF-antagonist therapy for patients with a history of&#160;<br/>malignancy or when considering continuing treatment in patients who develop a malignancy.</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft974">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤ 18 years of age), including&#160;<br/>Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas.&#160;The other cases&#160;<br/>represented a variety of different malignancies and included rare malignancies typically associated&#160;<br/>with immunosuppression. A risk for the development of malignancies in children and adolescents&#160;<br/>treated with TNF-antagonists cannot be excluded.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft973"><i>Skin cancers<br/></i>Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with&#160;<br/>TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported&#160;<br/>very infrequently in patients treated with Enbrel.&#160;Periodic skin examination is recommended for all&#160;<br/>patients, particularly those with risk factors for skin cancer.</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft973">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients&#160;<br/>receiving Enbrel compared with control patients, particularly in patients with psoriasis.</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft972">Vaccinations</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft973">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary&#160;<br/>transmission of infection by live vaccines in patients receiving Enbrel. In a double blind, placebo&#160;<br/>controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received&#160;<br/>a multivalent pneumococcal polysaccharide vaccine at week 4. In this study most psoriatic arthritis&#160;</p>
</div>
<!-- Page 98 -->
<a name="98"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page98-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft980">98</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft984">patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal&#160;<br/>polysaccharide vaccine, but titres in aggregate were moderately lower and few patients had two-fold&#160;<br/>rises in titres compared to patients not receiving Enbrel. The clinical significance of this is unknown.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft982">Autoantibody formation</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft982">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft982">Haematologic reactions</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft984">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have&#160;<br/>been reported in patients treated with Enbrel. Caution should be exercised in patients being treated&#160;<br/>with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers&#160;<br/>should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or&#160;<br/>infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they&#160;<br/>should seek immediate medical advice. Such patients should be investigated urgently, including full&#160;<br/>blood count; if blood dyscrasias are confirmed,&#160;Enbrel should be discontinued.</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft982">Neurological disorders</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft983">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see&#160;<br/>section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies&#160;<br/>(including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy,&#160;<br/>demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have&#160;<br/>been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other&#160;<br/>TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful&#160;<br/>risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel&#160;<br/>to patients with pre-existing or recent onset of demyelinating&#160;disease, or to those who are considered&#160;<br/>to have an increased risk of developing demyelinating disease.</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft982">Combination therapy</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft984">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of&#160;<br/>Enbrel and methotrexate&#160;did not result in unexpected safety findings, and the safety profile of Enbrel&#160;<br/>when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel&#160;<br/>and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The&#160;<br/>long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs&#160;<br/>(DMARD) has not been established.</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft983">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of&#160;<br/>psoriasis has not been studied.</p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft982">Renal and hepatic impairment</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft983">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal&#160;<br/>or hepatic impairment; clinical experience in such patients is limited.</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft982">Congestive heart failure&#160;(Cardiac failure congestive)</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft984">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF).&#160;<br/>There have been postmarketing reports of worsening of CHF, with and without identifiable&#160;<br/>precipitating factors, in patients taking Enbrel.&#160;There have also been rare (&lt;&#160;0.1%) reports of new&#160;<br/>onset CHF, including CHF in patients without known pre-existing cardiovascular disease.&#160;Some of&#160;<br/>these patients have been under 50&#160;years of age.&#160;Two large clinical trials evaluating the use of&#160;Enbrel in&#160;<br/>the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data&#160;</p>
</div>
<!-- Page 99 -->
<a name="99"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page99-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:440px;white-space:nowrap" class="ft990">99</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft994">from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned&#160;<br/>to Enbrel treatment.&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft992">Alcoholic hepatitis</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft994">In&#160;a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or&#160;<br/>placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in&#160;<br/>patients treated with Enbrel was significantly higher after 6&#160;months. Consequently, Enbrel should not&#160;<br/>be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using&#160;<br/>Enbrel in patients who also have moderate to severe alcoholic hepatitis.</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft992">Wegener's granulomatosis</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft993">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard&#160;<br/>therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of&#160;<br/>25&#160;months, has not shown Enbrel to be an effective treatment for Wegener’s granulomatosis. The&#160;<br/>incidence of non-cutaneous malignancies of various types was significantly higher in patients treated&#160;<br/>with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft992">Hypoglycaemia in patients treated for diabetes</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft993">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving&#160;<br/>medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft992">Special&#160;populations</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft994"><i>Elderly<br/></i>In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall&#160;<br/>differences in adverse events, serious adverse events, and serious infections in patients age 65 or older&#160;<br/>who received Enbrel&#160;were observed compared with younger patients. However, caution should be&#160;<br/>exercised when treating the elderly and particular attention paid with respect to occurrence of&#160;<br/>infections.</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft995"><i>Paediatric population</i></p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft994"><i>Vaccinations<br/></i>It&#160;is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Enbrel therapy&#160;(see Vaccinations,&#160;<br/>above).</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft992">Sodium&#160;content</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft994">This medicinal product contains less than 1&#160;mmol sodium (23&#160;mg)&#160;per dosage unit. Patients on low&#160;<br/>sodium diets can be informed that this medicinal product is essentially ‘sodium-free’.</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft991"><b>4.5</b></p>
<p style="position:absolute;top:982px;left:149px;white-space:nowrap" class="ft991"><b>Interaction with other medicinal products and other forms of interaction</b></p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft992">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft994">Adult patients&#160;treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft993">In addition, in a double-blind placebo-controlled trial in adult patients&#160;receiving background&#160;<br/>methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The&#160;</p>
</div>
<!-- Page 100 -->
<a name="100"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page100-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1000">100</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1004">combination Enbrel and anakinra has not demonstrated increased clinical benefit and is therefore not&#160;<br/>recommended.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1002">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1004">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This&#160;combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see section 4.4).&#160;</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft1002">Concurrent treatment with sulfasalazine&#160;</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft1003">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which&#160;<br/>Enbrel was added, patients in the combination group experienced a statistically significant decrease in&#160;<br/>mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The&#160;<br/>clinical significance of this interaction is unknown.&#160;Physicians should use caution when considering&#160;<br/>combination therapy with sulfasalazine.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft1002">Non-interactions</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft1003">In clinical trials, no interactions have been observed when Enbrel was administered with&#160;<br/>glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs),&#160;<br/>analgesics, or methotrexate. See section 4.4 for vaccination advice.</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft1004">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with&#160;<br/>methotrexate,&#160;digoxin or warfarin.</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft1001"><b>4.6</b></p>
<p style="position:absolute;top:603px;left:149px;white-space:nowrap" class="ft1001"><b>Fertility,&#160;pregnancy and lactation</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft1002">Women of childbearing potential</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1004">Women of childbearing potential should&#160;consider&#160;the&#160;use&#160;of&#160;appropriate contraception to avoid&#160;<br/>becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft1002">Pregnancy&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft1003">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the&#160;<br/>foetus or neonatal rat due to etanercept.&#160;The effects of etanercept on pregnancy outcomes have been&#160;<br/>investigated in two observational cohort studies. A&#160;higher rate of major birth defects was observed in&#160;<br/>one observational study comparing pregnancies exposed to etanercept (n=370) during the first&#160;<br/>trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds&#160;<br/>ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most&#160;<br/>commonly reported in the general population and no particular pattern of abnormalities was identified.&#160;<br/>No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed.&#160;In&#160;<br/>another observational multi-country registry study comparing the risk of adverse pregnancy outcomes&#160;<br/>in women exposed to etanercept&#160;during the first 90&#160;days of pregnancy (n=425)&#160;to those exposed to&#160;<br/>non-biologic drugs&#160;(n=3497), there was no observed increased risk of major birth defects (crude odds&#160;<br/>ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for&#160;<br/>country, maternal disease, parity, maternal age and smoking in early pregnancy).&#160;This study also&#160;<br/>showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year&#160;<br/>of life&#160;for infants born to women exposed to etanercept during pregnancy.&#160;Enbrel should only be used&#160;<br/>during&#160;pregnancy&#160;if&#160;clearly needed.</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft1003">Etanercept crosses the placenta and has been detected in the serum of&#160;infants born to female patients&#160;<br/>treated with&#160;Enbrel&#160;during pregnancy. The clinical impact of this is unknown, however, infants may be&#160;<br/>at increased risk of infection. Administration of live vaccines to infants for 16&#160;weeks after the&#160;<br/>mother’s last dose of&#160;Enbrel&#160;is generally not recommended.</p>
</div>
<!-- Page 101 -->
<a name="101"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page101-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1010">101</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1012">Breast-feeding</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1014">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and&#160;<br/>detected in the serum of pups.&#160;Limited information from the published literature indicates etanercept&#160;<br/>has been detected at low levels in human milk.&#160;Etanercept could be considered for use during&#160;<br/>breast-feeding taking into account&#160;the benefit of breast-feeding for the child and the benefit of therapy&#160;<br/>for the woman.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft1013">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely&#160;<br/>degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant&#160;<br/>are&#160;available. Therefore, the administration of live vaccines&#160;(e.g., BCG)&#160;to a breastfed infant when the&#160;<br/>mother is receiving etanercept&#160;could be considered 16 weeks after stopping breast-feeding (or at an&#160;<br/>earlier timepoint if the infant etanercept serum levels are undetectable).&#160;</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft1012">Fertility</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1013">Preclinical data about peri-&#160;and postnatal toxicity of etanercept and of effects of etanercept on fertility&#160;<br/>and general reproductive performance are not available.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft1011"><b>4.7</b></p>
<p style="position:absolute;top:488px;left:149px;white-space:nowrap" class="ft1011"><b>Effects on&#160;ability to drive and use machines</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft1012">Enbrel&#160;has no or negligible influence on the ability to drive&#160;and&#160;use machines.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft1011"><b>4.8</b></p>
<p style="position:absolute;top:564px;left:149px;white-space:nowrap" class="ft1011"><b>Undesirable effects</b></p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1012">Summary of the safety profile</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft1014">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling,&#160;<br/>itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections,&#160;<br/>bronchitis, bladder infections and skin infections),&#160;headache,&#160;allergic reactions, development of&#160;<br/>autoantibodies, itching, and fever.</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft1014">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect&#160;<br/>the immune system and their use may affect the body’s defenses against infection and cancer. Serious&#160;<br/>infections affect fewer than 1 in 100 patients treated&#160;with Enbrel. Reports have included fatal and&#160;<br/>life-threatening infections and sepsis. Various malignancies have also been reported with use of&#160;<br/>Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma). &#160;</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft1013">Serious haematological,&#160;neurological and autoimmune reactions have also been reported. These&#160;<br/>include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral&#160;<br/>demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have&#160;<br/>been rare reports of lupus, lupus-related conditions, and vasculitis.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft1012">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft1013">The following list of adverse reactions is based on experience from clinical trials and on&#160;<br/>postmarketing experience.</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft1013">Within the organ system classes, adverse reactions are listed under headings of frequency (number of&#160;<br/>patients expected to experience the reaction), using the following categories: very common (≥&#160;1/10);&#160;<br/>common (≥&#160;1/100 to &lt;&#160;1/10); uncommon (≥&#160;1/1,000 to &lt;&#160;1/100); rare&#160;(≥&#160;1/10,000 to &lt;&#160;1/1,000); very&#160;<br/>rare (&lt;&#160;1/10,000); not known (cannot be estimated from the available data).</p>
</div>
<!-- Page 102 -->
<a name="102"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page102-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1020">102</p>
<p style="position:absolute;top:109px;left:104px;white-space:nowrap" class="ft10212"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:206px;white-space:nowrap" class="ft10212"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:285px;white-space:nowrap" class="ft10212"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:380px;white-space:nowrap" class="ft10212"><b>Uncommon<br/>≥&#160;1/1,000 to &lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:509px;white-space:nowrap" class="ft10212"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:619px;white-space:nowrap" class="ft10212"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:700px;white-space:nowrap" class="ft10212"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:187px;left:104px;white-space:nowrap" class="ft10213">Infections and&#160;<br/>infestations</p>
<p style="position:absolute;top:187px;left:206px;white-space:nowrap" class="ft10213">Infection&#160;<br/>(including&#160;<br/>upper&#160;<br/>respiratory&#160;<br/>tract&#160;<br/>infection,&#160;<br/>bronchitis,&#160;<br/>cystitis,&#160;<br/>skin&#160;<br/>infection)*</p>
<p style="position:absolute;top:187px;left:380px;white-space:nowrap" class="ft10213">Serious infections&#160;<br/>(including&#160;<br/>pneumonia,&#160;<br/>cellulitis, arthritis&#160;<br/>bacterial, sepsis&#160;and&#160;<br/>parasitic infection)*</p>
<p style="position:absolute;top:187px;left:509px;white-space:nowrap" class="ft10213">Tuberculosis,&#160;<br/>opportunistic&#160;<br/>infection<br/>(including&#160;<br/>invasive fungal,&#160;<br/>protozoal,&#160;<br/>bacterial,&#160;<br/>atypical&#160;<br/>mycobacterial,&#160;<br/>viral infections,<br/>and Legionella)*</p>
<p style="position:absolute;top:187px;left:700px;white-space:nowrap" class="ft10213">Hepatitis B&#160;<br/>reactivation,&#160;<br/>listeria</p>
<p style="position:absolute;top:358px;left:104px;white-space:nowrap" class="ft10213">Neoplasms&#160;<br/>benign,&#160;<br/>malignant and&#160;<br/>unspecified<br/>(including&#160;<br/>cysts and&#160;<br/>polyps)</p>
<p style="position:absolute;top:358px;left:380px;white-space:nowrap" class="ft10213">Non-melanoma skin&#160;<br/>cancers* (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:358px;left:509px;white-space:nowrap" class="ft10213">Malignant&#160;<br/>melanoma (see&#160;<br/>section 4.4),&#160;<br/>lymphoma,&#160;<br/>leukaemia&#160;</p>
<p style="position:absolute;top:358px;left:700px;white-space:nowrap" class="ft10213">Merkel cell&#160;<br/>carcinoma (see&#160;<br/>section 4.4),&#160;<br/>Kaposi’s&#160;<br/>sarcoma</p>
<p style="position:absolute;top:468px;left:104px;white-space:nowrap" class="ft10213">Blood and&#160;<br/>lymphatic&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:468px;left:380px;white-space:nowrap" class="ft10213">Thrombocytopenia,&#160;<br/>anaemia,&#160;<br/>leukopenia,&#160;<br/>neutropenia</p>
<p style="position:absolute;top:468px;left:509px;white-space:nowrap" class="ft10211">Pancytopenia*</p>
<p style="position:absolute;top:468px;left:619px;white-space:nowrap" class="ft10213">Aplastic&#160;<br/>anaemia*</p>
<p style="position:absolute;top:468px;left:700px;white-space:nowrap" class="ft10213">Histiocytosis&#160;<br/>haematophagic&#160;<br/>(macrophage&#160;<br/>activation&#160;<br/>syndrome)*</p>
<p style="position:absolute;top:546px;left:104px;white-space:nowrap" class="ft10213">Immune&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:546px;left:285px;white-space:nowrap" class="ft10213">Allergic&#160;<br/>reactions (see&#160;<br/>Skin and&#160;<br/>subcutaneous&#160;<br/>tissue&#160;<br/>disorders),&#160;<br/>autoantibody&#160;<br/>formation*</p>
<p style="position:absolute;top:546px;left:380px;white-space:nowrap" class="ft10213">Vasculitis&#160;<br/>(including&#160;anti-<br/>neutrophilic&#160;<br/>cytoplasmic antibody&#160;<br/>positive vasculitis)</p>
<p style="position:absolute;top:546px;left:509px;white-space:nowrap" class="ft10213">Serious&#160;<br/>allergic/anaphyla<br/>ctic reactions&#160;<br/>(including&#160;<br/>angioedema,&#160;<br/>bronchospasm),&#160;<br/>sarcoidosis</p>
<p style="position:absolute;top:546px;left:700px;white-space:nowrap" class="ft10213">Worsening of&#160;<br/>symptoms of&#160;<br/>dermatomyositis</p>
<p style="position:absolute;top:671px;left:104px;white-space:nowrap" class="ft10213">Nervous&#160;<br/>system&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:671px;left:206px;white-space:nowrap" class="ft10211">Headache</p>
<p style="position:absolute;top:671px;left:509px;white-space:nowrap" class="ft10213">CNS&#160;<br/>demyelinating&#160;<br/>events&#160;<br/>suggestive of&#160;<br/>multiple&#160;<br/>sclerosis or&#160;<br/>localised&#160;<br/>demyelinating&#160;<br/>conditions, such&#160;<br/>as optic neuritis&#160;<br/>and transverse&#160;<br/>myelitis (see&#160;<br/>section 4.4),&#160;<br/>peripheral&#160;<br/>demyelinating&#160;<br/>events, including&#160;<br/>Guillain-Barré&#160;<br/>syndrome,&#160;<br/>chronic&#160;<br/>inflammatory&#160;<br/>demyelinating&#160;<br/>polyneuropathy,&#160;<br/>demyelinating&#160;<br/>polyneuropathy,&#160;<br/>and multifocal&#160;<br/>motor&#160;<br/>neuropathy (see&#160;<br/>section 4.4),&#160;<br/>seizure</p>
<p style="position:absolute;top:1122px;left:104px;white-space:nowrap" class="ft10211">Eye disorders&#160;</p>
<p style="position:absolute;top:1122px;left:380px;white-space:nowrap" class="ft10211">Uveitis, scleritis</p>
<p style="position:absolute;top:1138px;left:104px;white-space:nowrap" class="ft10213">Cardiac&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:1138px;left:380px;white-space:nowrap" class="ft10213">Worsening of&#160;<br/>cardiac failure&#160;</p>
<p style="position:absolute;top:1138px;left:509px;white-space:nowrap" class="ft10213">New onset&#160;<br/>cardiac&#160;failure&#160;</p>
</div>
<!-- Page 103 -->
<a name="103"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page103-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1030">103</p>
<p style="position:absolute;top:109px;left:104px;white-space:nowrap" class="ft10312"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:206px;white-space:nowrap" class="ft10312"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:285px;white-space:nowrap" class="ft10312"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:380px;white-space:nowrap" class="ft10312"><b>Uncommon<br/>≥&#160;1/1,000 to &lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:509px;white-space:nowrap" class="ft10312"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:619px;white-space:nowrap" class="ft10312"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:700px;white-space:nowrap" class="ft10312"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:187px;left:380px;white-space:nowrap" class="ft10313">congestive (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:187px;left:509px;white-space:nowrap" class="ft10313">congestive (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:219px;left:104px;white-space:nowrap" class="ft10313">Respiratory,&#160;<br/>thoracic, and&#160;<br/>mediastinal&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:219px;left:509px;white-space:nowrap" class="ft10313">Interstitial lung&#160;<br/>disease&#160;<br/>(including&#160;<br/>pneumonitis and&#160;<br/>pulmonary&#160;<br/>fibrosis)*</p>
<p style="position:absolute;top:312px;left:104px;white-space:nowrap" class="ft10313">Gastrointestinal&#160;<br/>disorders</p>
<p style="position:absolute;top:312px;left:380px;white-space:nowrap" class="ft10313">Inflammatory bowel&#160;<br/>disease</p>
<p style="position:absolute;top:344px;left:104px;white-space:nowrap" class="ft10313">Hepatobiliary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:344px;left:380px;white-space:nowrap" class="ft10313">Elevated liver&#160;<br/>enzymes*</p>
<p style="position:absolute;top:344px;left:509px;white-space:nowrap" class="ft10313">Autoimmune&#160;<br/>hepatitis*</p>
<p style="position:absolute;top:376px;left:104px;white-space:nowrap" class="ft10313">Skin and&#160;<br/>subcutaneous&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:376px;left:285px;white-space:nowrap" class="ft10311">Pruritus, rash</p>
<p style="position:absolute;top:376px;left:380px;white-space:nowrap" class="ft10313">Angioedema,&#160;<br/>psoriasis (including&#160;<br/>new onset or&#160;<br/>worsening and&#160;<br/>pustular, primarily&#160;<br/>palms and soles),&#160;<br/>urticaria,&#160;<br/>psoriasiform rash</p>
<p style="position:absolute;top:376px;left:509px;white-space:nowrap" class="ft10313">Stevens-Johnson&#160;<br/>syndrome,&#160;<br/>cutaneous&#160;<br/>vasculitis&#160;<br/>(including&#160;<br/>hypersensitivity&#160;<br/>vasculitis),&#160;<br/>erythema&#160;<br/>multiforme,&#160;<br/>lichenoid&#160;<br/>reactions</p>
<p style="position:absolute;top:376px;left:619px;white-space:nowrap" class="ft10313">Toxic&#160;<br/>epidermal&#160;<br/>necrolysis</p>
<p style="position:absolute;top:548px;left:104px;white-space:nowrap" class="ft10313">Musculoskeleta<br/>l and&#160;<br/>connective&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:548px;left:509px;white-space:nowrap" class="ft10313">Cutaneous lupus&#160;<br/>erythematosus,&#160;<br/>subacute&#160;<br/>cutaneous lupus&#160;<br/>erythematosus,&#160;<br/>lupus-like&#160;<br/>syndrome</p>
<p style="position:absolute;top:657px;left:104px;white-space:nowrap" class="ft10313">General&#160;<br/>disorders and&#160;<br/>administration&#160;<br/>site conditions&#160;</p>
<p style="position:absolute;top:657px;left:206px;white-space:nowrap" class="ft10313">Injection&#160;<br/>site&#160;<br/>reactions&#160;<br/>(including&#160;<br/>bleeding,&#160;<br/>bruising,&#160;<br/>erythema,&#160;<br/>itching,&#160;<br/>pain,&#160;<br/>swelling)*</p>
<p style="position:absolute;top:657px;left:285px;white-space:nowrap" class="ft10311">Pyrexia</p>
<p style="position:absolute;top:813px;left:104px;white-space:nowrap" class="ft10311">*see Description of selected adverse reactions, below.</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft1032">Description of selected adverse reactions</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft1034"><i>Malignancies and lymphoproliferative disorders<br/></i>One hundred and twenty-nine new malignancies of various types were observed in 4,114 rheumatoid&#160;<br/>arthritis patients treated in clinical trials with Enbrel for up to&#160;approximately 6&#160;years, including&#160;<br/>231&#160;patients treated with Enbrel in combination with methotrexate in the 2-year active-controlled&#160;<br/>study. The observed rates and incidences in these clinical trials were similar to those expected for the&#160;<br/>population studied.&#160;A total of 2 malignancies were reported in clinical studies of approximately 2&#160;<br/>years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical studies conducted&#160;<br/>for more than 2&#160;years with 351 ankylosing spondylitis patients, 6&#160;malignancies were reported in&#160;<br/>Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in&#160;<br/>double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin&#160;<br/>cancers were reported.</p>
<p style="position:absolute;top:1114px;left:106px;white-space:nowrap" class="ft1033">In a group of 7,416&#160;patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing&#160;<br/>spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</p>
</div>
<!-- Page 104 -->
<a name="104"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page104-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1040">104</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1044">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been<br/>received in the postmarketing period (see section 4.4).</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1044"><i>Injection site reactions<br/></i>Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher&#160;<br/>incidence of injection site reactions (36% vs. 9%). Injection site&#160;reactions usually occurred in the first&#160;<br/>month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of&#160;<br/>injection site reactions in the Enbrel treatment groups, and the majority of patients who were given&#160;<br/>treatment received topical preparations such as corticosteroids, or oral antihistamines. Additionally,&#160;<br/>some patients developed recall injection site reactions characterised by a skin reaction at the most&#160;<br/>recent site of injection along with the simultaneous appearance of injection site reactions at previous&#160;<br/>injection sites. These reactions were generally transient and did not recur with treatment.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1043">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with&#160;<br/>Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the&#160;<br/>first 12 weeks of treatment.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1043"><i>Serious infections<br/></i>In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life threatening, or&#160;<br/>requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3%&#160;<br/>of rheumatoid arthritis patients treated with Enbrel for up to 48&#160;months. These included abscess (at&#160;<br/>various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis,&#160;diarrhoea, diverticulitis,&#160;<br/>endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection,&#160;<br/>osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin&#160;<br/>infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year&#160;<br/>active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or&#160;<br/>Enbrel in combination with methotrexate, the rates of serious infections were similar&#160;among the&#160;<br/>treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate&#160;<br/>could be associated with an increase in the rate of infections.</p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft1043">There were no differences in rates of infection among patients treated with Enbrel&#160;and those treated&#160;<br/>with placebo for plaque psoriasis&#160;in placebo-controlled trials of up to 24 weeks duration. Serious&#160;<br/>infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia,&#160;<br/>cholecystitis, osteomyelitis, gastritis,&#160;appendicitis, Streptococcal fasciitis, myositis, septic shock,&#160;<br/>diverticulitis&#160;and abscess. In the double-blind and open-label psoriatic arthritis trials, 1&#160;patient reported&#160;<br/>a serious infection (pneumonia).</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft1044">Serious and fatal infections have been reported&#160;during use of Enbrel; reported pathogens include&#160;<br/>bacteria, mycobacteria (including&#160;tuberculosis), viruses and fungi. Some have occurred within a few&#160;<br/>weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes,&#160;<br/>congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis&#160;<br/>(see section&#160;4.4). Enbrel treatment may increase mortality in patients with established sepsis.</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft1044">Opportunistic infections have been reported in association with Enbrel, including invasive fungal,&#160;<br/>parasitic (including&#160;protozoal),&#160;viral (including herpes zoster),&#160;bacterial (including&#160;<i>Listeria&#160;</i>and&#160;<br/><i>Legionella</i>), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall&#160;<br/>incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. The&#160;<br/>exposure-adjusted rate was 0.06&#160;events per 100&#160;patient-years. In postmarketing experience,&#160;<br/>approximately half of all of the case reports of opportunistic infections worldwide were invasive&#160;<br/>fungal infections.&#160;The most commonly reported invasive fungal infections&#160;included&#160;<i>Candida,<br/>Pneumocystis,&#160;Aspergillus,&#160;</i>and&#160;<i>Histoplasma</i>. Invasive fungal infections accounted for more than half&#160;<br/>of the fatalities amongst patients who developed opportunistic infections. The majority of the reports&#160;<br/>with a fatal outcome were in patients with&#160;<i>Pneumocystis&#160;</i>pneumonia, unspecified systemic fungal&#160;<br/>infections, and aspergillosis (see section 4.4).</p>
</div>
<!-- Page 105 -->
<a name="105"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page105-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1050">105</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1058"><i>Autoantibodies<br/></i>Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid&#160;<br/>arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients&#160;who developed&#160;<br/>new positive ANA (</p>
<p style="position:absolute;top:165px;left:240px;white-space:nowrap" class="ft10514">&#160;1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft1054">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA&#160;<br/>antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel&#160;compared to 4%&#160;<br/>of placebo-treated patients) and by&#160;<i>Crithidia luciliae&#160;</i>assay (3% of patients treated with Enbrel&#160;<br/>compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who&#160;<br/>developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.&#160;<br/>The impact of long-term treatment with Enbrel on the development of autoimmune diseases is&#160;<br/>unknown.</p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft1054">There have been rare reports of patients, including rheumatoid factor positive patients, who have&#160;<br/>developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are&#160;<br/>compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft1053"><i>Pancytopenia and aplastic anaemia<br/></i>There have been postmarketing reports&#160;of pancytopenia and aplastic anaemia, some of which had fatal&#160;<br/>outcomes (see section 4.4).</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft1053"><i>Interstitial lung disease<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47%&#160;<br/>(frequency uncommon).&#160;There have been postmarketing reports of interstitial lung disease (including&#160;<br/>pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft1058"><i>Concurrent treatment with anakinra&#160;<br/></i>In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of&#160;<br/>serious infections compared to Enbrel alone was&#160;observed and 2% of patients (3/139) developed&#160;<br/>neutropenia (absolute neutrophil count&#160;</p>
<p style="position:absolute;top:699px;left:366px;white-space:nowrap" class="ft10514">&#160;1000/mm3). While neutropenic, one patient developed&#160;</p>
<p style="position:absolute;top:719px;left:106px;white-space:nowrap" class="ft1052">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</p>
<p style="position:absolute;top:758px;left:106px;white-space:nowrap" class="ft1054"><i>Elevated liver enzymes<br/></i>In&#160;the&#160;double-blind&#160;periods of&#160;controlled clinical trials of etanercept across all indications, the&#160;<br/>frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving&#160;<br/>etanercept without concomitant methotrexate was 0.54% (frequency&#160;uncommon). In&#160;the double-blind&#160;<br/>periods of controlled clinical trials&#160;that allowed&#160;concomitant treatment with etanercept and&#160;<br/>methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was&#160;<br/>4.18% (frequency common).</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft1054"><i>Autoimmune hepatitis<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02%&#160;<br/>(frequency rare). In the controlled&#160;clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24%&#160;<br/>(frequency uncommon).</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft1052">Paediatric population</p>
<p style="position:absolute;top:1082px;left:106px;white-space:nowrap" class="ft1053"><i>Undesirable effects in paediatric patients with&#160;juvenile idiopathic arthritis<br/></i>In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in&#160;<br/>frequency and type to those seen in adult patients. Differences from adults and other special&#160;<br/>considerations are discussed in the following paragraphs.</p>
</div>
<!-- Page 106 -->
<a name="106"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page106-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1060">106</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1063">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18&#160;years&#160;<br/>were generally mild to moderate and consistent with those commonly seen in outpatient paediatric&#160;<br/>populations. Severe adverse events reported included varicella with signs and symptoms of aseptic&#160;<br/>meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis,&#160;<br/>depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic&#160;<br/>shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1064">In one study in children with juvenile idiopathic arthritis aged 4 to 17&#160;years, 43 of 69 (62%) children&#160;<br/>experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and&#160;<br/>the frequency and severity of infections was similar in 58 patients completing 12&#160;months of open-label&#160;<br/>extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients&#160;<br/>were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the&#160;<br/>majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic&#160;<br/>arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients.&#160;<br/>These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per&#160;<br/>patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events&#160;per&#160;<br/>patient year).</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft1062">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft1064"><i>Undesirable effects in paediatric patients with plaque psoriasis<br/></i>In a 48-week study in 211 children aged 4 to 17&#160;years with paediatric plaque psoriasis, the adverse&#160;<br/>events reported were similar to those seen in previous studies in adults with plaque psoriasis.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft1062">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1064">Reporting suspected adverse reactions after authorisation&#160;of the medicinal product is important. It&#160;<br/>allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare&#160;<br/>professionals are asked to report any suspected adverse&#160;reactions&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft1061"><b>4.9</b></p>
<p style="position:absolute;top:696px;left:149px;white-space:nowrap" class="ft1061"><b>Overdose</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft1063">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The&#160;<br/>highest dose level&#160;evaluated has been an intravenous loading dose of 32&#160;mg/m2&#160;followed by&#160;<br/>subcutaneous doses of 16&#160;mg/m2&#160;administered twice weekly. One rheumatoid arthritis patient&#160;<br/>mistakenly self-administered 62&#160;mg Enbrel subcutaneously twice weekly for 3 weeks without&#160;<br/>experiencing undesirable effects. There is no known antidote to Enbrel.</p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft1061"><b>5.</b></p>
<p style="position:absolute;top:867px;left:146px;white-space:nowrap" class="ft1061"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft1061"><b>5.1</b></p>
<p style="position:absolute;top:905px;left:149px;white-space:nowrap" class="ft1061"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft1063">Pharmacotherapeutic group: Immunosuppressants,&#160;Tumour Necrosis Factor alpha (TNF-α) inhibitors,<br/>ATC code:&#160;L04AB01</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft1064">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid&#160;<br/>arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with&#160;<br/>psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque&#160;<br/>psoriasis, infiltration by inflammatory cells including T-cells leads to increased TNF levels in psoriatic&#160;<br/>lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF-binding&#160;<br/>to its cell surface receptors and thereby inhibits the biological activity of TNF. TNF and lymphotoxin&#160;<br/>are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55-kilodalton (p55)&#160;<br/>and 75-kilodalton (p75) tumour necrosis factor receptors&#160;(TNFRs). Both TNFRs exist naturally in&#160;<br/>membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity.</p>
</div>
<!-- Page 107 -->
<a name="107"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page107-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1070">107</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1073">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on&#160;<br/>cross-linking of cell surface TNFRs. Dimeric soluble receptors such as etanercept possess a higher&#160;<br/>affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of&#160;<br/>TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion&#160;<br/>element in the construction of a dimeric receptor imparts a longer serum half-life.</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft1072">Mechanism of action</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft1073">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in&#160;<br/>plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by&#160;<br/>TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF&#160;<br/>binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering&#160;TNF&#160;<br/>biologically inactive. Etanercept may also modulate biologic responses controlled by additional&#160;<br/>downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or&#160;<br/>regulated by TNF.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1072">Clinical&#160;efficacy and safety</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft1074">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis,&#160;<br/>one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis,&#160;two&#160;studies<br/>in adults with non-radiographic axial spondyloarthritis,&#160;four studies in adults with plaque psoriasis,&#160;<br/>three studies in juvenile idiopathic arthritis&#160;and&#160;one study in paediatric patients with plaque psoriasis.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft1073"><i>Adult patients with rheumatoid arthritis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The&#160;<br/>study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least&#160;<br/>one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel&#160;or placebo were administered subcutaneously twice a week for 6&#160;consecutive months.&#160;<br/>The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis&#160;<br/>using American College of Rheumatology (ACR) response criteria.&#160;</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft1073">ACR&#160;20 and 50 responses were higher in patients treated with Enbrel at 3 and 6&#160;months than in&#160;<br/>patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and&#160;<br/>6&#160;months respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months&#160;3 and 6,&#160;<br/>respectively; p&#160;&lt;&#160;0.01 Enbrel vs placebo at all timepoints for both ACR 20 and ACR 50 responses).&#160;</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft1074">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month&#160;3 and&#160;<br/>month&#160;6&#160;compared to fewer than 5% of subjects in the&#160;placebo arm. Among patients receiving Enbrel,&#160;<br/>the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly&#160;<br/>always occurred by 3 months. A dose response was seen; results with 10&#160;mg were intermediate&#160;<br/>between placebo and 25&#160;mg. Enbrel was significantly better than placebo in all components of the&#160;<br/>ACR criteria as well as other measures of rheumatoid arthritis disease activity not included in the ACR&#160;<br/>response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which&#160;<br/>included disability, vitality, mental health, general health status, and arthritis-associated health status&#160;<br/>subdomains, was administered every 3&#160;months during the trial. All subdomains of the HAQ were&#160;<br/>improved in patients treated with&#160;Enbrel compared to controls at 3 and 6&#160;months.&#160;</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft1073">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month.&#160;<br/>Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same&#160;<br/>magnitudes of&#160;responses as patients who received Enbrel without interruption of therapy based on&#160;<br/>results of open-label studies. Continued durable responses have been seen for up to 10&#160;years in&#160;<br/>open-label extension treatment trials when patients received Enbrel without interruption.&#160;</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft1073">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with&#160;<br/>blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid&#160;</p>
</div>
<!-- Page 108 -->
<a name="108"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page108-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1080">108</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1083">arthritis (&lt;3 years duration) who had never&#160;received treatment with methotrexate. Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel were administered SC twice a week for up to 24 months. Methotrexate doses were&#160;<br/>escalated from 7.5&#160;mg/week to a maximum of 20&#160;mg/week over the first 8&#160;weeks of the trial and&#160;<br/>continued for&#160;up to 24&#160;months. Clinical improvement including onset of action within 2&#160;weeks with&#160;<br/>Enbrel 25&#160;mg was similar to that seen in the previous trials, and was maintained for up to 24&#160;months.&#160;<br/>At baseline, patients had a moderate degree of disability, with mean&#160;HAQ scores of 1.4 to 1.5.&#160;<br/>Treatment with Enbrel 25&#160;mg resulted in substantial improvement at 12&#160;months, with about 44% of&#160;<br/>patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year&#160;2 of this&#160;<br/>study.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1084">In this study, structural&#160;joint damage was assessed radiographically and expressed as change in Total&#160;<br/>Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score.&#160;<br/>Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24&#160;months.&#160;The 10&#160;mg&#160;<br/>Enbrel dose had consistently less effect on structural damage than the 25&#160;mg dose. Enbrel 25&#160;mg was&#160;<br/>significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in&#160;<br/>TSS and JSN were not statistically significant between methotrexate and Enbrel 25&#160;mg. The results are&#160;<br/>shown in the figure below.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft10823"><b>Radiographic Progression: Comparison of Enbrel vs Methotrexate in Patients with RA of&#160;<br/>&lt;3&#160;Years Duration</b></p>
<p style="position:absolute;top:666px;left:132px;white-space:nowrap" class="ft10817">C</p>
<p style="position:absolute;top:655px;left:132px;white-space:nowrap" class="ft10817">ha</p>
<p style="position:absolute;top:639px;left:132px;white-space:nowrap" class="ft10817">ng</p>
<p style="position:absolute;top:623px;left:132px;white-space:nowrap" class="ft10817">e&#160;</p>
<p style="position:absolute;top:611px;left:132px;white-space:nowrap" class="ft10817">fr</p>
<p style="position:absolute;top:601px;left:132px;white-space:nowrap" class="ft10817">o</p>
<p style="position:absolute;top:593px;left:132px;white-space:nowrap" class="ft10817">m</p>
<p style="position:absolute;top:581px;left:132px;white-space:nowrap" class="ft10817">&#160;B</p>
<p style="position:absolute;top:567px;left:132px;white-space:nowrap" class="ft10817">as</p>
<p style="position:absolute;top:552px;left:132px;white-space:nowrap" class="ft10817">e</p>
<p style="position:absolute;top:543px;left:132px;white-space:nowrap" class="ft10817">lin</p>
<p style="position:absolute;top:529px;left:132px;white-space:nowrap" class="ft10817">e</p>
<p style="position:absolute;top:702px;left:145px;white-space:nowrap" class="ft10818"><b>0.0</b></p>
<p style="position:absolute;top:665px;left:145px;white-space:nowrap" class="ft10818"><b>0.5</b></p>
<p style="position:absolute;top:628px;left:145px;white-space:nowrap" class="ft10818"><b>1.0</b></p>
<p style="position:absolute;top:590px;left:145px;white-space:nowrap" class="ft10818"><b>1.5</b></p>
<p style="position:absolute;top:553px;left:145px;white-space:nowrap" class="ft10818"><b>2.0</b></p>
<p style="position:absolute;top:516px;left:145px;white-space:nowrap" class="ft10818"><b>2.5</b></p>
<p style="position:absolute;top:702px;left:484px;white-space:nowrap" class="ft10818"><b>0.0</b></p>
<p style="position:absolute;top:666px;left:484px;white-space:nowrap" class="ft10818"><b>0.5</b></p>
<p style="position:absolute;top:629px;left:484px;white-space:nowrap" class="ft10818"><b>1.0</b></p>
<p style="position:absolute;top:592px;left:484px;white-space:nowrap" class="ft10818"><b>1.5</b></p>
<p style="position:absolute;top:555px;left:484px;white-space:nowrap" class="ft10818"><b>2.0</b></p>
<p style="position:absolute;top:518px;left:484px;white-space:nowrap" class="ft10818"><b>2.5</b></p>
<p style="position:absolute;top:748px;left:433px;white-space:nowrap" class="ft10819"><b>MTX</b></p>
<p style="position:absolute;top:762px;left:434px;white-space:nowrap" class="ft10819"><b>Enbrel&#160;25 mg</b></p>
<p style="position:absolute;top:511px;left:251px;white-space:nowrap" class="ft10819"><b>12 Months</b></p>
<p style="position:absolute;top:511px;left:598px;white-space:nowrap" class="ft10819"><b>24 Months</b></p>
<p style="position:absolute;top:720px;left:221px;white-space:nowrap" class="ft10820"><b>TSS</b></p>
<p style="position:absolute;top:720px;left:269px;white-space:nowrap" class="ft10820"><b>Erosions</b></p>
<p style="position:absolute;top:721px;left:351px;white-space:nowrap" class="ft10820"><b>JSN</b></p>
<p style="position:absolute;top:722px;left:554px;white-space:nowrap" class="ft10820"><b>TSS</b></p>
<p style="position:absolute;top:722px;left:608px;white-space:nowrap" class="ft10820"><b>Erosions</b></p>
<p style="position:absolute;top:722px;left:688px;white-space:nowrap" class="ft10820"><b>JSN</b></p>
<p style="position:absolute;top:591px;left:208px;white-space:nowrap" class="ft10819"><b>1.3</b></p>
<p style="position:absolute;top:629px;left:233px;white-space:nowrap" class="ft10819"><b>0.8</b></p>
<p style="position:absolute;top:621px;left:276px;white-space:nowrap" class="ft10819"><b>0.9</b></p>
<p style="position:absolute;top:659px;left:301px;white-space:nowrap" class="ft10819"><b>0.4*</b></p>
<p style="position:absolute;top:659px;left:344px;white-space:nowrap" class="ft10819"><b>0.4&#160;0.4</b></p>
<p style="position:absolute;top:524px;left:547px;white-space:nowrap" class="ft10819"><b>2.2</b></p>
<p style="position:absolute;top:599px;left:571px;white-space:nowrap" class="ft10819"><b>1.2</b></p>
<p style="position:absolute;top:591px;left:615px;white-space:nowrap" class="ft10819"><b>1.3</b></p>
<p style="position:absolute;top:643px;left:638px;white-space:nowrap" class="ft10819"><b>0.6*</b></p>
<p style="position:absolute;top:621px;left:681px;white-space:nowrap" class="ft10819"><b>0.9</b></p>
<p style="position:absolute;top:643px;left:705px;white-space:nowrap" class="ft10819"><b>0.6</b></p>
<p style="position:absolute;top:789px;left:420px;white-space:nowrap" class="ft10819"><b>*p &lt; 0.05</b></p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft1084">In another active-controlled,&#160;double-blind, randomised study, clinical efficacy, safety, and&#160;<br/>radiographic progression in RA patients treated with Enbrel alone (25&#160;mg twice weekly), methotrexate&#160;<br/>alone (7.5 to 20&#160;mg&#160;weekly, median dose 20&#160;mg), and of the combination of Enbrel and methotrexate&#160;<br/>initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6&#160;months&#160;<br/>to 20&#160;years duration (median 5&#160;years) who had a less than satisfactory response to at least 1&#160;<br/>disease-modifying antirheumatic drug (DMARD) other than methotrexate.</p>
<p style="position:absolute;top:974px;left:106px;white-space:nowrap" class="ft1083">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher&#160;<br/>ACR&#160;20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and&#160;<br/>52&#160;weeks than patients in either of the single therapy&#160;groups (results shown in table below).&#160;<br/>Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months.</p>
</div>
<!-- Page 109 -->
<a name="109"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page109-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1090">109</p>
<p style="position:absolute;top:108px;left:103px;white-space:nowrap" class="ft1091"><b>Clinical Efficacy Results at 12&#160;Months: Comparison&#160;of&#160;Enbrel vs Methotrexate vs Enbrel in&#160;</b></p>
<p style="position:absolute;top:127px;left:117px;white-space:nowrap" class="ft1091"><b>Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration</b></p>
<p style="position:absolute;top:165px;left:85px;white-space:nowrap" class="ft1091"><b>Endpoint</b></p>
<p style="position:absolute;top:165px;left:316px;white-space:nowrap" class="ft1092">Methotrexate</p>
<p style="position:absolute;top:184px;left:325px;white-space:nowrap" class="ft1092">(n =&#160;228)</p>
<p style="position:absolute;top:165px;left:482px;white-space:nowrap" class="ft1092">Enbrel</p>
<p style="position:absolute;top:184px;left:469px;white-space:nowrap" class="ft1092">(n = 223)</p>
<p style="position:absolute;top:146px;left:645px;white-space:nowrap" class="ft1092">Enbrel +</p>
<p style="position:absolute;top:165px;left:626px;white-space:nowrap" class="ft1092">Methotrexate</p>
<p style="position:absolute;top:184px;left:639px;white-space:nowrap" class="ft1092">(n = 231)</p>
<p style="position:absolute;top:223px;left:85px;white-space:nowrap" class="ft1091"><b>ACR Responsesa</b></p>
<p style="position:absolute;top:242px;left:114px;white-space:nowrap" class="ft1092">ACR 20</p>
<p style="position:absolute;top:243px;left:338px;white-space:nowrap" class="ft1092">58.8%</p>
<p style="position:absolute;top:243px;left:482px;white-space:nowrap" class="ft1092">65.5%</p>
<p style="position:absolute;top:243px;left:644px;white-space:nowrap" class="ft1092">74.5%&#160;<b>†,</b></p>
<p style="position:absolute;top:262px;left:114px;white-space:nowrap" class="ft1092">ACR 50</p>
<p style="position:absolute;top:263px;left:338px;white-space:nowrap" class="ft1092">36.4%</p>
<p style="position:absolute;top:263px;left:482px;white-space:nowrap" class="ft1092">43.0%</p>
<p style="position:absolute;top:263px;left:644px;white-space:nowrap" class="ft1092">63.2%&#160;<b>†,</b></p>
<p style="position:absolute;top:282px;left:114px;white-space:nowrap" class="ft1092">ACR 70</p>
<p style="position:absolute;top:283px;left:338px;white-space:nowrap" class="ft1092">16.7%</p>
<p style="position:absolute;top:283px;left:482px;white-space:nowrap" class="ft1092">22.0%</p>
<p style="position:absolute;top:284px;left:644px;white-space:nowrap" class="ft1092">39.8%&#160;<b>†,</b></p>
<p style="position:absolute;top:322px;left:85px;white-space:nowrap" class="ft1091"><b>DAS</b></p>
<p style="position:absolute;top:341px;left:114px;white-space:nowrap" class="ft1092">Baseline scoreb</p>
<p style="position:absolute;top:341px;left:349px;white-space:nowrap" class="ft1092">5.5</p>
<p style="position:absolute;top:341px;left:493px;white-space:nowrap" class="ft1092">5.7</p>
<p style="position:absolute;top:341px;left:664px;white-space:nowrap" class="ft1092">5.5</p>
<p style="position:absolute;top:360px;left:114px;white-space:nowrap" class="ft1092">Week 52 scoreb</p>
<p style="position:absolute;top:360px;left:349px;white-space:nowrap" class="ft1092">3.0</p>
<p style="position:absolute;top:360px;left:493px;white-space:nowrap" class="ft1092">3.0</p>
<p style="position:absolute;top:361px;left:657px;white-space:nowrap" class="ft1092">2.3<b>†,</b></p>
<p style="position:absolute;top:380px;left:114px;white-space:nowrap" class="ft1092">Remissionc</p>
<p style="position:absolute;top:380px;left:345px;white-space:nowrap" class="ft1092">14%</p>
<p style="position:absolute;top:380px;left:489px;white-space:nowrap" class="ft1092">18%</p>
<p style="position:absolute;top:381px;left:652px;white-space:nowrap" class="ft1092">37%<b>†,</b></p>
<p style="position:absolute;top:419px;left:85px;white-space:nowrap" class="ft1091"><b>HAQ</b></p>
<p style="position:absolute;top:438px;left:113px;white-space:nowrap" class="ft1092">Baseline</p>
<p style="position:absolute;top:438px;left:349px;white-space:nowrap" class="ft1092">1.7</p>
<p style="position:absolute;top:438px;left:493px;white-space:nowrap" class="ft1092">1.7</p>
<p style="position:absolute;top:438px;left:664px;white-space:nowrap" class="ft1092">1.8</p>
<p style="position:absolute;top:457px;left:113px;white-space:nowrap" class="ft1092">Week 52</p>
<p style="position:absolute;top:457px;left:349px;white-space:nowrap" class="ft1092">1.1</p>
<p style="position:absolute;top:457px;left:493px;white-space:nowrap" class="ft1092">1.0</p>
<p style="position:absolute;top:458px;left:657px;white-space:nowrap" class="ft1092">0.8<b>†,</b></p>
<p style="position:absolute;top:478px;left:127px;white-space:nowrap" class="ft1098">a: Patients who did not complete 12&#160;months in the study were considered to be non-responders.<br/>b: Values for Disease Activity Score (DAS) are means.<br/>c: Remission is defined as DAS &lt;1.6<br/>Pairwise comparison p-values:&#160;†&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs methotrexate&#160;<br/>and&#160;</p>
<p style="position:absolute;top:553px;left:155px;white-space:nowrap" class="ft10914">&#160;=&#160;p &lt; 0.05 for comparisons of Enbrel + methotrexate vs Enbrel</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft1094">Radiographic progression at 12&#160;months was significantly less in the Enbrel group than in the&#160;<br/>methotrexate group, while the combination was significantly better than either monotherapy at&#160;<br/>slowing&#160;radiographic progression (see figure below).</p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft10924"><b>Radiographic Progression: Comparison of Enbrel vs Methotrexate vs Enbrel in Combination&#160;<br/>with Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration (12&#160;Month Results)</b></p>
<p style="position:absolute;top:1097px;left:233px;white-space:nowrap" class="ft1098">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs&#160;<br/>methotrexate, † = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:1134px;left:351px;white-space:nowrap" class="ft10914">&#160;= p&#160;&lt;&#160;0.05 for comparisons of Enbrel + methotrexate vs Enbrel</p>
<p style="position:absolute;top:948px;left:206px;white-space:nowrap" class="ft10925">C</p>
<p style="position:absolute;top:938px;left:206px;white-space:nowrap" class="ft10925">ha</p>
<p style="position:absolute;top:922px;left:206px;white-space:nowrap" class="ft10925">ng</p>
<p style="position:absolute;top:906px;left:206px;white-space:nowrap" class="ft10925">e&#160;</p>
<p style="position:absolute;top:894px;left:206px;white-space:nowrap" class="ft10925">fr</p>
<p style="position:absolute;top:885px;left:206px;white-space:nowrap" class="ft10925">om</p>
<p style="position:absolute;top:865px;left:206px;white-space:nowrap" class="ft10925">&#160;B</p>
<p style="position:absolute;top:852px;left:206px;white-space:nowrap" class="ft10925">as</p>
<p style="position:absolute;top:837px;left:206px;white-space:nowrap" class="ft10925">el</p>
<p style="position:absolute;top:826px;left:206px;white-space:nowrap" class="ft10925">in</p>
<p style="position:absolute;top:815px;left:206px;white-space:nowrap" class="ft10925">e</p>
<p style="position:absolute;top:1034px;left:232px;white-space:nowrap" class="ft1090">-1.0</p>
<p style="position:absolute;top:997px;left:232px;white-space:nowrap" class="ft1090">-0.5</p>
<p style="position:absolute;top:959px;left:236px;white-space:nowrap" class="ft1090">0.0</p>
<p style="position:absolute;top:922px;left:236px;white-space:nowrap" class="ft1090">0.5</p>
<p style="position:absolute;top:884px;left:236px;white-space:nowrap" class="ft1090">1.0</p>
<p style="position:absolute;top:846px;left:236px;white-space:nowrap" class="ft1090">1.5</p>
<p style="position:absolute;top:809px;left:236px;white-space:nowrap" class="ft1090">2.0</p>
<p style="position:absolute;top:771px;left:236px;white-space:nowrap" class="ft1090">2.5</p>
<p style="position:absolute;top:734px;left:236px;white-space:nowrap" class="ft1090">3.0</p>
<p style="position:absolute;top:747px;left:552px;white-space:nowrap" class="ft10926"><b>Methotrexate</b></p>
<p style="position:absolute;top:762px;left:551px;white-space:nowrap" class="ft10926"><b>Enbrel&#160;</b></p>
<p style="position:absolute;top:777px;left:552px;white-space:nowrap" class="ft10926"><b>Enbrel + Methotrexate</b></p>
<p style="position:absolute;top:738px;left:334px;white-space:nowrap" class="ft10926"><b>2.80</b></p>
<p style="position:absolute;top:908px;left:361px;white-space:nowrap" class="ft10926"><b>0.52*</b></p>
<p style="position:absolute;top:1011px;left:380px;white-space:nowrap" class="ft10926"><b>-0.54†</b>,</p>
<p style="position:absolute;top:821px;left:443px;white-space:nowrap" class="ft10926"><b>1.68</b></p>
<p style="position:absolute;top:931px;left:469px;white-space:nowrap" class="ft10926"><b>0.21*</b></p>
<p style="position:absolute;top:994px;left:489px;white-space:nowrap" class="ft10926"><b>-0.30†</b></p>
<p style="position:absolute;top:863px;left:551px;white-space:nowrap" class="ft10926"><b>1.12</b></p>
<p style="position:absolute;top:923px;left:577px;white-space:nowrap" class="ft10926"><b>0.32</b></p>
<p style="position:absolute;top:988px;left:599px;white-space:nowrap" class="ft10926"><b>-0.23†</b>,</p>
<p style="position:absolute;top:1043px;left:352px;white-space:nowrap" class="ft10927"><b>TSS</b></p>
<p style="position:absolute;top:1043px;left:442px;white-space:nowrap" class="ft10927"><b>Erosions</b></p>
<p style="position:absolute;top:1043px;left:571px;white-space:nowrap" class="ft10927"><b>JSN</b></p>
</div>
<!-- Page 110 -->
<a name="110"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page110-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1100">110</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1103">Significant advantages for&#160;Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months. Similarly, the&#160;<br/>significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also&#160;<br/>observed&#160;after 24&#160;months.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1104">In an analysis in which all patients who dropped out of the study for any reason were considered to&#160;<br/>have progressed, the percentage of patients without progression (TSS change&#160;≤&#160;0.5) at 24&#160;months was&#160;<br/>higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and&#160;<br/>methotrexate alone groups&#160;(62%, 50%, and 36%, respectively; p&lt;&#160;0.05). The difference between&#160;<br/>Enbrel alone and methotrexate alone was also significant (p&lt;&#160;0.05). Among patients who completed a&#160;<br/>full 24&#160;months of therapy in the study, the non-progression rates were 78%, 70%, and 61%,&#160;<br/>respectively.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft1104">The safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered once weekly were&#160;<br/>evaluated in a double-blind, placebo-controlled study of 420&#160;patients with active RA. In this study, 53&#160;<br/>patients received placebo, 214 patients received 50&#160;mg&#160;Enbrel once weekly and 153 patients received&#160;<br/>25&#160;mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens&#160;<br/>were comparable&#160;at week 8 in their effect on signs and symptoms of RA; data at week 16&#160;did not show&#160;<br/>comparability (non-inferiority) between the two regimens.&#160;A single 50&#160;mg/ml injection of Enbrel was&#160;<br/>found to be bioequivalent to two simultaneous injections of 25&#160;mg/ml.</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft1108"><i>Adult patients with psoriatic arthritis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205&#160;<br/>patients with psoriatic arthritis. Patients were between 18 and 70&#160;years of age and had active psoriatic&#160;<br/>arthritis (</p>
<p style="position:absolute;top:563px;left:167px;white-space:nowrap" class="ft11014">&#160;3 swollen joints and&#160;&#160;3 tender joints) in at least one of the following forms: (1)&#160;distal&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft1108">interphalangeal (DIP) involvement; (2)&#160;polyarticular arthritis (absence of rheumatoid nodules and&#160;<br/>presence of psoriasis); (3)&#160;arthritis mutilans; (4)&#160;asymmetric psoriatic arthritis; or (5)&#160;spondylitis-like&#160;<br/>ankylosis. Patients also had plaque psoriasis with a qualifying target lesion&#160;</p>
<p style="position:absolute;top:621px;left:604px;white-space:nowrap" class="ft11014">&#160;2&#160;cm in diameter.&#160;</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft1108">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids&#160;<br/>(24%).&#160;Patients currently on methotrexate therapy (stable for&#160;</p>
<p style="position:absolute;top:660px;left:512px;white-space:nowrap" class="ft11014">&#160;2 months) could continue at a stable&#160;</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft1102">dose of&#160;</p>
<p style="position:absolute;top:680px;left:159px;white-space:nowrap" class="ft11014">&#160;25&#160;mg/week methotrexate. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in&#160;</p>
<p style="position:absolute;top:701px;left:106px;white-space:nowrap" class="ft1103">patients with rheumatoid arthritis) or placebo were administered SC&#160;twice a week for 6&#160;months. At the&#160;<br/>end of the double-blind study, patients could enter a long-term open-label extension study for a total&#160;<br/>duration of up to 2&#160;years.</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft1104">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and&#160;70&#160;<br/>response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results&#160;<br/>are summarised in the table below.</p>
<p style="position:absolute;top:853px;left:239px;white-space:nowrap" class="ft1101"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:872px;left:389px;white-space:nowrap" class="ft1101"><b>Controlled Trial</b></p>
<p style="position:absolute;top:892px;left:495px;white-space:nowrap" class="ft1102">Percent of Patients</p>
<p style="position:absolute;top:911px;left:473px;white-space:nowrap" class="ft1102">Placebo</p>
<p style="position:absolute;top:911px;left:586px;white-space:nowrap" class="ft1102">Enbrela</p>
<p style="position:absolute;top:930px;left:226px;white-space:nowrap" class="ft1102">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:930px;left:474px;white-space:nowrap" class="ft1102">n = 104</p>
<p style="position:absolute;top:930px;left:585px;white-space:nowrap" class="ft1102">n = 101</p>
<p style="position:absolute;top:969px;left:226px;white-space:nowrap" class="ft11023"><b>&#160;&#160;ACR 20<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:988px;left:491px;white-space:nowrap" class="ft1102">15</p>
<p style="position:absolute;top:988px;left:600px;white-space:nowrap" class="ft1102">59b</p>
<p style="position:absolute;top:1007px;left:226px;white-space:nowrap" class="ft1102">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:1007px;left:491px;white-space:nowrap" class="ft1102">13</p>
<p style="position:absolute;top:1007px;left:600px;white-space:nowrap" class="ft1102">50b</p>
<p style="position:absolute;top:1045px;left:226px;white-space:nowrap" class="ft11024"><b>&#160;&#160;ACR 50<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:1064px;left:495px;white-space:nowrap" class="ft1102">4</p>
<p style="position:absolute;top:1064px;left:600px;white-space:nowrap" class="ft1102">38b</p>
<p style="position:absolute;top:1083px;left:226px;white-space:nowrap" class="ft1102">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:1083px;left:495px;white-space:nowrap" class="ft1102">4</p>
<p style="position:absolute;top:1083px;left:600px;white-space:nowrap" class="ft1102">37b</p>
<p style="position:absolute;top:1121px;left:226px;white-space:nowrap" class="ft11023"><b>&#160;&#160;ACR 70<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:1140px;left:495px;white-space:nowrap" class="ft1102">0</p>
<p style="position:absolute;top:1140px;left:600px;white-space:nowrap" class="ft1102">11b</p>
<p style="position:absolute;top:1159px;left:226px;white-space:nowrap" class="ft1102">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:1159px;left:495px;white-space:nowrap" class="ft1102">1</p>
<p style="position:absolute;top:1159px;left:604px;white-space:nowrap" class="ft1102">9c</p>
</div>
<!-- Page 111 -->
<a name="111"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page111-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1110">111</p>
<p style="position:absolute;top:108px;left:239px;white-space:nowrap" class="ft1111"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:127px;left:389px;white-space:nowrap" class="ft1111"><b>Controlled Trial</b></p>
<p style="position:absolute;top:146px;left:495px;white-space:nowrap" class="ft1112">Percent of Patients</p>
<p style="position:absolute;top:165px;left:473px;white-space:nowrap" class="ft1112">Placebo</p>
<p style="position:absolute;top:165px;left:586px;white-space:nowrap" class="ft1112">Enbrela</p>
<p style="position:absolute;top:184px;left:226px;white-space:nowrap" class="ft1112">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:184px;left:474px;white-space:nowrap" class="ft1112">n = 104</p>
<p style="position:absolute;top:184px;left:585px;white-space:nowrap" class="ft1112">n = 101</p>
<p style="position:absolute;top:222px;left:226px;white-space:nowrap" class="ft11124"><b>&#160;&#160;PsARC<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:241px;left:491px;white-space:nowrap" class="ft1112">31</p>
<p style="position:absolute;top:241px;left:600px;white-space:nowrap" class="ft1112">72b</p>
<p style="position:absolute;top:260px;left:226px;white-space:nowrap" class="ft1112">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:260px;left:491px;white-space:nowrap" class="ft1112">23</p>
<p style="position:absolute;top:260px;left:600px;white-space:nowrap" class="ft1112">70b</p>
<p style="position:absolute;top:280px;left:236px;white-space:nowrap" class="ft1114">a: 25&#160;mg Enbrel SC twice weekly<br/>b: p &lt; 0.001, Enbrel vs. placebo<br/>c: p &lt; 0.01, Enbrel vs. placebo</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft1113">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at&#160;<br/>the time of the first visit&#160;(4&#160;weeks) and were maintained through 6&#160;months of therapy. Enbrel was&#160;<br/>significantly better than placebo in all measures of disease activity (p&#160;&lt;&#160;0.001), and responses were&#160;<br/>similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis&#160;<br/>patients was assessed at every timepoint using the disability index of the HAQ. The disability index&#160;<br/>score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel,&#160;<br/>relative to placebo (p&#160;&lt;&#160;0.001).&#160;</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft1113">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists&#160;<br/>were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in&#160;<br/>the Table below. In an analysis in which all patients who dropped out of the study for any reason were&#160;<br/>considered to have progressed, the percentage of patients without progression (TSS change&#160;≤ 0.5) at&#160;<br/>12&#160;months was higher in the Enbrel group compared with the placebo group (73% vs. 47%,&#160;<br/>respectively, p&#160;≤&#160;0.001).&#160;The effect of Enbrel on radiographic progression was maintained in patients&#160;<br/>who continued on treatment during the second year. The slowing of peripheral joint damage was&#160;<br/>observed in patients with polyarticular symmetrical joint involvement. &#160;</p>
<p style="position:absolute;top:697px;left:238px;white-space:nowrap" class="ft1111"><b>Mean (SE) Annualized Change from Baseline in Total Sharp Score</b></p>
<p style="position:absolute;top:725px;left:469px;white-space:nowrap" class="ft1112">Placebo</p>
<p style="position:absolute;top:725px;left:684px;white-space:nowrap" class="ft1112">Etanercept</p>
<p style="position:absolute;top:753px;left:232px;white-space:nowrap" class="ft1112">Time</p>
<p style="position:absolute;top:753px;left:464px;white-space:nowrap" class="ft1112">(n = 104)</p>
<p style="position:absolute;top:753px;left:688px;white-space:nowrap" class="ft1112">(n = 101)</p>
<p style="position:absolute;top:782px;left:217px;white-space:nowrap" class="ft1112">Month 12</p>
<p style="position:absolute;top:782px;left:458px;white-space:nowrap" class="ft1112">1.00 (0.29)</p>
<p style="position:absolute;top:782px;left:677px;white-space:nowrap" class="ft1112">-0.03 (0.09)a</p>
<p style="position:absolute;top:802px;left:123px;white-space:nowrap" class="ft1114">SE = standard error. &#160;<br/>a. p = 0.0001. &#160;</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft1113">Enbrel treatment resulted in improvement in physical function during the&#160;double-blind period, and this&#160;<br/>benefit was maintained during the longer-term exposure of up to 2&#160;years.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft1113">There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and&#160;<br/>arthritis mutilans&#160;psoriatic arthropathies due&#160;to the small number of patients studied.<br/>No study has been performed in patients with psoriatic arthritis using the 50&#160;mg once weekly dosing&#160;<br/>regimen. Evidence of efficacy for the once weekly dosing regimen in this patient population has been&#160;<br/>based on data&#160;from the study in patients with ankylosing spondylitis.</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft1118"><i>Adult patients with ankylosing spondylitis<br/></i>The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies&#160;<br/>comparing twice weekly administration of 25&#160;mg Enbrel with placebo. A total of 401 patients were&#160;<br/>enrolled from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled&#160;<br/>patients who were between 18 and 70&#160;years of age and had active ankylosing spondylitis defined as&#160;<br/>visual analog scale&#160;(VAS) scores of&#160;</p>
<p style="position:absolute;top:1118px;left:347px;white-space:nowrap" class="ft11114">&#160;30 for average of duration and intensity of morning stiffness&#160;</p>
<p style="position:absolute;top:1140px;left:106px;white-space:nowrap" class="ft1112">plus VAS scores of&#160;</p>
<p style="position:absolute;top:1138px;left:239px;white-space:nowrap" class="ft11114">&#160;30 for at least 2 of the following 3 parameters: patient global assessment;&#160;</p>
<p style="position:absolute;top:1159px;left:106px;white-space:nowrap" class="ft1112">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the&#160;</p>
</div>
<!-- Page 112 -->
<a name="112"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page112-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1120">112</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1124">Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or&#160;<br/>corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine&#160;<br/>were not included in the study. Doses of 25&#160;mg&#160;of Enbrel (based on dose-finding studies in patients&#160;<br/>with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6&#160;months in&#160;<br/>138&#160;patients.</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft1122">The primary measure of efficacy (ASAS 20) was a&#160;</p>
<p style="position:absolute;top:221px;left:446px;white-space:nowrap" class="ft11214">&#160;20% improvement in at least 3 of the&#160;4&#160;</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft1124">Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain,&#160;<br/>BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70&#160;<br/>responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft1124">Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20,&#160;<br/>ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</p>
<p style="position:absolute;top:375px;left:255px;white-space:nowrap" class="ft1121"><b>Responses of Patients with Ankylosing Spondylitis in a&#160;</b></p>
<p style="position:absolute;top:394px;left:358px;white-space:nowrap" class="ft1121"><b>Placebo-Controlled Trial</b></p>
<p style="position:absolute;top:414px;left:482px;white-space:nowrap" class="ft1122">Percent of Patients</p>
<p style="position:absolute;top:453px;left:242px;white-space:nowrap" class="ft1122">&#160;&#160;Ankylosing Spondylitis&#160;</p>
<p style="position:absolute;top:472px;left:249px;white-space:nowrap" class="ft1122">Response</p>
<p style="position:absolute;top:434px;left:464px;white-space:nowrap" class="ft1122">Placebo</p>
<p style="position:absolute;top:453px;left:462px;white-space:nowrap" class="ft1122">N = 139</p>
<p style="position:absolute;top:434px;left:576px;white-space:nowrap" class="ft1122">Enbrel</p>
<p style="position:absolute;top:453px;left:570px;white-space:nowrap" class="ft1122">N = 138</p>
<p style="position:absolute;top:493px;left:241px;white-space:nowrap" class="ft1122">&#160;&#160;ASAS 20&#160;</p>
<p style="position:absolute;top:513px;left:259px;white-space:nowrap" class="ft1122">2 weeks</p>
<p style="position:absolute;top:513px;left:481px;white-space:nowrap" class="ft1122">22</p>
<p style="position:absolute;top:513px;left:587px;white-space:nowrap" class="ft1122">46a</p>
<p style="position:absolute;top:533px;left:259px;white-space:nowrap" class="ft1122">3 months</p>
<p style="position:absolute;top:533px;left:481px;white-space:nowrap" class="ft1122">27</p>
<p style="position:absolute;top:533px;left:587px;white-space:nowrap" class="ft1122">60a</p>
<p style="position:absolute;top:553px;left:259px;white-space:nowrap" class="ft1122">6&#160;months</p>
<p style="position:absolute;top:553px;left:481px;white-space:nowrap" class="ft1122">23</p>
<p style="position:absolute;top:553px;left:587px;white-space:nowrap" class="ft1122">58a</p>
<p style="position:absolute;top:582px;left:241px;white-space:nowrap" class="ft1122">&#160;&#160;ASAS 50&#160;</p>
<p style="position:absolute;top:602px;left:259px;white-space:nowrap" class="ft1122">2 weeks</p>
<p style="position:absolute;top:602px;left:485px;white-space:nowrap" class="ft1122">7</p>
<p style="position:absolute;top:602px;left:587px;white-space:nowrap" class="ft1122">24a</p>
<p style="position:absolute;top:622px;left:259px;white-space:nowrap" class="ft1122">3 months</p>
<p style="position:absolute;top:622px;left:481px;white-space:nowrap" class="ft1122">13</p>
<p style="position:absolute;top:622px;left:587px;white-space:nowrap" class="ft1122">45a</p>
<p style="position:absolute;top:642px;left:259px;white-space:nowrap" class="ft1122">6&#160;months</p>
<p style="position:absolute;top:642px;left:481px;white-space:nowrap" class="ft1122">10</p>
<p style="position:absolute;top:642px;left:587px;white-space:nowrap" class="ft1122">42a</p>
<p style="position:absolute;top:671px;left:241px;white-space:nowrap" class="ft1122">&#160;&#160;ASAS 70:</p>
<p style="position:absolute;top:691px;left:259px;white-space:nowrap" class="ft1122">2 weeks</p>
<p style="position:absolute;top:691px;left:485px;white-space:nowrap" class="ft1122">2</p>
<p style="position:absolute;top:691px;left:586px;white-space:nowrap" class="ft1122">12b</p>
<p style="position:absolute;top:711px;left:259px;white-space:nowrap" class="ft1122">3 months</p>
<p style="position:absolute;top:711px;left:485px;white-space:nowrap" class="ft1122">7</p>
<p style="position:absolute;top:711px;left:586px;white-space:nowrap" class="ft1122">29b</p>
<p style="position:absolute;top:732px;left:259px;white-space:nowrap" class="ft1122">6&#160;months&#160;</p>
<p style="position:absolute;top:732px;left:485px;white-space:nowrap" class="ft1122">5</p>
<p style="position:absolute;top:732px;left:586px;white-space:nowrap" class="ft1122">28b</p>
<p style="position:absolute;top:761px;left:246px;white-space:nowrap" class="ft1128">a: p&#160;&lt;0.001, Enbrel vs. Placebo<br/>b: p = 0.002, Enbrel vs. placebo</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft1123">Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent&#160;<br/>at the time of the&#160;first visit (2&#160;weeks) and were maintained through 6&#160;months of therapy. Responses&#160;<br/>were similar in patients who were or were not receiving concomitant therapies at baseline.</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft1122">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft1123">In a&#160;fourth study, the safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered&#160;<br/>once weekly vs 25&#160;mg Enbrel administered twice weekly were evaluated in a double-blind,&#160;<br/>placebo-controlled study of 356&#160;patients with active ankylosing spondylitis. The safety and efficacy&#160;<br/>profiles of the 50&#160;mg once weekly and 25&#160;mg twice weekly regimens were similar.</p>
<p style="position:absolute;top:1029px;left:106px;white-space:nowrap" class="ft1125"><i>Adult patients with&#160;non-radiographic axial spondyloarthritis</i></p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft1123"><i>Study 1<br/></i>The efficacy of Enbrel in patients with non-radiographic axial&#160;spondyloarthritis (nr-AxSpa) was&#160;<br/>assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated&#160;<br/>215&#160;adult patients&#160;(modified intent-to-treat population)&#160;with active nr-AxSpa (18 to 49&#160;years of age),<br/>defined as those patients&#160;meeting the ASAS&#160;classification criteria of&#160;axial&#160;spondyloarthritis but did not&#160;</p>
</div>
<!-- Page 113 -->
<a name="113"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page113-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1130">113</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1133">meet the modified New York criteria for AS.&#160;Patients were also required to have an&#160;inadequate&#160;<br/>response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel&#160;<br/>50&#160;mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40%&#160;<br/>improvement in at least three of the four ASAS domains and absence of deterioration in the remaining&#160;<br/>domain. The double-blind period was followed by&#160;an open-label period during which all patients&#160;<br/>receive&#160;Enbrel 50&#160;mg weekly for up to an additional 92 weeks.&#160;MRIs of the sacroiliac joint and spine&#160;<br/>were obtained to assess inflammation at baseline and at weeks&#160;12&#160;and 104.</p>
<p style="position:absolute;top:264px;left:106px;white-space:nowrap" class="ft1134">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the&#160;<br/>ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial&#160;<br/>remission and BASDAI 50.&#160;Week 12&#160;results are shown in the table below.</p>
<p style="position:absolute;top:340px;left:106px;white-space:nowrap" class="ft11323"><b>Efficacy Response&#160;in Placebo-Controlled nr-AxSpa Study:&#160;Percent of Patients Achieving&#160;<br/>Endpoints</b></p>
<p style="position:absolute;top:378px;left:141px;white-space:nowrap" class="ft1134">Double-Blind Clinical<br/>Responses at Week 12&#160;</p>
<p style="position:absolute;top:378px;left:481px;white-space:nowrap" class="ft1132">Placebo</p>
<p style="position:absolute;top:397px;left:457px;white-space:nowrap" class="ft1132">N=106 to 109*</p>
<p style="position:absolute;top:378px;left:661px;white-space:nowrap" class="ft1132">Enbrel</p>
<p style="position:absolute;top:397px;left:633px;white-space:nowrap" class="ft1132">N=103 to 105*</p>
<p style="position:absolute;top:417px;left:141px;white-space:nowrap" class="ft1132">ASAS** 40</p>
<p style="position:absolute;top:417px;left:493px;white-space:nowrap" class="ft1132">15.7</p>
<p style="position:absolute;top:417px;left:666px;white-space:nowrap" class="ft1132">32.4b</p>
<p style="position:absolute;top:437px;left:141px;white-space:nowrap" class="ft1132">ASAS 20</p>
<p style="position:absolute;top:437px;left:493px;white-space:nowrap" class="ft1132">36.1</p>
<p style="position:absolute;top:437px;left:666px;white-space:nowrap" class="ft1132">52.4c</p>
<p style="position:absolute;top:456px;left:141px;white-space:nowrap" class="ft1132">ASAS 5/6</p>
<p style="position:absolute;top:456px;left:493px;white-space:nowrap" class="ft1132">10.4</p>
<p style="position:absolute;top:456px;left:666px;white-space:nowrap" class="ft1132">33.0a</p>
<p style="position:absolute;top:476px;left:141px;white-space:nowrap" class="ft1132">ASAS partial remission</p>
<p style="position:absolute;top:476px;left:493px;white-space:nowrap" class="ft1132">11.9</p>
<p style="position:absolute;top:476px;left:666px;white-space:nowrap" class="ft1132">24.8c</p>
<p style="position:absolute;top:496px;left:141px;white-space:nowrap" class="ft1132">BASDAI***50</p>
<p style="position:absolute;top:496px;left:493px;white-space:nowrap" class="ft1132">23.9</p>
<p style="position:absolute;top:496px;left:666px;white-space:nowrap" class="ft1132">43.8b</p>
<p style="position:absolute;top:516px;left:149px;white-space:nowrap" class="ft1134">*Some patients did not provide complete data for each endpoint<br/>**ASAS=Assessments in Spondyloarthritis International Society<br/>***Bath Ankylosing Spondylitis Disease Activity Index<br/>a: p&#160;&lt;0.001,&#160;b:&lt;0.01 and&#160;c:&lt;0.05,&#160;respectively between&#160;Enbrel and placebo</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft1133">At week&#160;12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis&#160;<br/>Research Consortium of Canada) score&#160;for the sacroiliac joint&#160;(SIJ)&#160;as measured by MRI for patients<br/>receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8&#160;<br/>for placebo treated (n=105) patients (p&lt;0.001).&#160;At week&#160;104, the mean change from baseline in the&#160;<br/>SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and&#160;<br/>1.40&#160;the spine (n=154).</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft1133">Enbrel showed statistically significantly greater improvement&#160;from baseline to week 12 compared to&#160;<br/>placebo&#160;in&#160;most health-related quality of life and physical function assessments, including&#160;BASFI<br/>(Bath Ankylosing Spondylitis Functional Index),&#160;EuroQol 5D&#160;Overall Health State Score and SF-36&#160;<br/>Physical Component Score.</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft1133">Clinical responses among&#160;nr-AxSpa&#160;patients who received Enbrel were apparent at the time of the first&#160;<br/>visit (2&#160;weeks) and were maintained through&#160;2&#160;years&#160;of therapy.&#160;Improvements in health-related&#160;<br/>quality of life and physical function&#160;were also maintained through 2&#160;years of therapy. The 2&#160;year data&#160;<br/>did not reveal any new safety findings.&#160;At week&#160;104, 8&#160;subjects had progressed to a score of bilateral&#160;<br/>Grade&#160;2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial&#160;<br/>spondyloarthropathy.</p>
<p style="position:absolute;top:971px;left:106px;white-space:nowrap" class="ft1134"><i>Study 2<br/></i>This multi-center, open-label,&#160;phase 4,&#160;3-period study evaluated the withdrawal and retreatment of&#160;<br/>Enbrel&#160;in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined&#160;<br/>as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3)&#160;<br/>following 24&#160;weeks of treatment.&#160;</p>
<p style="position:absolute;top:1085px;left:106px;white-space:nowrap" class="ft1134">209&#160;adult patients with active nr-AxSpa (18 to 49&#160;years of age), defined as those patients meeting the&#160;<br/>Assessment of SpondyloArthritis&#160;International&#160;Society (ASAS) classification criteria of axial&#160;<br/>spondyloarthritis (but not meeting the modified New York criteria for AS), having&#160;positive&#160;MRI&#160;<br/>findings (active inflammation on MRI highly suggestive of&#160;sacroiliitis&#160;associated with SpA) and/or&#160;</p>
</div>
<!-- Page 114 -->
<a name="114"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page114-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1140">114</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1144">positive hsCRP&#160;(defined as high sensitivity C-reactive protein&#160;[hsCRP]&#160;&gt;&#160;3&#160;mg/l), and&#160;active&#160;<br/>symptoms defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received&#160;<br/>open-label Enbrel 50&#160;mg weekly&#160;plus stable background NSAID at the optimal tolerated&#160;<br/>anti-inflammatory dosage&#160;for 24&#160;weeks in Period 1. Patients were also required to have an inadequate&#160;<br/>response or intolerance to two or more NSAIDs. At week&#160;24, 119 (57%) patients achieved inactive&#160;<br/>disease and entered into the Period&#160;2&#160;40-week withdrawal&#160;phase&#160;where subjects discontinued&#160;<br/>etanercept, yet maintained the background NSAID. The&#160;primary measure of efficacy was the&#160;<br/>occurrence of flare (defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal&#160;<br/>to 2.1) within 40&#160;weeks following&#160;withdrawal of Enbrel. Patients who flared were retreated with&#160;<br/>Enbrel 50&#160;mg weekly for 12&#160;weeks (Period 3).</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1143">In Period&#160;2, the proportion of patients experiencing&#160;≥1 flare increased from 22% (25/112) at week 4 to&#160;<br/>67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within&#160;<br/>40&#160;weeks following withdrawal of Enbrel.&#160;</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft1144">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and&#160;<br/>additionally&#160;compare&#160;the time to flare to&#160;patients from&#160;Study 1 who met the Study&#160;2 withdrawal phase&#160;<br/>entry requirements and continued Enbrel therapy.&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1144">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24&#160;weeks).&#160;Less&#160;<br/>than 25% of patients in Study&#160;1 who did not have treatment withdrawn experienced a flare&#160;over the<br/>equivalent&#160;40-weeks&#160;as in&#160;Period 2&#160;Study 2. The time to flare was statistically significantly shorter in&#160;<br/>subjects who discontinued&#160;Enbrel&#160;treatment (Study 2) compared to subjects who received continuous&#160;<br/>etanercept treatment (Study 1), p&lt;0.0001.</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft1143">Of the 87&#160;patients who entered Period 3 and were retreated with Enbrel 50&#160;mg weekly for 12&#160;weeks,&#160;<br/>62% (54/87) reachieved inactive disease,&#160;with 50% of&#160;them&#160;reachieving&#160;it&#160;within 5&#160;weeks (95% CI:&#160;<br/>4-8&#160;weeks).</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft1143"><i>Adult patients with&#160;plaque psoriasis<br/></i>Enbrel is recommended for use in patients as defined in section 4.1. Patients who “failed to respond&#160;<br/>to” in the target population is defined by insufficient response (PASI&lt;&#160;50 or PGA less than good), or&#160;<br/>worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long&#160;<br/>duration to assess response with at least&#160;one&#160;of the three major systemic therapies as available.</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft1143">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe&#160;psoriasis&#160;<br/>(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel&#160;<br/>with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four&#160;<br/>randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies&#160;<br/>was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75%&#160;<br/>improvement in the Psoriasis Area and Severity Index score from baseline) at 12&#160;weeks.</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft1142">Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving&#160;</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft1148">&#160;10% of the body surface area that were&#160;&#160;18 years old. One hundred and twelve (112) patients were&#160;<br/>randomised to receive a dose of 25&#160;mg of Enbrel (n=57) or placebo&#160;(n=55) twice a week for 24&#160;weeks.</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft1143">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study&#160;<br/>1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel&#160;<br/>was administered at doses of 25&#160;mg once a week, 25&#160;mg twice a week or 50&#160;mg twice a week for&#160;<br/>6&#160;consecutive months. During the first 12 weeks of the double-blind treatment period, patients&#160;<br/>received placebo or one of the above three Enbrel doses. After 12&#160;weeks of treatment, patients in the&#160;<br/>placebo group began treatment with blinded Enbrel (25&#160;mg twice a week); patients in the active&#160;<br/>treatment groups continued to week&#160;24 on the dose to which they were originally randomised.</p>
</div>
<!-- Page 115 -->
<a name="115"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page115-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1150">115</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1154">Study&#160;3 evaluated 583 patients and had the same inclusion criteria as study&#160;2. Patients in this study&#160;<br/>received a dose of 25&#160;mg or 50&#160;mg Enbrel, or placebo twice a week for 12&#160;weeks and then all patients&#160;<br/>received open-label 25&#160;mg&#160;Enbrel twice weekly for an additional 24&#160;weeks.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1154">Study&#160;4 evaluated 142 patients and had similar inclusion criteria to studies&#160;2 and 3. Patients in this&#160;<br/>study received a dose of 50&#160;mg Enbrel or placebo once weekly for 12&#160;weeks and then all patients&#160;<br/>received open-label 50&#160;mg&#160;Enbrel once weekly for an additional 12&#160;weeks.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1154">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75&#160;<br/>response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;&#160;0.0001). At 24 weeks,&#160;<br/>56% of patients in the Enbrel-treated group had achieved the PASI 75&#160;compared to 5% of&#160;<br/>placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</p>
<p style="position:absolute;top:354px;left:260px;white-space:nowrap" class="ft1151"><b>Responses of Patients with Psoriasis in Studies 2, 3 And 4</b></p>
<p style="position:absolute;top:510px;left:118px;white-space:nowrap" class="ft1152">Respons</p>
<p style="position:absolute;top:529px;left:127px;white-space:nowrap" class="ft1152">e (%)</p>
<p style="position:absolute;top:375px;left:192px;white-space:nowrap" class="ft1152">------------------Study 2--------------</p>
<p style="position:absolute;top:394px;left:294px;white-space:nowrap" class="ft1152">-</p>
<p style="position:absolute;top:375px;left:421px;white-space:nowrap" class="ft1152">---------------Study 3------------</p>
<p style="position:absolute;top:394px;left:510px;white-space:nowrap" class="ft1152">-</p>
<p style="position:absolute;top:375px;left:623px;white-space:nowrap" class="ft1152">---------------Study 4------------</p>
<p style="position:absolute;top:394px;left:713px;white-space:nowrap" class="ft1152">-</p>
<p style="position:absolute;top:452px;left:191px;white-space:nowrap" class="ft1152">Placebo</p>
<p style="position:absolute;top:414px;left:262px;white-space:nowrap" class="ft1152">----------Enbrel---------</p>
<p style="position:absolute;top:452px;left:421px;white-space:nowrap" class="ft1152">Placebo</p>
<p style="position:absolute;top:414px;left:488px;white-space:nowrap" class="ft1152">--------Enbrel-------</p>
<p style="position:absolute;top:452px;left:623px;white-space:nowrap" class="ft1152">Placebo</p>
<p style="position:absolute;top:414px;left:696px;white-space:nowrap" class="ft1152">-------Enbrel------</p>
<p style="position:absolute;top:432px;left:270px;white-space:nowrap" class="ft1152">25&#160;mg&#160;</p>
<p style="position:absolute;top:452px;left:275px;white-space:nowrap" class="ft1152">BIW</p>
<p style="position:absolute;top:432px;left:351px;white-space:nowrap" class="ft1152">50&#160;mg&#160;</p>
<p style="position:absolute;top:452px;left:356px;white-space:nowrap" class="ft1152">BIW</p>
<p style="position:absolute;top:432px;left:493px;white-space:nowrap" class="ft1152">25&#160;mg</p>
<p style="position:absolute;top:452px;left:497px;white-space:nowrap" class="ft1152">BIW</p>
<p style="position:absolute;top:432px;left:561px;white-space:nowrap" class="ft1152">50&#160;mg</p>
<p style="position:absolute;top:452px;left:565px;white-space:nowrap" class="ft1152">BIW</p>
<p style="position:absolute;top:432px;left:696px;white-space:nowrap" class="ft1152">50&#160;mg&#160;</p>
<p style="position:absolute;top:452px;left:702px;white-space:nowrap" class="ft1152">QW</p>
<p style="position:absolute;top:432px;left:763px;white-space:nowrap" class="ft1152">50&#160;mg</p>
<p style="position:absolute;top:452px;left:769px;white-space:nowrap" class="ft1152">QW</p>
<p style="position:absolute;top:470px;left:192px;white-space:nowrap" class="ft1152">n = 166</p>
<p style="position:absolute;top:490px;left:196px;white-space:nowrap" class="ft1152">wk 12</p>
<p style="position:absolute;top:470px;left:260px;white-space:nowrap" class="ft1152">n =&#160;</p>
<p style="position:absolute;top:490px;left:258px;white-space:nowrap" class="ft1152">162</p>
<p style="position:absolute;top:508px;left:260px;white-space:nowrap" class="ft1152">wk&#160;</p>
<p style="position:absolute;top:527px;left:262px;white-space:nowrap" class="ft1152">12</p>
<p style="position:absolute;top:470px;left:300px;white-space:nowrap" class="ft1152">n =&#160;</p>
<p style="position:absolute;top:490px;left:298px;white-space:nowrap" class="ft1152">162</p>
<p style="position:absolute;top:508px;left:301px;white-space:nowrap" class="ft1154">wk&#160;<br/>24a</p>
<p style="position:absolute;top:470px;left:341px;white-space:nowrap" class="ft1152">n =&#160;</p>
<p style="position:absolute;top:490px;left:339px;white-space:nowrap" class="ft1152">164</p>
<p style="position:absolute;top:508px;left:341px;white-space:nowrap" class="ft1152">wk&#160;</p>
<p style="position:absolute;top:527px;left:343px;white-space:nowrap" class="ft1152">12</p>
<p style="position:absolute;top:470px;left:381px;white-space:nowrap" class="ft1152">n&#160;=&#160;</p>
<p style="position:absolute;top:490px;left:379px;white-space:nowrap" class="ft1152">164</p>
<p style="position:absolute;top:508px;left:382px;white-space:nowrap" class="ft1154">wk&#160;<br/>24a</p>
<p style="position:absolute;top:470px;left:422px;white-space:nowrap" class="ft1152">n = 193</p>
<p style="position:absolute;top:490px;left:426px;white-space:nowrap" class="ft1152">wk 12</p>
<p style="position:absolute;top:470px;left:489px;white-space:nowrap" class="ft1152">n = 196</p>
<p style="position:absolute;top:490px;left:493px;white-space:nowrap" class="ft1152">wk 12</p>
<p style="position:absolute;top:470px;left:557px;white-space:nowrap" class="ft1152">n = 196</p>
<p style="position:absolute;top:490px;left:561px;white-space:nowrap" class="ft1152">wk 12</p>
<p style="position:absolute;top:470px;left:628px;white-space:nowrap" class="ft1152">n = 46</p>
<p style="position:absolute;top:490px;left:628px;white-space:nowrap" class="ft1152">wk 12</p>
<p style="position:absolute;top:470px;left:695px;white-space:nowrap" class="ft1152">n = 96</p>
<p style="position:absolute;top:490px;left:696px;white-space:nowrap" class="ft1152">wk 12</p>
<p style="position:absolute;top:470px;left:763px;white-space:nowrap" class="ft1152">n = 90</p>
<p style="position:absolute;top:490px;left:761px;white-space:nowrap" class="ft1152">wk 24a</p>
<p style="position:absolute;top:549px;left:114px;white-space:nowrap" class="ft1152">PASI 50</p>
<p style="position:absolute;top:549px;left:208px;white-space:nowrap" class="ft1152">14</p>
<p style="position:absolute;top:549px;left:258px;white-space:nowrap" class="ft1152">58*</p>
<p style="position:absolute;top:549px;left:302px;white-space:nowrap" class="ft1152">70</p>
<p style="position:absolute;top:549px;left:339px;white-space:nowrap" class="ft1152">74*</p>
<p style="position:absolute;top:549px;left:383px;white-space:nowrap" class="ft1152">77</p>
<p style="position:absolute;top:549px;left:441px;white-space:nowrap" class="ft1152">9</p>
<p style="position:absolute;top:549px;left:501px;white-space:nowrap" class="ft1152">64*</p>
<p style="position:absolute;top:549px;left:568px;white-space:nowrap" class="ft1152">77*</p>
<p style="position:absolute;top:549px;left:644px;white-space:nowrap" class="ft1152">9</p>
<p style="position:absolute;top:549px;left:703px;white-space:nowrap" class="ft1152">69*</p>
<p style="position:absolute;top:549px;left:775px;white-space:nowrap" class="ft1152">83</p>
<p style="position:absolute;top:570px;left:114px;white-space:nowrap" class="ft1152">PASI 75</p>
<p style="position:absolute;top:570px;left:212px;white-space:nowrap" class="ft1152">4</p>
<p style="position:absolute;top:570px;left:258px;white-space:nowrap" class="ft1152">34*</p>
<p style="position:absolute;top:570px;left:302px;white-space:nowrap" class="ft1152">44</p>
<p style="position:absolute;top:570px;left:339px;white-space:nowrap" class="ft1152">49*</p>
<p style="position:absolute;top:570px;left:383px;white-space:nowrap" class="ft1152">59</p>
<p style="position:absolute;top:570px;left:441px;white-space:nowrap" class="ft1152">3</p>
<p style="position:absolute;top:570px;left:501px;white-space:nowrap" class="ft1152">34*</p>
<p style="position:absolute;top:570px;left:568px;white-space:nowrap" class="ft1152">49*</p>
<p style="position:absolute;top:570px;left:644px;white-space:nowrap" class="ft1152">2</p>
<p style="position:absolute;top:570px;left:703px;white-space:nowrap" class="ft1152">38*</p>
<p style="position:absolute;top:570px;left:775px;white-space:nowrap" class="ft1152">71</p>
<p style="position:absolute;top:595px;left:114px;white-space:nowrap" class="ft1153">DSGAb,&#160;<br/>clear or&#160;<br/>almost&#160;<br/>clear</p>
<p style="position:absolute;top:652px;left:212px;white-space:nowrap" class="ft1152">5</p>
<p style="position:absolute;top:652px;left:258px;white-space:nowrap" class="ft1152">34*</p>
<p style="position:absolute;top:652px;left:302px;white-space:nowrap" class="ft1152">39</p>
<p style="position:absolute;top:652px;left:339px;white-space:nowrap" class="ft1152">49*</p>
<p style="position:absolute;top:652px;left:383px;white-space:nowrap" class="ft1152">55</p>
<p style="position:absolute;top:652px;left:441px;white-space:nowrap" class="ft1152">4</p>
<p style="position:absolute;top:652px;left:501px;white-space:nowrap" class="ft1152">39*</p>
<p style="position:absolute;top:652px;left:568px;white-space:nowrap" class="ft1152">57*</p>
<p style="position:absolute;top:652px;left:644px;white-space:nowrap" class="ft1152">4</p>
<p style="position:absolute;top:652px;left:703px;white-space:nowrap" class="ft1152">39*</p>
<p style="position:absolute;top:652px;left:775px;white-space:nowrap" class="ft1152">64</p>
<p style="position:absolute;top:673px;left:114px;white-space:nowrap" class="ft1152">*p&#160;</p>
<p style="position:absolute;top:671px;left:135px;white-space:nowrap" class="ft11514">&#160;0.0001 compared with placebo</p>
<p style="position:absolute;top:692px;left:114px;white-space:nowrap" class="ft1153">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original&#160;<br/>placebo group began receiving Enbrel 25&#160;mg BIW or 50&#160;mg once weekly from week 13 to week 24.<br/>b. Dermatologist Static Global&#160;Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft1153">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo&#160;<br/>were apparent at the time of the first visit (2 weeks) and were maintained through&#160;24 weeks of therapy.</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1158">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement&#160;<br/>of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the&#160;<br/>occurrence of rebound (PASI&#160;</p>
<p style="position:absolute;top:862px;left:304px;white-space:nowrap" class="ft11514">&#160;150% of baseline) and for the time to relapse (defined as a loss of at&#160;</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1154">least half of the improvement achieved between baseline and week 24). During the withdrawal period,&#160;<br/>symptoms of psoriasis gradually returned with a median time to disease relapse of 3 months. No&#160;<br/>rebound flare of disease and no psoriasis-related serious adverse events were observed. There was&#160;<br/>some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to&#160;<br/>treatment.</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1154">In study 3, the majority of patients (77%) who were initially randomised to 50&#160;mg twice weekly and&#160;<br/>had their Enbrel dose decreased at week 12 to 25&#160;mg twice weekly maintained their PASI 75 response&#160;<br/>through week 36. For patients who received 25&#160;mg twice weekly throughout the study, the PASI 75&#160;<br/>response continued to improve between weeks 12 and 36.</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft1154">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12&#160;<br/>(38%) compared to the placebo-treated group (2%) (p&lt;0.0001). For patients who received 50&#160;mg once&#160;<br/>weekly throughout&#160;the study, the efficacy responses continued to improve with 71% achieving PASI&#160;<br/>75 at week 24.</p>
</div>
<!-- Page 116 -->
<a name="116"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page116-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1160">116</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1164">In long-term&#160;(up to 34&#160;months) open-label studies where Enbrel was given without interruption,&#160;<br/>clinical responses were sustained and safety was comparable to shorter-term studies.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1164">An analysis of clinical trial data&#160;did not reveal any&#160;baseline disease characteristics that would assist&#160;<br/>clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently,&#160;<br/>the choice of intermittent&#160;or continuous therapy should be based upon physician judgment and&#160;<br/>individual patient needs.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft1164"><i>Antibodies to Enbrel<br/></i>Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept.&#160;<br/>These antibodies have all been non-neutralising and are generally transient. There appears to be no&#160;<br/>correlation between antibody development and clinical response or adverse events.</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft1163">In subjects treated with approved doses of etanercept in clinical trials for up to 12&#160;months, cumulative&#160;<br/>rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5%&#160;<br/>of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with&#160;<br/>psoriasis, 9.7% of subjects with paediatric psoriasis, and&#160;4.8%&#160;of subjects with juvenile idiopathic&#160;<br/>arthritis.&#160;</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft1163">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to&#160;<br/>3.5&#160;years) increases over time, as expected. However, due to their transient nature, the incidence of&#160;<br/>antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis&#160;<br/>subjects and psoriasis subjects.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft1164">In a long-term psoriasis study in which patients received 50&#160;mg twice weekly for 96&#160;weeks, the&#160;<br/>incidence of antibodies observed at each assessment point was up to approximately 9%.</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft1162">Paediatric population</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1168"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with&#160;<br/>polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset&#160;<br/>types (polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to&#160;<br/>severely active polyarticular-course&#160;juvenile idiopathic arthritis refractory to, or intolerant of,&#160;<br/>methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal&#160;<br/>anti-inflammatory drug and/or prednisone (&lt;&#160;0.2&#160;mg/kg/day or 10&#160;mg maximum). In part 1, all patients&#160;<br/>received 0.4&#160;mg/kg (maximum&#160;25&#160;mg per dose) Enbrel subcutaneously twice weekly. In part 2,&#160;<br/>patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for&#160;<br/>four months and assessed for disease flare. Responses were measured using the ACR Pedi 30, defined&#160;<br/>as&#160;</p>
<p style="position:absolute;top:868px;left:124px;white-space:nowrap" class="ft11614">&#160;30% improvement in at least three of six and&#160;&#160;30% worsening in no more than one of six JRA&#160;</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft1168">core set criteria, including active joint count, limitation of motion, physician and patient/parent global&#160;<br/>assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was&#160;<br/>defined as a&#160;</p>
<p style="position:absolute;top:926px;left:189px;white-space:nowrap" class="ft11614">&#160;30% worsening in three of six JRA core set criteria and&#160;&#160;30% improvement in not&#160;</p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft1162">more than one of the six JRA core set criteria and a minimum of two active joints.</p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft1163">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In&#160;<br/>part 2, 6&#160;of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of&#160;<br/>26&#160;(77%) patients receiving placebo (p=0.007). From the start of part 2, the&#160;median time to flare was&#160;</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft1164">&#160;116&#160;days for patients who received Enbrel and 28 days for patients who received placebo. Of&#160;<br/>patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the&#160;<br/>patients remaining on Enbrel continued to improve from month 3 through month 7, while those who&#160;<br/>received placebo did not improve.</p>
</div>
<!-- Page 117 -->
<a name="117"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page117-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1170">117</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1174">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of&#160;<br/>4&#160;years at time of enrolment) continued to receive Enbrel&#160;for up to 10&#160;years.&#160;Rates of serious adverse&#160;<br/>events and serious infections did not increase with long-term&#160;exposure.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1173">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate&#160;<br/>monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18&#160;years&#160;<br/>with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more&#160;<br/>commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus&#160;<br/>2%), and the infections associated with etanercept use were of a more severe nature.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1174">In another open-label&#160;single-arm&#160;study&#160;(n=127),&#160;60&#160;patients with extended oligoarthritis&#160;(EO)&#160;<br/>(15&#160;patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged&#160;12 to 17&#160;years old),&#160;38 patients&#160;<br/>with&#160;enthesitis-related arthritis (12 to 17&#160;years old),&#160;and 29 patients with&#160;psoriatic arthritis (12 to&#160;<br/>17&#160;years old) were treated with Enbrel at a dose of&#160;0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose)&#160;<br/>administered weekly for 12&#160;weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi&#160;<br/>30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender&#160;<br/>joints and&#160;physician global assessment. The safety profile was consistent with that observed in other&#160;<br/>JIA studies.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1174">Of the 127&#160;patients in the parent study, 109 participated in the open-label extension study and were&#160;<br/>followed for&#160;an additional&#160;8 years&#160;for a total&#160;of up to 10 years.&#160;At the end of the extension study,&#160;<br/>84/109 (77%) patients had completed the study; 27 (25%) while actively taking&#160;Enbrel, 7 (6%) had&#160;<br/>withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started&#160;Enbrel&#160;following an&#160;<br/>earlier withdrawal from treatment; and 45 (41%) had stopped&#160;Enbrel&#160;(but remained under&#160;<br/>observation);&#160;25/109 (23%) patients&#160;permanently discontinued from the&#160;study.&#160;Improvements in&#160;<br/>clinical status achieved in the parent study were generally maintained for all efficacy endpoints during&#160;<br/>the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-<br/>retreatment period once during the extension study based on investigator’s judgement of clinical&#160;<br/>response. 30&#160;patients entered the withdrawal period. 17&#160;patients were reported to have a flare (defined&#160;<br/>as&#160;≥&#160;30% worsening in at least 3 of the 6 ACR Pedi components with&#160;≥&#160;30% improvement in not more&#160;<br/>than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after<br/>Enbrel withdrawal was 190&#160;days. 13&#160;patients were&#160;re-treated and the median time to re-treatment from&#160;<br/>withdrawal was estimated as 274&#160;days. Due to the small number of data points, these results should be&#160;<br/>interpreted with caution.</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft1172">The safety profile was consistent with that observed in&#160;the parent study.</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft1173">Studies have not been done in patients with&#160;juvenile idiopathic arthritis to assess the effects of&#160;<br/>continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy.&#160;<br/>Additionally, studies have not been conducted to assess&#160;the effects of&#160;reducing the recommended dose&#160;<br/>of Enbrel following its long-term&#160;use in patients with JIA.</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft1173"><i>Paediatric patients with plaque psoriasis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211&#160;<br/>paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by a sPGA&#160;<br/>score&#160;≥&#160;3, involving&#160;≥&#160;10% of the BSA, and PASI&#160;≥&#160;12).&#160;Eligible patients had a history of receiving&#160;<br/>phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</p>
<p style="position:absolute;top:1023px;left:106px;white-space:nowrap" class="ft1173">Patients received Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) or placebo once weekly for 12 weeks. At week 12,&#160;<br/>more patients randomised to Enbrel had positive efficacy responses (e.g. PASI 75) than those&#160;<br/>randomised to placebo.</p>
</div>
<!-- Page 118 -->
<a name="118"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page118-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1180">118</p>
<p style="position:absolute;top:117px;left:263px;white-space:nowrap" class="ft1181"><b>Paediatric Plaque Psoriasis Outcomes at 12 Weeks</b></p>
<p style="position:absolute;top:145px;left:495px;white-space:nowrap" class="ft1181"><b>Enbrel</b></p>
<p style="position:absolute;top:164px;left:465px;white-space:nowrap" class="ft1181"><b>0.8&#160;mg/kg Once&#160;</b></p>
<p style="position:absolute;top:183px;left:493px;white-space:nowrap" class="ft1181"><b>Weekly</b></p>
<p style="position:absolute;top:202px;left:487px;white-space:nowrap" class="ft1181"><b>(N = 106)</b></p>
<p style="position:absolute;top:183px;left:647px;white-space:nowrap" class="ft1181"><b>Placebo</b></p>
<p style="position:absolute;top:202px;left:642px;white-space:nowrap" class="ft1181"><b>(N = 105)</b></p>
<p style="position:absolute;top:222px;left:136px;white-space:nowrap" class="ft1182">PASI 75, n (%)</p>
<p style="position:absolute;top:222px;left:486px;white-space:nowrap" class="ft1182">60 (57%)a</p>
<p style="position:absolute;top:222px;left:644px;white-space:nowrap" class="ft1182">12 (11%)</p>
<p style="position:absolute;top:241px;left:136px;white-space:nowrap" class="ft1182">PASI 50, n (%)</p>
<p style="position:absolute;top:241px;left:486px;white-space:nowrap" class="ft1182">79&#160;(75%)a</p>
<p style="position:absolute;top:241px;left:644px;white-space:nowrap" class="ft1182">24 (23%)</p>
<p style="position:absolute;top:273px;left:136px;white-space:nowrap" class="ft1182">sPGA “clear” or “minimal”, n (%)</p>
<p style="position:absolute;top:273px;left:486px;white-space:nowrap" class="ft1182">56&#160;(53%)a</p>
<p style="position:absolute;top:273px;left:644px;white-space:nowrap" class="ft1182">14 (13%)</p>
<p style="position:absolute;top:292px;left:136px;white-space:nowrap" class="ft1184">Abbreviation: sPGA-static Physician Global Assessment.<br/>a.&#160;p &lt; 0.0001 compared with placebo.</p>
<p style="position:absolute;top:369px;left:106px;white-space:nowrap" class="ft1183">After the 12-week double-blind treatment period, all patients received Enbrel 0.8&#160;mg/kg (up&#160;to 50&#160;mg)&#160;<br/>once weekly for additional 24 weeks. Responses observed during the open-label period were similar to&#160;<br/>those observed in the double-blind period.</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft1184">During a randomised withdrawal period, significantly more patients re-randomised to placebo&#160;<br/>experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to&#160;<br/>Enbrel. With continued therapy, responses were maintained up to 48 weeks.</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft1184">The long-term safety and effectiveness of Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) once weekly was assessed&#160;<br/>in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years&#160;<br/>beyond the 48 week study discussed above. Long-term experience with Enbrel was generally&#160;<br/>comparable to the original 48-week study and did not reveal any new safety findings.&#160;</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft1181"><b>5.2</b></p>
<p style="position:absolute;top:618px;left:149px;white-space:nowrap" class="ft1181"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft1183">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA)&#160;<br/>method, which may detect ELISA-reactive degradation products as well as the parent compound.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft1182">Absorption</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1188">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum&#160;<br/>concentration approximately 48&#160;hours after a single dose. The absolute bioavailability is 76%. With&#160;<br/>twice weekly doses, it is anticipated that steady-state concentrations are approximately twice as high&#160;<br/>as those observed after single doses. After a single subcutaneous dose of 25&#160;mg Enbrel, the average&#160;<br/>maximum serum concentration observed in healthy volunteers was 1.65&#160;</p>
<p style="position:absolute;top:826px;left:585px;white-space:nowrap" class="ft11814">&#160;0.66&#160;g/ml, and the area&#160;</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft1182">under the curve was 235</p>
<p style="position:absolute;top:846px;left:272px;white-space:nowrap" class="ft11814">&#160;96.6&#160;ghr/ml.</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft1184">Mean serum concentration profiles at steady state in treated RA patients were Cmax&#160;of 2.4&#160;mg/l vs.&#160;<br/>2.6&#160;mg/l, Cmin&#160;of 1.2&#160;mg/l vs. 1.4&#160;mg/l, and partial AUC of 297&#160;mgh/l vs. 316&#160;mgh/l for 50&#160;mg Enbrel&#160;<br/>once weekly (n=21)&#160;vs. 25&#160;mg Enbrel twice weekly (n=16), respectively. In an open-label, single-<br/>dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single&#160;<br/>50&#160;mg/ml injection was found to be bioequivalent to two simultaneous injections of&#160;25&#160;mg/ml.</p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft1188">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady&#160;<br/>state AUCs were 466</p>
<p style="position:absolute;top:1018px;left:251px;white-space:nowrap" class="ft11814">ghr/ml and 474&#160;ghr/ml for 50&#160;mg Enbrel once weekly (N&#160;= 154) and 25&#160;mg&#160;</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft1182">twice weekly (N = 148), respectively.</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft1182">Distribution</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft1184">A biexponential curve is required to describe the concentration time curve of etanercept. The central&#160;<br/>volume of distribution of etanercept is 7.6&#160;l, while the volume of distribution at steady-state is 10.4&#160;l.</p>
</div>
<!-- Page 119 -->
<a name="119"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page119-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1190">119</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1192">Elimination</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1193">Etanercept is cleared slowly from the body. The half-life is long, approximately 70&#160;hours. Clearance is&#160;<br/>approximately 0.066&#160;l/hr in patients with rheumatoid arthritis, somewhat lower than the value of&#160;<br/>0.11&#160;l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid&#160;<br/>arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1192">There is no apparent pharmacokinetic difference between males and females.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1192">Linearity</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1194">Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance&#160;<br/>across the dosing range.</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft1192">Special populations</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft1194"><i>Renal impairment<br/></i>Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept&#160;<br/>to patients and volunteers, increased&#160;etanercept concentrations were not observed in patients with&#160;<br/>acute renal failure. The presence of renal impairment should not require a change in dosage.</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft1194"><i>Hepatic impairment<br/></i>Increased etanercept concentrations were not observed in patients with acute&#160;hepatic failure. The&#160;<br/>presence of hepatic impairment should not require a change in dosage.</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft1193"><i>Elderly<br/></i>The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept&#160;<br/>serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to&#160;<br/>estimates in patients less than 65 years of age.</p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft1192">Paediatric population</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft1194"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients&#160;(aged&#160;4 to 17&#160;years)&#160;<br/>were administered 0.4&#160;mg&#160;Enbrel/kg twice weekly for three months. Serum concentration profiles&#160;<br/>were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4&#160;years of age)&#160;<br/>had reduced clearance (increased clearance when normalised by weight) compared with older children&#160;<br/>(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17&#160;years of&#160;<br/>age) will have serum levels close to those seen in adults, younger children will have appreciably lower&#160;<br/>levels.</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft1193"><i>Paediatric patients with plaque psoriasis<br/></i>Patients with paediatric plaque psoriasis (aged 4 to 17&#160;years) were administered 0.8&#160;mg/kg (up to a&#160;<br/>maximum dose of 50&#160;mg per week) of etanercept once weekly for up to 48 weeks. The mean serum&#160;<br/>steady state trough concentrations ranged from 1.6&#160;to 2.1&#160;mcg/ml at weeks 12, 24, and 48. These mean&#160;<br/>concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed&#160;<br/>in patients with&#160;juvenile idiopathic arthritis&#160;(treated with 0.4&#160;mg/kg etanercept twice weekly, up to&#160;<br/>maximum dose of 50&#160;mg per week). These mean concentrations were similar to those seen in adult&#160;<br/>patients with plaque psoriasis treated with 25&#160;mg etanercept twice weekly.</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1191"><b>5.3</b></p>
<p style="position:absolute;top:1059px;left:149px;white-space:nowrap" class="ft1191"><b>Preclinical safety data</b></p>
<p style="position:absolute;top:1097px;left:106px;white-space:nowrap" class="ft1193">In&#160;the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel&#160;<br/>was considered to be non-genotoxic from a battery of&#160;<i>in vitro&#160;</i>and&#160;<i>in vivo&#160;</i>studies. Carcinogenicity&#160;<br/>studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel&#160;<br/>due to the development of neutralising antibodies in rodents.</p>
</div>
<!-- Page 120 -->
<a name="120"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page120-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1200">120</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1204">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single&#160;<br/>subcutaneous dose of 2000&#160;mg/kg or a single intravenous dose of 1000&#160;mg/kg. Enbrel did not elicit&#160;<br/>dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous&#160;<br/>administration for 4 or 26&#160;consecutive weeks at a dose (15&#160;mg/kg) that resulted in AUC-based serum&#160;<br/>drug concentrations that were over 27-fold higher than that obtained in humans at the recommended&#160;<br/>dose of 25&#160;mg.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1201"><b>6.</b></p>
<p style="position:absolute;top:278px;left:146px;white-space:nowrap" class="ft1201"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1201"><b>6.1</b></p>
<p style="position:absolute;top:316px;left:149px;white-space:nowrap" class="ft1201"><b>List of excipients</b></p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft1203">Sucrose&#160;<br/>Sodium chloride<br/>L-Arginine hydrochloride<br/>Sodium phosphate monobasic dihydrate<br/>Sodium&#160;phosphate dibasic dihydrate<br/>Water for injections</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft1201"><b>6.2</b></p>
<p style="position:absolute;top:487px;left:149px;white-space:nowrap" class="ft1201"><b>Incompatibilities</b></p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft1204">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft1201"><b>6.3</b></p>
<p style="position:absolute;top:582px;left:149px;white-space:nowrap" class="ft1201"><b>Shelf life</b></p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft1202">30 months.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft1201"><b>6.4</b></p>
<p style="position:absolute;top:658px;left:149px;white-space:nowrap" class="ft1201"><b>Special precautions for storage</b></p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft1202">Store in a refrigerator (2</p>
<p style="position:absolute;top:695px;left:267px;white-space:nowrap" class="ft12014">C&#160;–&#160;8C).&#160;</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft1202">Do not freeze.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft1202">Enbrel may be stored at temperatures up to a maximum of 25</p>
<p style="position:absolute;top:753px;left:511px;white-space:nowrap" class="ft12014">C for a single period of up to four&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1204">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within&#160;<br/>four&#160;weeks of removal from refrigeration.</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft1202">Keep the pre-filled pens in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft1201"><b>6.5</b></p>
<p style="position:absolute;top:869px;left:149px;white-space:nowrap" class="ft1201"><b>Nature and contents of container</b></p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft1202">25&#160;mg solution for injection in pre-filled pen</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft1203">Pre-filled pen (MYCLIC) containing a&#160;25&#160;mg pre-filled syringe of Enbrel. The syringe inside the pen&#160;<br/>is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic&#160;<br/>plunger. The needle cap of the pre-filled pen contains dry natural rubber (a derivative of&#160;latex). See&#160;<br/>section 4.4.&#160;</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft1203">Cartons contain&#160;4,&#160;8&#160;or&#160;24&#160;pre-filled pens of Enbrel with&#160;4,&#160;8&#160;or&#160;24&#160;alcohol swabs. Not all pack sizes&#160;<br/>may be marketed.</p>
<p style="position:absolute;top:1097px;left:106px;white-space:nowrap" class="ft1202">50&#160;mg solution for injection in pre-filled pen</p>
<p style="position:absolute;top:1135px;left:106px;white-space:nowrap" class="ft1203">Pre-filled pen (MYCLIC) containing a&#160;50&#160;mg&#160;pre-filled syringe of Enbrel. The syringe inside the pen&#160;<br/>is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic&#160;</p>
</div>
<!-- Page 121 -->
<a name="121"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page121-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1210">121</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1214">plunger. The needle cap of the pre-filled pen contains dry natural rubber (a derivative of latex). See&#160;<br/>section&#160;4.4.&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1214">Cartons contain 2, 4 or 12 pre-filled pens of Enbrel with&#160;2, 4 or 12&#160;alcohol swabs.&#160;Not all pack sizes&#160;<br/>may be marketed.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1211"><b>6.6</b></p>
<p style="position:absolute;top:222px;left:149px;white-space:nowrap" class="ft1211"><b>Special precautions for disposal and other handling</b></p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1212">Instructions for use and handling</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1214">Before injection, Enbrel single-use&#160;pre-filled pens should be allowed to reach room temperature&#160;<br/>(approximately 15 to 30 minutes). The needle cover should not be removed while allowing the pre-<br/>filled pen to reach room temperature. By looking through the inspection window, the solution should&#160;<br/>be clear&#160;to slightly opalescent,&#160;colourless&#160;to&#160;pale yellow&#160;or pale brown&#160;and&#160;may contain small&#160;<br/>translucent or white particles of protein.&#160;</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft1214">Comprehensive instructions for administration are given in the package leaflet, section 7, &#34;Using the&#160;<br/>MYCLIC pre-filled pen to inject Enbrel.&#34;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1213">Any unused&#160;medicinal&#160;product or waste material should be disposed of in accordance with local&#160;<br/>requirements.&#160;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1211"><b>7.</b></p>
<p style="position:absolute;top:544px;left:146px;white-space:nowrap" class="ft1211"><b>MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft1214">Pfizer Europe MA EEIG<br/>Boulevard de&#160;la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft1211"><b>8.</b></p>
<p style="position:absolute;top:696px;left:146px;white-space:nowrap" class="ft1211"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft1214">Enbrel&#160;25&#160;mg solution for injection in pre-filled pen<br/>EU/1/99/126/023<br/>EU/1/99/126/024<br/>EU/1/99/126/025</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft1214">Enbrel&#160;50&#160;mg solution for injection in pre-filled pen<br/>EU/1/99/126/019<br/>EU/1/99/126/020<br/>EU/1/99/126/021</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft1211"><b>9.</b></p>
<p style="position:absolute;top:942px;left:146px;white-space:nowrap" class="ft1211"><b>DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft1213">Date of first authorisation:&#160;03 February 2000<br/>Date of last renewal:&#160;26&#160;November&#160;2009</p>
<p style="position:absolute;top:1056px;left:106px;white-space:nowrap" class="ft1211"><b>10.</b></p>
<p style="position:absolute;top:1056px;left:146px;white-space:nowrap" class="ft1211"><b>DATE OF REVISION OF THE TEXT</b></p>
<p style="position:absolute;top:1094px;left:106px;white-space:nowrap" class="ft1214">Detailed information on this&#160;medicinal&#160;product is available on the website of the European Medicines&#160;<br/>Agency&#160;<a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</p>
</div>
<!-- Page 122 -->
<a name="122"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page122-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1220">122</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1221"><b>1.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft1221"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1222">Enbrel 10&#160;mg powder and solvent for solution for injection for paediatric use</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1221"><b>2.</b></p>
<p style="position:absolute;top:203px;left:146px;white-space:nowrap" class="ft1221"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION</b></p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1223">Each vial contains 10&#160;mg of etanercept. When reconstituted, the solution contains 10&#160;mg/ml of&#160;<br/>etanercept.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1224">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant&#160;<br/>DNA technology in a Chinese hamster ovary (CHO) mammalian expression system.&#160;</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft1222">For&#160;the&#160;full list of excipients, see section 6.1.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft1221"><b>3.</b></p>
<p style="position:absolute;top:411px;left:146px;white-space:nowrap" class="ft1221"><b>PHARMACEUTICAL FORM</b></p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft1222">Powder and solvent for solution for injection (powder for injection).</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft1222">The powder is white. The solvent is a clear, colourless liquid.</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1221"><b>4.</b></p>
<p style="position:absolute;top:544px;left:146px;white-space:nowrap" class="ft1221"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft1221"><b>4.1</b></p>
<p style="position:absolute;top:582px;left:149px;white-space:nowrap" class="ft1221"><b>Therapeutic indications</b></p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft1222">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft1224">Treatment of&#160;polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis&#160;in&#160;<br/>children and adolescents from the age of 2&#160;years who have had an inadequate response to, or who have&#160;<br/>proved intolerant of, methotrexate.&#160;</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft1224">Treatment of&#160;psoriatic arthritis in adolescents from the age of 12&#160;years who have had an inadequate&#160;<br/>response to, or who have proved intolerant of, methotrexate.</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft1223">Treatment of enthesitis-related arthritis in adolescents from the age of 12&#160;years who have had an&#160;<br/>inadequate response to, or who have proved intolerant of, conventional therapy.&#160;</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft1222">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft1223">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6&#160;years who&#160;<br/>are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft1221"><b>4.2</b></p>
<p style="position:absolute;top:944px;left:149px;white-space:nowrap" class="ft1221"><b>Posology and method of administration</b></p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft1224">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the&#160;<br/>diagnosis and treatment of juvenile&#160;idiopathic arthritis or paediatric plaque psoriasis. Patients treated&#160;<br/>with Enbrel should be given the Patient Card.</p>
</div>
<!-- Page 123 -->
<a name="123"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page123-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1230">123</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1232">Posology</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1235"><i>Special populations</i></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1233">Renal and hepatic impairment<br/>No dose adjustment is required.</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft1235"><i>Paediatric population</i></p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft1233">The 10&#160;mg&#160;presentation&#160;is&#160;for paediatric patients prescribed a dose of 10&#160;mg or less.&#160;Each vial of Enbrel&#160;<br/>10&#160;mg&#160;should&#160;be&#160;used&#160;on&#160;a single&#160;occasion&#160;in&#160;a&#160;single&#160;patient,&#160;and&#160;the&#160;remainder&#160;of&#160;the&#160;vial&#160;should&#160;be&#160;<br/>discarded.</p>
<p style="position:absolute;top:357px;left:107px;white-space:nowrap" class="ft1235"><i>Juvenile idiopathic arthritis&#160;</i></p>
<p style="position:absolute;top:377px;left:106px;white-space:nowrap" class="ft1234">The recommended dose is 0.4&#160;mg/kg (up to a maximum of 25&#160;mg per dose) given twice weekly as a&#160;<br/>subcutaneous injection with an interval of 3-4&#160;days between doses&#160;or 0.8&#160;mg/kg (up to a maximum of&#160;<br/>50&#160;mg per dose) given once weekly.&#160;Discontinuation of treatment should be considered in patients&#160;<br/>who show no response after 4 months.</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft1234">No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety&#160;<br/>data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar&#160;<br/>to that seen in adults and children aged 4 years and older, when dosed every week with 0.8&#160;mg/kg&#160;<br/>subcutaneously (see section 5.1).</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft1234">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile&#160;<br/>idiopathic arthritis.</p>
<p style="position:absolute;top:623px;left:107px;white-space:nowrap" class="ft1235"><i>Paediatric plaque psoriasis (age 6 years and above)</i></p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft1233">The recommended dose is 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly for up to&#160;<br/>24&#160;weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</p>
<p style="position:absolute;top:700px;left:106px;white-space:nowrap" class="ft1234">If re-treatment&#160;with Enbrel is indicated, the above guidance on treatment duration should be followed.&#160;<br/>The dose should be 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly.</p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft1234">There is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft1232">Method of administration</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft1234">Enbrel is administered by subcutaneous injection.&#160;Enbrel powder for solution must be reconstituted in&#160;<br/>1&#160;ml of solvent before use&#160;(see section 6.6).</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft1234">Comprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are&#160;<br/>given in the package leaflet, section 7, &#34;Instructions for preparation and giving an injection of Enbrel.&#34;<br/>Detailed instructions on unintentional dosing or scheduling variations, including missed doses, are&#160;<br/>provided in section 3 of the package leaflet.</p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft1231"><b>4.3</b></p>
<p style="position:absolute;top:1003px;left:149px;white-space:nowrap" class="ft1231"><b>Contraindications</b></p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft1232">Hypersensitivity to the active substance or to any of the excipients&#160;listed in section 6.1.</p>
<p style="position:absolute;top:1079px;left:106px;white-space:nowrap" class="ft1232">Sepsis or risk of sepsis.</p>
<p style="position:absolute;top:1117px;left:106px;white-space:nowrap" class="ft1234">Treatment with Enbrel should not be initiated in patients with&#160;active infections, including chronic or&#160;<br/>localised infections.</p>
</div>
<!-- Page 124 -->
<a name="124"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page124-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1240">124</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1241"><b>4.4</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft1241"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1243">In order to improve the traceability of biological medicinal products, the&#160;brand name&#160;and batch&#160;<br/>number of the administered product should be clearly recorded (or stated) in the patient file.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1242">Infections</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft1244">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into&#160;<br/>consideration that the mean elimination half-life of etanercept is approximately 70&#160;hours (range 7 to&#160;<br/>300&#160;hours).</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft1244">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal&#160;<br/>infections,&#160;listeriosis and legionellosis,&#160;have been reported with the use of Enbrel (see section 4.8).&#160;<br/>These infections were due to bacteria, mycobacteria, fungi,&#160;viruses&#160;and parasites (including protozoa).&#160;<br/>In some cases, particular fungal and other opportunistic infections have not been recognised, resulting&#160;<br/>in delay of appropriate treatment and sometimes death. In evaluating patients for&#160;infections, the&#160;<br/>patient’s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be&#160;<br/>considered.&#160;</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft1244">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored&#160;<br/>closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The&#160;<br/>safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians&#160;<br/>should exercise caution when considering the use of Enbrel in patients with a history of recurring or&#160;<br/>chronic infections or with underlying conditions that may predispose patients to infections, such as&#160;<br/>advanced or poorly controlled diabetes.</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1242">Tuberculosis</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft1244">Cases of active tuberculosis, including miliary tuberculosis and tuberculosis&#160;with extra-pulmonary&#160;<br/>location, have been reported in patients treated with Enbrel.</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft1243">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive&#160;<br/>(‘latent’) tuberculosis. This evaluation should include a detailed medical history with personal history&#160;<br/>of tuberculosis or possible previous contact with tuberculosis and previous and/or current&#160;<br/>immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray,&#160;<br/>should be performed in all patients (local recommendations may apply). It is recommended that the&#160;<br/>conduct of these tests should be recorded in the&#160;Patient&#160;Card. Prescribers are reminded of the risk of&#160;<br/>false negative tuberculin skin test results, especially in patients who are severely ill&#160;or&#160;<br/>immunocompromised.</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft1244">If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (‘latent’)&#160;<br/>tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis&#160;<br/>therapy before the initiation of Enbrel, and in accordance with local recommendations. In this&#160;<br/>situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft1244">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis&#160;<br/>(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft1242">Hepatitis B reactivation</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft1243">Reactivation of hepatitis B in patients who&#160;were previously infected with the&#160;hepatitis B virus (HBV)&#160;<br/>and had received concomitant&#160;TNF-antagonists, including Enbrel, has been reported.&#160;This&#160;includes&#160;<br/>reports of reactivation of&#160;hepatitis B&#160;in patients who were anti-HBc positive but HBsAg negative.<br/>Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who&#160;<br/>test positive for HBV infection, consultation with a physician with expertise in the treatment of&#160;<br/>hepatitis B is recommended.&#160;Caution should be exercised when administering Enbrel&#160;in&#160;patients&#160;</p>
</div>
<!-- Page 125 -->
<a name="125"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page125-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1250">125</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1254">previously infected with&#160;HBV.&#160;These&#160;patients should be monitored for signs and symptoms of active&#160;<br/>HBV infection&#160;throughout therapy and for several weeks following termination of therapy.&#160;Adequate&#160;<br/>data from treating patients infected with&#160;HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be&#160;<br/>stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1252">Worsening of hepatitis C</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1254">There have been reports of worsening&#160;of hepatitis C in patients receiving Enbrel.&#160;Enbrel should be&#160;<br/>used with caution in patients with a history of hepatitis C.</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft1252">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1254">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of&#160;serious&#160;<br/>infections and neutropenia compared to Enbrel alone. This combination has not demonstrated&#160;<br/>increased clinical benefit. Thus, the combined use of Enbrel and anakinra is not recommended (see&#160;<br/>sections 4.5 and 4.8).</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft1252">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft1254">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see&#160;section 4.5).</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft1252">Allergic reactions</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft1254">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic&#160;<br/>reactions have included angioedema and urticaria; serious reactions have occurred. If any serious&#160;<br/>allergic or&#160;anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and&#160;<br/>appropriate therapy initiated.</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft1253">The rubber tip cap (closure) of the diluent syringe contains latex (dry natural rubber) that may cause&#160;<br/>hypersensitivity reactions when handled by, or when Enbrel is administered to, persons with known or&#160;<br/>possible latex sensitivity.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1252">Immunosuppression</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft1253">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections&#160;<br/>and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a&#160;<br/>study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector cell populations.</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft1254">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of&#160;<br/>aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella&#160;<br/>virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with&#160;<br/>Varicella Zoster Immune Globulin.</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft1252">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1252">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:1097px;left:106px;white-space:nowrap" class="ft1254"><i>Solid and haematopoietic malignancies (excluding skin cancers)<br/></i>Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been&#160;<br/>received in the postmarketing period (see section 4.8).&#160;</p>
</div>
<!-- Page 126 -->
<a name="126"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page126-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1260">126</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1264">In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been&#160;<br/>observed among patients receiving a TNF-antagonist compared with control patients. However, the&#160;<br/>occurrence was rare, and the follow-up period of placebo patients was shorter than for patients&#160;<br/>receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported&#160;<br/>in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and&#160;<br/>leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates risk estimation.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1264">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other&#160;<br/>haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded.&#160;<br/>Caution should be exercised when considering TNF-antagonist therapy for patients with a history of&#160;<br/>malignancy or when considering continuing treatment in patients who develop a malignancy.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft1263">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤&#160;18&#160;years of age), including&#160;<br/>Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases&#160;<br/>represented a variety of different malignancies and included rare malignancies typically associated&#160;<br/>with immunosuppression. A risk for the development of malignancies in children and adolescents&#160;<br/>treated with TNF-antagonists cannot be excluded.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft1264"><i>Skin&#160;cancers<br/></i>Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with&#160;<br/>TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported&#160;<br/>very infrequently in patients treated with Enbrel. Periodic&#160;skin examination is recommended for all&#160;<br/>patients, particularly those with risk factors for skin cancer.</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1264">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients&#160;<br/>receiving Enbrel compared with control patients, particularly in patients with psoriasis.</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft1262">Vaccinations</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft1263">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary&#160;<br/>transmission of infection by live vaccines in patients receiving Enbrel. In a double-blind,&#160;<br/>placebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also&#160;<br/>received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic&#160;<br/>arthritis patients receiving Enbrel were able to mount effective B-cell immune response to&#160;<br/>pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients&#160;<br/>had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this&#160;<br/>is unknown.</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft1262">Autoantibody formation</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft1262">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft1262">Haematologic reactions</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft1264">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have&#160;<br/>been reported in&#160;patients treated with Enbrel. Caution should be exercised in patients being treated&#160;<br/>with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers&#160;<br/>should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or&#160;<br/>infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they&#160;<br/>should seek immediate medical advice. Such patients should be investigated urgently, including full&#160;<br/>blood count; if blood dyscrasias are confirmed,&#160;Enbrel should be discontinued.</p>
</div>
<!-- Page 127 -->
<a name="127"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page127-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1270">127</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1272">Neurological disorders</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1273">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see&#160;<br/>section 4.8).&#160;Additionally, there have been rare reports of peripheral demyelinating polyneuropathies&#160;<br/>(including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy,&#160;<br/>demyelinating polyneuropathy, and multifocal motor neuropathy).&#160;Although no clinical trials have&#160;<br/>been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other&#160;<br/>TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful&#160;<br/>risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel&#160;<br/>to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered&#160;<br/>to have an increased risk of developing demyelinating disease.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1272">Combination therapy</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft1274">In&#160;a controlled clinical trial of two years duration in adult rheumatoid arthritis patients, the&#160;<br/>combination of Enbrel and methotrexate did not result in unexpected safety findings, and the safety&#160;<br/>profile of Enbrel when given in combination with methotrexate&#160;was similar to the profiles reported in&#160;<br/>studies of Enbrel and methotrexate alone. Long-term studies to assess the safety of the combination&#160;<br/>are ongoing. The long-term safety of Enbrel in combination with other disease-modifying&#160;<br/>antirheumatic drugs (DMARD)&#160;has not been established.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft1274">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of&#160;<br/>psoriasis has not been studied.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft1272">Renal and hepatic impairment</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft1274">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal&#160;<br/>or hepatic impairment; clinical experience in such patients is limited.</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft1272">Congestive heart failure&#160;(Cardiac failure congestive)</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft1273">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF).&#160;<br/>There have been postmarketing reports of worsening of CHF, with and without identifiable&#160;<br/>precipitating factors, in patients taking Enbrel.&#160;There have also been rare (&lt;&#160;0.1%) reports of new&#160;<br/>onset CHF, including CHF in patients without known pre-existing cardiovascular disease.&#160;Some of&#160;<br/>these patients have been under 50&#160;years of age.&#160;Two large clinical trials evaluating the use of Enbrel in&#160;<br/>the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data&#160;<br/>from one of&#160;these trials suggest a possible tendency toward worsening CHF in those patients assigned&#160;<br/>to Enbrel treatment.&#160;</p>
<p style="position:absolute;top:870px;left:106px;white-space:nowrap" class="ft1272">Alcoholic hepatitis</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft1273">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or&#160;<br/>placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in&#160;<br/>patients treated with Enbrel was significantly higher after 6&#160;months. Consequently, Enbrel should not&#160;<br/>be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using&#160;<br/>Enbrel in patients who also have moderate to severe alcoholic hepatitis.</p>
<p style="position:absolute;top:1022px;left:106px;white-space:nowrap" class="ft1272">Wegener's granulomatosis</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1273">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard&#160;<br/>therapy (including&#160;cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of&#160;<br/>25&#160;months, has not shown Enbrel to be an effective treatment for Wegener’s granulomatosis. The&#160;<br/>incidence of non-cutaneous malignancies of various types was significantly higher&#160;in patients treated&#160;<br/>with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis.</p>
</div>
<!-- Page 128 -->
<a name="128"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page128-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1280">128</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1282">Hypoglycaemia in patients treated for diabetes</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1284">There have been reports of hypoglycaemia following initiation of Enbrel in&#160;patients receiving&#160;<br/>medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1282">Special populations</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1283"><i>Elderly<br/></i>In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no&#160;overall&#160;<br/>differences in adverse events, serious adverse events, and serious infections in patients age 65 or older&#160;<br/>who received Enbrel were observed compared with younger patients. However, caution should be&#160;<br/>exercised when treating the elderly and particular attention paid with respect to occurrence of&#160;<br/>infections.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft1285"><i>Paediatric population</i></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft1283"><i>Vaccinations&#160;<br/></i>It&#160;is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior&#160;to initiating Enbrel therapy (see Vaccinations,&#160;<br/>above).</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft1281"><b>4.5</b></p>
<p style="position:absolute;top:525px;left:149px;white-space:nowrap" class="ft1281"><b>Interaction with other medicinal products and other forms of interaction</b></p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft1282">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1284">Adult patients treated with Enbrel and anakinra were observed to have a higher rate&#160;of serious&#160;<br/>infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft1284">In addition, in a double-blind, placebo-controlled trial in adult patients receiving background&#160;<br/>methotrexate, patients treated with Enbrel and&#160;anakinra were observed to have a higher rate of serious&#160;<br/>infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The&#160;<br/>combination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not<br/>recommended.</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft1282">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft1284">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see section 4.4).&#160;</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft1282">Concurrent treatment with sulfasalazine&#160;</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft1284">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which&#160;<br/>Enbrel was added, patients in the combination group experienced a statistically significant decrease in&#160;<br/>mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The&#160;<br/>clinical significance of this interaction is unknown. Physicians should use caution when considering&#160;<br/>combination therapy&#160;with sulfasalazine.</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft1282">Non-interactions</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft1283">In clinical trials, no interactions have been observed when Enbrel was administered with&#160;<br/>glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs),&#160;<br/>analgesics, or methotrexate. See section 4.4 for vaccination advice.</p>
<p style="position:absolute;top:1153px;left:106px;white-space:nowrap" class="ft1282">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with&#160;</p>
</div>
<!-- Page 129 -->
<a name="129"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page129-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1290">129</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1292">methotrexate,&#160;digoxin or warfarin.</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1291"><b>4.6</b></p>
<p style="position:absolute;top:146px;left:149px;white-space:nowrap" class="ft1291"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1292">Women of childbearing potential</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1294">Women of childbearing potential should&#160;consider&#160;the&#160;use&#160;of&#160;appropriate contraception to avoid&#160;<br/>becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1292">Pregnancy&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1294">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the&#160;<br/>foetus or neonatal rat due to etanercept.&#160;The effects of etanercept on pregnancy outcomes have been&#160;<br/>investigated in two observational cohort studies. A&#160;higher rate of major birth defects was observed in&#160;<br/>one observational study comparing pregnancies exposed to etanercept (n=370) during the first&#160;<br/>trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds&#160;<br/>ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most&#160;<br/>commonly reported in the general population and no particular pattern of abnormalities was identified.&#160;<br/>No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed.&#160;In&#160;<br/>another observational multi-country registry study comparing the risk of adverse pregnancy outcomes&#160;<br/>in women exposed to etanercept&#160;during the first 90&#160;days of pregnancy (n=425)&#160;to those exposed to&#160;<br/>non-biologic drugs&#160;(n=3497), there was no observed increased risk of major birth defects (crude odds&#160;<br/>ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for&#160;<br/>country, maternal disease, parity, maternal age and smoking in early pregnancy).&#160;This study also&#160;<br/>showed no increased risks of minor birth defects,&#160;preterm birth, stillbirth, or infections in the first year&#160;<br/>of life&#160;for infants born to women exposed to etanercept during pregnancy.&#160;Enbrel should only be used&#160;<br/>during&#160;pregnancy&#160;if&#160;clearly needed.</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft1294">Etanercept crosses the placenta and has been detected in the serum of&#160;infants born to female patients&#160;<br/>treated with&#160;Enbrel&#160;during pregnancy. The clinical impact of this is unknown, however, infants may be&#160;<br/>at increased risk of infection. Administration of live vaccines to infants for 16&#160;weeks after the&#160;<br/>mother’s last dose of&#160;Enbrel&#160;is generally not recommended.</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft1292">Breast-feeding</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft1294">In lactating rats following subcutaneous administration, etanercept was excreted in the milk and&#160;<br/>detected in the serum of pups.&#160;Limited information from the published literature indicates etanercept&#160;<br/>has been detected at low levels in human milk.&#160;Etanercept could be considered for use during&#160;<br/>breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy&#160;<br/>for the woman.</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft1293">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely&#160;<br/>degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant&#160;<br/>are&#160;available. Therefore, the administration of live vaccines&#160;(e.g., BCG)&#160;to a breastfed infant when the&#160;<br/>mother is receiving etanercept&#160;could be considered 16 weeks after stopping breast-feeding (or at an&#160;<br/>earlier timepoint if the infant etanercept serum levels are undetectable).&#160;</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft1292">Fertility</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft1293">Preclinical data about peri-&#160;and postnatal toxicity of etanercept and of effects of etanercept on fertility&#160;<br/>and general reproductive performance are not available.</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft1291"><b>4.7</b></p>
<p style="position:absolute;top:1095px;left:149px;white-space:nowrap" class="ft1291"><b>Effects on ability to drive and use machines</b></p>
<p style="position:absolute;top:1133px;left:106px;white-space:nowrap" class="ft1292">Enbrel&#160;has no or negligible influence on the ability to drive&#160;and&#160;use machines.</p>
</div>
<!-- Page 130 -->
<a name="130"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page130-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1300">130</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1301"><b>4.8</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft1301"><b>Undesirable effects</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1302">Summary of the safety profile</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1305"><i>Paediatric population</i></p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft1304">Undesirable effects in paediatric patients with juvenile idiopathic arthritis<br/>In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in&#160;<br/>frequency and type to those seen in adult patients (see below,&#160;Undesirable effects in&#160;adults).&#160;<br/>Differences from adults and other special considerations&#160;are discussed in the following paragraphs.</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft1303">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18&#160;years&#160;<br/>were generally mild to moderate and consistent with those commonly seen in outpatient paediatric&#160;<br/>populations. Severe adverse events reported included varicella with signs and symptoms of aseptic&#160;<br/>meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis,&#160;<br/>depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic&#160;<br/>shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft1304">In one study in children with juvenile idiopathic arthritis aged 4 to 17&#160;years, 43 of 69 (62%) children&#160;<br/>experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and&#160;<br/>the frequency and severity of infections was similar in 58 patients completing 12&#160;months of open-label&#160;<br/>extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients&#160;<br/>were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the&#160;<br/>majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic&#160;<br/>arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients.&#160;<br/>These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per&#160;<br/>patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%,&#160;0.74 events per&#160;<br/>patient year).</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft1302">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft1303">Undesirable effects in paediatric patients with plaque psoriasis<br/>In a 48-week study in 211 children aged 4 to 17&#160;years with paediatric plaque psoriasis, the adverse&#160;<br/>events reported were similar to those seen in previous studies in adults with plaque psoriasis.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1305"><i>Adult population</i></p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft1303">Undesirable effects in&#160;adults<br/>The most commonly reported adverse reactions are injection&#160;site reactions (such as pain, swelling,&#160;<br/>itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections,&#160;<br/>bronchitis, bladder infections and skin infections),&#160;headache,&#160;allergic reactions, development of&#160;<br/>autoantibodies, itching, and fever.</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft1304">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect&#160;<br/>the immune system and their use may affect the body’s defenses against infection and cancer. Serious&#160;<br/>infections affect fewer than&#160;1 in 100 patients treated with Enbrel. Reports have included fatal and&#160;<br/>life-threatening infections and sepsis. Various malignancies have also been reported with use of&#160;<br/>Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma). &#160;</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft1304">Serious haematological, neurological and autoimmune reactions have also been reported. These&#160;<br/>include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral&#160;<br/>demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have&#160;<br/>been rare reports of lupus, lupus-related conditions, and vasculitis.</p>
</div>
<!-- Page 131 -->
<a name="131"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft13135{font-size:14px;line-height:16px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page131-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1310">131</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1312">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1313">The following list of adverse reactions is based on experience from clinical trials and on&#160;<br/>postmarketing experience.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1313">Within the organ system classes, adverse reactions are listed under headings of frequency (number of&#160;<br/>patients expected to experience the reaction), using the following categories: very common (≥&#160;1/10);&#160;<br/>common (≥&#160;1/100 to &lt;&#160;1/10); uncommon (≥&#160;1/1,000 to &lt;&#160;1/100); rare (≥&#160;1/10,000 to &lt;&#160;1/1,000); very&#160;<br/>rare (&lt;&#160;1/10,000); not known (cannot be estimated from the available data).</p>
<p style="position:absolute;top:298px;left:100px;white-space:nowrap" class="ft13112"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:298px;left:202px;white-space:nowrap" class="ft13112"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:298px;left:282px;white-space:nowrap" class="ft13112"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:298px;left:377px;white-space:nowrap" class="ft13112"><b>Uncommon<br/>≥&#160;1/1,000 to &lt;&#160;1/100</b></p>
<p style="position:absolute;top:298px;left:505px;white-space:nowrap" class="ft13112"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:298px;left:615px;white-space:nowrap" class="ft13112"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:298px;left:696px;white-space:nowrap" class="ft13112"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated from&#160;<br/>Available Data)</b></p>
<p style="position:absolute;top:361px;left:100px;white-space:nowrap" class="ft13113">Infections and&#160;<br/>infestations</p>
<p style="position:absolute;top:361px;left:202px;white-space:nowrap" class="ft13113">Infection&#160;<br/>(including&#160;<br/>upper&#160;<br/>respiratory&#160;<br/>tract&#160;<br/>infection,&#160;<br/>bronchitis,&#160;<br/>cystitis,&#160;<br/>skin&#160;<br/>infection)*</p>
<p style="position:absolute;top:361px;left:377px;white-space:nowrap" class="ft13113">Serious infections&#160;<br/>(including&#160;<br/>pneumonia,&#160;<br/>cellulitis,&#160;arthritis&#160;<br/>bacterial, sepsis&#160;and&#160;<br/>parasitic infection)*</p>
<p style="position:absolute;top:361px;left:505px;white-space:nowrap" class="ft13113">Tuberculosis,&#160;<br/>opportunistic&#160;<br/>infection<br/>(including&#160;<br/>invasive fungal,&#160;<br/>protozoal,&#160;<br/>bacterial,&#160;<br/>atypical&#160;<br/>mycobacterial,&#160;<br/>viral infections,<br/>and Legionella)*</p>
<p style="position:absolute;top:361px;left:696px;white-space:nowrap" class="ft13113">Hepatitis B&#160;<br/>reactivation,&#160;<br/>listeria</p>
<p style="position:absolute;top:533px;left:100px;white-space:nowrap" class="ft13113">Neoplasms&#160;<br/>benign,&#160;<br/>malignant and&#160;<br/>unspecified&#160;<br/>(including&#160;<br/>cysts and&#160;<br/>polyps)</p>
<p style="position:absolute;top:533px;left:377px;white-space:nowrap" class="ft13113">Non-melanoma skin&#160;<br/>cancers* (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:533px;left:505px;white-space:nowrap" class="ft13113">Malignant&#160;<br/>melanoma (see&#160;<br/>section 4.4),&#160;<br/>lymphoma,&#160;<br/>leukaemia&#160;</p>
<p style="position:absolute;top:533px;left:696px;white-space:nowrap" class="ft13113">Merkel cell&#160;<br/>carcinoma (see&#160;<br/>section 4.4),&#160;<br/>Kaposi’s sarcoma</p>
<p style="position:absolute;top:642px;left:100px;white-space:nowrap" class="ft13113">Blood and&#160;<br/>lymphatic&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:642px;left:377px;white-space:nowrap" class="ft13113">Thrombocytopenia,&#160;<br/>anaemia,&#160;<br/>leukopenia,&#160;<br/>neutropenia</p>
<p style="position:absolute;top:642px;left:505px;white-space:nowrap" class="ft13111">Pancytopenia*</p>
<p style="position:absolute;top:642px;left:615px;white-space:nowrap" class="ft13113">Aplastic&#160;<br/>anaemia*</p>
<p style="position:absolute;top:642px;left:696px;white-space:nowrap" class="ft13135">Histiocytosis&#160;<br/>haematophagic&#160;<br/>(macrophage&#160;<br/>activation&#160;<br/>syndrome)†</p>
<p style="position:absolute;top:722px;left:100px;white-space:nowrap" class="ft13113">Immune&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:722px;left:282px;white-space:nowrap" class="ft13113">Allergic&#160;<br/>reactions (see&#160;<br/>Skin and&#160;<br/>subcutaneous&#160;<br/>tissue&#160;<br/>disorders),&#160;<br/>autoantibody&#160;<br/>formation*</p>
<p style="position:absolute;top:722px;left:377px;white-space:nowrap" class="ft13113">Vasculitis&#160;<br/>(including&#160;anti-<br/>neutrophilic&#160;<br/>cytoplasmic antibody&#160;<br/>positive vasculitis)</p>
<p style="position:absolute;top:722px;left:505px;white-space:nowrap" class="ft13113">Serious&#160;<br/>allergic/anaphyla<br/>ctic reactions&#160;<br/>(including&#160;<br/>angioedema,&#160;<br/>bronchospasm),&#160;<br/>sarcoidosis</p>
<p style="position:absolute;top:722px;left:696px;white-space:nowrap" class="ft13113">Worsening of&#160;<br/>symptoms of&#160;<br/>dermatomyositis</p>
</div>
<!-- Page 132 -->
<a name="132"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page132-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1320">132</p>
<p style="position:absolute;top:109px;left:100px;white-space:nowrap" class="ft13212"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:202px;white-space:nowrap" class="ft13212"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:282px;white-space:nowrap" class="ft13212"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:377px;white-space:nowrap" class="ft13212"><b>Uncommon<br/>≥&#160;1/1,000 to &lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:505px;white-space:nowrap" class="ft13212"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:615px;white-space:nowrap" class="ft13212"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:696px;white-space:nowrap" class="ft13212"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated from&#160;<br/>Available Data)</b></p>
<p style="position:absolute;top:171px;left:100px;white-space:nowrap" class="ft13213">Nervous&#160;<br/>system&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:171px;left:202px;white-space:nowrap" class="ft13211">Headache</p>
<p style="position:absolute;top:171px;left:505px;white-space:nowrap" class="ft13213">CNS&#160;<br/>demyelinating&#160;<br/>events&#160;<br/>suggestive of&#160;<br/>multiple&#160;<br/>sclerosis or&#160;<br/>localised<br/>demyelinating&#160;<br/>conditions, such&#160;<br/>as optic neuritis&#160;<br/>and transverse&#160;<br/>myelitis (see&#160;<br/>section 4.4),&#160;<br/>peripheral&#160;<br/>demyelinating&#160;<br/>events, including&#160;<br/>Guillain-Barré&#160;<br/>syndrome,&#160;<br/>chronic&#160;<br/>inflammatory&#160;<br/>demyelinating&#160;<br/>polyneuropathy,&#160;<br/>demyelinating&#160;<br/>polyneuropathy,&#160;<br/>and multifocal<br/>motor&#160;<br/>neuropathy (see&#160;<br/>section 4.4),&#160;<br/>seizure</p>
<p style="position:absolute;top:622px;left:100px;white-space:nowrap" class="ft13211">Eye disorders&#160;</p>
<p style="position:absolute;top:622px;left:377px;white-space:nowrap" class="ft13211">Uveitis, scleritis</p>
<p style="position:absolute;top:638px;left:100px;white-space:nowrap" class="ft13213">Cardiac&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:638px;left:377px;white-space:nowrap" class="ft13213">Worsening of&#160;<br/>cardiac failure&#160;<br/>congestive (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:638px;left:505px;white-space:nowrap" class="ft13213">New onset&#160;<br/>cardiac failure&#160;<br/>congestive (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:701px;left:100px;white-space:nowrap" class="ft13213">Respiratory,&#160;<br/>thoracic, and&#160;<br/>mediastinal&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:701px;left:505px;white-space:nowrap" class="ft13213">Interstitial lung&#160;<br/>disease&#160;<br/>(including&#160;<br/>pneumonitis and&#160;<br/>pulmonary&#160;<br/>fibrosis)*</p>
<p style="position:absolute;top:795px;left:100px;white-space:nowrap" class="ft13213">Gastrointestinal&#160;<br/>disorders</p>
<p style="position:absolute;top:795px;left:377px;white-space:nowrap" class="ft13213">Inflammatory bowel&#160;<br/>disease</p>
<p style="position:absolute;top:827px;left:100px;white-space:nowrap" class="ft13213">Hepatobiliary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:827px;left:377px;white-space:nowrap" class="ft13213">Elevated liver&#160;<br/>enzymes*</p>
<p style="position:absolute;top:827px;left:505px;white-space:nowrap" class="ft13213">Autoimmune&#160;<br/>hepatitis*</p>
<p style="position:absolute;top:859px;left:100px;white-space:nowrap" class="ft13213">Skin and&#160;<br/>subcutaneous&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:859px;left:282px;white-space:nowrap" class="ft13211">Pruritus, rash</p>
<p style="position:absolute;top:859px;left:377px;white-space:nowrap" class="ft13213">Angioedema,&#160;<br/>psoriasis (including&#160;<br/>new onset or&#160;<br/>worsening and&#160;<br/>pustular, primarily&#160;<br/>palms and soles),&#160;<br/>urticaria,&#160;<br/>psoriasiform rash</p>
<p style="position:absolute;top:859px;left:505px;white-space:nowrap" class="ft13213">Stevens-Johnson&#160;<br/>syndrome,&#160;<br/>cutaneous&#160;<br/>vasculitis&#160;<br/>(including&#160;<br/>hypersensitivity&#160;<br/>vasculitis),&#160;<br/>erythema&#160;<br/>multiforme,&#160;<br/>lichenoid&#160;<br/>reactions</p>
<p style="position:absolute;top:859px;left:615px;white-space:nowrap" class="ft13213">Toxic&#160;<br/>epidermal&#160;<br/>necrolysis</p>
<p style="position:absolute;top:1030px;left:100px;white-space:nowrap" class="ft13213">Musculoskeleta<br/>l and&#160;<br/>connective&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:1030px;left:505px;white-space:nowrap" class="ft13213">Cutaneous lupus&#160;<br/>erythematosus,&#160;<br/>subacute&#160;<br/>cutaneous lupus&#160;<br/>erythematosus,&#160;<br/>lupus-like&#160;<br/>syndrome</p>
</div>
<!-- Page 133 -->
<a name="133"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page133-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1330">133</p>
<p style="position:absolute;top:109px;left:100px;white-space:nowrap" class="ft13312"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:202px;white-space:nowrap" class="ft13312"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:282px;white-space:nowrap" class="ft13312"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:377px;white-space:nowrap" class="ft13312"><b>Uncommon<br/>≥&#160;1/1,000 to &lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:505px;white-space:nowrap" class="ft13312"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:615px;white-space:nowrap" class="ft13312"><b>Very Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:696px;white-space:nowrap" class="ft13312"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated from&#160;<br/>Available Data)</b></p>
<p style="position:absolute;top:171px;left:100px;white-space:nowrap" class="ft13313">General&#160;<br/>disorders and&#160;<br/>administration&#160;<br/>site conditions&#160;</p>
<p style="position:absolute;top:171px;left:202px;white-space:nowrap" class="ft13313">Injection&#160;<br/>site&#160;<br/>reactions&#160;<br/>(including&#160;<br/>bleeding,&#160;<br/>bruising,&#160;<br/>erythema,&#160;<br/>itching,&#160;<br/>pain,&#160;<br/>swelling)*</p>
<p style="position:absolute;top:171px;left:282px;white-space:nowrap" class="ft13311">Pyrexia</p>
<p style="position:absolute;top:327px;left:100px;white-space:nowrap" class="ft13313">*see Description of selected adverse reactions, below.<br/>†Please see sub-section ‘Undesirable&#160;effects in paediatric patients with juvenile idiopathic arthritis’ above.</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft1332">Description of selected adverse reactions</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft1334"><i>Malignancies and lymphoproliferative disorders<br/></i>One hundred and twenty-nine (129) new malignancies of various types were observed in 4,114<br/>rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6&#160;years,&#160;<br/>including 231&#160;patients treated with Enbrel in combination with methotrexate in the 2-year&#160;<br/>active-controlled study. The observed rates and incidences in these clinical trials were similar to those&#160;<br/>expected for the population studied. A total of 2 malignancies were reported in clinical studies of&#160;<br/>approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical&#160;<br/>studies conducted for more than 2&#160;years with 351 ankylosing spondylitis patients, 6&#160;malignancies were&#160;<br/>reported in Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in&#160;<br/>double-blind and open-label studies of up to 2.5 years, 30&#160;malignancies and 43 nonmelanoma skin&#160;<br/>cancers were reported.</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft1334">In a group of 7,416&#160;patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing&#160;<br/>spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</p>
<p style="position:absolute;top:701px;left:106px;white-space:nowrap" class="ft1333">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been&#160;<br/>received in the postmarketing period (see section 4.4).</p>
<p style="position:absolute;top:758px;left:106px;white-space:nowrap" class="ft1333"><i>Injection site reactions<br/></i>Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly&#160;higher&#160;<br/>incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first&#160;<br/>month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of&#160;<br/>injection site reactions in the Enbrel treatment groups, and the majority of patients who were given&#160;<br/>treatment received topical preparations, such as corticosteroids, or oral antihistamines. Additionally,&#160;<br/>some patients developed recall injection site reactions characterised by a skin reaction at the most&#160;<br/>recent site of injection, along with the simultaneous appearance of injection site reactions at previous&#160;<br/>injection sites. These reactions were generally transient and did not recur with treatment.</p>
<p style="position:absolute;top:948px;left:106px;white-space:nowrap" class="ft1334">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with&#160;<br/>Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the&#160;<br/>first 12 weeks of treatment.</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft1333"><i>Serious infections<br/></i>In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or&#160;<br/>requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3%&#160;<br/>of rheumatoid arthritis patients treated with Enbrel for up to 48&#160;months. These included abscess (at&#160;<br/>various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis,&#160;<br/>endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection,&#160;<br/>osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin&#160;<br/>infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year&#160;</p>
</div>
<!-- Page 134 -->
<a name="134"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page134-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1340">134</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1343">active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or&#160;<br/>Enbrel in&#160;combination with methotrexate, the rates of serious infections were similar among the&#160;<br/>treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate&#160;<br/>could be associated with an increase in the rate of infections.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1343">There&#160;were no differences in rates of infection among patients treated with Enbrel and those treated&#160;<br/>with placebo for plaque psoriasis&#160;in placebo-controlled trials of up to 24 weeks duration. Serious&#160;<br/>infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia,&#160;<br/>cholecystitis, osteomyelitis, gastritis, appendicitis,&#160;<i>Streptococcal&#160;</i>fasciitis, myositis, septic shock,&#160;<br/>diverticulitis&#160;and abscess. In the double-blind and open-label psoriatic arthritis trials, 1&#160;patient reported&#160;<br/>a serious infection (pneumonia).</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1344">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include&#160;<br/>bacteria, mycobacteria (including&#160;tuberculosis), viruses and fungi. Some have occurred within a few&#160;<br/>weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes,&#160;<br/>congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis&#160;<br/>(see section&#160;4.4). Enbrel treatment may increase mortality in patients with established sepsis.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft1344">Opportunistic infections have been reported in association with Enbrel, including invasive fungal,&#160;<br/>parasitic (including&#160;protozoal),&#160;viral (including herpes zoster),&#160;bacterial (including&#160;<i>Listeria&#160;</i>and&#160;<br/><i>Legionella</i>), and atypical&#160;mycobacterial infections. In a pooled data set of clinical trials, the overall&#160;<br/>incidence of opportunistic infections was 0.09% for the 15,402&#160;subjects who received Enbrel. The&#160;<br/>exposure-adjusted rate was 0.06&#160;events per 100&#160;patient-years. In postmarketing experience,&#160;<br/>approximately half of all of the case reports of opportunistic infections worldwide were invasive&#160;<br/>fungal infections.&#160;The most commonly reported invasive fungal infections&#160;included&#160;<i>Candida,<br/>Pneumocystis,&#160;Aspergillus,&#160;</i>and&#160;<i>Histoplasma</i>. Invasive fungal infections accounted for more than half&#160;<br/>of the fatalities amongst patients who developed opportunistic infections. The majority of the reports&#160;<br/>with a fatal outcome were in patients with&#160;<i>Pneumocystis&#160;</i>pneumonia, unspecified systemic fungal&#160;<br/>infections,&#160;and aspergillosis (see section 4.4).</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft1348"><i>Autoantibodies<br/></i>Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid&#160;<br/>arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed&#160;<br/>new positive ANA (</p>
<p style="position:absolute;top:734px;left:240px;white-space:nowrap" class="ft13414">&#160;1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft1343">patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA&#160;<br/>antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4%&#160;<br/>of placebo-treated patients) and by&#160;<i>Crithidia luciliae&#160;</i>assay (3% of patients treated with Enbrel&#160;<br/>compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who&#160;<br/>developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.&#160;<br/>The impact of long-term treatment with Enbrel on the development of autoimmune diseases is&#160;<br/>unknown.</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft1344">There have been rare reports of patients, including rheumatoid factor positive&#160;patients, who have&#160;<br/>developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are&#160;<br/>compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft1343"><i>Pancytopenia and aplastic anaemia<br/></i>There have been&#160;postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal&#160;<br/>outcomes (see section 4.4).</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1344"><i>Interstitial lung disease<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47%&#160;</p>
</div>
<!-- Page 135 -->
<a name="135"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page135-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1350">135</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1354">(frequency uncommon).&#160;There have been postmarketing reports of interstitial lung disease (including&#160;<br/>pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1358"><i>Concurrent treatment with anakinra&#160;<br/></i>In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of&#160;<br/>serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed&#160;<br/>neutropenia (absolute neutrophil count&#160;</p>
<p style="position:absolute;top:221px;left:366px;white-space:nowrap" class="ft13514">&#160;1000/mm3). While neutropenic, one patient developed&#160;</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft1352">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft1354"><i>Elevated liver enzymes<br/></i>In&#160;the&#160;double-blind&#160;periods of&#160;controlled clinical trials of etanercept across all indications, the&#160;<br/>frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving&#160;<br/>etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In&#160;the double-blind&#160;<br/>periods of controlled clinical trials&#160;that allowed&#160;concomitant treatment with etanercept and&#160;<br/>methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was&#160;<br/>4.18% (frequency common).</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft1354"><i>Autoimmune hepatitis<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24%&#160;<br/>(frequency uncommon).</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft1352">Paediatric population</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft1352">See Summary of the safety profile, above.</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft1352">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft1353">Reporting suspected adverse reactions after authorisation&#160;of the medicinal product is important. It&#160;<br/>allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare&#160;<br/>professionals are asked to report any suspected adverse&#160;reactions&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1351"><b>4.9</b></p>
<p style="position:absolute;top:774px;left:149px;white-space:nowrap" class="ft1351"><b>Overdose</b></p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft1354">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The&#160;<br/>highest dose level evaluated has been an intravenous loading dose of 32&#160;mg/m2&#160;followed by&#160;<br/>subcutaneous doses of 16&#160;mg/m2&#160;administered twice weekly. One rheumatoid arthritis patient&#160;<br/>mistakenly self-administered 62&#160;mg Enbrel subcutaneously twice weekly for 3 weeks without&#160;<br/>experiencing undesirable effects. There is no known antidote to Enbrel.</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft1351"><b>5.</b></p>
<p style="position:absolute;top:945px;left:146px;white-space:nowrap" class="ft1351"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft1351"><b>5.1</b></p>
<p style="position:absolute;top:983px;left:149px;white-space:nowrap" class="ft1351"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft1354">Pharmacotherapeutic group: Immunosuppressants,&#160;Tumour Necrosis Factor alpha (TNF-α) inhibitors,&#160;<br/>ATC code:&#160;L04AB01</p>
<p style="position:absolute;top:1078px;left:106px;white-space:nowrap" class="ft1353">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid&#160;<br/>arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with&#160;<br/>psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque&#160;<br/>psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in&#160;<br/>psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of&#160;</p>
</div>
<!-- Page 136 -->
<a name="136"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page136-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1360">136</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1364">TNF binding to&#160;its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and&#160;<br/>lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the&#160;<br/>55-kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs&#160;<br/>exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF&#160;<br/>biological activity.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1363">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on&#160;<br/>cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher&#160;<br/>affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of&#160;<br/>TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion&#160;<br/>element in the construction of a dimeric receptor imparts a longer serum half-life.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1362">Mechanism of action</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft1363">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in&#160;<br/>plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by&#160;<br/>TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF&#160;<br/>binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF&#160;<br/>biologically inactive. Etanercept may also modulate biologic responses controlled by additional&#160;<br/>downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or&#160;<br/>regulated by TNF.</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft1362">Clinical efficacy and safety</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft1364">This section presents data from&#160;three&#160;studies&#160;in juvenile idiopathic arthritis, one study in paediatric&#160;<br/>patients with plaque psoriasis, four studies in adults with rheumatoid arthritis, and four studies in&#160;<br/>adults with plaque psoriasis.</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft1362">Paediatric population</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1368"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with&#160;<br/>polyarticular-course&#160;juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset&#160;<br/>types&#160;(polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to&#160;<br/>severely active polyarticular-course&#160;juvenile idiopathic arthritis refractory to, or intolerant of,&#160;<br/>methotrexate were enrolled; patients&#160;remained on a stable dose of a single nonsteroidal&#160;<br/>anti-inflammatory drug and/or prednisone (&lt;&#160;0.2&#160;mg/kg/day or 10&#160;mg maximum). In part 1, all patients&#160;<br/>received 0.4&#160;mg/kg (maximum 25&#160;mg per dose) Enbrel subcutaneously twice weekly. In part 2,&#160;<br/>patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for&#160;<br/>four months and assessed for disease flare. Responses were measured using the&#160;ACR Pedi 30, defined&#160;<br/>as&#160;</p>
<p style="position:absolute;top:868px;left:124px;white-space:nowrap" class="ft13614">&#160;30% improvement in at least three of six and&#160;&#160;30% worsening&#160;in no more than one of six JRA&#160;</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft1368">core set criteria, including active joint count, limitation of motion, physician and patient/parent global&#160;<br/>assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was&#160;<br/>defined as a&#160;</p>
<p style="position:absolute;top:926px;left:189px;white-space:nowrap" class="ft13614">&#160;30% worsening in three of six JRA core set criteria and&#160;&#160;30% improvement in not&#160;</p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft1362">more than one of the six JRA core set criteria and a minimum of two active joints.</p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft1363">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part&#160;2. In&#160;<br/>part 2, 6&#160;of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of&#160;<br/>26&#160;(77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was&#160;</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft1364">&#160;116&#160;days for patients who received Enbrel and 28&#160;days for patients who received placebo. Of&#160;<br/>patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the&#160;<br/>patients remaining on Enbrel continued to improve from month 3 through month 7, while those who&#160;<br/>received placebo did not improve.</p>
</div>
<!-- Page 137 -->
<a name="137"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page137-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1370">137</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1374">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of&#160;<br/>4&#160;years at time of enrolment) continued to receive Enbrel for up to 10 years.&#160;Rates of serious adverse&#160;<br/>events and serious infections&#160;did not increase with long-term&#160;exposure.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1373">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate&#160;<br/>monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18 years&#160;<br/>with juvenile&#160;idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more&#160;<br/>commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus&#160;<br/>2%), and the infections associated with etanercept use were of a more&#160;severe nature.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1374">In another open-label&#160;single-arm&#160;study&#160;(n=127),&#160;60&#160;patients with extended oligoarthritis&#160;(EO)&#160;<br/>(15&#160;patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged&#160;12 to 17 years old),&#160;38 patients&#160;<br/>with&#160;enthesitis-related arthritis (12 to 17 years old),&#160;and 29 patients with&#160;psoriatic arthritis (12 to&#160;<br/>17&#160;years old) were treated with Enbrel at a dose of 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose)&#160;<br/>administered weekly for 12 weeks. In each of the JIA subtypes, the&#160;majority of patients met ACR Pedi&#160;<br/>30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender&#160;<br/>joints and physician global assessment. The safety profile was consistent with that observed in other&#160;<br/>JIA studies.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1374">Of the&#160;127&#160;patients in the parent study, 109 participated in the open-label extension study and were&#160;<br/>followed for&#160;an additional&#160;8 years&#160;for a total of up to 10 years.&#160;At the end of the extension study,&#160;<br/>84/109 (77%) patients had completed the study; 27 (25%) while&#160;actively taking&#160;Enbrel, 7 (6%) had&#160;<br/>withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started&#160;Enbrel&#160;following an&#160;<br/>earlier withdrawal from treatment; and 45 (41%) had stopped&#160;Enbrel&#160;(but remained under&#160;<br/>observation);&#160;25/109 (23%) patients&#160;permanently discontinued from the&#160;study.&#160;Improvements in&#160;<br/>clinical status achieved in the parent study were generally maintained for all efficacy endpoints during&#160;<br/>the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-<br/>retreatment period once during the extension study based on investigator’s judgement of clinical&#160;<br/>response. 30&#160;patients entered the withdrawal period. 17&#160;patients were reported to have a flare (defined&#160;<br/>as&#160;≥&#160;30% worsening in at least 3 of the 6 ACR Pedi components with&#160;≥&#160;30% improvement in not more&#160;<br/>than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after&#160;<br/>Enbrel withdrawal was 190&#160;days. 13&#160;patients were&#160;re-treated and the median time to re-treatment from&#160;<br/>withdrawal was estimated as 274&#160;days. Due to the small number of data points, these results should be&#160;<br/>interpreted with caution.</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft1372">The safety profile was consistent with that observed in&#160;the parent study.</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft1373">Studies have not been done in patients with juvenile idiopathic&#160;arthritis to assess the effects of&#160;<br/>continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy.&#160;<br/>Additionally, studies have not been conducted to assess&#160;the effects of&#160;reducing the recommended dose&#160;<br/>of Enbrel following its long-term&#160;use in patients with JIA.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft1373"><i>Paediatric patients with plaque psoriasis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211&#160;<br/>paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by an sPGA&#160;<br/>score&#160;≥&#160;3, involving&#160;≥&#160;10% of the BSA, and PASI&#160;≥&#160;12). Eligible patients had a history of receiving&#160;<br/>phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</p>
<p style="position:absolute;top:1022px;left:106px;white-space:nowrap" class="ft1373">Patients received Enbrel 0.8&#160;mg/kg (up&#160;to 50&#160;mg) or placebo once weekly for 12 weeks. At week 12,&#160;<br/>more patients randomised to Enbrel had positive efficacy responses (e.g., PASI 75) than those&#160;<br/>randomised to placebo.</p>
</div>
<!-- Page 138 -->
<a name="138"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page138-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1380">138</p>
<p style="position:absolute;top:117px;left:261px;white-space:nowrap" class="ft1381"><b>Paediatric Plaque Psoriasis Outcomes at 12 Weeks</b></p>
<p style="position:absolute;top:145px;left:495px;white-space:nowrap" class="ft1381"><b>Enbrel</b></p>
<p style="position:absolute;top:164px;left:465px;white-space:nowrap" class="ft1381"><b>0.8&#160;mg/kg Once&#160;</b></p>
<p style="position:absolute;top:183px;left:493px;white-space:nowrap" class="ft1381"><b>Weekly</b></p>
<p style="position:absolute;top:202px;left:487px;white-space:nowrap" class="ft1381"><b>(N = 106)</b></p>
<p style="position:absolute;top:183px;left:647px;white-space:nowrap" class="ft1381"><b>Placebo</b></p>
<p style="position:absolute;top:202px;left:642px;white-space:nowrap" class="ft1381"><b>(N = 105)</b></p>
<p style="position:absolute;top:222px;left:136px;white-space:nowrap" class="ft1382">PASI 75, n (%)</p>
<p style="position:absolute;top:222px;left:486px;white-space:nowrap" class="ft1382">60 (57%)a</p>
<p style="position:absolute;top:222px;left:644px;white-space:nowrap" class="ft1382">12 (11%)</p>
<p style="position:absolute;top:241px;left:136px;white-space:nowrap" class="ft1382">PASI 50, n (%)</p>
<p style="position:absolute;top:241px;left:486px;white-space:nowrap" class="ft1382">79 (75%)a</p>
<p style="position:absolute;top:241px;left:644px;white-space:nowrap" class="ft1382">24 (23%)</p>
<p style="position:absolute;top:273px;left:136px;white-space:nowrap" class="ft1382">sPGA “clear” or “minimal”, n (%)</p>
<p style="position:absolute;top:273px;left:486px;white-space:nowrap" class="ft1382">56&#160;(53%)a</p>
<p style="position:absolute;top:273px;left:644px;white-space:nowrap" class="ft1382">14 (13%)</p>
<p style="position:absolute;top:292px;left:136px;white-space:nowrap" class="ft1384">Abbreviation: sPGA-static Physician Global Assessment<br/>a.&#160;p &lt; 0.0001 compared with placebo</p>
<p style="position:absolute;top:350px;left:106px;white-space:nowrap" class="ft1383">After&#160;the 12-week double-blind treatment period, all patients received Enbrel 0.8&#160;mg/kg (up to 50&#160;mg)&#160;<br/>once weekly for additional 24 weeks. Responses observed during the open-label period were similar to&#160;<br/>those observed in the double-blind period.</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft1384">During a randomised withdrawal period, significantly more patients re-randomised to placebo&#160;<br/>experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to&#160;<br/>Enbrel. With continued therapy, responses were maintained up to 48 weeks.</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft1384">The&#160;long-term safety and effectiveness of Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) once weekly was assessed in&#160;<br/>an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years beyond&#160;<br/>the 48 week study discussed above. Long-term experience&#160;with Enbrel was generally comparable to the&#160;<br/>original 48-week study and did not reveal any new safety findings.&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft1384"><i>Adult patients with rheumatoid arthritis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The&#160;<br/>study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least&#160;<br/>one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel or placebo were administered subcutaneously twice&#160;a week for 6&#160;consecutive months.&#160;<br/>The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis&#160;<br/>using American College of Rheumatology (ACR) response criteria.</p>
<p style="position:absolute;top:751px;left:106px;white-space:nowrap" class="ft1384">ACR 20 and 50 responses were higher in patients treated&#160;with Enbrel at 3 and 6&#160;months than in&#160;<br/>patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and&#160;<br/>6&#160;months, respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6,&#160;<br/>respectively; p&lt;0.01 Enbrel vs. placebo at all timepoints for both ACR 20 and ACR 50 responses).&#160;</p>
<p style="position:absolute;top:846px;left:106px;white-space:nowrap" class="ft1383">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month&#160;3 and&#160;<br/>month&#160;6&#160;compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel,&#160;<br/>the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly&#160;<br/>always occurred by 3 months. A dose response was seen; results with 10&#160;mg were intermediate&#160;<br/>between placebo and 25&#160;mg. Enbrel was significantly better than placebo in all components of the&#160;<br/>ACR criteria, as well as other measures of rheumatoid arthritis disease activity not included in the&#160;<br/>ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which&#160;<br/>included disability, vitality,&#160;mental health, general health status, and arthritis-associated health status&#160;<br/>subdomains, was administered every 3&#160;months during the trial. All subdomains of the HAQ were&#160;<br/>improved in patients treated with Enbrel compared to controls at 3 and 6&#160;months.&#160;</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft1384">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month.&#160;<br/>Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same&#160;<br/>magnitudes of responses as patients who received Enbrel without interruption of therapy based on&#160;<br/>results of&#160;open-label studies. Continued durable responses have been seen for up to&#160;10&#160;years in&#160;<br/>open-label extension treatment trials when patients received Enbrel without interruption.&#160;</p>
</div>
<!-- Page 139 -->
<a name="139"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page139-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1390">139</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1393">The efficacy of Enbrel was compared&#160;to methotrexate in a randomised, active-controlled study with&#160;<br/>blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid&#160;<br/>arthritis (&lt;&#160;3&#160;years duration) who had never received treatment with methotrexate. Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel were administered subcutaneously (SC) twice a week for up to 24&#160;months. Methotrexate&#160;<br/>doses were escalated from 7.5&#160;mg/week to a maximum of 20&#160;mg/week over the first 8&#160;weeks of the&#160;<br/>trial and continued for up to 24&#160;months. Clinical improvement, including onset of action within&#160;<br/>2&#160;weeks with Enbrel 25&#160;mg, was similar to that seen in the previous trials and was maintained for up to&#160;<br/>24&#160;months. At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to&#160;<br/>1.5. Treatment with Enbrel 25&#160;mg resulted in substantial improvement at 12&#160;months, with about 44%&#160;<br/>of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year&#160;2 of&#160;<br/>this study.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1393">In this study, structural joint damage was assessed&#160;radiographically and expressed as change in Total&#160;<br/>Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score.&#160;<br/>Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24&#160;months. The 10&#160;mg&#160;<br/>Enbrel dose had&#160;consistently less effect on structural damage than the 25&#160;mg dose. Enbrel 25&#160;mg was&#160;<br/>significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in&#160;<br/>TSS and JSN were not statistically significant between methotrexate and Enbrel 25&#160;mg. The results are&#160;<br/>shown in the figure below.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft13924"><b>Radiographic Progression: Comparison of Enbrel vs. Methotrexate in Patients with RA of&#160;<br/>&lt;&#160;3&#160;Years Duration</b></p>
<p style="position:absolute;top:700px;left:132px;white-space:nowrap" class="ft13917">C</p>
<p style="position:absolute;top:689px;left:132px;white-space:nowrap" class="ft13917">ha</p>
<p style="position:absolute;top:673px;left:132px;white-space:nowrap" class="ft13917">ng</p>
<p style="position:absolute;top:658px;left:132px;white-space:nowrap" class="ft13917">e&#160;</p>
<p style="position:absolute;top:646px;left:132px;white-space:nowrap" class="ft13917">fr</p>
<p style="position:absolute;top:636px;left:132px;white-space:nowrap" class="ft13917">om</p>
<p style="position:absolute;top:616px;left:132px;white-space:nowrap" class="ft13917">&#160;B</p>
<p style="position:absolute;top:602px;left:132px;white-space:nowrap" class="ft13917">as</p>
<p style="position:absolute;top:587px;left:132px;white-space:nowrap" class="ft13917">e</p>
<p style="position:absolute;top:579px;left:132px;white-space:nowrap" class="ft13917">lin</p>
<p style="position:absolute;top:565px;left:132px;white-space:nowrap" class="ft13917">e</p>
<p style="position:absolute;top:736px;left:145px;white-space:nowrap" class="ft13918"><b>0.0</b></p>
<p style="position:absolute;top:699px;left:145px;white-space:nowrap" class="ft13918"><b>0.5</b></p>
<p style="position:absolute;top:662px;left:145px;white-space:nowrap" class="ft13918"><b>1.0</b></p>
<p style="position:absolute;top:625px;left:145px;white-space:nowrap" class="ft13918"><b>1.5</b></p>
<p style="position:absolute;top:589px;left:145px;white-space:nowrap" class="ft13918"><b>2.0</b></p>
<p style="position:absolute;top:552px;left:145px;white-space:nowrap" class="ft13918"><b>2.5</b></p>
<p style="position:absolute;top:736px;left:485px;white-space:nowrap" class="ft13918"><b>0.0</b></p>
<p style="position:absolute;top:700px;left:485px;white-space:nowrap" class="ft13918"><b>0.5</b></p>
<p style="position:absolute;top:663px;left:485px;white-space:nowrap" class="ft13918"><b>1.0</b></p>
<p style="position:absolute;top:627px;left:485px;white-space:nowrap" class="ft13918"><b>1.5</b></p>
<p style="position:absolute;top:590px;left:485px;white-space:nowrap" class="ft13918"><b>2.0</b></p>
<p style="position:absolute;top:554px;left:485px;white-space:nowrap" class="ft13918"><b>2.5</b></p>
<p style="position:absolute;top:782px;left:434px;white-space:nowrap" class="ft13919"><b>MTX</b></p>
<p style="position:absolute;top:796px;left:435px;white-space:nowrap" class="ft13919"><b>Enbrel&#160;25 mg</b></p>
<p style="position:absolute;top:547px;left:252px;white-space:nowrap" class="ft13919"><b>12 Months</b></p>
<p style="position:absolute;top:547px;left:600px;white-space:nowrap" class="ft13919"><b>24 Months</b></p>
<p style="position:absolute;top:754px;left:222px;white-space:nowrap" class="ft13920"><b>TSS</b></p>
<p style="position:absolute;top:754px;left:269px;white-space:nowrap" class="ft13920"><b>Erosions</b></p>
<p style="position:absolute;top:755px;left:352px;white-space:nowrap" class="ft13920"><b>JSN</b></p>
<p style="position:absolute;top:756px;left:555px;white-space:nowrap" class="ft13920"><b>TSS</b></p>
<p style="position:absolute;top:756px;left:609px;white-space:nowrap" class="ft13920"><b>Erosions</b></p>
<p style="position:absolute;top:756px;left:690px;white-space:nowrap" class="ft13920"><b>JSN</b></p>
<p style="position:absolute;top:626px;left:209px;white-space:nowrap" class="ft13919"><b>1.3</b></p>
<p style="position:absolute;top:663px;left:233px;white-space:nowrap" class="ft13919"><b>0.8</b></p>
<p style="position:absolute;top:656px;left:277px;white-space:nowrap" class="ft13919"><b>0.9</b></p>
<p style="position:absolute;top:693px;left:301px;white-space:nowrap" class="ft13919"><b>0.4*</b></p>
<p style="position:absolute;top:693px;left:344px;white-space:nowrap" class="ft13919"><b>0.4&#160;0.4</b></p>
<p style="position:absolute;top:560px;left:549px;white-space:nowrap" class="ft13919"><b>2.2</b></p>
<p style="position:absolute;top:634px;left:573px;white-space:nowrap" class="ft13919"><b>1.2</b></p>
<p style="position:absolute;top:626px;left:616px;white-space:nowrap" class="ft13919"><b>1.3</b></p>
<p style="position:absolute;top:678px;left:639px;white-space:nowrap" class="ft13919"><b>0.6*</b></p>
<p style="position:absolute;top:656px;left:682px;white-space:nowrap" class="ft13919"><b>0.9</b></p>
<p style="position:absolute;top:678px;left:707px;white-space:nowrap" class="ft13919"><b>0.6</b></p>
<p style="position:absolute;top:823px;left:421px;white-space:nowrap" class="ft13919"><b>*p &lt; 0.05</b></p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft1393">In another active-controlled, double-blind, randomised&#160;study, clinical efficacy, safety, and&#160;<br/>radiographic progression in RA patients treated with Enbrel alone (25&#160;mg twice weekly), methotrexate&#160;<br/>alone (7.5 to 20&#160;mg&#160;weekly, median dose 20&#160;mg), and the combination of Enbrel and methotrexate&#160;<br/>initiated concurrently&#160;were compared in 682 adult patients with active rheumatoid arthritis of 6&#160;months&#160;<br/>to 20&#160;years duration (median 5&#160;years) who had a less than satisfactory response to at least 1 disease-<br/>modifying antirheumatic drug (DMARD) other than methotrexate.</p>
<p style="position:absolute;top:988px;left:106px;white-space:nowrap" class="ft1394">Patients&#160;in the Enbrel in combination with methotrexate therapy group had significantly higher&#160;<br/>ACR&#160;20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and&#160;<br/>52&#160;weeks than patients in either of the single therapy groups (results shown in table below).&#160;<br/>Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months.</p>
</div>
<!-- Page 140 -->
<a name="140"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page140-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1400">140</p>
<p style="position:absolute;top:108px;left:145px;white-space:nowrap" class="ft1401"><b>Clinical Efficacy Results at 12&#160;Months: Comparison of Enbrel vs. Methotrexate vs.&#160;</b></p>
<p style="position:absolute;top:127px;left:160px;white-space:nowrap" class="ft1401"><b>Enbrel in Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To&#160;</b></p>
<p style="position:absolute;top:146px;left:371px;white-space:nowrap" class="ft1401"><b>20&#160;Years Duration</b></p>
<p style="position:absolute;top:184px;left:139px;white-space:nowrap" class="ft1401"><b>Endpoint</b></p>
<p style="position:absolute;top:184px;left:298px;white-space:nowrap" class="ft1402">Methotrexate</p>
<p style="position:absolute;top:203px;left:307px;white-space:nowrap" class="ft1402">(n =&#160;228)</p>
<p style="position:absolute;top:184px;left:464px;white-space:nowrap" class="ft1402">Enbrel</p>
<p style="position:absolute;top:203px;left:451px;white-space:nowrap" class="ft1402">(n = 223)</p>
<p style="position:absolute;top:165px;left:620px;white-space:nowrap" class="ft1402">Enbrel +</p>
<p style="position:absolute;top:184px;left:601px;white-space:nowrap" class="ft1402">Methotrexate</p>
<p style="position:absolute;top:203px;left:614px;white-space:nowrap" class="ft1402">(n = 231)</p>
<p style="position:absolute;top:242px;left:139px;white-space:nowrap" class="ft1401"><b>ACR Responses</b>a</p>
<p style="position:absolute;top:261px;left:168px;white-space:nowrap" class="ft1402">ACR 20</p>
<p style="position:absolute;top:262px;left:320px;white-space:nowrap" class="ft1402">58.8%</p>
<p style="position:absolute;top:262px;left:464px;white-space:nowrap" class="ft1402">65.5%</p>
<p style="position:absolute;top:262px;left:619px;white-space:nowrap" class="ft1402">74.5%&#160;<b>†,</b></p>
<p style="position:absolute;top:281px;left:168px;white-space:nowrap" class="ft1402">ACR 50</p>
<p style="position:absolute;top:282px;left:320px;white-space:nowrap" class="ft1402">36.4%</p>
<p style="position:absolute;top:282px;left:464px;white-space:nowrap" class="ft1402">43.0%</p>
<p style="position:absolute;top:282px;left:619px;white-space:nowrap" class="ft1402">63.2%&#160;<b>†,</b></p>
<p style="position:absolute;top:301px;left:168px;white-space:nowrap" class="ft1402">ACR 70</p>
<p style="position:absolute;top:302px;left:320px;white-space:nowrap" class="ft1402">16.7%</p>
<p style="position:absolute;top:302px;left:464px;white-space:nowrap" class="ft1402">22.0%</p>
<p style="position:absolute;top:303px;left:619px;white-space:nowrap" class="ft1402">39.8%&#160;<b>†,</b></p>
<p style="position:absolute;top:341px;left:139px;white-space:nowrap" class="ft1401"><b>DAS</b></p>
<p style="position:absolute;top:360px;left:168px;white-space:nowrap" class="ft1402">Baseline&#160;</p>
<p style="position:absolute;top:378px;left:139px;white-space:nowrap" class="ft1402">scoreb</p>
<p style="position:absolute;top:360px;left:331px;white-space:nowrap" class="ft1402">5.5</p>
<p style="position:absolute;top:360px;left:475px;white-space:nowrap" class="ft1402">5.7</p>
<p style="position:absolute;top:360px;left:639px;white-space:nowrap" class="ft1402">5.5</p>
<p style="position:absolute;top:398px;left:168px;white-space:nowrap" class="ft1402">Week 52&#160;</p>
<p style="position:absolute;top:416px;left:139px;white-space:nowrap" class="ft1402">scoreb</p>
<p style="position:absolute;top:398px;left:331px;white-space:nowrap" class="ft1402">3.0</p>
<p style="position:absolute;top:398px;left:475px;white-space:nowrap" class="ft1402">3.0</p>
<p style="position:absolute;top:399px;left:632px;white-space:nowrap" class="ft1402">2.3<b>†,</b></p>
<p style="position:absolute;top:436px;left:168px;white-space:nowrap" class="ft1402">Remissionc</p>
<p style="position:absolute;top:436px;left:327px;white-space:nowrap" class="ft1402">14%</p>
<p style="position:absolute;top:436px;left:471px;white-space:nowrap" class="ft1402">18%</p>
<p style="position:absolute;top:437px;left:627px;white-space:nowrap" class="ft1402">37%<b>†,</b></p>
<p style="position:absolute;top:475px;left:139px;white-space:nowrap" class="ft1401"><b>HAQ</b></p>
<p style="position:absolute;top:494px;left:166px;white-space:nowrap" class="ft1402">Baseline</p>
<p style="position:absolute;top:494px;left:331px;white-space:nowrap" class="ft1402">1.7</p>
<p style="position:absolute;top:494px;left:475px;white-space:nowrap" class="ft1402">1.7</p>
<p style="position:absolute;top:494px;left:639px;white-space:nowrap" class="ft1402">1.8</p>
<p style="position:absolute;top:513px;left:166px;white-space:nowrap" class="ft1402">Week 52</p>
<p style="position:absolute;top:513px;left:331px;white-space:nowrap" class="ft1402">1.1</p>
<p style="position:absolute;top:513px;left:475px;white-space:nowrap" class="ft1402">1.0</p>
<p style="position:absolute;top:514px;left:632px;white-space:nowrap" class="ft1402">0.8<b>†,</b></p>
<p style="position:absolute;top:533px;left:163px;white-space:nowrap" class="ft1408">a: Patients who did not complete 12 months in the study were&#160;considered to be non-<br/>responders.<br/>b: Values for Disease Activity Score (DAS) are means.<br/>c: Remission is defined as DAS &lt;1.6.<br/>Pairwise comparison p-values:&#160;†&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs.&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:628px;left:281px;white-space:nowrap" class="ft14014">&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs. Enbrel.</p>
<p style="position:absolute;top:668px;left:106px;white-space:nowrap" class="ft1404">Radiographic progression at 12&#160;months was significantly less in the Enbrel group than in the&#160;<br/>methotrexate group, while the combination was significantly better than either monotherapy at&#160;<br/>slowing radiographic progression (see figure below).</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft14023"><b>Radiographic Progression: Comparison of Enbrel vs. Methotrexate vs. Enbrel in Combination&#160;<br/>with Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration (12&#160;Month Results)</b></p>
<p style="position:absolute;top:1023px;left:206px;white-space:nowrap" class="ft14025">C</p>
<p style="position:absolute;top:1012px;left:206px;white-space:nowrap" class="ft14025">ha</p>
<p style="position:absolute;top:997px;left:206px;white-space:nowrap" class="ft14025">ng</p>
<p style="position:absolute;top:981px;left:206px;white-space:nowrap" class="ft14025">e&#160;</p>
<p style="position:absolute;top:969px;left:206px;white-space:nowrap" class="ft14025">fr</p>
<p style="position:absolute;top:960px;left:206px;white-space:nowrap" class="ft14025">om</p>
<p style="position:absolute;top:940px;left:206px;white-space:nowrap" class="ft14025">&#160;B</p>
<p style="position:absolute;top:927px;left:206px;white-space:nowrap" class="ft14025">as</p>
<p style="position:absolute;top:911px;left:206px;white-space:nowrap" class="ft14025">el</p>
<p style="position:absolute;top:900px;left:206px;white-space:nowrap" class="ft14025">in</p>
<p style="position:absolute;top:889px;left:206px;white-space:nowrap" class="ft14025">e</p>
<p style="position:absolute;top:1109px;left:232px;white-space:nowrap" class="ft1400">-1.0</p>
<p style="position:absolute;top:1071px;left:232px;white-space:nowrap" class="ft1400">-0.5</p>
<p style="position:absolute;top:1034px;left:236px;white-space:nowrap" class="ft1400">0.0</p>
<p style="position:absolute;top:996px;left:236px;white-space:nowrap" class="ft1400">0.5</p>
<p style="position:absolute;top:959px;left:236px;white-space:nowrap" class="ft1400">1.0</p>
<p style="position:absolute;top:921px;left:236px;white-space:nowrap" class="ft1400">1.5</p>
<p style="position:absolute;top:884px;left:236px;white-space:nowrap" class="ft1400">2.0</p>
<p style="position:absolute;top:846px;left:236px;white-space:nowrap" class="ft1400">2.5</p>
<p style="position:absolute;top:809px;left:236px;white-space:nowrap" class="ft1400">3.0</p>
<p style="position:absolute;top:822px;left:552px;white-space:nowrap" class="ft14026"><b>Methotrexate</b></p>
<p style="position:absolute;top:837px;left:551px;white-space:nowrap" class="ft14026"><b>Enbrel&#160;</b></p>
<p style="position:absolute;top:852px;left:552px;white-space:nowrap" class="ft14026"><b>Enbrel + Methotrexate</b></p>
<p style="position:absolute;top:812px;left:334px;white-space:nowrap" class="ft14026"><b>2.80</b></p>
<p style="position:absolute;top:983px;left:361px;white-space:nowrap" class="ft14026"><b>0.52*</b></p>
<p style="position:absolute;top:1086px;left:380px;white-space:nowrap" class="ft14026"><b>-0.54†</b>,</p>
<p style="position:absolute;top:896px;left:443px;white-space:nowrap" class="ft14026"><b>1.68</b></p>
<p style="position:absolute;top:1006px;left:469px;white-space:nowrap" class="ft14026"><b>0.21*</b></p>
<p style="position:absolute;top:1069px;left:489px;white-space:nowrap" class="ft14026"><b>-0.30†</b></p>
<p style="position:absolute;top:938px;left:551px;white-space:nowrap" class="ft14026"><b>1.12</b></p>
<p style="position:absolute;top:998px;left:577px;white-space:nowrap" class="ft14026"><b>0.32</b></p>
<p style="position:absolute;top:1062px;left:599px;white-space:nowrap" class="ft14026"><b>-0.23†</b>,</p>
<p style="position:absolute;top:1118px;left:352px;white-space:nowrap" class="ft14027"><b>TSS</b></p>
<p style="position:absolute;top:1117px;left:442px;white-space:nowrap" class="ft14027"><b>Erosions</b></p>
<p style="position:absolute;top:1117px;left:571px;white-space:nowrap" class="ft14027"><b>JSN</b></p>
</div>
<!-- Page 141 -->
<a name="141"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page141-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1410">141</p>
<p style="position:absolute;top:108px;left:233px;white-space:nowrap" class="ft1418">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs.&#160;<br/>methotrexate, † = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs.&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:145px;left:351px;white-space:nowrap" class="ft14114">&#160;= p&#160;&lt;&#160;0.05 for comparisons of Enbrel + methotrexate vs.&#160;</p>
<p style="position:absolute;top:166px;left:233px;white-space:nowrap" class="ft1412">Enbrel.</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft1413">Significant advantages for&#160;Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months. Similarly, the&#160;<br/>significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also&#160;<br/>observed&#160;after 24&#160;months.</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft1414">In an analysis in which all patients who dropped out of the study for any reason were considered to&#160;<br/>have progressed, the percentage of patients without progression (TSS change&#160;≤ 0.5) at 24&#160;months was&#160;<br/>higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and&#160;<br/>methotrexate alone groups&#160;(62%, 50%, and 36%, respectively; p&lt;0.05). The difference between&#160;<br/>Enbrel alone and methotrexate alone was also significant (p&lt;0.05). Among patients who completed a&#160;<br/>full 24&#160;months of therapy in the study, the non-progression rates were 78%, 70%, and 61%,&#160;<br/>respectively.</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft1413">The safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered once weekly were&#160;<br/>evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53&#160;<br/>patients received placebo, 214 patients received 50&#160;mg&#160;Enbrel once weekly and 153 patients received&#160;<br/>25&#160;mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens&#160;<br/>were comparable at&#160;week 8 in their effect on signs and symptoms of RA; data at week 16&#160;did not show&#160;<br/>comparability (non-inferiority) between the two regimens.</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft1414"><i>Adult patients with plaque psoriasis<br/></i>Enbrel is recommended for use in patients as defined in section 4.1. Patients&#160;who “failed to respond&#160;<br/>to” in the target population is defined by insufficient response (PASI&lt;50 or PGA less than good), or&#160;<br/>worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long&#160;<br/>duration to assess response with&#160;at least&#160;one&#160;of the three major systemic therapies as available.</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft1414">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis&#160;<br/>(responsive to other systemic therapies) has not been evaluated in studies directly&#160;comparing Enbrel&#160;<br/>with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four&#160;<br/>randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies&#160;<br/>was the proportion of patients in each&#160;treatment group who achieved the PASI 75 (i.e., at least a 75%&#160;<br/>improvement in the Psoriasis Area and Severity Index score from baseline) at 12&#160;weeks.</p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft1412">Study 1 was a Phase 2 study in patients with active, but clinically stable, plaque psoriasis involving&#160;</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft1418">&#160;10% of the body surface area who were&#160;&#160;18 years old. One hundred and twelve (112) patients were&#160;<br/>randomised to receive a dose of 25&#160;mg of Enbrel (n=57) or placebo (n=55) twice a week for 24&#160;weeks.</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft1413">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study&#160;<br/>1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel&#160;<br/>was administered at doses of 25&#160;mg once a week, 25&#160;mg twice a week or 50&#160;mg twice a week for&#160;<br/>6&#160;consecutive months. During the first 12 weeks of the double-blind treatment period, patients&#160;<br/>received placebo or one of the above three Enbrel doses. After 12&#160;weeks of treatment, patients in the&#160;<br/>placebo group began treatment with blinded Enbrel (25&#160;mg twice a week); patients in the active&#160;<br/>treatment groups continued to week&#160;24 on the dose to which they were originally randomised.</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1414">Study&#160;3 evaluated 583 patients and had the same inclusion criteria as study&#160;2. Patients in this study&#160;<br/>received a dose of 25&#160;mg or 50&#160;mg Enbrel,&#160;or placebo twice a week for 12&#160;weeks and then all patients&#160;<br/>received open-label 25&#160;mg&#160;Enbrel twice weekly for an additional 24&#160;weeks.</p>
</div>
<!-- Page 142 -->
<a name="142"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page142-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1420">142</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1424">Study&#160;4 evaluated 142 patients and had similar inclusion criteria to studies&#160;2 and 3. Patients in this&#160;<br/>study received a dose of 50&#160;mg Enbrel or placebo once weekly for 12&#160;weeks and then all patients&#160;<br/>received open-label 50&#160;mg&#160;Enbrel once weekly for an additional 12&#160;weeks.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1424">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75&#160;<br/>response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;0.0001). At 24 weeks,&#160;<br/>56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of&#160;<br/>placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</p>
<p style="position:absolute;top:278px;left:262px;white-space:nowrap" class="ft1421"><b>Responses of Patients with Psoriasis in Studies 2, 3 and 4</b></p>
<p style="position:absolute;top:416px;left:118px;white-space:nowrap" class="ft1422">Respons</p>
<p style="position:absolute;top:435px;left:127px;white-space:nowrap" class="ft1422">e (%)</p>
<p style="position:absolute;top:299px;left:273px;white-space:nowrap" class="ft1422">Study 2</p>
<p style="position:absolute;top:299px;left:489px;white-space:nowrap" class="ft1422">Study 3</p>
<p style="position:absolute;top:299px;left:691px;white-space:nowrap" class="ft1422">Study 4</p>
<p style="position:absolute;top:357px;left:191px;white-space:nowrap" class="ft1422">Placebo</p>
<p style="position:absolute;top:320px;left:262px;white-space:nowrap" class="ft1422">----------Enbrel---------</p>
<p style="position:absolute;top:357px;left:421px;white-space:nowrap" class="ft1422">Placebo</p>
<p style="position:absolute;top:320px;left:488px;white-space:nowrap" class="ft1422">--------Enbrel-------</p>
<p style="position:absolute;top:357px;left:623px;white-space:nowrap" class="ft1422">Placebo</p>
<p style="position:absolute;top:320px;left:696px;white-space:nowrap" class="ft1422">-------Enbrel------</p>
<p style="position:absolute;top:339px;left:270px;white-space:nowrap" class="ft1422">25&#160;mg&#160;</p>
<p style="position:absolute;top:357px;left:275px;white-space:nowrap" class="ft1422">BIW</p>
<p style="position:absolute;top:339px;left:351px;white-space:nowrap" class="ft1422">50&#160;mg&#160;</p>
<p style="position:absolute;top:357px;left:356px;white-space:nowrap" class="ft1422">BIW</p>
<p style="position:absolute;top:339px;left:493px;white-space:nowrap" class="ft1422">25&#160;mg</p>
<p style="position:absolute;top:357px;left:497px;white-space:nowrap" class="ft1422">BIW</p>
<p style="position:absolute;top:339px;left:561px;white-space:nowrap" class="ft1422">50&#160;mg</p>
<p style="position:absolute;top:357px;left:565px;white-space:nowrap" class="ft1422">BIW</p>
<p style="position:absolute;top:339px;left:696px;white-space:nowrap" class="ft1422">50&#160;mg&#160;</p>
<p style="position:absolute;top:357px;left:702px;white-space:nowrap" class="ft1422">QW</p>
<p style="position:absolute;top:339px;left:763px;white-space:nowrap" class="ft1422">50&#160;mg</p>
<p style="position:absolute;top:357px;left:769px;white-space:nowrap" class="ft1422">QW</p>
<p style="position:absolute;top:377px;left:192px;white-space:nowrap" class="ft1422">n = 166</p>
<p style="position:absolute;top:395px;left:196px;white-space:nowrap" class="ft1422">wk 12</p>
<p style="position:absolute;top:377px;left:260px;white-space:nowrap" class="ft1422">n =&#160;</p>
<p style="position:absolute;top:395px;left:258px;white-space:nowrap" class="ft1422">162</p>
<p style="position:absolute;top:414px;left:260px;white-space:nowrap" class="ft1422">wk&#160;</p>
<p style="position:absolute;top:433px;left:262px;white-space:nowrap" class="ft1422">12</p>
<p style="position:absolute;top:377px;left:300px;white-space:nowrap" class="ft1422">n =&#160;</p>
<p style="position:absolute;top:395px;left:298px;white-space:nowrap" class="ft1422">162</p>
<p style="position:absolute;top:414px;left:301px;white-space:nowrap" class="ft1424">wk&#160;<br/>24a</p>
<p style="position:absolute;top:377px;left:341px;white-space:nowrap" class="ft1422">n =&#160;</p>
<p style="position:absolute;top:395px;left:339px;white-space:nowrap" class="ft1422">164</p>
<p style="position:absolute;top:414px;left:341px;white-space:nowrap" class="ft1422">wk&#160;</p>
<p style="position:absolute;top:433px;left:343px;white-space:nowrap" class="ft1422">12</p>
<p style="position:absolute;top:377px;left:381px;white-space:nowrap" class="ft1422">n =&#160;</p>
<p style="position:absolute;top:395px;left:379px;white-space:nowrap" class="ft1422">164</p>
<p style="position:absolute;top:414px;left:382px;white-space:nowrap" class="ft1424">wk&#160;<br/>24a</p>
<p style="position:absolute;top:377px;left:422px;white-space:nowrap" class="ft1422">n = 193</p>
<p style="position:absolute;top:395px;left:426px;white-space:nowrap" class="ft1422">wk 12</p>
<p style="position:absolute;top:377px;left:489px;white-space:nowrap" class="ft1422">n = 196</p>
<p style="position:absolute;top:395px;left:493px;white-space:nowrap" class="ft1422">wk 12</p>
<p style="position:absolute;top:377px;left:557px;white-space:nowrap" class="ft1422">n = 196</p>
<p style="position:absolute;top:395px;left:561px;white-space:nowrap" class="ft1422">wk 12</p>
<p style="position:absolute;top:377px;left:628px;white-space:nowrap" class="ft1422">n = 46</p>
<p style="position:absolute;top:395px;left:628px;white-space:nowrap" class="ft1422">wk 12</p>
<p style="position:absolute;top:377px;left:695px;white-space:nowrap" class="ft1422">n = 96</p>
<p style="position:absolute;top:395px;left:696px;white-space:nowrap" class="ft1422">wk 12</p>
<p style="position:absolute;top:377px;left:763px;white-space:nowrap" class="ft1422">n = 90</p>
<p style="position:absolute;top:395px;left:761px;white-space:nowrap" class="ft1422">wk 24a</p>
<p style="position:absolute;top:455px;left:114px;white-space:nowrap" class="ft1422">PASI 50</p>
<p style="position:absolute;top:455px;left:208px;white-space:nowrap" class="ft1422">14</p>
<p style="position:absolute;top:455px;left:258px;white-space:nowrap" class="ft1422">58*</p>
<p style="position:absolute;top:455px;left:302px;white-space:nowrap" class="ft1422">70</p>
<p style="position:absolute;top:455px;left:339px;white-space:nowrap" class="ft1422">74*</p>
<p style="position:absolute;top:455px;left:383px;white-space:nowrap" class="ft1422">77</p>
<p style="position:absolute;top:455px;left:441px;white-space:nowrap" class="ft1422">9</p>
<p style="position:absolute;top:455px;left:501px;white-space:nowrap" class="ft1422">64*</p>
<p style="position:absolute;top:455px;left:568px;white-space:nowrap" class="ft1422">77*</p>
<p style="position:absolute;top:455px;left:644px;white-space:nowrap" class="ft1422">9</p>
<p style="position:absolute;top:455px;left:703px;white-space:nowrap" class="ft1422">69*</p>
<p style="position:absolute;top:455px;left:775px;white-space:nowrap" class="ft1422">83</p>
<p style="position:absolute;top:476px;left:114px;white-space:nowrap" class="ft1422">PASI 75</p>
<p style="position:absolute;top:476px;left:212px;white-space:nowrap" class="ft1422">4</p>
<p style="position:absolute;top:476px;left:258px;white-space:nowrap" class="ft1422">34*</p>
<p style="position:absolute;top:476px;left:302px;white-space:nowrap" class="ft1422">44</p>
<p style="position:absolute;top:476px;left:339px;white-space:nowrap" class="ft1422">49*</p>
<p style="position:absolute;top:476px;left:383px;white-space:nowrap" class="ft1422">59</p>
<p style="position:absolute;top:476px;left:441px;white-space:nowrap" class="ft1422">3</p>
<p style="position:absolute;top:476px;left:501px;white-space:nowrap" class="ft1422">34*</p>
<p style="position:absolute;top:476px;left:568px;white-space:nowrap" class="ft1422">49*</p>
<p style="position:absolute;top:476px;left:644px;white-space:nowrap" class="ft1422">2</p>
<p style="position:absolute;top:476px;left:703px;white-space:nowrap" class="ft1422">38*</p>
<p style="position:absolute;top:476px;left:775px;white-space:nowrap" class="ft1422">71</p>
<p style="position:absolute;top:501px;left:114px;white-space:nowrap" class="ft1424">DSGAb,&#160;<br/>clear or&#160;<br/>almost&#160;<br/>clear</p>
<p style="position:absolute;top:558px;left:212px;white-space:nowrap" class="ft1422">5</p>
<p style="position:absolute;top:558px;left:258px;white-space:nowrap" class="ft1422">34*</p>
<p style="position:absolute;top:558px;left:302px;white-space:nowrap" class="ft1422">39</p>
<p style="position:absolute;top:558px;left:339px;white-space:nowrap" class="ft1422">49*</p>
<p style="position:absolute;top:558px;left:383px;white-space:nowrap" class="ft1422">55</p>
<p style="position:absolute;top:558px;left:441px;white-space:nowrap" class="ft1422">4</p>
<p style="position:absolute;top:558px;left:501px;white-space:nowrap" class="ft1422">39*</p>
<p style="position:absolute;top:558px;left:568px;white-space:nowrap" class="ft1422">57*</p>
<p style="position:absolute;top:558px;left:644px;white-space:nowrap" class="ft1422">4</p>
<p style="position:absolute;top:558px;left:703px;white-space:nowrap" class="ft1422">39*</p>
<p style="position:absolute;top:558px;left:775px;white-space:nowrap" class="ft1422">64</p>
<p style="position:absolute;top:579px;left:114px;white-space:nowrap" class="ft1422">*p&#160;</p>
<p style="position:absolute;top:577px;left:135px;white-space:nowrap" class="ft14214">&#160;0.0001 compared with placebo</p>
<p style="position:absolute;top:598px;left:114px;white-space:nowrap" class="ft1424">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original&#160;<br/>placebo group began receiving Enbrel 25&#160;mg BIW or 50&#160;mg once&#160;weekly from week 13 to week 24.<br/>b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1424">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo&#160;<br/>were apparent at the&#160;time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft1428">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement&#160;<br/>of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the&#160;<br/>occurrence of rebound (PASI&#160;</p>
<p style="position:absolute;top:768px;left:304px;white-space:nowrap" class="ft14214">150% of baseline) and for the time to relapse (defined as a loss of at&#160;</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft1424">least half of the improvement achieved between baseline and week 24). During the withdrawal period,&#160;<br/>symptoms of psoriasis gradually&#160;returned, with a median time to disease relapse of 3 months. No&#160;<br/>rebound flare of disease and no psoriasis-related serious adverse events were observed. There was&#160;<br/>some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to&#160;<br/>treatment.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft1424">In study 3, the majority of patients (77%) who were initially randomised to 50&#160;mg twice weekly and&#160;<br/>had their Enbrel dose decreased at week 12 to 25&#160;mg twice weekly maintained their PASI 75 response&#160;<br/>through week 36. For patients who received 25&#160;mg twice weekly throughout the study, the PASI 75&#160;<br/>response continued to improve between weeks 12 and 36.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1424">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12&#160;<br/>(38%) compared to the placebo-treated group (2%)&#160;(p&lt;0.0001). For patients who received 50&#160;mg once&#160;<br/>weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI&#160;<br/>75 at week 24.</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft1424">In long-term&#160;(up to 34 months) open-label studies where Enbrel was given without interruption,&#160;<br/>clinical responses were sustained and safety was comparable to shorter-term studies.</p>
</div>
<!-- Page 143 -->
<a name="143"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page143-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1430">143</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1433">An analysis of clinical trial data&#160;did not reveal any&#160;baseline disease characteristics that would assist&#160;<br/>clinicians in selecting the most appropriate dosing option&#160;(intermittent or continuous). Consequently,&#160;<br/>the choice of intermittent or continuous therapy should be based upon physician judgment and&#160;<br/>individual patient needs.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1433"><i>Antibodies to Enbrel<br/></i>Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept.&#160;<br/>These antibodies have all been non-neutralising and are generally transient. There appears to be no&#160;<br/>correlation between antibody development and clinical response or adverse events.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft1434">In subjects treated with approved doses of etanercept in clinical trials for up to 12 months, cumulative&#160;<br/>rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5%&#160;<br/>of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with&#160;<br/>psoriasis, 9.7% of subjects with paediatric psoriasis, and&#160;4.8% of subjects with juvenile idiopathic&#160;<br/>arthritis.&#160;</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft1434">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to&#160;<br/>3.5&#160;years) increases over time, as expected. However, due to their transient nature, the incidence of&#160;<br/>antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis&#160;<br/>subjects and psoriasis subjects.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft1434">In a long-term psoriasis study in which patients received 50&#160;mg twice weekly for 96&#160;weeks, the&#160;<br/>incidence of antibodies observed at each assessment point was up to approximately 9%.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft1431"><b>5.2</b></p>
<p style="position:absolute;top:564px;left:149px;white-space:nowrap" class="ft1431"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1434">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA)&#160;<br/>method, which may detect ELISA-reactive degradation products as well as the parent compound.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft1432">Special populations</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft1434"><i>Renal impairment<br/></i>Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept&#160;<br/>to patients and volunteers, increased etanercept concentrations were not observed in patients with&#160;<br/>acute renal failure. The presence of renal impairment should not require a change in dosage.</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft1434"><i>Hepatic impairment<br/></i>Increased etanercept concentrations were not observed in patients with acute&#160;hepatic failure. The&#160;<br/>presence of hepatic impairment should not require a change in dosage.</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft1432">Paediatric population</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft1434"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>In a polyarticular-course&#160;juvenile idiopathic arthritis trial with Enbrel, 69 patients&#160;(aged&#160;4 to 17 years)&#160;<br/>were administered 0.4&#160;mg&#160;Enbrel/kg twice weekly for three months. Serum concentration profiles&#160;<br/>were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4 years of age)&#160;<br/>had reduced clearance (increased&#160;clearance when normalised by weight) compared with older children&#160;<br/>(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17 years of&#160;<br/>age) will have serum levels close to those seen in adults, younger children will have appreciably lower&#160;<br/>levels.</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft1433"><i>Paediatric patients with plaque psoriasis<br/></i>Patients with paediatric plaque psoriasis (aged 4 to 17 years) were administered 0.8&#160;mg/kg (up to a&#160;<br/>maximum dose of 50&#160;mg per week) of etanercept once weekly for up to 48 weeks. The mean serum&#160;<br/>steady-state trough concentrations ranged from 1.6&#160;to 2.1&#160;mcg/ml at weeks 12, 24, and 48. These mean&#160;<br/>concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed&#160;</p>
</div>
<!-- Page 144 -->
<a name="144"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page144-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1440">144</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1444">in patients with&#160;juvenile idiopathic arthritis&#160;(treated with 0.4&#160;mg/kg etanercept twice weekly, up to&#160;<br/>maximum dose of 50&#160;mg per week). These mean concentrations were similar to those seen in adult&#160;<br/>patients with plaque psoriasis treated with 25&#160;mg etanercept twice-weekly.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1442">Adults</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1448"><i>Absorption<br/></i>Etanercept&#160;is slowly absorbed from the site of subcutaneous injection, reaching maximum&#160;<br/>concentration approximately 48&#160;hours after a single dose. The absolute bioavailability is 76%. With&#160;<br/>twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high&#160;<br/>as those observed after single doses. After a single subcutaneous dose of 25&#160;mg Enbrel, the average&#160;<br/>maximum serum concentration observed in healthy volunteers was 1.65&#160;</p>
<p style="position:absolute;top:316px;left:585px;white-space:nowrap" class="ft14414">&#160;0.66&#160;g/ml, and the area&#160;</p>
<p style="position:absolute;top:338px;left:106px;white-space:nowrap" class="ft1442">under the curve was 235</p>
<p style="position:absolute;top:336px;left:272px;white-space:nowrap" class="ft14414">&#160;96.6&#160;ghr/ml.&#160;Mean serum concentration profiles at steady state in treated&#160;</p>
<p style="position:absolute;top:357px;left:106px;white-space:nowrap" class="ft1444">RA patients were Cmax&#160;of 2.4&#160;mg/l vs. 2.6&#160;mg/l, Cmin&#160;of 1.2&#160;mg/l vs. 1.4&#160;mg/l, and partial AUC of&#160;<br/>297&#160;mgh/l vs. 316&#160;mgh/l for 50&#160;mg Enbrel once weekly (n=21) vs. 25&#160;mg Enbrel twice weekly (n=16),&#160;<br/>respectively. In an open-label, single-dose, two-treatment, crossover study in healthy volunteers,&#160;<br/>etanercept administered as a single 50&#160;mg/ml injection was found to be bioequivalent to two&#160;<br/>simultaneous injections of 25&#160;mg/ml.</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft1448">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady&#160;<br/>state AUCs were 466</p>
<p style="position:absolute;top:489px;left:251px;white-space:nowrap" class="ft14414">ghr/ml and 474&#160;ghr/ml for 50&#160;mg Enbrel once weekly (N= 154) and 25&#160;mg&#160;</p>
<p style="position:absolute;top:510px;left:106px;white-space:nowrap" class="ft1442">twice weekly (N = 148), respectively.</p>
<p style="position:absolute;top:548px;left:106px;white-space:nowrap" class="ft1444"><i>Distribution<br/></i>A biexponential curve is&#160;required to describe the concentration time curve of etanercept. The central&#160;<br/>volume of distribution of etanercept is 7.6&#160;l, while the volume of distribution at steady-state is 10.4&#160;l.</p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft1444"><i>Elimination<br/></i>Etanercept is cleared slowly from the body. The half-life&#160;is long, approximately 70&#160;hours. Clearance is&#160;<br/>approximately 0.066&#160;l/hr in patients with rheumatoid arthritis, somewhat lower than the value of&#160;<br/>0.11&#160;l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid&#160;<br/>arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.<br/>There is no apparent pharmacokinetic difference between males and females.</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft1443"><i>Linearity<br/></i>Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance&#160;<br/>across the dosing range.</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft1441"><b>5.3</b></p>
<p style="position:absolute;top:833px;left:149px;white-space:nowrap" class="ft1441"><b>Preclinical safety data</b></p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft1443">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel&#160;<br/>was considered to be non-genotoxic from a battery of&#160;<i>in vitro&#160;</i>and&#160;<i>in vivo&#160;</i>studies. Carcinogenicity&#160;<br/>studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel&#160;<br/>due to the development of neutralising antibodies in rodents.</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft1443">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single&#160;<br/>subcutaneous dose of 2000&#160;mg/kg or a single intravenous dose of 1000&#160;mg/kg. Enbrel did not elicit&#160;<br/>dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous&#160;<br/>administration for 4 or 26&#160;consecutive weeks at&#160;a dose (15&#160;mg/kg) that resulted in AUC-based serum&#160;<br/>drug concentrations that were over 27-fold higher than that obtained in humans at the recommended&#160;<br/>dose of 25&#160;mg.</p>
</div>
<!-- Page 145 -->
<a name="145"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page145-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1450">145</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1451"><b>6.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft1451"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1451"><b>6.1</b></p>
<p style="position:absolute;top:146px;left:149px;white-space:nowrap" class="ft1451"><b>List of excipients</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1452">Powder</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1453">Mannitol (E421)<br/>Sucrose<br/>Trometamol</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1452">Solvent</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1452">Water for injections</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft1451"><b>6.2</b></p>
<p style="position:absolute;top:373px;left:149px;white-space:nowrap" class="ft1451"><b>Incompatibilities</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft1454">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1451"><b>6.3</b></p>
<p style="position:absolute;top:468px;left:149px;white-space:nowrap" class="ft1451"><b>Shelf life</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft1452">3 years.</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1458">From a microbiological point of view, the&#160;reconstituted medicinal product should be used&#160;<br/>immediately.&#160;Chemical and physical in-use stability has been demonstrated for 6 hours at temperatures&#160;<br/>not above 25</p>
<p style="position:absolute;top:581px;left:192px;white-space:nowrap" class="ft14514">C after reconstitution.</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft1451"><b>6.4</b></p>
<p style="position:absolute;top:621px;left:149px;white-space:nowrap" class="ft1451"><b>Special precautions for storage</b></p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft1452">Store in a refrigerator (2</p>
<p style="position:absolute;top:658px;left:267px;white-space:nowrap" class="ft14514">C&#160;-&#160;8C).&#160;Do not freeze.</p>
<p style="position:absolute;top:700px;left:106px;white-space:nowrap" class="ft1452">Enbrel may be stored at temperatures up to a maximum of 25</p>
<p style="position:absolute;top:698px;left:511px;white-space:nowrap" class="ft14514">&#160;C for a single period of up to four&#160;</p>
<p style="position:absolute;top:719px;left:106px;white-space:nowrap" class="ft1453">weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within&#160;<br/>four weeks of removal from refrigeration.</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft1452">For storage conditions of the reconstituted medicinal product, see section 6.3.</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft1451"><b>6.5</b></p>
<p style="position:absolute;top:813px;left:149px;white-space:nowrap" class="ft1451"><b>Nature and contents of container</b></p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft1454">Clear glass vial (2&#160;ml, type I glass) with rubber stopper, aluminium seal, and flip-off plastic cap.&#160;<br/>Enbrel is supplied with&#160;pre-filled syringes containing water for injection. The syringes are type I glass.<br/>The syringe cover contains dry natural rubber (latex) (see section 4.4).&#160;Cartons contain&#160;4 vials of&#160;<br/>Enbrel,&#160;4 pre-filled syringes of water for injections, 4 needles, 4 vial adaptors and 8 alcohol swabs. &#160;</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft1451"><b>6.6</b></p>
<p style="position:absolute;top:946px;left:149px;white-space:nowrap" class="ft1451"><b>Special precautions for disposal and other handling</b></p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft1452">Instructions for use and handling</p>
<p style="position:absolute;top:1023px;left:106px;white-space:nowrap" class="ft1454">Enbrel is reconstituted with 1 ml water for injections before use, and administered by subcutaneous&#160;<br/>injection. The solution should be clear and colourless to pale yellow&#160;or pale brown, with no lumps,&#160;<br/>flakes or particles. Some white foam may remain in the vial&#160;–&#160;this is normal. Enbrel should not be&#160;<br/>used if all the powder in the vial is not dissolved within 10 minutes. Start again with another vial.</p>
<p style="position:absolute;top:1118px;left:106px;white-space:nowrap" class="ft1454">Comprehensive instructions for the preparation&#160;and&#160;administration of the reconstituted Enbrel vial are&#160;<br/>given in the package leaflet, section 7, &#34;Instructions for preparation and giving an injection of Enbrel&#34;.</p>
</div>
<!-- Page 146 -->
<a name="146"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page146-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1460">146</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1464">Any unused&#160;medicinal&#160;product&#160;or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1461"><b>7.</b></p>
<p style="position:absolute;top:184px;left:146px;white-space:nowrap" class="ft1461"><b>MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1464">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1461"><b>8.</b></p>
<p style="position:absolute;top:335px;left:146px;white-space:nowrap" class="ft1461"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft1462">EU/1/99/126/022</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft1461"><b>9.</b></p>
<p style="position:absolute;top:430px;left:146px;white-space:nowrap" class="ft1461"><b>DATE OF&#160;FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1463">Date of first authorisation:&#160;03 February 2000<br/>Date of last renewal:&#160;26&#160;November&#160;2009</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1461"><b>10.</b></p>
<p style="position:absolute;top:544px;left:146px;white-space:nowrap" class="ft1461"><b>DATE OF REVISION OF THE TEXT</b></p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft1464">Detailed information on this&#160;medicinal&#160;product is available on the website of the&#160;European Medicines&#160;<br/>Agency&#160;<a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</p>
</div>
<!-- Page 147 -->
<a name="147"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page147-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1470">147</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1471"><b>1.</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft1471"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1473">Enbrel 25&#160;mg&#160;solution for injection in dose-dispenser cartridge<br/>Enbrel 50&#160;mg&#160;solution for injection in dose-dispenser cartridge</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1471"><b>2.</b></p>
<p style="position:absolute;top:222px;left:146px;white-space:nowrap" class="ft1471"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION</b></p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1472">Enbrel 25&#160;mg&#160;solution for injection in dose-dispenser cartridge</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1472">Each dose-dispenser cartridge&#160;contains 25&#160;mg of&#160;etanercept.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1472">Enbrel 50&#160;mg&#160;solution for injection in dose-dispenser cartridge</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft1472">Each&#160;dose-dispenser cartridge&#160;contains 50&#160;mg of&#160;etanercept.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft1474">Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant&#160;<br/>DNA technology in a Chinese hamster ovary (CHO) mammalian expression system.&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1472">For&#160;the&#160;full list of&#160;excipients, see section 6.1.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft1471"><b>3.</b></p>
<p style="position:absolute;top:525px;left:146px;white-space:nowrap" class="ft1471"><b>PHARMACEUTICAL FORM</b></p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft1472">Solution for injection.</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft1472">The solution is clear, and colourless&#160;to&#160;pale yellow&#160;or pale brown.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft1471"><b>4.</b></p>
<p style="position:absolute;top:658px;left:146px;white-space:nowrap" class="ft1471"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft1471"><b>4.1</b></p>
<p style="position:absolute;top:696px;left:149px;white-space:nowrap" class="ft1471"><b>Therapeutic indications</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft1472">Rheumatoid arthritis</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft1473">Enbrel in combination with&#160;methotrexate is indicated for the treatment of moderate to severe active&#160;<br/>rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including&#160;<br/>methotrexate (unless contraindicated), has been inadequate.</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft1473">Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued&#160;<br/>treatment with methotrexate is inappropriate.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft1474">Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults&#160;<br/>not previously treated with methotrexate.</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft1474">Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression&#160;<br/>of joint damage as measured by X-ray and to improve physical function.</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft1472">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft1473">Treatment of&#160;polyarthritis&#160;(rheumatoid factor positive or negative)&#160;and extended oligoarthritis in&#160;<br/>children and adolescents from the age of 2&#160;years who have had an inadequate response to, or who have&#160;<br/>proved intolerant of, methotrexate.&#160;</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft1473">Treatment of&#160;psoriatic arthritis in&#160;adolescents from the age of 12&#160;years who have had an inadequate&#160;<br/>response to, or who have proved intolerant of, methotrexate.</p>
</div>
<!-- Page 148 -->
<a name="148"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page148-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1480">148</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1484">Treatment of enthesitis-related arthritis in adolescents from the age&#160;of 12&#160;years who have had an&#160;<br/>inadequate response to, or who have proved intolerant of, conventional therapy.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1482">Psoriatic arthritis</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1484">Treatment of active and progressive psoriatic arthritis in adults when the response to previous&#160;<br/>disease-modifying antirheumatic drug therapy has been inadequate.&#160;Enbrel has been shown to improve&#160;<br/>physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral<br/>joint damage as measured by X-ray in patients with&#160;polyarticular&#160;symmetrical subtypes of the disease.</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft1482">Axial spondyloarthritis</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1483"><i>Ankylosing spondylitis (AS)<br/></i>Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to&#160;<br/>conventional therapy.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1484"><i>Non-radiographic axial spondyloarthritis<br/></i>Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of&#160;<br/>inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging&#160;<br/>(MRI) evidence, who have had an inadequate response&#160;to&#160;nonsteroidal anti-inflammatory drugs<br/>(NSAIDs).</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft1482">Plaque psoriasis</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft1484">Treatment of adults with&#160;moderate to severe plaque psoriasis who failed to respond to, or who have a&#160;<br/>contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or&#160;<br/>psoralen and ultraviolet-A light (PUVA) (see section 5.1).</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft1482">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft1484">Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6&#160;years who&#160;<br/>are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft1481"><b>4.2</b></p>
<p style="position:absolute;top:755px;left:149px;white-space:nowrap" class="ft1481"><b>Posology and method of administration</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft1484">Enbrel treatment should be initiated and supervised by specialist physicians experienced in the&#160;<br/>diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis,&#160;psoriatic arthritis,&#160;<br/>ankylosing spondylitis,&#160;non-radiographic axial spondyloarthritis,&#160;plaque psoriasis or paediatric plaque&#160;<br/>psoriasis. Patients treated with Enbrel should be given the Patient Card.</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft1484">The Enbrel&#160;dose-dispenser cartridge&#160;is available in&#160;25&#160;mg and&#160;50&#160;mg strengths. Other presentations of&#160;<br/>Enbrel are available in strengths&#160;of 10&#160;mg, 25&#160;mg,&#160;and 50&#160;mg.</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft1482">Posology</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft1483"><i>Rheumatoid arthritis<br/></i>25&#160;mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50&#160;mg administered&#160;<br/>once weekly has been shown to be safe and effective (see section 5.1).</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1484"><i>Psoriatic arthritis,&#160;ankylosing spondylitis&#160;and non-radiographic axial spondyloarthritis<br/></i>The recommended dose is 25&#160;mg Enbrel administered twice weekly, or 50&#160;mg administered once&#160;<br/>weekly.&#160;</p>
</div>
<!-- Page 149 -->
<a name="149"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page149-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1490">149</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1494">For all of the above indications, available data suggest that a clinical response is usually achieved&#160;<br/>within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not&#160;<br/>responding within this time period.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1494"><i>Plaque psoriasis<br/></i>The recommended dose of Enbrel is 25&#160;mg administered twice weekly or 50&#160;mg administered&#160;once&#160;<br/>weekly. Alternatively, 50&#160;mg given twice weekly may be used for up to 12&#160;weeks followed, if&#160;<br/>necessary, by a dose of 25&#160;mg twice weekly or 50&#160;mg&#160;once weekly. Treatment with Enbrel should&#160;<br/>continue until remission is achieved, for up to 24&#160;weeks.&#160;Continuous therapy beyond 24&#160;weeks may be&#160;<br/>appropriate for some adult patients (see section 5.1).&#160;Treatment should be discontinued in patients who&#160;<br/>show no response after 12&#160;weeks. If re-treatment with Enbrel is indicated, the same guidance on&#160;<br/>treatment duration should be followed. The dose should be 25&#160;mg twice weekly or 50&#160;mg once&#160;<br/>weekly.&#160;</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft1492">Special populations</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft1496"><i>Renal and hepatic impairment<br/></i>No dose adjustment is required.</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft1493"><i>Elderly<br/></i>No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of&#160;<br/>age.</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft1493"><i>Paediatric population<br/></i>The dosage of Enbrel is based on body weight&#160;for paediatric patients. Patients weighing less than&#160;<br/>62.5&#160;kg should be accurately dosed on a mg/kg basis using&#160;the&#160;powder and solvent for solution&#160;for&#160;<br/>injection&#160;presentations or the powder for solution for injection presentations&#160;(see below for dosing for<br/>specific indication). Patients weighing 62.5&#160;kg or more, may be dosed using a fixed-dose&#160;pre-filled&#160;<br/>syringe&#160;, pre-filled pen,&#160;or dose-dispenser cartridge.</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1492">The safety and&#160;efficacy of&#160;Enbrel&#160;in children aged less than 2 years has not been established.</p>
<p style="position:absolute;top:698px;left:107px;white-space:nowrap" class="ft1492">No&#160;data are available.</p>
<p style="position:absolute;top:736px;left:107px;white-space:nowrap" class="ft1495"><i>Juvenile idiopathic arthritis&#160;</i></p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft1494">The recommended dose is 0.4&#160;mg/kg (up to a maximum of 25&#160;mg per dose), given twice weekly as a&#160;<br/>subcutaneous injection with an interval of 3-4&#160;days between doses or 0.8&#160;mg/kg (up to a maximum of&#160;<br/>50&#160;mg per&#160;dose) given once weekly.&#160;Discontinuation of treatment should be considered in patients&#160;<br/>who show no response after 4 months.</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft1494">The 10&#160;mg&#160;vial strength may be more appropriate for administration to children with JIA below the&#160;<br/>weight of 25&#160;kg.</p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft1493">No formal&#160;clinical trials have been conducted in children aged 2 to 3 years. However, limited safety&#160;<br/>data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar&#160;<br/>to that seen in adults and children aged 4 years and older, when dosed every week with 0.8&#160;mg/kg&#160;<br/>subcutaneously (see section 5.1).</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft1493">There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile&#160;<br/>idiopathic arthritis.</p>
<p style="position:absolute;top:1059px;left:107px;white-space:nowrap" class="ft1492">Paediatric plaque psoriasis (age 6 years and above)</p>
<p style="position:absolute;top:1079px;left:106px;white-space:nowrap" class="ft1494">The recommended dose is 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly for up to&#160;<br/>24&#160;weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</p>
<p style="position:absolute;top:1135px;left:106px;white-space:nowrap" class="ft1493">If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed.&#160;<br/>The dose should be 0.8&#160;mg/kg (up to a maximum of 50&#160;mg per dose) once weekly.</p>
</div>
<!-- Page 150 -->
<a name="150"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page150-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1500">150</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1504">There is generally no applicable use of Enbrel in children aged below 6&#160;years in the indication plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1502">Method of administration</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1502">Subcutaneous use</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1504">The total content (0.5&#160;ml for the 25&#160;mg dose strength or 1&#160;ml for the 50&#160;mg&#160;dose strength) of the&#160;<br/>dose-dispenser cartridge should be administered using the SMARTCLIC&#160;injection device&#160;for a&#160;<br/>subcutaneous injection only. Suitable sites for&#160;injection would include the abdomen, upper thighs, or&#160;<br/>by caregiver only in the outer area of the upper arms.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft1504">Enbrel&#160;solution for injection in a dose-dispenser cartridge is intended for single-use in conjunction&#160;<br/>with the&#160;SMARTCLIC device. After proper&#160;training on the injection technique, patients may&#160;<br/>self-inject using the&#160;SMARTCLIC device&#160;with the single-use dose-dispenser cartridge if their&#160;<br/>physician&#160;determines that it is appropriate and&#160;will receive&#160;medical follow-up as necessary. The&#160;<br/>physician should&#160;discuss with the patient which injection presentation option is the most appropriate.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1503">For administration, the instructions for use at the end of the Package Leaflet and in the user manual&#160;<br/>provided with the SMARTCLIC device should be followed&#160;(see section&#160;6.6).&#160;Detailed instructions on&#160;<br/>unintentional dosing or scheduling variations, including missed doses, are provided in section 3 of the&#160;<br/>package leaflet.</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft1501"><b>4.3</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft1501"><b>Contraindications</b></p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft1502">Hypersensitivity to the active substance or to any of the excipients&#160;listed in&#160;section 6.1.</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft1502">Sepsis or risk of sepsis.</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft1504">Treatment with Enbrel should not be initiated in patients with active infections including chronic or&#160;<br/>localised infections.</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft1501"><b>4.4</b></p>
<p style="position:absolute;top:734px;left:149px;white-space:nowrap" class="ft1501"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft1504">In order to improve the traceability of biological medicinal products, the&#160;brand name&#160;and batch&#160;<br/>number of the administered product should be clearly recorded (or stated) in the patient file.</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft1502">Infections</p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft1503">Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into&#160;<br/>consideration that the mean elimination half-life of etanercept is approximately 70&#160;hours (range 7 to&#160;<br/>300&#160;hours).</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft1503">Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal&#160;<br/>infections,&#160;listeriosis and&#160;legionellosis,&#160;have been reported with the use of Enbrel (see section 4.8).&#160;<br/>These infections were due to bacteria, mycobacteria, fungi,&#160;viruses&#160;and parasites (including protozoa).&#160;<br/>In some cases, particular fungal and other opportunistic infections have not&#160;been recognised, resulting&#160;<br/>in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the&#160;<br/>patient’s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be&#160;<br/>considered.&#160;</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft1504">Patients who develop a new infection while undergoing treatment with Enbrel should be monitored&#160;<br/>closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The&#160;<br/>safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians&#160;<br/>should exercise caution when considering the use of Enbrel in patients with a history of recurring or&#160;</p>
</div>
<!-- Page 151 -->
<a name="151"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page151-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1510">151</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1514">chronic infections or with underlying conditions that may predispose patients to infections such as&#160;<br/>advanced or poorly controlled diabetes.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1512">Tuberculosis</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1514">Cases of active tuberculosis including miliary tuberculosis and tuberculosis with extra-pulmonary&#160;<br/>location have been reported in patients treated with Enbrel.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1513">Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive&#160;<br/>(‘latent’) tuberculosis. This evaluation should include a detailed medical history with personal history&#160;<br/>of tuberculosis or possible previous contact with tuberculosis and previous and/or current&#160;<br/>immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray,&#160;<br/>should be performed in all patients (local recommendations may apply). It is recommended that the&#160;<br/>conduct of these tests should be recorded in the&#160;Patient&#160;Card. Prescribers are reminded of the risk of&#160;<br/>false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1513">If active tuberculosis is diagnosed, Enbrel therapy must not&#160;be initiated. If inactive (‘latent’)&#160;<br/>tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis&#160;<br/>therapy before the initiation of Enbrel, and in accordance with local recommendations. In this&#160;<br/>situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft1513">All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis&#160;<br/>(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft1512">Hepatitis B reactivation</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft1514">Reactivation of hepatitis B in patients who&#160;were previously infected with the&#160;hepatitis B virus (HBV)&#160;<br/>and had received concomitant&#160;TNF-antagonists,&#160;including Enbrel,&#160;has been reported.&#160;This&#160;includes&#160;<br/>reports of reactivation of&#160;hepatitis B&#160;in patients who were anti-HBc positive but HBsAg negative.<br/>Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who&#160;<br/>test positive for HBV infection, consultation with a physician with expertise in the treatment of&#160;<br/>hepatitis B is recommended.&#160;Caution should be exercised when administering Enbrel&#160;in&#160;patients&#160;<br/>previously infected with&#160;HBV.&#160;These&#160;patients should be monitored for signs and symptoms of active&#160;<br/>HBV infection&#160;throughout therapy and for several weeks following termination of therapy.&#160;Adequate&#160;<br/>data from treating patients infected with&#160;HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy are not available. In patients who develop HBV infection,&#160;Enbrel should be&#160;<br/>stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft1512">Worsening of hepatitis C</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft1514">There have been reports of worsening of hepatitis C in patients receiving Enbrel.&#160;Enbrel should be&#160;<br/>used with caution in patients with a history of hepatitis C.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft1512">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft1514">Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious&#160;<br/>infections and neutropenia compared to Enbrel alone. This&#160;combination has not demonstrated&#160;<br/>increased clinical benefit. Thus the combined use of Enbrel and anakinra is not recommended (see&#160;<br/>sections 4.5 and 4.8).</p>
<p style="position:absolute;top:1078px;left:106px;white-space:nowrap" class="ft1512">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft1513">In clinical studies, concurrent administration of abatacept and&#160;Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see&#160;section 4.5).</p>
</div>
<!-- Page 152 -->
<a name="152"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page152-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1520">152</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1522">Allergic reactions</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1524">Allergic reactions associated with Enbrel administration have been reported commonly. Allergic&#160;<br/>reactions have included angioedema and urticaria; serious reactions have occurred. If any serious&#160;<br/>allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and&#160;<br/>appropriate therapy initiated.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1523">The needle cap of the dose-dispenser cartridge contains latex (dry natural rubber) that may cause&#160;<br/>hypersensitivity reactions when handled by, or when Enbrel is administered to persons with known or&#160;<br/>possible latex sensitivity.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1523">The needle cover of&#160;the pre-filled syringe in dose-dispenser cartridge contains latex (dry natural&#160;<br/>rubber). Patients or caregivers should contact their physician or healthcare professional before using&#160;<br/>Enbrel if the needle cover will be handled by or if Enbrel will be given&#160;to someone with a known or&#160;<br/>possible hypersensitivity (allergy) to latex.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1522">Immunosuppression</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft1523">The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections&#160;<br/>and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a&#160;<br/>study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector cell populations.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft1523">Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of&#160;<br/>aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella&#160;<br/>virus should temporarily discontinue&#160;Enbrel therapy and be considered for prophylactic treatment with&#160;<br/>Varicella Zoster Immune Globulin.</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft1522">The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft1522">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft1524"><i>Solid and haematopoietic malignancies (excluding skin cancers)<br/></i>Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been&#160;<br/>received in the postmarketing period (see section 4.8).&#160;</p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft1524">In the controlled portions of clinical trials of&#160;TNF-antagonists, more cases of lymphoma have been&#160;<br/>observed among patients receiving a TNF-antagonist compared with control patients. However, the&#160;<br/>occurrence was rare, and the follow-up period of placebo patients was shorter than for patients&#160;<br/>receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported&#160;<br/>in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and&#160;<br/>leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates risk estimation.</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft1524">Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other&#160;<br/>haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded.&#160;<br/>Caution should be exercised when considering TNF-antagonist therapy for patients with a history of&#160;<br/>malignancy or when considering continuing treatment in patients who develop a malignancy.</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft1524">Malignancies, some fatal, have been reported among children,&#160;adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤ 18 years of age), including&#160;<br/>Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases&#160;<br/>represented a variety&#160;of different malignancies and included rare malignancies typically associated&#160;</p>
</div>
<!-- Page 153 -->
<a name="153"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page153-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1530">153</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1534">with immunosuppression. A risk for the development of malignancies in children and adolescents&#160;<br/>treated with TNF-antagonists cannot be excluded.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1534"><i>Skin cancers<br/></i>Melanoma and&#160;non-melanoma skin cancer (NMSC) have been reported in patients treated with&#160;<br/>TNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported&#160;<br/>very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all&#160;<br/>patients, particularly those with risk factors for skin cancer.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft1533">Combining the results of controlled clinical trials, more cases of NMSC were observed in patients&#160;<br/>receiving Enbrel compared with control patients, particularly in patients&#160;with psoriasis.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1532">Vaccinations</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft1533">Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary&#160;<br/>transmission of infection by live vaccines in patients receiving Enbrel. In a double blind, placebo&#160;<br/>controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received&#160;<br/>a multivalent pneumococcal polysaccharide vaccine at week 4. In this study most psoriatic arthritis&#160;<br/>patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal&#160;<br/>polysaccharide vaccine, but titres in aggregate were moderately lower and few patients had two-fold&#160;<br/>rises in titres compared to patients not receiving Enbrel. The clinical significance of this is unknown.</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft1532">Autoantibody formation</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft1532">Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft1532">Haematologic reactions</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft1534">Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have&#160;<br/>been reported in patients treated with Enbrel. Caution should be exercised in patients being treated&#160;<br/>with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers&#160;<br/>should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or&#160;<br/>infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they&#160;<br/>should seek immediate medical advice. Such patients should be investigated urgently, including full&#160;<br/>blood count; if blood dyscrasias are confirmed,&#160;Enbrel should be discontinued.</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft1532">Neurological disorders</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft1534">There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see&#160;<br/>section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies&#160;<br/>(including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy,&#160;<br/>demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have&#160;<br/>been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other&#160;<br/>TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful&#160;<br/>risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel&#160;<br/>to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered&#160;<br/>to have an increased risk of developing demyelinating disease.</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft1532">Combination therapy</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1533">In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of&#160;<br/>Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel&#160;<br/>when&#160;given in combination with methotrexate was similar to the profiles reported in studies of Enbrel&#160;<br/>and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The&#160;<br/>long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs&#160;<br/>(DMARD) has not been established.</p>
</div>
<!-- Page 154 -->
<a name="154"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page154-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1540">154</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1544">The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of&#160;<br/>psoriasis has not been studied.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1542">Renal and hepatic impairment</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1544">Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal&#160;<br/>or hepatic impairment; clinical experience in such patients is limited.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft1542">Congestive heart failure&#160;(Cardiac failure congestive)</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft1543">Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF).&#160;<br/>There have been postmarketing reports of worsening of CHF, with and without identifiable&#160;<br/>precipitating factors, in patients taking Enbrel.&#160;There have also been rare (&lt;&#160;0.1%) reports of new&#160;<br/>onset CHF, including CHF in patients without known pre-existing cardiovascular disease.&#160;Some of&#160;<br/>these patients have been under 50&#160;years of age.&#160;Two large clinical trials evaluating the use of Enbrel in&#160;<br/>the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data&#160;<br/>from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned&#160;<br/>to Enbrel treatment.&#160;</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft1542">Alcoholic hepatitis</p>
<p style="position:absolute;top:527px;left:106px;white-space:nowrap" class="ft1543">In a phase II randomised placebo-controlled study of 48 hospitalised patients treated&#160;with Enbrel or&#160;<br/>placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in&#160;<br/>patients treated with Enbrel was significantly higher after 6&#160;months. Consequently, Enbrel should not&#160;<br/>be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using&#160;<br/>Enbrel in patients who also have moderate to severe alcoholic hepatitis.</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft1542">Wegener's granulomatosis</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1543">A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in&#160;addition to standard&#160;<br/>therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of&#160;<br/>25&#160;months, has not shown Enbrel to be an effective treatment for Wegener’s granulomatosis. The&#160;<br/>incidence of non-cutaneous malignancies of various types was significantly higher in patients treated&#160;<br/>with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis.</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft1542">Hypoglycaemia in patients treated for diabetes</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft1543">There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving&#160;<br/>medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft1542">Special populations</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft1544"><i>Elderly<br/></i>In the Phase 3 studies in rheumatoid arthritis, psoriatic&#160;arthritis, and ankylosing spondylitis, no overall&#160;<br/>differences in adverse events, serious adverse events, and serious infections in patients age 65 or older&#160;<br/>who received Enbrel were observed compared with younger patients. However, caution should be&#160;<br/>exercised when treating the elderly and particular attention paid with respect to occurrence of&#160;<br/>infections.</p>
</div>
<!-- Page 155 -->
<a name="155"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page155-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1550">155</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1555"><i>Paediatric population</i></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1553"><i>Vaccinations<br/></i>It&#160;is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations,&#160;<br/>above).</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1552">Sodium content</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1553">This medicinal product contains less than 1&#160;mmol sodium (23&#160;mg) per dosage unit. Patients on low&#160;<br/>sodium diets can be informed that this medicinal product is essentially ‘sodium-free’.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1551"><b>4.5</b></p>
<p style="position:absolute;top:335px;left:149px;white-space:nowrap" class="ft1551"><b>Interaction with other medicinal products and other forms of interaction</b></p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft1552">Concurrent treatment with anakinra&#160;</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft1554">Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft1553">In addition, in a double-blind placebo-controlled trial in adult patients receiving background&#160;<br/>methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious&#160;<br/>infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The&#160;<br/>combination Enbrel and anakinra has not demonstrated increased clinical benefit and is therefore not&#160;<br/>recommended.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft1552">Concurrent treatment with abatacept&#160;</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft1554">In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences&#160;<br/>of serious adverse events. This combination has not demonstrated increased clinical benefit; such use&#160;<br/>is not recommended (see section 4.4).&#160;</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft1552">Concurrent treatment with sulfasalazine&#160;</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft1554">In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which&#160;<br/>Enbrel was added, patients in the combination group experienced a statistically significant decrease in&#160;<br/>mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The&#160;<br/>clinical significance of this interaction is unknown. Physicians should use caution when considering&#160;<br/>combination therapy with sulfasalazine.</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft1552">Non-interactions</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft1553">In clinical trials, no interactions have been observed when Enbrel was administered with&#160;<br/>glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs),&#160;<br/>analgesics, or methotrexate. See section&#160;4.4 for vaccination advice.</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft1554">No clinically significant pharmacokinetic drug-drug interactions were observed in studies with&#160;<br/>methotrexate, digoxin or warfarin.</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft1551"><b>4.6</b></p>
<p style="position:absolute;top:1021px;left:149px;white-space:nowrap" class="ft1551"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1552">Women of childbearing potential</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft1553">Women of childbearing potential should&#160;consider&#160;the&#160;use&#160;of&#160;appropriate contraception to avoid&#160;<br/>becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</p>
</div>
<!-- Page 156 -->
<a name="156"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page156-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1560">156</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1562">Pregnancy&#160;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1564">Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the&#160;<br/>foetus or neonatal rat due to etanercept.&#160;The effects of etanercept on pregnancy outcomes have been&#160;<br/>investigated in two observational cohort studies. A&#160;higher rate of major birth defects was observed in&#160;<br/>one observational study comparing pregnancies exposed to etanercept (n=370) during the first&#160;<br/>trimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds&#160;<br/>ratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most&#160;<br/>commonly reported in the general population and no particular pattern of abnormalities was identified.&#160;<br/>No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed.&#160;In&#160;<br/>another observational multi-country registry study comparing the risk of adverse pregnancy outcomes&#160;<br/>in women exposed to etanercept&#160;during the first 90&#160;days of pregnancy (n=425)&#160;to those exposed to&#160;<br/>non-biologic drugs&#160;(n=3497), there was no observed increased risk of major birth defects (crude odds&#160;<br/>ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for&#160;<br/>country, maternal disease, parity, maternal age and smoking in early pregnancy).&#160;This study also&#160;<br/>showed no increased risks of minor birth defects,&#160;preterm birth, stillbirth, or infections in the first year&#160;<br/>of life&#160;for infants born to women exposed to etanercept during pregnancy.&#160;Enbrel should only be used&#160;<br/>during&#160;pregnancy&#160;if&#160;clearly needed.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1563">Etanercept crosses the placenta and has been detected in the serum of&#160;infants born to female patients&#160;<br/>treated with&#160;Enbrel&#160;during pregnancy. The clinical impact of this is unknown, however, infants may be&#160;<br/>at increased risk of infection. Administration of live vaccines to infants for 16&#160;weeks after the&#160;<br/>mother’s last dose of&#160;Enbrel&#160;is generally not recommended.</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft1562">Breast-feeding</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1563">In lactating rats following&#160;subcutaneous administration, etanercept was excreted in the milk and&#160;<br/>detected in the serum of pups.&#160;Limited information from the published literature indicates etanercept&#160;<br/>has been detected at low levels in human milk.&#160;Etanercept could be considered for use during&#160;<br/>breast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy&#160;<br/>for the woman.</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft1564">While systemic exposure in a breastfed infant is expected to be low because etanercept is largely&#160;<br/>degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant&#160;<br/>are&#160;available. Therefore, the administration of live vaccines&#160;(e.g., BCG)&#160;to a breastfed infant when the&#160;<br/>mother is receiving etanercept&#160;could be considered 16 weeks after stopping breast-feeding (or at an&#160;<br/>earlier timepoint if the infant etanercept serum levels are undetectable).</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft1562">Fertility</p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft1564">Preclinical data about peri-&#160;and postnatal toxicity of etanercept and of effects of etanercept on fertility&#160;<br/>and general reproductive performance are not available.</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft1561"><b>4.7</b></p>
<p style="position:absolute;top:924px;left:149px;white-space:nowrap" class="ft1561"><b>Effects on ability to drive and use machines</b></p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft1562">Enbrel&#160;has no or negligible influence on the ability to drive&#160;and&#160;use machines.</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft1561"><b>4.8</b></p>
<p style="position:absolute;top:1000px;left:149px;white-space:nowrap" class="ft1561"><b>Undesirable effects</b></p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft1562">Summary of the safety profile</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft1564">The most commonly reported adverse reactions are injection site reactions (such as pain, swelling,&#160;<br/>itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections,&#160;<br/>bronchitis, bladder infections and skin infections),&#160;headache,&#160;allergic reactions, development of&#160;<br/>autoantibodies, itching, and fever.</p>
</div>
<!-- Page 157 -->
<a name="157"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page157-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1570">157</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1574">Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect&#160;<br/>the immune system and their use may affect the body’s defenses against infection and cancer. Serious&#160;<br/>infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and&#160;<br/>life-threatening infections and sepsis. Various malignancies have also been reported with use of&#160;<br/>Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma). &#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1573">Serious haematological, neurological and autoimmune reactions have also been reported.&#160;These&#160;<br/>include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral&#160;<br/>demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have&#160;<br/>been rare reports of lupus, lupus-related conditions, and vasculitis.<br/>Tabulated list of adverse reactions</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1573">The following list of adverse reactions is based on experience from clinical trials and on&#160;<br/>postmarketing experience.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft1573">Within the organ system classes, adverse reactions are listed under headings&#160;of frequency (number of&#160;<br/>patients expected to experience the reaction), using the following categories: very common (≥&#160;1/10);&#160;<br/>common (≥&#160;1/100 to &lt;&#160;1/10); uncommon (≥&#160;1/1,000 to &lt;&#160;1/100); rare (≥&#160;1/10,000 to &lt;&#160;1/1,000); very&#160;<br/>rare (&lt;&#160;1/10,000); not known (cannot be estimated from the available data).</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft15712"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:488px;left:211px;white-space:nowrap" class="ft15712"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:488px;left:286px;white-space:nowrap" class="ft15712"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:488px;left:375px;white-space:nowrap" class="ft15712"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:488px;left:498px;white-space:nowrap" class="ft15712"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:488px;left:626px;white-space:nowrap" class="ft15712"><b>Very&#160;<br/>Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:488px;left:701px;white-space:nowrap" class="ft15712"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from&#160;<br/>Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft15713">Infections&#160;and&#160;<br/>infestations</p>
<p style="position:absolute;top:582px;left:211px;white-space:nowrap" class="ft15713">Infection&#160;<br/>(including&#160;<br/>upper&#160;<br/>respiratory&#160;<br/>tract&#160;<br/>infection,&#160;<br/>bronchitis,&#160;<br/>cystitis,&#160;<br/>skin&#160;<br/>infection)*</p>
<p style="position:absolute;top:582px;left:375px;white-space:nowrap" class="ft15713">Serious infections&#160;<br/>(including&#160;<br/>pneumonia,&#160;<br/>cellulitis, arthritis&#160;<br/>bacterial, sepsis<br/>and parasitic&#160;<br/>infection)*</p>
<p style="position:absolute;top:582px;left:498px;white-space:nowrap" class="ft15713">Tuberculosis,&#160;<br/>opportunistic&#160;<br/>infection&#160;(including&#160;<br/>invasive fungal,&#160;<br/>protozoal, bacterial,&#160;<br/>atypical&#160;<br/>mycobacterial, viral&#160;<br/>infections,&#160;and&#160;<br/>Legionella)*</p>
<p style="position:absolute;top:582px;left:701px;white-space:nowrap" class="ft15713">Hepatitis B&#160;<br/>reactivation,&#160;<br/>listeria</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft15713">Neoplasms&#160;<br/>benign,&#160;<br/>malignant and&#160;<br/>unspecified&#160;<br/>(including cysts&#160;<br/>and polyps)</p>
<p style="position:absolute;top:738px;left:375px;white-space:nowrap" class="ft15713">Non-melanoma&#160;<br/>skin cancers* (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:738px;left:498px;white-space:nowrap" class="ft15713">Malignant&#160;<br/>melanoma (see&#160;<br/>section 4.4),&#160;<br/>lymphoma,&#160;<br/>leukaemia&#160;</p>
<p style="position:absolute;top:738px;left:701px;white-space:nowrap" class="ft15713">Merkel cell&#160;<br/>carcinoma (see&#160;<br/>section 4.4),&#160;<br/>Kaposi’s&#160;<br/>sarcoma</p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft15713">Blood and&#160;<br/>lymphatic&#160;<br/>system&#160;<br/>disorders</p>
<p style="position:absolute;top:832px;left:375px;white-space:nowrap" class="ft15713">Thrombocytopenia,&#160;<br/>anaemia,&#160;<br/>leukopenia,&#160;<br/>neutropenia</p>
<p style="position:absolute;top:832px;left:498px;white-space:nowrap" class="ft15711">Pancytopenia*</p>
<p style="position:absolute;top:832px;left:626px;white-space:nowrap" class="ft15713">Aplastic&#160;<br/>anaemia*</p>
<p style="position:absolute;top:832px;left:701px;white-space:nowrap" class="ft15713">Histiocytosis&#160;<br/>haematophagic&#160;<br/>(macrophage&#160;<br/>activation&#160;<br/>syndrome)*</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft15713">Immune system&#160;<br/>disorders</p>
<p style="position:absolute;top:910px;left:286px;white-space:nowrap" class="ft15713">Allergic&#160;<br/>reactions&#160;<br/>(see Skin and&#160;<br/>subcutaneous&#160;<br/>tissue&#160;<br/>disorders),&#160;<br/>autoantibody&#160;<br/>formation*</p>
<p style="position:absolute;top:910px;left:375px;white-space:nowrap" class="ft15713">Vasculitis&#160;<br/>(including&#160;anti-<br/>neutrophilic&#160;<br/>cytoplasmic&#160;<br/>antibody positive&#160;<br/>vasculitis)</p>
<p style="position:absolute;top:910px;left:498px;white-space:nowrap" class="ft15713">Serious&#160;<br/>allergic/anaphylactic&#160;<br/>reactions (including&#160;<br/>angioedema,&#160;<br/>bronchospasm),&#160;<br/>sarcoidosis</p>
<p style="position:absolute;top:910px;left:701px;white-space:nowrap" class="ft15713">Worsening of&#160;<br/>symptoms of&#160;<br/>dermatomyositis</p>
</div>
<!-- Page 158 -->
<a name="158"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page158-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1580">158</p>
<p style="position:absolute;top:109px;left:106px;white-space:nowrap" class="ft15812"><b>System&#160;Organ&#160;<br/>Class</b></p>
<p style="position:absolute;top:109px;left:211px;white-space:nowrap" class="ft15812"><b>Very&#160;<br/>Common<br/>≥&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:286px;white-space:nowrap" class="ft15812"><b>Common<br/>≥&#160;1/100&#160;to&#160;<br/>&lt;&#160;1/10</b></p>
<p style="position:absolute;top:109px;left:375px;white-space:nowrap" class="ft15812"><b>Uncommon<br/>≥&#160;1/1,000 to&#160;<br/>&lt;&#160;1/100</b></p>
<p style="position:absolute;top:109px;left:498px;white-space:nowrap" class="ft15812"><b>Rare<br/>≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000</b></p>
<p style="position:absolute;top:109px;left:626px;white-space:nowrap" class="ft15812"><b>Very&#160;<br/>Rare<br/>&lt;&#160;1/10,000</b></p>
<p style="position:absolute;top:109px;left:701px;white-space:nowrap" class="ft15812"><b>Not Known&#160;<br/>(Cannot be&#160;<br/>Estimated&#160;<br/>from&#160;<br/>Available&#160;<br/>Data)</b></p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft15813">Nervous system&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:202px;left:211px;white-space:nowrap" class="ft15811">Headache</p>
<p style="position:absolute;top:202px;left:498px;white-space:nowrap" class="ft15813">CNS demyelinating&#160;<br/>events suggestive of&#160;<br/>multiple sclerosis or&#160;<br/>localised<br/>demyelinating&#160;<br/>conditions, such as&#160;<br/>optic neuritis and&#160;<br/>transverse myelitis&#160;<br/>(see section 4.4),&#160;<br/>peripheral&#160;<br/>demyelinating&#160;<br/>events, including&#160;<br/>Guillain-Barré&#160;<br/>syndrome, chronic&#160;<br/>inflammatory&#160;<br/>demyelinating&#160;<br/>polyneuropathy,&#160;<br/>demyelinating&#160;<br/>polyneuropathy, and&#160;<br/>multifocal&#160;motor&#160;<br/>neuropathy (see&#160;<br/>section 4.4), seizure</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft15811">Eye disorders&#160;</p>
<p style="position:absolute;top:545px;left:375px;white-space:nowrap" class="ft15811">Uveitis, scleritis</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft15813">Cardiac&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:561px;left:375px;white-space:nowrap" class="ft15813">Worsening of&#160;<br/>cardiac failure&#160;<br/>congestive (see&#160;<br/>section 4.4)</p>
<p style="position:absolute;top:561px;left:498px;white-space:nowrap" class="ft15813">New onset cardiac&#160;<br/>failure congestive&#160;<br/>(see section 4.4)</p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft15813">Respiratory,&#160;<br/>thoracic, and&#160;<br/>mediastinal&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:624px;left:498px;white-space:nowrap" class="ft15813">Interstitial lung&#160;<br/>disease (including&#160;<br/>pneumonitis and&#160;<br/>pulmonary&#160;<br/>fibrosis)*</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft15813">Gastrointestinal&#160;<br/>disorders</p>
<p style="position:absolute;top:702px;left:375px;white-space:nowrap" class="ft15813">Inflammatory&#160;<br/>bowel disease</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft15813">Hepatobiliary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:734px;left:375px;white-space:nowrap" class="ft15813">Elevated liver&#160;<br/>enzymes*</p>
<p style="position:absolute;top:734px;left:498px;white-space:nowrap" class="ft15813">Autoimmune&#160;<br/>hepatitis*</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft15813">Skin and&#160;<br/>subcutaneous&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:766px;left:286px;white-space:nowrap" class="ft15811">Pruritus, rash</p>
<p style="position:absolute;top:766px;left:375px;white-space:nowrap" class="ft15813">Angioedema,&#160;<br/>psoriasis (including&#160;<br/>new onset or&#160;<br/>worsening and&#160;<br/>pustular, primarily&#160;<br/>palms and soles),&#160;<br/>urticaria,&#160;<br/>psoriasiform rash</p>
<p style="position:absolute;top:766px;left:498px;white-space:nowrap" class="ft15813">Stevens-Johnson&#160;<br/>syndrome,&#160;<br/>cutaneous vasculitis&#160;<br/>(including&#160;<br/>hypersensitivity&#160;<br/>vasculitis), erythema&#160;<br/>multiforme,&#160;<br/>lichenoid reactions</p>
<p style="position:absolute;top:766px;left:626px;white-space:nowrap" class="ft15813">Toxic&#160;<br/>epidermal&#160;<br/>necrolysis</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft15813">Musculoskeletal&#160;<br/>and connective&#160;<br/>tissue disorders&#160;</p>
<p style="position:absolute;top:891px;left:498px;white-space:nowrap" class="ft15813">Cutaneous lupus&#160;<br/>erythematosus,&#160;<br/>subacute cutaneous&#160;<br/>lupus&#160;<br/>erythematosus,&#160;<br/>lupus-like syndrome</p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft15813">General&#160;<br/>disorders and&#160;<br/>administration&#160;<br/>site conditions&#160;</p>
<p style="position:absolute;top:985px;left:211px;white-space:nowrap" class="ft15813">Injection&#160;<br/>site&#160;<br/>reactions&#160;<br/>(including&#160;<br/>bleeding,&#160;<br/>bruising,&#160;<br/>erythema,&#160;<br/>itching,&#160;<br/>pain,&#160;<br/>swelling)*</p>
<p style="position:absolute;top:985px;left:286px;white-space:nowrap" class="ft15811">Pyrexia</p>
<p style="position:absolute;top:1140px;left:106px;white-space:nowrap" class="ft15811">*see Description of selected adverse reactions, below.</p>
</div>
<!-- Page 159 -->
<a name="159"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page159-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1590">159</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1592">Description of selected adverse&#160;reactions</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1594"><i>Malignancies and lymphoproliferative disorders<br/></i>One hundred and twenty-nine new malignancies of various types were observed in 4,114 rheumatoid&#160;<br/>arthritis patients treated in clinical trials with Enbrel for up to approximately 6&#160;years, including&#160;<br/>231&#160;patients treated with Enbrel in combination with methotrexate in the 2-year active-controlled&#160;<br/>study. The observed rates and incidences in these clinical trials were similar to those expected for the&#160;<br/>population studied. A total of 2 malignancies were reported in clinical studies of approximately 2&#160;<br/>years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical studies conducted&#160;<br/>for more than 2&#160;years with 351 ankylosing spondylitis patients, 6&#160;malignancies were reported in&#160;<br/>Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in&#160;<br/>double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin&#160;<br/>cancers were reported.</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft1593">In a group of 7,416&#160;patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing&#160;<br/>spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1593">Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been&#160;<br/>received in the postmarketing period (see section 4.4).</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft1593"><i>Injection site reactions<br/></i>Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher&#160;<br/>incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first<br/>month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of&#160;<br/>injection site reactions in the Enbrel treatment groups, and the majority of patients who were given&#160;<br/>treatment received topical preparations such as corticosteroids, or oral antihistamines. Additionally,&#160;<br/>some patients developed recall injection site reactions characterised by a skin reaction at the most&#160;<br/>recent site of injection along with the simultaneous appearance of injection site reactions at previous&#160;<br/>injection sites. These reactions were generally transient and did not recur with treatment.</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1594">In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with&#160;<br/>Enbrel developed injection site reactions compared with 3.4% of&#160;placebo-treated patients during the&#160;<br/>first 12 weeks of treatment.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft1593"><i>Serious infections<br/></i>In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life threatening, or&#160;<br/>requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3%&#160;<br/>of rheumatoid arthritis patients treated with Enbrel for up to 48&#160;months. These included abscess (at&#160;<br/>various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis,&#160;<br/>endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection,&#160;<br/>osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin&#160;<br/>infection, skin ulcer, urinary tract infection, vasculitis,&#160;and wound infection. In the 2-year&#160;<br/>active-controlled study where patients were treated with either Enbrel alone, methotrexate alone or&#160;<br/>Enbrel in combination with methotrexate, the rates of serious infections were similar among the&#160;<br/>treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate&#160;<br/>could be associated with an increase in the rate of infections.</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft1594">There were no differences in rates of infection among patients treated with Enbrel and those treated&#160;<br/>with placebo for&#160;plaque psoriasis&#160;in placebo-controlled trials of up to 24 weeks duration. Serious&#160;<br/>infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia,&#160;<br/>cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock,&#160;<br/>diverticulitis&#160;and abscess. In the double-blind and open-label psoriatic arthritis trials, 1&#160;patient reported&#160;<br/>a serious infection (pneumonia).</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft1593">Serious and fatal infections have been reported during use of Enbrel; reported pathogens include&#160;<br/>bacteria, mycobacteria (including&#160;tuberculosis), viruses and fungi. Some have occurred within a few&#160;</p>
</div>
<!-- Page 160 -->
<a name="160"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page160-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1600">160</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1604">weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes,&#160;<br/>congestive heart failure, history of&#160;active or chronic infections) in addition to their rheumatoid arthritis&#160;<br/>(see section&#160;4.4). Enbrel treatment may increase mortality in patients with established sepsis.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1604">Opportunistic infections have been reported in association with Enbrel, including invasive fungal,&#160;<br/>parasitic (including&#160;protozoal),&#160;viral (including herpes zoster),&#160;bacterial (including&#160;<i>Listeria&#160;</i>and&#160;<br/><i>Legionella</i>), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall&#160;<br/>incidence of opportunistic infections&#160;was 0.09% for the 15,402 subjects who received Enbrel. The&#160;<br/>exposure-adjusted rate was 0.06&#160;events per 100&#160;patient-years. In postmarketing experience,&#160;<br/>approximately half of all of the case reports of opportunistic infections worldwide were invasive&#160;<br/>fungal infections.&#160;The most commonly reported invasive fungal infections&#160;included&#160;<i>Candida,<br/>Pneumocystis,&#160;Aspergillus,&#160;</i>and&#160;<i>Histoplasma</i>. Invasive fungal infections accounted for more than half&#160;<br/>of the fatalities amongst patients who developed opportunistic infections. The majority of the reports&#160;<br/>with a fatal outcome were in patients with&#160;<i>Pneumocystis&#160;</i>pneumonia, unspecified systemic fungal&#160;<br/>infections, and aspergillosis (see section 4.4).</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft1608"><i>Autoantibodies<br/></i>Adult patients had serum samples tested for autoantibodies at&#160;multiple timepoints. Of the rheumatoid&#160;<br/>arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed&#160;<br/>new positive ANA (</p>
<p style="position:absolute;top:468px;left:240px;white-space:nowrap" class="ft16014">&#160;1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated&#160;</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft1604">patients (5%).&#160;The percentage of patients who developed new positive anti-double-stranded DNA&#160;<br/>antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4%&#160;<br/>of placebo-treated patients) and by&#160;<i>Crithidia luciliae&#160;</i>assay (3% of patients&#160;treated with Enbrel&#160;<br/>compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who&#160;<br/>developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.&#160;<br/>The impact of long-term treatment with&#160;Enbrel on the development of autoimmune diseases is&#160;<br/>unknown.</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft1603">There have been rare reports of patients, including rheumatoid factor positive patients, who have&#160;<br/>developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are&#160;<br/>compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft1604"><i>Pancytopenia and aplastic anaemia<br/></i>There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal&#160;<br/>outcomes (see section 4.4).</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft1604"><i>Interstitial lung disease<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06%&#160;<br/>(frequency rare). In&#160;the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47%&#160;<br/>(frequency uncommon).&#160;There have been postmarketing reports of interstitial lung&#160;disease (including&#160;<br/>pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft1608"><i>Concurrent treatment with anakinra&#160;<br/></i>In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of&#160;<br/>serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed&#160;<br/>neutropenia (absolute neutrophil count&#160;</p>
<p style="position:absolute;top:1002px;left:366px;white-space:nowrap" class="ft16014">&#160;1000/mm3). While neutropenic, one patient developed&#160;</p>
<p style="position:absolute;top:1023px;left:106px;white-space:nowrap" class="ft1602">cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft1604"><i>Elevated liver&#160;enzymes<br/></i>In&#160;the&#160;double-blind&#160;periods of&#160;controlled clinical trials of etanercept across all indications, the&#160;<br/>frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving&#160;<br/>etanercept without concomitant methotrexate was&#160;0.54% (frequency uncommon). In&#160;the double-blind&#160;<br/>periods of controlled clinical trials&#160;that allowed&#160;concomitant treatment with etanercept and&#160;</p>
</div>
<!-- Page 161 -->
<a name="161"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page161-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1610">161</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1614">methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was&#160;<br/>4.18% (frequency&#160;common).</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1613"><i>Autoimmune hepatitis<br/></i>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of&#160;<br/>autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02%&#160;<br/>(frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept&#160;<br/>and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24%&#160;<br/>(frequency uncommon).</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft1612">Paediatric population</p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft1614"><i>Undesirable effects in paediatric&#160;patients with juvenile idiopathic arthritis<br/></i>In general, the adverse events in paediatric patients with juvenile idiopathic arthritis were similar in&#160;<br/>frequency and type to those seen in adult patients. Differences from adults and other special&#160;<br/>considerations are discussed in the following paragraphs.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft1614">The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18&#160;years&#160;<br/>were generally mild to moderate and consistent with those commonly seen in outpatient paediatric&#160;<br/>populations. Severe adverse events reported included varicella with signs and symptoms of aseptic&#160;<br/>meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis,&#160;<br/>depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic&#160;<br/>shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft1613">In one study in children with juvenile idiopathic arthritis aged 4 to 17&#160;years, 43 of 69 (62%) children&#160;<br/>experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and&#160;<br/>the frequency and severity of infections was similar in 58 patients completing 12&#160;months of open-label&#160;<br/>extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients&#160;<br/>were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the&#160;<br/>majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic&#160;<br/>arthritis patients receiving 3&#160;months of Enbrel compared to the 349 adult rheumatoid arthritis patients.&#160;<br/>These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per&#160;<br/>patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per&#160;<br/>patient year).</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1612">There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft1614"><i>Undesirable effects in paediatric patients with plaque psoriasis<br/></i>In a 48-week study in 211 children aged 4 to 17&#160;years with paediatric plaque psoriasis, the adverse&#160;<br/>events reported were similar to those seen in previous studies in adults with plaque psoriasis.</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft1612">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft1614">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It&#160;<br/>allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare&#160;<br/>professionals are asked to report any suspected adverse&#160;reactions&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>.</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft1611"><b>4.9</b></p>
<p style="position:absolute;top:1021px;left:149px;white-space:nowrap" class="ft1611"><b>Overdose</b></p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1614">No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The&#160;<br/>highest dose level evaluated has been&#160;an intravenous loading dose of 32&#160;mg/m2&#160;followed by&#160;<br/>subcutaneous doses of 16&#160;mg/m2&#160;administered twice weekly. One rheumatoid arthritis patient&#160;<br/>mistakenly self-administered 62&#160;mg Enbrel subcutaneously twice weekly for 3 weeks without&#160;<br/>experiencing undesirable effects. There is no known antidote to Enbrel.</p>
</div>
<!-- Page 162 -->
<a name="162"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page162-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1620">162</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft1621"><b>5.</b></p>
<p style="position:absolute;top:127px;left:146px;white-space:nowrap" class="ft1621"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1621"><b>5.1</b></p>
<p style="position:absolute;top:165px;left:149px;white-space:nowrap" class="ft1621"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1624">Pharmacotherapeutic group: Immunosuppressants,&#160;Tumour Necrosis Factor alpha (TNF-α) inhibitors,<br/>ATC code:&#160;L04AB01</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1624">Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid&#160;<br/>arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with&#160;<br/>psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque&#160;<br/>psoriasis, infiltration by inflammatory cells including T-cells leads to increased TNF levels in psoriatic&#160;<br/>lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF-binding&#160;<br/>to its cell surface receptors and thereby inhibits the biological activity of TNF. TNF and lymphotoxin&#160;<br/>are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55-kilodalton (p55)&#160;<br/>and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs exist naturally in&#160;<br/>membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft1623">TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on&#160;<br/>cross-linking of cell surface TNFRs.&#160;Dimeric soluble receptors such as etanercept possess a higher&#160;<br/>affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of&#160;<br/>TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion&#160;<br/>element in the construction of a dimeric receptor imparts a longer serum half-life.</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft1622">Mechanism of action</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1623">Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in&#160;<br/>plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by&#160;<br/>TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF&#160;<br/>binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF&#160;<br/>biologically&#160;inactive. Etanercept may also modulate biologic responses controlled by additional&#160;<br/>downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or&#160;<br/>regulated by TNF.</p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft1622">Clinical efficacy and safety</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft1624">This section presents data from four randomised controlled trials in adults with rheumatoid arthritis,&#160;<br/>one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis,&#160;two studies&#160;<br/>in adults with non-radiographic axial spondyloarthritis,&#160;four studies in adults with plaque psoriasis,&#160;<br/>three studies in juvenile idiopathic arthritis and one study in paediatric patients with plaque psoriasis.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft1624"><i>Adult patients with rheumatoid arthritis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The&#160;<br/>study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least&#160;<br/>one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel or placebo were administered subcutaneously twice a week for 6&#160;consecutive months.&#160;<br/>The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis&#160;<br/>using American College of Rheumatology (ACR) response criteria.&#160;</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft1623">ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6&#160;months than in&#160;<br/>patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and&#160;<br/>6&#160;months respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6,&#160;<br/>respectively; p&#160;&lt;&#160;0.01 Enbrel vs placebo at all timepoints for both ACR 20 and ACR 50 responses).&#160;</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft1623">Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month&#160;3 and&#160;<br/>month&#160;6&#160;compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel,&#160;</p>
</div>
<!-- Page 163 -->
<a name="163"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page163-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1630">163</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1634">the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly&#160;<br/>always occurred by 3 months. A dose response was seen; results with 10&#160;mg were intermediate&#160;<br/>between placebo and 25&#160;mg. Enbrel was significantly better than placebo in all components of the&#160;<br/>ACR criteria as well as other measures of rheumatoid arthritis disease activity not included in the ACR&#160;<br/>response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which&#160;<br/>included disability, vitality, mental health, general health status, and arthritis-associated health status&#160;<br/>subdomains, was administered every 3&#160;months during the trial. All subdomains&#160;of the HAQ were&#160;<br/>improved in patients treated with Enbrel compared to controls at 3 and 6&#160;months.&#160;</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1633">After discontinuation of Enbrel, symptoms of arthritis generally returned within a month.&#160;<br/>Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same&#160;<br/>magnitudes of responses as patients who received Enbrel without interruption of therapy based on&#160;<br/>results of open-label studies. Continued durable responses have been seen for up to 10&#160;years in&#160;<br/>open-label extension treatment trials when patients received Enbrel without interruption.&#160;</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft1633">The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with&#160;<br/>blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid&#160;<br/>arthritis (&lt;3 years duration) who had never received treatment with methotrexate. Doses of 10&#160;mg or&#160;<br/>25&#160;mg Enbrel were administered SC twice a week for up to 24 months. Methotrexate doses were&#160;<br/>escalated from 7.5&#160;mg/week to a maximum of 20&#160;mg/week over the first 8&#160;weeks of the trial and&#160;<br/>continued for up to 24&#160;months. Clinical improvement including onset of action within 2&#160;weeks with&#160;<br/>Enbrel 25&#160;mg was similar to that seen in the previous trials, and was maintained for up to 24&#160;months.&#160;<br/>At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to 1.5.&#160;<br/>Treatment with Enbrel 25&#160;mg resulted in substantial improvement at 12&#160;months, with about 44% of&#160;<br/>patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year&#160;2 of this&#160;<br/>study.</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft1634">In this study, structural joint damage was assessed radiographically and expressed as change in Total&#160;<br/>Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score.&#160;<br/>Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24&#160;months. The 10&#160;mg&#160;<br/>Enbrel dose had consistently less effect on structural damage than the 25&#160;mg dose. Enbrel 25&#160;mg was&#160;<br/>significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in&#160;<br/>TSS and JSN were not statistically significant between methotrexate and Enbrel 25&#160;mg. The results are&#160;<br/>shown in the figure below.</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft16323"><b>Radiographic Progression: Comparison of Enbrel vs Methotrexate in Patients with RA of&#160;<br/>&lt;3&#160;Years Duration</b></p>
<p style="position:absolute;top:988px;left:132px;white-space:nowrap" class="ft16317">C</p>
<p style="position:absolute;top:977px;left:132px;white-space:nowrap" class="ft16317">ha</p>
<p style="position:absolute;top:961px;left:132px;white-space:nowrap" class="ft16317">ng</p>
<p style="position:absolute;top:945px;left:132px;white-space:nowrap" class="ft16317">e&#160;</p>
<p style="position:absolute;top:933px;left:132px;white-space:nowrap" class="ft16317">fr</p>
<p style="position:absolute;top:924px;left:132px;white-space:nowrap" class="ft16317">o</p>
<p style="position:absolute;top:916px;left:132px;white-space:nowrap" class="ft16317">m</p>
<p style="position:absolute;top:903px;left:132px;white-space:nowrap" class="ft16317">&#160;B</p>
<p style="position:absolute;top:889px;left:132px;white-space:nowrap" class="ft16317">as</p>
<p style="position:absolute;top:874px;left:132px;white-space:nowrap" class="ft16317">e</p>
<p style="position:absolute;top:866px;left:132px;white-space:nowrap" class="ft16317">lin</p>
<p style="position:absolute;top:851px;left:132px;white-space:nowrap" class="ft16317">e</p>
<p style="position:absolute;top:1024px;left:145px;white-space:nowrap" class="ft16318"><b>0.0</b></p>
<p style="position:absolute;top:987px;left:145px;white-space:nowrap" class="ft16318"><b>0.5</b></p>
<p style="position:absolute;top:950px;left:145px;white-space:nowrap" class="ft16318"><b>1.0</b></p>
<p style="position:absolute;top:913px;left:145px;white-space:nowrap" class="ft16318"><b>1.5</b></p>
<p style="position:absolute;top:876px;left:145px;white-space:nowrap" class="ft16318"><b>2.0</b></p>
<p style="position:absolute;top:839px;left:145px;white-space:nowrap" class="ft16318"><b>2.5</b></p>
<p style="position:absolute;top:1025px;left:484px;white-space:nowrap" class="ft16318"><b>0.0</b></p>
<p style="position:absolute;top:988px;left:484px;white-space:nowrap" class="ft16318"><b>0.5</b></p>
<p style="position:absolute;top:951px;left:484px;white-space:nowrap" class="ft16318"><b>1.0</b></p>
<p style="position:absolute;top:914px;left:484px;white-space:nowrap" class="ft16318"><b>1.5</b></p>
<p style="position:absolute;top:877px;left:484px;white-space:nowrap" class="ft16318"><b>2.0</b></p>
<p style="position:absolute;top:840px;left:484px;white-space:nowrap" class="ft16318"><b>2.5</b></p>
<p style="position:absolute;top:1071px;left:433px;white-space:nowrap" class="ft16319"><b>MTX</b></p>
<p style="position:absolute;top:1085px;left:434px;white-space:nowrap" class="ft16319"><b>Enbrel&#160;25 mg</b></p>
<p style="position:absolute;top:833px;left:251px;white-space:nowrap" class="ft16319"><b>12 Months</b></p>
<p style="position:absolute;top:833px;left:598px;white-space:nowrap" class="ft16319"><b>24 Months</b></p>
<p style="position:absolute;top:1043px;left:221px;white-space:nowrap" class="ft16320"><b>TSS</b></p>
<p style="position:absolute;top:1043px;left:269px;white-space:nowrap" class="ft16320"><b>Erosions</b></p>
<p style="position:absolute;top:1044px;left:351px;white-space:nowrap" class="ft16320"><b>JSN</b></p>
<p style="position:absolute;top:1045px;left:554px;white-space:nowrap" class="ft16320"><b>TSS</b></p>
<p style="position:absolute;top:1045px;left:608px;white-space:nowrap" class="ft16320"><b>Erosions</b></p>
<p style="position:absolute;top:1045px;left:688px;white-space:nowrap" class="ft16320"><b>JSN</b></p>
<p style="position:absolute;top:914px;left:208px;white-space:nowrap" class="ft16319"><b>1.3</b></p>
<p style="position:absolute;top:951px;left:233px;white-space:nowrap" class="ft16319"><b>0.8</b></p>
<p style="position:absolute;top:943px;left:276px;white-space:nowrap" class="ft16319"><b>0.9</b></p>
<p style="position:absolute;top:981px;left:301px;white-space:nowrap" class="ft16319"><b>0.4*</b></p>
<p style="position:absolute;top:981px;left:344px;white-space:nowrap" class="ft16319"><b>0.4&#160;0.4</b></p>
<p style="position:absolute;top:847px;left:547px;white-space:nowrap" class="ft16319"><b>2.2</b></p>
<p style="position:absolute;top:922px;left:571px;white-space:nowrap" class="ft16319"><b>1.2</b></p>
<p style="position:absolute;top:913px;left:615px;white-space:nowrap" class="ft16319"><b>1.3</b></p>
<p style="position:absolute;top:966px;left:638px;white-space:nowrap" class="ft16319"><b>0.6*</b></p>
<p style="position:absolute;top:943px;left:681px;white-space:nowrap" class="ft16319"><b>0.9</b></p>
<p style="position:absolute;top:966px;left:705px;white-space:nowrap" class="ft16319"><b>0.6</b></p>
<p style="position:absolute;top:1112px;left:420px;white-space:nowrap" class="ft16319"><b>*p &lt; 0.05</b></p>
</div>
<!-- Page 164 -->
<a name="164"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page164-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1640">164</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1643">In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and&#160;<br/>radiographic progression in RA patients treated with Enbrel alone (25&#160;mg twice weekly), methotrexate&#160;<br/>alone (7.5 to 20&#160;mg&#160;weekly, median dose 20&#160;mg), and of the combination of Enbrel and methotrexate&#160;<br/>initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6&#160;months&#160;<br/>to 20&#160;years duration (median 5&#160;years) who had a less than satisfactory response to at least 1&#160;<br/>disease-modifying antirheumatic drug (DMARD) other than methotrexate.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1644">Patients in the Enbrel in combination with methotrexate therapy group had significantly higher&#160;<br/>ACR&#160;20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and&#160;<br/>52&#160;weeks&#160;than patients in either of the single therapy groups (results shown in table below).&#160;<br/>Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months.</p>
<p style="position:absolute;top:354px;left:103px;white-space:nowrap" class="ft1641"><b>Clinical Efficacy Results at 12&#160;Months: Comparison of Enbrel vs Methotrexate vs Enbrel in&#160;</b></p>
<p style="position:absolute;top:373px;left:117px;white-space:nowrap" class="ft1641"><b>Combination with&#160;Methotrexate in Patients with RA of 6&#160;Months To 20&#160;Years Duration</b></p>
<p style="position:absolute;top:412px;left:85px;white-space:nowrap" class="ft1641"><b>Endpoint</b></p>
<p style="position:absolute;top:412px;left:316px;white-space:nowrap" class="ft1642">Methotrexate</p>
<p style="position:absolute;top:431px;left:325px;white-space:nowrap" class="ft1642">(n =&#160;228)</p>
<p style="position:absolute;top:412px;left:482px;white-space:nowrap" class="ft1642">Enbrel</p>
<p style="position:absolute;top:431px;left:469px;white-space:nowrap" class="ft1642">(n = 223)</p>
<p style="position:absolute;top:393px;left:645px;white-space:nowrap" class="ft1642">Enbrel +</p>
<p style="position:absolute;top:412px;left:626px;white-space:nowrap" class="ft1642">Methotrexate</p>
<p style="position:absolute;top:431px;left:639px;white-space:nowrap" class="ft1642">(n = 231)</p>
<p style="position:absolute;top:470px;left:85px;white-space:nowrap" class="ft1641"><b>ACR&#160;Responsesa</b></p>
<p style="position:absolute;top:489px;left:114px;white-space:nowrap" class="ft1642">ACR 20</p>
<p style="position:absolute;top:489px;left:338px;white-space:nowrap" class="ft1642">58.8%</p>
<p style="position:absolute;top:489px;left:482px;white-space:nowrap" class="ft1642">65.5%</p>
<p style="position:absolute;top:490px;left:644px;white-space:nowrap" class="ft1642">74.5%&#160;<b>†,</b></p>
<p style="position:absolute;top:509px;left:114px;white-space:nowrap" class="ft1642">ACR 50</p>
<p style="position:absolute;top:510px;left:338px;white-space:nowrap" class="ft1642">36.4%</p>
<p style="position:absolute;top:510px;left:482px;white-space:nowrap" class="ft1642">43.0%</p>
<p style="position:absolute;top:510px;left:644px;white-space:nowrap" class="ft1642">63.2%&#160;<b>†,</b></p>
<p style="position:absolute;top:529px;left:114px;white-space:nowrap" class="ft1642">ACR 70</p>
<p style="position:absolute;top:530px;left:338px;white-space:nowrap" class="ft1642">16.7%</p>
<p style="position:absolute;top:530px;left:482px;white-space:nowrap" class="ft1642">22.0%</p>
<p style="position:absolute;top:530px;left:644px;white-space:nowrap" class="ft1642">39.8%&#160;<b>†,</b></p>
<p style="position:absolute;top:568px;left:85px;white-space:nowrap" class="ft1641"><b>DAS</b></p>
<p style="position:absolute;top:587px;left:114px;white-space:nowrap" class="ft1642">Baseline scoreb</p>
<p style="position:absolute;top:587px;left:349px;white-space:nowrap" class="ft1642">5.5</p>
<p style="position:absolute;top:587px;left:493px;white-space:nowrap" class="ft1642">5.7</p>
<p style="position:absolute;top:587px;left:664px;white-space:nowrap" class="ft1642">5.5</p>
<p style="position:absolute;top:606px;left:114px;white-space:nowrap" class="ft1642">Week 52 scoreb</p>
<p style="position:absolute;top:606px;left:349px;white-space:nowrap" class="ft1642">3.0</p>
<p style="position:absolute;top:606px;left:493px;white-space:nowrap" class="ft1642">3.0</p>
<p style="position:absolute;top:607px;left:657px;white-space:nowrap" class="ft1642">2.3<b>†,</b></p>
<p style="position:absolute;top:626px;left:114px;white-space:nowrap" class="ft1642">Remissionc</p>
<p style="position:absolute;top:626px;left:345px;white-space:nowrap" class="ft1642">14%</p>
<p style="position:absolute;top:626px;left:489px;white-space:nowrap" class="ft1642">18%</p>
<p style="position:absolute;top:628px;left:652px;white-space:nowrap" class="ft1642">37%<b>†,</b></p>
<p style="position:absolute;top:666px;left:85px;white-space:nowrap" class="ft1641"><b>HAQ</b></p>
<p style="position:absolute;top:685px;left:113px;white-space:nowrap" class="ft1642">Baseline</p>
<p style="position:absolute;top:685px;left:349px;white-space:nowrap" class="ft1642">1.7</p>
<p style="position:absolute;top:685px;left:493px;white-space:nowrap" class="ft1642">1.7</p>
<p style="position:absolute;top:685px;left:664px;white-space:nowrap" class="ft1642">1.8</p>
<p style="position:absolute;top:704px;left:113px;white-space:nowrap" class="ft1642">Week 52</p>
<p style="position:absolute;top:704px;left:349px;white-space:nowrap" class="ft1642">1.1</p>
<p style="position:absolute;top:704px;left:493px;white-space:nowrap" class="ft1642">1.0</p>
<p style="position:absolute;top:705px;left:657px;white-space:nowrap" class="ft1642">0.8<b>†,</b></p>
<p style="position:absolute;top:724px;left:127px;white-space:nowrap" class="ft1648">a: Patients who did not complete 12 months in the study were considered to be non-responders.<br/>b: Values for Disease Activity Score (DAS) are means.<br/>c: Remission is defined as DAS &lt;1.6<br/>Pairwise comparison p-values:&#160;†&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs methotrexate&#160;<br/>and&#160;</p>
<p style="position:absolute;top:800px;left:155px;white-space:nowrap" class="ft16414">&#160;= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs Enbrel</p>
<p style="position:absolute;top:840px;left:106px;white-space:nowrap" class="ft1643">Radiographic progression at 12&#160;months was significantly less in the Enbrel group than in the&#160;<br/>methotrexate group, while&#160;the combination was significantly better than either monotherapy at&#160;<br/>slowing radiographic progression (see figure below).</p>
</div>
<!-- Page 165 -->
<a name="165"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page165-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1650">165</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft16523"><b>Radiographic Progression: Comparison of Enbrel vs Methotrexate vs Enbrel in Combination&#160;<br/>with Methotrexate in Patients with RA of&#160;6&#160;Months To 20&#160;Years Duration (12&#160;Month Results)</b></p>
<p style="position:absolute;top:535px;left:233px;white-space:nowrap" class="ft1658">Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs&#160;<br/>methotrexate, † = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs&#160;<br/>methotrexate and&#160;</p>
<p style="position:absolute;top:572px;left:351px;white-space:nowrap" class="ft16514">&#160;= p&#160;&lt;&#160;0.05 for comparisons of Enbrel + methotrexate vs Enbrel</p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft1654">Significant advantages for Enbrel in combination with methotrexate compared with Enbrel&#160;<br/>monotherapy and methotrexate monotherapy were also observed after 24&#160;months. Similarly, the&#160;<br/>significant advantages for Enbrel monotherapy compared&#160;with methotrexate monotherapy were also&#160;<br/>observed after 24&#160;months.</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft1654">In an analysis in which all patients who dropped out of the study for any reason were considered to&#160;<br/>have progressed, the percentage of patients without progression (TSS change&#160;≤&#160;0.5) at 24&#160;months was&#160;<br/>higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and&#160;<br/>methotrexate alone groups&#160;(62%, 50%, and 36%, respectively; p&lt;&#160;0.05). The difference between&#160;<br/>Enbrel alone and methotrexate alone was also significant&#160;(p&lt;&#160;0.05). Among patients who completed a&#160;<br/>full 24&#160;months of therapy in the study, the non-progression rates were 78%, 70%, and 61%,&#160;<br/>respectively.</p>
<p style="position:absolute;top:858px;left:106px;white-space:nowrap" class="ft1654">The safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered once weekly were&#160;<br/>evaluated in&#160;a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53&#160;<br/>patients received placebo, 214 patients received 50&#160;mg&#160;Enbrel once weekly and 153 patients received&#160;<br/>25&#160;mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens&#160;<br/>were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16&#160;did not show&#160;<br/>comparability (non-inferiority) between the two regimens. A single 50&#160;mg/ml injection of Enbrel was&#160;<br/>found to be bioequivalent to two simultaneous injections of 25&#160;mg/ml.</p>
<p style="position:absolute;top:1010px;left:106px;white-space:nowrap" class="ft1658"><i>Adult patients with psoriatic arthritis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205&#160;<br/>patients with psoriatic arthritis. Patients were between 18 and 70&#160;years of age and had active psoriatic&#160;<br/>arthritis (</p>
<p style="position:absolute;top:1067px;left:167px;white-space:nowrap" class="ft16514">&#160;3 swollen joints and&#160;&#160;3 tender joints) in at least one of the following forms: (1)&#160;distal&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft1658">interphalangeal (DIP) involvement; (2)&#160;polyarticular arthritis (absence of rheumatoid nodules and&#160;<br/>presence of psoriasis); (3)&#160;arthritis mutilans; (4)&#160;asymmetric psoriatic arthritis; or (5)&#160;spondylitis-like&#160;<br/>ankylosis. Patients also had plaque psoriasis with a qualifying target lesion&#160;</p>
<p style="position:absolute;top:1125px;left:604px;white-space:nowrap" class="ft16514">&#160;2&#160;cm in diameter.&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1652">Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids&#160;</p>
<p style="position:absolute;top:386px;left:206px;white-space:nowrap" class="ft16525">C</p>
<p style="position:absolute;top:376px;left:206px;white-space:nowrap" class="ft16525">ha</p>
<p style="position:absolute;top:360px;left:206px;white-space:nowrap" class="ft16525">ng</p>
<p style="position:absolute;top:344px;left:206px;white-space:nowrap" class="ft16525">e&#160;</p>
<p style="position:absolute;top:332px;left:206px;white-space:nowrap" class="ft16525">fr</p>
<p style="position:absolute;top:323px;left:206px;white-space:nowrap" class="ft16525">om</p>
<p style="position:absolute;top:303px;left:206px;white-space:nowrap" class="ft16525">&#160;B</p>
<p style="position:absolute;top:290px;left:206px;white-space:nowrap" class="ft16525">as</p>
<p style="position:absolute;top:275px;left:206px;white-space:nowrap" class="ft16525">el</p>
<p style="position:absolute;top:264px;left:206px;white-space:nowrap" class="ft16525">in</p>
<p style="position:absolute;top:253px;left:206px;white-space:nowrap" class="ft16525">e</p>
<p style="position:absolute;top:473px;left:232px;white-space:nowrap" class="ft1650">-1.0</p>
<p style="position:absolute;top:435px;left:232px;white-space:nowrap" class="ft1650">-0.5</p>
<p style="position:absolute;top:397px;left:236px;white-space:nowrap" class="ft1650">0.0</p>
<p style="position:absolute;top:360px;left:236px;white-space:nowrap" class="ft1650">0.5</p>
<p style="position:absolute;top:322px;left:236px;white-space:nowrap" class="ft1650">1.0</p>
<p style="position:absolute;top:285px;left:236px;white-space:nowrap" class="ft1650">1.5</p>
<p style="position:absolute;top:247px;left:236px;white-space:nowrap" class="ft1650">2.0</p>
<p style="position:absolute;top:209px;left:236px;white-space:nowrap" class="ft1650">2.5</p>
<p style="position:absolute;top:172px;left:236px;white-space:nowrap" class="ft1650">3.0</p>
<p style="position:absolute;top:185px;left:552px;white-space:nowrap" class="ft16526"><b>Methotrexate</b></p>
<p style="position:absolute;top:200px;left:551px;white-space:nowrap" class="ft16526"><b>Enbrel&#160;</b></p>
<p style="position:absolute;top:215px;left:552px;white-space:nowrap" class="ft16526"><b>Enbrel + Methotrexate</b></p>
<p style="position:absolute;top:176px;left:334px;white-space:nowrap" class="ft16526"><b>2.80</b></p>
<p style="position:absolute;top:346px;left:361px;white-space:nowrap" class="ft16526"><b>0.52*</b></p>
<p style="position:absolute;top:449px;left:380px;white-space:nowrap" class="ft16526"><b>-0.54†</b>,</p>
<p style="position:absolute;top:259px;left:443px;white-space:nowrap" class="ft16526"><b>1.68</b></p>
<p style="position:absolute;top:369px;left:469px;white-space:nowrap" class="ft16526"><b>0.21*</b></p>
<p style="position:absolute;top:432px;left:489px;white-space:nowrap" class="ft16526"><b>-0.30†</b></p>
<p style="position:absolute;top:301px;left:551px;white-space:nowrap" class="ft16526"><b>1.12</b></p>
<p style="position:absolute;top:361px;left:577px;white-space:nowrap" class="ft16526"><b>0.32</b></p>
<p style="position:absolute;top:426px;left:599px;white-space:nowrap" class="ft16526"><b>-0.23†</b>,</p>
<p style="position:absolute;top:481px;left:352px;white-space:nowrap" class="ft16527"><b>TSS</b></p>
<p style="position:absolute;top:481px;left:442px;white-space:nowrap" class="ft16527"><b>Erosions</b></p>
<p style="position:absolute;top:481px;left:571px;white-space:nowrap" class="ft16527"><b>JSN</b></p>
</div>
<!-- Page 166 -->
<a name="166"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page166-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1660">166</p>
<p style="position:absolute;top:109px;left:106px;white-space:nowrap" class="ft1662">(24%). Patients currently on methotrexate therapy&#160;(stable for&#160;</p>
<p style="position:absolute;top:107px;left:512px;white-space:nowrap" class="ft16614">&#160;2 months) could continue at a stable&#160;</p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft1662">dose of&#160;</p>
<p style="position:absolute;top:127px;left:159px;white-space:nowrap" class="ft16614">&#160;25&#160;mg/week methotrexate. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in&#160;</p>
<p style="position:absolute;top:148px;left:106px;white-space:nowrap" class="ft1664">patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6&#160;months. At the&#160;<br/>end of the double-blind study, patients could enter a long-term open-label extension study for a total&#160;<br/>duration of up to 2&#160;years.</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft1663">Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70&#160;<br/>response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results&#160;<br/>are summarised in the table below.</p>
<p style="position:absolute;top:300px;left:239px;white-space:nowrap" class="ft1661"><b>Responses of Patients with Psoriatic Arthritis in a Placebo-</b></p>
<p style="position:absolute;top:319px;left:389px;white-space:nowrap" class="ft1661"><b>Controlled Trial</b></p>
<p style="position:absolute;top:339px;left:495px;white-space:nowrap" class="ft1662">Percent of Patients</p>
<p style="position:absolute;top:358px;left:473px;white-space:nowrap" class="ft1662">Placebo</p>
<p style="position:absolute;top:358px;left:586px;white-space:nowrap" class="ft1662">Enbrela</p>
<p style="position:absolute;top:377px;left:226px;white-space:nowrap" class="ft1662">&#160;&#160;Psoriatic Arthritis Response</p>
<p style="position:absolute;top:377px;left:474px;white-space:nowrap" class="ft1662">n = 104</p>
<p style="position:absolute;top:377px;left:585px;white-space:nowrap" class="ft1662">n&#160;= 101</p>
<p style="position:absolute;top:416px;left:226px;white-space:nowrap" class="ft16624"><b>&#160;&#160;ACR 20<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:435px;left:491px;white-space:nowrap" class="ft1662">15</p>
<p style="position:absolute;top:435px;left:600px;white-space:nowrap" class="ft1662">59b</p>
<p style="position:absolute;top:454px;left:226px;white-space:nowrap" class="ft1662">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:454px;left:491px;white-space:nowrap" class="ft1662">13</p>
<p style="position:absolute;top:454px;left:600px;white-space:nowrap" class="ft1662">50b</p>
<p style="position:absolute;top:492px;left:226px;white-space:nowrap" class="ft16623"><b>&#160;&#160;ACR 50<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:510px;left:495px;white-space:nowrap" class="ft1662">4</p>
<p style="position:absolute;top:510px;left:600px;white-space:nowrap" class="ft1662">38b</p>
<p style="position:absolute;top:530px;left:226px;white-space:nowrap" class="ft1662">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:530px;left:495px;white-space:nowrap" class="ft1662">4</p>
<p style="position:absolute;top:530px;left:600px;white-space:nowrap" class="ft1662">37b</p>
<p style="position:absolute;top:567px;left:226px;white-space:nowrap" class="ft16623"><b>&#160;&#160;ACR 70<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:586px;left:495px;white-space:nowrap" class="ft1662">0</p>
<p style="position:absolute;top:586px;left:600px;white-space:nowrap" class="ft1662">11b</p>
<p style="position:absolute;top:605px;left:226px;white-space:nowrap" class="ft1662">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:605px;left:495px;white-space:nowrap" class="ft1662">1</p>
<p style="position:absolute;top:605px;left:604px;white-space:nowrap" class="ft1662">9c</p>
<p style="position:absolute;top:643px;left:226px;white-space:nowrap" class="ft16624"><b>&#160;&#160;PsARC<br/></b>&#160; &#160; &#160;Month 3</p>
<p style="position:absolute;top:662px;left:491px;white-space:nowrap" class="ft1662">31</p>
<p style="position:absolute;top:662px;left:600px;white-space:nowrap" class="ft1662">72b</p>
<p style="position:absolute;top:681px;left:226px;white-space:nowrap" class="ft1662">&#160; &#160; &#160;Month 6</p>
<p style="position:absolute;top:681px;left:491px;white-space:nowrap" class="ft1662">23</p>
<p style="position:absolute;top:681px;left:600px;white-space:nowrap" class="ft1662">70b</p>
<p style="position:absolute;top:701px;left:236px;white-space:nowrap" class="ft1664">a: 25&#160;mg Enbrel SC&#160;twice weekly<br/>b: p &lt; 0.001, Enbrel vs. placebo<br/>c: p &lt; 0.01, Enbrel vs. placebo</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft1663">Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at&#160;<br/>the time of the first visit (4&#160;weeks) and were maintained through 6&#160;months&#160;of therapy. Enbrel was&#160;<br/>significantly better than placebo in all measures of disease activity (p&#160;&lt;&#160;0.001), and responses were&#160;<br/>similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis&#160;<br/>patients was assessed at every timepoint using the disability index of the HAQ. The disability index&#160;<br/>score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel,&#160;<br/>relative to placebo (p&#160;&lt;&#160;0.001).&#160;</p>
<p style="position:absolute;top:929px;left:106px;white-space:nowrap" class="ft1663">Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists&#160;<br/>were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in&#160;<br/>the Table below. In an analysis in which all patients who dropped out of the study for any reason were&#160;<br/>considered to have progressed, the percentage of patients without progression (TSS change&#160;≤ 0.5) at&#160;<br/>12&#160;months was higher in the Enbrel group compared with the placebo group (73% vs. 47%,&#160;<br/>respectively, p&#160;≤&#160;0.001). The effect of Enbrel on radiographic progression was maintained in patients&#160;<br/>who continued on treatment during the second year. The slowing of peripheral joint damage was&#160;<br/>observed in patients with polyarticular symmetrical joint involvement. &#160;</p>
</div>
<!-- Page 167 -->
<a name="167"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page167-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1670">167</p>
<p style="position:absolute;top:121px;left:238px;white-space:nowrap" class="ft1671"><b>Mean (SE) Annualized Change from Baseline in Total Sharp Score</b></p>
<p style="position:absolute;top:150px;left:469px;white-space:nowrap" class="ft1672">Placebo</p>
<p style="position:absolute;top:150px;left:684px;white-space:nowrap" class="ft1672">Etanercept</p>
<p style="position:absolute;top:178px;left:232px;white-space:nowrap" class="ft1672">Time</p>
<p style="position:absolute;top:178px;left:464px;white-space:nowrap" class="ft1672">(n = 104)</p>
<p style="position:absolute;top:178px;left:688px;white-space:nowrap" class="ft1672">(n = 101)</p>
<p style="position:absolute;top:207px;left:217px;white-space:nowrap" class="ft1672">Month 12</p>
<p style="position:absolute;top:207px;left:458px;white-space:nowrap" class="ft1672">1.00 (0.29)</p>
<p style="position:absolute;top:207px;left:677px;white-space:nowrap" class="ft1672">-0.03 (0.09)a</p>
<p style="position:absolute;top:226px;left:123px;white-space:nowrap" class="ft1674">SE = standard error. &#160;<br/>a. p = 0.0001. &#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1673">Enbrel treatment resulted in improvement in physical function during the double-blind period, and this&#160;<br/>benefit was maintained&#160;during the longer-term exposure of up to 2&#160;years.</p>
<p style="position:absolute;top:334px;left:106px;white-space:nowrap" class="ft1673">There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis-like and&#160;<br/>arthritis mutilans&#160;psoriatic arthropathies due to the small number of patients studied.<br/>No study has been performed in patients with psoriatic arthritis using the 50&#160;mg once weekly dosing&#160;<br/>regimen. Evidence of efficacy for the once weekly dosing regimen in this patient population has been&#160;<br/>based on data from the study in patients with ankylosing spondylitis.</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft1678"><i>Adult patients with ankylosing spondylitis<br/></i>The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies&#160;<br/>comparing twice weekly administration of 25&#160;mg Enbrel with placebo. A total of 401 patients were&#160;<br/>enrolled from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled&#160;<br/>patients who were between 18 and 70&#160;years of age and had active ankylosing spondylitis defined as&#160;<br/>visual analog scale (VAS) scores of&#160;</p>
<p style="position:absolute;top:543px;left:347px;white-space:nowrap" class="ft16714">&#160;30 for average of duration and intensity of morning stiffness&#160;</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft1672">plus VAS scores of&#160;</p>
<p style="position:absolute;top:563px;left:239px;white-space:nowrap" class="ft16714">&#160;30 for at least 2 of the following 3 parameters: patient global assessment;&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft1674">average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the&#160;<br/>Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or&#160;<br/>corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine&#160;<br/>were not included in the study. Doses of 25&#160;mg of Enbrel (based on dose-finding studies in patients&#160;<br/>with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6&#160;months in&#160;<br/>138&#160;patients.</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft1672">The primary measure of efficacy (ASAS 20) was a&#160;</p>
<p style="position:absolute;top:716px;left:446px;white-space:nowrap" class="ft16714">&#160;20% improvement in at least 3 of the 4&#160;</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft1674">Assessment in Ankylosing Spondylitis (ASAS)&#160;domains (patient global assessments, back pain,&#160;<br/>BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70&#160;<br/>responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft1674">Compared to placebo,&#160;treatment with Enbrel resulted in significant improvements in the ASAS 20,&#160;<br/>ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</p>
<p style="position:absolute;top:870px;left:255px;white-space:nowrap" class="ft1671"><b>Responses of Patients with Ankylosing Spondylitis in a&#160;</b></p>
<p style="position:absolute;top:889px;left:358px;white-space:nowrap" class="ft1671"><b>Placebo-Controlled Trial</b></p>
<p style="position:absolute;top:909px;left:482px;white-space:nowrap" class="ft1672">Percent of Patients</p>
<p style="position:absolute;top:948px;left:242px;white-space:nowrap" class="ft1672">&#160;&#160;Ankylosing Spondylitis&#160;</p>
<p style="position:absolute;top:967px;left:249px;white-space:nowrap" class="ft1672">Response</p>
<p style="position:absolute;top:929px;left:464px;white-space:nowrap" class="ft1672">Placebo</p>
<p style="position:absolute;top:948px;left:462px;white-space:nowrap" class="ft1672">N = 139</p>
<p style="position:absolute;top:929px;left:576px;white-space:nowrap" class="ft1672">Enbrel</p>
<p style="position:absolute;top:948px;left:570px;white-space:nowrap" class="ft1672">N = 138</p>
<p style="position:absolute;top:987px;left:241px;white-space:nowrap" class="ft1672">&#160;&#160;ASAS 20&#160;</p>
<p style="position:absolute;top:1008px;left:259px;white-space:nowrap" class="ft1672">2 weeks</p>
<p style="position:absolute;top:1008px;left:481px;white-space:nowrap" class="ft1672">22</p>
<p style="position:absolute;top:1008px;left:587px;white-space:nowrap" class="ft1672">46a</p>
<p style="position:absolute;top:1028px;left:259px;white-space:nowrap" class="ft1672">3 months</p>
<p style="position:absolute;top:1028px;left:481px;white-space:nowrap" class="ft1672">27</p>
<p style="position:absolute;top:1028px;left:587px;white-space:nowrap" class="ft1672">60a</p>
<p style="position:absolute;top:1048px;left:259px;white-space:nowrap" class="ft1672">6&#160;months</p>
<p style="position:absolute;top:1048px;left:481px;white-space:nowrap" class="ft1672">23</p>
<p style="position:absolute;top:1048px;left:587px;white-space:nowrap" class="ft1672">58a</p>
<p style="position:absolute;top:1077px;left:241px;white-space:nowrap" class="ft1672">&#160;&#160;ASAS 50&#160;</p>
<p style="position:absolute;top:1097px;left:259px;white-space:nowrap" class="ft1672">2 weeks</p>
<p style="position:absolute;top:1097px;left:485px;white-space:nowrap" class="ft1672">7</p>
<p style="position:absolute;top:1097px;left:587px;white-space:nowrap" class="ft1672">24a</p>
<p style="position:absolute;top:1117px;left:259px;white-space:nowrap" class="ft1672">3 months</p>
<p style="position:absolute;top:1117px;left:481px;white-space:nowrap" class="ft1672">13</p>
<p style="position:absolute;top:1117px;left:587px;white-space:nowrap" class="ft1672">45a</p>
<p style="position:absolute;top:1137px;left:259px;white-space:nowrap" class="ft1672">6&#160;months</p>
<p style="position:absolute;top:1137px;left:481px;white-space:nowrap" class="ft1672">10</p>
<p style="position:absolute;top:1137px;left:587px;white-space:nowrap" class="ft1672">42a</p>
</div>
<!-- Page 168 -->
<a name="168"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page168-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1680">168</p>
<p style="position:absolute;top:108px;left:241px;white-space:nowrap" class="ft1682">&#160;&#160;ASAS 70:</p>
<p style="position:absolute;top:128px;left:259px;white-space:nowrap" class="ft1682">2 weeks</p>
<p style="position:absolute;top:128px;left:485px;white-space:nowrap" class="ft1682">2</p>
<p style="position:absolute;top:128px;left:586px;white-space:nowrap" class="ft1682">12b</p>
<p style="position:absolute;top:149px;left:259px;white-space:nowrap" class="ft1682">3 months</p>
<p style="position:absolute;top:149px;left:485px;white-space:nowrap" class="ft1682">7</p>
<p style="position:absolute;top:149px;left:586px;white-space:nowrap" class="ft1682">29b</p>
<p style="position:absolute;top:169px;left:259px;white-space:nowrap" class="ft1682">6&#160;months&#160;</p>
<p style="position:absolute;top:169px;left:485px;white-space:nowrap" class="ft1682">5</p>
<p style="position:absolute;top:169px;left:586px;white-space:nowrap" class="ft1682">28b</p>
<p style="position:absolute;top:198px;left:246px;white-space:nowrap" class="ft1688">a: p&#160;&lt;0.001, Enbrel vs. Placebo<br/>b: p = 0.002, Enbrel vs. placebo</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1683">Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent&#160;<br/>at the time of the first visit (2&#160;weeks) and were maintained through 6&#160;months&#160;of therapy. Responses&#160;<br/>were similar in patients who were or were not receiving concomitant therapies at baseline.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1682">Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1683">In a fourth study, the safety and efficacy of 50&#160;mg Enbrel (two 25&#160;mg SC injections) administered&#160;<br/>once weekly vs 25&#160;mg Enbrel administered twice weekly were evaluated in a double-blind,&#160;<br/>placebo-controlled study of 356&#160;patients with active ankylosing spondylitis. The safety and efficacy&#160;<br/>profiles of the 50&#160;mg once weekly and 25&#160;mg twice weekly regimens were similar.</p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft1685"><i>Adult patients with&#160;non-radiographic axial spondyloarthritis</i></p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft1683"><i>Study 1<br/></i>The efficacy of Enbrel in patients with non-radiographic axial spondyloarthritis (nr-AxSpa) was&#160;<br/>assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated&#160;<br/>215&#160;adult patients&#160;(modified intent-to-treat population)&#160;with active nr-AxSpa (18 to 49&#160;years of age),<br/>defined as those patients meeting the ASAS&#160;classification criteria of&#160;axial&#160;spondyloarthritis but did not&#160;<br/>meet the modified New York criteria for AS.&#160;Patients were also required to have an&#160;inadequate&#160;<br/>response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel&#160;<br/>50&#160;mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40%&#160;<br/>improvement in at least three of the four ASAS domains and absence of deterioration in the remaining&#160;<br/>domain. The double-blind period was followed by an open-label period during which all patients&#160;<br/>receive Enbrel 50&#160;mg weekly for up to an additional 92 weeks.&#160;MRIs of the sacroiliac joint and spine&#160;<br/>were obtained to assess inflammation at baseline and at weeks&#160;12&#160;and 104.</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft1684">Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the&#160;<br/>ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial&#160;<br/>remission and BASDAI 50.&#160;Week 12&#160;results are shown in the table below.</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft16824"><b>Efficacy Response&#160;in Placebo-Controlled nr-AxSpa&#160;Study: Percent of Patients Achieving&#160;<br/>Endpoints</b></p>
<p style="position:absolute;top:871px;left:141px;white-space:nowrap" class="ft1683">Double-Blind Clinical<br/>Responses at Week 12&#160;</p>
<p style="position:absolute;top:871px;left:481px;white-space:nowrap" class="ft1682">Placebo</p>
<p style="position:absolute;top:890px;left:457px;white-space:nowrap" class="ft1682">N=106 to 109*</p>
<p style="position:absolute;top:871px;left:661px;white-space:nowrap" class="ft1682">Enbrel</p>
<p style="position:absolute;top:890px;left:633px;white-space:nowrap" class="ft1682">N=103 to 105*</p>
<p style="position:absolute;top:910px;left:141px;white-space:nowrap" class="ft1682">ASAS** 40</p>
<p style="position:absolute;top:910px;left:493px;white-space:nowrap" class="ft1682">15.7</p>
<p style="position:absolute;top:910px;left:666px;white-space:nowrap" class="ft1682">32.4b</p>
<p style="position:absolute;top:930px;left:141px;white-space:nowrap" class="ft1682">ASAS 20</p>
<p style="position:absolute;top:930px;left:493px;white-space:nowrap" class="ft1682">36.1</p>
<p style="position:absolute;top:930px;left:666px;white-space:nowrap" class="ft1682">52.4c</p>
<p style="position:absolute;top:949px;left:141px;white-space:nowrap" class="ft1682">ASAS 5/6</p>
<p style="position:absolute;top:949px;left:493px;white-space:nowrap" class="ft1682">10.4</p>
<p style="position:absolute;top:949px;left:666px;white-space:nowrap" class="ft1682">33.0a</p>
<p style="position:absolute;top:969px;left:141px;white-space:nowrap" class="ft1682">ASAS partial remission</p>
<p style="position:absolute;top:969px;left:493px;white-space:nowrap" class="ft1682">11.9</p>
<p style="position:absolute;top:969px;left:666px;white-space:nowrap" class="ft1682">24.8c</p>
<p style="position:absolute;top:989px;left:141px;white-space:nowrap" class="ft1682">BASDAI***50</p>
<p style="position:absolute;top:989px;left:493px;white-space:nowrap" class="ft1682">23.9</p>
<p style="position:absolute;top:989px;left:666px;white-space:nowrap" class="ft1682">43.8b</p>
<p style="position:absolute;top:1009px;left:149px;white-space:nowrap" class="ft1684">*Some patients did not provide complete data for each endpoint<br/>**ASAS=Assessments in Spondyloarthritis International Society<br/>***Bath Ankylosing Spondylitis Disease Activity Index<br/>a: p &lt;0.001,&#160;b:&lt;0.01 and&#160;c:&lt;0.05,&#160;respectively between&#160;Enbrel and&#160;placebo</p>
<p style="position:absolute;top:1104px;left:106px;white-space:nowrap" class="ft1684">At week&#160;12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis&#160;<br/>Research Consortium of Canada) score&#160;for the sacroiliac joint&#160;(SIJ) as measured by MRI for patients&#160;<br/>receiving Enbrel. Adjusted mean change from baseline&#160;was 3.8 for Enbrel treated (n=95) versus 0.8&#160;</p>
</div>
<!-- Page 169 -->
<a name="169"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page169-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1690">169</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1694">for placebo treated (n=105) patients (p&lt;0.001). At week&#160;104, the mean change from baseline in the&#160;<br/>SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and&#160;<br/>1.40&#160;the spine (n=154).</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1694">Enbrel showed statistically significantly greater improvement from baseline to week 12 compared to&#160;<br/>placebo in most health-related quality of life and physical function assessments, including BASFI&#160;<br/>(Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36&#160;<br/>Physical Component Score.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1694">Clinical responses among&#160;nr-AxSpa&#160;patients who received Enbrel were apparent at the time of the first&#160;<br/>visit (2&#160;weeks) and were maintained through&#160;2&#160;years&#160;of therapy.&#160;Improvements in health-related&#160;<br/>quality of life and physical function&#160;were also maintained through 2&#160;years of therapy. The 2&#160;year data&#160;<br/>did not reveal any new safety findings.&#160;At week&#160;104, 8&#160;subjects had progressed to a score of bilateral&#160;<br/>Grade&#160;2 on spinal X-ray according to&#160;the modified New York Radiological Grade, indicative of axial&#160;<br/>spondyloarthropathy.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft1693"><i>Study 2<br/></i>This multi-center, open-label,&#160;phase 4,&#160;3-period study evaluated the withdrawal and retreatment of&#160;<br/>Enbrel&#160;in patients with active nr-AxSpa who achieved an adequate&#160;response (inactive disease defined&#160;<br/>as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3)&#160;<br/>following 24&#160;weeks of treatment.&#160;</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft1693">209&#160;adult patients with active nr-AxSpa (18 to 49&#160;years of age), defined as those patients meeting the&#160;<br/>Assessment of SpondyloArthritis International Society (ASAS) classification criteria of axial&#160;<br/>spondyloarthritis (but not meeting the modified New York criteria for AS), having&#160;positive&#160;MRI&#160;<br/>findings (active inflammation on MRI highly suggestive of&#160;sacroiliitis&#160;associated with SpA) and/or&#160;<br/>positive hsCRP (defined as high sensitivity C-reactive protein&#160;[hsCRP]&#160;&gt;&#160;3&#160;mg/l), and&#160;active&#160;<br/>symptoms defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received&#160;<br/>open-label Enbrel 50&#160;mg weekly&#160;plus stable background NSAID at the optimal tolerated&#160;<br/>anti-inflammatory dosage&#160;for 24&#160;weeks in Period 1. Patients were also required to have an inadequate&#160;<br/>response or intolerance to two or more NSAIDs. At week&#160;24, 119 (57%) patients achieved inactive&#160;<br/>disease and entered into the Period&#160;2&#160;40-week withdrawal phase&#160;where subjects discontinued&#160;<br/>etanercept, yet maintained the background NSAID. The&#160;primary measure of efficacy was the&#160;<br/>occurrence of flare (defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal&#160;<br/>to 2.1) within 40&#160;weeks following withdrawal of Enbrel. Patients who flared were retreated with&#160;<br/>Enbrel 50&#160;mg weekly for 12&#160;weeks (Period 3).</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft1694">In Period&#160;2, the proportion of patients experiencing&#160;≥1 flare increased from 22% (25/112) at week 4 to&#160;<br/>67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within&#160;<br/>40&#160;weeks following withdrawal of Enbrel.&#160;</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft1694">The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and&#160;<br/>additionally&#160;compare&#160;the time to flare to&#160;patients from Study 1 who met the Study&#160;2 withdrawal phase&#160;<br/>entry requirements and continued Enbrel therapy.&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft1693">The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24&#160;weeks).&#160;Less&#160;<br/>than 25% of patients in Study&#160;1 who did not have treatment withdrawn experienced a flare&#160;over the&#160;<br/>equivalent&#160;40-weeks&#160;as in Period 2 Study 2. The time to flare was statistically significantly shorter in&#160;<br/>subjects who discontinued&#160;Enbrel&#160;treatment (Study 2) compared to subjects who received continuous&#160;<br/>etanercept treatment (Study 1), p&lt;0.0001.</p>
<p style="position:absolute;top:1075px;left:106px;white-space:nowrap" class="ft1694">Of the 87&#160;patients who entered Period 3 and were retreated with Enbrel 50&#160;mg weekly for 12&#160;weeks,&#160;<br/>62% (54/87) reachieved inactive disease,&#160;with 50% of&#160;them&#160;reachieving&#160;it&#160;within 5&#160;weeks (95% CI:&#160;<br/>4-8&#160;weeks).</p>
</div>
<!-- Page 170 -->
<a name="170"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page170-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1700">170</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1704"><i>Adult patients with plaque psoriasis<br/></i>Enbrel is recommended for use in patients as defined in section 4.1. Patients who “failed to respond&#160;<br/>to” in the target population is defined by insufficient&#160;response (PASI&lt;&#160;50 or PGA less than good), or&#160;<br/>worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long&#160;<br/>duration to assess response with at least&#160;one&#160;of the three major systemic therapies as available.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1704">The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis&#160;<br/>(responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel&#160;<br/>with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four&#160;<br/>randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies&#160;<br/>was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75%&#160;<br/>improvement in the Psoriasis Area and Severity Index score from baseline) at 12&#160;weeks.</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1702">Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving&#160;</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft1708">&#160;10% of the body surface area that were&#160;&#160;18 years old. One hundred and twelve (112) patients were&#160;<br/>randomised to receive a dose of 25&#160;mg of Enbrel (n=57) or placebo (n=55) twice a week for 24&#160;weeks.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft1703">Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study&#160;<br/>1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel&#160;<br/>was administered at doses of 25&#160;mg once a week, 25&#160;mg twice a week or 50&#160;mg twice a week for&#160;<br/>6&#160;consecutive months. During the first 12 weeks of the double-blind treatment period, patients&#160;<br/>received placebo or one of the above three Enbrel doses. After 12&#160;weeks of treatment, patients in the&#160;<br/>placebo group began treatment with blinded Enbrel (25&#160;mg twice a week); patients in the active&#160;<br/>treatment groups continued to week&#160;24 on the dose to which they were originally randomised.</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft1704">Study&#160;3 evaluated 583 patients and had the same inclusion criteria as study&#160;2. Patients in this study&#160;<br/>received a dose of 25&#160;mg or 50&#160;mg Enbrel, or placebo twice a week for 12&#160;weeks and then all patients&#160;<br/>received open-label&#160;25&#160;mg&#160;Enbrel twice weekly for an additional 24&#160;weeks.</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft1704">Study&#160;4 evaluated 142 patients and had similar inclusion criteria to studies&#160;2 and 3. Patients in this&#160;<br/>study received a dose of 50&#160;mg Enbrel or placebo once weekly for 12&#160;weeks and then all patients&#160;<br/>received open-label 50&#160;mg&#160;Enbrel once weekly for an additional 12&#160;weeks.</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft1704">In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75&#160;<br/>response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;&#160;0.0001).&#160;At 24 weeks,&#160;<br/>56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of&#160;<br/>placebo-treated patients. Key results of studies 2, 3 and 4 are shown below.</p>
<p style="position:absolute;top:830px;left:260px;white-space:nowrap" class="ft1701"><b>Responses of Patients with Psoriasis in Studies 2, 3 And 4</b></p>
<p style="position:absolute;top:986px;left:118px;white-space:nowrap" class="ft1702">Respons</p>
<p style="position:absolute;top:1005px;left:127px;white-space:nowrap" class="ft1702">e (%)</p>
<p style="position:absolute;top:851px;left:192px;white-space:nowrap" class="ft1702">------------------Study 2--------------</p>
<p style="position:absolute;top:870px;left:294px;white-space:nowrap" class="ft1702">-</p>
<p style="position:absolute;top:851px;left:421px;white-space:nowrap" class="ft1702">---------------Study 3------------</p>
<p style="position:absolute;top:870px;left:510px;white-space:nowrap" class="ft1702">-</p>
<p style="position:absolute;top:851px;left:623px;white-space:nowrap" class="ft1702">---------------Study 4------------</p>
<p style="position:absolute;top:870px;left:713px;white-space:nowrap" class="ft1702">-</p>
<p style="position:absolute;top:928px;left:191px;white-space:nowrap" class="ft1702">Placebo</p>
<p style="position:absolute;top:890px;left:262px;white-space:nowrap" class="ft1702">----------Enbrel---------</p>
<p style="position:absolute;top:928px;left:421px;white-space:nowrap" class="ft1702">Placebo</p>
<p style="position:absolute;top:890px;left:488px;white-space:nowrap" class="ft1702">--------Enbrel-------</p>
<p style="position:absolute;top:928px;left:623px;white-space:nowrap" class="ft1702">Placebo</p>
<p style="position:absolute;top:890px;left:696px;white-space:nowrap" class="ft1702">-------Enbrel------</p>
<p style="position:absolute;top:909px;left:270px;white-space:nowrap" class="ft1702">25&#160;mg&#160;</p>
<p style="position:absolute;top:928px;left:275px;white-space:nowrap" class="ft1702">BIW</p>
<p style="position:absolute;top:909px;left:351px;white-space:nowrap" class="ft1702">50&#160;mg&#160;</p>
<p style="position:absolute;top:928px;left:356px;white-space:nowrap" class="ft1702">BIW</p>
<p style="position:absolute;top:909px;left:493px;white-space:nowrap" class="ft1702">25&#160;mg</p>
<p style="position:absolute;top:928px;left:497px;white-space:nowrap" class="ft1702">BIW</p>
<p style="position:absolute;top:909px;left:561px;white-space:nowrap" class="ft1702">50&#160;mg</p>
<p style="position:absolute;top:928px;left:565px;white-space:nowrap" class="ft1702">BIW</p>
<p style="position:absolute;top:909px;left:696px;white-space:nowrap" class="ft1702">50&#160;mg&#160;</p>
<p style="position:absolute;top:928px;left:702px;white-space:nowrap" class="ft1702">QW</p>
<p style="position:absolute;top:909px;left:763px;white-space:nowrap" class="ft1702">50&#160;mg</p>
<p style="position:absolute;top:928px;left:769px;white-space:nowrap" class="ft1702">QW</p>
<p style="position:absolute;top:947px;left:192px;white-space:nowrap" class="ft1702">n = 166</p>
<p style="position:absolute;top:966px;left:196px;white-space:nowrap" class="ft1702">wk 12</p>
<p style="position:absolute;top:947px;left:260px;white-space:nowrap" class="ft1702">n =&#160;</p>
<p style="position:absolute;top:966px;left:258px;white-space:nowrap" class="ft1702">162</p>
<p style="position:absolute;top:985px;left:260px;white-space:nowrap" class="ft1702">wk&#160;</p>
<p style="position:absolute;top:1003px;left:262px;white-space:nowrap" class="ft1702">12</p>
<p style="position:absolute;top:947px;left:300px;white-space:nowrap" class="ft1702">n =&#160;</p>
<p style="position:absolute;top:966px;left:298px;white-space:nowrap" class="ft1702">162</p>
<p style="position:absolute;top:985px;left:301px;white-space:nowrap" class="ft1704">wk&#160;<br/>24a</p>
<p style="position:absolute;top:947px;left:341px;white-space:nowrap" class="ft1702">n =&#160;</p>
<p style="position:absolute;top:966px;left:339px;white-space:nowrap" class="ft1702">164</p>
<p style="position:absolute;top:985px;left:341px;white-space:nowrap" class="ft1702">wk&#160;</p>
<p style="position:absolute;top:1003px;left:343px;white-space:nowrap" class="ft1702">12</p>
<p style="position:absolute;top:947px;left:381px;white-space:nowrap" class="ft1702">n =&#160;</p>
<p style="position:absolute;top:966px;left:379px;white-space:nowrap" class="ft1702">164</p>
<p style="position:absolute;top:985px;left:382px;white-space:nowrap" class="ft1704">wk&#160;<br/>24a</p>
<p style="position:absolute;top:947px;left:422px;white-space:nowrap" class="ft1702">n = 193</p>
<p style="position:absolute;top:966px;left:426px;white-space:nowrap" class="ft1702">wk 12</p>
<p style="position:absolute;top:947px;left:489px;white-space:nowrap" class="ft1702">n = 196</p>
<p style="position:absolute;top:966px;left:493px;white-space:nowrap" class="ft1702">wk 12</p>
<p style="position:absolute;top:947px;left:557px;white-space:nowrap" class="ft1702">n = 196</p>
<p style="position:absolute;top:966px;left:561px;white-space:nowrap" class="ft1702">wk 12</p>
<p style="position:absolute;top:947px;left:628px;white-space:nowrap" class="ft1702">n = 46</p>
<p style="position:absolute;top:966px;left:628px;white-space:nowrap" class="ft1702">wk 12</p>
<p style="position:absolute;top:947px;left:695px;white-space:nowrap" class="ft1702">n = 96</p>
<p style="position:absolute;top:966px;left:696px;white-space:nowrap" class="ft1702">wk 12</p>
<p style="position:absolute;top:947px;left:763px;white-space:nowrap" class="ft1702">n = 90</p>
<p style="position:absolute;top:966px;left:761px;white-space:nowrap" class="ft1702">wk 24a</p>
<p style="position:absolute;top:1025px;left:114px;white-space:nowrap" class="ft1702">PASI 50</p>
<p style="position:absolute;top:1025px;left:208px;white-space:nowrap" class="ft1702">14</p>
<p style="position:absolute;top:1025px;left:258px;white-space:nowrap" class="ft1702">58*</p>
<p style="position:absolute;top:1025px;left:302px;white-space:nowrap" class="ft1702">70</p>
<p style="position:absolute;top:1025px;left:339px;white-space:nowrap" class="ft1702">74*</p>
<p style="position:absolute;top:1025px;left:383px;white-space:nowrap" class="ft1702">77</p>
<p style="position:absolute;top:1025px;left:441px;white-space:nowrap" class="ft1702">9</p>
<p style="position:absolute;top:1025px;left:501px;white-space:nowrap" class="ft1702">64*</p>
<p style="position:absolute;top:1025px;left:568px;white-space:nowrap" class="ft1702">77*</p>
<p style="position:absolute;top:1025px;left:644px;white-space:nowrap" class="ft1702">9</p>
<p style="position:absolute;top:1025px;left:703px;white-space:nowrap" class="ft1702">69*</p>
<p style="position:absolute;top:1025px;left:775px;white-space:nowrap" class="ft1702">83</p>
<p style="position:absolute;top:1046px;left:114px;white-space:nowrap" class="ft1702">PASI 75</p>
<p style="position:absolute;top:1046px;left:212px;white-space:nowrap" class="ft1702">4</p>
<p style="position:absolute;top:1046px;left:258px;white-space:nowrap" class="ft1702">34*</p>
<p style="position:absolute;top:1046px;left:302px;white-space:nowrap" class="ft1702">44</p>
<p style="position:absolute;top:1046px;left:339px;white-space:nowrap" class="ft1702">49*</p>
<p style="position:absolute;top:1046px;left:383px;white-space:nowrap" class="ft1702">59</p>
<p style="position:absolute;top:1046px;left:441px;white-space:nowrap" class="ft1702">3</p>
<p style="position:absolute;top:1046px;left:501px;white-space:nowrap" class="ft1702">34*</p>
<p style="position:absolute;top:1046px;left:568px;white-space:nowrap" class="ft1702">49*</p>
<p style="position:absolute;top:1046px;left:644px;white-space:nowrap" class="ft1702">2</p>
<p style="position:absolute;top:1046px;left:703px;white-space:nowrap" class="ft1702">38*</p>
<p style="position:absolute;top:1046px;left:775px;white-space:nowrap" class="ft1702">71</p>
<p style="position:absolute;top:1071px;left:114px;white-space:nowrap" class="ft1704">DSGAb,&#160;<br/>clear or&#160;<br/>almost&#160;<br/>clear</p>
<p style="position:absolute;top:1128px;left:212px;white-space:nowrap" class="ft1702">5</p>
<p style="position:absolute;top:1128px;left:258px;white-space:nowrap" class="ft1702">34*</p>
<p style="position:absolute;top:1128px;left:302px;white-space:nowrap" class="ft1702">39</p>
<p style="position:absolute;top:1128px;left:339px;white-space:nowrap" class="ft1702">49*</p>
<p style="position:absolute;top:1128px;left:383px;white-space:nowrap" class="ft1702">55</p>
<p style="position:absolute;top:1128px;left:441px;white-space:nowrap" class="ft1702">4</p>
<p style="position:absolute;top:1128px;left:501px;white-space:nowrap" class="ft1702">39*</p>
<p style="position:absolute;top:1128px;left:568px;white-space:nowrap" class="ft1702">57*</p>
<p style="position:absolute;top:1128px;left:644px;white-space:nowrap" class="ft1702">4</p>
<p style="position:absolute;top:1128px;left:703px;white-space:nowrap" class="ft1702">39*</p>
<p style="position:absolute;top:1128px;left:775px;white-space:nowrap" class="ft1702">64</p>
</div>
<!-- Page 171 -->
<a name="171"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page171-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1710">171</p>
<p style="position:absolute;top:110px;left:114px;white-space:nowrap" class="ft1712">*p&#160;</p>
<p style="position:absolute;top:108px;left:135px;white-space:nowrap" class="ft17114">&#160;0.0001 compared with placebo</p>
<p style="position:absolute;top:129px;left:114px;white-space:nowrap" class="ft1713">a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original&#160;<br/>placebo group began receiving Enbrel 25&#160;mg BIW&#160;or 50&#160;mg once weekly from week 13 to week 24.<br/>b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</p>
<p style="position:absolute;top:205px;left:106px;white-space:nowrap" class="ft1714">Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo&#160;<br/>were&#160;apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft1718">Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement&#160;<br/>of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the&#160;<br/>occurrence of rebound (PASI&#160;</p>
<p style="position:absolute;top:299px;left:304px;white-space:nowrap" class="ft17114">&#160;150% of baseline) and for the time to relapse (defined as a loss of at&#160;</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft1713">least half of the improvement achieved between baseline and week 24). During the withdrawal period,&#160;<br/>symptoms of psoriasis gradually returned with a median time to disease relapse of 3 months. No&#160;<br/>rebound flare of disease and no psoriasis-related serious adverse events were observed. There was&#160;<br/>some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to&#160;<br/>treatment.</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft1713">In study 3, the majority of patients (77%) who were initially randomised to 50&#160;mg twice weekly and&#160;<br/>had their Enbrel dose decreased at week 12 to 25&#160;mg twice weekly maintained their PASI 75 response&#160;<br/>through week 36. For patients&#160;who received 25&#160;mg twice weekly throughout the study, the PASI 75&#160;<br/>response continued to improve between weeks 12 and 36.</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft1713">In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12&#160;<br/>(38%) compared to the placebo-treated&#160;group (2%) (p&lt;0.0001). For patients who received 50&#160;mg once&#160;<br/>weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI&#160;<br/>75 at week 24.</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft1714">In long-term&#160;(up to 34&#160;months) open-label studies where Enbrel was given without interruption,&#160;<br/>clinical responses were sustained and safety was comparable to shorter-term studies.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft1714">An analysis of clinical trial data&#160;did not reveal any&#160;baseline disease characteristics that would assist&#160;<br/>clinicians in selecting the most appropriate dosing&#160;option (intermittent or continuous). Consequently,&#160;<br/>the choice of intermittent or continuous therapy should be based upon physician judgment and&#160;<br/>individual patient needs.</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft1714"><i>Antibodies to Enbrel<br/></i>Antibodies to etanercept have been detected in the sera of some&#160;subjects treated with etanercept.&#160;<br/>These antibodies have all been non-neutralising and are generally transient. There appears to be no&#160;<br/>correlation between antibody development and clinical response or adverse events.</p>
<p style="position:absolute;top:870px;left:106px;white-space:nowrap" class="ft1714">In subjects treated with approved doses&#160;of etanercept in clinical trials for up to 12&#160;months, cumulative&#160;<br/>rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5%&#160;<br/>of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of&#160;subjects with&#160;<br/>psoriasis, 9.7% of subjects with paediatric psoriasis, and 4.8% of subjects with juvenile idiopathic&#160;<br/>arthritis.&#160;</p>
<p style="position:absolute;top:984px;left:106px;white-space:nowrap" class="ft1714">The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to&#160;<br/>3.5&#160;years) increases over time, as expected. However, due to their transient nature, the incidence of&#160;<br/>antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis&#160;<br/>subjects and psoriasis subjects.</p>
<p style="position:absolute;top:1079px;left:106px;white-space:nowrap" class="ft1713">In a long-term psoriasis study in which patients received 50&#160;mg twice weekly for 96&#160;weeks, the&#160;<br/>incidence of antibodies observed at each assessment point was up to approximately 9%.</p>
</div>
<!-- Page 172 -->
<a name="172"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page172-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1720">172</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1722">Paediatric population</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft1728"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>The safety and efficacy of Enbrel were assessed in&#160;a two-part study in 69 children with&#160;<br/>polyarticular-course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset&#160;<br/>types (polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to&#160;<br/>severely&#160;active polyarticular-course&#160;juvenile idiopathic arthritis refractory to, or intolerant of,&#160;<br/>methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal&#160;<br/>anti-inflammatory drug and/or prednisone (&lt;&#160;0.2&#160;mg/kg/day or 10&#160;mg maximum).&#160;In part 1, all patients&#160;<br/>received 0.4&#160;mg/kg (maximum 25&#160;mg per dose) Enbrel subcutaneously twice weekly. In part 2,&#160;<br/>patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for&#160;<br/>four months and assessed for disease&#160;flare. Responses were measured using the ACR Pedi 30, defined&#160;<br/>as&#160;</p>
<p style="position:absolute;top:336px;left:124px;white-space:nowrap" class="ft17214">&#160;30% improvement in at least three of six and&#160;&#160;30% worsening in no more than one of six JRA&#160;</p>
<p style="position:absolute;top:357px;left:106px;white-space:nowrap" class="ft1728">core set criteria, including active joint count, limitation of motion, physician and patient/parent global&#160;<br/>assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was&#160;<br/>defined as a&#160;</p>
<p style="position:absolute;top:394px;left:189px;white-space:nowrap" class="ft17214">&#160;30% worsening in three of six JRA core set criteria and&#160;&#160;30% improvement in not&#160;</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft1722">more than one of the six JRA core set criteria and a minimum of two active joints.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft1723">In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In&#160;<br/>part 2, 6&#160;of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of&#160;<br/>26&#160;(77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was&#160;<br/>&#160;116&#160;days for patients who received Enbrel and 28 days for patients who received placebo. Of&#160;<br/>patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the&#160;<br/>patients remaining on Enbrel continued to improve from month 3 through month 7, while those who&#160;<br/>received placebo did not improve.</p>
<p style="position:absolute;top:606px;left:106px;white-space:nowrap" class="ft1724">In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of&#160;<br/>4&#160;years at time of enrolment) continued to receive Enbrel for up to 10&#160;years.&#160;Rates of serious adverse&#160;<br/>events and serious infections did not increase with long-term&#160;exposure.</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft1723">Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or&#160;methotrexate&#160;<br/>monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18&#160;years&#160;<br/>with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more&#160;<br/>commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus&#160;<br/>2%), and the infections associated with etanercept use were of a more severe nature.</p>
<p style="position:absolute;top:796px;left:106px;white-space:nowrap" class="ft1723">In another open-label single-arm&#160;study&#160;(n=127), 60 patients with extended oligoarthritis&#160;(EO)&#160;<br/>(15&#160;patients aged&#160;2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17&#160;years old), 38 patients&#160;<br/>with enthesitis-related arthritis (12 to 17&#160;years old),&#160;and 29 patients with psoriatic arthritis (12 to&#160;<br/>17&#160;years old) were treated with Enbrel at a dose of 0.8&#160;mg/kg (up&#160;to a maximum of 50&#160;mg per dose)&#160;<br/>administered weekly for 12&#160;weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi&#160;<br/>30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender&#160;<br/>joints and physician global assessment. The safety profile was consistent with that observed in other&#160;<br/>JIA studies.</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft1724">Of the 127&#160;patients in the parent study, 109 participated in the open-label extension study and were&#160;<br/>followed for&#160;an additional&#160;8 years&#160;for a total of up to 10&#160;years.&#160;At the end of the extension study,&#160;<br/>84/109 (77%) patients had completed the study; 27 (25%) while actively taking&#160;Enbrel, 7 (6%) had&#160;<br/>withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started&#160;Enbrel&#160;following an&#160;<br/>earlier withdrawal from treatment; and 45 (41%) had stopped&#160;Enbrel&#160;(but remained under&#160;<br/>observation);&#160;25/109 (23%) patients&#160;permanently discontinued from the&#160;study.&#160;Improvements in&#160;<br/>clinical status achieved in the parent study were generally maintained for all efficacy endpoints&#160;during&#160;<br/>the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-<br/>retreatment period once during the extension study based on investigator’s judgement of clinical&#160;<br/>response. 30&#160;patients entered the withdrawal period. 17&#160;patients were reported to have a flare (defined&#160;<br/>as&#160;≥&#160;30% worsening in at least 3 of the 6 ACR Pedi components with&#160;≥&#160;30% improvement in not more&#160;</p>
</div>
<!-- Page 173 -->
<a name="173"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page173-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1730">173</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1733">than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after&#160;<br/>Enbrel withdrawal was 190&#160;days. 13&#160;patients were&#160;re-treated and the median time to re-treatment from&#160;<br/>withdrawal was estimated as 274&#160;days. Due to the small number of data points, these results should be&#160;<br/>interpreted with caution.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1732">The safety profile was consistent with that observed in&#160;the parent study.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1733">Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of&#160;<br/>continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy.&#160;<br/>Additionally, studies have not been conducted to assess&#160;the effects of&#160;reducing the recommended dose&#160;<br/>of Enbrel following its long-term&#160;use in patients with JIA.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1733"><i>Paediatric patients with plaque psoriasis<br/></i>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211&#160;<br/>paediatric patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by a sPGA&#160;<br/>score&#160;≥&#160;3, involving&#160;≥&#160;10% of the BSA, and PASI&#160;≥&#160;12). Eligible patients had a history&#160;of receiving&#160;<br/>phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft1733">Patients received Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) or placebo once weekly for 12 weeks. At week 12,&#160;<br/>more patients randomised to Enbrel had positive efficacy responses (e.g. PASI 75) than those&#160;<br/>randomised to placebo.</p>
<p style="position:absolute;top:540px;left:263px;white-space:nowrap" class="ft1731"><b>Paediatric Plaque Psoriasis Outcomes at 12 Weeks</b></p>
<p style="position:absolute;top:569px;left:495px;white-space:nowrap" class="ft1731"><b>Enbrel</b></p>
<p style="position:absolute;top:588px;left:465px;white-space:nowrap" class="ft1731"><b>0.8&#160;mg/kg Once&#160;</b></p>
<p style="position:absolute;top:607px;left:493px;white-space:nowrap" class="ft1731"><b>Weekly</b></p>
<p style="position:absolute;top:626px;left:487px;white-space:nowrap" class="ft1731"><b>(N = 106)</b></p>
<p style="position:absolute;top:607px;left:647px;white-space:nowrap" class="ft1731"><b>Placebo</b></p>
<p style="position:absolute;top:626px;left:642px;white-space:nowrap" class="ft1731"><b>(N = 105)</b></p>
<p style="position:absolute;top:645px;left:136px;white-space:nowrap" class="ft1732">PASI 75, n (%)</p>
<p style="position:absolute;top:645px;left:486px;white-space:nowrap" class="ft1732">60 (57%)a</p>
<p style="position:absolute;top:645px;left:644px;white-space:nowrap" class="ft1732">12 (11%)</p>
<p style="position:absolute;top:664px;left:136px;white-space:nowrap" class="ft1732">PASI 50, n (%)</p>
<p style="position:absolute;top:664px;left:486px;white-space:nowrap" class="ft1732">79 (75%)a</p>
<p style="position:absolute;top:664px;left:644px;white-space:nowrap" class="ft1732">24 (23%)</p>
<p style="position:absolute;top:696px;left:136px;white-space:nowrap" class="ft1732">sPGA&#160;“clear” or “minimal”, n (%)</p>
<p style="position:absolute;top:696px;left:486px;white-space:nowrap" class="ft1732">56&#160;(53%)a</p>
<p style="position:absolute;top:696px;left:644px;white-space:nowrap" class="ft1732">14 (13%)</p>
<p style="position:absolute;top:716px;left:136px;white-space:nowrap" class="ft1734">Abbreviation: sPGA-static Physician Global Assessment.<br/>a.&#160;p &lt; 0.0001 compared with placebo.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft1733">After the 12-week double-blind treatment period, all patients received Enbrel 0.8&#160;mg/kg (up to 50&#160;mg)&#160;<br/>once&#160;weekly for additional 24 weeks. Responses observed during the open-label period were similar to&#160;<br/>those observed in the double-blind period.</p>
<p style="position:absolute;top:870px;left:106px;white-space:nowrap" class="ft1733">During a randomised withdrawal period, significantly more patients re-randomised to placebo&#160;<br/>experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to&#160;<br/>Enbrel. With continued therapy, responses were maintained up to 48 weeks.</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft1733">The long-term safety and effectiveness of Enbrel 0.8&#160;mg/kg (up to 50&#160;mg) once weekly was assessed&#160;<br/>in an open-label extension study of 181 paediatric subjects with plaque psoriasis for up to 2 years&#160;<br/>beyond the 48 week study discussed above. Long-term experience with Enbrel was generally&#160;<br/>comparable to the original 48-week study and did not reveal any new safety findings.&#160;</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft1731"><b>5.2</b></p>
<p style="position:absolute;top:1041px;left:149px;white-space:nowrap" class="ft1731"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:1079px;left:106px;white-space:nowrap" class="ft1733">Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA)&#160;<br/>method, which may detect ELISA-reactive degradation products as well as the parent compound.</p>
</div>
<!-- Page 174 -->
<a name="174"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page174-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1740">174</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1742">Absorption</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1748">Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum&#160;<br/>concentration approximately 48&#160;hours after a single dose. The absolute bioavailability is 76%. With&#160;<br/>twice weekly doses, it is anticipated that steady-state concentrations are approximately twice as high&#160;<br/>as those observed after single doses. After a single subcutaneous dose of 25&#160;mg Enbrel, the average&#160;<br/>maximum serum concentration observed in healthy volunteers was 1.65&#160;</p>
<p style="position:absolute;top:221px;left:585px;white-space:nowrap" class="ft17414">&#160;0.66&#160;g/ml, and the area&#160;</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1742">under the curve was 235</p>
<p style="position:absolute;top:241px;left:272px;white-space:nowrap" class="ft17414">&#160;96.6&#160;ghr/ml.</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft1743">Mean serum concentration profiles at steady state in treated RA patients were Cmax&#160;of 2.4&#160;mg/l vs.&#160;<br/>2.6&#160;mg/l, Cmin&#160;of 1.2&#160;mg/l vs. 1.4&#160;mg/l, and partial AUC of 297&#160;mgh/l vs. 316&#160;mgh/l for 50&#160;mg Enbrel&#160;<br/>once weekly (n=21)&#160;vs. 25&#160;mg Enbrel twice weekly (n=16), respectively. In an open-label, single-<br/>dose, two-treatment, crossover study in healthy volunteers, etanercept administered as a single&#160;<br/>50&#160;mg/ml injection was found to be bioequivalent to two simultaneous injections of&#160;25&#160;mg/ml.</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft1748">In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady&#160;<br/>state AUCs were 466</p>
<p style="position:absolute;top:413px;left:251px;white-space:nowrap" class="ft17414">ghr/ml and 474&#160;ghr/ml for 50&#160;mg Enbrel once weekly (N&#160;= 154) and 25&#160;mg&#160;</p>
<p style="position:absolute;top:434px;left:106px;white-space:nowrap" class="ft1742">twice weekly (N = 148), respectively.</p>
<p style="position:absolute;top:472px;left:106px;white-space:nowrap" class="ft1742">Distribution</p>
<p style="position:absolute;top:510px;left:106px;white-space:nowrap" class="ft1744">A biexponential curve is required to describe the concentration time curve of etanercept. The central&#160;<br/>volume of distribution of etanercept is 7.6&#160;l, while the volume of distribution at steady-state is 10.4&#160;l.</p>
<p style="position:absolute;top:567px;left:106px;white-space:nowrap" class="ft1742">Elimination</p>
<p style="position:absolute;top:605px;left:106px;white-space:nowrap" class="ft1744">Etanercept is cleared slowly from the body. The half-life is long, approximately 70&#160;hours. Clearance is&#160;<br/>approximately 0.066&#160;l/hr in patients with rheumatoid arthritis, somewhat lower than the value of&#160;<br/>0.11&#160;l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid&#160;<br/>arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</p>
<p style="position:absolute;top:700px;left:106px;white-space:nowrap" class="ft1742">There is no apparent pharmacokinetic difference between males and females.</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft1742">Linearity</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft1744">Dose proportionality has not been formally evaluated, but there is&#160;no apparent saturation of clearance&#160;<br/>across the dosing range.</p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft1742">Special populations</p>
<p style="position:absolute;top:870px;left:106px;white-space:nowrap" class="ft1743"><i>Renal impairment<br/></i>Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept&#160;<br/>to patients and volunteers, increased etanercept concentrations were not observed in patients with&#160;<br/>acute renal failure. The presence of renal impairment should not require a change in dosage.</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft1744"><i>Hepatic impairment<br/></i>Increased etanercept concentrations were not observed in patients with acute hepatic failure.&#160;The&#160;<br/>presence of hepatic impairment should not require a change in dosage.</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft1744"><i>Elderly<br/></i>The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept&#160;<br/>serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to&#160;<br/>estimates in patients less than 65 years of age.</p>
</div>
<!-- Page 175 -->
<a name="175"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page175-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1750">175</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1752">Paediatric population</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft1754"><i>Paediatric patients with juvenile idiopathic arthritis<br/></i>In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged&#160;4 to 17&#160;years)&#160;<br/>were administered 0.4&#160;mg&#160;Enbrel/kg twice weekly for three months. Serum concentration profiles&#160;<br/>were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4&#160;years of age)&#160;<br/>had reduced clearance (increased clearance when&#160;normalised by weight) compared with older children&#160;<br/>(12 years of age) and adults. Simulation of dosing suggests that while older children (10-17&#160;years of&#160;<br/>age) will have serum levels close to those seen in adults, younger children will have appreciably lower<br/>levels.</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft1753"><i>Paediatric patients with plaque psoriasis<br/></i>Patients with paediatric plaque psoriasis (aged 4 to 17&#160;years) were administered 0.8&#160;mg/kg (up to a&#160;<br/>maximum dose of 50&#160;mg per week) of etanercept once weekly for up to 48 weeks. The mean serum&#160;<br/>steady state trough concentrations ranged from 1.6&#160;to 2.1&#160;mcg/ml at weeks 12, 24, and 48. These mean&#160;<br/>concentrations in patients with paediatric plaque psoriasis were similar to the concentrations observed&#160;<br/>in patients with&#160;juvenile idiopathic arthritis&#160;(treated with 0.4&#160;mg/kg etanercept twice weekly, up to&#160;<br/>maximum dose of 50&#160;mg per week). These mean concentrations were similar to those seen in adult&#160;<br/>patients with plaque psoriasis treated with 25&#160;mg etanercept twice weekly.</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft1751"><b>5.3</b></p>
<p style="position:absolute;top:489px;left:149px;white-space:nowrap" class="ft1751"><b>Preclinical safety data</b></p>
<p style="position:absolute;top:527px;left:106px;white-space:nowrap" class="ft1754">In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel&#160;<br/>was considered to be non-genotoxic from a battery of&#160;<i>in vitro&#160;</i>and&#160;<i>in vivo&#160;</i>studies. Carcinogenicity&#160;<br/>studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel&#160;<br/>due to the development of neutralising antibodies in rodents.</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft1754">Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single&#160;<br/>subcutaneous dose of 2000&#160;mg/kg or a single intravenous dose of&#160;1000&#160;mg/kg. Enbrel did not elicit&#160;<br/>dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous&#160;<br/>administration for 4 or 26&#160;consecutive weeks at a dose (15&#160;mg/kg) that resulted in AUC-based serum&#160;<br/>drug concentrations that were over 27-fold higher than that obtained in humans at the recommended&#160;<br/>dose of 25&#160;mg.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1751"><b>6.</b></p>
<p style="position:absolute;top:774px;left:146px;white-space:nowrap" class="ft1751"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft1751"><b>6.1</b></p>
<p style="position:absolute;top:812px;left:149px;white-space:nowrap" class="ft1751"><b>List of excipients</b></p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft1754">Sucrose&#160;<br/>Sodium chloride<br/>L-Arginine hydrochloride<br/>Sodium phosphate monobasic dihydrate<br/>Sodium phosphate dibasic&#160;dihydrate<br/>Water for injections</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft1751"><b>6.2</b></p>
<p style="position:absolute;top:983px;left:149px;white-space:nowrap" class="ft1751"><b>Incompatibilities</b></p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft1754">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft1751"><b>6.3</b></p>
<p style="position:absolute;top:1077px;left:149px;white-space:nowrap" class="ft1751"><b>Shelf life</b></p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft1752">30 months.</p>
</div>
<!-- Page 176 -->
<a name="176"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page176-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1760">176</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1761"><b>6.4</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft1761"><b>Special precautions for storage</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft1762">Store in a&#160;refrigerator (2</p>
<p style="position:absolute;top:145px;left:267px;white-space:nowrap" class="ft17614">C&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft1763">Enbrel may be stored&#160;at temperatures&#160;up to&#160;a maximum of&#160;25°C for a single period of up to&#160;four&#160;<br/>weeks; after which,&#160;it&#160;should not be refrigerated again. Enbrel should be discarded if not used within&#160;<br/>four weeks of removal from refrigeration.</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft1762">Keep the dose-dispenser&#160;cartridges in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft1761"><b>6.5</b></p>
<p style="position:absolute;top:299px;left:149px;white-space:nowrap" class="ft1761"><b>Nature and contents of container</b></p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft1764">25&#160;mg solution for injection in dose-dispenser cartridge<br/>Dose-dispenser cartridge&#160;with integrated&#160;25&#160;mg pre-filled Enbrel&#160;syringe. The pre-filled syringe inside&#160;<br/>the&#160;dose-dispenser cartridge&#160;is made from clear type 1 glass with a staked stainless steel 27 gauge&#160;<br/>needle, rigid needle&#160;cover, and rubber stopper. The rigid needle&#160;cover&#160;of the pre-filled syringe&#160;contains&#160;<br/>dry natural rubber (a derivative of latex). See section 4.4.&#160;</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft1764">Cartons contain 4, 8 or 24 Enbrel&#160;dose-dispenser cartridges with&#160;8, 16 or 48&#160;alcohol swabs. Not all&#160;<br/>pack sizes may be marketed.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft1763">50&#160;mg solution for injection in dose-dispenser&#160;cartridge<br/>Dose-dispenser cartridge&#160;with integrated&#160;50&#160;mg pre-filled Enbrel&#160;syringe. The pre-filled syringe inside&#160;<br/>the&#160;dose-dispenser cartridge&#160;is made from clear type 1 glass with a staked stainless steel 27 gauge&#160;<br/>needle, rigid needle&#160;cover, and rubber stopper. The rigid needle&#160;cover&#160;of the&#160;pre-filled syringe&#160;contains&#160;<br/>dry natural rubber (a derivative of latex). See section 4.4.&#160;</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft1763">Cartons contain 2, 4 or 12 Enbrel dose-dispenser cartridges with&#160;4, 8 or 24&#160;alcohol swabs.&#160;Not all pack&#160;<br/>sizes may be marketed.</p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft1761"><b>6.6</b></p>
<p style="position:absolute;top:678px;left:149px;white-space:nowrap" class="ft1761"><b>Special precautions for disposal and other handling</b></p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft1761"><b>Instructions for use and handling</b></p>
<p style="position:absolute;top:754px;left:106px;white-space:nowrap" class="ft1764">Before injection, Enbrel dose-dispenser cartridges should be allowed to reach room temperature&#160;<br/>(approximately 15 to 30&#160;minutes). The needle&#160;cover&#160;should not be removed while allowing the&#160;<br/>dose-dispenser cartridge to reach room temperature.&#160;By looking through the inspection window, the&#160;<br/>solution should be clear to slightly opalescent, colourless to pale yellow or pale brown and may&#160;<br/>contain small white or almost transparent particles of protein.&#160;</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft1764">Comprehensive instructions for the preparation and administration of Enbrel dose-dispenser cartridge&#160;<br/>are given in the package leaflet and in the user manual provided with the SMARTCLIC device.</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft1764">This medicinal product (dose-dispenser cartridge) is for single use only&#160;in conjunction with the&#160;<br/>SMARTCLIC device.</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft1763">Any unused&#160;medicinal&#160;product or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft1761"><b>7.</b></p>
<p style="position:absolute;top:1058px;left:146px;white-space:nowrap" class="ft1761"><b>MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft1763">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
</div>
<!-- Page 177 -->
<a name="177"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page177-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1770">177</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft1771"><b>8.</b></p>
<p style="position:absolute;top:146px;left:146px;white-space:nowrap" class="ft1771"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft1774">Enbrel 25&#160;mg solution for injection in dose-dispenser cartridge<br/>EU/1/99/126/027<br/>EU/1/99/126/028<br/>EU/1/99/126/029</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1774">Enbrel 50&#160;mg solution&#160;for injection in dose-dispenser cartridge<br/>EU/1/99/126/030<br/>EU/1/99/126/031<br/>EU/1/99/126/032</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft1771"><b>9.</b></p>
<p style="position:absolute;top:392px;left:146px;white-space:nowrap" class="ft1771"><b>DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft1773">Date of first authorisation:&#160;03 February 2000<br/>Date of last renewal:&#160;26&#160;November&#160;2009</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft1771"><b>10.</b></p>
<p style="position:absolute;top:506px;left:146px;white-space:nowrap" class="ft1771"><b>DATE OF&#160;REVISION OF THE TEXT</b></p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1774">Detailed information on this&#160;medicinal&#160;product is available on the website of the European Medicines&#160;<br/>Agency&#160;<a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>.</p>
</div>
<!-- Page 178 -->
<a name="178"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page178-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1780">178</p>
<p style="position:absolute;top:544px;left:409px;white-space:nowrap" class="ft1781"><b>ANNEX II</b></p>
<p style="position:absolute;top:582px;left:192px;white-space:nowrap" class="ft1781"><b>A.&#160;MANUFACTURER OF THE&#160;BIOLOGICAL ACTIVE SUBSTANCE&#160;AND</b></p>
<p style="position:absolute;top:601px;left:223px;white-space:nowrap" class="ft1781"><b>MANUFACTURER&#160;RESPONSIBLE FOR BATCH&#160;RELEASE</b></p>
<p style="position:absolute;top:639px;left:192px;white-space:nowrap" class="ft1781"><b>B.&#160;CONDITIONS&#160;OR RESTRICTIONS REGARDING SUPPLY AND USE</b></p>
<p style="position:absolute;top:677px;left:192px;white-space:nowrap" class="ft1781"><b>C.&#160;OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING</b></p>
<p style="position:absolute;top:696px;left:223px;white-space:nowrap" class="ft1781"><b>AUTHORISATION</b></p>
<p style="position:absolute;top:734px;left:192px;white-space:nowrap" class="ft1781"><b>D.&#160;CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND&#160;</b></p>
<p style="position:absolute;top:753px;left:221px;white-space:nowrap" class="ft1781"><b>EFFECTIVE USE OF THE MEDICINAL PRODUCT</b></p>
</div>
<!-- Page 179 -->
<a name="179"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page179-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1790">179</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1791"><b>A.</b></p>
<p style="position:absolute;top:108px;left:147px;white-space:nowrap" class="ft17923"><b>MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND&#160;<br/>MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</b></p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1792">Name and address of the manufacturer of the biological active substance</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1794">Pfizer Ireland Pharmaceuticals<br/>Grange Castle&#160;Business Park<br/>Clondalkin<br/>Dublin 22<br/>Ireland</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1792">Name and address of the manufacturer responsible for batch release</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft1794">Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1791"><b>B.</b></p>
<p style="position:absolute;top:468px;left:149px;white-space:nowrap" class="ft1791"><b>CONDITIONS&#160;OR RESTRICTIONS REGARDING SUPPLY AND USE</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft1793">Medicinal product&#160;subject to restricted medical prescription (see Annex I: Summary of Product&#160;<br/>Characteristics,&#160;section&#160;4.2).</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft1791"><b>C.</b></p>
<p style="position:absolute;top:583px;left:147px;white-space:nowrap" class="ft17923"><b>OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING<br/>AUTHORISATION</b></p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft17914">&#160;<b>Periodic&#160;safety&#160;update&#160;reports&#160;(PSURs)</b></p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1793">The requirements&#160;for submission of&#160;PSURs&#160;for this medicinal product are&#160;set out in the list of Union&#160;<br/>reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and&#160;any&#160;<br/>subsequent updates&#160;published on the European medicines web-portal.</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft1791"><b>D.</b></p>
<p style="position:absolute;top:776px;left:147px;white-space:nowrap" class="ft17923"><b>CONDITIONS OR&#160;RESTRICTIONS WITH REGARD TO THE SAFE AND&#160;<br/>EFFECTIVE USE OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft17914">&#160;<b>Risk&#160;management&#160;plan (RMP)</b></p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft1794">The&#160;marketing authorisation holder (MAH)&#160;shall perform the required pharmacovigilance activities&#160;<br/>and interventions detailed in the agreed RMP presented in Module 1.8.2 of the&#160;marketing&#160;authorisation&#160;<br/>and any agreed subsequent updates of the RMP.</p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft1792">An updated RMP should be submitted:</p>
<p style="position:absolute;top:966px;left:120px;white-space:nowrap" class="ft17914">&#160;At the request of the European Medicines Agency;</p>
<p style="position:absolute;top:986px;left:120px;white-space:nowrap" class="ft17914">&#160;Whenever the risk management system is modified, especially as the&#160;result of new information&#160;</p>
<p style="position:absolute;top:1007px;left:147px;white-space:nowrap" class="ft1794">being received that may lead to a significant change to the benefit/risk profile or as the result of&#160;<br/>an important (pharmacovigilance or risk minimisation) milestone being reached.</p>
<p style="position:absolute;top:1063px;left:106px;white-space:nowrap" class="ft17914"></p>
<p style="position:absolute;top:1065px;left:149px;white-space:nowrap" class="ft1791"><b>Additional risk minimisation measures&#160;</b></p>
<p style="position:absolute;top:1103px;left:106px;white-space:nowrap" class="ft1793">Prior to&#160;the use of etanercept in each Member State the Marketing Authorisation Holder (MAH) must&#160;<br/>agree about the content and format of the educational programme, including communication media,&#160;</p>
</div>
<!-- Page 180 -->
<a name="180"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft18036{font-size:17px;font-family:PZJVUM+CourierNew;color:#000000;}
	.ft18037{font-size:17px;font-family:PZJVUM+Wingdings;color:#000000;}
-->
</style>
<div id="page180-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1800">180</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft1804">distribution modalities, and any other aspects of the programme, with the National Competent&#160;<br/>Authority.&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1804">The educational programme is aimed at&#160;reducing the risk of serious infections and congestive heart&#160;<br/>failure&#160;and&#160;ensuring the traceability of etanercept drug product.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1803">The MAH shall ensure that in each Member State where&#160;etanercept is marketed, all healthcare&#160;<br/>professionals who are expected to prescribe etanercept and all patients who are expected to use&#160;<br/>etanercept have access to/are provided with the following educational materials:</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft18014">&#160;Patient&#160;Card</p>
<p style="position:absolute;top:339px;left:160px;white-space:nowrap" class="ft18036">o&#160;Patient&#160;Cards are provided&#160;to etanercept prescribing physicians for distribution to patients&#160;</p>
<p style="position:absolute;top:359px;left:187px;white-space:nowrap" class="ft1809">receiving etanercept. This card provides the following important safety information for&#160;<br/>patients:</p>
<p style="position:absolute;top:411px;left:241px;white-space:nowrap" class="ft18037"></p>
<p style="position:absolute;top:411px;left:268px;white-space:nowrap" class="ft1809">Etanercept treatment may increase the risk of infection and congestive heart<br/>failure in adults</p>
<p style="position:absolute;top:464px;left:241px;white-space:nowrap" class="ft18037"></p>
<p style="position:absolute;top:464px;left:268px;white-space:nowrap" class="ft1809">Signs or symptoms of these safety concerns and when to seek attention from a&#160;<br/>healthcare professional&#160;</p>
<p style="position:absolute;top:516px;left:241px;white-space:nowrap" class="ft18037"></p>
<p style="position:absolute;top:516px;left:268px;white-space:nowrap" class="ft1809">Instructions to record the brand name and batch number of the medication to&#160;<br/>ensure traceability&#160;</p>
<p style="position:absolute;top:569px;left:241px;white-space:nowrap" class="ft18037"></p>
<p style="position:absolute;top:569px;left:268px;white-space:nowrap" class="ft1802">Contact details of the etanercept prescriber</p>
</div>
<!-- Page 181 -->
<a name="181"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page181-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1810">181</p>
<p style="position:absolute;top:506px;left:406px;white-space:nowrap" class="ft1811"><b>ANNEX III</b></p>
<p style="position:absolute;top:544px;left:294px;white-space:nowrap" class="ft1811"><b>LABELLING AND PACKAGE LEAFLET</b></p>
</div>
<!-- Page 182 -->
<a name="182"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page182-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1820">182</p>
<p style="position:absolute;top:525px;left:387px;white-space:nowrap" class="ft1821"><b>A. LABELLING</b></p>
</div>
<!-- Page 183 -->
<a name="183"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page183-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1830">183</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1831"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1831"><b>CARTON TEXT&#160;–&#160;EU/1/99/126/002</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1831"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1831"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1834">Enbrel&#160;25&#160;mg&#160;powder for solution for injection<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft1831"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft1831"><b>STATEMENT OF ACTIVE SUBSTANCE(S)</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft1832">Each vial of Enbrel contains&#160;25&#160;mg&#160;etanercept.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft1831"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft1831"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft1833">The other ingredients in Enbrel are:<br/>Powder: Mannitol, sucrose and trometamol.</p>
<p style="position:absolute;top:532px;left:115px;white-space:nowrap" class="ft1831"><b>4.</b></p>
<p style="position:absolute;top:532px;left:157px;white-space:nowrap" class="ft1831"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft1833">Powder for solution for injection<br/>4 vials of powder<br/>8 alcohol swabs</p>
<p style="position:absolute;top:666px;left:115px;white-space:nowrap" class="ft1831"><b>5.</b></p>
<p style="position:absolute;top:666px;left:157px;white-space:nowrap" class="ft1831"><b>METHOD AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft1833">Read the package leaflet before use.<br/>Subcutaneous use.</p>
<p style="position:absolute;top:782px;left:115px;white-space:nowrap" class="ft1831"><b>6.</b></p>
<p style="position:absolute;top:782px;left:157px;white-space:nowrap" class="ft18323"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:839px;left:106px;white-space:nowrap" class="ft1832">Keep out of the&#160;sight&#160;and&#160;reach&#160;of children.</p>
<p style="position:absolute;top:897px;left:115px;white-space:nowrap" class="ft1831"><b>7.</b></p>
<p style="position:absolute;top:897px;left:157px;white-space:nowrap" class="ft1831"><b>OTHER SPECIAL WARNING(S), IF NECESSARY</b></p>
<p style="position:absolute;top:955px;left:115px;white-space:nowrap" class="ft1831"><b>8.</b></p>
<p style="position:absolute;top:955px;left:157px;white-space:nowrap" class="ft1831"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1832">EXP</p>
</div>
<!-- Page 184 -->
<a name="184"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page184-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1840">184</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1841"><b>9.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft1841"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft1844">Store in a&#160;refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft1842">Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft1842">After preparing the Enbrel solution, immediate use is recommended (up to a maximum of 6 hours).&#160;</p>
<p style="position:absolute;top:300px;left:115px;white-space:nowrap" class="ft1841"><b>10.</b></p>
<p style="position:absolute;top:300px;left:157px;white-space:nowrap" class="ft18423"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:396px;left:115px;white-space:nowrap" class="ft1841"><b>11.</b></p>
<p style="position:absolute;top:396px;left:157px;white-space:nowrap" class="ft1841"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:435px;left:106px;white-space:nowrap" class="ft1843">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:549px;left:115px;white-space:nowrap" class="ft1841"><b>12.</b></p>
<p style="position:absolute;top:549px;left:157px;white-space:nowrap" class="ft1841"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft1842">EU/1/99/126/002</p>
<p style="position:absolute;top:646px;left:115px;white-space:nowrap" class="ft1841"><b>13.</b></p>
<p style="position:absolute;top:646px;left:157px;white-space:nowrap" class="ft1841"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft1842">Lot</p>
<p style="position:absolute;top:742px;left:115px;white-space:nowrap" class="ft1841"><b>14.</b></p>
<p style="position:absolute;top:742px;left:157px;white-space:nowrap" class="ft1841"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:800px;left:115px;white-space:nowrap" class="ft1841"><b>15.</b></p>
<p style="position:absolute;top:800px;left:157px;white-space:nowrap" class="ft1841"><b>INSTRUCTIONS ON USE</b></p>
<p style="position:absolute;top:839px;left:106px;white-space:nowrap" class="ft1842">You will also need 1&#160;ml&#160;of water for injections and a syringe to administer Enbrel</p>
<p style="position:absolute;top:897px;left:115px;white-space:nowrap" class="ft1841"><b>16.</b></p>
<p style="position:absolute;top:897px;left:157px;white-space:nowrap" class="ft1841"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft1842">Enbrel&#160;25&#160;mg</p>
<p style="position:absolute;top:995px;left:106px;white-space:nowrap" class="ft1841"><b>17.</b></p>
<p style="position:absolute;top:995px;left:149px;white-space:nowrap" class="ft1841"><b>UNIQUE IDENTIFIER&#160;-&#160;2D BARCODE</b></p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft1842">2D barcode carrying the unique identifier included.</p>
</div>
<!-- Page 185 -->
<a name="185"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page185-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1850">185</p>
<p style="position:absolute;top:109px;left:115px;white-space:nowrap" class="ft1851"><b>18.</b></p>
<p style="position:absolute;top:109px;left:157px;white-space:nowrap" class="ft1851"><b>UNIQUE IDENTIFIER&#160;-&#160;HUMAN READABLE DATA</b></p>
<p style="position:absolute;top:148px;left:106px;white-space:nowrap" class="ft1854">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 186 -->
<a name="186"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page186-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1860">186</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1861"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1861"><b>TEXT FOR VIAL LABEL&#160;–&#160;EU/1/99/126/002</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1861"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1861"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1863">Enbrel&#160;25&#160;mg&#160;powder for injection<br/>etanercept<br/>Subcutaneous use</p>
<p style="position:absolute;top:339px;left:115px;white-space:nowrap" class="ft1861"><b>2.</b></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft1861"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft1862">Read the package leaflet before use.</p>
<p style="position:absolute;top:436px;left:115px;white-space:nowrap" class="ft1861"><b>3.</b></p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft1861"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft1862">EXP</p>
<p style="position:absolute;top:532px;left:115px;white-space:nowrap" class="ft1861"><b>4.</b></p>
<p style="position:absolute;top:532px;left:157px;white-space:nowrap" class="ft1861"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft1862">Lot</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft1861"><b>5.</b></p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft1861"><b>CONTENTS&#160;BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft1861"><b>6.</b></p>
<p style="position:absolute;top:691px;left:149px;white-space:nowrap" class="ft1861"><b>OTHER</b></p>
</div>
<!-- Page 187 -->
<a name="187"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page187-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1870">187</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1871"><b>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1871"><b>TEXT FOR TRAY BACKING&#160;–&#160;EU/1/99/126/002</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1871"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1871"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1874">Enbrel&#160;25&#160;mg&#160;powder for solution for injection<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft1871"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft1871"><b>NAME OF THE&#160;MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft1872">Pfizer&#160;Europe MA EEIG</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft1871"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft1871"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft1872">EXP</p>
<p style="position:absolute;top:513px;left:115px;white-space:nowrap" class="ft1871"><b>4.</b></p>
<p style="position:absolute;top:513px;left:157px;white-space:nowrap" class="ft1871"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft1872">Lot</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft1871"><b>5.</b></p>
<p style="position:absolute;top:611px;left:149px;white-space:nowrap" class="ft1871"><b>OTHER</b></p>
</div>
<!-- Page 188 -->
<a name="188"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page188-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1880">188</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1881"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1881"><b>CARTON TEXT&#160;–&#160;EU/1/99/126/003-005</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1881"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1881"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1884">Enbrel&#160;25&#160;mg&#160;powder and solvent for solution for injection<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft1881"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft1881"><b>STATEMENT OF ACTIVE SUBSTANCE(S)</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft1882">Each vial of Enbrel contains&#160;25&#160;mg&#160;etanercept.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft1881"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft1881"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft1884">The other ingredients in Enbrel are:<br/>Powder: Mannitol, sucrose and trometamol<br/>Solvent: Water for injections</p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft1881"><b>4.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft1881"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft1882">Powder and solvent for solution for injection</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft1883">4 vials of powder<br/>4 pre-filled syringes of 1&#160;ml&#160;solvent<br/>4 stainless steel injection needles<br/>4 vial adaptors<br/>8 alcohol swabs</p>
<p style="position:absolute;top:741px;left:106px;white-space:nowrap" class="ft1884">8 vials of&#160;powder<br/>8 pre-filled syringes of 1&#160;ml&#160;solvent<br/>8 stainless steel injection needles<br/>8 vial adaptors<br/>16&#160;alcohol swabs</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft1883">24 vials of powder<br/>24 pre-filled syringes of 1&#160;ml&#160;solvent<br/>24 stainless steel injection needles<br/>24 vial adaptors<br/>48 alcohol swabs</p>
<p style="position:absolute;top:989px;left:115px;white-space:nowrap" class="ft1881"><b>5.</b></p>
<p style="position:absolute;top:989px;left:157px;white-space:nowrap" class="ft1881"><b>METHOD&#160;AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft1883">Read the package leaflet before use.<br/>Subcutaneous use.</p>
</div>
<!-- Page 189 -->
<a name="189"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page189-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1890">189</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1891"><b>6.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft18923"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft1892">Keep out of the&#160;sight&#160;and&#160;reach&#160;of children.</p>
<p style="position:absolute;top:224px;left:115px;white-space:nowrap" class="ft1891"><b>7.</b></p>
<p style="position:absolute;top:224px;left:157px;white-space:nowrap" class="ft1891"><b>OTHER SPECIAL&#160;WARNING(S), IF NECESSARY</b></p>
<p style="position:absolute;top:282px;left:115px;white-space:nowrap" class="ft1891"><b>8.</b></p>
<p style="position:absolute;top:282px;left:157px;white-space:nowrap" class="ft1891"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:321px;left:106px;white-space:nowrap" class="ft1892">EXP</p>
<p style="position:absolute;top:378px;left:115px;white-space:nowrap" class="ft1891"><b>9.</b></p>
<p style="position:absolute;top:378px;left:157px;white-space:nowrap" class="ft1891"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft1893">Store in a refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft1892">Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft1892">After preparing the Enbrel solution, immediate use is recommended (up to&#160;a maximum of 6 hours).</p>
<p style="position:absolute;top:570px;left:115px;white-space:nowrap" class="ft1891"><b>10.</b></p>
<p style="position:absolute;top:570px;left:157px;white-space:nowrap" class="ft18924"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:685px;left:115px;white-space:nowrap" class="ft1891"><b>11.</b></p>
<p style="position:absolute;top:685px;left:157px;white-space:nowrap" class="ft1891"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft1893">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:838px;left:115px;white-space:nowrap" class="ft1891"><b>12.</b></p>
<p style="position:absolute;top:838px;left:157px;white-space:nowrap" class="ft1891"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft1894">EU/1/99/126/003 &#160;4 vials&#160;<br/>EU/1/99/126/004 &#160;8 vials&#160;<br/>EU/1/99/126/005 &#160;24 vials</p>
<p style="position:absolute;top:973px;left:115px;white-space:nowrap" class="ft1891"><b>13.</b></p>
<p style="position:absolute;top:973px;left:157px;white-space:nowrap" class="ft1891"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:1011px;left:106px;white-space:nowrap" class="ft1892">Lot</p>
<p style="position:absolute;top:1069px;left:115px;white-space:nowrap" class="ft1891"><b>14.</b></p>
<p style="position:absolute;top:1069px;left:157px;white-space:nowrap" class="ft1891"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
</div>
<!-- Page 190 -->
<a name="190"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page190-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1900">190</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1901"><b>15.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft1901"><b>INSTRUCTIONS&#160;ON USE</b></p>
<p style="position:absolute;top:167px;left:115px;white-space:nowrap" class="ft1901"><b>16.</b></p>
<p style="position:absolute;top:167px;left:157px;white-space:nowrap" class="ft1901"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft1902">Enbrel&#160;25&#160;mg</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft1901"><b>17.</b></p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft1901"><b>UNIQUE IDENTIFIER&#160;-&#160;2D BARCODE</b></p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft1902">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:363px;left:115px;white-space:nowrap" class="ft1901"><b>18.</b></p>
<p style="position:absolute;top:363px;left:157px;white-space:nowrap" class="ft1901"><b>UNIQUE IDENTIFIER&#160;-&#160;HUMAN READABLE DATA</b></p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft1904">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 191 -->
<a name="191"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page191-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1910">191</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1911"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE&#160;PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1911"><b>TEXT FOR VIAL LABEL&#160;–&#160;EU/1/99/126/003-005</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1911"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1911"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1913">Enbrel&#160;25&#160;mg&#160;powder for injection<br/>etanercept<br/>Subcutaneous use</p>
<p style="position:absolute;top:339px;left:115px;white-space:nowrap" class="ft1911"><b>2.</b></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft1911"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft1912">Read the package leaflet before&#160;use.</p>
<p style="position:absolute;top:436px;left:115px;white-space:nowrap" class="ft1911"><b>3.</b></p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft1911"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft1912">EXP</p>
<p style="position:absolute;top:532px;left:115px;white-space:nowrap" class="ft1911"><b>4.</b></p>
<p style="position:absolute;top:532px;left:157px;white-space:nowrap" class="ft1911"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft1912">Lot</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft1911"><b>5.</b></p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft1911"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft1911"><b>6.</b></p>
<p style="position:absolute;top:691px;left:149px;white-space:nowrap" class="ft1911"><b>OTHER</b></p>
</div>
<!-- Page 192 -->
<a name="192"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page192-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1920">192</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1921"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1921"><b>TEXT FOR SYRINGE LABEL&#160;–&#160;EU/1/99/126/003-005</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1921"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1921"><b>NAME OF THE MEDICINAL&#160;PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1924">Solvent for Enbrel<br/>Subcutaneous use</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft1921"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft1921"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft1922">Read the package leaflet before use.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft1921"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft1921"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft1922">EXP</p>
<p style="position:absolute;top:513px;left:115px;white-space:nowrap" class="ft1921"><b>4.</b></p>
<p style="position:absolute;top:513px;left:157px;white-space:nowrap" class="ft1921"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft1922">Lot</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft1921"><b>5.</b></p>
<p style="position:absolute;top:611px;left:149px;white-space:nowrap" class="ft1921"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:651px;left:106px;white-space:nowrap" class="ft1922">1&#160;ml water for&#160;injections</p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft1921"><b>6.</b></p>
<p style="position:absolute;top:710px;left:149px;white-space:nowrap" class="ft1921"><b>OTHER</b></p>
</div>
<!-- Page 193 -->
<a name="193"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page193-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1930">193</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1931"><b>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1931"><b>TEXT FOR TRAY BACKING&#160;–&#160;EU/1/99/126/003-005</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1931"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1931"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1934">Enbrel&#160;25&#160;mg&#160;powder and solvent for solution for injection<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft1931"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft1931"><b>NAME OF THE&#160;MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft1932">Pfizer&#160;Europe MA EEIG</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft1931"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft1931"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft1932">EXP</p>
<p style="position:absolute;top:513px;left:115px;white-space:nowrap" class="ft1931"><b>4.</b></p>
<p style="position:absolute;top:513px;left:157px;white-space:nowrap" class="ft1931"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft1932">Lot</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft1931"><b>5.</b></p>
<p style="position:absolute;top:611px;left:149px;white-space:nowrap" class="ft1931"><b>OTHER</b></p>
</div>
<!-- Page 194 -->
<a name="194"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page194-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1940">194</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1941"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING &#160;</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1941"><b>CARTON TEXT&#160;–&#160;EU/1/99/126/013-015, EU/1/99/126/026&#160;(25&#160;mg&#160;Pre-filled Syringe)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1941"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1941"><b>NAME OF&#160;THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1944">Enbrel&#160;25&#160;mg&#160;solution for injection in pre-filled syringe<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft1941"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft1941"><b>STATEMENT OF ACTIVE SUBSTANCE(S)</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft1942">Each pre-filled syringe of Enbrel contains&#160;25&#160;mg&#160;etanercept.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft1941"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft1941"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft1944">The other ingredients in Enbrel&#160;are:<br/>Sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate monobasic dihydrate, sodium&#160;<br/>phosphate dibasic dihydrate and water for injections.</p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft1941"><b>4.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft1941"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft1942">Solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft1943">4 pre-filled syringes<br/>4 alcohol swabs</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft1943">8 pre-filled syringes<br/>8 alcohol swabs</p>
<p style="position:absolute;top:741px;left:106px;white-space:nowrap" class="ft1944">12 pre-filled syringes<br/>12 alcohol swabs</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft1944">24 pre-filled syringes<br/>24 alcohol swabs</p>
<p style="position:absolute;top:875px;left:115px;white-space:nowrap" class="ft1941"><b>5.</b></p>
<p style="position:absolute;top:875px;left:157px;white-space:nowrap" class="ft1941"><b>METHOD AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft1944">Read the package leaflet before use.<br/>Subcutaneous use.</p>
<p style="position:absolute;top:971px;left:106px;white-space:nowrap" class="ft1944">Injection&#160;advice:<br/>Inject the solution after it has reached room temperature (15 to 30 minutes after taking the product&#160;<br/>from the refrigerator).&#160;<br/>Inject slowly, at an angle of 45° to 90° to the skin.</p>
</div>
<!-- Page 195 -->
<a name="195"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page195-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1950">195</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1951"><b>6.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft19523"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft1952">Keep out of the&#160;sight&#160;and&#160;reach&#160;of children.</p>
<p style="position:absolute;top:224px;left:115px;white-space:nowrap" class="ft1951"><b>7.</b></p>
<p style="position:absolute;top:224px;left:157px;white-space:nowrap" class="ft1951"><b>OTHER SPECIAL WARNING(S), IF NECESSARY</b></p>
<p style="position:absolute;top:301px;left:115px;white-space:nowrap" class="ft1951"><b>8.</b></p>
<p style="position:absolute;top:301px;left:157px;white-space:nowrap" class="ft1951"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:340px;left:106px;white-space:nowrap" class="ft1952">EXP</p>
<p style="position:absolute;top:398px;left:115px;white-space:nowrap" class="ft1951"><b>9.</b></p>
<p style="position:absolute;top:398px;left:157px;white-space:nowrap" class="ft1951"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft1954">Store in&#160;a refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft1952">Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft1952">Keep the pre-filled syringes in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:589px;left:115px;white-space:nowrap" class="ft1951"><b>10.</b></p>
<p style="position:absolute;top:589px;left:157px;white-space:nowrap" class="ft19523"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE&#160;MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:685px;left:115px;white-space:nowrap" class="ft1951"><b>11.</b></p>
<p style="position:absolute;top:685px;left:157px;white-space:nowrap" class="ft1951"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft1953">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:838px;left:115px;white-space:nowrap" class="ft1951"><b>12.</b></p>
<p style="position:absolute;top:838px;left:157px;white-space:nowrap" class="ft1951"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft1954">EU/1/99/126/013&#160;&#160;4 pre-filled syringes<br/>EU/1/99/126/014&#160;&#160;8 pre-filled syringes<br/>EU/1/99/126/015&#160;&#160;24 pre-filled syringes<br/>EU/1/99/126/026 &#160;12 pre-filled syringes</p>
<p style="position:absolute;top:992px;left:115px;white-space:nowrap" class="ft1951"><b>13.</b></p>
<p style="position:absolute;top:992px;left:157px;white-space:nowrap" class="ft1951"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:1030px;left:106px;white-space:nowrap" class="ft1952">Lot</p>
<p style="position:absolute;top:1088px;left:115px;white-space:nowrap" class="ft1951"><b>14.</b></p>
<p style="position:absolute;top:1088px;left:157px;white-space:nowrap" class="ft1951"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
</div>
<!-- Page 196 -->
<a name="196"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page196-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1960">196</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1961"><b>15.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft1961"><b>INSTRUCTIONS ON USE</b></p>
<p style="position:absolute;top:167px;left:115px;white-space:nowrap" class="ft1961"><b>16.</b></p>
<p style="position:absolute;top:167px;left:157px;white-space:nowrap" class="ft1961"><b>INFORMATION IN&#160;BRAILLE</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft1962">Enbrel&#160;25&#160;mg</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft1961"><b>17.</b></p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft1961"><b>UNIQUE IDENTIFIER&#160;-&#160;2D BARCODE</b></p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft1962">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:363px;left:115px;white-space:nowrap" class="ft1961"><b>18.</b></p>
<p style="position:absolute;top:363px;left:157px;white-space:nowrap" class="ft1961"><b>UNIQUE IDENTIFIER&#160;-&#160;HUMAN READABLE DATA</b></p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft1964">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 197 -->
<a name="197"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page197-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1970">197</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1971"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft19723"><b>TEXT FOR&#160;PRE-FILLED SYRINGE LABEL&#160;–&#160;EU/1/99/126/013-015, EU/1/99/126/026&#160;(25&#160;mg<br/>Pre-filled Syringe)</b></p>
<p style="position:absolute;top:224px;left:115px;white-space:nowrap" class="ft1971"><b>1.</b></p>
<p style="position:absolute;top:224px;left:157px;white-space:nowrap" class="ft1971"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft1974">Enbrel&#160;25&#160;mg&#160;injection&#160;<br/>etanercept<br/>Subcutaneous use</p>
<p style="position:absolute;top:358px;left:115px;white-space:nowrap" class="ft1971"><b>2.</b></p>
<p style="position:absolute;top:358px;left:157px;white-space:nowrap" class="ft1971"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft1972">Read the&#160;package leaflet before use.</p>
<p style="position:absolute;top:454px;left:115px;white-space:nowrap" class="ft1971"><b>3.</b></p>
<p style="position:absolute;top:454px;left:157px;white-space:nowrap" class="ft1971"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft1972">EXP</p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft1971"><b>4.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft1971"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft1972">Lot</p>
<p style="position:absolute;top:649px;left:106px;white-space:nowrap" class="ft1971"><b>5.</b></p>
<p style="position:absolute;top:649px;left:149px;white-space:nowrap" class="ft1971"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:689px;left:106px;white-space:nowrap" class="ft1972">25&#160;mg/0.5&#160;ml</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft1971"><b>6.</b></p>
<p style="position:absolute;top:748px;left:149px;white-space:nowrap" class="ft1971"><b>OTHER</b></p>
</div>
<!-- Page 198 -->
<a name="198"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page198-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1980">198</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1981"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft1981"><b>CARTON TEXT&#160;–&#160;EU/1/99/126/016-018 (50&#160;mg&#160;Pre-filled&#160;Syringe)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft1981"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft1981"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft1984">Enbrel&#160;50&#160;mg&#160;solution for injection in pre-filled syringe<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft1981"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft1981"><b>STATEMENT OF ACTIVE SUBSTANCE(S)</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft1982">Each pre-filled syringe of Enbrel contains&#160;50&#160;mg&#160;etanercept.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft1981"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft1981"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft1984">The other&#160;ingredients in Enbrel are:<br/>Sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate monobasic dihydrate, sodium&#160;<br/>phosphate dibasic dihydrate and water for injections.</p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft1981"><b>4.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft1981"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft1982">solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft1983">2 pre-filled syringes<br/>2 alcohol swabs</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft1983">4 pre-filled syringes<br/>4 alcohol swabs</p>
<p style="position:absolute;top:741px;left:106px;white-space:nowrap" class="ft1984">12 pre-filled syringes<br/>12 alcohol swabs</p>
<p style="position:absolute;top:818px;left:115px;white-space:nowrap" class="ft1981"><b>5.</b></p>
<p style="position:absolute;top:818px;left:157px;white-space:nowrap" class="ft1981"><b>METHOD AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft1983">Read the package leaflet before use.<br/>Subcutaneous use.</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft1983">Injection advice:<br/>Inject the solution after it has reached room temperature (15 to 30 minutes after taking the product&#160;<br/>from the refrigerator).&#160;<br/>Inject slowly, at an angle of 45° to 90° to the skin.</p>
<p style="position:absolute;top:1028px;left:115px;white-space:nowrap" class="ft1981"><b>6.</b></p>
<p style="position:absolute;top:1028px;left:157px;white-space:nowrap" class="ft19824"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1086px;left:106px;white-space:nowrap" class="ft1982">Keep out of the&#160;sight&#160;and&#160;reach&#160;of children.</p>
</div>
<!-- Page 199 -->
<a name="199"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page199-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft1990">199</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft1991"><b>7.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft1991"><b>OTHER SPECIAL WARNING(S), IF NECESSARY</b></p>
<p style="position:absolute;top:167px;left:115px;white-space:nowrap" class="ft1991"><b>8.</b></p>
<p style="position:absolute;top:167px;left:157px;white-space:nowrap" class="ft1991"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft1992">EXP</p>
<p style="position:absolute;top:263px;left:115px;white-space:nowrap" class="ft1991"><b>9.</b></p>
<p style="position:absolute;top:263px;left:157px;white-space:nowrap" class="ft1991"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft1994">Store in a refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft1992">Refer to package leaflet for&#160;alternative storage details.</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft1992">Keep the pre-filled syringes in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:454px;left:115px;white-space:nowrap" class="ft1991"><b>10.</b></p>
<p style="position:absolute;top:454px;left:157px;white-space:nowrap" class="ft19924"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft1991"><b>11.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft1991"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft1993">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:704px;left:115px;white-space:nowrap" class="ft1991"><b>12.</b></p>
<p style="position:absolute;top:704px;left:157px;white-space:nowrap" class="ft1991"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft1993">EU/1/99/126/016&#160;&#160;2 pre-filled syringes<br/>EU/1/99/126/017&#160;&#160;4 pre-filled syringes<br/>EU/1/99/126/018&#160;&#160;12 pre-filled syringes</p>
<p style="position:absolute;top:838px;left:115px;white-space:nowrap" class="ft1991"><b>13.</b></p>
<p style="position:absolute;top:838px;left:157px;white-space:nowrap" class="ft1991"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft1992">Lot</p>
<p style="position:absolute;top:935px;left:115px;white-space:nowrap" class="ft1991"><b>14.</b></p>
<p style="position:absolute;top:935px;left:157px;white-space:nowrap" class="ft1991"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:993px;left:115px;white-space:nowrap" class="ft1991"><b>15.</b></p>
<p style="position:absolute;top:993px;left:157px;white-space:nowrap" class="ft1991"><b>INSTRUCTIONS ON USE</b></p>
<p style="position:absolute;top:1052px;left:115px;white-space:nowrap" class="ft1991"><b>16.</b></p>
<p style="position:absolute;top:1052px;left:157px;white-space:nowrap" class="ft1991"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft1992">Enbrel&#160;50&#160;mg</p>
</div>
<!-- Page 200 -->
<a name="200"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page200-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2000">200</p>
<p style="position:absolute;top:110px;left:106px;white-space:nowrap" class="ft2001"><b>17.</b></p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft2001"><b>UNIQUE IDENTIFIER&#160;-&#160;2D BARCODE</b></p>
<p style="position:absolute;top:150px;left:106px;white-space:nowrap" class="ft2002">2D barcode carrying the unique identifier&#160;included.</p>
<p style="position:absolute;top:208px;left:115px;white-space:nowrap" class="ft2001"><b>18.</b></p>
<p style="position:absolute;top:208px;left:157px;white-space:nowrap" class="ft2001"><b>UNIQUE IDENTIFIER&#160;-&#160;HUMAN READABLE DATA</b></p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft2004">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 201 -->
<a name="201"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page201-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2010">201</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2011"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2011"><b>TEXT FOR PRE-FILLED SYRINGE&#160;–&#160;EU/1/99/126/016-018 (50&#160;mg&#160;Pre-filled Syringe)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2011"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2011"><b>NAME OF THE MEDICINAL PRODUCT AND&#160;ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2013">Enbrel&#160;50&#160;mg&#160;injection<br/>etanercept<br/>Subcutaneous use</p>
<p style="position:absolute;top:339px;left:115px;white-space:nowrap" class="ft2011"><b>2.</b></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft2011"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2012">Read the package leaflet before use.</p>
<p style="position:absolute;top:436px;left:115px;white-space:nowrap" class="ft2011"><b>3.</b></p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft2011"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2012">EXP</p>
<p style="position:absolute;top:532px;left:115px;white-space:nowrap" class="ft2011"><b>4.</b></p>
<p style="position:absolute;top:532px;left:157px;white-space:nowrap" class="ft2011"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft2012">Lot</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft2011"><b>5.</b></p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft2011"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft2012">50&#160;mg/1&#160;ml</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft2011"><b>6.</b></p>
<p style="position:absolute;top:729px;left:149px;white-space:nowrap" class="ft2011"><b>OTHER</b></p>
</div>
<!-- Page 202 -->
<a name="202"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page202-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2020">202</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2021"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2021"><b>CARTON TEXT&#160;–&#160;EU/1/99/126/019-021&#160;(50&#160;mg&#160;Pre-filled Pen)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2021"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2021"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2024">Enbrel&#160;50&#160;mg&#160;solution for injection in pre-filled pen<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft2021"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft2021"><b>STATEMENT OF ACTIVE&#160;SUBSTANCE(S)</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2022">Each pre-filled pen of Enbrel contains&#160;50&#160;mg&#160;etanercept.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft2021"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft2021"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft2024">The other ingredients in Enbrel are:<br/>Sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate monobasic dihydrate, sodium&#160;<br/>phosphate dibasic&#160;dihydrate and water for injections.</p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft2021"><b>4.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft2021"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft2022">Solution for injection in a pre-filled pen (MYCLIC)</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft2023">2 MYCLIC pre-filled pens<br/>2 alcohol swabs</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft2023">4 MYCLIC pre-filled pens<br/>4 alcohol swabs</p>
<p style="position:absolute;top:741px;left:106px;white-space:nowrap" class="ft2024">12 MYCLIC&#160;pre-filled pens<br/>12 alcohol swabs</p>
<p style="position:absolute;top:818px;left:115px;white-space:nowrap" class="ft2021"><b>5.</b></p>
<p style="position:absolute;top:818px;left:157px;white-space:nowrap" class="ft2021"><b>METHOD AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft2023">Read the package leaflet before use.<br/>Subcutaneous use.</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft2024">Injection advice:<br/>Inject the solution after it has reached room temperature (15 to 30 minutes after taking the product&#160;<br/>from the refrigerator).&#160;</p>
<p style="position:absolute;top:1009px;left:115px;white-space:nowrap" class="ft2021"><b>6.</b></p>
<p style="position:absolute;top:1009px;left:157px;white-space:nowrap" class="ft20223"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft2022">Keep out of the&#160;sight&#160;and&#160;reach&#160;of children.</p>
</div>
<!-- Page 203 -->
<a name="203"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page203-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2030">203</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2031"><b>7.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft2031"><b>OTHER SPECIAL WARNING(S), IF NECESSARY</b></p>
<p style="position:absolute;top:167px;left:115px;white-space:nowrap" class="ft2031"><b>8.</b></p>
<p style="position:absolute;top:167px;left:157px;white-space:nowrap" class="ft2031"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft2032">EXP</p>
<p style="position:absolute;top:263px;left:115px;white-space:nowrap" class="ft2031"><b>9.</b></p>
<p style="position:absolute;top:263px;left:157px;white-space:nowrap" class="ft2031"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft2034">Store in a&#160;refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2032">Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft2032">Keep the pre-filled pens in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:454px;left:115px;white-space:nowrap" class="ft2031"><b>10.</b></p>
<p style="position:absolute;top:454px;left:157px;white-space:nowrap" class="ft20324"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE MATERIALS&#160;DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft2031"><b>11.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft2031"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft2033">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:704px;left:115px;white-space:nowrap" class="ft2031"><b>12.</b></p>
<p style="position:absolute;top:704px;left:157px;white-space:nowrap" class="ft2031"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft2033">EU/1/99/126/019&#160;&#160;2 pre-filled pens<br/>EU/1/99/126/020&#160;&#160;4 pre-filled pens<br/>EU/1/99/126/021&#160;&#160;12 pre-filled pens</p>
<p style="position:absolute;top:838px;left:115px;white-space:nowrap" class="ft2031"><b>13.</b></p>
<p style="position:absolute;top:838px;left:157px;white-space:nowrap" class="ft2031"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft2032">Lot</p>
<p style="position:absolute;top:935px;left:115px;white-space:nowrap" class="ft2031"><b>14.</b></p>
<p style="position:absolute;top:935px;left:157px;white-space:nowrap" class="ft2031"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:993px;left:115px;white-space:nowrap" class="ft2031"><b>15.</b></p>
<p style="position:absolute;top:993px;left:157px;white-space:nowrap" class="ft2031"><b>INSTRUCTIONS ON USE</b></p>
<p style="position:absolute;top:1052px;left:115px;white-space:nowrap" class="ft2031"><b>16.</b></p>
<p style="position:absolute;top:1052px;left:157px;white-space:nowrap" class="ft2031"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft2032">Enbrel&#160;50&#160;mg</p>
</div>
<!-- Page 204 -->
<a name="204"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page204-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2040">204</p>
<p style="position:absolute;top:110px;left:106px;white-space:nowrap" class="ft2041"><b>17.</b></p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft2041"><b>UNIQUE IDENTIFIER&#160;-&#160;2D BARCODE</b></p>
<p style="position:absolute;top:150px;left:106px;white-space:nowrap" class="ft2042">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:208px;left:115px;white-space:nowrap" class="ft2041"><b>18.</b></p>
<p style="position:absolute;top:208px;left:157px;white-space:nowrap" class="ft2041"><b>UNIQUE IDENTIFIER&#160;-&#160;HUMAN READABLE DATA</b></p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft2044">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 205 -->
<a name="205"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page205-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2050">205</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2051"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2051"><b>TEXT FOR PRE-FILLED PEN&#160;–&#160;EU/1/99/126/019-021&#160;(50&#160;mg&#160;Pre-filled Pen)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2051"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2051"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2053">Enbrel&#160;50&#160;mg&#160;solution for&#160;injection&#160;in pre-filled pen<br/>etanercept<br/>Subcutaneous use</p>
<p style="position:absolute;top:339px;left:115px;white-space:nowrap" class="ft2051"><b>2.</b></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft2051"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2052">Read the package leaflet before use.</p>
<p style="position:absolute;top:436px;left:115px;white-space:nowrap" class="ft2051"><b>3.</b></p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft2051"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2052">EXP</p>
<p style="position:absolute;top:532px;left:115px;white-space:nowrap" class="ft2051"><b>4.</b></p>
<p style="position:absolute;top:532px;left:157px;white-space:nowrap" class="ft2051"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft2052">Lot</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft2051"><b>5.</b></p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft2051"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft2052">50&#160;mg/1&#160;ml</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft2051"><b>6.</b></p>
<p style="position:absolute;top:729px;left:149px;white-space:nowrap" class="ft2051"><b>OTHER</b></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft2052">MYCLIC Pre-filled pen&#160;</p>
</div>
<!-- Page 206 -->
<a name="206"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page206-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2060">206</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2061"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2061"><b>CARTON TEXT&#160;–&#160;EU/1/99/126/022&#160;(For paediatric use)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2061"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2061"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2064">Enbrel 10&#160;mg&#160;powder and solvent for solution for injection for paediatric use<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft2061"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft2061"><b>STATEMENT OF ACTIVE SUBSTANCE(S)</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2062">Each vial of Enbrel contains 10&#160;mg etanercept.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft2061"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft2061"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft2064">The other ingredients in Enbrel are:<br/>Powder: Mannitol, sucrose and&#160;trometamol<br/>Solvent: Water for injections</p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft2061"><b>4.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft2061"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft2062">Powder and solvent for solution for injection</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft2063">4 vials of powder<br/>4 pre-filled syringes of 1&#160;ml solvent<br/>4 stainless steel injection needles<br/>4 vial adaptors&#160;<br/>8 alcohol swabs</p>
<p style="position:absolute;top:761px;left:115px;white-space:nowrap" class="ft2061"><b>5.</b></p>
<p style="position:absolute;top:761px;left:157px;white-space:nowrap" class="ft2061"><b>METHOD AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft2063">Read the package leaflet before use.<br/>Subcutaneous use.</p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft2063">The 10&#160;mg&#160;vial is for children prescribed a dose of 10&#160;mg or less. Follow the directions given by the&#160;<br/>doctor.</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft2064">Each vial should be used for just one dose in&#160;one patient, and any remaining solution should be&#160;<br/>discarded.</p>
<p style="position:absolute;top:990px;left:115px;white-space:nowrap" class="ft2061"><b>6.</b></p>
<p style="position:absolute;top:990px;left:157px;white-space:nowrap" class="ft20624"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1048px;left:106px;white-space:nowrap" class="ft2062">Keep out of the&#160;sight&#160;and&#160;reach&#160;of children.</p>
<p style="position:absolute;top:1106px;left:115px;white-space:nowrap" class="ft2061"><b>7.</b></p>
<p style="position:absolute;top:1106px;left:157px;white-space:nowrap" class="ft2061"><b>OTHER SPECIAL WARNING(S), IF NECESSARY</b></p>
</div>
<!-- Page 207 -->
<a name="207"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page207-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2070">207</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2071"><b>8.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft2071"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft2072">EXP</p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2071"><b>9.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2071"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2074">Store in a refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft2072">Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:338px;left:106px;white-space:nowrap" class="ft2072">After preparing the Enbrel solution, immediate use is recommended&#160;(up to a maximum of 6 hours).&#160;</p>
<p style="position:absolute;top:396px;left:115px;white-space:nowrap" class="ft2071"><b>10.</b></p>
<p style="position:absolute;top:396px;left:157px;white-space:nowrap" class="ft20723"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:492px;left:115px;white-space:nowrap" class="ft2071"><b>11.</b></p>
<p style="position:absolute;top:492px;left:157px;white-space:nowrap" class="ft2071"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft2074">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050&#160;Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:646px;left:115px;white-space:nowrap" class="ft2071"><b>12.</b></p>
<p style="position:absolute;top:646px;left:157px;white-space:nowrap" class="ft2071"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft2072">EU/1/99/126/022</p>
<p style="position:absolute;top:742px;left:115px;white-space:nowrap" class="ft2071"><b>13.</b></p>
<p style="position:absolute;top:742px;left:157px;white-space:nowrap" class="ft2071"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:781px;left:106px;white-space:nowrap" class="ft2072">Lot</p>
<p style="position:absolute;top:838px;left:115px;white-space:nowrap" class="ft2071"><b>14.</b></p>
<p style="position:absolute;top:838px;left:157px;white-space:nowrap" class="ft2071"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:897px;left:115px;white-space:nowrap" class="ft2071"><b>15.</b></p>
<p style="position:absolute;top:897px;left:157px;white-space:nowrap" class="ft2071"><b>INSTRUCTIONS ON USE</b></p>
<p style="position:absolute;top:955px;left:115px;white-space:nowrap" class="ft2071"><b>16.</b></p>
<p style="position:absolute;top:955px;left:157px;white-space:nowrap" class="ft2071"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft2072">Enbrel 10&#160;mg</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft2071"><b>17.</b></p>
<p style="position:absolute;top:1053px;left:149px;white-space:nowrap" class="ft2071"><b>UNIQUE IDENTIFIER&#160;-&#160;2D BARCODE</b></p>
<p style="position:absolute;top:1093px;left:106px;white-space:nowrap" class="ft2072">2D&#160;barcode carrying the unique identifier included.</p>
</div>
<!-- Page 208 -->
<a name="208"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page208-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2080">208</p>
<p style="position:absolute;top:109px;left:115px;white-space:nowrap" class="ft2081"><b>18.</b></p>
<p style="position:absolute;top:109px;left:157px;white-space:nowrap" class="ft2081"><b>UNIQUE IDENTIFIER&#160;-&#160;HUMAN READABLE DATA</b></p>
<p style="position:absolute;top:148px;left:106px;white-space:nowrap" class="ft2084">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 209 -->
<a name="209"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page209-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2090">209</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2091"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2091"><b>TEXT FOR VIAL LABEL&#160;–&#160;EU/1/99/126/022&#160;(For paediatric use)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2091"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2091"><b>NAME OF THE&#160;MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2093">Enbrel 10&#160;mg powder for injection<br/>etanercept<br/>Subcutaneous use</p>
<p style="position:absolute;top:339px;left:115px;white-space:nowrap" class="ft2091"><b>2.</b></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft2091"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2092">Read the package leaflet before use.</p>
<p style="position:absolute;top:436px;left:115px;white-space:nowrap" class="ft2091"><b>3.</b></p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft2091"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2092">EXP</p>
<p style="position:absolute;top:532px;left:115px;white-space:nowrap" class="ft2091"><b>4.</b></p>
<p style="position:absolute;top:532px;left:157px;white-space:nowrap" class="ft2091"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft2092">Lot</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft2091"><b>5.</b></p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft2091"><b>CONTENTS BY WEIGHT, BY&#160;VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft2091"><b>6.</b></p>
<p style="position:absolute;top:691px;left:149px;white-space:nowrap" class="ft2091"><b>OTHER</b></p>
</div>
<!-- Page 210 -->
<a name="210"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page210-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2100">210</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2101"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2101"><b>TEXT FOR SYRINGE LABEL&#160;–&#160;EU/1/99/126/022&#160;(For paediatric use)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2101"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2101"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2104">Solvent for Enbrel<br/>Subcutaneous use</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft2101"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft2101"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2102">Read the package leaflet before use.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft2101"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft2101"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft2102">EXP</p>
<p style="position:absolute;top:513px;left:115px;white-space:nowrap" class="ft2101"><b>4.</b></p>
<p style="position:absolute;top:513px;left:157px;white-space:nowrap" class="ft2101"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft2102">Lot</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft2101"><b>5.</b></p>
<p style="position:absolute;top:611px;left:149px;white-space:nowrap" class="ft2101"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:651px;left:106px;white-space:nowrap" class="ft2102">1&#160;ml water for injections</p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft2101"><b>6.</b></p>
<p style="position:absolute;top:710px;left:149px;white-space:nowrap" class="ft2101"><b>OTHER</b></p>
</div>
<!-- Page 211 -->
<a name="211"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page211-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2110">211</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2111"><b>MINIMUM PARTICULARS TO APPEAR ON&#160;BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2111"><b>TEXT FOR TRAY BACKING&#160;–&#160;EU/1/99/126/022&#160;(For paediatric use)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2111"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2111"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2114">Enbrel 10&#160;mg<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft2111"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft2111"><b>NAME OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2112">Pfizer&#160;Europe MA EEIG</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft2111"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft2111"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft2112">EXP</p>
<p style="position:absolute;top:513px;left:115px;white-space:nowrap" class="ft2111"><b>4.</b></p>
<p style="position:absolute;top:513px;left:157px;white-space:nowrap" class="ft2111"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft2112">Lot</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft2111"><b>5.</b></p>
<p style="position:absolute;top:611px;left:149px;white-space:nowrap" class="ft2111"><b>OTHER</b></p>
</div>
<!-- Page 212 -->
<a name="212"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page212-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2120">212</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2121"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2121"><b>CARTON TEXT&#160;–&#160;EU/1/99/126/023-025&#160;(25&#160;mg Pre-filled Pen)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2121"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2121"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2124">Enbrel&#160;25&#160;mg solution for injection in pre-filled pen<br/>etanercept</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft2121"><b>2.</b></p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft2121"><b>STATEMENT OF ACTIVE&#160;SUBSTANCE(S)</b></p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2122">Each pre-filled pen of Enbrel contains&#160;25&#160;mg etanercept.</p>
<p style="position:absolute;top:416px;left:115px;white-space:nowrap" class="ft2121"><b>3.</b></p>
<p style="position:absolute;top:416px;left:157px;white-space:nowrap" class="ft2121"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft2124">The other ingredients in Enbrel are:<br/>Sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate monobasic dihydrate, sodium&#160;<br/>phosphate dibasic&#160;dihydrate and water for injections.</p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft2121"><b>4.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft2121"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft2122">Solution for injection in a pre-filled pen (MYCLIC)</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft2123">4&#160;MYCLIC pre-filled pens<br/>4&#160;alcohol swabs</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft2123">8 MYCLIC pre-filled pens<br/>8 alcohol swabs</p>
<p style="position:absolute;top:741px;left:106px;white-space:nowrap" class="ft2124">24 MYCLIC&#160;pre-filled pens<br/>24 alcohol swabs</p>
<p style="position:absolute;top:818px;left:115px;white-space:nowrap" class="ft2121"><b>5.</b></p>
<p style="position:absolute;top:818px;left:157px;white-space:nowrap" class="ft2121"><b>METHOD AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft2123">Read the package leaflet before use.<br/>Subcutaneous use.</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft2124">Injection advice:<br/>Inject the solution after it has reached room temperature (15 to 30 minutes after taking the product&#160;<br/>from the refrigerator).&#160;</p>
<p style="position:absolute;top:1009px;left:115px;white-space:nowrap" class="ft2121"><b>6.</b></p>
<p style="position:absolute;top:1009px;left:157px;white-space:nowrap" class="ft21223"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE&#160;SIGHT&#160;AND&#160;REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft2122">Keep out of the&#160;sight&#160;and&#160;reach&#160;of children.</p>
</div>
<!-- Page 213 -->
<a name="213"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page213-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2130">213</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2131"><b>7.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft2131"><b>OTHER SPECIAL WARNING(S), IF NECESSARY</b></p>
<p style="position:absolute;top:167px;left:115px;white-space:nowrap" class="ft2131"><b>8.</b></p>
<p style="position:absolute;top:167px;left:157px;white-space:nowrap" class="ft2131"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft2132">EXP</p>
<p style="position:absolute;top:263px;left:115px;white-space:nowrap" class="ft2131"><b>9.</b></p>
<p style="position:absolute;top:263px;left:157px;white-space:nowrap" class="ft2131"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft2134">Store in a&#160;refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2132">Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft2132">Keep the pre-filled pens in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:454px;left:115px;white-space:nowrap" class="ft2131"><b>10.</b></p>
<p style="position:absolute;top:454px;left:157px;white-space:nowrap" class="ft21324"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE MATERIALS&#160;DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft2131"><b>11.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft2131"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft2133">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:704px;left:115px;white-space:nowrap" class="ft2131"><b>12.</b></p>
<p style="position:absolute;top:704px;left:157px;white-space:nowrap" class="ft2131"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft2133">EU/1/99/126/023&#160;&#160;4 pre-filled pens<br/>EU/1/99/126/024&#160;&#160;8 pre-filled pens<br/>EU/1/99/126/025&#160;&#160;24 pre-filled pens</p>
<p style="position:absolute;top:838px;left:115px;white-space:nowrap" class="ft2131"><b>13.</b></p>
<p style="position:absolute;top:838px;left:157px;white-space:nowrap" class="ft2131"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft2132">Lot</p>
<p style="position:absolute;top:935px;left:115px;white-space:nowrap" class="ft2131"><b>14.</b></p>
<p style="position:absolute;top:935px;left:157px;white-space:nowrap" class="ft2131"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:993px;left:115px;white-space:nowrap" class="ft2131"><b>15.</b></p>
<p style="position:absolute;top:993px;left:157px;white-space:nowrap" class="ft2131"><b>INSTRUCTIONS ON USE</b></p>
<p style="position:absolute;top:1052px;left:115px;white-space:nowrap" class="ft2131"><b>16.</b></p>
<p style="position:absolute;top:1052px;left:157px;white-space:nowrap" class="ft2131"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft2132">Enbrel&#160;25&#160;mg</p>
</div>
<!-- Page 214 -->
<a name="214"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page214-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2140">214</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2141"><b>17.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft2141"><b>UNIQUE IDENTIFIER-2D BARCODE</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft2142">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2141"><b>18.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2141"><b>UNIQUE IDENTIFIER-HUMAN READABLE DATA</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2143">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 215 -->
<a name="215"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page215-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2150">215</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2151"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:146px;left:115px;white-space:nowrap" class="ft2151"><b>TEXT FOR PRE-FILLED PEN&#160;–&#160;EU/1/99/126/023-025&#160;(25&#160;mg Pre-filled Pen)</b></p>
<p style="position:absolute;top:205px;left:115px;white-space:nowrap" class="ft2151"><b>1.</b></p>
<p style="position:absolute;top:205px;left:157px;white-space:nowrap" class="ft2151"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft2153">Enbrel&#160;25&#160;mg&#160;solution for&#160;injection&#160;in pre-filled pen<br/>etanercept<br/>Subcutaneous use</p>
<p style="position:absolute;top:339px;left:115px;white-space:nowrap" class="ft2151"><b>2.</b></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft2151"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2152">Read the package leaflet before use.</p>
<p style="position:absolute;top:436px;left:115px;white-space:nowrap" class="ft2151"><b>3.</b></p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft2151"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2152">EXP</p>
<p style="position:absolute;top:532px;left:115px;white-space:nowrap" class="ft2151"><b>4.</b></p>
<p style="position:absolute;top:532px;left:157px;white-space:nowrap" class="ft2151"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft2152">Lot</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft2151"><b>5.</b></p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft2151"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft2152">25&#160;mg/0.5&#160;ml</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft2151"><b>6.</b></p>
<p style="position:absolute;top:729px;left:149px;white-space:nowrap" class="ft2151"><b>OTHER</b></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft2152">MYCLIC Pre-filled pen&#160;</p>
</div>
<!-- Page 216 -->
<a name="216"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page216-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2160">216</p>
<p style="position:absolute;top:127px;left:115px;white-space:nowrap" class="ft2161"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:165px;left:115px;white-space:nowrap" class="ft2161"><b>OUTER CARTON&#160;–&#160;EU/1/99/126/027-029 (25&#160;mg Dose-Dispenser Cartridge)</b></p>
<p style="position:absolute;top:224px;left:115px;white-space:nowrap" class="ft2161"><b>1.</b></p>
<p style="position:absolute;top:224px;left:157px;white-space:nowrap" class="ft2161"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft2163">Enbrel 25&#160;mg solution for injection in dose<b>-</b>dispenser cartridge<br/>etanercept</p>
<p style="position:absolute;top:339px;left:115px;white-space:nowrap" class="ft2161"><b>2.</b></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft2161"><b>STATEMENT OF ACTIVE SUBSTANCE(S)</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2162">Each dose<b>-</b>dispenser cartridge of Enbrel contains 25&#160;mg etanercept.</p>
<p style="position:absolute;top:436px;left:115px;white-space:nowrap" class="ft2161"><b>3.</b></p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft2161"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2164">The other ingredients&#160;in&#160;Enbrel are:&#160;<br/>Sucrose,&#160;sodium chloride, L-arginine hydrochloride, sodium phosphate monobasic dihydrate, sodium&#160;<br/>phosphate dibasic dihydrate and water for injections.</p>
<p style="position:absolute;top:570px;left:115px;white-space:nowrap" class="ft2161"><b>4.</b></p>
<p style="position:absolute;top:570px;left:157px;white-space:nowrap" class="ft2161"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft2162">Solution for injection in dose<b>-</b>dispenser cartridge&#160;</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft2164">4 single-use dose<b>-</b>dispenser cartridges&#160;for use in SMARTCLIC device only<br/>8 alcohol swabs</p>
<p style="position:absolute;top:703px;left:106px;white-space:nowrap" class="ft2164">8 single-use dose<b>-</b>dispenser cartridges&#160;for use in SMARTCLIC device only<br/>16 alcohol swabs</p>
<p style="position:absolute;top:760px;left:106px;white-space:nowrap" class="ft2164">24 single-use dose<b>-</b>dispenser cartridges&#160;for use in SMARTCLIC device only<br/>48 alcohol swabs</p>
<p style="position:absolute;top:837px;left:115px;white-space:nowrap" class="ft2161"><b>5.</b></p>
<p style="position:absolute;top:837px;left:157px;white-space:nowrap" class="ft2161"><b>METHOD AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft2164">Read the package leaflet before use.<br/>Subcutaneous use.</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft2163">Injection advice:<br/>Inject the solution after it has reached room temperature (15 to 30&#160;minutes after taking the product&#160;<br/>from the refrigerator).&#160;</p>
<p style="position:absolute;top:1028px;left:115px;white-space:nowrap" class="ft2161"><b>6.</b></p>
<p style="position:absolute;top:1028px;left:157px;white-space:nowrap" class="ft21624"><b>SPECIAL&#160;WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE SIGHT AND REACH OF CHILDREN</b></p>
<p style="position:absolute;top:1086px;left:106px;white-space:nowrap" class="ft2162">Keep out of the sight and reach of children.</p>
</div>
<!-- Page 217 -->
<a name="217"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page217-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2170">217</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2171"><b>7.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft2171"><b>OTHER SPECIAL WARNING(S), IF NECESSARY</b></p>
<p style="position:absolute;top:167px;left:115px;white-space:nowrap" class="ft2171"><b>8.</b></p>
<p style="position:absolute;top:167px;left:157px;white-space:nowrap" class="ft2171"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft2172">EXP</p>
<p style="position:absolute;top:263px;left:115px;white-space:nowrap" class="ft2171"><b>9.</b></p>
<p style="position:absolute;top:263px;left:157px;white-space:nowrap" class="ft2171"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft2174">Store in a&#160;refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2172">Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft2172">Keep the dose<b>-</b>dispenser cartridges in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:454px;left:115px;white-space:nowrap" class="ft2171"><b>10.</b></p>
<p style="position:absolute;top:454px;left:157px;white-space:nowrap" class="ft21724"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE&#160;MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft2171"><b>11.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft2171"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft2173">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:704px;left:115px;white-space:nowrap" class="ft2171"><b>12.</b></p>
<p style="position:absolute;top:704px;left:157px;white-space:nowrap" class="ft2171"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft2173">EU/1/99/126/027&#160;&#160;4 dose<b>-</b>dispenser cartridges<br/>EU/1/99/126/028&#160;&#160;8&#160;dose<b>-</b>dispenser cartridges<br/>EU/1/99/126/029&#160;&#160;24&#160;dose<b>-</b>dispenser cartridges</p>
<p style="position:absolute;top:838px;left:115px;white-space:nowrap" class="ft2171"><b>13.</b></p>
<p style="position:absolute;top:838px;left:157px;white-space:nowrap" class="ft2171"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft2172">Lot</p>
<p style="position:absolute;top:935px;left:115px;white-space:nowrap" class="ft2171"><b>14.</b></p>
<p style="position:absolute;top:935px;left:157px;white-space:nowrap" class="ft2171"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:993px;left:115px;white-space:nowrap" class="ft2171"><b>15.</b></p>
<p style="position:absolute;top:993px;left:157px;white-space:nowrap" class="ft2171"><b>INSTRUCTIONS ON USE</b></p>
<p style="position:absolute;top:1052px;left:115px;white-space:nowrap" class="ft2171"><b>16.</b></p>
<p style="position:absolute;top:1052px;left:157px;white-space:nowrap" class="ft2171"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft2172">Enbrel&#160;25&#160;mg</p>
</div>
<!-- Page 218 -->
<a name="218"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page218-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2180">218</p>
<p style="position:absolute;top:110px;left:106px;white-space:nowrap" class="ft2181"><b>17.</b></p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft2181"><b>UNIQUE IDENTIFIER&#160;-&#160;2D BARCODE</b></p>
<p style="position:absolute;top:150px;left:106px;white-space:nowrap" class="ft2182">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:208px;left:115px;white-space:nowrap" class="ft2181"><b>18.</b></p>
<p style="position:absolute;top:208px;left:157px;white-space:nowrap" class="ft2181"><b>UNIQUE IDENTIFIER&#160;-&#160;HUMAN READABLE DATA</b></p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft2184">PC&#160;<br/>SN<br/>NN&#160;</p>
</div>
<!-- Page 219 -->
<a name="219"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page219-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2190">219</p>
<p style="position:absolute;top:127px;left:115px;white-space:nowrap" class="ft2191"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:165px;left:115px;white-space:nowrap" class="ft2191"><b>OUTER CARTON&#160;–&#160;EU/1/99/126/030-032 (50&#160;mg Dose-dispenser cartridge)</b></p>
<p style="position:absolute;top:224px;left:115px;white-space:nowrap" class="ft2191"><b>1.</b></p>
<p style="position:absolute;top:224px;left:157px;white-space:nowrap" class="ft2191"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft2193">Enbrel 50&#160;mg solution for injection in dose<b>-</b>dispenser cartridge<br/>etanercept</p>
<p style="position:absolute;top:339px;left:115px;white-space:nowrap" class="ft2191"><b>2.</b></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft2191"><b>STATEMENT OF ACTIVE SUBSTANCE(S)</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2192">Each dose<b>-</b>dispenser cartridge of Enbrel contains 50&#160;mg etanercept.</p>
<p style="position:absolute;top:436px;left:115px;white-space:nowrap" class="ft2191"><b>3.</b></p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft2191"><b>LIST OF&#160;EXCIPIENTS</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2194">The other ingredients&#160;in&#160;Enbrel are:&#160;<br/>Sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate monobasic dihydrate, sodium&#160;<br/>phosphate dibasic dihydrate and water for injections.</p>
<p style="position:absolute;top:570px;left:115px;white-space:nowrap" class="ft2191"><b>4.</b></p>
<p style="position:absolute;top:570px;left:157px;white-space:nowrap" class="ft2191"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft2192">Solution for&#160;injection in dose<b>-</b>dispenser cartridge</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft2194">2 single-use dose<b>-</b>dispenser cartridges for use in SMARTCLIC device only<br/>4 alcohol swabs</p>
<p style="position:absolute;top:703px;left:106px;white-space:nowrap" class="ft2194">4 single-use dose<b>-</b>dispenser cartridges&#160;for use in SMARTCLIC device only<br/>8 alcohol swabs</p>
<p style="position:absolute;top:760px;left:106px;white-space:nowrap" class="ft2194">12 single-use dose<b>-</b>dispenser cartridges&#160;for use in SMARTCLIC device only<br/>24 alcohol swabs</p>
<p style="position:absolute;top:837px;left:115px;white-space:nowrap" class="ft2191"><b>5.</b></p>
<p style="position:absolute;top:837px;left:157px;white-space:nowrap" class="ft2191"><b>METHOD AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft2194">Read the package leaflet before use.<br/>Subcutaneous use.</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft2193">Injection advice:<br/>Inject the solution after it has reached room temperature (15 to 30&#160;minutes after taking the product&#160;<br/>from the refrigerator).&#160;</p>
<p style="position:absolute;top:1028px;left:115px;white-space:nowrap" class="ft2191"><b>6.</b></p>
<p style="position:absolute;top:1028px;left:157px;white-space:nowrap" class="ft21924"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT&#160;<br/>OF THE SIGHT AND REACH OF CHILDREN</b></p>
<p style="position:absolute;top:1086px;left:106px;white-space:nowrap" class="ft2192">Keep out of the sight and&#160;reach of children.</p>
</div>
<!-- Page 220 -->
<a name="220"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page220-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2200">220</p>
<p style="position:absolute;top:108px;left:115px;white-space:nowrap" class="ft2201"><b>7.</b></p>
<p style="position:absolute;top:108px;left:157px;white-space:nowrap" class="ft2201"><b>OTHER SPECIAL WARNING(S), IF NECESSARY</b></p>
<p style="position:absolute;top:167px;left:115px;white-space:nowrap" class="ft2201"><b>8.</b></p>
<p style="position:absolute;top:167px;left:157px;white-space:nowrap" class="ft2201"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft2202">EXP</p>
<p style="position:absolute;top:263px;left:115px;white-space:nowrap" class="ft2201"><b>9.</b></p>
<p style="position:absolute;top:263px;left:157px;white-space:nowrap" class="ft2201"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft2204">Store in a refrigerator.<br/>Do not freeze.</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft2202">Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft2202">Keep the dose<b>-</b>dispenser cartridges&#160;in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:454px;left:115px;white-space:nowrap" class="ft2201"><b>10.</b></p>
<p style="position:absolute;top:454px;left:157px;white-space:nowrap" class="ft22024"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS&#160;<br/>OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:551px;left:115px;white-space:nowrap" class="ft2201"><b>11.</b></p>
<p style="position:absolute;top:551px;left:157px;white-space:nowrap" class="ft2201"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft2203">Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:704px;left:115px;white-space:nowrap" class="ft2201"><b>12.</b></p>
<p style="position:absolute;top:704px;left:157px;white-space:nowrap" class="ft2201"><b>MARKETING AUTHORISATION NUMBER(S)</b></p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft2203">EU/1/99/126/030&#160;&#160;2 dose<b>-</b>dispenser cartridges<br/>EU/1/99/126/031&#160;&#160;4&#160;dose<b>-</b>dispenser cartridges<br/>EU/1/99/126/032&#160;&#160;12&#160;dose<b>-</b>dispenser cartridges</p>
<p style="position:absolute;top:838px;left:115px;white-space:nowrap" class="ft2201"><b>13.</b></p>
<p style="position:absolute;top:838px;left:157px;white-space:nowrap" class="ft2201"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft2202">Lot</p>
<p style="position:absolute;top:935px;left:115px;white-space:nowrap" class="ft2201"><b>14.</b></p>
<p style="position:absolute;top:935px;left:157px;white-space:nowrap" class="ft2201"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:993px;left:115px;white-space:nowrap" class="ft2201"><b>15.</b></p>
<p style="position:absolute;top:993px;left:157px;white-space:nowrap" class="ft2201"><b>INSTRUCTIONS ON USE</b></p>
<p style="position:absolute;top:1052px;left:115px;white-space:nowrap" class="ft2201"><b>16.</b></p>
<p style="position:absolute;top:1052px;left:157px;white-space:nowrap" class="ft2201"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft2202">Enbrel 50&#160;mg</p>
</div>
<!-- Page 221 -->
<a name="221"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page221-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2210">221</p>
<p style="position:absolute;top:110px;left:106px;white-space:nowrap" class="ft2211"><b>17.</b></p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft2211"><b>UNIQUE IDENTIFIER&#160;-&#160;2D BARCODE</b></p>
<p style="position:absolute;top:150px;left:106px;white-space:nowrap" class="ft2212">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:208px;left:115px;white-space:nowrap" class="ft2211"><b>18.</b></p>
<p style="position:absolute;top:208px;left:157px;white-space:nowrap" class="ft2211"><b>UNIQUE IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE DATA</b></p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft2214">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 222 -->
<a name="222"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page222-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2220">222</p>
<p style="position:absolute;top:127px;left:115px;white-space:nowrap" class="ft2221"><b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:165px;left:115px;white-space:nowrap" class="ft2221"><b>DOSE-DISPENSER CARTRIDGE LABEL</b></p>
<p style="position:absolute;top:224px;left:115px;white-space:nowrap" class="ft2221"><b>1.</b></p>
<p style="position:absolute;top:224px;left:157px;white-space:nowrap" class="ft2221"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft2223">Enbrel 25&#160;mg&#160;injection&#160;<br/>Enbrel 50&#160;mg&#160;injection&#160;<br/>etanercept<br/>SC</p>
<p style="position:absolute;top:377px;left:115px;white-space:nowrap" class="ft2221"><b>2.</b></p>
<p style="position:absolute;top:377px;left:157px;white-space:nowrap" class="ft2221"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft2222">Read the package leaflet before use.</p>
<p style="position:absolute;top:473px;left:115px;white-space:nowrap" class="ft2221"><b>3.</b></p>
<p style="position:absolute;top:473px;left:157px;white-space:nowrap" class="ft2221"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft2222">EXP</p>
<p style="position:absolute;top:570px;left:115px;white-space:nowrap" class="ft2221"><b>4.</b></p>
<p style="position:absolute;top:570px;left:157px;white-space:nowrap" class="ft2221"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft2222">Lot</p>
<p style="position:absolute;top:668px;left:106px;white-space:nowrap" class="ft2221"><b>5.</b></p>
<p style="position:absolute;top:668px;left:149px;white-space:nowrap" class="ft2221"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:708px;left:106px;white-space:nowrap" class="ft2224">0.5&#160;ml<br/>1&#160;ml</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft2221"><b>6.</b></p>
<p style="position:absolute;top:767px;left:149px;white-space:nowrap" class="ft2221"><b>OTHER</b></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft2222">Needle end</p>
</div>
<!-- Page 223 -->
<a name="223"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page223-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2230">223</p>
<p style="position:absolute;top:582px;left:355px;white-space:nowrap" class="ft2231"><b>B. PACKAGE LEAFLET</b></p>
</div>
<!-- Page 224 -->
<a name="224"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page224-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2240">224</p>
<p style="position:absolute;top:108px;left:298px;white-space:nowrap" class="ft2241"><b>Package&#160;Leaflet: Information for the User</b></p>
<p style="position:absolute;top:146px;left:282px;white-space:nowrap" class="ft2241"><b>Enbrel&#160;25&#160;mg&#160;powder for solution for injection</b></p>
<p style="position:absolute;top:165px;left:413px;white-space:nowrap" class="ft2242">etanercept</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft22423"><b>Read all of this leaflet carefully before you start using this medicine&#160;because it contains&#160;<br/>important information for you.</b></p>
<p style="position:absolute;top:240px;left:123px;white-space:nowrap" class="ft22414"></p>
<p style="position:absolute;top:242px;left:162px;white-space:nowrap" class="ft2242">Keep this leaflet. You may need to&#160;read it again.</p>
<p style="position:absolute;top:260px;left:123px;white-space:nowrap" class="ft22414"></p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft2242">Your doctor will also give you a Patient Card, which contains important safety information that&#160;</p>
<p style="position:absolute;top:281px;left:164px;white-space:nowrap" class="ft2242">you need to be aware of before and during treatment with Enbrel.</p>
<p style="position:absolute;top:299px;left:123px;white-space:nowrap" class="ft22414"></p>
<p style="position:absolute;top:301px;left:162px;white-space:nowrap" class="ft2242">If you have any further questions, ask your doctor,&#160;pharmacist&#160;or nurse.</p>
<p style="position:absolute;top:319px;left:123px;white-space:nowrap" class="ft22414"></p>
<p style="position:absolute;top:321px;left:162px;white-space:nowrap" class="ft2242">This medicine has been prescribed for you or a child in your care. Do not pass it on to others. It&#160;</p>
<p style="position:absolute;top:340px;left:164px;white-space:nowrap" class="ft2244">may harm them, even if their&#160;signs of illness&#160;are the same as yours or those of the child you are&#160;<br/>caring for.</p>
<p style="position:absolute;top:378px;left:123px;white-space:nowrap" class="ft22414"></p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft2242">If you&#160;get&#160;any side effects,&#160;talk to&#160;your doctor or pharmacist.&#160;This includes any possible side&#160;</p>
<p style="position:absolute;top:398px;left:164px;white-space:nowrap" class="ft2242">effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft2241"><b>What is in this leaflet</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2242">Information in this leaflet is organised under the following 7 sections:</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft2242">1.</p>
<p style="position:absolute;top:512px;left:149px;white-space:nowrap" class="ft2242">What Enbrel is and what it is used for</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft2242">2.</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft2242">What you need to&#160;know before you use Enbrel</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft2242">3.</p>
<p style="position:absolute;top:550px;left:149px;white-space:nowrap" class="ft2242">How to use Enbrel</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft2242">4.</p>
<p style="position:absolute;top:569px;left:149px;white-space:nowrap" class="ft2242">Possible side effects</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft2242">5.</p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft2242">How to store Enbrel</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft2242">6.</p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft2242">Contents of the pack and other information</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft2242">7.</p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft2242">Instructions for preparing and giving an injection of Enbrel (See overleaf).</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft2241"><b>1.</b></p>
<p style="position:absolute;top:683px;left:146px;white-space:nowrap" class="ft2241"><b>What Enbrel is and what it is&#160;used for</b></p>
<p style="position:absolute;top:721px;left:106px;white-space:nowrap" class="ft2244">Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in&#160;<br/>the body that causes inflammation. Enbrel works by reducing the inflammation associated with certain&#160;<br/>diseases.</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft2244">In adults (aged 18 and over),&#160;Enbrel can be used for moderate or severe&#160;<b>rheumatoid arthritis</b>,&#160;<br/><b>psoriatic arthritis</b>, severe&#160;<b>axial spondyloarthritis&#160;</b>including&#160;<b>ankylosing spondylitis,&#160;</b>and moderate&#160;<br/>or severe&#160;<b>psoriasis&#160;</b>–&#160;in each case usually when other widely used treatments have not worked&#160;well&#160;<br/>enough or are not suitable for you.</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft2244">For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may&#160;<br/>also be used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in&#160;<br/>combination with&#160;methotrexate, Enbrel can slow down the damage to your joints caused by the&#160;<br/>rheumatoid arthritis and improve your ability to do normal daily activities.</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft2244">For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do&#160;<br/>normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands,&#160;<br/>wrists and feet), Enbrel can slow down the structural damage to those joints caused by the disease.&#160;</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft2242">Enbrel is also prescribed for the treatment of the following diseases in children and adolescents</p>
<p style="position:absolute;top:1100px;left:106px;white-space:nowrap" class="ft22414"></p>
<p style="position:absolute;top:1102px;left:146px;white-space:nowrap" class="ft2242">For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not&#160;</p>
<p style="position:absolute;top:1120px;left:147px;white-space:nowrap" class="ft2242">worked well enough or is not suitable for them:</p>
</div>
<!-- Page 225 -->
<a name="225"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page225-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2250">225</p>
<p style="position:absolute;top:107px;left:187px;white-space:nowrap" class="ft22514">&#160;Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in&#160;</p>
<p style="position:absolute;top:128px;left:214px;white-space:nowrap" class="ft2252">patients from the age of 2 years</p>
<p style="position:absolute;top:165px;left:187px;white-space:nowrap" class="ft22514">&#160;Psoriatic arthritis in patients from the age of 12 years</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:206px;left:146px;white-space:nowrap" class="ft2252">For enthesitis-related arthritis in patients from the age of 12 years when other widely used&#160;</p>
<p style="position:absolute;top:225px;left:147px;white-space:nowrap" class="ft2252">treatments have not worked well enough or are not suitable for them</p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:264px;left:146px;white-space:nowrap" class="ft2252">Severe psoriasis in patients from the age of 6 years who have had an inadequate response to (or&#160;</p>
<p style="position:absolute;top:283px;left:147px;white-space:nowrap" class="ft2252">are unable to take) phototherapies or other systemic therapies.</p>
<p style="position:absolute;top:340px;left:106px;white-space:nowrap" class="ft2251"><b>2.</b></p>
<p style="position:absolute;top:340px;left:146px;white-space:nowrap" class="ft2251"><b>What you need to know before you use Enbrel&#160;</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2251"><b>Do not use Enbrel</b></p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:417px;left:146px;white-space:nowrap" class="ft2252">if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of&#160;</p>
<p style="position:absolute;top:436px;left:147px;white-space:nowrap" class="ft2254">Enbrel&#160;(listed in section 6). If you or the child experience allergic reactions such as chest&#160;<br/>tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor&#160;<br/>immediately.</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:494px;left:146px;white-space:nowrap" class="ft2252">if you or the child have,&#160;or are at risk of developing a serious blood infection called sepsis. If&#160;</p>
<p style="position:absolute;top:513px;left:147px;white-space:nowrap" class="ft2252">you are not sure, please contact your doctor.</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:533px;left:146px;white-space:nowrap" class="ft2252">if you&#160;or the child,&#160;have an infection of any kind. If you are not sure, please talk to your doctor.</p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft2251"><b>Warnings and precautions&#160;</b></p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft2252">Talk to your doctor before taking Enbrel.</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:648px;left:147px;white-space:nowrap" class="ft2254"><b>Allergic reactions</b>: If you or the child experience allergic reactions such as chest tightness,&#160;<br/>wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:688px;left:147px;white-space:nowrap" class="ft2254"><b>Infections/surgery</b>: If you or the child develop a new infection, or are about to have any major&#160;<br/>surgery, your doctor may wish to monitor the treatment with Enbrel.</p>
<p style="position:absolute;top:725px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:727px;left:147px;white-space:nowrap" class="ft2254"><b>Infections/diabetes:&#160;</b>Tell your doctor if you or the child have a history of recurrent infections or&#160;<br/>suffer from diabetes or other conditions that increase the risk of infection.</p>
<p style="position:absolute;top:764px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:766px;left:147px;white-space:nowrap" class="ft2251"><b>Infections/monitoring:&#160;</b>Tell your doctor of any recent travel outside the&#160;European region. If you&#160;</p>
<p style="position:absolute;top:785px;left:147px;white-space:nowrap" class="ft2254">or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor&#160;<br/>immediately. Your doctor may decide to continue to monitor you or the child for the presence of&#160;<br/>infections after you or the child stop&#160;using Enbrel.</p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:843px;left:147px;white-space:nowrap" class="ft2251"><b>Tuberculosis:&#160;</b>As cases of tuberculosis have been reported in patients treated with Enbrel, your&#160;</p>
<p style="position:absolute;top:862px;left:147px;white-space:nowrap" class="ft2254">doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may&#160;<br/>include a thorough medical history, a chest X-ray and a&#160;tuberculin test. The conduct of these&#160;<br/>tests should be recorded on the Patient Card. It is very important that you tell your doctor if you&#160;<br/>or the child have ever had tuberculosis, or have been in close contact with someone who has had&#160;<br/>tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:977px;left:147px;white-space:nowrap" class="ft2251"><b>Hepatitis B:&#160;</b>Tell your&#160;doctor if you or the child have or have ever had hepatitis B.&#160;Your doctor&#160;</p>
<p style="position:absolute;top:996px;left:147px;white-space:nowrap" class="ft2253">should test&#160;for the presence of hepatitis B infection before you or the child begin treatment with&#160;<br/>Enbrel.&#160;Treatment with Enbrel may result in reactivation of hepatitis B in patients who have&#160;<br/>previously been infected with the hepatitis B virus. If this occurs, you should stop using Enbrel.</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:1054px;left:147px;white-space:nowrap" class="ft2251"><b>Hepatitis C:&#160;</b>Tell your doctor if you or the child have hepatitis C. Your doctor may wish to&#160;</p>
<p style="position:absolute;top:1073px;left:147px;white-space:nowrap" class="ft2252">monitor the treatment with Enbrel in case the infection worsens.</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft22514"></p>
<p style="position:absolute;top:1093px;left:147px;white-space:nowrap" class="ft2254"><b>Blood disorders:&#160;</b>Seek medical advice immediately if&#160;you or the child have any signs or&#160;<br/>symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms&#160;<br/>may point to the existence of potentially life-threatening blood disorders, which may require&#160;<br/>discontinuation of Enbrel.</p>
</div>
<!-- Page 226 -->
<a name="226"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page226-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2260">226</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft22614"></p>
<p style="position:absolute;top:109px;left:147px;white-space:nowrap" class="ft2264"><b>Nervous system and eye disorders:&#160;</b>Tell your doctor if you or the child have multiple sclerosis,&#160;<br/>optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of&#160;<br/>the spinal cord). Your doctor will determine if Enbrel is an appropriate treatment.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft22614"></p>
<p style="position:absolute;top:167px;left:147px;white-space:nowrap" class="ft2264"><b>Congestive heart failure:&#160;</b>Tell your doctor if you or the child have a history of congestive heart&#160;<br/>failure, because Enbrel needs to be used with caution under these circumstances.</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft22614"></p>
<p style="position:absolute;top:206px;left:147px;white-space:nowrap" class="ft2264"><b>Cancer:&#160;</b>Tell your doctor if you have or have ever had lymphoma&#160;(a type of blood cancer) or&#160;<br/>any other cancer before you are given Enbrel.</p>
<p style="position:absolute;top:244px;left:147px;white-space:nowrap" class="ft2264">Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at&#160;<br/>higher than average risk of developing lymphoma.<br/>Children and adults taking Enbrel may&#160;have an increased risk of developing lymphoma or&#160;<br/>another cancer.<br/>Some children and teenage patients who have received Enbrel or other medicines that work the&#160;<br/>same way as Enbrel have developed cancers, including unusual types, which sometimes resulted&#160;<br/>in death.<br/>Some patients receiving Enbrel have developed skin cancers.&#160;Tell&#160;your doctor if you or the child&#160;<br/>develop any change in the appearance of the skin&#160;or growths on the skin.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft22614"></p>
<p style="position:absolute;top:416px;left:147px;white-space:nowrap" class="ft2264"><b>Chickenpox:&#160;</b>Tell your doctor if you or the child are exposed to chickenpox when&#160;using Enbrel.&#160;<br/>Your doctor will determine if preventive treatment for chickenpox is appropriate.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft22614"></p>
<p style="position:absolute;top:455px;left:147px;white-space:nowrap" class="ft2264"><b>Alcohol abuse</b>: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.&#160;<br/>Please tell your doctor if you or the child in your care have&#160;a history of alcohol abuse.</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft22614"></p>
<p style="position:absolute;top:494px;left:147px;white-space:nowrap" class="ft2264"><b>Wegener’s granulomatosis</b>: Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener’s&#160;<br/>granulomatosis, talk to your doctor.</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft22614"></p>
<p style="position:absolute;top:552px;left:147px;white-space:nowrap" class="ft2263"><b>Anti-diabetic medicines</b>: Tell your doctor if you or the child have diabetes or are taking&#160;<br/>medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic&#160;<br/>medicine while taking Enbrel.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft2261"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:666px;left:106px;white-space:nowrap" class="ft2264"><b>Vaccinations:&#160;</b>If possible, children should be up to date with all vaccinations before using Enbrel.&#160;<br/>Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult&#160;<br/>your doctor before you or the child receive any vaccines.</p>
<p style="position:absolute;top:742px;left:106px;white-space:nowrap" class="ft2263">Enbrel should not normally be used in children with&#160;polyarthritis or extended oligoarthritis&#160;below the&#160;<br/>age of 2 years,&#160;or in children with enthesitis-related&#160;arthritis&#160;or psoriatic arthritis&#160;below the age of 12&#160;<br/>years,&#160;or in children with psoriasis below the age of&#160;6&#160;years.</p>
<p style="position:absolute;top:818px;left:106px;white-space:nowrap" class="ft2261"><b>Other medicines&#160;and Enbrel</b></p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft2263">Tell&#160;your&#160;doctor or pharmacist if you or the child are taking,&#160;have recently taken&#160;or might take&#160;any&#160;<br/>other medicines (including anakinra, abatacept or sulfasalazine), even those not prescribed by the&#160;<br/>doctor. You or the&#160;child should not use Enbrel with medicines that contain the active substance&#160;<br/>anakinra or abatacept.</p>
<p style="position:absolute;top:951px;left:106px;white-space:nowrap" class="ft2261"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:989px;left:106px;white-space:nowrap" class="ft2263">Enbrel&#160;should only be used&#160;during pregnancy&#160;if clearly needed.&#160;You should consult your doctor if you<br/>become pregnant,&#160;think you may be pregnant, or are planning to have a baby.</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft2263">If you received Enbrel during pregnancy,&#160;your&#160;baby may have a higher risk&#160;of&#160;getting an infection.&#160;In&#160;<br/>addition,&#160;one study&#160;found&#160;more birth defects when the mother had received&#160;Enbrel&#160;in pregnancy,&#160;<br/>compared&#160;with&#160;mothers who had not received&#160;Enbrel&#160;or other similar medicines (TNF-antagonists),&#160;<br/>but there was no&#160;particular kind of birth defect&#160;reported.&#160;Another study found no increased risk of birth&#160;<br/>defects when the mother had received Enbrel in pregnancy.&#160;Your doctor will help you to decide&#160;<br/>whether the benefits of treatment outweigh the potential risk to your baby.</p>
</div>
<!-- Page 227 -->
<a name="227"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page227-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2270">227</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft2273">Talk to your doctor if you want to breastfeed while on Enbrel treatment.&#160;It&#160;is important that you&#160;tell&#160;<br/>your&#160;baby’s doctors and other healthcare professionals about the use of Enbrel during pregnancy and&#160;<br/>breastfeeding before&#160;your&#160;baby receives any vaccine.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft2271"><b>Driving and using machines</b></p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft2272">The use of Enbrel is not expected to affect the ability to drive or&#160;use machines.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft2271"><b>3.</b></p>
<p style="position:absolute;top:298px;left:146px;white-space:nowrap" class="ft2271"><b>How to use Enbrel</b></p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft2273">Always use&#160;this medicine&#160;exactly as the doctor has told you.&#160;Check with the doctor or pharmacist if&#160;<br/>you are not sure.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft2272">If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft2271"><b>Dosing for adult patients (aged 18 years or over)</b></p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft2272">Rheumatoid arthritis, psoriatic arthritis,&#160;and&#160;axial spondyloarthritis including&#160;ankylosing spondylitis</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft2274">The usual dose is 25&#160;mg given twice a week or 50&#160;mg&#160;once a week as an injection under the skin.&#160;<br/>However, your doctor may determine an alternative frequency at which to inject Enbrel.&#160;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft2272">Plaque psoriasis</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft2272">The usual dose is 25&#160;mg twice a week or 50&#160;mg once a&#160;week. &#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft2274">Alternatively, 50&#160;mg&#160;may be given twice a week for up to 12 weeks, followed by 25&#160;mg twice a week&#160;<br/>or 50&#160;mg once a week.&#160;</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft2273">Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on&#160;<br/>your response. If Enbrel has no effect on your condition after 12 weeks, your doctor may tell you to&#160;<br/>stop taking this medicine.</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft2271"><b>Use in&#160;children&#160;and adolescents</b></p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft2274">The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight&#160;<br/>and disease. The&#160;doctor will provide you with detailed directions for preparing and measuring the&#160;<br/>appropriate dose.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft2274">For&#160;polyarthritis or extended oligoarthritis&#160;in patients from the age of 2 years,&#160;or enthesitis-related&#160;<br/>arthritis or psoriatic arthritis in patients from the age of 12 years,&#160;the usual dose is 0.4&#160;mg of Enbrel&#160;<br/>per kg bodyweight (up to a maximum of 25&#160;mg) given twice weekly,&#160;or 0.8&#160;mg of Enbrel per kg of&#160;<br/>bodyweight (up to a maximum of 50&#160;mg) given once weekly.</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft2273">For psoriasis in patients from the age of&#160;6&#160;years, the usual dose is 0.8&#160;mg of Enbrel per kg bodyweight&#160;<br/>(up to a maximum of 50&#160;mg), and should be given once weekly. If Enbrel has no effect on the child’s&#160;<br/>condition after 12 weeks, your doctor may tell you to stop using this medicine.</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft2271"><b>Method and route of administration</b></p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft2272">Enbrel is administered by an injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft2272">Enbrel can be taken with or without food or drink.</p>
</div>
<!-- Page 228 -->
<a name="228"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page228-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2280">228</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft22823">The powder must be dissolved before use.&#160;<b>Detailed instructions on how to prepare and inject&#160;<br/>Enbrel&#160;are provided in section 7, “Instructions for preparing and giving an injection of Enbrel”.&#160;<br/></b>Do not mix the Enbrel solution with any other medicine.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft2283">To help you remember, it may be helpful to write in a diary which day(s) of the week Enbrel should be&#160;<br/>used.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft2281"><b>If&#160;you use more Enbrel than you should</b></p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft2284">If you have used more Enbrel than you should (either by injecting too much on a single occasion or by&#160;<br/>using it too frequently), talk to a doctor or pharmacist immediately. Always have the outer carton of&#160;<br/>the medicine with you, even if it is empty.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft2281"><b>If&#160;you forget to inject Enbrel</b></p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2283">If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is&#160;<br/>the next day; in which case you should skip the missed dose. Then continue to inject the&#160;medicine on&#160;<br/>the usual day(s). If you do not remember until the day that the next injection is due, do not take a&#160;<br/>double dose (two doses on the same day) to make up for a forgotten dose.</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft2281"><b>If&#160;you stop using Enbrel&#160;</b></p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft2282">Your symptoms may return upon discontinuation.&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft2282">If you have any further questions on the use of this&#160;medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft2281"><b>4.</b></p>
<p style="position:absolute;top:620px;left:146px;white-space:nowrap" class="ft2281"><b>Possible side effects</b></p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft2282">Like all medicines,&#160;this medicine&#160;can cause side effects, although not everybody gets them.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft2281"><b>Allergic reactions</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft2284">If any of the following happen, do not inject more Enbrel. Tell your doctor immediately, or go to the&#160;<br/>casualty department at your nearest hospital.</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft22814"></p>
<p style="position:absolute;top:792px;left:149px;white-space:nowrap" class="ft2282">Trouble swallowing or breathing</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft22814"></p>
<p style="position:absolute;top:812px;left:149px;white-space:nowrap" class="ft2282">Swelling of the face, throat, hands, or feet</p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft22814"></p>
<p style="position:absolute;top:832px;left:149px;white-space:nowrap" class="ft2284">Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm&#160;<br/>feeling</p>
<p style="position:absolute;top:870px;left:106px;white-space:nowrap" class="ft22814"></p>
<p style="position:absolute;top:872px;left:149px;white-space:nowrap" class="ft2282">Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft2284">Serious allergic&#160;reactions are rare. However, any of the above symptoms may indicate an allergic&#160;<br/>reaction to Enbrel, so you should seek immediate medical attention.</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft2281"><b>Serious side effects</b></p>
<p style="position:absolute;top:1004px;left:106px;white-space:nowrap" class="ft2282">If you notice any of the following, you or the child may need urgent medical attention.</p>
<p style="position:absolute;top:1042px;left:106px;white-space:nowrap" class="ft22814"></p>
<p style="position:absolute;top:1043px;left:149px;white-space:nowrap" class="ft2284">Signs of&#160;<b>serious infections</b>, such as high fever that may be accompanied by cough, shortness of&#160;<br/>breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p>
<p style="position:absolute;top:1081px;left:106px;white-space:nowrap" class="ft22814"></p>
<p style="position:absolute;top:1082px;left:149px;white-space:nowrap" class="ft2282">Signs of&#160;<b>blood disorders</b>, such as bleeding, bruising, or paleness</p>
<p style="position:absolute;top:1101px;left:106px;white-space:nowrap" class="ft22814"></p>
<p style="position:absolute;top:1103px;left:149px;white-space:nowrap" class="ft2284">Signs of&#160;<b>nerve disorders</b>, such as numbness or tingling, changes in vision, eye pain, or onset of&#160;<br/>weakness in an arm or leg</p>
</div>
<!-- Page 229 -->
<a name="229"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page229-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2290">229</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft2294">Signs of&#160;<b>heart failure&#160;</b>or&#160;<b>worsening heart failure</b>, such as fatigue or shortness of breath with&#160;<br/>activity, swelling in the ankles, a feeling of fullness in the neck or abdomen, night-time&#160;<br/>shortness of breath or coughing, bluish colour of the nails or the lips</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:167px;left:149px;white-space:nowrap" class="ft2294"><b>Signs of cancers:&#160;</b>Cancers may affect any part of the body including the skin and blood, and&#160;<br/>possible signs will depend on the type and location of the cancer. These signs may include&#160;<br/>weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or&#160;<br/>growths on the skin</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft2294">Signs of&#160;<b>autoimmune reactions&#160;</b>(where antibodies are made that may harm normal tissues in&#160;<br/>the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft2294">Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or&#160;<br/>muscle pain, or fatigue</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:322px;left:149px;white-space:nowrap" class="ft2294">Signs of&#160;<b>inflammation of the blood vessels&#160;</b>such as&#160;pain, fever, redness or warmth of the skin,&#160;<br/>or itching.</p>
<p style="position:absolute;top:379px;left:106px;white-space:nowrap" class="ft2294">These are rare or uncommon side effects, but are serious conditions (some of which may rarely be&#160;<br/>fatal). If these signs occur, tell your doctor immediately, or visit the casualty department at your&#160;<br/>nearest hospital.<br/>The known side effects of Enbrel include the following in groups of decreasing frequency:</p>
<p style="position:absolute;top:473px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:475px;left:149px;white-space:nowrap" class="ft2294"><b>Very common&#160;</b>(may affect more than 1 in10&#160;people):<br/>Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections);&#160;<br/>injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling)&#160;(these<br/>do not occur as often after the first month of treatment;&#160;some patients have developed a reaction&#160;<br/>at an injection site that was&#160;recently&#160;used);&#160;and headache.</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:590px;left:149px;white-space:nowrap" class="ft2293"><b>Common&#160;</b>(may affect up to 1 in 10&#160;people):<br/>Allergic reactions; fever;&#160;rash;&#160;itching; antibodies directed against normal tissue (autoantibody&#160;<br/>formation).</p>
<p style="position:absolute;top:666px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:667px;left:149px;white-space:nowrap" class="ft2293"><b>Uncommon&#160;</b>(may affect up to 1 in 100&#160;people):<br/>Serious infections (including pneumonia, deep skin infections, joint infections, blood infection,&#160;<br/>and infections at various sites);&#160;worsening of congestive heart failure;&#160;low red blood cell count,&#160;<br/>low white blood cell count, low neutrophil (a type of white&#160;blood cell) count;&#160;low blood platelet&#160;<br/>count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives&#160;<br/>(elevated patches of red or pale skin that often itch); eye inflammation; psoriasis&#160;(new or&#160;<br/>worsening);&#160;inflammation of the blood vessels affecting multiple organs;&#160;elevated liver blood&#160;<br/>tests&#160;(in patients also receiving methotrexate treatment, the frequency of elevated liver blood&#160;<br/>tests is common);&#160;abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs&#160;<br/>of&#160;bowel problems).</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft22914"></p>
<p style="position:absolute;top:877px;left:149px;white-space:nowrap" class="ft2293"><b>Rare&#160;</b>(may affect up to 1 in 1,000&#160;people):<br/>Serious allergic reactions (including severe localised swelling of the skin and wheezing);&#160;<br/>lymphoma (a type of blood cancer);&#160;leukaemia (cancer affecting the blood and bone marrow);<br/>melanoma&#160;(a type of skin cancer);&#160;combined low platelet, red, and white blood cell count;&#160;<br/>nervous system disorders (with&#160;severe muscle weakness and&#160;signs and symptoms similar to&#160;<br/>those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord);&#160;<br/>tuberculosis;&#160;new onset&#160;congestive heart failure; seizures; lupus or lupus-like syndrome&#160;<br/>(symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may&#160;<br/>lead to severe blistering and peeling of the skin;&#160;lichenoid reactions (itchy reddish-purple skin&#160;<br/>rash and/or threadlike white-grey lines on mucous membranes);&#160;inflammation of the liver&#160;<br/>caused by the body's own immune system (autoimmune hepatitis;&#160;in patients also receiving&#160;<br/>methotrexate treatment, the frequency is uncommon); immune disorder that can affect the lungs,&#160;<br/>skin and lymph nodes (sarcoidosis);&#160;inflammation or scarring of the lungs&#160;(in patients also&#160;<br/>receiving methotrexate treatment, the frequency&#160;of&#160;inflammation or scarring of the lungs is&#160;<br/>uncommon).</p>
</div>
<!-- Page 230 -->
<a name="230"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page230-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2300">230</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft23014"></p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft2304"><b>Very rare&#160;</b>(may affect up to 1 in 10,000&#160;people):&#160;failure of the bone marrow to produce crucial&#160;<br/>blood cells.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft23014"></p>
<p style="position:absolute;top:186px;left:149px;white-space:nowrap" class="ft2304"><b>Not known&#160;</b>(frequency cannot be estimated from the available data):&#160;Merkel cell carcinoma (a&#160;<br/>type of skin cancer);&#160;Kaposi’s sarcoma (a rare cancer related to&#160;infection with human herpes&#160;<br/>virus 8. Kaposi’s sarcoma most commonly appear as purple lesions on the skin);&#160;excessive&#160;<br/>activation of white blood cells associated with inflammation (macrophage activation&#160;<br/>syndrome);&#160;recurrence of hepatitis B (a liver infection);&#160;worsening of a condition called&#160;<br/>dermatomyositis (muscle inflammation and weakness&#160;with&#160;an&#160;accompanying&#160;skin rash).</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft2301"><b>Additional side effects in children and adolescents</b></p>
<p style="position:absolute;top:357px;left:106px;white-space:nowrap" class="ft2304">The side effects and their frequencies seen in children and adolescents are similar&#160;to those described&#160;<br/>above.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft2301"><b>Reporting of side effects</b></p>
<p style="position:absolute;top:452px;left:106px;white-space:nowrap" class="ft2304">If you get any side effects, talk to your doctor&#160;or&#160;pharmacist.&#160;This includes any possible&#160;side effects&#160;<br/>not listed in this leaflet.&#160;You can also report side effects&#160;directly&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>. By reporting side effects you can help provide more information on the safety of&#160;<br/>this medicine.</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft2301"><b>5.</b></p>
<p style="position:absolute;top:566px;left:146px;white-space:nowrap" class="ft2301"><b>How to store Enbrel</b></p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft2302">Keep&#160;this medicine&#160;out of the&#160;sight and&#160;reach of children.</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft2303">Do not use&#160;this medicine&#160;after the expiry date which is stated on the carton and the label after “EXP”.&#160;<br/>The expiry date refers to the last day of that month.</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft2302">Store in&#160;a refrigerator (2</p>
<p style="position:absolute;top:698px;left:267px;white-space:nowrap" class="ft23014">C&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft2308">Before preparing the Enbrel solution, Enbrel may be stored outside of the refrigerator at temperatures&#160;<br/>up to a maximum of 25</p>
<p style="position:absolute;top:756px;left:261px;white-space:nowrap" class="ft23014">C for a single period of up to four weeks; after which, it should not be&#160;</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft2304">refrigerated again. Enbrel should be discarded if not used within four weeks after removal from the&#160;<br/>refrigerator. It is recommended that you record the date that Enbrel is removed from the refrigerator&#160;<br/>and the date after which Enbrel should be discarded (no more than 4&#160;weeks following the removal&#160;<br/>from the refrigerator).</p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft2308">After preparing the Enbrel solution, immediate use is recommended. However, the solution may be&#160;<br/>used for up to 6&#160;hours when stored at temperatures of up to 25</p>
<p style="position:absolute;top:890px;left:517px;white-space:nowrap" class="ft23014">C.&#160;</p>
<p style="position:absolute;top:930px;left:106px;white-space:nowrap" class="ft2304">Do not use&#160;this medicine&#160;if you notice&#160;the solution is not clear or contains particles. The solution&#160;<br/>should be clear, colourless&#160;to&#160;pale yellow&#160;or pale brown, with no lumps or flakes or particles.</p>
<p style="position:absolute;top:987px;left:106px;white-space:nowrap" class="ft2302">Carefully dispose of any Enbrel solution that has not been injected within 6&#160;hours.</p>
<p style="position:absolute;top:1025px;left:106px;white-space:nowrap" class="ft2304">Do not throw&#160;away any medicines via wastewater or household waste. Ask your pharmacist how to&#160;<br/>throw away&#160;medicines&#160;you&#160;no longer&#160;use. These measures will help protect the environment.</p>
</div>
<!-- Page 231 -->
<a name="231"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page231-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2310">231</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2311"><b>6.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft2311"><b>Contents&#160;of&#160;the pack and other&#160;information&#160;</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2311"><b>What Enbrel contains</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft2312">The active substance in Enbrel is etanercept. Each vial of Enbrel&#160;25&#160;mg&#160;contains&#160;25&#160;mg&#160;of etanercept. &#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft2314">The other ingredients are:<br/>Powder: Mannitol&#160;(E421), sucrose and trometamol</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft2311"><b>What Enbrel looks like and contents of the pack</b></p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft2314">Enbrel&#160;25&#160;mg&#160;is supplied as&#160;a white powder for solution for injection&#160;(powder for injection). Each&#160;<br/>pack contains 4&#160;single-dose vials and 8 alcohol swabs.</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft2311"><b>Marketing Authorisation Holder and Manufacturer</b></p>
<p style="position:absolute;top:411px;left:114px;white-space:nowrap" class="ft2313"><i>Marketing Authorisation Holder:<br/></i>Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:525px;left:114px;white-space:nowrap" class="ft2314"><i>Manufacturer:<br/></i>Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
<p style="position:absolute;top:649px;left:106px;white-space:nowrap" class="ft2313">For any information about this medicinal product, please contact the local representative of the&#160;<br/>Marketing Authorisation Holder.</p>
<p style="position:absolute;top:706px;left:114px;white-space:nowrap" class="ft2313"><b>België/Belgique/Belgien<br/>Luxembourg/Luxemburg<br/></b>Pfizer&#160;NV/SA<br/>Tél/Tel: +32 (0)2 554 62 11</p>
<p style="position:absolute;top:706px;left:452px;white-space:nowrap" class="ft2318"><b>Kύπρος<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.&#160;(CYPRUS BRANCH)&#160;<br/>T</p>
<p style="position:absolute;top:743px;left:462px;white-space:nowrap" class="ft23114">: +357 22 817690</p>
<p style="position:absolute;top:800px;left:114px;white-space:nowrap" class="ft2314"><b>Česká Republika<br/></b>Pfizer, spol.&#160;s&#160;r.o.<br/>Tel:&#160;+420-283-004-111</p>
<p style="position:absolute;top:800px;left:452px;white-space:nowrap" class="ft2314"><b>Magyarország<br/></b>Pfizer Kft.<br/>Tel: +36 1 488 3700</p>
<p style="position:absolute;top:876px;left:114px;white-space:nowrap" class="ft2313"><b>Danmark<br/></b>Pfizer ApS<br/>Tlf: +45 44&#160;201&#160;100</p>
<p style="position:absolute;top:876px;left:452px;white-space:nowrap" class="ft2313"><b>Malta<br/></b>Vivian Corporation Ltd.<br/>Tel: +35621 344610</p>
<p style="position:absolute;top:952px;left:114px;white-space:nowrap" class="ft2313"><b>Deutschland<br/></b>Pfizer Pharma GmbH<br/>Tel: +49 (0)30 550055-51000</p>
<p style="position:absolute;top:952px;left:452px;white-space:nowrap" class="ft2313"><b>Nederland<br/></b>Pfizer bv<br/>Tel: +31 (0)800 63 34 636</p>
<p style="position:absolute;top:1030px;left:114px;white-space:nowrap" class="ft2314"><b>България<br/></b>Пфайзер Люксембург САРЛ,&#160;<br/>Клон България<br/>Teл:&#160;+359 2 970 4333</p>
<p style="position:absolute;top:1030px;left:452px;white-space:nowrap" class="ft2314"><b>Norge<br/></b>Pfizer AS<br/>Tlf: +47 67&#160;52&#160;61&#160;00</p>
</div>
<!-- Page 232 -->
<a name="232"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page232-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2320">232</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft2324"><b>Eesti<br/></b>Pfizer Luxembourg SARL Eesti filiaal<br/>Tel:&#160;+372 666 7500</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft2324"><b>Österreich<br/></b>Pfizer Corporation Austria Ges.m.b.H.<br/>Tel: +43&#160;(0)1 521 15-0</p>
<p style="position:absolute;top:184px;left:114px;white-space:nowrap" class="ft2324"><b>Ελλάδα<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.<br/>Τηλ.: +30 210 67&#160;85 800</p>
<p style="position:absolute;top:184px;left:452px;white-space:nowrap" class="ft2324"><b>Polska<br/></b>Pfizer Polska Sp. z o.o.<br/>Tel.: +48 22 335 61 00</p>
<p style="position:absolute;top:269px;left:114px;white-space:nowrap" class="ft2324"><b>España<br/></b>Pfizer, S.L.<br/>Télf: +34&#160;91&#160;490&#160;99&#160;00</p>
<p style="position:absolute;top:269px;left:452px;white-space:nowrap" class="ft2324"><b>Portugal<br/></b>Laboratórios Pfizer, Lda.<br/>Tel: (+351) 21 423 55 00</p>
<p style="position:absolute;top:350px;left:114px;white-space:nowrap" class="ft2323"><b>France<br/></b>Pfizer<br/>Tél&#160;+33 (0)1 58&#160;07 34 40</p>
<p style="position:absolute;top:350px;left:452px;white-space:nowrap" class="ft2323"><b>România<br/></b>Pfizer Romania S.R.L<br/>Tel: +40 (0) 21 207 28 00</p>
<p style="position:absolute;top:426px;left:114px;white-space:nowrap" class="ft2324"><b>Hrvatska<br/></b>Pfizer Croatia&#160;d.o.o.<br/>Tel: +385 1&#160;3908&#160;777</p>
<p style="position:absolute;top:426px;left:452px;white-space:nowrap" class="ft2324"><b>Slovenija<br/></b>Pfizer Luxembourg SARL<i>,&#160;</i>Pfizer, podružnica&#160;<br/>za&#160;svetovanje s področja farmacevtske&#160;<br/>dejavnosti, Ljubljana<br/>Tel: +386 (0)1 52 11&#160;400</p>
<p style="position:absolute;top:540px;left:114px;white-space:nowrap" class="ft2324"><b>Ireland<br/></b>Pfizer Healthcare Ireland<br/>Tel: +1800 633 363 (toll free)<br/>Tel: +44 (0)1304 616161</p>
<p style="position:absolute;top:540px;left:452px;white-space:nowrap" class="ft2324"><b>Slovenská Republika<br/></b>Pfizer Luxembourg SARL, organizačná zložka&#160;<br/>Tel: +421 2 3355 5500</p>
<p style="position:absolute;top:635px;left:114px;white-space:nowrap" class="ft2324"><b>Ísland<br/></b>Icepharma&#160;hf.<br/>Tel: +354&#160;540 8000</p>
<p style="position:absolute;top:635px;left:452px;white-space:nowrap" class="ft2324"><b>Suomi/Finland<br/></b>Pfizer Oy<br/>Puh/Tel: +358 (0)9&#160;430 040</p>
<p style="position:absolute;top:715px;left:114px;white-space:nowrap" class="ft2324"><b>Italia<br/></b>Pfizer S.r.l.<br/>Tel: +39 06 33 18 21</p>
<p style="position:absolute;top:715px;left:452px;white-space:nowrap" class="ft2324"><b>Sverige&#160;<br/></b>Pfizer AB<br/>Tel: +46 (0)8&#160;550&#160;520 00</p>
<p style="position:absolute;top:794px;left:114px;white-space:nowrap" class="ft2324"><b>Latvija<br/></b>Pfizer Luxembourg SARL filiāle Latvijā<br/>Tel. +371 67035775</p>
<p style="position:absolute;top:794px;left:452px;white-space:nowrap" class="ft2324"><b>United Kingdom&#160;(Northern Ireland)<br/></b>Pfizer Limited<br/>Tel:&#160;+44 (0)1304&#160;616161</p>
<p style="position:absolute;top:874px;left:114px;white-space:nowrap" class="ft2324"><b>Lietuva<br/></b>Pfizer Luxembourg SARL filialas Lietuvoje<br/>Tel. +3705 2514000</p>
<p style="position:absolute;top:972px;left:106px;white-space:nowrap" class="ft2321"><b>This leaflet was last&#160;revised&#160;in</b></p>
<p style="position:absolute;top:1010px;left:106px;white-space:nowrap" class="ft2323">Detailed information on this&#160;medicine&#160;is available on the&#160;European Medicines Agency&#160;web&#160;site:<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>
</div>
<!-- Page 233 -->
<a name="233"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page233-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2330">233</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2331"><b>7.</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft2331"><b>Instructions for preparing and giving an injection of Enbrel</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2332">This section is divided into the following sub-sections:</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft2331"><b>a.</b></p>
<p style="position:absolute;top:184px;left:149px;white-space:nowrap" class="ft2331"><b>Introduction</b></p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft2331"><b>b.</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft2331"><b>Setting up for an injection</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft2331"><b>c.</b></p>
<p style="position:absolute;top:222px;left:149px;white-space:nowrap" class="ft2331"><b>Preparing the Enbrel dose for injection</b></p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft2331"><b>d.</b></p>
<p style="position:absolute;top:240px;left:149px;white-space:nowrap" class="ft2331"><b>Adding water for injections</b></p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft2331"><b>e.</b></p>
<p style="position:absolute;top:260px;left:149px;white-space:nowrap" class="ft2331"><b>Withdrawing the Enbrel solution from the vial</b></p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft2331"><b>f.</b></p>
<p style="position:absolute;top:278px;left:149px;white-space:nowrap" class="ft2331"><b>Choosing an injection site&#160;</b></p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft2331"><b>g.</b></p>
<p style="position:absolute;top:297px;left:149px;white-space:nowrap" class="ft2331"><b>Preparing the injection site and injecting the Enbrel solution</b></p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft2331"><b>h.</b></p>
<p style="position:absolute;top:316px;left:149px;white-space:nowrap" class="ft2331"><b>Disposing of supplies</b></p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft2331"><b>a.</b></p>
<p style="position:absolute;top:354px;left:149px;white-space:nowrap" class="ft2331"><b>Introduction</b></p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2333">The following instructions explain how to prepare and inject Enbrel. Please&#160;read the instructions&#160;<br/>carefully and follow them step by step. You will be instructed by your doctor or his/her assistant on&#160;<br/>the techniques of self-injection or on giving an injection to a child. Do not attempt to administer an&#160;<br/>injection until you are sure&#160;that you understand how to prepare and give the injection.</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft2332">This injection should not be mixed with any other medicine.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft2331"><b>b.</b></p>
<p style="position:absolute;top:525px;left:149px;white-space:nowrap" class="ft2331"><b>Setting up for an injection</b></p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:564px;left:149px;white-space:nowrap" class="ft2332">Wash your hands thoroughly.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:584px;left:149px;white-space:nowrap" class="ft2332">Select a clean, well-lit, flat working surface.</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:605px;left:149px;white-space:nowrap" class="ft2332">Take the ENBREL vial out of the refrigerator and place it on a flat surface.</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:625px;left:149px;white-space:nowrap" class="ft2332">You will also need the following items:</p>
<p style="position:absolute;top:644px;left:191px;white-space:nowrap" class="ft2334">A sterile syringe and needle(s) of 25 gauge x 16&#160;mm or similar<br/>A vial or ampoule of water for injections<br/>2 alcohol swabs</p>
<p style="position:absolute;top:700px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:702px;left:149px;white-space:nowrap" class="ft2334">Inspect the expiry dates on both the Enbrel vial&#160;label and the water for injections. They should&#160;<br/>not be used after the month and year shown.</p>
<p style="position:absolute;top:759px;left:106px;white-space:nowrap" class="ft2331"><b>c.</b></p>
<p style="position:absolute;top:759px;left:149px;white-space:nowrap" class="ft2331"><b>Preparing&#160;the Enbrel dose for injection</b></p>
<p style="position:absolute;top:796px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:798px;left:149px;white-space:nowrap" class="ft2334">Remove the plastic cap from the Enbrel vial.&#160;<b>Do NOT&#160;</b>remove the grey stopper or aluminium&#160;<br/>ring around the top of the vial.</p>
<p style="position:absolute;top:835px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:837px;left:149px;white-space:nowrap" class="ft2334">Use a new alcohol swab to clean the grey stopper on the Enbrel vial. After cleaning, do not&#160;<br/>touch the stopper with your hands.</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:876px;left:149px;white-space:nowrap" class="ft2334">Check that a needle is on your syringe; if you are not sure how to attach a needle ask your&#160;<br/>doctor or nurse.</p>
<p style="position:absolute;top:913px;left:106px;white-space:nowrap" class="ft23314"></p>
<p style="position:absolute;top:915px;left:149px;white-space:nowrap" class="ft2333">Remove the needle cover by firmly pulling it straight off the syringe taking care not to touch the&#160;<br/>needle or allow the needle to touch any surfaces (see Diagram 1). Be careful not to bend or twist&#160;<br/>the cover during removal to avoid damage to the needle.</p>
</div>
<!-- Page 234 -->
<a name="234"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page234-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2340">234</p>
<p style="position:absolute;top:108px;left:411px;white-space:nowrap" class="ft2342">Diagram 1</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft23414"></p>
<p style="position:absolute;top:305px;left:149px;white-space:nowrap" class="ft2342">Check&#160;your syringe contains 1&#160;ml&#160;of water for injections. &#160;</p>
<p style="position:absolute;top:323px;left:106px;white-space:nowrap" class="ft23414"></p>
<p style="position:absolute;top:325px;left:149px;white-space:nowrap" class="ft2342">If&#160;you are not sure how to fill your syringe ask your doctor or nurse.</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft23414"></p>
<p style="position:absolute;top:345px;left:149px;white-space:nowrap" class="ft2342">Make sure your syringe does not contain any air bubbles.</p>
<p style="position:absolute;top:363px;left:106px;white-space:nowrap" class="ft23414"></p>
<p style="position:absolute;top:365px;left:149px;white-space:nowrap" class="ft2344">With the Enbrel vial upright on a flat surface, such as a table, insert the syringe needle straight&#160;<br/>down through the centre ring of the grey stopper of the vial (see Diagram 2). If the needle is&#160;<br/>correctly lined up, you should feel a slight resistance and then a “<i>pop”&#160;</i>as the needle goes&#160;<br/>through the centre of the stopper. Look for&#160;the needle tip inside the stopper window (see&#160;<br/>Diagram 3). If the needle is not correctly lined up, you will feel constant resistance as it goes&#160;<br/>through the stopper and no “<i>pop”</i>. Do not insert the needle at an angle, this may cause the&#160;<br/>needle to bend and/or prevent proper addition of the solvent into the vial (see Diagram 4). &#160;</p>
<p style="position:absolute;top:517px;left:208px;white-space:nowrap" class="ft2342">Diagram 2</p>
<p style="position:absolute;top:517px;left:448px;white-space:nowrap" class="ft2342">Diagram 3</p>
<p style="position:absolute;top:517px;left:651px;white-space:nowrap" class="ft2342">Diagram 4</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft2341"><b>d.</b></p>
<p style="position:absolute;top:730px;left:149px;white-space:nowrap" class="ft2341"><b>Adding water for injections</b></p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft23414"></p>
<p style="position:absolute;top:769px;left:149px;white-space:nowrap" class="ft2344">Push the plunger in&#160;<b>VERY SLOWLY&#160;</b>until all the water for injections is in the vial. This will&#160;<br/>help reduce foaming (lots of bubbles) (see Diagram 5). &#160;&#160;</p>
<p style="position:absolute;top:826px;left:411px;white-space:nowrap" class="ft2342">Diagram 5</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft23414"></p>
<p style="position:absolute;top:1030px;left:149px;white-space:nowrap" class="ft2343">Leave the syringe in place. Gently move the vial in circles a few times, to dissolve the powder&#160;<br/>(see Diagram 6).&#160;<b>Do NOT&#160;</b>shake the vial. Wait until all the powder dissolves (usually less than&#160;<br/>10&#160;minutes). The solution should be clear and colourless&#160;to pale yellow or pale brown, with no&#160;<br/>lumps, flakes, or particles. Some white foam may remain in the vial&#160;&#160;this is normal.&#160;<b>Do&#160;NOT<br/></b>use Enbrel if all the powder in the vial is not dissolved within 10 minutes. Start again with a&#160;<br/>new Enbrel vial, water for injections, syringe, needle and swabs.</p>
</div>
<!-- Page 235 -->
<a name="235"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page235-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2350">235</p>
<p style="position:absolute;top:108px;left:411px;white-space:nowrap" class="ft2352">Diagram 6</p>
<p style="position:absolute;top:312px;left:106px;white-space:nowrap" class="ft2351"><b>e.</b></p>
<p style="position:absolute;top:312px;left:149px;white-space:nowrap" class="ft2351"><b>Withdrawing the Enbrel solution from the vial</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft23514"></p>
<p style="position:absolute;top:351px;left:149px;white-space:nowrap" class="ft2354">With the needle still in&#160;the vial, hold the vial upside down at eye level. Slowly pull the plunger&#160;<br/>back to draw the liquid into the syringe (see Diagram 7). As the liquid level drops in the vial,&#160;<br/>you may need to withdraw the needle partially to keep the tip of the needle in the liquid. For&#160;<br/>adult patients, withdraw the entire volume. For children, remove only the portion of liquid as&#160;<br/>directed by your child’s doctor.</p>
<p style="position:absolute;top:465px;left:411px;white-space:nowrap" class="ft2352">Diagram 7</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft23514"></p>
<p style="position:absolute;top:675px;left:149px;white-space:nowrap" class="ft2354">With the needle still inserted in the vial, check the syringe for air bubbles. Gently tap the&#160;<br/>syringe&#160;to make any bubbles rise to the top of the syringe, near the needle (see Diagram 8).&#160;<br/>Slowly press the plunger to push bubbles out of the syringe and into the vial. When you do this,&#160;<br/>if you accidentally push liquid back into the vial, slowly pull the plunger to draw the liquid back&#160;<br/>into the syringe.&#160;</p>
<p style="position:absolute;top:789px;left:411px;white-space:nowrap" class="ft2352">Diagram 8</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft23514"></p>
<p style="position:absolute;top:1023px;left:149px;white-space:nowrap" class="ft2354">Pull the needle completely out of the vial. Again, do not touch the needle or allow it to touch&#160;<br/>any surface.&#160;</p>
<p style="position:absolute;top:1080px;left:106px;white-space:nowrap" class="ft2357"><i>(Note: After you have completed these steps, a small amount of liquid may remain in&#160;the vial. This is&#160;<br/>normal.)</i></p>
</div>
<!-- Page 236 -->
<a name="236"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page236-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2360">236</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2361"><b>f.</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft2361"><b>Choosing an injection site</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft23614"></p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft2364">The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2)&#160;<br/>the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper&#160;<br/>arms&#160;(see Diagram 9). If you are self injecting, you should not use the outer area of the upper&#160;<br/>arms.</p>
<p style="position:absolute;top:242px;left:411px;white-space:nowrap" class="ft2362">Diagram 9</p>
<p style="position:absolute;top:461px;left:106px;white-space:nowrap" class="ft23614"></p>
<p style="position:absolute;top:463px;left:147px;white-space:nowrap" class="ft2364">A different site should be used for each new injection. Each new injection should be given at&#160;<br/>least&#160;3&#160;cm from an old site.&#160;Do not&#160;inject into areas where the skin is tender, bruised, red, or&#160;<br/>hard. Avoid areas with scars or stretch marks. (It may be helpful to keep notes on the location of&#160;<br/>the previous injections.)</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft23614"></p>
<p style="position:absolute;top:540px;left:147px;white-space:nowrap" class="ft2364">If&#160;you or the child have psoriasis, you should try not to inject directly into any raised, thick, red,&#160;<br/>or scaly skin patches (“psoriasis skin lesions”).</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft2361"><b>g.</b></p>
<p style="position:absolute;top:597px;left:149px;white-space:nowrap" class="ft2361"><b>Preparing the injection site and injecting the Enbrel solution</b></p>
<p style="position:absolute;top:634px;left:106px;white-space:nowrap" class="ft23614"></p>
<p style="position:absolute;top:636px;left:149px;white-space:nowrap" class="ft23623">Wipe the site where Enbrel is to be injected with an alcohol swab, using a circular motion.&#160;<b>Do<br/>NOT&#160;</b>touch this area again before giving the injection.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft23614"></p>
<p style="position:absolute;top:675px;left:149px;white-space:nowrap" class="ft2364">When the cleaned area of skin has dried, pinch and hold it firmly with one hand. With the other&#160;<br/>hand, hold the syringe like a pencil. &#160; &#160;</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft23614"></p>
<p style="position:absolute;top:715px;left:149px;white-space:nowrap" class="ft2363">With a quick, short motion, push the needle all the way into the skin at an&#160;angle between 45°&#160;<br/>and 90° (see Diagram 10). With experience, you will find the angle that is most comfortable for&#160;<br/>you or the child. Be careful not to push the needle into the skin too slowly, or with great force.</p>
<p style="position:absolute;top:799px;left:407px;white-space:nowrap" class="ft2362">Diagram 10</p>
</div>
<!-- Page 237 -->
<a name="237"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page237-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2370">237</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft23714"></p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft2374">When the needle is completely inserted into the skin, release the skin that you are holding. With&#160;<br/>your free hand, hold the syringe near its base to stabilise it. Then push the plunger to inject all of&#160;<br/>the solution at a&#160;<b>slow</b>, steady rate (see Diagram 11).</p>
<p style="position:absolute;top:185px;left:407px;white-space:nowrap" class="ft2372">Diagram 11</p>
<p style="position:absolute;top:423px;left:106px;white-space:nowrap" class="ft23714"></p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft2374">When the&#160;syringe is empty, remove the needle from the skin, being careful to keep it at the same&#160;<br/>angle it was when it was inserted.</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft23714"></p>
<p style="position:absolute;top:465px;left:149px;white-space:nowrap" class="ft23723">Press a cotton ball over the injection site for 10 seconds. Slight bleeding may occur.&#160;<b>Do NOT<br/></b>rub the injection site. A bandage is optional.</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft2371"><b>h.</b></p>
<p style="position:absolute;top:521px;left:149px;white-space:nowrap" class="ft2371"><b>Disposing of supplies</b></p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft23714"></p>
<p style="position:absolute;top:560px;left:149px;white-space:nowrap" class="ft2374">The syringe and needle should&#160;<b>NEVER&#160;</b>be re-used.&#160;<b>Never&#160;</b>recap a needle. Dispose of the needle&#160;<br/>and syringe as instructed by your doctor, nurse or pharmacist.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft23724"><b>If&#160;you have any questions, please talk to a doctor, nurse or&#160;pharmacist who is familiar with&#160;<br/>Enbrel.</b></p>
</div>
<!-- Page 238 -->
<a name="238"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page238-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2380">238</p>
<p style="position:absolute;top:108px;left:298px;white-space:nowrap" class="ft2381"><b>Package Leaflet: Information for the User</b></p>
<p style="position:absolute;top:146px;left:240px;white-space:nowrap" class="ft2381"><b>Enbrel&#160;25&#160;mg&#160;powder and solvent for solution for injection</b></p>
<p style="position:absolute;top:165px;left:413px;white-space:nowrap" class="ft2382">etanercept</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft23823"><b>Read all of this leaflet carefully before you start using this medicine&#160;because it contains&#160;<br/>important information for you.</b></p>
<p style="position:absolute;top:240px;left:123px;white-space:nowrap" class="ft23814"></p>
<p style="position:absolute;top:242px;left:162px;white-space:nowrap" class="ft2382">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:260px;left:123px;white-space:nowrap" class="ft23814"></p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft2382">Your doctor will also give you a Patient Card, which contains important safety information that&#160;</p>
<p style="position:absolute;top:281px;left:164px;white-space:nowrap" class="ft2382">you need to be aware of before and during treatment with Enbrel.</p>
<p style="position:absolute;top:299px;left:123px;white-space:nowrap" class="ft23814"></p>
<p style="position:absolute;top:301px;left:162px;white-space:nowrap" class="ft2382">If you have any further questions, ask your doctor,&#160;pharmacist&#160;or nurse.</p>
<p style="position:absolute;top:319px;left:123px;white-space:nowrap" class="ft23814"></p>
<p style="position:absolute;top:321px;left:162px;white-space:nowrap" class="ft2382">This medicine has been prescribed for you or a child in your care. Do not pass it on to others. It&#160;</p>
<p style="position:absolute;top:340px;left:164px;white-space:nowrap" class="ft2384">may harm them, even if their&#160;signs of illness&#160;are the same as yours or those&#160;of the child you are&#160;<br/>caring for.</p>
<p style="position:absolute;top:378px;left:123px;white-space:nowrap" class="ft23814"></p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft2382">If you&#160;get&#160;any side effects,&#160;talk to&#160;your doctor or pharmacist.&#160;This includes any possible side&#160;</p>
<p style="position:absolute;top:398px;left:164px;white-space:nowrap" class="ft2382">effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft2381"><b>What is in this leaflet</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2382">Information in this leaflet is organised under&#160;the following 7 sections:</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft2382">1.</p>
<p style="position:absolute;top:512px;left:149px;white-space:nowrap" class="ft2382">What Enbrel is and what it is used for</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft2382">2.</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft2382">What you need to know before you use Enbrel</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft2382">3.</p>
<p style="position:absolute;top:550px;left:149px;white-space:nowrap" class="ft2382">How to use Enbrel</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft2382">4.</p>
<p style="position:absolute;top:569px;left:149px;white-space:nowrap" class="ft2382">Possible side effects</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft2382">5.</p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft2382">How to store Enbrel</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft2382">6.</p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft2382">Contents of the pack and other&#160;information</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft2382">7.</p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft2382">Instructions for&#160;preparing and giving an injection of Enbrel (See overleaf)</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft2381"><b>1.</b></p>
<p style="position:absolute;top:683px;left:146px;white-space:nowrap" class="ft2381"><b>What Enbrel is and what it is used for</b></p>
<p style="position:absolute;top:721px;left:106px;white-space:nowrap" class="ft2384">Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in&#160;<br/>the body that causes inflammation. Enbrel works&#160;by reducing the inflammation associated with certain&#160;<br/>diseases.</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft2384">In adults (aged 18 and over), Enbrel can be used for moderate or severe&#160;<b>rheumatoid arthritis</b>,&#160;<br/><b>psoriatic arthritis</b>, severe&#160;<b>axial spondyloarthritis&#160;</b>including&#160;<b>ankylosing spondylitis,&#160;</b>and moderate&#160;<br/>or severe&#160;<b>psoriasis&#160;</b>–&#160;in each case usually when other widely used treatments have not worked well&#160;<br/>enough or are not suitable for you.</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft2384">For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may&#160;<br/>also be&#160;used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in&#160;<br/>combination with methotrexate, Enbrel can slow down the damage to your joints caused by the&#160;<br/>rheumatoid arthritis and improve your ability to do normal daily activities.</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft2384">For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do&#160;<br/>normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands,&#160;<br/>wrists and feet), Enbrel can slow down the structural damage to those joints caused by the disease.&#160;</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft2382">Enbrel is also prescribed for the treatment of the following diseases in children and adolescents</p>
<p style="position:absolute;top:1100px;left:106px;white-space:nowrap" class="ft23814"></p>
<p style="position:absolute;top:1102px;left:147px;white-space:nowrap" class="ft2382">For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not&#160;</p>
<p style="position:absolute;top:1120px;left:149px;white-space:nowrap" class="ft2382">worked well enough or is not suitable for them:</p>
</div>
<!-- Page 239 -->
<a name="239"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page239-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2390">239</p>
<p style="position:absolute;top:107px;left:214px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:109px;left:257px;white-space:nowrap" class="ft2394">Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis&#160;<br/>in patients from the age of 2 years</p>
<p style="position:absolute;top:165px;left:214px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:167px;left:257px;white-space:nowrap" class="ft2392">Psoriatic arthritis in patients from the age of 12 years</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:206px;left:147px;white-space:nowrap" class="ft2392">For enthesitis-related arthritis in patients from the age of 12 years when other widely used&#160;</p>
<p style="position:absolute;top:225px;left:149px;white-space:nowrap" class="ft2392">treatments have not worked well enough or are not suitable for them</p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:264px;left:147px;white-space:nowrap" class="ft2392">Severe psoriasis in patients from the age of 6 years who have had an inadequate response to (or&#160;</p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft2392">are unable to take)&#160;phototherapies or other systemic therapies.</p>
<p style="position:absolute;top:340px;left:106px;white-space:nowrap" class="ft2391"><b>2.</b></p>
<p style="position:absolute;top:340px;left:146px;white-space:nowrap" class="ft2391"><b>What you need to know before you use Enbrel&#160;</b></p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2391"><b>Do not use Enbrel</b></p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:417px;left:147px;white-space:nowrap" class="ft2394">if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of&#160;<br/>Enbrel&#160;(listed in section 6). If you or&#160;the child experience allergic reactions such as chest&#160;<br/>tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor&#160;<br/>immediately.</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:494px;left:147px;white-space:nowrap" class="ft2394">if you or the child have, or are at risk of developing a serious blood infection called sepsis. If&#160;<br/>you are not sure, please contact your doctor.</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:533px;left:147px;white-space:nowrap" class="ft2392">if you or the child have an infection of any kind. If you are not sure, please talk to your doctor.</p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft2391"><b>Warnings and precautions&#160;</b></p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft2392">Talk to your doctor before taking Enbrel.</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:648px;left:149px;white-space:nowrap" class="ft2394"><b>Allergic reactions</b>: If you or the&#160;child experience allergic reactions such as chest tightness,&#160;<br/>wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:688px;left:149px;white-space:nowrap" class="ft2393"><b>Latex</b>:&#160;The syringe rubber tip is made from latex (dry natural rubber). Contact your doctor&#160;<br/>before using Enbrel if the syringe will be handled by, or Enbrel will be given to, someone with a&#160;<br/>known or possible hypersensitivity (allergy) to latex.</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:746px;left:149px;white-space:nowrap" class="ft2394"><b>Infections/surgery</b>: If you or the child develop a new infection, or are about to have any major&#160;<br/>surgery, your&#160;doctor may wish to monitor the treatment with Enbrel.</p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:785px;left:149px;white-space:nowrap" class="ft2394"><b>Infections/diabetes:&#160;</b>Tell your doctor if you or the child have a history of recurrent infections or&#160;<br/>suffer from diabetes or other conditions that increase the risk of infection.</p>
<p style="position:absolute;top:822px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:824px;left:147px;white-space:nowrap" class="ft2391"><b>Infections/monitoring:&#160;</b>Tell your doctor of any recent travel outside the European region. If you&#160;</p>
<p style="position:absolute;top:843px;left:149px;white-space:nowrap" class="ft2393">or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor&#160;<br/>immediately. Your doctor may decide to continue to monitor you or the child for the presence of&#160;<br/>infections after you or the child stop using Enbrel.</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:901px;left:147px;white-space:nowrap" class="ft2391"><b>Tuberculosis:&#160;</b>As cases of tuberculosis have been reported in patients treated with Enbrel, your&#160;</p>
<p style="position:absolute;top:920px;left:149px;white-space:nowrap" class="ft2394">doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may&#160;<br/>include&#160;a thorough medical history, a chest X-ray and a tuberculin test. The conduct of these&#160;<br/>tests should be recorded on the Patient Card. It is very important that you tell your doctor if you&#160;<br/>or the child have ever had tuberculosis, or have been in close contact with someone who has had&#160;<br/>tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p>
<p style="position:absolute;top:1033px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:1035px;left:147px;white-space:nowrap" class="ft2391"><b>Hepatitis B:&#160;</b>Tell your&#160;doctor if you or the child have or have ever had hepatitis B.&#160;Your doctor&#160;</p>
<p style="position:absolute;top:1054px;left:149px;white-space:nowrap" class="ft2394">should test&#160;for the presence of hepatitis B infection before you or the child begin treatment with&#160;<br/>Enbrel.&#160;Treatment with Enbrel may result in reactivation of hepatitis B in patients who have&#160;<br/>previously been infected with the hepatitis B virus. If this occurs, you should stop using Enbrel.</p>
<p style="position:absolute;top:1110px;left:106px;white-space:nowrap" class="ft23914"></p>
<p style="position:absolute;top:1112px;left:147px;white-space:nowrap" class="ft2391"><b>Hepatitis C:&#160;</b>Tell your doctor if you or the child have hepatitis C. Your doctor may wish to&#160;</p>
<p style="position:absolute;top:1131px;left:149px;white-space:nowrap" class="ft2392">monitor the treatment with Enbrel in case the infection worsens.</p>
</div>
<!-- Page 240 -->
<a name="240"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page240-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2400">240</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft24014"></p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft2404"><b>Blood disorders:&#160;</b>Seek medical advice immediately if you or the child have any signs or&#160;<br/>symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms&#160;<br/>may point to the existence of potentially life-threatening blood disorders, which may require&#160;<br/>discontinuation of Enbrel.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft24014"></p>
<p style="position:absolute;top:186px;left:147px;white-space:nowrap" class="ft2404"><b>Nervous system and eye disorders:&#160;</b>Tell your doctor if you or the child have multiple sclerosis,&#160;<br/>optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of&#160;<br/>the spinal cord). Your doctor will determine if Enbrel is an appropriate treatment.</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft24014"></p>
<p style="position:absolute;top:244px;left:147px;white-space:nowrap" class="ft2404"><b>Congestive heart failure:&#160;</b>Tell your doctor if you or the child have a history of congestive heart&#160;<br/>failure, because Enbrel needs to be used with caution under these circumstances.</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft24014"></p>
<p style="position:absolute;top:283px;left:147px;white-space:nowrap" class="ft2404"><b>Cancer:&#160;</b>Tell&#160;your doctor if you have or have ever had lymphoma (a type of blood cancer) or&#160;<br/>any other cancer before you are given Enbrel.</p>
<p style="position:absolute;top:321px;left:147px;white-space:nowrap" class="ft2403">Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at&#160;<br/>higher than average risk of developing lymphoma.<br/>Children and adults taking Enbrel may have an increased risk of developing lymphoma or&#160;<br/>another cancer.<br/>Some children and teenage patients who have received Enbrel or other medicines that work the&#160;<br/>same way as Enbrel have developed cancers,&#160;including unusual types, which sometimes resulted&#160;<br/>in death.<br/>Some patients receiving Enbrel have developed skin cancers.&#160;Tell&#160;your doctor if you or the child&#160;<br/>develop any change in the appearance of the skin&#160;or growths on the skin.</p>
<p style="position:absolute;top:491px;left:106px;white-space:nowrap" class="ft24014"></p>
<p style="position:absolute;top:493px;left:147px;white-space:nowrap" class="ft2404"><b>Chickenpox:&#160;</b>Tell your doctor if you or the child are exposed to chickenpox when using Enbrel.&#160;<br/>Your doctor will determine if preventive treatment for chickenpox is appropriate.</p>
<p style="position:absolute;top:530px;left:106px;white-space:nowrap" class="ft24014"></p>
<p style="position:absolute;top:532px;left:147px;white-space:nowrap" class="ft2404"><b>Alcohol abuse</b>: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.&#160;<br/>Please tell your doctor if you or the child in your care have a history of alcohol abuse.</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft24014"></p>
<p style="position:absolute;top:571px;left:147px;white-space:nowrap" class="ft2404"><b>Wegener’s granulomatosis</b>: Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener’s&#160;<br/>granulomatosis, talk to your doctor.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft24014"></p>
<p style="position:absolute;top:630px;left:147px;white-space:nowrap" class="ft2404"><b>Anti-diabetic medicines</b>: Tell your doctor if you or the child have diabetes or are taking&#160;<br/>medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic&#160;<br/>medicine while taking Enbrel.</p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft2401"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft2404"><b>Vaccinations:&#160;</b>If possible, children should be up to date with all vaccinations before using Enbrel.&#160;<br/>Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult&#160;<br/>your doctor before you or the child receive any vaccines.</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft2404">Enbrel should not normally be used in children with&#160;polyarthritis or extended oligoarthritis&#160;below the&#160;<br/>age of 2 years,&#160;or in children with enthesitis-related arthritis or psoriatic arthritis below the age of&#160;<br/>12&#160;years,&#160;or in children with psoriasis below the age of&#160;6&#160;years.</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft2401"><b>Other medicines&#160;and Enbrel</b></p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft2403">Tell&#160;your&#160;doctor or pharmacist if you or the child are taking,&#160;have recently taken&#160;or might take&#160;any&#160;<br/>other medicines (including anakinra, abatacept or sulfasalazine), even those&#160;not prescribed by the&#160;<br/>doctor. You or the child should not use Enbrel with medicines that contain the active substance&#160;<br/>anakinra or abatacept.</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft2401"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:1066px;left:106px;white-space:nowrap" class="ft2404">Enbrel&#160;should only be used&#160;during pregnancy&#160;if clearly needed.&#160;You should consult&#160;your doctor if you<br/>become pregnant,&#160;think you may be pregnant, or are planning to have a baby.</p>
<p style="position:absolute;top:1123px;left:106px;white-space:nowrap" class="ft2404">If you received Enbrel during pregnancy,&#160;your&#160;baby may have a higher risk&#160;of&#160;getting an infection.&#160;In&#160;<br/>addition,&#160;one study&#160;found&#160;more birth defects when the mother had received&#160;Enbrel&#160;in pregnancy,&#160;</p>
</div>
<!-- Page 241 -->
<a name="241"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page241-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2410">241</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2413">compared&#160;with&#160;mothers who had not received&#160;Enbrel&#160;or other similar medicines (TNF-antagonists),&#160;<br/>but there was no&#160;particular kind of birth defect&#160;reported.&#160;Another study found no increased risk of birth&#160;<br/>defects&#160;when the mother had received Enbrel in pregnancy.&#160;Your doctor will help you to decide&#160;<br/>whether the benefits of treatment outweigh the potential risk to your baby.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft2414">Talk to your doctor if you want to breastfeed while on Enbrel treatment.&#160;It&#160;is important that you tell&#160;<br/>your&#160;baby’s doctors and other healthcare professionals about the use of Enbrel during pregnancy and&#160;<br/>breastfeeding before&#160;your&#160;baby receives any vaccine.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft2411"><b>Driving and using machines</b></p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft2412">The use of Enbrel&#160;is not expected to affect the ability to drive or use machines.</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft2411"><b>3.</b></p>
<p style="position:absolute;top:374px;left:146px;white-space:nowrap" class="ft2411"><b>How to use Enbrel</b></p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft2414">Always use&#160;this medicine&#160;exactly as the doctor has told you.&#160;Check with the doctor or pharmacist if&#160;<br/>you are not sure.</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft2412">If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft2411"><b>Dosing for adult patients (aged 18 years or over)</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft2412">Rheumatoid arthritis, psoriatic arthritis,&#160;and&#160;axial spondyloarthritis including&#160;ankylosing spondylitis</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft2414">The usual dose is 25&#160;mg given twice a week or 50&#160;mg&#160;once a week as an injection under the skin.&#160;<br/>However, your doctor may determine an alternative frequency at which to inject Enbrel.&#160;</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft2412">Plaque psoriasis</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft2412">The usual dose is 25&#160;mg twice a week or 50&#160;mg once a&#160;week. &#160;</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft2413">Alternatively, 50&#160;mg&#160;may be given twice a week for up to 12 weeks, followed by 25&#160;mg twice a week&#160;<br/>or 50&#160;mg once a week.&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft2414">Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on&#160;<br/>your response. If Enbrel has no effect on your condition after 12 weeks, your doctor may tell you to&#160;<br/>stop taking this medicine.</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft2411"><b>Use in&#160;children&#160;and adolescents</b></p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft2413">The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight&#160;<br/>and disease. The&#160;doctor will provide you with detailed directions for preparing and measuring the&#160;<br/>appropriate dose.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft2413">For&#160;polyarthritis or extended oligoarthritis&#160;in patients from the age of 2 years,&#160;or enthesitis-related&#160;<br/>arthritis or psoriatic arthritis in patients from the age of 12 years,&#160;the usual dose is 0.4&#160;mg of Enbrel&#160;<br/>per kg bodyweight (up to a maximum of 25&#160;mg) given twice weekly,&#160;or 0.8&#160;mg of Enbrel per kg of&#160;<br/>bodyweight (up to a maximum of 50&#160;mg) given once weekly.</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft2413">For psoriasis in patients from the age of&#160;6&#160;years, the usual dose is 0.8&#160;mg of Enbrel per kg bodyweight&#160;<br/>(up to a maximum of 50&#160;mg), and should be given once weekly. If Enbrel has no effect on the child’s&#160;<br/>condition after 12 weeks, your doctor may tell you to stop using this medicine.</p>
</div>
<!-- Page 242 -->
<a name="242"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page242-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2420">242</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2421"><b>Method and route of&#160;administration</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2422">Enbrel is administered by an injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft2422">Enbrel can be taken with or without food or drink.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft24224">The powder must be dissolved before use.&#160;<b>Detailed instructions on how to prepare and inject&#160;<br/>Enbrel are&#160;provided in section 7, “Instructions for preparing and giving an injection of Enbrel”.&#160;<br/></b>Do not mix the Enbrel solution with any other medicine.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft2424">To help you remember, it may be helpful to write in a diary which day(s) of the week Enbrel should be&#160;<br/>used.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft2421"><b>If&#160;you use more Enbrel than you should</b></p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2424">If you have used more Enbrel than you should (either by injecting too much on a single occasion or by&#160;<br/>using it too frequently), talk to a doctor or pharmacist immediately. Always have the outer carton of&#160;<br/>the medicine with you, even if it is empty.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft2421"><b>If&#160;you forget to inject Enbrel</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft2424">If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is&#160;<br/>the next day; in which case you should skip the missed dose. Then continue to inject the medicine on&#160;<br/>the usual day(s). If you do not remember until the day that the next injection is due, do not take a&#160;<br/>double dose (two doses on the same day) to make up for a forgotten dose.</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft2421"><b>If&#160;you stop using Enbrel&#160;</b></p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft2422">Your symptoms may return upon discontinuation.&#160;</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft2422">If you have any further questions on the use of this&#160;medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft2421"><b>4.</b></p>
<p style="position:absolute;top:734px;left:146px;white-space:nowrap" class="ft2421"><b>Possible side effects</b></p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft2422">Like all medicines,&#160;this medicine&#160;can cause side effects, although not everybody gets them.</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft2421"><b>Allergic reactions</b></p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft2423">If any of the&#160;following happen, do not inject more Enbrel. Tell your doctor immediately, or go to the&#160;<br/>casualty department at your nearest hospital.</p>
<p style="position:absolute;top:904px;left:106px;white-space:nowrap" class="ft24214"></p>
<p style="position:absolute;top:906px;left:149px;white-space:nowrap" class="ft2422">Trouble swallowing or breathing</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft24214"></p>
<p style="position:absolute;top:926px;left:149px;white-space:nowrap" class="ft2422">Swelling of the face, throat, hands, or feet</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft24214"></p>
<p style="position:absolute;top:946px;left:149px;white-space:nowrap" class="ft2424">Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm&#160;<br/>feeling</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft24214"></p>
<p style="position:absolute;top:985px;left:149px;white-space:nowrap" class="ft2422">Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p>
<p style="position:absolute;top:1023px;left:106px;white-space:nowrap" class="ft2423">Serious allergic reactions are rare. However, any of the above symptoms may indicate an allergic&#160;<br/>reaction to Enbrel, so you should seek immediate medical attention.</p>
</div>
<!-- Page 243 -->
<a name="243"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page243-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2430">243</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2431"><b>Serious side effects</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2432">If you notice any of the following, you or the child may need urgent medical attention.</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft2434">Signs of&#160;<b>serious infections</b>, such as high fever that may be accompanied by cough, shortness&#160;of&#160;<br/>breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft2432">Signs of&#160;<b>blood disorders</b>, such as bleeding, bruising, or paleness</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft2434">Signs of&#160;<b>nerve disorders</b>, such as numbness or tingling, changes in vision, eye pain, or onset of&#160;<br/>weakness&#160;in an arm or leg</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft2434">Signs of&#160;<b>heart failure&#160;</b>or&#160;<b>worsening heart failure</b>, such as fatigue or shortness of breath with&#160;<br/>activity, swelling in the ankles, a feeling of fullness in the neck or abdomen, night-time&#160;<br/>shortness of breath or coughing, bluish colour of the nails or the lips</p>
<p style="position:absolute;top:340px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft2433"><b>Signs of cancers:&#160;</b>Cancers may affect any part of the body including the skin and blood, and&#160;<br/>possible signs will depend on the type and location of the cancer. These signs may include&#160;<br/>weight loss, fever, swelling (with or without pain),&#160;persistent cough, presence of lumps or&#160;<br/>growths on the skin</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:418px;left:149px;white-space:nowrap" class="ft2434">Signs of&#160;<b>autoimmune reactions&#160;</b>(where antibodies are made that may harm normal tissues in&#160;<br/>the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:458px;left:149px;white-space:nowrap" class="ft2434">Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or&#160;<br/>muscle pain, or fatigue</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:497px;left:149px;white-space:nowrap" class="ft2434">Signs of&#160;<b>inflammation of the blood vessels&#160;</b>such as pain, fever, redness or warmth of the skin,&#160;<br/>or itching.</p>
<p style="position:absolute;top:554px;left:106px;white-space:nowrap" class="ft2434">These are rare or uncommon side effects, but are serious conditions (some of which may rarely be&#160;<br/>fatal). If these signs occur, tell your doctor immediately, or visit the casualty department at your&#160;<br/>nearest hospital.</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft2432">The known side effects of Enbrel include the following in groups of decreasing frequency:</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:669px;left:149px;white-space:nowrap" class="ft2434"><b>Very common&#160;</b>(may affect more than 1 in 10&#160;people):<br/>Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections);&#160;<br/>injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling)&#160;(these&#160;<br/>do not occur as often after the first month of treatment;&#160;some patients have developed a reaction&#160;<br/>at an injection site that was&#160;recently&#160;used);&#160;and headache.</p>
<p style="position:absolute;top:782px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:784px;left:149px;white-space:nowrap" class="ft2434"><b>Common&#160;</b>(may affect up to 1 in 10&#160;people):<br/>Allergic reactions; fever;&#160;rash;&#160;itching; antibodies directed against normal tissue (autoantibody&#160;<br/>formation).</p>
<p style="position:absolute;top:859px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft2433"><b>Uncommon&#160;</b>(may affect up to 1 in 100&#160;people):<br/>Serious infections (including pneumonia, deep skin infections, joint infections, blood infection,&#160;<br/>and infections at various sites);&#160;worsening of congestive heart failure;&#160;low red blood cell count,&#160;<br/>low white blood cell count, low neutrophil (a type of white blood cell) count;&#160;low blood platelet&#160;<br/>count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives&#160;<br/>(elevated patches of red or pale skin that often itch); eye inflammation; psoriasis&#160;(new or&#160;<br/>worsening);&#160;inflammation of the blood vessels affecting multiple organs; elevated liver blood&#160;<br/>tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood&#160;<br/>tests is common);&#160;abdominal cramps and pain,&#160;diarrhoea, weight loss or blood in the stool (signs&#160;<br/>of bowel problems).</p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft24314"></p>
<p style="position:absolute;top:1071px;left:149px;white-space:nowrap" class="ft2433"><b>Rare&#160;</b>(may affect up to 1 in 1,000&#160;people):<br/>Serious allergic reactions (including severe localised swelling of the skin and wheezing);&#160;<br/>lymphoma (a type of blood cancer);&#160;leukaemia (cancer affecting the blood and bone marrow);<br/>melanoma&#160;(a type of skin cancer);&#160;combined low platelet, red, and white blood cell count;&#160;<br/>nervous system disorders (with&#160;severe muscle weakness and&#160;signs and symptoms similar to&#160;</p>
</div>
<!-- Page 244 -->
<a name="244"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page244-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2440">244</p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft2444">those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord);&#160;<br/>tuberculosis;&#160;new onset&#160;congestive heart failure; seizures; lupus or lupus-like syndrome&#160;<br/>(symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may&#160;<br/>lead to severe blistering and peeling of the skin;&#160;lichenoid reactions (itchy reddish-purple skin&#160;<br/>rash and/or threadlike white-grey lines on mucous membranes);&#160;inflammation of the liver&#160;<br/>caused by the body's own immune system (autoimmune hepatitis;&#160;in patients also receiving&#160;<br/>methotrexate treatment, the frequency is uncommon);&#160;immune disorder that can affect the lungs,&#160;<br/>skin and lymph nodes (sarcoidosis);&#160;inflammation or scarring of the lungs&#160;(in patients also&#160;<br/>receiving methotrexate treatment, the frequency&#160;of&#160;inflammation or scarring of the lungs is&#160;<br/>uncommon).</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft24414"></p>
<p style="position:absolute;top:318px;left:149px;white-space:nowrap" class="ft2444"><b>Very rare&#160;</b>(may affect up to 1 in 10,000&#160;people):&#160;failure of the bone marrow to produce crucial&#160;<br/>blood cells.</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft24414"></p>
<p style="position:absolute;top:376px;left:149px;white-space:nowrap" class="ft2444"><b>Not known&#160;</b>(frequency cannot be estimated from the available data):&#160;Merkel cell carcinoma (a&#160;<br/>type of skin cancer);&#160;Kaposi’s sarcoma (a rare cancer related to infection with human herpes&#160;<br/>virus 8. Kaposi’s sarcoma most commonly appear as purple lesions on the skin);&#160;excessive&#160;<br/>activation of white blood cells associated with inflammation (macrophage activation&#160;<br/>syndrome);&#160;recurrence of hepatitis B (a liver infection);&#160;worsening of a condition called&#160;<br/>dermatomyositis (muscle inflammation and weakness&#160;with&#160;an&#160;accompanying&#160;skin rash).</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft2441"><b>Additional side effects in children and&#160;adolescents</b></p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft2443">The side effects and their frequencies seen in children and adolescents are similar to those described&#160;<br/>above.</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft2441"><b>Reporting of side effects</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft2444">If you get any side effects, talk to your doctor&#160;or&#160;pharmacist.&#160;This includes any possible&#160;side effects&#160;<br/>not listed in this leaflet.&#160;You can also report side effects&#160;directly&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>. By reporting side effects you can help provide more information on the safety of&#160;<br/>this medicine.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft2441"><b>5.</b></p>
<p style="position:absolute;top:755px;left:146px;white-space:nowrap" class="ft2441"><b>How to store Enbrel</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft2442">Keep&#160;this medicine&#160;out of the&#160;sight and&#160;reach of children.</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft2443">Do not use&#160;this medicine&#160;after the expiry date which is stated on the carton and the label after “EXP”.&#160;<br/>The expiry date refers to the last day of that month.</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft2442">Store in a refrigerator (2</p>
<p style="position:absolute;top:887px;left:267px;white-space:nowrap" class="ft24414">C&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft2448">Before preparing the Enbrel solution, Enbrel may be stored outside of the refrigerator at temperatures&#160;<br/>up to a maximum of 25</p>
<p style="position:absolute;top:946px;left:261px;white-space:nowrap" class="ft24414">C for a&#160;single period of up to four weeks; after which, it should not be&#160;</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft2444">refrigerated again. Enbrel should be discarded if not used within four weeks after removal from the&#160;<br/>refrigerator. It is recommended that you record the date that Enbrel is removed from the refrigerator&#160;<br/>and the date after which Enbrel should be discarded (no more than 4 weeks following the removal&#160;<br/>from the refrigerator).</p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft2448">After preparing the Enbrel solution, immediate use is recommended. However, the solution may be&#160;<br/>used for up to 6&#160;hours when&#160;stored at temperatures of up to 25</p>
<p style="position:absolute;top:1080px;left:517px;white-space:nowrap" class="ft24414">C.&#160;</p>
<p style="position:absolute;top:1119px;left:106px;white-space:nowrap" class="ft2444">Do not use&#160;this medicine&#160;if you notice the solution is not clear or contains particles. The solution&#160;<br/>should be clear, colourless&#160;to&#160;pale yellow&#160;or pale brown, with no lumps or flakes or particles.</p>
</div>
<!-- Page 245 -->
<a name="245"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page245-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2450">245</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2452">Carefully dispose&#160;of any Enbrel solution that has not been injected within 6&#160;hours.</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2453">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to&#160;<br/>throw away&#160;medicines&#160;you&#160;no longer&#160;use. These measures will help protect the environment.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft2451"><b>6.</b></p>
<p style="position:absolute;top:222px;left:146px;white-space:nowrap" class="ft2451"><b>Contents&#160;of&#160;the pack and other information&#160;</b></p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft2451"><b>What Enbrel contains</b></p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft2453">The active substance in Enbrel is etanercept. Each vial of Enbrel 25&#160;mg contains 25&#160;mg of etanercept. &#160;<br/>The other ingredients are:&#160;<br/>Powder: Mannitol&#160;(E421), sucrose and trometamol<br/>Solvent:&#160;Water for injections</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2451"><b>What Enbrel looks like and contents of the pack</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft2453">Enbrel&#160;25&#160;mg&#160;is supplied as a white powder and solvent for solution for injection&#160;(powder for&#160;<br/>injection). Each pack contains 4, 8 or 24 single dose vials, 4, 8 or 24 pre-filled syringes&#160;of water for&#160;<br/>injections, 4, 8 or 24 needles, 4, 8 or 24 vial adaptors and 8, 16&#160;or 48 alcohol swabs. Not all pack sizes&#160;<br/>may be marketed.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft2451"><b>Marketing Authorisation Holder and Manufacturer</b></p>
<p style="position:absolute;top:563px;left:114px;white-space:nowrap" class="ft2454"><i>Marketing Authorisation Holder:<br/></i>Pfizer Europe MA EEIG<br/>Boulevard de&#160;la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:677px;left:114px;white-space:nowrap" class="ft2454"><i>Manufacturer:<br/></i>Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft2453">For any information about this medicinal product, please contact the local representative of the&#160;<br/>Marketing Authorisation Holder.</p>
<p style="position:absolute;top:857px;left:114px;white-space:nowrap" class="ft2453"><b>België/Belgique/Belgien<br/>Luxembourg/Luxemburg<br/></b>Pfizer&#160;NV/SA<br/>Tél/Tel: +32 (0)2 554 62 11</p>
<p style="position:absolute;top:857px;left:452px;white-space:nowrap" class="ft2458"><b>Kύπρος<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.&#160;(CYPRUS BRANCH)&#160;<br/>T</p>
<p style="position:absolute;top:895px;left:462px;white-space:nowrap" class="ft24514">: +357 22 817690</p>
<p style="position:absolute;top:952px;left:114px;white-space:nowrap" class="ft2453"><b>Česká Republika<br/></b>Pfizer, spol.&#160;s&#160;r.o.<br/>Tel:&#160;+420-283-004-111</p>
<p style="position:absolute;top:952px;left:452px;white-space:nowrap" class="ft2453"><b>Magyarország<br/></b>Pfizer Kft.<br/>Tel: +36 1 488 3700</p>
<p style="position:absolute;top:1028px;left:114px;white-space:nowrap" class="ft2454"><b>Danmark<br/></b>Pfizer ApS<br/>Tlf: +45 44&#160;201&#160;100</p>
<p style="position:absolute;top:1028px;left:452px;white-space:nowrap" class="ft2454"><b>Malta<br/></b>Vivian Corporation Ltd.<br/>Tel: +35621 344610</p>
</div>
<!-- Page 246 -->
<a name="246"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page246-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2460">246</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft2464"><b>Deutschland<br/></b>Pfizer Pharma GmbH<br/>Tel: +49 (0)30 550055-51000</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft2464"><b>Nederland<br/></b>Pfizer bv<br/>Tel: +31 (0)800 63 34 636</p>
<p style="position:absolute;top:186px;left:114px;white-space:nowrap" class="ft2464"><b>България<br/></b>Пфайзер Люксембург САРЛ,&#160;<br/>Клон България<br/>Teл:&#160;+359 2 970 4333</p>
<p style="position:absolute;top:186px;left:452px;white-space:nowrap" class="ft2463"><b>Norge<br/></b>Pfizer AS<br/>Tlf: +47 67&#160;52&#160;61&#160;00</p>
<p style="position:absolute;top:280px;left:114px;white-space:nowrap" class="ft2464"><b>Eesti<br/></b>Pfizer Luxembourg SARL Eesti filiaal<br/>Tel:&#160;+372 666 7500</p>
<p style="position:absolute;top:280px;left:452px;white-space:nowrap" class="ft2464"><b>Österreich<br/></b>Pfizer Corporation Austria Ges.m.b.H.<br/>Tel: +43&#160;(0)1 521 15-0</p>
<p style="position:absolute;top:356px;left:114px;white-space:nowrap" class="ft2463"><b>Ελλάδα<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.<br/>Τηλ.: +30 210 67&#160;85 800</p>
<p style="position:absolute;top:356px;left:452px;white-space:nowrap" class="ft2463"><b>Polska<br/></b>Pfizer Polska Sp. z o.o.<br/>Tel.: +48 22 335 61 00</p>
<p style="position:absolute;top:442px;left:114px;white-space:nowrap" class="ft2463"><b>España<br/></b>Pfizer, S.L.<br/>Télf: +34&#160;91&#160;490&#160;99&#160;00</p>
<p style="position:absolute;top:442px;left:452px;white-space:nowrap" class="ft2463"><b>Portugal<br/></b>Laboratórios Pfizer, Lda.<br/>Tel: (+351) 21 423 55 00</p>
<p style="position:absolute;top:523px;left:114px;white-space:nowrap" class="ft2464"><b>France<br/></b>Pfizer<br/>Tél&#160;+33 (0)1&#160;58 07 34 40</p>
<p style="position:absolute;top:523px;left:452px;white-space:nowrap" class="ft2464"><b>România<br/></b>Pfizer Romania S.R.L<br/>Tel: +40 (0) 21 207 28 00</p>
<p style="position:absolute;top:599px;left:114px;white-space:nowrap" class="ft2464"><b>Hrvatska<br/></b>Pfizer Croatia&#160;d.o.o.<br/>Tel: +385 1&#160;3908&#160;777</p>
<p style="position:absolute;top:599px;left:452px;white-space:nowrap" class="ft2463"><b>Slovenija<br/></b>Pfizer Luxembourg SARL<i>,&#160;</i>Pfizer, podružnica&#160;<br/>za&#160;svetovanje s področja farmacevtske&#160;<br/>dejavnosti, Ljubljana<br/>Tel: +386 (0)1 52&#160;11 400</p>
<p style="position:absolute;top:713px;left:114px;white-space:nowrap" class="ft2463"><b>Ireland<br/></b>Pfizer Healthcare Ireland<br/>Tel: +1800 633 363 (toll free)<br/>Tel: +44 (0)1304 616161</p>
<p style="position:absolute;top:713px;left:452px;white-space:nowrap" class="ft2464"><b>Slovenská Republika<br/></b>Pfizer Luxembourg SARL, organizačná zložka&#160;<br/>Tel: +421 2 3355 5500</p>
<p style="position:absolute;top:808px;left:114px;white-space:nowrap" class="ft2464"><b>Ísland<br/></b>Icepharma&#160;hf.<br/>Tel: +354&#160;540 8000</p>
<p style="position:absolute;top:808px;left:452px;white-space:nowrap" class="ft2464"><b>Suomi/Finland<br/></b>Pfizer Oy<br/>Puh/Tel: +358 (0)9&#160;430 040</p>
<p style="position:absolute;top:887px;left:114px;white-space:nowrap" class="ft2464"><b>Italia<br/></b>Pfizer S.r.l.<br/>Tel: +39 06 33 18 21</p>
<p style="position:absolute;top:887px;left:452px;white-space:nowrap" class="ft2464"><b>Sverige&#160;<br/></b>Pfizer AB<br/>Tel: +46 (0)8&#160;550&#160;520 00</p>
<p style="position:absolute;top:967px;left:114px;white-space:nowrap" class="ft2464"><b>Latvija<br/></b>Pfizer Luxembourg SARL filiāle Latvijā<br/>Tel. +371 67035775</p>
<p style="position:absolute;top:967px;left:452px;white-space:nowrap" class="ft2464"><b>United Kingdom&#160;(Northern Ireland)<br/></b>Pfizer Limited<br/>Tel:&#160;+44 (0)1304&#160;616161</p>
<p style="position:absolute;top:1046px;left:114px;white-space:nowrap" class="ft2464"><b>Lietuva<br/></b>Pfizer Luxembourg SARL filialas Lietuvoje<br/>Tel. +3705 2514000</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft2461"><b>This leaflet was last&#160;revised&#160;in</b></p>
</div>
<!-- Page 247 -->
<a name="247"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page247-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2470">247</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft2474">Detailed information on this&#160;medicine&#160;is available on the&#160;European Medicines Agency&#160;web&#160;site:<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft2471"><b>7.</b></p>
<p style="position:absolute;top:203px;left:146px;white-space:nowrap" class="ft2471"><b>Instructions for preparing and giving an injection of Enbrel</b></p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft2472">This section is divided into the following sub-sections:</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft2471"><b>a.</b></p>
<p style="position:absolute;top:278px;left:149px;white-space:nowrap" class="ft2471"><b>Introduction</b></p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft2471"><b>b.</b></p>
<p style="position:absolute;top:297px;left:149px;white-space:nowrap" class="ft2471"><b>Setting up for an injection</b></p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft2471"><b>c.</b></p>
<p style="position:absolute;top:316px;left:149px;white-space:nowrap" class="ft2471"><b>Preparing the Enbrel dose for injection&#160;</b></p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft2471"><b>d.</b></p>
<p style="position:absolute;top:335px;left:149px;white-space:nowrap" class="ft2471"><b>Adding solvent</b></p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft2471"><b>e.</b></p>
<p style="position:absolute;top:354px;left:149px;white-space:nowrap" class="ft2471"><b>Withdrawing the Enbrel solution from the vial</b></p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft2471"><b>f.</b></p>
<p style="position:absolute;top:373px;left:149px;white-space:nowrap" class="ft2471"><b>Placing the needle on the syringe</b></p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2471"><b>g.</b></p>
<p style="position:absolute;top:392px;left:149px;white-space:nowrap" class="ft2471"><b>Choosing an injection site&#160;</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft2471"><b>h.</b></p>
<p style="position:absolute;top:411px;left:149px;white-space:nowrap" class="ft2471"><b>Preparing the injection site and injecting the Enbrel solution</b></p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft2471"><b>i.</b></p>
<p style="position:absolute;top:430px;left:149px;white-space:nowrap" class="ft2471"><b>Disposing of supplies</b></p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft2471"><b>a.</b></p>
<p style="position:absolute;top:468px;left:149px;white-space:nowrap" class="ft2471"><b>Introduction</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft2474">The following instructions explain how to&#160;prepare and inject Enbrel. Please read the instructions&#160;<br/>carefully and follow them step by step. You will be instructed by your doctor or his/her assistant on&#160;<br/>the techniques of self-injection or on giving an injection to a child. Do not attempt to administer an&#160;<br/>injection until you are sure that you understand how to prepare and give the injection.</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft2472">This injection should not be mixed with any other medicine.</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft2471"><b>b.</b></p>
<p style="position:absolute;top:639px;left:149px;white-space:nowrap" class="ft2471"><b>Setting up for an injection</b></p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft24714"></p>
<p style="position:absolute;top:678px;left:149px;white-space:nowrap" class="ft2472">Wash your hands thoroughly.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft24714"></p>
<p style="position:absolute;top:698px;left:149px;white-space:nowrap" class="ft2472">Select a clean well-lit, flat working surface.</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft24714"></p>
<p style="position:absolute;top:719px;left:149px;white-space:nowrap" class="ft2474">The dose tray should contain the items listed below. (If not, don’t use the dose tray and consult&#160;<br/>your pharmacist). Use only the items listed.&#160;<b>Do&#160;NOT&#160;</b>use any other syringe.</p>
<p style="position:absolute;top:756px;left:170px;white-space:nowrap" class="ft2476"><i>1 Enbrel vial<br/>1 Pre-filled syringe containing clear, colourless solvent (water for injections)<br/>1 Needle<br/>1 Vial adaptor<br/>2 Alcohol swabs</i></p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft24714"></p>
<p style="position:absolute;top:852px;left:149px;white-space:nowrap" class="ft2474">Inspect the expiry dates on both the vial label and the syringe label. They should not be used&#160;<br/>after the month and year shown.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft2471"><b>c.</b></p>
<p style="position:absolute;top:909px;left:149px;white-space:nowrap" class="ft2471"><b>Preparing&#160;the Enbrel dose for injection</b></p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft24714"></p>
<p style="position:absolute;top:949px;left:149px;white-space:nowrap" class="ft2472">Remove the contents of the tray</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft24714"></p>
<p style="position:absolute;top:969px;left:149px;white-space:nowrap" class="ft2474">Remove the plastic cap from the Enbrel vial (see Diagram 1).&#160;<b>Do NOT&#160;</b>remove the grey stopper&#160;<br/>or aluminium ring around the top of the vial.</p>
</div>
<!-- Page 248 -->
<a name="248"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page248-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2480">248</p>
<p style="position:absolute;top:108px;left:411px;white-space:nowrap" class="ft2482">Diagram 1</p>
<p style="position:absolute;top:288px;left:106px;white-space:nowrap" class="ft24814"></p>
<p style="position:absolute;top:290px;left:149px;white-space:nowrap" class="ft2484">Use a new alcohol swab to clean the grey stopper on the Enbrel vial. After cleaning, do not&#160;<br/>touch the stopper with your hands or allow it to touch any surface.</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft24814"></p>
<p style="position:absolute;top:329px;left:149px;white-space:nowrap" class="ft2482">Place the vial upright on a clean, flat surface.</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft24814"></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft2482">Remove the paper backing from the vial adaptor package.</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft24814"></p>
<p style="position:absolute;top:369px;left:149px;white-space:nowrap" class="ft2484">While still in the plastic package, place the vial adaptor on top of the Enbrel vial so that the vial&#160;<br/>adaptor spike is centered within the raised circle on top of the vial stopper (see Diagram 2).</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft24814"></p>
<p style="position:absolute;top:408px;left:149px;white-space:nowrap" class="ft2484">Hold the vial firmly on the flat surface with one hand. With the other hand, push&#160;<b>STRAIGHT&#160;<br/>DOWN FIRMLY&#160;</b>on the adaptor package until you feel the adaptor spike penetrate the vial&#160;<br/>stopper and&#160;<b>FEEL AND HEAR THE ADAPTOR RIM LOCK INTO PLACE&#160;</b>(see Diagram&#160;<br/>3).&#160;<b>Do&#160;NOT&#160;</b>push down the adaptor at an angle (see Diagram 4). It is important that the vial&#160;<br/>adaptor spike completely penetrates the vial stopper.</p>
<p style="position:absolute;top:522px;left:264px;white-space:nowrap" class="ft2482">Diagram 2.</p>
<p style="position:absolute;top:522px;left:409px;white-space:nowrap" class="ft2482">Diagram 3.</p>
<p style="position:absolute;top:522px;left:555px;white-space:nowrap" class="ft2482">Diagram 4.</p>
<p style="position:absolute;top:679px;left:405px;white-space:nowrap" class="ft2481"><b>CORRECT</b></p>
<p style="position:absolute;top:679px;left:542px;white-space:nowrap" class="ft2481"><b>INCORRECT</b></p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft24814"></p>
<p style="position:absolute;top:719px;left:149px;white-space:nowrap" class="ft2484">While holding the vial in one hand, remove the plastic packaging from the vial adaptor (see&#160;<br/>Diagram 5).</p>
<p style="position:absolute;top:757px;left:410px;white-space:nowrap" class="ft2482">Diagram 5.</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft24814"></p>
<p style="position:absolute;top:940px;left:149px;white-space:nowrap" class="ft2484">Remove the protective cover from the syringe tip by breaking the white cap along the&#160;<br/>perforation. This is done by holding the collar of the white cap while grasping the end of the&#160;<br/>white cap with the other hand and bending it down and then up until it is broken (see Diagram&#160;<br/>6).&#160;<b>Do&#160;NOT remove the white collar that remains on the syringe</b>.</p>
</div>
<!-- Page 249 -->
<a name="249"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page249-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2490">249</p>
<p style="position:absolute;top:108px;left:411px;white-space:nowrap" class="ft2492">Diagram 6</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft24914"></p>
<p style="position:absolute;top:285px;left:149px;white-space:nowrap" class="ft2492">Do not use the syringe if this&#160;perforation is already broken.&#160;Start again with another dose tray.</p>
<p style="position:absolute;top:304px;left:106px;white-space:nowrap" class="ft24914"></p>
<p style="position:absolute;top:305px;left:149px;white-space:nowrap" class="ft2493">Holding the glass barrel of the syringe (not the white collar)&#160;in one hand, and the vial adaptor&#160;<br/>(not the vial) in the other, connect the syringe to the vial adaptor by inserting the tip into the&#160;<br/>opening and turn clockwise until completely secured (see Diagram 7).</p>
<p style="position:absolute;top:381px;left:411px;white-space:nowrap" class="ft2492">Diagram 7</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft2491"><b>d.</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft2491"><b>Adding solvent</b></p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft24914"></p>
<p style="position:absolute;top:602px;left:149px;white-space:nowrap" class="ft2494">While holding the vial&#160;upright on the flat surface, push the plunger VERY SLOWLY until all&#160;<br/>the solvent is in the vial. This will help to reduce foaming (lots of bubbles) (see Diagram 8).</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft24914"></p>
<p style="position:absolute;top:641px;left:149px;white-space:nowrap" class="ft2494">Once the solvent is added to the Enbrel, the plunger may move up by itself. This is due to air&#160;<br/>pressure and should not be of concern.</p>
<p style="position:absolute;top:699px;left:411px;white-space:nowrap" class="ft2492">Diagram 8</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft24914"></p>
<p style="position:absolute;top:876px;left:149px;white-space:nowrap" class="ft2494">With the syringe still attached, gently move the vial in circles a few times, to dissolve the&#160;<br/>powder (see Diagram 9).&#160;<b>Do NOT&#160;</b>shake the vial. Wait until all the powder dissolves (usually&#160;<br/>less than 10&#160;minutes). The solution should be clear and colourless&#160;to pale yellow or pale brown,&#160;<br/>with no lumps, flakes, or particles. Some white foam may remain in the vial&#160;&#160;this is normal.&#160;<b>Do&#160;<br/>NOT&#160;</b>use Enbrel if all the powder in the vial is not&#160;dissolved within 10 minutes. Start again with&#160;<br/>another dose tray.</p>
<p style="position:absolute;top:1009px;left:411px;white-space:nowrap" class="ft2492">Diagram 9</p>
</div>
<!-- Page 250 -->
<a name="250"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page250-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2500">250</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft2501"><b>e.</b></p>
<p style="position:absolute;top:127px;left:149px;white-space:nowrap" class="ft2501"><b>Withdrawing the Enbrel solution from the vial</b></p>
<p style="position:absolute;top:164px;left:106px;white-space:nowrap" class="ft25014"></p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft2504">With the syringe still attached to the vial and vial adaptor, hold the vial upside down at eye&#160;<br/>level. Push the plunger all the&#160;way into the syringe (see Diagram 10).</p>
<p style="position:absolute;top:232px;left:407px;white-space:nowrap" class="ft2502">Diagram 10</p>
<p style="position:absolute;top:410px;left:106px;white-space:nowrap" class="ft25014"></p>
<p style="position:absolute;top:412px;left:149px;white-space:nowrap" class="ft2504">Then, slowly pull the plunger back to draw the liquid into the syringe (see Diagram 11). For&#160;<br/>adult patients, withdraw the entire volume. For children, remove only the portion of liquid as&#160;<br/>directed by your child’s doctor.&#160;After you have withdrawn the Enbrel from the vial, you may&#160;<br/>have some air in the syringe. Do not be concerned, as you will remove the air in a later step.</p>
<p style="position:absolute;top:506px;left:407px;white-space:nowrap" class="ft2502">Diagram 11</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft25014"></p>
<p style="position:absolute;top:678px;left:149px;white-space:nowrap" class="ft2504">With the vial held upside down, unscrew the syringe from the vial adaptor by turning it&#160;<br/>anti-clockwise (see Diagram 12).</p>
<p style="position:absolute;top:744px;left:407px;white-space:nowrap" class="ft2502">Diagram 12</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft25014"></p>
<p style="position:absolute;top:924px;left:149px;white-space:nowrap" class="ft2504">Place the filled syringe on the clean, flat surface. Make sure that the tip does not touch anything.&#160;<br/>Be careful not to push down on the plunger.</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft2503">(Note: After you have completed these&#160;steps, a small amount of liquid may remain in the vial. This is&#160;<br/>normal.)</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft2501"><b>f.</b></p>
<p style="position:absolute;top:1038px;left:149px;white-space:nowrap" class="ft2501"><b>Placing the needle on the syringe</b></p>
<p style="position:absolute;top:1075px;left:106px;white-space:nowrap" class="ft25014"></p>
<p style="position:absolute;top:1077px;left:149px;white-space:nowrap" class="ft2502">The needle has been placed in a plastic container to keep it sterile.</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft25014"></p>
<p style="position:absolute;top:1097px;left:149px;white-space:nowrap" class="ft2504">To open the plastic container, hold the short, wide end in one hand. Place your other hand on the&#160;<br/>longer portion of the container.</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft25014"></p>
<p style="position:absolute;top:1136px;left:149px;white-space:nowrap" class="ft2502">To break the seal, bend the larger end down and then up until broken (see Diagram 13).</p>
</div>
<!-- Page 251 -->
<a name="251"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page251-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2510">251</p>
<p style="position:absolute;top:108px;left:407px;white-space:nowrap" class="ft2512">Diagram 13</p>
<p style="position:absolute;top:288px;left:106px;white-space:nowrap" class="ft25114"></p>
<p style="position:absolute;top:290px;left:149px;white-space:nowrap" class="ft2512">Once the seal has been broken, remove the short, wide end of the plastic container.</p>
<p style="position:absolute;top:308px;left:106px;white-space:nowrap" class="ft25114"></p>
<p style="position:absolute;top:310px;left:149px;white-space:nowrap" class="ft2512">The needle will&#160;remain in the long part of the package.</p>
<p style="position:absolute;top:328px;left:106px;white-space:nowrap" class="ft25114"></p>
<p style="position:absolute;top:330px;left:149px;white-space:nowrap" class="ft2514">While holding the needle and container in one hand, pick up the syringe and insert the syringe&#160;<br/>tip into the needle opening.</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft25114"></p>
<p style="position:absolute;top:369px;left:149px;white-space:nowrap" class="ft2512">Attach the syringe to the needle by turning it clockwise until completely secured (see&#160;Diagram&#160;</p>
<p style="position:absolute;top:388px;left:160px;white-space:nowrap" class="ft2512">14).</p>
<p style="position:absolute;top:426px;left:407px;white-space:nowrap" class="ft2512">Diagram 14</p>
<p style="position:absolute;top:605px;left:106px;white-space:nowrap" class="ft25114"></p>
<p style="position:absolute;top:607px;left:154px;white-space:nowrap" class="ft2513">Remove the needle cover by firmly pulling it straight off the syringe taking care not to touch&#160;<br/>the needle or allow the needle to touch&#160;any surfaces (see Diagram 15).&#160;Be careful not to bend or&#160;<br/>twist the cover during removal to avoid damage to the needle.</p>
<p style="position:absolute;top:682px;left:407px;white-space:nowrap" class="ft2512">Diagram 15</p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft25114"></p>
<p style="position:absolute;top:864px;left:149px;white-space:nowrap" class="ft2514">While holding the syringe upright, remove any air bubbles by slowly pushing on the plunger&#160;<br/>until the air is removed (see Diagram 16).</p>
<p style="position:absolute;top:921px;left:407px;white-space:nowrap" class="ft2512">Diagram 16</p>
</div>
<!-- Page 252 -->
<a name="252"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page252-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2520">252</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2521"><b>g.</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft2521"><b>Choosing an injection site</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft25214"></p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft2524">The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2)&#160;<br/>the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper&#160;<br/>arms (see Diagram 17). If you are self injecting, you should&#160;not use the outer area of the upper&#160;<br/>arms.</p>
<p style="position:absolute;top:242px;left:407px;white-space:nowrap" class="ft2522">Diagram 17</p>
<p style="position:absolute;top:510px;left:106px;white-space:nowrap" class="ft25214"></p>
<p style="position:absolute;top:512px;left:147px;white-space:nowrap" class="ft2522">A different site should be used for each new injection. Each new injection should be given at&#160;</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft2524">least&#160;3&#160;cm from an old site.&#160;<b>Do&#160;NOT&#160;</b>inject into areas where the skin is tender, bruised, red, or&#160;<br/>hard. Avoid areas with scars or stretch marks. (It may be helpful to keep notes on the location of&#160;<br/>the previous injections.)</p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft25214"></p>
<p style="position:absolute;top:589px;left:147px;white-space:nowrap" class="ft2522">If you or the child have psoriasis, you should try not to inject directly into any raised, thick, red,&#160;</p>
<p style="position:absolute;top:608px;left:149px;white-space:nowrap" class="ft2522">or scaly skin&#160;patches (“psoriasis skin lesions”).</p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft2521"><b>h.</b></p>
<p style="position:absolute;top:646px;left:149px;white-space:nowrap" class="ft2521"><b>Preparing the injection site and injecting the Enbrel solution</b></p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft25214"></p>
<p style="position:absolute;top:685px;left:147px;white-space:nowrap" class="ft2522">Wipe the site where Enbrel is to be injected with an alcohol swab, using a circular motion.&#160;<b>Do</b></p>
<p style="position:absolute;top:704px;left:149px;white-space:nowrap" class="ft2521"><b>NOT&#160;</b>touch this area again before giving the injection.</p>
<p style="position:absolute;top:722px;left:106px;white-space:nowrap" class="ft25214"></p>
<p style="position:absolute;top:724px;left:147px;white-space:nowrap" class="ft2522">When&#160;the cleaned area of skin has dried, pinch and hold it firmly with one hand. With the other&#160;</p>
<p style="position:absolute;top:743px;left:149px;white-space:nowrap" class="ft2522">hand, hold the syringe like a pencil.</p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft25214"></p>
<p style="position:absolute;top:763px;left:147px;white-space:nowrap" class="ft2523">With a quick, short motion, push the needle all the way into the skin at an angle between 45°&#160;<br/>and 90° (see Diagram 18). With experience, you will find the angle that is most comfortable for&#160;<br/>you or the child. Be careful not to push the needle into the skin too slowly, or with great force.</p>
<p style="position:absolute;top:834px;left:407px;white-space:nowrap" class="ft2522">Diagram 18</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft25214"></p>
<p style="position:absolute;top:1073px;left:149px;white-space:nowrap" class="ft2524">When the needle is completely inserted into the skin, release&#160;the skin that you&#160;are holding.&#160;With&#160;<br/>your free hand, hold the syringe near its base to stabilise it. Then push the plunger to inject all of&#160;<br/>the solution at a&#160;<b>slow</b>, steady rate (see Diagram 19).</p>
</div>
<!-- Page 253 -->
<a name="253"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page253-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2530">253</p>
<p style="position:absolute;top:108px;left:407px;white-space:nowrap" class="ft2532">Diagram 19</p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft25314"></p>
<p style="position:absolute;top:355px;left:149px;white-space:nowrap" class="ft2534">When the syringe is empty, remove the needle from the skin; being&#160;careful to keep it at the same&#160;<br/>angle it was when it was inserted.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft25314"></p>
<p style="position:absolute;top:394px;left:149px;white-space:nowrap" class="ft25323">Press a cotton ball over the injection site for 10 seconds. Slight bleeding may occur.&#160;<b>Do NOT<br/></b>rub the injection site. A bandage is optional.</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft2531"><b>i.</b></p>
<p style="position:absolute;top:450px;left:149px;white-space:nowrap" class="ft2531"><b>Disposing of supplies</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft25314"></p>
<p style="position:absolute;top:490px;left:149px;white-space:nowrap" class="ft2534">The syringe and needles should&#160;<b>NEVER&#160;</b>be re-used. Dispose of the needles and syringe as&#160;<br/>instructed by your doctor, nurse or pharmacist.</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft25323"><b>If&#160;you have any questions, please talk to a doctor, nurse or pharmacist who is familiar with&#160;<br/>Enbrel.</b></p>
</div>
<!-- Page 254 -->
<a name="254"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page254-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2540">254</p>
<p style="position:absolute;top:108px;left:298px;white-space:nowrap" class="ft2541"><b>Package Leaflet:&#160;Information for the User</b></p>
<p style="position:absolute;top:146px;left:252px;white-space:nowrap" class="ft25424"><b>Enbrel&#160;25&#160;mg&#160;solution for injection in pre-filled syringe<br/>Enbrel 50&#160;mg solution for injection in pre-filled syringe</b></p>
<p style="position:absolute;top:184px;left:413px;white-space:nowrap" class="ft2542">etanercept</p>
<p style="position:absolute;top:222px;left:123px;white-space:nowrap" class="ft25423"><b>Read all of this leaflet carefully before you start using this medicine&#160;because it contains&#160;<br/>important information for you.<br/></b></p>
<p style="position:absolute;top:261px;left:162px;white-space:nowrap" class="ft2542">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:279px;left:123px;white-space:nowrap" class="ft25414"></p>
<p style="position:absolute;top:281px;left:162px;white-space:nowrap" class="ft2542">Your doctor will also give you a Patient Card, which contains important safety information that&#160;</p>
<p style="position:absolute;top:300px;left:164px;white-space:nowrap" class="ft2542">you need to be aware of before and during treatment with Enbrel.</p>
<p style="position:absolute;top:318px;left:123px;white-space:nowrap" class="ft25414"></p>
<p style="position:absolute;top:320px;left:162px;white-space:nowrap" class="ft2542">If you have any further questions, ask your doctor,&#160;pharmacist&#160;or nurse.</p>
<p style="position:absolute;top:338px;left:123px;white-space:nowrap" class="ft25414"></p>
<p style="position:absolute;top:340px;left:162px;white-space:nowrap" class="ft2542">This medicine has been prescribed for you or a child in your care. Do not pass it on to others. It&#160;</p>
<p style="position:absolute;top:359px;left:164px;white-space:nowrap" class="ft2543">may harm them, even if their&#160;signs of illness&#160;are the same as yours or those of the child you are&#160;<br/>caring for.</p>
<p style="position:absolute;top:396px;left:123px;white-space:nowrap" class="ft25414"></p>
<p style="position:absolute;top:398px;left:162px;white-space:nowrap" class="ft2542">If you&#160;get&#160;any side effects,&#160;talk to&#160;your doctor or pharmacist.&#160;This includes any possible side&#160;</p>
<p style="position:absolute;top:417px;left:164px;white-space:nowrap" class="ft2542">effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft2541"><b>What is in this leaflet:&#160;</b></p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft2542">Information in&#160;this leaflet is organised under the following 7 sections:</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft2542">1.</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft2542">What Enbrel is and what it is used for</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft2542">2.</p>
<p style="position:absolute;top:550px;left:149px;white-space:nowrap" class="ft2542">What you need to know before you use Enbrel</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft2542">3.</p>
<p style="position:absolute;top:569px;left:149px;white-space:nowrap" class="ft2542">How to use Enbrel</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft2542">4.</p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft2542">Possible side effects</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft2542">5.</p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft2542">How to store Enbrel</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft2542">6.</p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft2542">Contents of the pack and other information</p>
<p style="position:absolute;top:645px;left:106px;white-space:nowrap" class="ft2542">7.</p>
<p style="position:absolute;top:645px;left:149px;white-space:nowrap" class="ft2542">Instructions for preparing and giving an injection of Enbrel (See overleaf)</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft2541"><b>1.</b></p>
<p style="position:absolute;top:702px;left:146px;white-space:nowrap" class="ft2541"><b>What Enbrel is and what it is used for</b></p>
<p style="position:absolute;top:740px;left:106px;white-space:nowrap" class="ft2543">Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in&#160;<br/>the body that causes&#160;inflammation. Enbrel works by reducing the inflammation associated with certain&#160;<br/>diseases.</p>
<p style="position:absolute;top:816px;left:106px;white-space:nowrap" class="ft2543">In adults (aged 18 and over), Enbrel can be used for moderate or severe&#160;<b>rheumatoid arthritis</b>,&#160;<br/><b>psoriatic arthritis</b>, severe&#160;<b>axial spondyloarthritis&#160;</b>including&#160;<b>ankylosing spondylitis,&#160;</b>and moderate&#160;<br/>or severe&#160;<b>psoriasis&#160;</b>–&#160;in each case usually when other widely used treatments have not worked well&#160;<br/>enough or are not suitable for you.</p>
<p style="position:absolute;top:911px;left:106px;white-space:nowrap" class="ft2543">For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may&#160;<br/>also be used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in&#160;<br/>combination with methotrexate, Enbrel can slow down the damage to your joints caused by the&#160;<br/>rheumatoid arthritis and improve your ability to do&#160;normal daily activities.</p>
<p style="position:absolute;top:1005px;left:106px;white-space:nowrap" class="ft2544">For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do&#160;<br/>normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands,&#160;<br/>wrists and feet), Enbrel can slow down the structural damage to those joints caused by the disease.&#160;</p>
</div>
<!-- Page 255 -->
<a name="255"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page255-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2550">255</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2552">Enbrel is also prescribed for the treatment of the following diseases in children and adolescents</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:147px;left:147px;white-space:nowrap" class="ft2552">For the following types of juvenile idiopathic arthritis when treatment with&#160;methotrexate has not&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft2552">worked well enough or is not suitable for them:</p>
<p style="position:absolute;top:203px;left:214px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:205px;left:257px;white-space:nowrap" class="ft2554">Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis&#160;<br/>in patients from the age of 2 years</p>
<p style="position:absolute;top:261px;left:214px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:263px;left:257px;white-space:nowrap" class="ft2552">Psoriatic arthritis in patients from the age of 12 years</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:302px;left:147px;white-space:nowrap" class="ft2552">For enthesitis-related arthritis in patients from the age of 12 years when other widely used&#160;</p>
<p style="position:absolute;top:321px;left:149px;white-space:nowrap" class="ft2552">treatments have not worked well enough or are not suitable for them</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:360px;left:147px;white-space:nowrap" class="ft2552">Severe psoriasis in patients from the age of&#160;6&#160;years who have had an inadequate response to (or&#160;</p>
<p style="position:absolute;top:379px;left:149px;white-space:nowrap" class="ft2552">are&#160;unable to take) phototherapies or other systemic therapies.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft2551"><b>2.</b></p>
<p style="position:absolute;top:436px;left:146px;white-space:nowrap" class="ft2551"><b>What you need to know before you use Enbrel&#160;</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2551"><b>Do not use Enbrel</b></p>
<p style="position:absolute;top:511px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:513px;left:147px;white-space:nowrap" class="ft2553">if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of&#160;<br/>Enbrel&#160;(listed in section 6). If you or the child experience allergic reactions such as chest&#160;<br/>tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor&#160;<br/>immediately.</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:590px;left:147px;white-space:nowrap" class="ft2554">if you or the child have, or are at risk of developing a serious blood infection&#160;called sepsis. If&#160;<br/>you are not sure, please contact your doctor.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:630px;left:147px;white-space:nowrap" class="ft2552">if you or the child have an infection of any kind. If you are not sure, please talk to your doctor.</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft2551"><b>Warning and precautions&#160;</b></p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft2552">Talk to your doctor before taking Enbrel.</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:745px;left:149px;white-space:nowrap" class="ft2554"><b>Allergic reactions</b>: If&#160;you or the child experience allergic reactions such as chest tightness,&#160;<br/>wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:782px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:784px;left:149px;white-space:nowrap" class="ft2554"><b>Infections/surgery</b>: If you or the child develop a new infection, or are about to have any&#160;major&#160;<br/>surgery, your doctor may wish to monitor the treatment with Enbrel.</p>
<p style="position:absolute;top:821px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft2554"><b>Infections/diabetes:&#160;</b>Tell your doctor if you or the child have a history of recurrent infections or&#160;<br/>suffer from diabetes or other conditions that increase the risk of infection.</p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:862px;left:147px;white-space:nowrap" class="ft2551"><b>Infections/monitoring:&#160;</b>Tell your doctor of any recent travel outside the European region. If you&#160;</p>
<p style="position:absolute;top:881px;left:149px;white-space:nowrap" class="ft2553">or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor&#160;<br/>immediately. Your doctor may decide to continue to monitor you or&#160;the child for the presence of&#160;<br/>infections after you or the child stop using Enbrel.</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:939px;left:147px;white-space:nowrap" class="ft2551"><b>Tuberculosis:&#160;</b>As cases of tuberculosis have been reported in patients treated with Enbrel, your&#160;</p>
<p style="position:absolute;top:958px;left:149px;white-space:nowrap" class="ft2554">doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may&#160;<br/>include a thorough medical history, a chest X-ray and a tuberculin test. The conduct of these&#160;<br/>tests should be recorded on the Patient Card. It is very important that you tell your doctor if you&#160;<br/>or the child have ever had tuberculosis, or have&#160;been in close contact with someone who has had&#160;<br/>tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft25514"></p>
<p style="position:absolute;top:1073px;left:147px;white-space:nowrap" class="ft2551"><b>Hepatitis B:&#160;</b>Tell your&#160;doctor if you or the child have or have ever had hepatitis B.&#160;Your doctor&#160;</p>
<p style="position:absolute;top:1092px;left:149px;white-space:nowrap" class="ft2554">should test&#160;for the presence of hepatitis B infection before you or the child begin treatment with&#160;<br/>Enbrel.&#160;Treatment with Enbrel may result in reactivation of hepatitis B in&#160;patients who have&#160;<br/>previously been infected with the hepatitis B virus. If this occurs, you should stop using Enbrel.</p>
</div>
<!-- Page 256 -->
<a name="256"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page256-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2560">256</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:109px;left:147px;white-space:nowrap" class="ft2561"><b>Hepatitis C:&#160;</b>Tell your doctor if you or the child have hepatitis C. Your doctor may wish to&#160;</p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft2562">monitor the treatment with Enbrel in case the infection worsens.</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft2563"><b>Blood disorders:&#160;</b>Seek medical advice immediately if you or the child have any signs or&#160;<br/>symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms&#160;<br/>may point to the existence of potentially life-threatening blood disorders, which may require&#160;<br/>discontinuation of Enbrel.</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:225px;left:149px;white-space:nowrap" class="ft2563"><b>Nervous system and eye disorders:&#160;</b>Tell your doctor if you or the child have multiple sclerosis,&#160;<br/>optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of&#160;<br/>the spinal cord). Your doctor will&#160;determine if Enbrel is an appropriate treatment.</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft2564"><b>Congestive heart failure:&#160;</b>Tell your doctor if you or the child have a history of congestive heart&#160;<br/>failure, because Enbrel needs to be used with caution under these circumstances.</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:322px;left:149px;white-space:nowrap" class="ft2564"><b>Cancer:&#160;</b>Tell your doctor if&#160;you have or have ever had lymphoma (a type of blood cancer) or&#160;<br/>any other cancer before you are given Enbrel.</p>
<p style="position:absolute;top:360px;left:147px;white-space:nowrap" class="ft2564">Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at&#160;<br/>higher than average risk of developing lymphoma.<br/>Children and adults taking Enbrel may have an increased risk of developing lymphoma or&#160;<br/>another cancer.<br/>Some children and teenage patients who have received Enbrel or other medicines that work the&#160;<br/>same way as Enbrel have developed cancers, including unusual types, which sometimes resulted&#160;<br/>in death.<br/>Some patients receiving Enbrel have developed skin cancers.&#160;Tell&#160;your doctor if you or the child&#160;<br/>develop any change in the appearance of the skin&#160;or growths on the skin.</p>
<p style="position:absolute;top:530px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:532px;left:147px;white-space:nowrap" class="ft2564"><b>Chickenpox:&#160;</b>Tell your doctor if you or the child are exposed to chickenpox when using Enbrel.&#160;<br/>Your doctor will determine if preventive treatment for chickenpox is appropriate.</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:571px;left:147px;white-space:nowrap" class="ft2564"><b>Latex:&#160;</b>The needle cover is made from latex (dry natural rubber). Contact your doctor before&#160;<br/>using Enbrel if the needle cover&#160;will be handled by, or Enbrel will be given to, someone with a&#160;<br/>known or possible hypersensitivity (allergy) to latex.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:630px;left:147px;white-space:nowrap" class="ft2564"><b>Alcohol abuse</b>: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.&#160;<br/>Please tell your doctor if you or the&#160;child in your care have a history of alcohol abuse.</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:669px;left:147px;white-space:nowrap" class="ft2564"><b>Wegener’s granulomatosis</b>: Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener’s&#160;<br/>granulomatosis, talk to your&#160;doctor.</p>
<p style="position:absolute;top:725px;left:106px;white-space:nowrap" class="ft25614"></p>
<p style="position:absolute;top:727px;left:147px;white-space:nowrap" class="ft2564"><b>Anti-diabetic medicines</b>: Tell your doctor if you or the child have diabetes or are taking&#160;<br/>medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic&#160;<br/>medicine while taking Enbrel.</p>
<p style="position:absolute;top:803px;left:106px;white-space:nowrap" class="ft2561"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft2563"><b>Vaccinations:&#160;</b>If possible, children should be up to date with all vaccinations before using Enbrel.&#160;<br/>Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult&#160;<br/>your doctor before you or the child receive any vaccines.</p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft2564">Enbrel should not normally be used in children with&#160;polyarthritis or extended oligoarthritis&#160;below the&#160;<br/>age of 2 years,&#160;or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12&#160;<br/>years,&#160;or in children with psoriasis below the age of&#160;6&#160;years.</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft2561"><b>Other medicines&#160;and Enbrel</b></p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft2564">Tell&#160;your&#160;doctor or pharmacist if you or the child are taking,&#160;have recently taken&#160;or might take&#160;any&#160;<br/>other medicines (including anakinra, abatacept or sulfasalazine), even&#160;those not prescribed by the&#160;<br/>doctor. You or the child should not use Enbrel with medicines that contain the active substance&#160;<br/>anakinra or abatacept.</p>
</div>
<!-- Page 257 -->
<a name="257"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page257-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2570">257</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2571"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2573">Enbrel&#160;should only be used&#160;during pregnancy&#160;if clearly needed.&#160;You should&#160;consult your doctor if you<br/>become pregnant,&#160;think you may be pregnant, or are planning to have a baby.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft2573">If you received Enbrel during pregnancy,&#160;your&#160;baby may have a higher risk&#160;of&#160;getting an infection.&#160;In&#160;<br/>addition,&#160;one study&#160;found&#160;more birth defects when the mother had received&#160;Enbrel&#160;in pregnancy,&#160;<br/>compared&#160;with&#160;mothers who had not received&#160;Enbrel&#160;or other similar medicines (TNF-antagonists),&#160;<br/>but there was no&#160;particular kind of birth defect&#160;reported.&#160;Another study found no increased&#160;risk of birth&#160;<br/>defects when the mother had received Enbrel in pregnancy.&#160;Your doctor will help you to decide&#160;<br/>whether the benefits of treatment outweigh the potential risk to your baby.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft2574">Talk to your doctor if you want to breastfeed while on Enbrel treatment.&#160;It&#160;is important that you tell&#160;<br/>your&#160;baby’s doctors and other healthcare professionals about the use of Enbrel during pregnancy and&#160;<br/>breastfeeding before&#160;your&#160;baby receives any vaccine.</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft2571"><b>Driving and using&#160;machines</b></p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft2572">The use of Enbrel is not expected to affect the ability to drive or use machines.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft2571"><b>Enbrel contains sodium</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft2573">This medicine&#160;contains less than 1&#160;mmol sodium (23&#160;mg) per dosage unit, that is to say&#160;essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft2571"><b>3.</b></p>
<p style="position:absolute;top:602px;left:146px;white-space:nowrap" class="ft2571"><b>How to use Enbrel</b></p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft2574">Always use&#160;this medicine&#160;exactly as the doctor has told you.&#160;Check with the doctor or pharmacist if&#160;<br/>you are not sure.</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft2572">If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft2572">The pre-filled syringe is available&#160;in dose strengths of 25&#160;mg and 50&#160;mg.&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft2571"><b>Dosing for adult patients (aged 18 years or over)</b></p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft2572">Rheumatoid arthritis, psoriatic arthritis,&#160;and&#160;axial spondyloarthritis including&#160;ankylosing spondylitis</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft2573">The usual dose is 25&#160;mg given twice a week or 50&#160;mg&#160;once a week as an injection under the skin.&#160;<br/>However, your doctor may determine an alternative frequency at which to inject Enbrel.&#160;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft2572">Plaque psoriasis</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft2572">The usual dose is 25&#160;mg twice a week or 50&#160;mg once a&#160;week. &#160;</p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft2574">Alternatively, 50&#160;mg&#160;may be given twice a week for up to 12 weeks, followed by 25&#160;mg twice a week&#160;<br/>or 50&#160;mg once a week.&#160;</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft2574">Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on&#160;<br/>your response. If Enbrel has no effect on your condition after 12 weeks, your doctor may tell you to&#160;<br/>stop taking this medicine.</p>
</div>
<!-- Page 258 -->
<a name="258"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page258-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2580">258</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2581"><b>Use in&#160;children&#160;and adolescents</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2584">The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight&#160;<br/>and disease.&#160;Your doctor will determine the correct dose for the child and will prescribe an appropriate&#160;<br/>strength of Enbrel (10&#160;mg, 25&#160;mg or 50&#160;mg).</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft2584">For&#160;polyarthritis or extended oligoarthritis&#160;in patients from the age of 2 years, or enthesitis-related&#160;<br/>arthritis or psoriatic&#160;arthritis in patients from the age of 12 years, the usual dose is 0.4&#160;mg of Enbrel&#160;<br/>per kg bodyweight (up to a maximum of 25&#160;mg) given twice weekly, or 0.8&#160;mg of Enbrel per kg of&#160;<br/>bodyweight (up to a maximum of 50&#160;mg) given once weekly.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft2583">For psoriasis in patients from the age of&#160;6&#160;years, the usual dose is 0.8&#160;mg of Enbrel per kg bodyweight&#160;<br/>(up to a maximum of 50&#160;mg), and should be given once weekly. If Enbrel has no effect on the child’s&#160;<br/>condition after 12 weeks, your doctor may tell you&#160;to stop using this medicine.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2582">The doctor will provide you with detailed directions for preparing and measuring the appropriate dose.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft2581"><b>Method and route of administration</b></p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft2582">Enbrel is administered by an injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft2582">Enbrel can be taken with or without food or drink.</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft2583"><b>Detailed instructions on how to inject Enbrel are provided in section 7, “Instructions for&#160;<br/>preparing and giving an injection of Enbrel”.&#160;</b>Do not mix the Enbrel solution with any other&#160;<br/>medicine.</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft2584">To help you&#160;remember, it may be helpful to write in a diary which day(s) of the week Enbrel should be&#160;<br/>used.</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft2581"><b>If&#160;you use more Enbrel than you should</b></p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft2584">If you have used more Enbrel than you should (either by injecting too much on a single occasion or by&#160;<br/>using it too frequently), talk to a doctor or pharmacist immediately. Always have the outer carton of&#160;<br/>the medicine with you, even if it is empty.</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft2581"><b>If&#160;you forget to inject Enbrel</b></p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft2584">If you forget a dose, you should inject it as soon as you remember, unless the next scheduled&#160;dose is&#160;<br/>the next day; in which case you should skip the missed dose. Then continue to inject the medicine on&#160;<br/>the usual day(s). If you do not remember until the day that the next injection is due, do not take a&#160;<br/>double dose (two doses on the same day) to make up for a forgotten dose.</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft2581"><b>If&#160;you stop using Enbrel&#160;</b></p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft2582">Your symptoms may return upon discontinuation.&#160;</p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft2582">If you have any further questions on the use of this&#160;medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:1056px;left:106px;white-space:nowrap" class="ft2581"><b>4.</b></p>
<p style="position:absolute;top:1056px;left:146px;white-space:nowrap" class="ft2581"><b>Possible side effects</b></p>
<p style="position:absolute;top:1094px;left:106px;white-space:nowrap" class="ft2582">Like all medicines,&#160;this&#160;medicine&#160;can cause side effects, although not everybody gets them.</p>
</div>
<!-- Page 259 -->
<a name="259"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page259-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2590">259</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2591"><b>Allergic reactions</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2593">If any of the following happen, do not inject more Enbrel. Tell your doctor immediately, or go to the&#160;<br/>casualty department at your nearest hospital.</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:204px;left:149px;white-space:nowrap" class="ft2592">Trouble swallowing&#160;or breathing</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft2592">Swelling of the face, throat, hands, or feet</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft2594">Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm&#160;<br/>feeling</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft2592">Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p>
<p style="position:absolute;top:321px;left:106px;white-space:nowrap" class="ft2593">Serious&#160;allergic reactions are rare. However, any of the above symptoms may indicate an allergic&#160;<br/>reaction to Enbrel, so you should seek immediate medical attention.</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2591"><b>Serious side effects</b></p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft2592">If you notice any of the following, you or the child may need urgent medical&#160;attention.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:455px;left:149px;white-space:nowrap" class="ft2594">Signs of&#160;<b>serious infections</b>, such as high fever that may be accompanied by cough, shortness of&#160;<br/>breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:494px;left:149px;white-space:nowrap" class="ft2592">Signs of&#160;<b>blood disorders</b>, such as bleeding, bruising, or paleness</p>
<p style="position:absolute;top:513px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:515px;left:149px;white-space:nowrap" class="ft2594">Signs of&#160;<b>nerve disorders</b>, such as numbness or tingling, changes in vision, eye pain, or onset of&#160;<br/>weakness in an arm or leg</p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:554px;left:149px;white-space:nowrap" class="ft2594">Signs of&#160;<b>heart failure&#160;</b>or&#160;<b>worsening heart failure</b>, such as fatigue or shortness of breath with&#160;<br/>activity, swelling in the ankles, a&#160;feeling of fullness in the neck or abdomen, night-time&#160;<br/>shortness of breath or coughing, bluish colour of the nails or the lips</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:612px;left:149px;white-space:nowrap" class="ft2593"><b>Signs of cancers:&#160;</b>Cancers may affect any part of the body including the skin and blood, and&#160;<br/>possible signs will depend on the type and location of the cancer. These signs may include&#160;<br/>weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or&#160;<br/>growths on the skin</p>
<p style="position:absolute;top:687px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:689px;left:149px;white-space:nowrap" class="ft2594">Signs of&#160;<b>autoimmune reactions&#160;</b>(where antibodies are made that may harm normal tissues in&#160;<br/>the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:728px;left:149px;white-space:nowrap" class="ft2594">Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or&#160;<br/>muscle pain, or fatigue</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:767px;left:149px;white-space:nowrap" class="ft2594">Signs of&#160;<b>inflammation of the blood vessels&#160;</b>such as pain, fever, redness or warmth of the skin,&#160;<br/>or itching.</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft2594">These are rare or uncommon side effects, but are serious conditions (some of which may rarely be&#160;<br/>fatal). If these signs occur, tell your doctor immediately, or visit the casualty department at your&#160;<br/>nearest hospital.</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft2592">The known side effects of Enbrel include the following in groups of decreasing frequency:</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:939px;left:149px;white-space:nowrap" class="ft2594"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10&#160;people):<br/>Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections);&#160;<br/>injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling)&#160;(these&#160;<br/>do not occur as often after the first month of treatment;&#160;some patients have developed a reaction&#160;<br/>at an injection site that was&#160;recently&#160;used);&#160;and headache.</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft25914"></p>
<p style="position:absolute;top:1054px;left:149px;white-space:nowrap" class="ft2594"><b>Common&#160;</b>(may affect up to 1 in 10&#160;people):<br/>Allergic reactions; fever;&#160;rash;&#160;itching; antibodies directed against normal tissue (autoantibody&#160;<br/>formation).</p>
</div>
<!-- Page 260 -->
<a name="260"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page260-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2600">260</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft26014"></p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft2603"><b>Uncommon&#160;</b>(may affect up to 1 in 100&#160;people):<br/>Serious infections (including pneumonia, deep skin infections, joint infections, blood infection,&#160;<br/>and infections at various sites);&#160;worsening of congestive heart failure;&#160;low red blood cell count,&#160;<br/>low white blood cell count, low neutrophil (a type of white blood cell) count;&#160;low blood platelet&#160;<br/>count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives&#160;<br/>(elevated patches of red or pale skin that often itch); eye inflammation; psoriasis&#160;(new or&#160;<br/>worsening);&#160;inflammation of the blood vessels affecting multiple organs; elevated liver blood&#160;<br/>tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood&#160;<br/>tests is common);&#160;abdominal cramps and pain,&#160;diarrhoea, weight loss or blood in the stool (signs&#160;<br/>of bowel problems).</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft26014"></p>
<p style="position:absolute;top:319px;left:149px;white-space:nowrap" class="ft2604"><b>Rare&#160;</b>(may affect up to 1 in 1,000&#160;people):<br/>Serious allergic reactions (including severe localised swelling of the skin and wheezing);<br/>lymphoma (a type of blood cancer);&#160;leukaemia (cancer affecting the blood and bone marrow);<br/>melanoma&#160;(a type of skin cancer);&#160;combined low platelet, red, and white blood cell count;&#160;<br/>nervous system disorders (with&#160;severe muscle weakness and&#160;signs and symptoms similar to&#160;<br/>those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord);&#160;<br/>tuberculosis;&#160;new onset&#160;congestive heart failure; seizures; lupus or lupus-like syndrome&#160;<br/>(symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may&#160;<br/>lead to severe blistering and peeling of the skin;&#160;lichenoid reactions (itchy reddish-purple skin&#160;<br/>rash and/or threadlike white-grey lines on mucous membranes);&#160;inflammation of the liver&#160;<br/>caused by the body's own&#160;immune system (autoimmune hepatitis;&#160;in patients also receiving&#160;<br/>methotrexate treatment, the frequency is uncommon);&#160;immune disorder that can affect the lungs,&#160;<br/>skin and lymph nodes (sarcoidosis);&#160;inflammation or scarring of the lungs&#160;(in patients also&#160;<br/>receiving methotrexate treatment, the frequency&#160;of&#160;inflammation or scarring of the lungs is&#160;<br/>uncommon).</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft26014"></p>
<p style="position:absolute;top:624px;left:149px;white-space:nowrap" class="ft2604"><b>Very rare&#160;</b>(may&#160;affect up to 1 in 10,000&#160;people):&#160;failure of the bone marrow to produce crucial&#160;<br/>blood cells.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft26014"></p>
<p style="position:absolute;top:682px;left:149px;white-space:nowrap" class="ft2604"><b>Not known&#160;</b>(frequency cannot be estimated from&#160;the available data):&#160;Merkel cell carcinoma (a&#160;<br/>type of skin cancer);&#160;Kaposi’s sarcoma (a rare cancer related to infection with human herpes&#160;<br/>virus 8. Kaposi’s sarcoma most commonly appear as purple lesions on the skin);&#160;excessive&#160;<br/>activation of white blood cells associated with inflammation (macrophage activation&#160;<br/>syndrome);&#160;recurrence of hepatitis B (a liver infection);&#160;worsening of a condition called&#160;<br/>dermatomyositis (muscle inflammation and weakness&#160;with&#160;an&#160;accompanying&#160;skin rash).</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft2601"><b>Additional side effects in&#160;children and adolescents</b></p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft2604">The side effects and their frequencies seen in children and adolescents are similar to those&#160;described&#160;<br/>above.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft2601"><b>Reporting of side effects</b></p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft2604">If you get any side effects, talk to your doctor&#160;or&#160;pharmacist.&#160;This includes any possible&#160;side effects&#160;<br/>not listed in this leaflet.&#160;You can also report side effects&#160;directly&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>. By reporting side effects you can help provide more information on the safety of&#160;<br/>this medicine.</p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft2601"><b>5.</b></p>
<p style="position:absolute;top:1061px;left:146px;white-space:nowrap" class="ft2601"><b>How to store Enbrel</b></p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft2602">Keep&#160;this medicine&#160;out of the&#160;sight and&#160;reach of children.</p>
<p style="position:absolute;top:1137px;left:106px;white-space:nowrap" class="ft2604">Do not use&#160;this medicine&#160;after the expiry date which is stated on the carton&#160;and pre-filled syringe&#160;after&#160;<br/>EXP. The expiry date refers to the last day of that month.</p>
</div>
<!-- Page 261 -->
<a name="261"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page261-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2610">261</p>
<p style="position:absolute;top:128px;left:106px;white-space:nowrap" class="ft2612">Store in a refrigerator (2</p>
<p style="position:absolute;top:126px;left:267px;white-space:nowrap" class="ft26114">&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft2612">Keep the pre-filled syringes in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft2614">After taking a syringe from the refrigerator,&#160;<b>wait&#160;approximately 15-30 minutes to allow the Enbrel&#160;<br/>solution&#160;in the syringe&#160;to reach room temperature</b>. Do not warm in any other way.&#160;Immediate use&#160;<br/>is then recommended. &#160;</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft2612">Enbrel may be stored outside of the refrigerator at temperatures up to a maximum of 25</p>
<p style="position:absolute;top:279px;left:684px;white-space:nowrap" class="ft26114">C for a single&#160;</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft2613">period of up to four weeks; after which, it should not be refrigerated again. Enbrel should be discarded&#160;<br/>if not used within four weeks after removal from the refrigerator. It is recommended that you record&#160;<br/>the date that Enbrel is removed from the refrigerator and the date after which Enbrel should be&#160;<br/>discarded (no more than 4 weeks following the removal from the refrigerator).</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft2614">Inspect the solution in the&#160;syringe.&#160;It&#160;should be&#160;clear&#160;or slightly&#160;opalescent, colourless&#160;to&#160;pale yellow<br/>or pale brown, and&#160;may&#160;contain&#160;small white or almost transparent particles of protein.&#160;This appearance&#160;<br/>is normal for Enbrel. Do not use the solution if it is discoloured, cloudy,&#160;or if particles other than those&#160;<br/>described above are present. If you are concerned with the appearance of the solution, then contact&#160;<br/>your pharmacist for assistance.</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft2614">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to&#160;<br/>throw away&#160;medicines&#160;you&#160;no longer&#160;use. These measures will help protect the environment.</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft2611"><b>6.</b></p>
<p style="position:absolute;top:585px;left:146px;white-space:nowrap" class="ft2611"><b>Contents of the pack and other information&#160;</b></p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft2611"><b>What Enbrel contains</b></p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft2614">Enbrel 25&#160;mg solution for injection in pre-filled syringe<br/>The active substance in Enbrel is etanercept. Each pre-filled syringe contains 0.5&#160;ml&#160;of solution,&#160;<br/>providing&#160;25&#160;mg&#160;of etanercept. &#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft2613">Enbrel 50&#160;mg solution for injection in pre-filled syringe<br/>The active substance in Enbrel&#160;is etanercept. Each pre-filled syringe contains 1.0&#160;ml of solution,&#160;<br/>providing 50&#160;mg of etanercept.&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft2613">The other ingredients are sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate&#160;<br/>monobasic dihydrate and sodium phosphate dibasic dihydrate,&#160;and water for injections.</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft2611"><b>What Enbrel looks like and contents of the pack</b></p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft2613">Enbrel 25&#160;mg solution for injection in pre-filled syringe<br/>Enbrel is supplied as a pre-filled syringe containing a clear, colourless&#160;to&#160;pale yellow&#160;or pale brown<br/>solution for injection&#160;(solution for injection). Each pack contains 4, 8, 12&#160;or 24 pre-filled syringes and&#160;<br/>4, 8, 12&#160;or 24&#160;alcohol swabs. Not all pack sizes may be marketed.</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft2613">Enbrel 50&#160;mg solution for injection in pre-filled syringe<br/>Enbrel is supplied as a&#160;pre-filled syringe containing a clear, colourless&#160;to&#160;pale yellow&#160;or pale brown<br/>solution for injection (solution for injection). Each pack contains 2, 4 or 12 pre-filled syringes and 2, 4&#160;<br/>or 12 alcohol swabs. Not all pack sizes may be marketed.</p>
</div>
<!-- Page 262 -->
<a name="262"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page262-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2620">262</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2621"><b>Marketing&#160;Authorisation Holder and Manufacturer</b></p>
<p style="position:absolute;top:146px;left:114px;white-space:nowrap" class="ft2624"><i>Marketing Authorisation Holder:<br/></i>Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:260px;left:114px;white-space:nowrap" class="ft2624"><i>Manufacturer:<br/></i>Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft2623">For any information about&#160;this medicinal product, please contact the local representative of the&#160;<br/>Marketing Authorisation Holder.</p>
<p style="position:absolute;top:440px;left:114px;white-space:nowrap" class="ft2624"><b>België/Belgique/Belgien<br/>Luxembourg/Luxemburg<br/></b>Pfizer&#160;NV/SA<br/>Tél/Tel: +32 (0)2 554 62 11</p>
<p style="position:absolute;top:440px;left:452px;white-space:nowrap" class="ft2628"><b>Kύπρος<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.&#160;(CYPRUS BRANCH)&#160;<br/>T</p>
<p style="position:absolute;top:477px;left:462px;white-space:nowrap" class="ft26214">: +357 22 817690</p>
<p style="position:absolute;top:535px;left:114px;white-space:nowrap" class="ft2623"><b>Česká Republika<br/></b>Pfizer, spol.&#160;s&#160;r.o.<br/>Tel: +420-283-004-111</p>
<p style="position:absolute;top:535px;left:452px;white-space:nowrap" class="ft2623"><b>Magyarország<br/></b>Pfizer Kft.<br/>Tel: +36 1 488 3700</p>
<p style="position:absolute;top:611px;left:114px;white-space:nowrap" class="ft2624"><b>Danmark<br/></b>Pfizer ApS<br/>Tlf: +45 44&#160;201&#160;100</p>
<p style="position:absolute;top:611px;left:452px;white-space:nowrap" class="ft2624"><b>Malta<br/></b>Vivian Corporation Ltd.<br/>Tel: +35621 344610</p>
<p style="position:absolute;top:687px;left:114px;white-space:nowrap" class="ft2623"><b>Deutschland<br/></b>Pfizer Pharma GmbH<br/>Tel: +49 (0)30 550055-51000</p>
<p style="position:absolute;top:687px;left:452px;white-space:nowrap" class="ft2623"><b>Nederland<br/></b>Pfizer bv<br/>Tel: +31 (0)800 63 34 636</p>
<p style="position:absolute;top:765px;left:114px;white-space:nowrap" class="ft2623"><b>България<br/></b>Пфайзер Люксембург САРЛ,&#160;<br/>Клон България<br/>Teл:&#160;+359 2 970 4333</p>
<p style="position:absolute;top:765px;left:452px;white-space:nowrap" class="ft2624"><b>Norge<br/></b>Pfizer AS<br/>Tlf: +47 67&#160;52&#160;61&#160;00</p>
<p style="position:absolute;top:859px;left:114px;white-space:nowrap" class="ft2624"><b>Eesti<br/></b>Pfizer&#160;Luxembourg SARL Eesti filiaal<br/>Tel:&#160;+372 666 7500</p>
<p style="position:absolute;top:859px;left:452px;white-space:nowrap" class="ft2624"><b>Österreich<br/></b>Pfizer Corporation Austria Ges.m.b.H.<br/>Tel: +43 (0)1 521 15-0</p>
<p style="position:absolute;top:935px;left:114px;white-space:nowrap" class="ft2624"><b>Ελλάδα<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.<br/>Τηλ.: +30 210 67&#160;85 800</p>
<p style="position:absolute;top:935px;left:452px;white-space:nowrap" class="ft2624"><b>Polska<br/></b>Pfizer Polska Sp. z o.o.<br/>Tel.: +48 22 335 61 00</p>
<p style="position:absolute;top:1021px;left:114px;white-space:nowrap" class="ft2624"><b>España<br/></b>Pfizer, S.L.<br/>Télf:&#160;+34&#160;91&#160;490&#160;99&#160;00</p>
<p style="position:absolute;top:1021px;left:452px;white-space:nowrap" class="ft2624"><b>Portugal<br/></b>Laboratórios Pfizer, Lda.<br/>Tel: (+351) 21 423 55 00</p>
<p style="position:absolute;top:1102px;left:114px;white-space:nowrap" class="ft2623"><b>France<br/></b>Pfizer<br/>Tél&#160;+33 (0)1 58 07 34 40</p>
<p style="position:absolute;top:1102px;left:452px;white-space:nowrap" class="ft2623"><b>România<br/></b>Pfizer Romania S.R.L<br/>Tel: +40 (0) 21 207 28 00</p>
</div>
<!-- Page 263 -->
<a name="263"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page263-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2630">263</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft2634"><b>Hrvatska<br/></b>Pfizer Croatia&#160;d.o.o.<br/>Tel: +385 1&#160;3908&#160;777</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft2634"><b>Slovenija<br/></b>Pfizer Luxembourg&#160;SARL<i>,&#160;</i>Pfizer, podružnica&#160;<br/>za&#160;svetovanje s področja farmacevtske&#160;<br/>dejavnosti, Ljubljana<br/>Tel: +386 (0)1 52 11 400</p>
<p style="position:absolute;top:222px;left:114px;white-space:nowrap" class="ft2634"><b>Ireland<br/></b>Pfizer Healthcare Ireland<br/>Tel: +1800 633 363 (toll free)<br/>Tel: +44 (0)1304 616161</p>
<p style="position:absolute;top:222px;left:452px;white-space:nowrap" class="ft2633"><b>Slovenská Republika<br/></b>Pfizer Luxembourg SARL, organizačná zložka&#160;<br/>Tel: +421 2 3355 5500</p>
<p style="position:absolute;top:316px;left:114px;white-space:nowrap" class="ft2633"><b>Ísland<br/></b>Icepharma&#160;hf.<br/>Tel: +354&#160;540 8000</p>
<p style="position:absolute;top:316px;left:452px;white-space:nowrap" class="ft2633"><b>Suomi/Finland<br/></b>Pfizer Oy<br/>Puh/Tel: +358 (0)9&#160;430 040</p>
<p style="position:absolute;top:396px;left:114px;white-space:nowrap" class="ft2634"><b>Italia<br/></b>Pfizer S.r.l.<br/>Tel: +39 06 33 18 21</p>
<p style="position:absolute;top:396px;left:452px;white-space:nowrap" class="ft2634"><b>Sverige&#160;<br/></b>Pfizer AB<br/>Tel: +46 (0)8&#160;550&#160;520 00</p>
<p style="position:absolute;top:476px;left:114px;white-space:nowrap" class="ft2633"><b>Latvija<br/></b>Pfizer Luxembourg SARL filiāle Latvijā<br/>Tel. +371 67035775</p>
<p style="position:absolute;top:476px;left:452px;white-space:nowrap" class="ft2633"><b>United Kingdom&#160;(Northern Ireland)<br/></b>Pfizer Limited<br/>Tel:&#160;+44 (0)1304 616161</p>
<p style="position:absolute;top:555px;left:114px;white-space:nowrap" class="ft2634"><b>Lietuva<br/></b>Pfizer Luxembourg SARL filialas Lietuvoje<br/>Tel. +3705 2514000</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft2631"><b>This leaflet was last&#160;revised&#160;in</b></p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft2633">Detailed information on this&#160;medicine&#160;is available on the&#160;European Medicines Agency&#160;web&#160;site:<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft2631"><b>7.</b></p>
<p style="position:absolute;top:768px;left:146px;white-space:nowrap" class="ft2631"><b>Instructions for preparing and giving an injection of Enbrel</b></p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft2632">This section is&#160;divided into the following subsections:</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft26323"><b>Introduction<br/>Step 1: Setting up for an injection<br/>Step 2: Choosing an injection site<br/>Step 3: Injecting the Enbrel solution<br/>Step 4: Disposing of supplies</b></p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft2631"><b>Introduction</b></p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft2634">The following instructions explain how to prepare and inject Enbrel. Please read the instructions&#160;<br/>carefully and follow them step by step. You will be instructed by your doctor or his/her assistant on&#160;<br/>the techniques of self-injection or on giving an injection to a child. Do not attempt to administer an&#160;<br/>injection until you are sure that you understand how to prepare and give the injection.</p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft2632">The Enbrel solution&#160;should not be mixed with any other medicine&#160;before use.</p>
</div>
<!-- Page 264 -->
<a name="264"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page264-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2640">264</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2641"><b>Step 1: Setting up for an injection</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2642">1.</p>
<p style="position:absolute;top:146px;left:147px;white-space:nowrap" class="ft2642">Select a clean, well-lit, flat working surface.</p>
<p style="position:absolute;top:179px;left:106px;white-space:nowrap" class="ft2642">2.</p>
<p style="position:absolute;top:179px;left:147px;white-space:nowrap" class="ft2642">Take&#160;the Enbrel&#160;carton containing the pre-filled syringes out of the refrigerator and place it on&#160;</p>
<p style="position:absolute;top:198px;left:149px;white-space:nowrap" class="ft2643">the flat work surface.&#160;Starting from one of the top corners, pull back the paper cover from the&#160;<br/>top and sides of the tray.&#160;Remove one pre-filled syringe and one&#160;alcohol swab and place them&#160;<br/>on the work surface. Do not shake the pre-filled syringe of Enbrel.&#160;Fold the paper cover back&#160;<br/>over the tray and place the carton containing any remaining pre-filled syringes back into the&#160;<br/>refrigerator. Please see section 5 for instructions on how to store Enbrel.&#160;If you have any&#160;<br/>questions about storage, contact your doctor, nurse, or pharmacist for further instructions.</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2642">3.</p>
<p style="position:absolute;top:325px;left:147px;white-space:nowrap" class="ft2641"><b>You should allow 15 to 30 minutes for the Enbrel&#160;solution&#160;in the syringe to reach room&#160;</b></p>
<p style="position:absolute;top:344px;left:149px;white-space:nowrap" class="ft2643"><b>temperature.&#160;Do&#160;NOT&#160;</b>remove the needle cover while allowing it to reach room temperature.&#160;<br/>Waiting until the solution reaches room temperature may make the injection more comfortable&#160;<br/>for you.&#160;Do not warm Enbrel&#160;in any other way (for example, do not warm it in a microwave or&#160;<br/>in hot&#160;water).</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft2642">4.</p>
<p style="position:absolute;top:433px;left:147px;white-space:nowrap" class="ft2642">Assemble the additional supplies you will need for your injection. These include&#160;the&#160;alcohol&#160;</p>
<p style="position:absolute;top:452px;left:149px;white-space:nowrap" class="ft2642">swab&#160;from the Enbrel carton&#160;and a cotton ball or gauze.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft2642">5.</p>
<p style="position:absolute;top:485px;left:147px;white-space:nowrap" class="ft2642">Wash your&#160;hands with soap and warm water.</p>
<p style="position:absolute;top:517px;left:106px;white-space:nowrap" class="ft2642">6.</p>
<p style="position:absolute;top:517px;left:147px;white-space:nowrap" class="ft2642">Inspect the solution in the&#160;syringe.&#160;It&#160;should be&#160;clear&#160;or slightly opalescent, colourless&#160;to&#160;pale&#160;</p>
<p style="position:absolute;top:536px;left:149px;white-space:nowrap" class="ft2643">yellow&#160;or pale brown, and&#160;may contain small white&#160;or almost transparent particles of protein.<br/>This appearance is normal for Enbrel. Do not use the solution if it is discoloured, cloudy,&#160;or if&#160;<br/>particles other than&#160;those described above are present. If you are concerned with the appearance&#160;<br/>of the solution, then contact your pharmacist for assistance.</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft2641"><b>Step 2: Choosing an injection site</b></p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft2642">1.</p>
<p style="position:absolute;top:664px;left:149px;white-space:nowrap" class="ft2643">The three recommended injection sites for Enbrel using a pre-filled syringe include: (1) the front&#160;<br/>of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3)&#160;<br/>the outer area of the upper arms (see Diagram 1). If you are&#160;self injecting, you should not use&#160;<br/>the outer area of the upper arms.</p>
<p style="position:absolute;top:754px;left:411px;white-space:nowrap" class="ft2642">Diagram 1</p>
<p style="position:absolute;top:1022px;left:106px;white-space:nowrap" class="ft2642">2.</p>
<p style="position:absolute;top:1022px;left:149px;white-space:nowrap" class="ft2643">A different site should be used for each new injection. Each new injection should be given at&#160;<br/>least 3&#160;cm from an old site. Do not inject into areas where the skin is tender, bruised, red, or&#160;<br/>hard. Avoid areas with scars or stretch marks. (It may be helpful to keep notes on the location of&#160;<br/>the previous injections.)</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft2642">3.</p>
<p style="position:absolute;top:1112px;left:149px;white-space:nowrap" class="ft2643">If you or the child have psoriasis, you should try not to inject directly into any raised, thick, red,&#160;<br/>or scaly skin patches (“psoriasis skin lesions”).</p>
</div>
<!-- Page 265 -->
<a name="265"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page265-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2650">265</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft2651"><b>Step 3: Injecting the Enbrel solution</b></p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft2652">1.</p>
<p style="position:absolute;top:165px;left:147px;white-space:nowrap" class="ft2652">Wipe the site where Enbrel is to be injected with&#160;the&#160;alcohol swab, using a circular motion.&#160;<b>Do</b></p>
<p style="position:absolute;top:184px;left:149px;white-space:nowrap" class="ft2651"><b>NOT&#160;</b>touch this area again before giving the injection.</p>
<p style="position:absolute;top:217px;left:106px;white-space:nowrap" class="ft2652">2.</p>
<p style="position:absolute;top:217px;left:147px;white-space:nowrap" class="ft2652">Pick up the pre-filled syringe from the flat work surface. Remove the needle cover by firmly&#160;</p>
<p style="position:absolute;top:236px;left:149px;white-space:nowrap" class="ft26524">pulling it straight off the syringe (see Diagram 2).&#160;<b>Be careful not to bend or twist the cover&#160;<br/>during removal to avoid damage to the needle.</b></p>
<p style="position:absolute;top:287px;left:147px;white-space:nowrap" class="ft2652">When you remove the&#160;needle cover, there may be a drop of liquid at the end of the needle; this is&#160;</p>
<p style="position:absolute;top:306px;left:149px;white-space:nowrap" class="ft2653">normal. Do not touch the needle or allow it to touch any surface. Do not touch or bump the&#160;<br/>plunger. Doing so could cause the liquid to leak out.</p>
<p style="position:absolute;top:357px;left:425px;white-space:nowrap" class="ft2652">Diagram 2</p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft2652">3.</p>
<p style="position:absolute;top:587px;left:147px;white-space:nowrap" class="ft2652">When the cleaned area of skin has dried, pinch and&#160;hold it firmly with one hand.&#160;With the other&#160;</p>
<p style="position:absolute;top:606px;left:149px;white-space:nowrap" class="ft2652">hand, hold the syringe like a pencil.</p>
<p style="position:absolute;top:634px;left:106px;white-space:nowrap" class="ft2652">4.</p>
<p style="position:absolute;top:634px;left:147px;white-space:nowrap" class="ft2652">With a quick, short motion, push the needle all the way into the skin at an angle between 45°&#160;</p>
<p style="position:absolute;top:653px;left:149px;white-space:nowrap" class="ft2653">and 90° (see Diagram 3). With experience, you will find the angle that is most comfortable for&#160;<br/>you or the child.&#160;Be careful not to push the needle into the skin too slowly, or with great force.&#160;</p>
<p style="position:absolute;top:723px;left:412px;white-space:nowrap" class="ft2652">Diagram 3</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft2652">5.</p>
<p style="position:absolute;top:933px;left:147px;white-space:nowrap" class="ft2652">When the needle is completely inserted into the skin, release&#160;the skin that you are holding.&#160;With&#160;</p>
<p style="position:absolute;top:952px;left:149px;white-space:nowrap" class="ft2653">your free hand, hold the syringe near its base to stabilise it. Then push the plunger to inject all of&#160;<br/>the solution at a&#160;<b>slow</b>, steady rate (see Diagram 4).</p>
</div>
<!-- Page 266 -->
<a name="266"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page266-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2660">266</p>
<p style="position:absolute;top:108px;left:411px;white-space:nowrap" class="ft2662">Diagram 4</p>
<p style="position:absolute;top:350px;left:106px;white-space:nowrap" class="ft2662">6.</p>
<p style="position:absolute;top:350px;left:147px;white-space:nowrap" class="ft2662">When the syringe is empty, pull the needle out of the skin, being careful&#160;to keep it at the same&#160;</p>
<p style="position:absolute;top:369px;left:149px;white-space:nowrap" class="ft2663">angle as inserted. There may be a little bleeding at the injection site. You can press a cotton ball&#160;<br/>or gauze over the injection site for 10 seconds. Do not rub the injection site. If needed, you may&#160;<br/>cover the injection site with a&#160;bandage.</p>
<p style="position:absolute;top:440px;left:106px;white-space:nowrap" class="ft2661"><b>Step 4:&#160;Disposing of supplies</b></p>
<p style="position:absolute;top:478px;left:106px;white-space:nowrap" class="ft26614"></p>
<p style="position:absolute;top:480px;left:149px;white-space:nowrap" class="ft2664">The pre-filled syringe is for single-use administration only. The syringe and needle should&#160;<br/><b>NEVER&#160;</b>be re-used.&#160;<b>NEVER&#160;</b>re-cap a needle. Dispose of the needle and syringe as instructed&#160;<br/>by your doctor, nurse or pharmacist.</p>
<p style="position:absolute;top:555px;left:106px;white-space:nowrap" class="ft26623"><b>If&#160;you have any questions, please talk to a doctor, nurse or pharmacist who is familiar with&#160;<br/>Enbrel.</b></p>
</div>
<!-- Page 267 -->
<a name="267"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page267-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2670">267</p>
<p style="position:absolute;top:108px;left:298px;white-space:nowrap" class="ft2671"><b>Package Leaflet: Information for the User</b></p>
<p style="position:absolute;top:146px;left:265px;white-space:nowrap" class="ft2671"><b>Enbrel&#160;25&#160;mg solution for injection in pre-filled pen</b></p>
<p style="position:absolute;top:165px;left:413px;white-space:nowrap" class="ft2672">etanercept</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft26723"><b>Read all of this leaflet carefully before you start using this medicine because it contains&#160;<br/>important information for you.</b></p>
<p style="position:absolute;top:240px;left:123px;white-space:nowrap" class="ft26714"></p>
<p style="position:absolute;top:242px;left:162px;white-space:nowrap" class="ft2672">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:260px;left:123px;white-space:nowrap" class="ft26714"></p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft2672">Your doctor will also give you a Patient Card, which contains important safety information that&#160;</p>
<p style="position:absolute;top:281px;left:164px;white-space:nowrap" class="ft2672">you need to be aware of before and during treatment with Enbrel.</p>
<p style="position:absolute;top:299px;left:123px;white-space:nowrap" class="ft26714"></p>
<p style="position:absolute;top:301px;left:162px;white-space:nowrap" class="ft2672">If you&#160;have&#160;any further questions, ask your doctor,&#160;pharmacist or nurse.</p>
<p style="position:absolute;top:319px;left:123px;white-space:nowrap" class="ft26714"></p>
<p style="position:absolute;top:321px;left:162px;white-space:nowrap" class="ft2672">This medicine has been prescribed for you or a child in your care. Do not pass it on to others. It&#160;</p>
<p style="position:absolute;top:340px;left:164px;white-space:nowrap" class="ft2674">may harm them, even if their&#160;signs of illness&#160;are the same as yours or those of the child you are&#160;<br/>caring for.</p>
<p style="position:absolute;top:378px;left:123px;white-space:nowrap" class="ft26714"></p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft2672">If you&#160;get&#160;any side effects,&#160;talk to&#160;your doctor or pharmacist.&#160;This includes any possible side&#160;</p>
<p style="position:absolute;top:398px;left:164px;white-space:nowrap" class="ft2672">effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft2671"><b>What is in this leaflet</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2672">Information in this leaflet is organised under the following 7 sections:</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft2672">1.</p>
<p style="position:absolute;top:512px;left:149px;white-space:nowrap" class="ft2672">What Enbrel is and what it is used for</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft2672">2.</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft2672">What you need to know before you use Enbrel</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft2672">3.</p>
<p style="position:absolute;top:550px;left:149px;white-space:nowrap" class="ft2672">How to use Enbrel</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft2672">4.</p>
<p style="position:absolute;top:569px;left:149px;white-space:nowrap" class="ft2672">Possible side effects</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft2672">5.</p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft2672">How to store Enbrel</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft2672">6.</p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft2672">Contents of the pack and other information</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft2672">7.</p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft2672">Using the MYCLIC pre-filled pen to inject Enbrel (See overleaf)</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft2671"><b>1.</b></p>
<p style="position:absolute;top:683px;left:146px;white-space:nowrap" class="ft2671"><b>What Enbrel is and what it is used&#160;for</b></p>
<p style="position:absolute;top:721px;left:106px;white-space:nowrap" class="ft2674">Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in&#160;<br/>the body that causes inflammation. Enbrel works by reducing the inflammation associated with certain&#160;<br/>diseases.</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft2674">In adults (aged 18 and over), Enbrel can be used for moderate or severe&#160;<b>rheumatoid arthritis</b>,&#160;<br/><b>psoriatic arthritis</b>, severe&#160;<b>axial spondyloarthritis&#160;</b>including&#160;<b>ankylosing spondylitis,&#160;</b>and moderate&#160;<br/>or severe&#160;<b>psoriasis&#160;</b>–&#160;in each case usually when other widely used treatments have not worked well&#160;<br/>enough or are not suitable for you.</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft2674">For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may&#160;<br/>also be used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in&#160;<br/>combination with methotrexate, Enbrel can slow down the damage to your joints caused by the&#160;<br/>rheumatoid arthritis and improve your ability to do normal daily activities.</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft2674">For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do&#160;<br/>normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands,&#160;<br/>wrists and feet), Enbrel can slow down the structural damage to those joints&#160;caused by the disease.&#160;</p>
</div>
<!-- Page 268 -->
<a name="268"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page268-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2680">268</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2682">Enbrel is also prescribed for the treatment of the following diseases in children and adolescents</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft26814">&#160;For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft2682">worked well enough or is not suitable for them:</p>
<p style="position:absolute;top:203px;left:214px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:205px;left:255px;white-space:nowrap" class="ft2682">Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis&#160;</p>
<p style="position:absolute;top:224px;left:257px;white-space:nowrap" class="ft2682">in patients from the age of 2 years</p>
<p style="position:absolute;top:261px;left:214px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:263px;left:255px;white-space:nowrap" class="ft2682">Psoriatic arthritis in patients from the age of 12 years</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:302px;left:147px;white-space:nowrap" class="ft2682">For enthesitis-related arthritis in patients from the age of 12&#160;years when other widely used&#160;</p>
<p style="position:absolute;top:321px;left:149px;white-space:nowrap" class="ft2682">treatments have not worked well enough or are not suitable for them</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:360px;left:147px;white-space:nowrap" class="ft2682">Severe psoriasis in patients from the age of 6 years who have had an inadequate response to (or&#160;</p>
<p style="position:absolute;top:379px;left:149px;white-space:nowrap" class="ft2682">are unable to take) phototherapies or other systemic therapies.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft2681"><b>2.</b></p>
<p style="position:absolute;top:436px;left:146px;white-space:nowrap" class="ft2681"><b>What you need to know before you use Enbrel&#160;</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2681"><b>Do not use Enbrel</b></p>
<p style="position:absolute;top:511px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:513px;left:147px;white-space:nowrap" class="ft2683">if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of&#160;<br/>Enbrel&#160;(listed in section 6). If you or the child experience allergic reactions&#160;such as chest&#160;<br/>tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor&#160;<br/>immediately.</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:590px;left:147px;white-space:nowrap" class="ft2684">if you or the child have, or are at risk of developing a serious blood infection called sepsis. If&#160;<br/>you are not sure, please contact your doctor.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:630px;left:147px;white-space:nowrap" class="ft2682">if you or the child have an infection of any kind. If you are not sure, please talk to your doctor.</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft2681"><b>Warnings and precautions&#160;</b></p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft2682">Talk to your doctor before taking Enbrel.</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:745px;left:149px;white-space:nowrap" class="ft2684"><b>Allergic reactions</b>: If you or the child experience allergic reactions such as&#160;chest tightness,&#160;<br/>wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:782px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:784px;left:149px;white-space:nowrap" class="ft2684"><b>Infections/surgery</b>: If you or the child develop a new infection, or are about to have any major&#160;<br/>surgery, your doctor may wish to monitor the treatment with Enbrel.</p>
<p style="position:absolute;top:821px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft2684"><b>Infections/diabetes:&#160;</b>Tell your doctor if you or the child have a history of recurrent infections or&#160;<br/>suffer from diabetes or other conditions that increase the risk of infection.</p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:862px;left:147px;white-space:nowrap" class="ft2681"><b>Infections/monitoring:&#160;</b>Tell your doctor of any recent travel&#160;outside the European region. If you&#160;</p>
<p style="position:absolute;top:881px;left:149px;white-space:nowrap" class="ft2683">or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor&#160;<br/>immediately. Your doctor may decide to continue to monitor you or the child for the presence of&#160;<br/>infections after you or the child stop using Enbrel.</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:939px;left:147px;white-space:nowrap" class="ft2681"><b>Tuberculosis:&#160;</b>As cases of tuberculosis have been reported in patients treated with Enbrel, your&#160;</p>
<p style="position:absolute;top:958px;left:149px;white-space:nowrap" class="ft2684">doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may&#160;<br/>include a thorough medical history, a chest&#160;X-ray and a tuberculin test. The conduct of these&#160;<br/>tests should be recorded on the Patient Card. It is very important that you tell your doctor if you&#160;<br/>or the child have ever had tuberculosis, or have been in close contact with someone who has had&#160;<br/>tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft26814"></p>
<p style="position:absolute;top:1073px;left:147px;white-space:nowrap" class="ft2681"><b>Hepatitis B:&#160;</b>Tell your&#160;doctor if you or the child have or have ever had&#160;hepatitis B.&#160;Your doctor&#160;</p>
<p style="position:absolute;top:1092px;left:149px;white-space:nowrap" class="ft2684">should test&#160;for the presence of hepatitis B infection before you or the child begin treatment with&#160;<br/>Enbrel.&#160;Treatment with Enbrel may result in reactivation of hepatitis B in patients who have&#160;<br/>previously been infected with the&#160;hepatitis B virus. If this occurs, you should stop using Enbrel.</p>
</div>
<!-- Page 269 -->
<a name="269"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page269-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2690">269</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:109px;left:147px;white-space:nowrap" class="ft2691"><b>Hepatitis C:&#160;</b>Tell your doctor if you or the child have hepatitis C. Your doctor may wish to&#160;</p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft2692">monitor the treatment with Enbrel in case the infection worsens.</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft2693"><b>Blood disorders:&#160;</b>Seek medical advice immediately if you or the child have any signs or&#160;<br/>symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms&#160;<br/>may point to the existence of potentially life-threatening blood disorders, which may require&#160;<br/>discontinuation of Enbrel.</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:225px;left:149px;white-space:nowrap" class="ft2693"><b>Nervous system and eye disorders:&#160;</b>Tell your doctor if you or the child have multiple sclerosis,&#160;<br/>optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of&#160;<br/>the spinal cord). Your doctor will&#160;determine if Enbrel is an appropriate treatment.</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft2694"><b>Congestive heart failure:&#160;</b>Tell your doctor if you or the child have a history of congestive heart&#160;<br/>failure, because Enbrel needs to be used with caution under these circumstances.</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:322px;left:149px;white-space:nowrap" class="ft2694"><b>Cancer:&#160;</b>Tell your doctor if&#160;you have or have ever had lymphoma (a type of blood cancer) or&#160;<br/>any other cancer before you are given Enbrel.<br/>Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at&#160;<br/>higher than average risk of developing lymphoma.<br/>Children and adults taking Enbrel may have an increased risk of developing lymphoma or&#160;<br/>another cancer.<br/>Some children and teenage patients who have received Enbrel or other medicines that work the&#160;<br/>same way as Enbrel have developed cancers, including unusual types, which sometimes resulted&#160;<br/>in death.<br/>Some patients receiving Enbrel have developed skin cancers.&#160;Tell&#160;your doctor if you or the child&#160;<br/>develop any change in the appearance of the skin&#160;or growths on the skin.</p>
<p style="position:absolute;top:530px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:532px;left:149px;white-space:nowrap" class="ft2694"><b>Chickenpox:&#160;</b>Tell your doctor if you or the child are exposed to chickenpox when using Enbrel.&#160;<br/>Your doctor will determine if preventive treatment for chickenpox is appropriate.</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:571px;left:149px;white-space:nowrap" class="ft2694"><b>Latex:&#160;</b>The needle cap of the MYCLIC pen is made from latex (dry natural rubber). Contact&#160;<br/>your doctor before using Enbrel if the needle cap will be handled by, or Enbrel will be given to,&#160;<br/>someone with a known or possible hypersensitivity (allergy) to latex.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft2694"><b>Alcohol abuse</b>: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.&#160;<br/>Please tell your doctor if&#160;you or the child in your care have a history of alcohol abuse.</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:669px;left:149px;white-space:nowrap" class="ft2694"><b>Wegener’s granulomatosis</b>: Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener’s&#160;<br/>granulomatosis,&#160;talk to your doctor.</p>
<p style="position:absolute;top:725px;left:106px;white-space:nowrap" class="ft26914"></p>
<p style="position:absolute;top:727px;left:149px;white-space:nowrap" class="ft2694"><b>Anti-diabetic medicines</b>: Tell your doctor if you or the child have diabetes or are taking&#160;<br/>medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic&#160;<br/>medicine while taking Enbrel.</p>
<p style="position:absolute;top:803px;left:106px;white-space:nowrap" class="ft2691"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft2693"><b>Vaccinations:&#160;</b>If possible, children should be up to date with all vaccinations before using Enbrel.&#160;<br/>Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult&#160;<br/>your doctor before you or the child receive any vaccines.</p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft2694">Enbrel should not normally be used in children with polyarthritis or extended oligoarthritis below the&#160;<br/>age of 2 years, or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12&#160;<br/>years, or in children with psoriasis below the age of 6 years.</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft2691"><b>Other medicines and Enbrel</b></p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft2694">Tell&#160;your&#160;doctor or pharmacist if you or the child are taking,&#160;have recently taken&#160;or might take&#160;any&#160;<br/>other medicines (including anakinra, abatacept or sulfasalazine), even those not prescribed by the<br/>doctor. You or the child should not use Enbrel with medicines that contain the active substance&#160;<br/>anakinra or abatacept.</p>
</div>
<!-- Page 270 -->
<a name="270"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page270-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2700">270</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2701"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2703">Enbrel&#160;should only be used&#160;during pregnancy&#160;if clearly needed.&#160;You should consult your doctor if you<br/>become pregnant,&#160;think you may be pregnant, or are planning to have a baby.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft2703">If you received Enbrel during pregnancy,&#160;your&#160;baby may have a higher risk&#160;of&#160;getting an infection.&#160;In&#160;<br/>addition,&#160;one study&#160;found&#160;more birth defects when the mother had received&#160;Enbrel&#160;in pregnancy,&#160;<br/>compared&#160;with&#160;mothers who had not received Enbrel or other similar medicines (TNF-antagonists),&#160;<br/>but there was no&#160;particular kind of birth defect&#160;reported.&#160;Another study found no increased risk of birth&#160;<br/>defects when the mother had received Enbrel in pregnancy.&#160;Your doctor will help you to decide&#160;<br/>whether the benefits of treatment outweigh the potential risk to your baby.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft2704">Talk to your doctor if you want to breastfeed while on Enbrel treatment.&#160;It&#160;is important that you tell&#160;<br/>your&#160;baby’s doctors and other healthcare professionals about the use of Enbrel during pregnancy and&#160;<br/>breastfeeding before&#160;your&#160;baby receives any vaccine.</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft2701"><b>Driving and using machines</b></p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft2702">The use of Enbrel is not expected to affect&#160;the ability to drive or use machines.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft2701"><b>Enbrel contains sodium</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft2703">This medicine&#160;contains less than 1&#160;mmol sodium (23&#160;mg) per dosage unit, that is to say&#160;essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft2701"><b>3.</b></p>
<p style="position:absolute;top:602px;left:146px;white-space:nowrap" class="ft2701"><b>How to use Enbrel</b></p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft2704">Always use&#160;this medicine&#160;exactly as your doctor has told you.&#160;Check with your doctor if or pharmacist<br/>you are not sure.</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft2702">If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft2704">You have been prescribed a&#160;25&#160;mg strength of Enbrel. A&#160;50&#160;mg strength of Enbrel is available for&#160;<br/>doses of&#160;50&#160;mg.&#160;</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft2701"><b>Dosing for adult patients (aged 18 years or over)</b></p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft2702">Rheumatoid arthritis, psoriatic arthritis,&#160;and&#160;axial spondyloarthritis including&#160;ankylosing spondylitis</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft2704">The usual dose is 25&#160;mg given twice a week or 50&#160;mg&#160;once a week as an injection under the skin.&#160;<br/>However, your doctor may determine an alternative frequency at which to inject Enbrel.&#160;</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft2702">Plaque psoriasis</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft2702">The usual dose is 25&#160;mg twice a week or 50&#160;mg once a&#160;week. &#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft2703">Alternatively, 50&#160;mg&#160;may be given twice a week for up to 12 weeks, followed by 25&#160;mg twice a week&#160;<br/>or 50&#160;mg once a week.&#160;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft2704">Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on&#160;<br/>your response. If Enbrel has no effect on your condition after 12 weeks, your doctor may tell you to&#160;<br/>stop taking this medicine.</p>
</div>
<!-- Page 271 -->
<a name="271"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page271-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2710">271</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2711"><b>Use in children and adolescents</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2714">The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight&#160;<br/>and disease. Your&#160;doctor will determine the correct dose for the child and will prescribe an appropriate&#160;<br/>strength of Enbrel (10&#160;mg, 25&#160;mg or 50&#160;mg).</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft2714">For polyarthritis or extended oligoarthritis in patients from the age of 2 years, or enthesitis-related&#160;<br/>arthritis or psoriatic arthritis in patients from the age of 12 years, the usual dose is 0.4&#160;mg of Enbrel&#160;<br/>per kg bodyweight (up to a maximum of 25&#160;mg) given twice weekly, or 0.8&#160;mg of Enbrel per kg of&#160;<br/>bodyweight (up to a maximum of 50&#160;mg) given once weekly.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft2713">For psoriasis in&#160;patients from the age of 6 years, the usual dose is 0.8&#160;mg of Enbrel per kg bodyweight&#160;<br/>(up to a maximum of 50&#160;mg), and should be given once weekly. If Enbrel has no effect on the child’s&#160;<br/>condition after 12 weeks, your doctor may tell you to stop using this&#160;medicine.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2712">The doctor will provide you with detailed directions for preparing and measuring the appropriate dose.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft2711"><b>Method and route of administration</b></p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft2712">Enbrel is administered by an injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft2712">Enbrel can be taken&#160;with or without food or drink.</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft27123"><b>Detailed instructions on how to inject Enbrel are provided in section 7, “Using the MYCLIC&#160;<br/>pre-filled pen to inject Enbrel”.&#160;</b>Do not mix the Enbrel solution with any other medicine.</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft2713">To help you remember, it may be helpful to&#160;write in a diary which day(s) of the week Enbrel should be&#160;<br/>used.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft2711"><b>If&#160;you use more Enbrel than you should</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft2714">If you have used more Enbrel than you should (either by injecting too much on a single occasion or by&#160;<br/>using it too frequently), talk to a doctor or&#160;pharmacist immediately. Always have the outer carton of&#160;<br/>the medicine with you, even if it is empty.</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft2711"><b>If&#160;you forget to inject Enbrel</b></p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft2713">If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is&#160;<br/>the next day; in which case you should skip the missed dose. Then continue to inject the medicine on&#160;<br/>the usual day(s). If you do not remember until the day that the next injection is due, do not take a&#160;<br/>double dose (two doses on the same day) to make up for a forgotten dose.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft2711"><b>If you stop using Enbrel&#160;</b></p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft2712">Your symptoms may return upon discontinuation.&#160;</p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft2712">If you have any further questions on the use of this&#160;medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft2711"><b>4.</b></p>
<p style="position:absolute;top:1037px;left:146px;white-space:nowrap" class="ft2711"><b>Possible side effects</b></p>
<p style="position:absolute;top:1075px;left:106px;white-space:nowrap" class="ft2712">Like all medicines,&#160;this medicine&#160;can cause side effects, although not everybody gets them.</p>
</div>
<!-- Page 272 -->
<a name="272"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page272-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2720">272</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2721"><b>Allergic reactions</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2723">If any of the following happen, do not inject more Enbrel. Tell your doctor immediately, or go to the&#160;<br/>casualty department at your nearest hospital.</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:204px;left:149px;white-space:nowrap" class="ft2722">Trouble swallowing or breathing</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft2722">Swelling of the face,&#160;throat, hands, or feet</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft2724">Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm&#160;<br/>feeling</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft2722">Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p>
<p style="position:absolute;top:321px;left:106px;white-space:nowrap" class="ft2723">Serious allergic reactions are rare. However, any of the above symptoms may indicate an allergic&#160;<br/>reaction to Enbrel, so you should seek immediate medical attention.</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2721"><b>Serious side effects</b></p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft2722">If you notice any of the following, you or the child may need urgent medical attention.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:455px;left:149px;white-space:nowrap" class="ft2724">Signs of&#160;<b>serious&#160;infections</b>, such as high fever that may be accompanied by cough, shortness of&#160;<br/>breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:494px;left:149px;white-space:nowrap" class="ft2722">Signs of&#160;<b>blood disorders</b>, such as bleeding, bruising, or paleness</p>
<p style="position:absolute;top:513px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:515px;left:149px;white-space:nowrap" class="ft2724">Signs of&#160;<b>nerve disorders</b>, such&#160;as numbness or tingling, changes in vision, eye pain, or onset of&#160;<br/>weakness in an arm or leg</p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:554px;left:149px;white-space:nowrap" class="ft2724">Signs of&#160;<b>heart failure&#160;</b>or&#160;<b>worsening heart failure</b>, such as fatigue or shortness of breath with&#160;<br/>activity, swelling in the ankles, a feeling of fullness in the neck&#160;or abdomen, night-time&#160;<br/>shortness of breath or coughing, bluish colour of the nails or the lips</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:612px;left:149px;white-space:nowrap" class="ft2723"><b>Signs of cancers:&#160;</b>Cancers may affect any part of the body including the skin and blood, and&#160;<br/>possible signs will depend on the type and location of the cancer. These signs may include&#160;<br/>weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or&#160;<br/>growths on the skin</p>
<p style="position:absolute;top:687px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:689px;left:149px;white-space:nowrap" class="ft2724">Signs of&#160;<b>autoimmune reactions&#160;</b>(where antibodies are made that may harm normal tissues in&#160;<br/>the body) such as pain, itching,&#160;weakness, and abnormal breathing, thinking, sensation, or vision</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:728px;left:149px;white-space:nowrap" class="ft2724">Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or&#160;<br/>muscle pain, or fatigue</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:767px;left:149px;white-space:nowrap" class="ft2724">Signs of&#160;<b>inflammation of the blood vessels&#160;</b>such as pain, fever, redness&#160;or warmth of the skin,&#160;<br/>or itching.</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft2724">These are rare or uncommon side effects, but are serious conditions (some of which may rarely be&#160;<br/>fatal). If these signs occur, tell your doctor immediately, or visit the casualty department at your&#160;<br/>nearest hospital.</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft2722">The known side effects of Enbrel include the following in groups of decreasing frequency:</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:939px;left:149px;white-space:nowrap" class="ft2724"><b>Very common&#160;</b>(may affect more than 1 in 10&#160;people):<br/>Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections);&#160;<br/>injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling) (these&#160;<br/>do not occur as often after the first month of treatment; some patients have developed a reaction&#160;<br/>at an injection site that was&#160;recently&#160;used); and headache.</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft27214"></p>
<p style="position:absolute;top:1054px;left:149px;white-space:nowrap" class="ft2724"><b>Common&#160;</b>(may affect up to 1 in 10&#160;people):<br/>Allergic reactions; fever;&#160;rash;&#160;itching; antibodies directed against normal tissue (autoantibody&#160;<br/>formation).</p>
</div>
<!-- Page 273 -->
<a name="273"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page273-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2730">273</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft27314"></p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft2733"><b>Uncommon&#160;</b>(may affect up to 1 in 100&#160;people):<br/>Serious infections (including pneumonia, deep skin infections, joint infections, blood infection,&#160;<br/>and infections at various sites);&#160;worsening of congestive heart failure;&#160;low red blood cell count,&#160;<br/>low white blood cell count, low neutrophil (a type of white&#160;blood cell) count;&#160;low blood platelet&#160;<br/>count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives&#160;<br/>(elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or&#160;<br/>worsening); inflammation of the blood vessels affecting multiple organs;&#160;elevated liver blood&#160;<br/>tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood&#160;<br/>tests is common);&#160;abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs&#160;<br/>of&#160;bowel problems).</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft27314"></p>
<p style="position:absolute;top:319px;left:149px;white-space:nowrap" class="ft2734"><b>Rare&#160;</b>(may affect up to 1 in 1,000&#160;people):<br/>Serious allergic reactions (including severe localised swelling of the skin and wheezing);&#160;<br/>lymphoma (a type of blood cancer);&#160;leukaemia (cancer affecting the blood and bone marrow);<br/>melanoma (a&#160;type of skin cancer); combined low platelet, red, and white blood cell count;&#160;<br/>nervous system disorders (with severe muscle weakness and signs and symptoms similar to&#160;<br/>those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord);&#160;<br/>tuberculosis;&#160;new onset&#160;congestive heart failure; seizures; lupus or lupus-like syndrome&#160;<br/>(symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may&#160;<br/>lead to severe blistering and peeling of the skin;&#160;lichenoid reactions (itchy reddish-purple skin&#160;<br/>rash and/or threadlike white-grey lines on mucous membranes);&#160;inflammation of the liver&#160;<br/>caused by the body's own immune system (autoimmune hepatitis;&#160;in patients also receiving&#160;<br/>methotrexate treatment, the frequency is uncommon);&#160;immune disorder that can affect the lungs,&#160;<br/>skin and lymph nodes (sarcoidosis);&#160;inflammation or scarring of the lungs&#160;(in patients also&#160;<br/>receiving methotrexate treatment, the frequency&#160;of&#160;inflammation or scarring of the lungs is&#160;<br/>uncommon).</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft27314"></p>
<p style="position:absolute;top:624px;left:149px;white-space:nowrap" class="ft2734"><b>Very rare&#160;</b>(may affect up to 1 in 10,000&#160;people): failure of the bone marrow to produce crucial&#160;<br/>blood cells.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft27314"></p>
<p style="position:absolute;top:682px;left:149px;white-space:nowrap" class="ft2734"><b>Not known&#160;</b>(frequency cannot be estimated from the available data): Merkel cell carcinoma (a&#160;<br/>type of skin cancer);&#160;Kaposi’s sarcoma (a rare cancer related to infection with human herpes&#160;<br/>virus 8. Kaposi’s sarcoma most commonly appear as purple lesions on the skin);&#160;excessive&#160;<br/>activation of white blood cells associated with inflammation (macrophage activation&#160;<br/>syndrome);&#160;recurrence of hepatitis B (a liver infection);&#160;worsening of a condition called&#160;<br/>dermatomyositis (muscle inflammation and weakness&#160;with&#160;an&#160;accompanying&#160;skin rash).</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft2731"><b>Additional side effects in children and adolescents</b></p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft2734">The side effects and their frequencies seen in children and adolescents are similar to&#160;those described&#160;<br/>above.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft2731"><b>Reporting of side effects</b></p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft2734">If you get any side effects, talk to your doctor&#160;or&#160;pharmacist.&#160;This includes any possible&#160;side effects&#160;<br/>not listed in this leaflet.&#160;You can also report side&#160;effects directly&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>. By reporting side effects you&#160;can help provide more information on the safety of&#160;<br/>this medicine.</p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft2731"><b>5.</b></p>
<p style="position:absolute;top:1061px;left:146px;white-space:nowrap" class="ft2731"><b>How to store Enbrel</b></p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft2732">Keep&#160;this medicine&#160;out of the sight and reach of children.</p>
<p style="position:absolute;top:1137px;left:106px;white-space:nowrap" class="ft2734">Do not use&#160;this medicine&#160;after the expiry date which is stated on the carton and on the MYCLIC pre-<br/>filled pen after EXP. The expiry date refers to the last day of that month.</p>
</div>
<!-- Page 274 -->
<a name="274"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page274-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2740">274</p>
<p style="position:absolute;top:128px;left:106px;white-space:nowrap" class="ft2742">Store in a refrigerator (2</p>
<p style="position:absolute;top:126px;left:267px;white-space:nowrap" class="ft27414">&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft2742">Keep the pre-filled pens in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft2743">After taking a pre-filled pen&#160;from the refrigerator,&#160;<b>wait&#160;approximately 15-30 minutes to allow the&#160;<br/>Enbrel solution&#160;in the pen&#160;to reach room temperature</b>. Do not warm in any other way.&#160;Immediate&#160;<br/>use is then recommended. &#160;</p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft2742">Enbrel may be stored outside of the refrigerator at temperatures up to a maximum of 25</p>
<p style="position:absolute;top:260px;left:684px;white-space:nowrap" class="ft27414">C&#160;for a single&#160;</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft2744">period of up to four weeks; after which, it should not be refrigerated again. Enbrel should be discarded&#160;<br/>if not used within four weeks after removal from the refrigerator. It is recommended that you record&#160;<br/>the date that Enbrel is removed from&#160;the refrigerator and the date after which Enbrel should be&#160;<br/>discarded (no more than 4 weeks following the removal from the refrigerator).</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft2743">Inspect the solution in the pen by looking through the clear inspection window.&#160;The solution should be&#160;<br/>clear&#160;or slightly opalescent, colourless&#160;to&#160;pale yellow&#160;or pale brown, and&#160;may&#160;contain small white or&#160;<br/>almost transparent particles of protein.&#160;This appearance is normal for Enbrel. Do not use the solution if&#160;<br/>it is discoloured, cloudy,&#160;or if particles other than those described above are present. If you are&#160;<br/>concerned with the appearance of the solution, then contact your pharmacist for assistance.</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft2743">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to&#160;<br/>throw away&#160;medicines&#160;you&#160;no longer&#160;use. These measures will help protect the environment.</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft2741"><b>6.</b></p>
<p style="position:absolute;top:566px;left:146px;white-space:nowrap" class="ft2741"><b>Contents of the pack and other information&#160;</b></p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft2741"><b>What Enbrel contains</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft2744">The active substance in Enbrel is etanercept. Each MYCLIC pre-filled pen contains&#160;25&#160;mg of&#160;<br/>etanercept. &#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft2744">The other ingredients are sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate&#160;<br/>monobasic dihydrate and sodium phosphate dibasic dihydrate, and water for injections.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft2741"><b>What Enbrel looks like and contents of the pack</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft2743">Enbrel is supplied as a solution for injection in a pre-filled pen (MYCLIC) (solution for injection). The&#160;<br/>MYCLIC pen contains a clear, colourless&#160;to&#160;pale yellow&#160;or pale brown&#160;solution for injection.&#160;Each&#160;<br/>pack&#160;contains&#160;4,&#160;8&#160;or&#160;24&#160;pens and&#160;4,&#160;8 or 24&#160;alcohol swabs. Not all pack sizes may be marketed.</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft2741"><b>Marketing Authorisation Holder and Manufacturer</b></p>
<p style="position:absolute;top:907px;left:114px;white-space:nowrap" class="ft2744"><i>Marketing Authorisation Holder:<br/></i>Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:1021px;left:114px;white-space:nowrap" class="ft2743"><i>Manufacturer:<br/></i>Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
</div>
<!-- Page 275 -->
<a name="275"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page275-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2750">275</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2754">For any information about this medicinal product, please contact the local representative of the&#160;<br/>Marketing Authorisation Holder.</p>
<p style="position:absolute;top:165px;left:114px;white-space:nowrap" class="ft2754"><b>België/Belgique/Belgien<br/>Luxembourg/Luxemburg<br/></b>Pfizer&#160;NV/SA<br/>Tél/Tel: +32 (0)2 554 62 11</p>
<p style="position:absolute;top:165px;left:452px;white-space:nowrap" class="ft2758"><b>Kύπρος<br/></b>PFIZER EΛΛAΣ&#160;A.E. (CYPRUS BRANCH)&#160;<br/>T</p>
<p style="position:absolute;top:202px;left:462px;white-space:nowrap" class="ft27514">: +357 22 817690</p>
<p style="position:absolute;top:260px;left:114px;white-space:nowrap" class="ft2753"><b>Česká Republika<br/></b>Pfizer, spol.&#160;s&#160;r.o.<br/>Tel: +420-283-004-111</p>
<p style="position:absolute;top:260px;left:452px;white-space:nowrap" class="ft2753"><b>Magyarország<br/></b>Pfizer Kft.<br/>Tel: +36 1 488 3700</p>
<p style="position:absolute;top:335px;left:114px;white-space:nowrap" class="ft2754"><b>Danmark<br/></b>Pfizer ApS<br/>Tlf: +45 44&#160;201&#160;100</p>
<p style="position:absolute;top:335px;left:452px;white-space:nowrap" class="ft2754"><b>Malta<br/></b>Vivian Corporation Ltd.<br/>Tel: +35621 344610</p>
<p style="position:absolute;top:411px;left:114px;white-space:nowrap" class="ft2754"><b>Deutschland<br/></b>Pfizer Pharma GmbH<br/>Tel: +49 (0)30 550055-51000</p>
<p style="position:absolute;top:411px;left:452px;white-space:nowrap" class="ft2754"><b>Nederland<br/></b>Pfizer bv<br/>Tel: +31 (0)800 63 34 636</p>
<p style="position:absolute;top:489px;left:114px;white-space:nowrap" class="ft2753"><b>България<br/></b>Пфайзер Люксембург САРЛ,&#160;<br/>Клон България<br/>Teл:&#160;+359 2 970 4333</p>
<p style="position:absolute;top:489px;left:452px;white-space:nowrap" class="ft2754"><b>Norge<br/></b>Pfizer AS<br/>Tlf: +47 67&#160;52&#160;61&#160;00</p>
<p style="position:absolute;top:584px;left:114px;white-space:nowrap" class="ft2754"><b>Eesti<br/></b>Pfizer Luxembourg SARL Eesti filiaal<br/>Tel:&#160;+372 666 7500</p>
<p style="position:absolute;top:584px;left:452px;white-space:nowrap" class="ft2754"><b>Österreich<br/></b>Pfizer Corporation Austria Ges.m.b.H.<br/>Tel: +43 (0)1 521 15-0</p>
<p style="position:absolute;top:660px;left:114px;white-space:nowrap" class="ft2754"><b>Ελλάδα<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.<br/>Τηλ.: +30 210 67 85 800</p>
<p style="position:absolute;top:660px;left:452px;white-space:nowrap" class="ft2754"><b>Polska<br/></b>Pfizer Polska Sp. z o.o.<br/>Tel.:&#160;+48 22 335 61 00</p>
<p style="position:absolute;top:745px;left:114px;white-space:nowrap" class="ft2754"><b>España<br/></b>Pfizer, S.L.<br/>Télf: +34 91 490 99 00</p>
<p style="position:absolute;top:745px;left:452px;white-space:nowrap" class="ft2754"><b>Portugal<br/></b>Laboratórios Pfizer, Lda.<br/>Tel: (+351) 21 423 55 00</p>
<p style="position:absolute;top:827px;left:114px;white-space:nowrap" class="ft2754"><b>France<br/></b>Pfizer<br/>Tél&#160;+33 (0)1 58 07 34 40</p>
<p style="position:absolute;top:827px;left:452px;white-space:nowrap" class="ft2754"><b>România<br/></b>Pfizer Romania S.R.L<br/>Tel: +40 (0) 21 207 28 00</p>
<p style="position:absolute;top:902px;left:114px;white-space:nowrap" class="ft2753"><b>Hrvatska<br/></b>Pfizer Croatia&#160;d.o.o.<br/>Tel: +385 1 3908 777</p>
<p style="position:absolute;top:902px;left:452px;white-space:nowrap" class="ft2754"><b>Slovenija<br/></b>Pfizer Luxembourg SARL<i>,&#160;</i>Pfizer, podružnica&#160;<br/>za&#160;svetovanje s področja farmacevtske&#160;<br/>dejavnosti, Ljubljana<br/>Tel: +386 (0)1 52 11 400</p>
<p style="position:absolute;top:1016px;left:114px;white-space:nowrap" class="ft2754"><b>Ireland<br/></b>Pfizer Healthcare Ireland<br/>Tel: +1800 633 363 (toll free)<br/>Tel: +44 (0)1304 616161</p>
<p style="position:absolute;top:1016px;left:452px;white-space:nowrap" class="ft2754"><b>Slovenská Republika<br/></b>Pfizer Luxembourg SARL, organizačná zložka&#160;<br/>Tel: +421 2 3355 5500</p>
</div>
<!-- Page 276 -->
<a name="276"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page276-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2760">276</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft2764"><b>Ísland<br/></b>Icepharma&#160;hf.<br/>Tel: +354&#160;540 8000</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft2764"><b>Suomi/Finland<br/></b>Pfizer Oy<br/>Puh/Tel: +358 (0)9&#160;430 040</p>
<p style="position:absolute;top:187px;left:114px;white-space:nowrap" class="ft2763"><b>Italia<br/></b>Pfizer S.r.l.<br/>Tel: +39 06 33 18 21</p>
<p style="position:absolute;top:187px;left:452px;white-space:nowrap" class="ft2763"><b>Sverige&#160;<br/></b>Pfizer AB<br/>Tel: +46&#160;(0)8&#160;550&#160;520 00</p>
<p style="position:absolute;top:267px;left:114px;white-space:nowrap" class="ft2764"><b>Latvija<br/></b>Pfizer Luxembourg SARL filiāle Latvijā<br/>Tel. +371 67035775</p>
<p style="position:absolute;top:267px;left:452px;white-space:nowrap" class="ft2764"><b>United Kingdom&#160;(Northern Ireland)<br/></b>Pfizer Limited<br/>Tel:&#160;+44 (0)1304 616161</p>
<p style="position:absolute;top:347px;left:114px;white-space:nowrap" class="ft2763"><b>Lietuva<br/></b>Pfizer Luxembourg SARL filialas Lietuvoje<br/>Tel. +3705 2514000</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2761"><b>This leaflet was last&#160;revised in</b></p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft2764">Detailed information on this&#160;medicine&#160;is available on the European Medicines Agency web&#160;site:<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft2761"><b>7.</b></p>
<p style="position:absolute;top:559px;left:146px;white-space:nowrap" class="ft2761"><b>Using the MYCLIC pre-filled pen to inject Enbrel</b></p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft2762">This section is divided into&#160;the following subsections:</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft27624"><b>Introduction<br/>Step 1: Preparing for an Enbrel injection<br/>Step 2: Choosing an injection site<br/>Step 3: Injecting the Enbrel solution<br/>Step 4: Disposing of the used MYCLIC pen</b></p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft2761"><b>Introduction</b></p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft2764">The instructions below explain how to use&#160;the MYCLIC pen to inject Enbrel. Please read the&#160;<br/>instructions carefully, and follow them step by step. Your doctor or nurse will tell you how to inject&#160;<br/>Enbrel. Do not attempt to administer an injection until you are sure that you understand how to use the&#160;<br/>MYCLIC&#160;pen properly. If you have questions&#160;about how to inject, please ask your doctor or nurse for&#160;<br/>help.</p>
<p style="position:absolute;top:1120px;left:106px;white-space:nowrap" class="ft2761"><b>Step 1: Preparing for an Enbrel injection</b></p>
<p style="position:absolute;top:1158px;left:106px;white-space:nowrap" class="ft2762">1.</p>
<p style="position:absolute;top:1158px;left:147px;white-space:nowrap" class="ft2762">Select a clean, well-lit, flat surface.</p>
</div>
<!-- Page 277 -->
<a name="277"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page277-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2770">277</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2772">2.</p>
<p style="position:absolute;top:108px;left:147px;white-space:nowrap" class="ft2772">Gather the items that you will need for your injection, and place them on the chosen surface:</p>
<p style="position:absolute;top:140px;left:214px;white-space:nowrap" class="ft2772">a.</p>
<p style="position:absolute;top:140px;left:255px;white-space:nowrap" class="ft2772">One MYCLIC pre-filled pen&#160;and&#160;one alcohol swab&#160;(take these from the carton&#160;</p>
<p style="position:absolute;top:159px;left:257px;white-space:nowrap" class="ft2772">of pens you keep in your refrigerator). Do not shake the pen.</p>
<p style="position:absolute;top:192px;left:214px;white-space:nowrap" class="ft2772">b.</p>
<p style="position:absolute;top:192px;left:255px;white-space:nowrap" class="ft2772">One cotton ball or gauze&#160;</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft2772">3.</p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft2773"><b>Check&#160;the expiry date (month/year) on the pen</b>. If the date&#160;has passed, do not use the pen and&#160;<br/>contact your pharmacist for assistance.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2772">4.</p>
<p style="position:absolute;top:276px;left:149px;white-space:nowrap" class="ft2773">Inspect the solution in the pen by looking through the clear inspection window. The solution&#160;<br/>should be clear or slightly opalescent, colourless&#160;to&#160;pale yellow&#160;or pale brown, and&#160;may contain&#160;<br/>small white or almost transparent&#160;particles of protein.&#160;This appearance is normal for Enbrel. Do&#160;<br/>not use the solution if it is discoloured, cloudy,&#160;or if particles other than those described above&#160;<br/>are present. If you are concerned with the appearance of the solution, then contact your&#160;<br/>pharmacist for assistance.</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft2772">5.</p>
<p style="position:absolute;top:403px;left:149px;white-space:nowrap" class="ft2773"><b>Leave the white needle cap in place and wait&#160;approximately 15-30 minutes&#160;</b>to allow the&#160;<br/>Enbrel solution&#160;in the pen to reach room temperature. Waiting until the solution reaches room&#160;<br/>temperature may make the injection more comfortable for you. Do not warm in any other way.<br/><b>Always leave the pen out of sight and reach of children.</b></p>
<p style="position:absolute;top:492px;left:106px;white-space:nowrap" class="ft2774">Whilst waiting for the solution in the pen to reach room temperature, read Step 2 (below), and choose&#160;<br/>an injection site.</p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft2771"><b>Step 2: Choosing an injection site (see&#160;Diagram 2)</b></p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft2772">1.</p>
<p style="position:absolute;top:587px;left:147px;white-space:nowrap" class="ft2772">The recommended injection site is the middle of the front of the thighs. If you prefer, you may&#160;</p>
<p style="position:absolute;top:606px;left:149px;white-space:nowrap" class="ft2774">alternatively use the stomach area, but make sure you choose a site at least 5 cm away from the&#160;<br/>belly button (navel). If someone else is giving you the injection, the outer area of the upper arms&#160;<br/>may also be used.</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft2772">2.</p>
<p style="position:absolute;top:969px;left:147px;white-space:nowrap" class="ft2772">Each injection should be given at least 3&#160;cm from where you last injected. Do not inject into&#160;</p>
<p style="position:absolute;top:988px;left:149px;white-space:nowrap" class="ft2773">tender, bruised or hard skin. Avoid scars or stretch marks. (It may be helpful to keep notes on&#160;<br/>the location of the previous injections.)</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft2772">3.</p>
<p style="position:absolute;top:1039px;left:147px;white-space:nowrap" class="ft2772">If&#160;you have psoriasis, you should try not to inject directly into any raised, thick, red, or scaly&#160;</p>
<p style="position:absolute;top:1058px;left:149px;white-space:nowrap" class="ft2772">skin.</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft2771"><b>Step 3: Injecting the Enbrel solution</b></p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft2772">1.</p>
<p style="position:absolute;top:1134px;left:147px;white-space:nowrap" class="ft2772">After waiting&#160;approximately 15-30 minutes for the solution in the pen to warm to room&#160;</p>
<p style="position:absolute;top:1153px;left:149px;white-space:nowrap" class="ft2772">temperature, wash your hands with soap and water.</p>
</div>
<!-- Page 278 -->
<a name="278"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page278-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2780">278</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2782">2.</p>
<p style="position:absolute;top:108px;left:147px;white-space:nowrap" class="ft2782">Clean the injection site with the alcohol swab using a circular motion, and allow it to dry.&#160;Do not&#160;</p>
<p style="position:absolute;top:127px;left:149px;white-space:nowrap" class="ft2782">touch this area again before injecting.</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft2782">3.</p>
<p style="position:absolute;top:159px;left:147px;white-space:nowrap" class="ft2782">Pick up the pen, and remove the white needle cap by pulling it straight off (see Diagram 3). To&#160;</p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft2783">avoid damaging the needle inside the pen, do&#160;not bend the white needle cap while you are&#160;<br/>removing it, and do not re-attach it once it has been removed.&#160;After removal of the needle cap, you&#160;<br/>will see a purple needle safety shield extending slightly from the end of the pen. The needle will&#160;<br/>remain protected inside the pen until the pen is activated.&#160;Do not use the pen if it is dropped with&#160;<br/>the needle cap off.</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft2782">4.</p>
<p style="position:absolute;top:643px;left:147px;white-space:nowrap" class="ft2782">Lightly pinching the skin&#160;around the injection site&#160;between the thumb and index finger of your free&#160;</p>
<p style="position:absolute;top:662px;left:149px;white-space:nowrap" class="ft2782">hand may make the injection easier and more comfortable.</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft2782">5.</p>
<p style="position:absolute;top:694px;left:147px;white-space:nowrap" class="ft2782">Hold the pen at a right angle&#160;(90º) to the injection site<b>.&#160;Push the open end of the pen firmly&#160;</b></p>
<p style="position:absolute;top:713px;left:149px;white-space:nowrap" class="ft2783"><b>against the skin</b>, so that the needle safety shield is pushed completely inside of the pen. A slight&#160;<br/>depression in the skin will be seen (see Diagram 4).&#160;The pen can only be activated when the&#160;<br/>needle shield is completely pushed inside the pen.</p>
<p style="position:absolute;top:1106px;left:106px;white-space:nowrap" class="ft2782">6.</p>
<p style="position:absolute;top:1106px;left:147px;white-space:nowrap" class="ft2782">Whilst pushing the pen&#160;<b>firmly&#160;</b>against the skin to ensure that the needle safety shield is fully&#160;</p>
<p style="position:absolute;top:1125px;left:149px;white-space:nowrap" class="ft2783">depressed inside the pen,&#160;<b>press&#160;the centre of&#160;the&#160;grey&#160;button&#160;</b>on top of the pen with your&#160;<br/>thumb to start the injection (see Diagram 5). On pressing the&#160;centre of&#160;the&#160;button, you will hear&#160;</p>
</div>
<!-- Page 279 -->
<a name="279"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page279-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2790">279</p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft2794">a click.&#160;<b>Continue to hold the pen firmly against your skin until&#160;you hear a second click,&#160;</b>or&#160;<br/>until 10&#160;seconds after the first click (whichever happens first).&#160;</p>
<p style="position:absolute;top:165px;left:149px;white-space:nowrap" class="ft2793">Note&#160;–&#160;If&#160;you are unable to start the injection as described, press the pen more firmly against&#160;<br/>your skin, then press the&#160;grey&#160;button again.</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft2792">7.</p>
<p style="position:absolute;top:540px;left:147px;white-space:nowrap" class="ft2792">On hearing the second ‘click’ (or, if you do not hear a second ‘click’, after 10&#160;seconds have&#160;</p>
<p style="position:absolute;top:559px;left:149px;white-space:nowrap" class="ft2793">passed), your injection will be complete (see&#160;Diagram 6). You may now lift the pen from your&#160;<br/>skin (see&#160;Diagram 7). As you lift the pen, the purple needle safety shield will automatically&#160;<br/>extend to cover the needle.</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft2792">8.</p>
<p style="position:absolute;top:1062px;left:147px;white-space:nowrap" class="ft2792">The pen’s inspection window should now be completely purple, confirming that the dose has&#160;</p>
<p style="position:absolute;top:1082px;left:149px;white-space:nowrap" class="ft2794">been injected correctly&#160;(see Diagram 8). If the window is not completely purple, contact your&#160;<br/>nurse or pharmacist for assistance, since the pen may not have injected the Enbrel solution&#160;<br/>completely. Do not try to use the pen again, and do not try to use another pen without agreement&#160;<br/>from your nurse or pharmacist.</p>
</div>
<!-- Page 280 -->
<a name="280"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page280-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2800">280</p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft2802">9.</p>
<p style="position:absolute;top:386px;left:147px;white-space:nowrap" class="ft2802">If you notice a spot of blood at the injection site, you should press the cotton ball or gauze over&#160;</p>
<p style="position:absolute;top:405px;left:149px;white-space:nowrap" class="ft2802">the injection site for 10 seconds. Do not rub the injection site.&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft28023"><b>Step 4: Disposing of the used MYCLIC pen<br/></b>&#160;The pen should be used once only&#160;-&#160;it should&#160;never&#160;be re-used. Dispose of the used pen as&#160;</p>
<p style="position:absolute;top:482px;left:133px;white-space:nowrap" class="ft2802">instructed by your doctor, nurse or pharmacist.&#160;Do not attempt to recap the pen.</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft28023"><b>If&#160;you have any questions, please talk to a doctor, nurse or pharmacist who is familiar with&#160;<br/>Enbrel.</b></p>
</div>
<!-- Page 281 -->
<a name="281"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page281-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2810">281</p>
<p style="position:absolute;top:108px;left:298px;white-space:nowrap" class="ft2811"><b>Package Leaflet: Information for the User</b></p>
<p style="position:absolute;top:146px;left:265px;white-space:nowrap" class="ft2811"><b>Enbrel&#160;50&#160;mg&#160;solution for injection in pre-filled pen</b></p>
<p style="position:absolute;top:165px;left:413px;white-space:nowrap" class="ft2812">etanercept</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft28123"><b>Read all of this leaflet carefully before you start using this medicine&#160;because it contains&#160;<br/>important information for you.</b></p>
<p style="position:absolute;top:240px;left:123px;white-space:nowrap" class="ft28114"></p>
<p style="position:absolute;top:242px;left:162px;white-space:nowrap" class="ft2812">Keep&#160;this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:260px;left:123px;white-space:nowrap" class="ft28114"></p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft2812">Your doctor will also give you a Patient Card, which contains important safety information that&#160;</p>
<p style="position:absolute;top:281px;left:164px;white-space:nowrap" class="ft2812">you need to be aware of before and during treatment with Enbrel.</p>
<p style="position:absolute;top:299px;left:123px;white-space:nowrap" class="ft28114"></p>
<p style="position:absolute;top:301px;left:162px;white-space:nowrap" class="ft2812">If you&#160;have&#160;any further questions, ask your doctor,&#160;pharmacist&#160;or nurse.</p>
<p style="position:absolute;top:319px;left:123px;white-space:nowrap" class="ft28114"></p>
<p style="position:absolute;top:321px;left:162px;white-space:nowrap" class="ft2812">This medicine has been prescribed for you&#160;or a child in your care. Do not pass it on to others. It&#160;</p>
<p style="position:absolute;top:340px;left:164px;white-space:nowrap" class="ft2814">may harm them, even if their&#160;signs of illness&#160;are the same as yours&#160;or those of the child you are&#160;<br/>caring for.</p>
<p style="position:absolute;top:378px;left:123px;white-space:nowrap" class="ft28114"></p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft2812">If you&#160;get&#160;any side effects,&#160;talk to&#160;your doctor or pharmacist.&#160;This includes any possible side&#160;</p>
<p style="position:absolute;top:398px;left:164px;white-space:nowrap" class="ft2812">effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft2811"><b>What is in this leaflet</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2812">Information in this leaflet is organised under the following 7 sections:</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft2812">1.</p>
<p style="position:absolute;top:512px;left:149px;white-space:nowrap" class="ft2812">What Enbrel is and what it is&#160;used for</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft2812">2.</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft2812">What you need to know before you use Enbrel</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft2812">3.</p>
<p style="position:absolute;top:550px;left:149px;white-space:nowrap" class="ft2812">How to use Enbrel</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft2812">4.</p>
<p style="position:absolute;top:569px;left:149px;white-space:nowrap" class="ft2812">Possible side effects</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft2812">5.</p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft2812">How to store Enbrel</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft2812">6.</p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft2812">Contents of the pack and other information</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft2812">7.</p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft2812">Using the MYCLIC pre-filled pen to inject Enbrel (See overleaf)</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft2811"><b>1.</b></p>
<p style="position:absolute;top:683px;left:146px;white-space:nowrap" class="ft2811"><b>What Enbrel&#160;is and what it is used for</b></p>
<p style="position:absolute;top:721px;left:106px;white-space:nowrap" class="ft2814">Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in&#160;<br/>the body that causes inflammation. Enbrel works by reducing the inflammation associated with certain&#160;<br/>diseases.</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft2814">In adults (aged 18 and over), Enbrel can be used for moderate or severe&#160;<b>rheumatoid arthritis</b>,&#160;<br/><b>psoriatic arthritis</b>, severe&#160;<b>axial spondyloarthritis&#160;</b>including&#160;<b>ankylosing spondylitis,&#160;</b>and moderate&#160;<br/>or severe&#160;<b>psoriasis&#160;</b>–&#160;in each case usually when other widely used treatments have not worked well&#160;<br/>enough or are not suitable for you.</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft2814">For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may&#160;<br/>also be used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in&#160;<br/>combination with methotrexate, Enbrel can slow down the damage to your joints caused by the&#160;<br/>rheumatoid arthritis and improve your ability to do normal daily activities.</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft2814">For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do&#160;<br/>normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands,&#160;<br/>wrists and feet), Enbrel can slow down the structural damage to those joints&#160;caused by the disease.&#160;</p>
</div>
<!-- Page 282 -->
<a name="282"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page282-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2820">282</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2822">Enbrel is also prescribed for the treatment of the following diseases in children and adolescents</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:147px;left:147px;white-space:nowrap" class="ft2822">For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft2822">worked well enough or is not&#160;suitable for them:</p>
<p style="position:absolute;top:203px;left:214px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:205px;left:255px;white-space:nowrap" class="ft2822">Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis&#160;</p>
<p style="position:absolute;top:224px;left:257px;white-space:nowrap" class="ft2822">in patients from the age of 2 years</p>
<p style="position:absolute;top:261px;left:214px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:263px;left:255px;white-space:nowrap" class="ft2822">Psoriatic arthritis in patients from the age of 12 years</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:302px;left:147px;white-space:nowrap" class="ft2822">For enthesitis-related arthritis in patients from the age&#160;of 12 years when other widely used&#160;</p>
<p style="position:absolute;top:321px;left:149px;white-space:nowrap" class="ft2822">treatments have not worked well enough or are not suitable for them</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:360px;left:147px;white-space:nowrap" class="ft2822">Severe psoriasis in patients from the age of&#160;6&#160;years who have had an inadequate response to (or&#160;</p>
<p style="position:absolute;top:379px;left:149px;white-space:nowrap" class="ft2822">are unable to take) phototherapies or other systemic&#160;therapies.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft2821"><b>2.</b></p>
<p style="position:absolute;top:436px;left:146px;white-space:nowrap" class="ft2821"><b>What you need to know before you use Enbrel&#160;</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft2821"><b>Do not use Enbrel</b></p>
<p style="position:absolute;top:511px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:513px;left:147px;white-space:nowrap" class="ft2823">if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of&#160;<br/>Enbrel&#160;(listed in section 6). If you or the child experience allergic reactions such as chest&#160;<br/>tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor&#160;<br/>immediately.</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:590px;left:147px;white-space:nowrap" class="ft2824">if you or the child have, or are at risk of developing a serious blood infection called sepsis. If&#160;<br/>you are not sure, please contact your doctor.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:630px;left:147px;white-space:nowrap" class="ft2822">if you or the child have an infection of any kind. If you are not sure, please talk to your doctor.</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft2821"><b>Warnings and precautions&#160;</b></p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft2822">Talk to your doctor before taking Enbrel.</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:745px;left:149px;white-space:nowrap" class="ft2824"><b>Allergic reactions</b>: If you or the child experience allergic reactions&#160;such as chest tightness,&#160;<br/>wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:782px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:784px;left:149px;white-space:nowrap" class="ft2824"><b>Infections/surgery</b>: If you or the child develop a new infection, or are about to have any major&#160;<br/>surgery, your doctor may wish to monitor&#160;the treatment with Enbrel.</p>
<p style="position:absolute;top:821px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft2824"><b>Infections/diabetes:&#160;</b>Tell your doctor if you or the child have a history of recurrent infections or&#160;<br/>suffer from diabetes or other conditions that increase the risk of infection.</p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:862px;left:147px;white-space:nowrap" class="ft2821"><b>Infections/monitoring:&#160;</b>Tell your doctor of any recent travel outside the European region. If you&#160;</p>
<p style="position:absolute;top:881px;left:149px;white-space:nowrap" class="ft2823">or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor&#160;<br/>immediately. Your doctor may decide to continue to monitor you or the child for the presence of&#160;<br/>infections after&#160;you or the child stop using Enbrel.</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:939px;left:147px;white-space:nowrap" class="ft2821"><b>Tuberculosis:&#160;</b>As cases of tuberculosis have been reported in patients treated with Enbrel, your&#160;</p>
<p style="position:absolute;top:958px;left:149px;white-space:nowrap" class="ft2824">doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may&#160;<br/>include a thorough medical history, a chest X-ray and a tuberculin test. The conduct of these&#160;<br/>tests should be recorded on the Patient Card. It is very important that you tell your doctor if you&#160;<br/>or the child have ever had tuberculosis, or have been in close contact with someone who has had&#160;<br/>tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft28214"></p>
<p style="position:absolute;top:1073px;left:147px;white-space:nowrap" class="ft2821"><b>Hepatitis B:&#160;</b>Tell your&#160;doctor if you or the child have or have&#160;ever had hepatitis B.&#160;Your doctor&#160;</p>
<p style="position:absolute;top:1092px;left:149px;white-space:nowrap" class="ft2824">should test&#160;for the presence of hepatitis B infection before you or the child begin treatment with&#160;<br/>Enbrel.&#160;Treatment with Enbrel may result in reactivation of hepatitis B in patients who have&#160;<br/>previously been infected with&#160;the hepatitis B virus. If this occurs, you should stop using Enbrel.</p>
</div>
<!-- Page 283 -->
<a name="283"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page283-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2830">283</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:109px;left:147px;white-space:nowrap" class="ft2831"><b>Hepatitis C:&#160;</b>Tell your doctor if you or the child have hepatitis C. Your doctor may wish to&#160;</p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft2832">monitor the treatment with Enbrel in case the infection worsens.</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft2833"><b>Blood disorders:&#160;</b>Seek medical&#160;advice immediately if you or the child have any signs or&#160;<br/>symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms&#160;<br/>may point to the existence of potentially life-threatening blood disorders, which may require&#160;<br/>discontinuation of Enbrel.</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:225px;left:147px;white-space:nowrap" class="ft2833"><b>Nervous system and eye disorders:&#160;</b>Tell your doctor if you or the child have multiple sclerosis,&#160;<br/>optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of&#160;<br/>the spinal cord). Your doctor will determine if&#160;Enbrel is an appropriate treatment.</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:283px;left:147px;white-space:nowrap" class="ft2834"><b>Congestive heart failure:&#160;</b>Tell your doctor if you or the child have a history of congestive heart&#160;<br/>failure, because Enbrel needs to be used with caution under these circumstances.</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:322px;left:147px;white-space:nowrap" class="ft2834"><b>Cancer:&#160;</b>Tell your doctor if you have or&#160;have ever had lymphoma (a type of blood cancer) or&#160;<br/>any other cancer before you are given Enbrel.<br/>Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at&#160;<br/>higher than average risk of developing lymphoma.<br/>Children and adults taking Enbrel may have an increased risk of developing lymphoma or&#160;<br/>another cancer.<br/>Some children and teenage patients who have received Enbrel or other medicines that work the&#160;<br/>same way as Enbrel have developed cancers, including unusual types, which sometimes resulted&#160;<br/>in death.<br/>Some patients receiving Enbrel have developed skin cancers.&#160;Tell&#160;your doctor if you or the child&#160;<br/>develop any change in the appearance of the skin&#160;or growths on the skin.</p>
<p style="position:absolute;top:530px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:532px;left:147px;white-space:nowrap" class="ft2834"><b>Chickenpox:&#160;</b>Tell your doctor if you or the child are exposed to chickenpox when using Enbrel.&#160;<br/>Your doctor will determine if preventive treatment for chickenpox is appropriate.</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:571px;left:147px;white-space:nowrap" class="ft2834"><b>Latex:&#160;</b>The needle cap of the MYCLIC pen is made from latex (dry natural rubber). Contact&#160;<br/>your doctor before using Enbrel if the needle cap&#160;will be handled by, or Enbrel will be given to,&#160;<br/>someone with a known or possible hypersensitivity (allergy) to latex.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:630px;left:147px;white-space:nowrap" class="ft2834"><b>Alcohol abuse</b>: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.&#160;<br/>Please tell your doctor if you or the&#160;child in your care have a history of alcohol abuse.</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:669px;left:147px;white-space:nowrap" class="ft2834"><b>Wegener’s granulomatosis</b>: Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener’s&#160;<br/>granulomatosis, talk to your&#160;doctor.</p>
<p style="position:absolute;top:725px;left:106px;white-space:nowrap" class="ft28314"></p>
<p style="position:absolute;top:727px;left:147px;white-space:nowrap" class="ft2834"><b>Anti-diabetic medicines</b>: Tell your doctor if you or the child have diabetes or are taking&#160;<br/>medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic&#160;<br/>medicine while taking Enbrel.</p>
<p style="position:absolute;top:803px;left:106px;white-space:nowrap" class="ft2831"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft2833"><b>Vaccinations:&#160;</b>If possible, children should be up to date with all vaccinations before using Enbrel.&#160;<br/>Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult&#160;<br/>your doctor before you or the child receive any vaccines.</p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft2834">Enbrel should not normally be used in children with&#160;polyarthritis or extended oligoarthritis below the&#160;<br/>age of 2 years, or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12&#160;<br/>years, or in children with&#160;psoriasis below the age of&#160;6&#160;years.</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft2831"><b>Other medicines&#160;and Enbrel</b></p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft2834">Tell&#160;your&#160;doctor or pharmacist if you or the child are taking,&#160;have recently taken&#160;or might take&#160;any&#160;<br/>other medicines (including anakinra, abatacept or sulfasalazine), even those not prescribed by the&#160;<br/>doctor. You or the child should not use Enbrel with medicines that contain the active substance&#160;<br/>anakinra or abatacept.</p>
</div>
<!-- Page 284 -->
<a name="284"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page284-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2840">284</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2841"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2843">Enbrel&#160;should only be used&#160;during pregnancy&#160;if clearly needed.&#160;You should consult your doctor if&#160;you<br/>become pregnant,&#160;think you may be pregnant, or are planning to have a baby.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft2843">If you received Enbrel during pregnancy,&#160;your&#160;baby may have a higher risk&#160;of&#160;getting an infection.&#160;In&#160;<br/>addition,&#160;one study&#160;found&#160;more birth defects when the mother had received&#160;Enbrel&#160;in pregnancy,&#160;<br/>compared&#160;with&#160;mothers who had not received&#160;Enbrel&#160;or other similar medicines (TNF-antagonists),&#160;<br/>but there was no&#160;particular kind of birth defect&#160;reported.&#160;Another study found no increased&#160;risk of birth&#160;<br/>defects when the mother had received Enbrel in pregnancy.&#160;Your doctor will help you to decide&#160;<br/>whether the benefits of treatment outweigh the potential risk to your baby.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft2844">Talk to your doctor if you want to breastfeed while on Enbrel treatment.&#160;It&#160;is important that you tell&#160;<br/>your&#160;baby’s doctors and other healthcare professionals about the use of Enbrel during pregnancy and&#160;<br/>breastfeeding before&#160;your&#160;baby receives any vaccine.</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft2841"><b>Driving and using&#160;machines</b></p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft2842">The use of Enbrel is not expected to affect the ability to drive or use machines.</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft2841"><b>Enbrel contains sodium</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft2843">This medicine&#160;contains less than 1&#160;mmol sodium (23&#160;mg) per dosage unit, that is to say&#160;essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft2841"><b>3.</b></p>
<p style="position:absolute;top:602px;left:146px;white-space:nowrap" class="ft2841"><b>How to use Enbrel</b></p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft2844">Always use&#160;this medicine&#160;exactly as your doctor has told you.&#160;Check with your doctor if or pharmacist<br/>you are not sure.</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft2842">If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft2844">You have been prescribed a&#160;50&#160;mg&#160;strength of Enbrel. A&#160;25&#160;mg&#160;strength of Enbrel is available for&#160;<br/>doses of&#160;25&#160;mg.&#160;</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft2841"><b>Dosing for adult patients (aged 18 years or over)</b></p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft2842">Rheumatoid arthritis, psoriatic arthritis,&#160;and&#160;axial spondyloarthritis including&#160;ankylosing spondylitis</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft2844">The usual dose is 25&#160;mg given twice a week or 50&#160;mg&#160;once a week as an injection under the skin.&#160;<br/>However, your doctor may determine an alternative frequency at which to inject Enbrel.&#160;</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft2842">Plaque psoriasis</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft2842">The usual dose is 25&#160;mg twice a week or 50&#160;mg once a&#160;week. &#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft2843">Alternatively, 50&#160;mg&#160;may be given twice a week for up to 12 weeks, followed by 25&#160;mg twice a week&#160;<br/>or 50&#160;mg once a week.&#160;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft2844">Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on&#160;<br/>your response. If Enbrel has no effect on your condition after 12 weeks, your doctor may tell you to&#160;<br/>stop taking this medicine.</p>
</div>
<!-- Page 285 -->
<a name="285"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page285-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2850">285</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2851"><b>Use in&#160;children&#160;and adolescents</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2854">The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight&#160;<br/>and disease.&#160;Your&#160;doctor will determine the correct dose for the child and will prescribe an appropriate&#160;<br/>strength of Enbrel (10&#160;mg, 25&#160;mg or 50&#160;mg).</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft2854">For polyarthritis or extended oligoarthritis in patients from the age of 2 years, or enthesitis-related&#160;<br/>arthritis or&#160;psoriatic arthritis in patients from the age of 12 years, the usual dose is 0.4&#160;mg of Enbrel&#160;<br/>per kg bodyweight (up to a maximum of 25&#160;mg) given twice weekly, or 0.8&#160;mg of Enbrel per kg of&#160;<br/>bodyweight (up to a maximum of 50&#160;mg) given once weekly.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft2853">For psoriasis in patients from the age of&#160;6&#160;years, the usual dose is 0.8&#160;mg of Enbrel per kg bodyweight&#160;<br/>(up to a maximum of 50&#160;mg), and should be given once weekly. If Enbrel has no effect on the child’s&#160;<br/>condition after 12 weeks, your doctor may tell you to stop using this medicine.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2852">The doctor will provide you with detailed directions for preparing and measuring the appropriate dose.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft2851"><b>Method and route of administration</b></p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft2852">Enbrel is administered by an injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft2852">Enbrel can be&#160;taken with or without food or drink.</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft28523"><b>Detailed instructions on how to inject Enbrel are provided in section 7, “Using the MYCLIC&#160;<br/>pre-filled pen to inject Enbrel”.&#160;</b>Do not mix the Enbrel solution with any other medicine.</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft2853">To help you remember, it may be helpful to write in a diary which day(s) of the week Enbrel should be&#160;<br/>used.</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft2851"><b>If&#160;you use more Enbrel than you should</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft2854">If you have used more Enbrel than you should (either by injecting too much on a single occasion or by&#160;<br/>using it too frequently), talk to a doctor or pharmacist immediately. Always have the outer carton of&#160;<br/>the medicine with you, even if it is empty.</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft2851"><b>If&#160;you forget to inject Enbrel</b></p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft2853">If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is&#160;<br/>the next day; in which case you should skip the missed dose. Then continue to inject the medicine on&#160;<br/>the usual day(s). If you do not remember until the day that the next injection is due, do not take a&#160;<br/>double dose (two doses on the same day) to make up for a forgotten dose.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft2851"><b>If&#160;you stop using Enbrel&#160;</b></p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft2852">Your symptoms may return upon discontinuation.&#160;</p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft2852">If you have any further questions on the use of this&#160;medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft2851"><b>4.</b></p>
<p style="position:absolute;top:1037px;left:146px;white-space:nowrap" class="ft2851"><b>Possible side effects</b></p>
<p style="position:absolute;top:1075px;left:106px;white-space:nowrap" class="ft2852">Like all medicines,&#160;this medicine&#160;can cause side effects, although not everybody gets them.</p>
</div>
<!-- Page 286 -->
<a name="286"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page286-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2860">286</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2861"><b>Allergic reactions</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2863">If any of the following happen, do not inject more Enbrel. Tell your doctor immediately, or go to the&#160;<br/>casualty department at your nearest hospital.</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:204px;left:149px;white-space:nowrap" class="ft2862">Trouble swallowing or breathing</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft2862">Swelling of the face, throat, hands, or feet</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft2864">Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm&#160;<br/>feeling</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft2862">Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p>
<p style="position:absolute;top:321px;left:106px;white-space:nowrap" class="ft2863">Serious allergic&#160;reactions are rare. However, any of the above symptoms may indicate an allergic&#160;<br/>reaction to Enbrel, so you should seek immediate medical attention.</p>
<p style="position:absolute;top:378px;left:106px;white-space:nowrap" class="ft2861"><b>Serious side effects</b></p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft2862">If you notice any of the following, you or the child may need urgent medical attention.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:455px;left:149px;white-space:nowrap" class="ft2864">Signs of&#160;<b>serious infections</b>, such as high fever that may be accompanied by cough, shortness of&#160;<br/>breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:494px;left:149px;white-space:nowrap" class="ft2862">Signs of&#160;<b>blood disorders</b>, such as bleeding, bruising, or paleness</p>
<p style="position:absolute;top:513px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:515px;left:149px;white-space:nowrap" class="ft2864">Signs of&#160;<b>nerve disorders</b>, such as numbness or tingling, changes in vision, eye pain, or onset of&#160;<br/>weakness in an arm or leg</p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:554px;left:149px;white-space:nowrap" class="ft2864">Signs of&#160;<b>heart failure&#160;</b>or&#160;<b>worsening heart failure</b>, such as fatigue or shortness of breath with&#160;<br/>activity, swelling in the ankles, a feeling of fullness in the neck or abdomen, night-time&#160;<br/>shortness of breath or coughing, bluish colour of the nails or the lips</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:612px;left:149px;white-space:nowrap" class="ft2863"><b>Signs of cancers:&#160;</b>Cancers may affect any part of the body including the skin and blood, and&#160;<br/>possible signs will depend on the type and&#160;location of the cancer. These signs may include&#160;<br/>weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or&#160;<br/>growths on the skin</p>
<p style="position:absolute;top:687px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:689px;left:149px;white-space:nowrap" class="ft2864">Signs of&#160;<b>autoimmune reactions&#160;</b>(where antibodies are made that may harm normal tissues in&#160;<br/>the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:728px;left:149px;white-space:nowrap" class="ft2864">Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or&#160;<br/>muscle pain, or fatigue</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:767px;left:149px;white-space:nowrap" class="ft2864">Signs of&#160;<b>inflammation of the blood vessels&#160;</b>such as pain, fever, redness or warmth of the skin,&#160;<br/>or itching.</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft2864">These are rare or uncommon side effects, but are serious conditions (some of which may rarely be&#160;<br/>fatal). If these signs occur, tell your doctor immediately, or visit the casualty department at&#160;your&#160;<br/>nearest hospital.</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft2862">The known side effects of Enbrel include the following in groups of decreasing frequency:</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:939px;left:149px;white-space:nowrap" class="ft2864"><b>Very common&#160;</b>(may affect more than 1 in 10&#160;people):<br/>Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections);&#160;<br/>injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling)&#160;(these&#160;<br/>do not occur as often after the first month of treatment;&#160;some patients have developed a reaction&#160;<br/>at an injection site that was&#160;recently&#160;used);&#160;and headache.</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft28614"></p>
<p style="position:absolute;top:1054px;left:149px;white-space:nowrap" class="ft2864"><b>Common&#160;</b>(may affect up to 1 in 10&#160;people):<br/>Allergic reactions; fever;&#160;rash;&#160;itching; antibodies directed against normal tissue (autoantibody&#160;<br/>formation).</p>
</div>
<!-- Page 287 -->
<a name="287"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page287-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2870">287</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft28714"></p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft2873"><b>Uncommon&#160;</b>(may affect up to 1 in 100&#160;people):<br/>Serious infections (including pneumonia, deep skin infections, joint infections, blood infection,&#160;<br/>and infections at various sites);&#160;worsening of congestive heart failure;&#160;low red blood cell count,&#160;<br/>low white blood cell count, low neutrophil (a type of white blood cell) count;&#160;low blood platelet&#160;<br/>count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives&#160;<br/>(elevated patches of red or pale skin that often itch); eye inflammation; psoriasis&#160;(new or&#160;<br/>worsening);&#160;inflammation of the blood vessels affecting multiple organs; elevated liver blood&#160;<br/>tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood&#160;<br/>tests is common);&#160;abdominal cramps and pain,&#160;diarrhoea, weight loss or blood in the stool (signs&#160;<br/>of bowel problems).</p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft28714"></p>
<p style="position:absolute;top:319px;left:149px;white-space:nowrap" class="ft2874"><b>Rare&#160;</b>(may affect up to 1 in 1,000&#160;people):<br/>Serious allergic reactions (including severe localised swelling of the skin and wheezing);&#160;<br/>lymphoma (a type of blood cancer);&#160;leukaemia&#160;(cancer affecting the blood and bone marrow);<br/>melanoma&#160;(a type of skin cancer);&#160;combined low platelet, red, and white blood cell count;&#160;<br/>nervous system disorders (with&#160;severe muscle weakness and&#160;signs and symptoms similar to&#160;<br/>those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord);&#160;<br/>tuberculosis;&#160;new onset&#160;congestive heart failure; seizures; lupus or lupus-like syndrome&#160;<br/>(symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may&#160;<br/>lead to severe blistering and peeling of the skin;&#160;lichenoid reactions (itchy reddish-purple skin&#160;<br/>rash and/or threadlike white-grey lines on mucous membranes);&#160;inflammation of the liver&#160;<br/>caused by the body's own&#160;immune system (autoimmune hepatitis;&#160;in patients also receiving&#160;<br/>methotrexate treatment, the frequency is uncommon);&#160;immune disorder that can affect the lungs,&#160;<br/>skin and lymph nodes (sarcoidosis);&#160;inflammation or scarring of the lungs&#160;(in patients also&#160;<br/>receiving methotrexate treatment, the frequency&#160;of&#160;inflammation or scarring of the lungs is&#160;<br/>uncommon).</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft28714"></p>
<p style="position:absolute;top:624px;left:149px;white-space:nowrap" class="ft2874"><b>Very rare&#160;</b>(may affect up to 1 in 10,000&#160;people):&#160;failure of the bone marrow to produce crucial&#160;<br/>blood cells.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft28714"></p>
<p style="position:absolute;top:682px;left:149px;white-space:nowrap" class="ft2874"><b>Not known&#160;</b>(frequency cannot be estimated&#160;from&#160;the available data):&#160;Merkel cell carcinoma (a&#160;<br/>type of skin cancer);&#160;Kaposi’s sarcoma (a rare cancer related to infection with human herpes&#160;<br/>virus 8. Kaposi’s sarcoma most commonly appear as purple lesions on the skin);&#160;excessive&#160;<br/>activation of white blood cells associated with inflammation (macrophage activation&#160;<br/>syndrome);&#160;recurrence of hepatitis B (a liver infection);&#160;worsening of a condition called&#160;<br/>dermatomyositis (muscle inflammation and weakness&#160;with&#160;an&#160;accompanying&#160;skin rash).</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft2871"><b>Additional side effects in&#160;children and adolescents</b></p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft2874">The side effects and their frequencies seen in children and adolescents are&#160;similar to those described&#160;<br/>above.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft2871"><b>Reporting of side effects</b></p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft2874">If you get any side effects, talk to your doctor&#160;or&#160;pharmacist.&#160;This includes any possible&#160;side effects&#160;<br/>not listed in this leaflet.&#160;You can also report side&#160;effects directly&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>. By reporting side effects you can help provide more information on the safety of&#160;<br/>this medicine.</p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft2871"><b>5.</b></p>
<p style="position:absolute;top:1061px;left:146px;white-space:nowrap" class="ft2871"><b>How to store Enbrel</b></p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft2872">Keep&#160;this medicine&#160;out of the&#160;sight and&#160;reach of children.</p>
<p style="position:absolute;top:1137px;left:106px;white-space:nowrap" class="ft2874">Do not use&#160;this medicine&#160;after the expiry date which is stated on the carton and on the MYCLIC pre-<br/>filled pen after EXP. The expiry date refers to the last day of that month.</p>
</div>
<!-- Page 288 -->
<a name="288"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page288-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2880">288</p>
<p style="position:absolute;top:128px;left:106px;white-space:nowrap" class="ft2882">Store in a refrigerator (2</p>
<p style="position:absolute;top:126px;left:267px;white-space:nowrap" class="ft28814">&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft2882">Keep the pre-filled pens in the outer carton in order&#160;to protect from light.</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft2883">After taking a pre-filled pen&#160;from the refrigerator,&#160;<b>wait&#160;approximately 15-30 minutes to allow the&#160;<br/>Enbrel solution&#160;in the pen&#160;to reach room temperature</b>. Do not warm in any other way.&#160;Immediate&#160;<br/>use is then recommended. &#160;</p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft2882">Enbrel may&#160;be stored outside of the refrigerator at temperatures up to a maximum of 25</p>
<p style="position:absolute;top:260px;left:684px;white-space:nowrap" class="ft28814">C for a single&#160;</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft2884">period of up to four weeks; after which, it should not be refrigerated again. Enbrel should be discarded&#160;<br/>if not used within four weeks after removal from the refrigerator. It is recommended that you record&#160;<br/>the date that Enbrel is removed from the refrigerator and the date after which Enbrel should be&#160;<br/>discarded (no more than 4 weeks following the removal from the refrigerator).</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft2883">Inspect the solution in the pen by looking through the clear inspection window.&#160;The solution should be&#160;<br/>clear&#160;or slightly opalescent, colourless&#160;to&#160;pale yellow&#160;or pale brown, and&#160;may&#160;contain small white or&#160;<br/>almost transparent particles of protein.&#160;This appearance is normal for Enbrel. Do not use&#160;the solution if&#160;<br/>it is discoloured, cloudy,&#160;or if particles other than those described above are present. If you are&#160;<br/>concerned with the appearance of the solution, then contact your pharmacist for assistance.</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft2883">Do not throw away any medicines via wastewater&#160;or household waste. Ask your pharmacist how to&#160;<br/>throw away&#160;medicines&#160;you&#160;no longer&#160;use. These measures will help protect the environment.</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft2881"><b>6.</b></p>
<p style="position:absolute;top:566px;left:146px;white-space:nowrap" class="ft2881"><b>Contents of the pack and other information&#160;</b></p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft2881"><b>What Enbrel contains</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft2884">The active substance in Enbrel is etanercept. Each MYCLIC pre-filled pen contains&#160;50&#160;mg&#160;of&#160;<br/>etanercept. &#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft2884">The other ingredients are sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate&#160;<br/>monobasic dihydrate and sodium phosphate dibasic&#160;dihydrate, and water for injections.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft2881"><b>What Enbrel looks like and contents of the pack</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft2883">Enbrel is supplied as a solution for injection in a pre-filled pen (MYCLIC)&#160;(solution for injection). The&#160;<br/>MYCLIC pen contains a clear, colourless&#160;to&#160;pale yellow&#160;or pale&#160;brown&#160;solution for injection.&#160;Each&#160;<br/>pack&#160;contains 2, 4 or 12 pens and&#160;2, 4 or 12&#160;alcohol swabs. Not all pack sizes may be marketed.</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft2881"><b>Marketing Authorisation Holder and Manufacturer</b></p>
<p style="position:absolute;top:907px;left:114px;white-space:nowrap" class="ft2884"><i>Marketing Authorisation Holder:<br/></i>Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:1021px;left:114px;white-space:nowrap" class="ft2883"><i>Manufacturer:<br/></i>Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
</div>
<!-- Page 289 -->
<a name="289"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page289-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2890">289</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2894">For any information about this medicinal product, please contact the local representative of the&#160;<br/>Marketing Authorisation Holder.</p>
<p style="position:absolute;top:165px;left:114px;white-space:nowrap" class="ft2894"><b>België/Belgique/Belgien<br/>Luxembourg/Luxemburg<br/></b>Pfizer&#160;NV/SA<br/>Tél/Tel: +32 (0)2 554 62 11</p>
<p style="position:absolute;top:165px;left:452px;white-space:nowrap" class="ft2898"><b>Kύπρος<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.&#160;(CYPRUS BRANCH)&#160;<br/>T</p>
<p style="position:absolute;top:202px;left:462px;white-space:nowrap" class="ft28914">: +357 22 817690</p>
<p style="position:absolute;top:260px;left:114px;white-space:nowrap" class="ft2893"><b>Česká Republika<br/></b>Pfizer, spol.&#160;s&#160;r.o.<br/>Tel:&#160;+420-283-004-111</p>
<p style="position:absolute;top:260px;left:452px;white-space:nowrap" class="ft2893"><b>Magyarország<br/></b>Pfizer Kft.<br/>Tel: +36 1 488 3700</p>
<p style="position:absolute;top:335px;left:114px;white-space:nowrap" class="ft2894"><b>Danmark<br/></b>Pfizer ApS<br/>Tlf: +45 44&#160;201&#160;100</p>
<p style="position:absolute;top:335px;left:452px;white-space:nowrap" class="ft2894"><b>Malta<br/></b>Vivian Corporation Ltd.<br/>Tel: +35621 344610</p>
<p style="position:absolute;top:411px;left:114px;white-space:nowrap" class="ft2894"><b>Deutschland<br/></b>Pfizer Pharma GmbH<br/>Tel: +49 (0)30 550055-51000</p>
<p style="position:absolute;top:411px;left:452px;white-space:nowrap" class="ft2894"><b>Nederland<br/></b>Pfizer bv<br/>Tel: +31 (0)800 63 34 636</p>
<p style="position:absolute;top:489px;left:114px;white-space:nowrap" class="ft2893"><b>България<br/></b>Пфайзер Люксембург САРЛ,&#160;<br/>Клон България<br/>Teл:&#160;+359 2 970 4333</p>
<p style="position:absolute;top:489px;left:452px;white-space:nowrap" class="ft2894"><b>Norge<br/></b>Pfizer AS<br/>Tlf: +47 67&#160;52&#160;61&#160;00</p>
<p style="position:absolute;top:584px;left:114px;white-space:nowrap" class="ft2894"><b>Eesti<br/></b>Pfizer Luxembourg SARL Eesti filiaal<br/>Tel:&#160;+372 666 7500</p>
<p style="position:absolute;top:584px;left:452px;white-space:nowrap" class="ft2894"><b>Österreich<br/></b>Pfizer Corporation Austria Ges.m.b.H.<br/>Tel: +43&#160;(0)1 521 15-0</p>
<p style="position:absolute;top:660px;left:114px;white-space:nowrap" class="ft2894"><b>Ελλάδα<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.<br/>Τηλ.: +30 210 67&#160;85 800</p>
<p style="position:absolute;top:660px;left:452px;white-space:nowrap" class="ft2894"><b>Polska<br/></b>Pfizer Polska Sp. z o.o.<br/>Tel.: +48 22 335 61 00</p>
<p style="position:absolute;top:745px;left:114px;white-space:nowrap" class="ft2894"><b>España<br/></b>Pfizer, S.L.<br/>Télf: +34&#160;91&#160;490&#160;99&#160;00</p>
<p style="position:absolute;top:745px;left:452px;white-space:nowrap" class="ft2894"><b>Portugal<br/></b>Laboratórios Pfizer, Lda.<br/>Tel: (+351) 21 423 55 00</p>
<p style="position:absolute;top:827px;left:114px;white-space:nowrap" class="ft2894"><b>France<br/></b>Pfizer<br/>Tél&#160;+33 (0)1 58&#160;07 34 40</p>
<p style="position:absolute;top:827px;left:452px;white-space:nowrap" class="ft2894"><b>România<br/></b>Pfizer Romania S.R.L<br/>Tel: +40 (0) 21 207 28 00</p>
<p style="position:absolute;top:902px;left:114px;white-space:nowrap" class="ft2893"><b>Hrvatska<br/></b>Pfizer Croatia&#160;d.o.o.<br/>Tel: +385 1&#160;3908&#160;777</p>
<p style="position:absolute;top:902px;left:452px;white-space:nowrap" class="ft2894"><b>Slovenija<br/></b>Pfizer Luxembourg SARL<i>,&#160;</i>Pfizer, podružnica&#160;<br/>za&#160;svetovanje s področja farmacevtske&#160;<br/>dejavnosti, Ljubljana<br/>Tel: +386 (0)1 52 11&#160;400</p>
<p style="position:absolute;top:1016px;left:114px;white-space:nowrap" class="ft2894"><b>Ireland<br/></b>Pfizer Healthcare Ireland<br/>Tel: +1800 633 363 (toll free)<br/>Tel: +44 (0)1304 616161</p>
<p style="position:absolute;top:1016px;left:452px;white-space:nowrap" class="ft2894"><b>Slovenská Republika<br/></b>Pfizer Luxembourg SARL, organizačná zložka&#160;<br/>Tel: +421 2 3355 5500</p>
</div>
<!-- Page 290 -->
<a name="290"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page290-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2900">290</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft2904"><b>Ísland<br/></b>Icepharma&#160;hf.<br/>Tel: +354&#160;540 8000</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft2904"><b>Suomi/Finland<br/></b>Pfizer Oy<br/>Puh/Tel: +358 (0)9&#160;430 040</p>
<p style="position:absolute;top:187px;left:114px;white-space:nowrap" class="ft2903"><b>Italia<br/></b>Pfizer S.r.l.<br/>Tel: +39 06 33 18 21</p>
<p style="position:absolute;top:187px;left:452px;white-space:nowrap" class="ft2903"><b>Sverige&#160;<br/></b>Pfizer AB<br/>Tel: +46 (0)8&#160;550&#160;520 00</p>
<p style="position:absolute;top:267px;left:114px;white-space:nowrap" class="ft2904"><b>Latvija<br/></b>Pfizer Luxembourg SARL filiāle Latvijā<br/>Tel. +371 67035775</p>
<p style="position:absolute;top:267px;left:452px;white-space:nowrap" class="ft2904"><b>United Kingdom&#160;(Northern Ireland)<br/></b>Pfizer Limited<br/>Tel:&#160;+44 (0)1304&#160;616161</p>
<p style="position:absolute;top:347px;left:114px;white-space:nowrap" class="ft2903"><b>Lietuva<br/></b>Pfizer Luxembourg SARL filialas Lietuvoje<br/>Tel. +3705 2514000</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2901"><b>This leaflet was last&#160;revised&#160;in</b></p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft2904">Detailed information on this&#160;medicine&#160;is available on the&#160;European Medicines Agency&#160;web&#160;site:<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft2901"><b>7.</b></p>
<p style="position:absolute;top:559px;left:146px;white-space:nowrap" class="ft2901"><b>Using the MYCLIC pre-filled pen to inject Enbrel</b></p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft2902">This section is divided into the following subsections:</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft29024"><b>Introduction<br/>Step 1: Preparing for an Enbrel injection<br/>Step 2: Choosing an injection site<br/>Step 3: Injecting the Enbrel&#160;solution<br/>Step 4: Disposing of the used MYCLIC pen</b></p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft2901"><b>Introduction</b></p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft2904">The instructions below explain how to use the MYCLIC pen to inject Enbrel. Please read the&#160;<br/>instructions carefully, and follow them step by step. Your doctor or nurse will tell you how to&#160;inject&#160;<br/>Enbrel. Do not attempt to administer an injection until you are sure that you understand how to use the&#160;<br/>MYCLIC&#160;pen properly. If you have questions&#160;about how to inject, please ask your doctor or nurse for&#160;<br/>help.</p>
<p style="position:absolute;top:901px;left:411px;white-space:nowrap" class="ft2902">Diagram 1</p>
<p style="position:absolute;top:939px;left:353px;white-space:nowrap" class="ft2902">The&#160;MYCLIC&#160;pre-filled pen</p>
<p style="position:absolute;top:1107px;left:106px;white-space:nowrap" class="ft2901"><b>Step 1: Preparing for an Enbrel injection</b></p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft2902">1.</p>
<p style="position:absolute;top:1145px;left:147px;white-space:nowrap" class="ft2902">Select a clean, well-lit, flat surface.</p>
<p style="position:absolute;top:1070px;left:360px;white-space:nowrap" class="ft2902">Expiry date</p>
<p style="position:absolute;top:1029px;left:654px;white-space:nowrap" class="ft2902">White needle cap</p>
<p style="position:absolute;top:1070px;left:541px;white-space:nowrap" class="ft2902">Clear inspection window</p>
<p style="position:absolute;top:969px;left:112px;white-space:nowrap" class="ft2902">Green activation button</p>
</div>
<!-- Page 291 -->
<a name="291"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page291-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2910">291</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2912">2.</p>
<p style="position:absolute;top:108px;left:147px;white-space:nowrap" class="ft2912">Gather the items that you will need for your injection, and place them on&#160;the chosen surface:</p>
<p style="position:absolute;top:140px;left:187px;white-space:nowrap" class="ft2912">a.&#160;One MYCLIC pre-filled pen&#160;and&#160;one alcohol swab&#160;(take these from the carton of pens&#160;</p>
<p style="position:absolute;top:159px;left:214px;white-space:nowrap" class="ft2912">you keep in your refrigerator). Do not shake the pen.</p>
<p style="position:absolute;top:192px;left:187px;white-space:nowrap" class="ft2912">b.&#160;One cotton ball or gauze&#160;</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft2912">3.</p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft2913"><b>Check&#160;the expiry date (month/year) on the pen</b>. If the date has&#160;passed, do not use the pen and&#160;<br/>contact your pharmacist for assistance.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2912">4.</p>
<p style="position:absolute;top:276px;left:149px;white-space:nowrap" class="ft2913">Inspect the solution in the pen by looking through the clear inspection window. The solution&#160;<br/>should be clear or slightly opalescent, colourless&#160;to&#160;pale yellow&#160;or pale brown, and&#160;may&#160;contain&#160;<br/>small white or almost transparent&#160;particles of protein.&#160;This appearance is normal for Enbrel. Do&#160;<br/>not use the solution if it is discoloured, cloudy,&#160;or if particles other than those described above&#160;<br/>are present. If you are concerned with the appearance of the solution, then contact your&#160;<br/>pharmacist for assistance.</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft2912">5.</p>
<p style="position:absolute;top:403px;left:149px;white-space:nowrap" class="ft2913"><b>Leave the white needle cap in place and wait&#160;approximately 15-30 minutes&#160;</b>to allow the&#160;<br/>Enbrel solution&#160;in the pen to reach room temperature. Waiting until the solution reaches room&#160;<br/>temperature may make the injection more comfortable for you. Do not warm in any other way.<br/><b>Always leave the pen out of sight and reach of children.</b></p>
<p style="position:absolute;top:492px;left:106px;white-space:nowrap" class="ft2914">Whilst waiting for the solution in the pen to reach room temperature, read Step 2 (below), and choose&#160;<br/>an injection&#160;site.</p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft2911"><b>Step 2: Choosing an injection site (see&#160;Diagram 2)</b></p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft2912">1.</p>
<p style="position:absolute;top:587px;left:147px;white-space:nowrap" class="ft2912">The recommended injection site is the middle of the front of the thighs. If you prefer, you may&#160;</p>
<p style="position:absolute;top:606px;left:149px;white-space:nowrap" class="ft2914">alternatively use the stomach area, but make sure you choose a site at least 5 cm away from the&#160;<br/>belly button (navel). If someone else is giving you the injection, the outer area of the upper arms&#160;<br/>may also be used.</p>
<p style="position:absolute;top:682px;left:411px;white-space:nowrap" class="ft2912">Diagram 2</p>
<p style="position:absolute;top:972px;left:106px;white-space:nowrap" class="ft2912">2.</p>
<p style="position:absolute;top:972px;left:147px;white-space:nowrap" class="ft2912">Each injection should be given at least 3&#160;cm from where you last injected. Do not inject into&#160;</p>
<p style="position:absolute;top:991px;left:149px;white-space:nowrap" class="ft2913">tender, bruised or hard skin. Avoid scars or stretch marks. (It may be helpful to keep notes on&#160;<br/>the location of the previous injections.)</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft2912">3.</p>
<p style="position:absolute;top:1043px;left:147px;white-space:nowrap" class="ft2912">If you have psoriasis, you should try not to inject directly into any raised, thick, red, or scaly&#160;</p>
<p style="position:absolute;top:1062px;left:149px;white-space:nowrap" class="ft2912">skin.</p>
<p style="position:absolute;top:1100px;left:106px;white-space:nowrap" class="ft2911"><b>Step 3: Injecting the&#160;Enbrel solution</b></p>
<p style="position:absolute;top:1138px;left:106px;white-space:nowrap" class="ft2912">1.</p>
<p style="position:absolute;top:1138px;left:147px;white-space:nowrap" class="ft2912">After waiting approximately 15-30 minutes for the solution in the pen to warm to room&#160;</p>
<p style="position:absolute;top:1157px;left:149px;white-space:nowrap" class="ft2912">temperature, wash your hands with soap and water.</p>
</div>
<!-- Page 292 -->
<a name="292"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page292-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2920">292</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2922">2.</p>
<p style="position:absolute;top:108px;left:147px;white-space:nowrap" class="ft2922">Clean the injection site with the alcohol swab using a circular motion, and allow it to dry.&#160;Do not&#160;</p>
<p style="position:absolute;top:127px;left:149px;white-space:nowrap" class="ft2922">touch this area again before injecting.</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft2922">3.</p>
<p style="position:absolute;top:159px;left:147px;white-space:nowrap" class="ft2922">Pick up the pen, and remove the white needle cap by pulling it straight off (see Diagram 3). To&#160;</p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft2923">avoid damaging the needle inside the pen, do&#160;not bend the white needle cap while you are&#160;<br/>removing it, and do not re-attach it once it has been removed.&#160;After removal of the needle cap, you&#160;<br/>will see a purple needle safety shield extending slightly from the end of the pen. The needle will&#160;<br/>remain protected inside the pen until the pen is activated.&#160;Do not use the pen if it is&#160;dropped with&#160;<br/>the needle cap off.</p>
<p style="position:absolute;top:287px;left:411px;white-space:nowrap" class="ft2922">Diagram 3</p>
<p style="position:absolute;top:324px;left:389px;white-space:nowrap" class="ft2922">White needle cap</p>
<p style="position:absolute;top:566px;left:443px;white-space:nowrap" class="ft2922">Purple needle safety shield</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft2922">4.</p>
<p style="position:absolute;top:604px;left:147px;white-space:nowrap" class="ft2922">Lightly pinching the skin&#160;around the injection site&#160;between the thumb and index finger of your free&#160;</p>
<p style="position:absolute;top:623px;left:149px;white-space:nowrap" class="ft2922">hand may make the injection easier and more comfortable.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft2922">5.</p>
<p style="position:absolute;top:655px;left:147px;white-space:nowrap" class="ft2922">Hold&#160;the pen at a right angle&#160;(90º) to the injection site<b>.&#160;Push the open end of the pen firmly&#160;</b></p>
<p style="position:absolute;top:674px;left:149px;white-space:nowrap" class="ft2923"><b>against the skin</b>, so that the needle safety shield is pushed completely inside of the pen. A slight&#160;<br/>depression in the skin will be seen (see Diagram 4).&#160;The pen can only be activated when the&#160;<br/>needle shield is completely pushed inside the pen.</p>
<p style="position:absolute;top:745px;left:411px;white-space:nowrap" class="ft2922">Diagram 4</p>
<p style="position:absolute;top:991px;left:404px;white-space:nowrap" class="ft2924">Needle safety shield&#160;<br/>disappears inside the pen</p>
<p style="position:absolute;top:1048px;left:106px;white-space:nowrap" class="ft2922">6.</p>
<p style="position:absolute;top:1048px;left:147px;white-space:nowrap" class="ft2922">Whilst pushing the pen&#160;<b>firmly&#160;</b>against the skin to ensure that the needle safety shield is fully&#160;</p>
<p style="position:absolute;top:1067px;left:149px;white-space:nowrap" class="ft2923">depressed inside the pen,&#160;<b>press&#160;the centre of&#160;the green button&#160;</b>on top of the pen with your&#160;<br/>thumb to start the injection (see Diagram 5). On pressing the&#160;centre of&#160;the&#160;button, you will hear&#160;<br/>a click.&#160;<b>Continue to hold the pen firmly against your skin until&#160;you hear a second click,&#160;</b>or&#160;<br/>until 10&#160;seconds after the first click (whichever happens first).&#160;</p>
</div>
<!-- Page 293 -->
<a name="293"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page293-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2930">293</p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft2933">Note&#160;–&#160;If&#160;you are unable to start the injection as described, press the pen more firmly against<br/>your skin, then press the green button again.</p>
<p style="position:absolute;top:159px;left:411px;white-space:nowrap" class="ft2932">Diagram 5</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft2932">7.</p>
<p style="position:absolute;top:438px;left:147px;white-space:nowrap" class="ft2932">On hearing the second ‘click’ (or, if you do not hear a second ‘click’, after 10&#160;seconds have&#160;</p>
<p style="position:absolute;top:457px;left:149px;white-space:nowrap" class="ft2933">passed), your injection will be complete (see&#160;Diagram 6). You may now lift the pen from your&#160;<br/>skin (see&#160;Diagram 7). As you lift the pen, the purple needle safety shield will automatically&#160;<br/>extend to cover the needle.</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft2932">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Diagram 6&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Diagram 7</p>
<p style="position:absolute;top:869px;left:431px;white-space:nowrap" class="ft2932">Purple&#160;needle safety&#160;</p>
<p style="position:absolute;top:888px;left:422px;white-space:nowrap" class="ft2932">shield extends to cover&#160;</p>
<p style="position:absolute;top:907px;left:477px;white-space:nowrap" class="ft2932">needle</p>
<p style="position:absolute;top:869px;left:611px;white-space:nowrap" class="ft2932">Inspection window will&#160;</p>
<p style="position:absolute;top:888px;left:627px;white-space:nowrap" class="ft2932">have turned purple</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft2932">8.</p>
<p style="position:absolute;top:964px;left:147px;white-space:nowrap" class="ft2932">The pen’s inspection window should now be completely purple, confirming that the dose has&#160;</p>
<p style="position:absolute;top:983px;left:149px;white-space:nowrap" class="ft2934">been injected correctly&#160;(see Diagram 8). If the window is not completely&#160;purple, contact your&#160;<br/>nurse or pharmacist for assistance, since the pen may not have injected the Enbrel solution&#160;<br/>completely. Do not try to use the pen again, and do not try to use another pen without agreement&#160;<br/>from your nurse or pharmacist.</p>
</div>
<!-- Page 294 -->
<a name="294"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page294-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2940">294</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft2942">9.</p>
<p style="position:absolute;top:403px;left:147px;white-space:nowrap" class="ft2942">If you notice a spot of blood at the injection site, you should press the cotton ball or gauze over&#160;</p>
<p style="position:absolute;top:422px;left:149px;white-space:nowrap" class="ft2942">the injection site for 10 seconds. Do not rub the injection site.&#160;</p>
<p style="position:absolute;top:460px;left:106px;white-space:nowrap" class="ft2941"><b>Step 4: Disposing of the used MYCLIC&#160;pen</b></p>
<p style="position:absolute;top:479px;left:106px;white-space:nowrap" class="ft29414"></p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft2944">The pen should be used once only&#160;-&#160;it should&#160;never&#160;be re-used. Dispose of the used pen as&#160;<br/>instructed by your doctor, nurse or pharmacist.&#160;Do not attempt to recap the pen.</p>
<p style="position:absolute;top:537px;left:106px;white-space:nowrap" class="ft29423"><b>If&#160;you have any questions, please talk to a doctor, nurse or pharmacist who is familiar with&#160;<br/>Enbrel.</b></p>
</div>
<!-- Page 295 -->
<a name="295"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page295-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2950">295</p>
<p style="position:absolute;top:108px;left:298px;white-space:nowrap" class="ft2951"><b>Package Leaflet: Information for the User</b></p>
<p style="position:absolute;top:146px;left:176px;white-space:nowrap" class="ft2951"><b>Enbrel 10&#160;mg powder and solvent for solution for injection for paediatric use</b></p>
<p style="position:absolute;top:165px;left:413px;white-space:nowrap" class="ft2952">etanercept</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft29523"><b>Read all of this leaflet carefully before you start using this medicine&#160;because it contains&#160;<br/>important information for you.</b></p>
<p style="position:absolute;top:240px;left:123px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:242px;left:162px;white-space:nowrap" class="ft2952">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:260px;left:123px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft2952">Your doctor will also give you a Patient Card, which contains important safety information that&#160;</p>
<p style="position:absolute;top:281px;left:164px;white-space:nowrap" class="ft2952">you need to be aware of before and during treatment with Enbrel.</p>
<p style="position:absolute;top:299px;left:123px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:301px;left:162px;white-space:nowrap" class="ft2952">If you have any further questions, ask your doctor,&#160;pharmacist&#160;or nurse.</p>
<p style="position:absolute;top:319px;left:123px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:321px;left:162px;white-space:nowrap" class="ft2952">This medicine has been prescribed for a child in your care. Do not pass it on to others. It may&#160;</p>
<p style="position:absolute;top:340px;left:164px;white-space:nowrap" class="ft2952">harm them, even if their&#160;signs of illness&#160;are the same as those of the child you&#160;are caring for.</p>
<p style="position:absolute;top:358px;left:123px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:360px;left:162px;white-space:nowrap" class="ft2952">If you&#160;get&#160;any side effects,&#160;talk to&#160;your doctor or pharmacist.&#160;This includes any possible side&#160;</p>
<p style="position:absolute;top:379px;left:164px;white-space:nowrap" class="ft2952">effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft2951"><b>What is in this leaflet</b></p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft2952">Information in this leaflet is organised under the following 7 sections:</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft2952">1.</p>
<p style="position:absolute;top:493px;left:149px;white-space:nowrap" class="ft2952">What Enbrel is and what it is used for</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft2952">2.</p>
<p style="position:absolute;top:512px;left:149px;white-space:nowrap" class="ft2952">What you need to know before you use Enbrel</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft2952">3.</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft2952">How to use Enbrel</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft2952">4.</p>
<p style="position:absolute;top:550px;left:149px;white-space:nowrap" class="ft2952">Possible side effects</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft2952">5.</p>
<p style="position:absolute;top:569px;left:149px;white-space:nowrap" class="ft2952">How to store Enbrel</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft2952">6.</p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft2952">Contents of the pack and other information</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft2952">7.</p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft2952">Instructions for preparing and giving an&#160;injection of Enbrel (See overleaf)</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft2951"><b>1.</b></p>
<p style="position:absolute;top:664px;left:146px;white-space:nowrap" class="ft2951"><b>What Enbrel is and what it is used for</b></p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft2954">Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in&#160;<br/>the body that causes inflammation. Enbrel works by reducing the&#160;inflammation associated with certain&#160;<br/>diseases.</p>
<p style="position:absolute;top:778px;left:106px;white-space:nowrap" class="ft2952">Enbrel is prescribed for the treatment of the following diseases in children and adolescents</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:817px;left:147px;white-space:nowrap" class="ft2952">For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not&#160;</p>
<p style="position:absolute;top:836px;left:149px;white-space:nowrap" class="ft2952">worked well&#160;enough or is not suitable for them:</p>
<p style="position:absolute;top:873px;left:214px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:875px;left:257px;white-space:nowrap" class="ft2954">Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis&#160;<br/>in patients from the age of 2 years</p>
<p style="position:absolute;top:931px;left:214px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:933px;left:257px;white-space:nowrap" class="ft2952">Psoriatic arthritis in patients from the age of 12 years</p>
<p style="position:absolute;top:970px;left:106px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:972px;left:147px;white-space:nowrap" class="ft2952">For enthesitis-related arthritis in patients from the age of 12 years when other widely used&#160;</p>
<p style="position:absolute;top:991px;left:149px;white-space:nowrap" class="ft2952">treatments have not worked well enough or are not suitable for them</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft29514"></p>
<p style="position:absolute;top:1030px;left:147px;white-space:nowrap" class="ft2952">Severe psoriasis in patients from the age of&#160;6&#160;years who have had an inadequate response to (or&#160;</p>
<p style="position:absolute;top:1049px;left:149px;white-space:nowrap" class="ft2952">are unable to take) phototherapies or other systemic therapies.</p>
</div>
<!-- Page 296 -->
<a name="296"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page296-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2960">296</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2961"><b>2.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft2961"><b>What you need to know before you use Enbrel&#160;</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2961"><b>Do not use Enbrel</b></p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:185px;left:147px;white-space:nowrap" class="ft2962">if the child you are caring for&#160;is&#160;allergic to etanercept or any of the other ingredients of Enbrel</p>
<p style="position:absolute;top:204px;left:149px;white-space:nowrap" class="ft2963">(listed in section 6). If the child experiences allergic&#160;reactions such as chest tightness, wheezing,&#160;<br/>dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:243px;left:147px;white-space:nowrap" class="ft2962">if the child has, or is at risk of developing a serious blood infection called sepsis. If you are not&#160;</p>
<p style="position:absolute;top:262px;left:149px;white-space:nowrap" class="ft2962">sure, please contact your&#160;doctor.</p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:282px;left:147px;white-space:nowrap" class="ft2962">if the child has an infection of any kind. If you are not sure, please talk to your doctor.</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft2961"><b>Warnings and precautions&#160;</b></p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft2962">Talk to your doctor before taking Enbrel.</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:397px;left:149px;white-space:nowrap" class="ft2964"><b>Allergic reactions</b>: If the child experiences allergic reactions such as chest&#160;tightness, wheezing,&#160;<br/>dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:434px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:436px;left:147px;white-space:nowrap" class="ft2961"><b>Latex</b>:&#160;The syringe rubber tip is made from latex (dry natural rubber). Contact your doctor&#160;</p>
<p style="position:absolute;top:455px;left:149px;white-space:nowrap" class="ft2964">before using Enbrel if the syringe will be handled by, or&#160;Enbrel will be given to, someone with a&#160;<br/>known or possible hypersensitivity (allergy) to latex.</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:494px;left:149px;white-space:nowrap" class="ft2964"><b>Infections/surgery:&#160;</b>If the child develops a new infection, or is about to have any major surgery,&#160;<br/>the doctor may wish to monitor the child's treatment with Enbrel.</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:533px;left:149px;white-space:nowrap" class="ft2964"><b>Infections/diabetes:&#160;</b>Tell your doctor if the child has a history of recurrent infections, or suffers&#160;<br/>from diabetes or other conditions that increase the risk of infection.</p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:573px;left:147px;white-space:nowrap" class="ft2961"><b>Infections/monitoring:&#160;</b>Tell your doctor of any recent travel outside the European&#160;region. If the&#160;</p>
<p style="position:absolute;top:591px;left:149px;white-space:nowrap" class="ft2964">child develops symptoms of an infection such as fever, chills or cough, notify your doctor&#160;<br/>immediately. Your doctor may decide to continue to monitor the child for the presence of&#160;<br/>infections after the child stops using Enbrel.</p>
<p style="position:absolute;top:648px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:650px;left:147px;white-space:nowrap" class="ft2961"><b>Tuberculosis:&#160;</b>As cases of tuberculosis have been reported in patients treated with Enbrel, your&#160;</p>
<p style="position:absolute;top:669px;left:149px;white-space:nowrap" class="ft2963">doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may&#160;<br/>include a thorough medical history, a chest X-ray and a tuberculin test. The conduct of these&#160;<br/>tests should be recorded on the Patient Card. It is very important that you tell your doctor if the&#160;<br/>child has ever had tuberculosis, or has been in close contact with someone who has had&#160;<br/>tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p>
<p style="position:absolute;top:782px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:784px;left:147px;white-space:nowrap" class="ft2961"><b>Hepatitis B:&#160;</b>Tell your&#160;doctor if&#160;the child&#160;has&#160;or&#160;has&#160;ever had hepatitis B.&#160;Your doctor&#160;should&#160;</p>
<p style="position:absolute;top:803px;left:149px;white-space:nowrap" class="ft2963">test&#160;for the presence of&#160;hepatitis B infection before the child begins treatment with Enbrel.&#160;<br/>Treatment with Enbrel may result in reactivation of hepatitis B in patients who have previously&#160;<br/>been infected with the hepatitis B virus. If this occurs, you should stop using Enbrel.</p>
<p style="position:absolute;top:859px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:861px;left:147px;white-space:nowrap" class="ft2961"><b>Hepatitis C:&#160;</b>Tell your doctor if the child has hepatitis C. Your doctor may wish to monitor the&#160;</p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft2962">treatment with Enbrel in case the infection worsens.</p>
<p style="position:absolute;top:898px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:900px;left:149px;white-space:nowrap" class="ft2964"><b>Blood disorders:&#160;</b>Seek medical advice immediately if the child has any signs or symptoms such&#160;<br/>as persistent&#160;fever, sore throat, bruising, bleeding or paleness. Such symptoms may point to the&#160;<br/>existence of potentially life-threatening blood disorders, which may require discontinuation of&#160;<br/>Enbrel.</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:977px;left:149px;white-space:nowrap" class="ft2964"><b>Nervous system and eye disorders:&#160;</b>Tell your doctor if the child has multiple sclerosis, optic&#160;<br/>neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of the&#160;<br/>spinal cord). Your doctor will determine if Enbrel is an appropriate treatment.</p>
<p style="position:absolute;top:1033px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:1035px;left:149px;white-space:nowrap" class="ft2964"><b>Congestive heart failure:&#160;</b>Tell your doctor if the child has a history of congestive heart failure,&#160;<br/>because Enbrel needs to be used with caution under these circumstances.</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft29614"></p>
<p style="position:absolute;top:1074px;left:149px;white-space:nowrap" class="ft2964"><b>Cancer:&#160;</b>Tell your doctor if the child has or has ever had lymphoma (a type of blood cancer) or&#160;<br/>any other cancer before the child is given Enbrel.</p>
<p style="position:absolute;top:1112px;left:147px;white-space:nowrap" class="ft2963">Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at&#160;<br/>higher than average risk of developing lymphoma.</p>
</div>
<!-- Page 297 -->
<a name="297"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page297-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2970">297</p>
<p style="position:absolute;top:108px;left:147px;white-space:nowrap" class="ft2974">Children and adults taking Enbrel may have an increased risk of developing lymphoma or&#160;<br/>another cancer.<br/>Some&#160;children and teenage patients who have received Enbrel or other medicines that work the&#160;<br/>same way as Enbrel have developed cancers, including unusual types, which sometimes resulted&#160;<br/>in death.<br/>Some patients receiving Enbrel have developed skin cancers.&#160;Tell&#160;your doctor if the child&#160;<br/>develops any change in the appearance of the skin&#160;or growths on the skin.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft29714"></p>
<p style="position:absolute;top:242px;left:149px;white-space:nowrap" class="ft2974"><b>Chickenpox:&#160;</b>Tell your doctor if the child is exposed to chickenpox when using Enbrel. Your&#160;<br/>doctor will determine if preventative treatment for chickenpox is&#160;appropriate.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft29714"></p>
<p style="position:absolute;top:281px;left:149px;white-space:nowrap" class="ft2974"><b>Alcohol abuse</b>: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.&#160;<br/>Please tell your doctor if the child in your care&#160;has&#160;a history of alcohol abuse.</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft29714"></p>
<p style="position:absolute;top:320px;left:149px;white-space:nowrap" class="ft2973"><b>Wegener’s granulomatosis</b>: Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis, a rare inflammatory disease. If the child in your care&#160;has&#160;Wegener’s&#160;<br/>granulomatosis, talk to your doctor.</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft29714"></p>
<p style="position:absolute;top:378px;left:149px;white-space:nowrap" class="ft2974"><b>Anti-diabetic medicines</b>: Tell your doctor if the child has diabetes or is taking medicines to&#160;<br/>treat diabetes. Your&#160;doctor may decide if the child needs less anti-diabetic medicine while&#160;<br/>taking Enbrel.</p>
<p style="position:absolute;top:454px;left:106px;white-space:nowrap" class="ft2971"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:492px;left:106px;white-space:nowrap" class="ft2973"><b>Vaccinations:&#160;</b>If possible, children should be up to date with all vaccinations before using Enbrel.&#160;<br/>Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult&#160;the&#160;<br/>child’s&#160;doctor before the child receives&#160;any vaccines.</p>
<p style="position:absolute;top:568px;left:106px;white-space:nowrap" class="ft2974">Enbrel should not normally be used in children with&#160;polyarthritis or extended oligoarthritis&#160;below the&#160;<br/>age of 2 years,&#160;or in children with&#160;enthesitis-related arthritis or psoriatic arthritis below the age of 12&#160;<br/>years,&#160;or in children with psoriasis below the age of&#160;6&#160;years.</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft2971"><b>Other medicines&#160;and Enbrel</b></p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft2974">Tell&#160;your&#160;doctor or pharmacist if the child is taking, has recently taken&#160;or might take&#160;any&#160;other&#160;<br/>medicines (including anakinra, abatacept or sulfasalazine), even those not prescribed by the child's&#160;<br/>doctor. The child should not use Enbrel with medicines that contain the active substance anakinra or&#160;<br/>abatacept.</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft2971"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft2974">Enbrel&#160;should only be used&#160;during pregnancy&#160;if clearly needed.&#160;You should consult your doctor if you<br/>become pregnant,&#160;think you may be pregnant, or are planning to have a baby.</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft2974">If you received Enbrel during pregnancy,&#160;your&#160;baby may have a higher risk&#160;of&#160;getting an infection.&#160;In&#160;<br/>addition,&#160;one study&#160;found&#160;more birth defects when the mother had received&#160;Enbrel&#160;in pregnancy,&#160;<br/>compared&#160;with&#160;mothers who had not received&#160;Enbrel&#160;or other similar medicines (TNF-antagonists),&#160;<br/>but there was no&#160;particular kind of birth defect&#160;reported.&#160;Another study found no increased risk of birth&#160;<br/>defects when the mother had received Enbrel in pregnancy.&#160;Your doctor will help you to decide&#160;<br/>whether the benefits of treatment outweigh the potential risk to your baby.</p>
<p style="position:absolute;top:1004px;left:106px;white-space:nowrap" class="ft2973">Talk to your doctor if you want to breastfeed while on Enbrel treatment.&#160;It&#160;is important that you tell&#160;<br/>your&#160;baby’s doctors and other healthcare professionals about the use of Enbrel during pregnancy and&#160;<br/>breastfeeding before&#160;your&#160;baby receives any vaccine.</p>
<p style="position:absolute;top:1080px;left:106px;white-space:nowrap" class="ft2971"><b>Driving and using machines</b></p>
<p style="position:absolute;top:1118px;left:106px;white-space:nowrap" class="ft2972">The use of Enbrel is not expected to affect the ability to drive or use machines.</p>
</div>
<!-- Page 298 -->
<a name="298"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page298-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2980">298</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2981"><b>3.</b></p>
<p style="position:absolute;top:108px;left:146px;white-space:nowrap" class="ft2981"><b>How to use Enbrel</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft2981"><b>Use in children&#160;and adolescents</b></p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft2983">Always use&#160;this medicine&#160;exactly as the doctor has told you.&#160;Check with the doctor or pharmacist if&#160;<br/>you are not sure.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft2982">If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft2984">The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight&#160;<br/>and disease. The doctor will provide you with detailed directions for preparing and measuring the&#160;<br/>appropriate dose.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft2984">The 10&#160;mg&#160;vial is for children prescribed a dose of 10&#160;mg or less.&#160;Each vial should be used for just one&#160;<br/>dose in one patient, and any remaining solution should be discarded.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft2984">For&#160;polyarthritis or extended oligoarthritis&#160;in patients from the age of 2 years,&#160;or enthesitis-related&#160;<br/>arthritis or psoriatic arthritis in patients from the age of 12 years,&#160;the usual dose is 0.4&#160;mg of Enbrel&#160;<br/>per kg bodyweight (up to a maximum of 25&#160;mg) given twice weekly,&#160;or 0.8&#160;mg of Enbrel per kg of&#160;<br/>bodyweight (up to a maximum of 50&#160;mg) given once weekly.</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft2984">For psoriasis in patients from the age of&#160;6&#160;years, the usual dose is&#160;0.8&#160;mg of Enbrel per kg bodyweight&#160;<br/>(up to a maximum of 50&#160;mg), and should be given once weekly. If Enbrel has no effect on the child’s&#160;<br/>condition after 12 weeks, your doctor may tell you to stop using this medicine.</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft2981"><b>Method and route of administration</b></p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft2982">Enbrel is administered by an injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft2982">Enbrel can be taken with or without food or drink.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft29823">The powder must be dissolved before use.&#160;<b>Detailed instructions on how to prepare and inject&#160;<br/>Enbrel are provided in section 7, “Instructions for preparing and giving an injection of Enbrel”.&#160;<br/></b>Do not mix the Enbrel solution with any other medicine.</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft2984">To help you remember, it may be helpful to write in a diary which day(s) of the week Enbrel should be&#160;<br/>used.</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft2981"><b>If&#160;you use more Enbrel&#160;than you should</b></p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft2983">If you have used more Enbrel than you should (either by injecting too much on a single occasion or by&#160;<br/>using it too frequently), talk to a doctor or pharmacist immediately. Always have the outer carton of&#160;<br/>the medicine with you, even if it is empty.</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft2981"><b>If&#160;you forget to inject Enbrel</b></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft2983">If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is&#160;<br/>the next day; in which case you should skip the missed dose. Then continue to inject the medicine on&#160;<br/>the usual day(s). If you do not remember until the day that the next injection is due, do not take a&#160;<br/>double dose (two doses on the same day) to make up for a forgotten dose.</p>
</div>
<!-- Page 299 -->
<a name="299"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page299-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft2990">299</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft2991"><b>If&#160;you stop using Enbrel&#160;</b></p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft2992">Your symptoms may return upon discontinuation.&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft2992">If you have any&#160;further questions on the use of this&#160;medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft2991"><b>4.</b></p>
<p style="position:absolute;top:239px;left:146px;white-space:nowrap" class="ft2991"><b>Possible side effects</b></p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft2992">Like all medicines,&#160;this medicine&#160;can cause side effects,&#160;although not everybody gets them.</p>
<p style="position:absolute;top:315px;left:106px;white-space:nowrap" class="ft2991"><b>Allergic reactions</b></p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft2993">If any of the following happen to the&#160;child, do not give the child more Enbrel. Tell your doctor&#160;<br/>immediately, or go to the casualty department at your nearest hospital.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:411px;left:149px;white-space:nowrap" class="ft2992">Trouble swallowing or breathing</p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:431px;left:149px;white-space:nowrap" class="ft2992">Swelling of the face, throat, hands, or feet</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:451px;left:149px;white-space:nowrap" class="ft2994">Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm&#160;<br/>feeling</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:490px;left:149px;white-space:nowrap" class="ft2992">Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft2993">Serious allergic reactions are rare. If the child has any of the above symptoms he/she may be having&#160;<br/>an allergic reaction to Enbrel, so you should seek immediate medical attention.&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft2991"><b>Serious side effects</b></p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft2994">If you notice any of the following, the child may need urgent medical attention.<br/></p>
<p style="position:absolute;top:643px;left:149px;white-space:nowrap" class="ft2994">Signs of&#160;<b>serious infections</b>, such as high fever that may be accompanied by cough, shortness of&#160;<br/>breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:682px;left:149px;white-space:nowrap" class="ft2992">Signs of&#160;<b>blood disorders</b>, such as bleeding, bruising, or paleness</p>
<p style="position:absolute;top:701px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:702px;left:149px;white-space:nowrap" class="ft2994">Signs of&#160;<b>nerve disorders</b>, such as numbness or tingling, changes in vision, eye pain, or onset of&#160;<br/>weakness in an arm or leg</p>
<p style="position:absolute;top:740px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:742px;left:149px;white-space:nowrap" class="ft2993">Signs of&#160;<b>heart failure&#160;</b>or&#160;<b>worsening heart failure</b>, such as fatigue or shortness of breath with&#160;<br/>activity, swelling in the ankles, a feeling of fullness in the neck or abdomen, night-time&#160;<br/>shortness of breath or coughing, bluish&#160;colour of the nails or the lips</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:800px;left:149px;white-space:nowrap" class="ft2994"><b>Signs of cancers:&#160;</b>Cancers may affect any part of the body including the skin and blood, and&#160;<br/>possible signs will depend on the type and location of the cancer. These signs may include&#160;<br/>weight loss, fever, swelling (with or&#160;without pain), persistent cough, presence of lumps or&#160;<br/>growths on the skin</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:877px;left:149px;white-space:nowrap" class="ft2994">Signs of&#160;<b>autoimmune reactions&#160;</b>(where antibodies are made that may harm normal tissues in&#160;<br/>the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:916px;left:149px;white-space:nowrap" class="ft2994">Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or&#160;<br/>muscle pain, or fatigue</p>
<p style="position:absolute;top:953px;left:106px;white-space:nowrap" class="ft29914"></p>
<p style="position:absolute;top:955px;left:149px;white-space:nowrap" class="ft2994">Signs of&#160;<b>inflammation of the blood vessels&#160;</b>such as pain, fever, redness or warmth of the skin,&#160;<br/>or itching.</p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft2994">These are rare or uncommon side effects, but are serious conditions (some of which may rarely be&#160;<br/>fatal). If these signs occur, tell your doctor immediately, or take the child to the casualty department at&#160;<br/>your nearest hospital.</p>
</div>
<!-- Page 300 -->
<a name="300"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page300-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3000">300</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3002">The known side effects of Enbrel include the following in groups of decreasing frequency:</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft30014"></p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft3003"><b>Very common&#160;</b>(may affect more than 1 in 10&#160;people):<br/>Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections);&#160;<br/>injection site reactions (including bleeding, bruising, redness,&#160;itching, pain, and swelling)&#160;(these<br/>do not occur as often after the first month of treatment;&#160;some patients have developed a reaction&#160;<br/>at an injection site that was&#160;recently&#160;used);&#160;and headache.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft30014"></p>
<p style="position:absolute;top:262px;left:149px;white-space:nowrap" class="ft3003"><b>Common&#160;</b>(may affect up to 1 in 10&#160;people):<br/>Allergic reactions; fever;&#160;rash;&#160;itching; antibodies directed against normal tissue (autoantibody&#160;<br/>formation).</p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft30014"></p>
<p style="position:absolute;top:339px;left:149px;white-space:nowrap" class="ft3003"><b>Uncommon&#160;</b>(may affect up to 1 in 100&#160;people):<br/>Serious infections (including pneumonia, deep skin infections, joint infections, blood infection,&#160;<br/>and infections at various sites);&#160;worsening of congestive heart failure;&#160;low red blood cell count,&#160;<br/>low white blood cell count, low neutrophil (a type of white&#160;blood cell) count;&#160;low blood platelet&#160;<br/>count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives&#160;<br/>(elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or&#160;<br/>worsening);&#160;inflammation of the blood vessels affecting multiple organs; elevated liver blood&#160;<br/>tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood&#160;<br/>tests is common);&#160;abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs&#160;<br/>of&#160;bowel problems).</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft30014"></p>
<p style="position:absolute;top:549px;left:149px;white-space:nowrap" class="ft3004"><b>Rare&#160;</b>(may affect up to 1 in 1,000&#160;people):<br/>Serious allergic reactions (including severe localised swelling of the skin and wheezing);&#160;<br/>lymphoma (a type of blood cancer);&#160;leukaemia (cancer affecting the blood and bone marrow);<br/>melanoma (a&#160;type of skin cancer); combined low platelet, red, and white blood cell count;&#160;<br/>nervous system disorders (with severe muscle weakness and signs and symptoms similar to&#160;<br/>those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord);&#160;<br/>tuberculosis;&#160;new onset&#160;congestive heart failure; seizures; lupus or lupus-like syndrome&#160;<br/>(symptoms may include persistent rash, fever, joint pain, and tiredness);&#160;skin rash, which may&#160;<br/>lead to severe blistering and peeling of the skin;&#160;lichenoid reactions (itchy reddish-purple skin&#160;<br/>rash and/or threadlike white-grey lines on mucous membranes);&#160;inflammation of the liver&#160;<br/>caused by the body's own immune system (autoimmune hepatitis;&#160;in patients also receiving&#160;<br/>methotrexate treatment, the frequency is uncommon);&#160;immune disorder that can affect the lungs,&#160;<br/>skin and lymph nodes (sarcoidosis);&#160;inflammation or scarring of the lungs&#160;(in patients also&#160;<br/>receiving methotrexate treatment, the frequency&#160;of&#160;inflammation or scarring of the lungs is&#160;<br/>uncommon).</p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft30014"></p>
<p style="position:absolute;top:854px;left:149px;white-space:nowrap" class="ft3004"><b>Very rare&#160;</b>(may affect up to 1 in 10,000&#160;people):&#160;failure of the bone marrow to produce crucial&#160;<br/>blood cells.</p>
<p style="position:absolute;top:910px;left:106px;white-space:nowrap" class="ft30014"></p>
<p style="position:absolute;top:912px;left:149px;white-space:nowrap" class="ft3004"><b>Not known&#160;</b>(frequency cannot be estimated from the available data): Merkel cell carcinoma (a&#160;<br/>type of skin cancer);&#160;Kaposi’s sarcoma (a rare cancer related to&#160;infection with human herpes&#160;<br/>virus 8. Kaposi’s sarcoma most commonly appear as purple lesions on the skin);&#160;excessive&#160;<br/>activation of white blood cells associated with inflammation (macrophage activation&#160;<br/>syndrome);&#160;recurrence of hepatitis B (a liver&#160;infection);&#160;worsening of a condition called&#160;<br/>dermatomyositis (muscle inflammation and weakness&#160;with&#160;an&#160;accompanying&#160;skin rash).</p>
<p style="position:absolute;top:1044px;left:106px;white-space:nowrap" class="ft3001"><b>Additional side effects in children and adolescents</b></p>
<p style="position:absolute;top:1082px;left:106px;white-space:nowrap" class="ft3004">The side effects&#160;and their frequencies seen in children and adolescents are&#160;similar to those described&#160;<br/>above.</p>
</div>
<!-- Page 301 -->
<a name="301"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page301-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3010">301</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3011"><b>Reporting of side effects</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3013">If you get any side effects, talk to your doctor&#160;or&#160;pharmacist.&#160;This includes any possible&#160;side effects&#160;<br/>not listed in this leaflet.&#160;You can also report&#160;side effects directly&#160;via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>. By reporting side effects you can help provide more information on the safety of&#160;<br/>this medicine.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft3011"><b>5.</b></p>
<p style="position:absolute;top:260px;left:146px;white-space:nowrap" class="ft3011"><b>How to store Enbrel</b></p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft3012">Keep&#160;this medicine&#160;out of the sight and reach of children.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft3013">Do not use&#160;this medicine&#160;after the expiry date which is stated on the carton after EXP. The expiry date&#160;<br/>refers to the last day of that month.</p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft3012">Store in a refrigerator&#160;(2</p>
<p style="position:absolute;top:392px;left:267px;white-space:nowrap" class="ft30114">C&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft3018">Before preparing the Enbrel solution, Enbrel may be stored outside of the refrigerator at temperatures&#160;<br/>up to a maximum of 25</p>
<p style="position:absolute;top:450px;left:261px;white-space:nowrap" class="ft30114">C for a single period of up to four weeks; after which, it should not be&#160;</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft3013">refrigerated again. Enbrel&#160;should be discarded if not used within four weeks after removal from the&#160;<br/>refrigerator. It is recommended that you record the date that Enbrel is removed from the refrigerator&#160;<br/>and the date after which Enbrel should be discarded (no more than 4 weeks following the removal&#160;<br/>from the refrigerator).&#160;This new expiry date should not exceed the expiry date recorded on the outer&#160;<br/>carton.</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft3018">After preparing the Enbrel solution, immediate use is recommended. However, the solution may be&#160;<br/>used for up to 6&#160;hours&#160;when&#160;stored&#160;at a temperature up to 25</p>
<p style="position:absolute;top:603px;left:504px;white-space:nowrap" class="ft30114">C.&#160;</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft3014">Do not use&#160;this medicine&#160;if you notice the solution is not clear or contains particles. The solution&#160;<br/>should be clear, colourless&#160;to&#160;pale yellow&#160;or pale brown, with no lumps or flakes or particles.&#160;</p>
<p style="position:absolute;top:700px;left:106px;white-space:nowrap" class="ft3014">Do not throw away any medicines&#160;via wastewater or household waste. Ask your pharmacist how to&#160;<br/>throw away&#160;medicines&#160;you&#160;no longer&#160;use. These measures will help protect the environment.</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft3011"><b>6.</b></p>
<p style="position:absolute;top:776px;left:146px;white-space:nowrap" class="ft3011"><b>Contents of the pack and other information&#160;</b></p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft3011"><b>What Enbrel contains</b></p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft3014">The active ingredient in Enbrel is etanercept. Each vial of Enbrel 10&#160;mg powder and solvent for&#160;<br/>solution for injection for paediatric use contains 10&#160;mg of etanercept. When reconstituted, the solution&#160;<br/>contains 10&#160;mg/ml of etanercept.</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft3013">The other ingredients are:<br/>Powder: Mannitol&#160;(E421), sucrose, and trometamol.<br/>Solvent: Water for injections.</p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft3011"><b>What Enbrel looks like and contents of the pack</b></p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft3014">Enbrel 10&#160;mg powder and solvent for solution for injection for paediatric use is supplied as a white&#160;<br/>powder with solvent for solution for injection (powder for injection). Each pack contains 4 vials, 4&#160;<br/>pre-filled syringes of water for injections, 4 needles, 4 vial adaptors and 8 alcohol swabs.&#160;</p>
</div>
<!-- Page 302 -->
<a name="302"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page302-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3020">302</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3021"><b>Marketing Authorisation Holder and Manufacturer</b></p>
<p style="position:absolute;top:146px;left:114px;white-space:nowrap" class="ft3024"><i>Marketing Authorisation Holder:<br/></i>Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:260px;left:114px;white-space:nowrap" class="ft3024"><i>Manufacturer:<br/></i>Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft3023">For any information about this medicinal product, please contact the local representative of the&#160;<br/>Marketing Authorisation&#160;Holder.</p>
<p style="position:absolute;top:440px;left:114px;white-space:nowrap" class="ft3024"><b>België/Belgique/Belgien<br/>Luxembourg/Luxemburg<br/></b>Pfizer&#160;NV/SA<br/>Tél/Tel: +32 (0)2 554 62 11</p>
<p style="position:absolute;top:440px;left:452px;white-space:nowrap" class="ft3028"><b>Kύπρος<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.&#160;(CYPRUS BRANCH)&#160;<br/>T</p>
<p style="position:absolute;top:477px;left:462px;white-space:nowrap" class="ft30214">: +357 22 817690</p>
<p style="position:absolute;top:535px;left:114px;white-space:nowrap" class="ft3023"><b>Česká Republika<br/></b>Pfizer, spol.&#160;s&#160;r.o.<br/>Tel: +420-283-004-111</p>
<p style="position:absolute;top:535px;left:452px;white-space:nowrap" class="ft3023"><b>Magyarország<br/></b>Pfizer Kft.<br/>Tel: +36 1 488 3700</p>
<p style="position:absolute;top:611px;left:114px;white-space:nowrap" class="ft3024"><b>Danmark<br/></b>Pfizer ApS<br/>Tlf: +45 44&#160;201&#160;100</p>
<p style="position:absolute;top:611px;left:452px;white-space:nowrap" class="ft3024"><b>Malta<br/></b>Vivian Corporation Ltd.<br/>Tel: +35621 344610</p>
<p style="position:absolute;top:687px;left:114px;white-space:nowrap" class="ft3023"><b>Deutschland<br/></b>Pfizer Pharma GmbH<br/>Tel: +49 (0)30 550055-51000</p>
<p style="position:absolute;top:687px;left:452px;white-space:nowrap" class="ft3023"><b>Nederland<br/></b>Pfizer bv<br/>Tel: +31&#160;(0)800 63 34 636</p>
<p style="position:absolute;top:765px;left:114px;white-space:nowrap" class="ft3023"><b>България<br/></b>Пфайзер Люксембург САРЛ,&#160;<br/>Клон България<br/>Teл:&#160;+359 2 970 4333</p>
<p style="position:absolute;top:765px;left:452px;white-space:nowrap" class="ft3024"><b>Norge<br/></b>Pfizer AS<br/>Tlf: +47 67&#160;52&#160;61&#160;00</p>
<p style="position:absolute;top:859px;left:114px;white-space:nowrap" class="ft3024"><b>Eesti<br/></b>Pfizer Luxembourg SARL Eesti filiaal<br/>Tel:&#160;+372 666 7500</p>
<p style="position:absolute;top:859px;left:452px;white-space:nowrap" class="ft3024"><b>Österreich<br/></b>Pfizer Corporation Austria Ges.m.b.H.<br/>Tel: +43 (0)1 521 15-0</p>
<p style="position:absolute;top:935px;left:114px;white-space:nowrap" class="ft3024"><b>Ελλάδα<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.<br/>Τηλ.: +30 210 67&#160;85 800</p>
<p style="position:absolute;top:935px;left:452px;white-space:nowrap" class="ft3024"><b>Polska<br/></b>Pfizer Polska Sp. z o.o.<br/>Tel.: +48 22 335 61 00</p>
<p style="position:absolute;top:1021px;left:114px;white-space:nowrap" class="ft3024"><b>España<br/></b>Pfizer, S.L.<br/>Télf: +34&#160;91&#160;490&#160;99&#160;00</p>
<p style="position:absolute;top:1021px;left:452px;white-space:nowrap" class="ft3024"><b>Portugal<br/></b>Laboratórios Pfizer, Lda.<br/>Tel: (+351) 21 423 55 00</p>
<p style="position:absolute;top:1102px;left:114px;white-space:nowrap" class="ft3023"><b>France<br/></b>Pfizer<br/>Tél&#160;+33 (0)1 58 07 34 40</p>
<p style="position:absolute;top:1102px;left:452px;white-space:nowrap" class="ft3023"><b>România<br/></b>Pfizer Romania S.R.L<br/>Tel: +40 (0) 21 207 28 00</p>
</div>
<!-- Page 303 -->
<a name="303"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page303-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3030">303</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft3034"><b>Hrvatska<br/></b>Pfizer Croatia&#160;d.o.o.<br/>Tel: +385 1&#160;3908&#160;777</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft3034"><b>Slovenija<br/></b>Pfizer Luxembourg SARL<i>,&#160;</i>Pfizer, podružnica&#160;<br/>za&#160;svetovanje s področja farmacevtske&#160;<br/>dejavnosti, Ljubljana<br/>Tel: +386&#160;(0)1 52 11 400</p>
<p style="position:absolute;top:222px;left:114px;white-space:nowrap" class="ft3034"><b>Ireland<br/></b>Pfizer Healthcare Ireland<br/>Tel: +1800 633 363 (toll free)<br/>Tel: +44 (0)1304 616161</p>
<p style="position:absolute;top:222px;left:452px;white-space:nowrap" class="ft3033"><b>Slovenská Republika<br/></b>Pfizer Luxembourg SARL, organizačná zložka&#160;<br/>Tel: +421 2 3355 5500</p>
<p style="position:absolute;top:316px;left:114px;white-space:nowrap" class="ft3033"><b>Ísland<br/></b>Icepharma&#160;hf.<br/>Tel: +354&#160;540 8000</p>
<p style="position:absolute;top:316px;left:452px;white-space:nowrap" class="ft3033"><b>Suomi/Finland<br/></b>Pfizer Oy<br/>Puh/Tel: +358 (0)9&#160;430 040</p>
<p style="position:absolute;top:396px;left:114px;white-space:nowrap" class="ft3034"><b>Italia<br/></b>Pfizer S.r.l.<br/>Tel: +39 06 33 18 21</p>
<p style="position:absolute;top:396px;left:452px;white-space:nowrap" class="ft3034"><b>Sverige&#160;<br/></b>Pfizer AB<br/>Tel: +46 (0)8&#160;550&#160;520 00</p>
<p style="position:absolute;top:476px;left:114px;white-space:nowrap" class="ft3033"><b>Latvija<br/></b>Pfizer Luxembourg SARL filiāle Latvijā<br/>Tel. +371 67035775</p>
<p style="position:absolute;top:476px;left:452px;white-space:nowrap" class="ft3033"><b>United Kingdom&#160;(Northern Ireland)<br/></b>Pfizer Limited<br/>Tel:&#160;+44&#160;(0)1304 616161</p>
<p style="position:absolute;top:555px;left:114px;white-space:nowrap" class="ft3034"><b>Lietuva<br/></b>Pfizer Luxembourg SARL filialas Lietuvoje<br/>Tel. +3705 2514000</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft3031"><b>This leaflet was last&#160;revised&#160;in</b></p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft3033">Detailed information on this&#160;medicine&#160;is available on the&#160;European Medicines Agency&#160;web&#160;site:<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft3031"><b>7.</b></p>
<p style="position:absolute;top:768px;left:146px;white-space:nowrap" class="ft3031"><b>Instructions for preparing and giving an injection of Enbrel</b></p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft3032">This section is divided into the following sub-sections:</p>
<p style="position:absolute;top:844px;left:127px;white-space:nowrap" class="ft30324"><b>a.&#160;Introduction<br/>b.&#160;Setting up for an injection<br/>c.&#160;Preparing the Enbrel dose&#160;for injection&#160;<br/>d.&#160;Adding solvent<br/>e.&#160;Withdrawing the Enbrel solution from the vial<br/>f.&#160;Placing the needle on the syringe<br/>g.&#160;Choosing an injection site&#160;<br/>h.&#160;Preparing the injection site and injecting the Enbrel solution<br/>i.&#160;Disposing of supplies</b></p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft3031"><b>a.</b></p>
<p style="position:absolute;top:1034px;left:149px;white-space:nowrap" class="ft3031"><b>Introduction</b></p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft3033">The following&#160;instructions explain how to prepare and inject Enbrel. Please read the instructions&#160;<br/>carefully and follow them step by step. You will be instructed by the child's doctor or his/her assistant&#160;<br/>on the technique of giving an injection and on the amount to be given to the child. Do not attempt to&#160;<br/>administer an injection until you are sure that you understand how to prepare and give the injection.</p>
</div>
<!-- Page 304 -->
<a name="304"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page304-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3040">304</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3044">This injection should not be mixed in the same syringe or vial with any other medicine. See section 5&#160;<br/>for instructions on how to store Enbrel.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft3041"><b>b.</b></p>
<p style="position:absolute;top:165px;left:149px;white-space:nowrap" class="ft3041"><b>Setting up for an injection</b></p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:204px;left:149px;white-space:nowrap" class="ft3042">Wash your hands thoroughly.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft3042">Select a clean well-lit, flat working surface.</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft3044">The dose tray should contain the items listed below. (If not, don’t use the dose tray and consult&#160;<br/>your pharmacist). Use only&#160;the items listed.&#160;<b>Do NOT&#160;</b>use any other syringe.</p>
<p style="position:absolute;top:282px;left:170px;white-space:nowrap" class="ft3046"><i>1 Enbrel vial<br/>1 Pre-filled syringe containing clear, colourless solvent (water for injections)<br/>1 Needle<br/>1 Vial adaptor<br/>2 Alcohol swabs</i></p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:378px;left:149px;white-space:nowrap" class="ft3044">Inspect the expiry dates on both the vial label and the syringe label.&#160;They should not be used&#160;<br/>after the month and year shown.</p>
<p style="position:absolute;top:435px;left:106px;white-space:nowrap" class="ft3041"><b>c.</b></p>
<p style="position:absolute;top:435px;left:149px;white-space:nowrap" class="ft3041"><b>Preparing&#160;the Enbrel dose for injection</b></p>
<p style="position:absolute;top:472px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:474px;left:149px;white-space:nowrap" class="ft3042">Remove the contents of the tray</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:494px;left:149px;white-space:nowrap" class="ft3044">Remove the plastic cap from the Enbrel vial (see Diagram 1).&#160;<b>Do NOT&#160;</b>remove the grey stopper&#160;<br/>or aluminium ring around the top of the vial.</p>
<p style="position:absolute;top:551px;left:411px;white-space:nowrap" class="ft3042">Diagram 1</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:733px;left:149px;white-space:nowrap" class="ft3044">Use a new alcohol swab to clean the grey stopper on the Enbrel vial. After cleaning, do not&#160;<br/>touch the stopper with your hands or allow it to touch any surface.</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:772px;left:149px;white-space:nowrap" class="ft3042">Place the vial upright on a clean, flat surface.</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:792px;left:149px;white-space:nowrap" class="ft3042">Remove the paper&#160;backing from the vial adaptor package.</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:813px;left:149px;white-space:nowrap" class="ft3044">While still in the plastic package, place the vial adaptor on top of the Enbrel vial so that the vial&#160;<br/>adaptor spike is centered within the raised circle on top of the vial stopper (see Diagram 2).</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft30414"></p>
<p style="position:absolute;top:852px;left:149px;white-space:nowrap" class="ft3044">Hold the vial firmly&#160;on the flat surface with one hand. With the other hand, push&#160;<b>STRAIGHT&#160;<br/>DOWN FIRMLY&#160;</b>on the adaptor package until you feel the adaptor spike penetrate the vial&#160;<br/>stopper and&#160;<b>FEEL AND HEAR THE ADAPTOR RIM LOCK INTO PLACE&#160;</b>(see Diagram&#160;<br/>3).&#160;<b>Do NOT&#160;</b>push down the adaptor at an angle (see Diagram 4). It is important that the vial&#160;<br/>adaptor spike completely penetrates the vial stopper.</p>
<p style="position:absolute;top:966px;left:266px;white-space:nowrap" class="ft3042">Diagram 2</p>
<p style="position:absolute;top:966px;left:411px;white-space:nowrap" class="ft3042">Diagram 3</p>
<p style="position:absolute;top:966px;left:557px;white-space:nowrap" class="ft3042">Diagram 4</p>
<p style="position:absolute;top:1123px;left:405px;white-space:nowrap" class="ft3041"><b>CORRECT</b></p>
<p style="position:absolute;top:1123px;left:542px;white-space:nowrap" class="ft3041"><b>INCORRECT</b></p>
</div>
<!-- Page 305 -->
<a name="305"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page305-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3050">305</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft30514"></p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft3054">While holding the vial in&#160;one hand, remove the plastic packaging from the vial adaptor (see&#160;<br/>Diagram 5).</p>
<p style="position:absolute;top:175px;left:411px;white-space:nowrap" class="ft3052">Diagram 5</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft30514"></p>
<p style="position:absolute;top:358px;left:149px;white-space:nowrap" class="ft3054">Remove the protective cover from the syringe tip by breaking the white cap along the&#160;<br/>perforation. This is done by holding the collar of the white cap while grasping the end of the&#160;<br/>white cap with the other hand and bending it down and then up until it is broken (see Diagram&#160;<br/>6).&#160;<b>Do NOT remove the white collar that remains on the syringe</b>.</p>
<p style="position:absolute;top:453px;left:411px;white-space:nowrap" class="ft3052">Diagram 6</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft30514"></p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft3054">Do not use the syringe if the perforation between the tip and collar is already broken. Start again&#160;<br/>with another dose tray.</p>
<p style="position:absolute;top:668px;left:106px;white-space:nowrap" class="ft30514"></p>
<p style="position:absolute;top:670px;left:149px;white-space:nowrap" class="ft3054">Holding the glass barrel of the&#160;syringe (not the white collar) in one hand, and the vial adaptor&#160;<br/>(not the vial) in the other, connect the syringe to the vial adaptor by inserting the tip into the&#160;<br/>opening and turn clockwise until completely secured (see Diagram 7).</p>
<p style="position:absolute;top:746px;left:411px;white-space:nowrap" class="ft3052">Diagram 7</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft3051"><b>d.</b></p>
<p style="position:absolute;top:908px;left:149px;white-space:nowrap" class="ft3051"><b>Adding solvent</b></p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft30514"></p>
<p style="position:absolute;top:947px;left:149px;white-space:nowrap" class="ft3054">While holding the vial upright on the flat surface, push the plunger VERY SLOWLY until all&#160;<br/>the solvent is in the vial. This will help to reduce foaming (lots of bubbles) (see Diagram 8).</p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft30514"></p>
<p style="position:absolute;top:987px;left:149px;white-space:nowrap" class="ft3054">Once the solvent is added to the Enbrel, the plunger may move up by itself. This is due to air&#160;<br/>pressure and should not be of concern.</p>
</div>
<!-- Page 306 -->
<a name="306"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page306-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3060">306</p>
<p style="position:absolute;top:108px;left:411px;white-space:nowrap" class="ft3062">Diagram 8</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft30614"></p>
<p style="position:absolute;top:285px;left:149px;white-space:nowrap" class="ft3064">With the syringe still attached, gently move the vial in circles a few times, to dissolve the&#160;<br/>powder (see Diagram 9).&#160;<b>Do NOT&#160;</b>shake the vial. Wait until all the powder dissolves (usually&#160;<br/>less than 10&#160;minutes). The solution should be clear and colourless&#160;to pale yellow or pale brown,&#160;<br/>with no lumps, flakes, or particles. Some white foam may remain in the vial&#160;&#160;this is normal.&#160;<b>Do&#160;<br/>NOT&#160;</b>use Enbrel if all the powder in the vial is not dissolved within 10 minutes. Start again with&#160;<br/>another dose tray.</p>
<p style="position:absolute;top:418px;left:411px;white-space:nowrap" class="ft3062">Diagram 9</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft3061"><b>e.</b></p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft3061"><b>Withdrawing the Enbrel solution from the vial</b></p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft30614"></p>
<p style="position:absolute;top:635px;left:149px;white-space:nowrap" class="ft3064">The doctor or his/her assistant should have instructed you on the proper amount of solution to&#160;<br/>be withdrawn from the vial. If the doctor has not given this instruction, please contact him/her.</p>
<p style="position:absolute;top:672px;left:106px;white-space:nowrap" class="ft30614"></p>
<p style="position:absolute;top:674px;left:149px;white-space:nowrap" class="ft3064">With the syringe still attached to the vial and vial adaptor, hold the vial upside down at eye&#160;<br/>level. Push the plunger all the way into the syringe (see Diagram 10).</p>
<p style="position:absolute;top:740px;left:407px;white-space:nowrap" class="ft3062">Diagram 10</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft30614"></p>
<p style="position:absolute;top:919px;left:149px;white-space:nowrap" class="ft3064">Then, slowly pull the plunger back to draw the liquid into the syringe (see Diagram 11).&#160;<br/>Remove only the portion of liquid as directed by your child’s doctor. After you have withdrawn&#160;<br/>the Enbrel from the vial, you&#160;may have some air in the syringe. Do not be concerned, as you&#160;<br/>will remove the air in a later step.</p>
</div>
<!-- Page 307 -->
<a name="307"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page307-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3070">307</p>
<p style="position:absolute;top:108px;left:407px;white-space:nowrap" class="ft3072">Diagram 11</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:280px;left:149px;white-space:nowrap" class="ft3074">With the vial held upside down, unscrew the syringe from the vial adaptor by turning it&#160;<br/>anti-clockwise (see Diagram 12).</p>
<p style="position:absolute;top:346px;left:407px;white-space:nowrap" class="ft3072">Diagram 12</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:525px;left:149px;white-space:nowrap" class="ft3074">Place&#160;the filled syringe on the clean, flat surface. Make sure that the tip does not touch anything.&#160;<br/>Be careful not to push down on the plunger.</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft3071"><b>f.</b></p>
<p style="position:absolute;top:582px;left:149px;white-space:nowrap" class="ft3071"><b>Placing the needle on the syringe</b></p>
<p style="position:absolute;top:619px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:621px;left:149px;white-space:nowrap" class="ft3072">The needle has been placed in a plastic container to keep it sterile.</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:641px;left:149px;white-space:nowrap" class="ft3074">To open the&#160;plastic container, hold the short, wide end in one hand. Place your other hand on the&#160;<br/>longer portion of the container.</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:681px;left:149px;white-space:nowrap" class="ft3072">To break the seal, bend the larger end down and then up until broken (see Diagram 13).</p>
<p style="position:absolute;top:728px;left:407px;white-space:nowrap" class="ft3072">Diagram 13</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:891px;left:149px;white-space:nowrap" class="ft3072">Once the seal has been broken, remove the short, wide end of the plastic container.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:911px;left:149px;white-space:nowrap" class="ft3072">The needle will remain in the long part of the package.</p>
<p style="position:absolute;top:929px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:931px;left:149px;white-space:nowrap" class="ft3074">While holding the needle and container in one hand, pick up the syringe and insert the syringe&#160;<br/>tip into the needle opening.</p>
<p style="position:absolute;top:968px;left:106px;white-space:nowrap" class="ft30714"></p>
<p style="position:absolute;top:970px;left:149px;white-space:nowrap" class="ft3072">Attach the syringe to the needle by turning it clockwise until completely secured (see Diagram&#160;</p>
<p style="position:absolute;top:989px;left:160px;white-space:nowrap" class="ft3072">14).</p>
</div>
<!-- Page 308 -->
<a name="308"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page308-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3080">308</p>
<p style="position:absolute;top:108px;left:407px;white-space:nowrap" class="ft3082">Diagram 14</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft30814"></p>
<p style="position:absolute;top:289px;left:154px;white-space:nowrap" class="ft3083">Remove the needle cover by firmly pulling it straight off the syringe taking care not to touch&#160;<br/>the needle or allow the needle to touch any surfaces (see Diagram 15). Be&#160;careful not to bend or&#160;<br/>twist the cover during removal to avoid damage to the needle.</p>
<p style="position:absolute;top:392px;left:407px;white-space:nowrap" class="ft3082">Diagram 15</p>
<p style="position:absolute;top:572px;left:106px;white-space:nowrap" class="ft30814"></p>
<p style="position:absolute;top:574px;left:149px;white-space:nowrap" class="ft3084">While holding the syringe upright, remove any air bubbles by slowly pushing on the plunger&#160;<br/>until the air is removed (see Diagram 16).</p>
<p style="position:absolute;top:630px;left:407px;white-space:nowrap" class="ft3082">Diagram 16</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft3081"><b>g.</b></p>
<p style="position:absolute;top:810px;left:149px;white-space:nowrap" class="ft3081"><b>Choosing an injection site</b></p>
<p style="position:absolute;top:847px;left:106px;white-space:nowrap" class="ft30814"></p>
<p style="position:absolute;top:849px;left:149px;white-space:nowrap" class="ft3084">The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2)&#160;<br/>the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper&#160;<br/>arms (see Diagram 17). If you are self injecting, you should not use the outer area of the upper&#160;<br/>arms.</p>
</div>
<!-- Page 309 -->
<a name="309"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page309-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3090">309</p>
<p style="position:absolute;top:108px;left:407px;white-space:nowrap" class="ft3092">Diagram 17</p>
<p style="position:absolute;top:377px;left:106px;white-space:nowrap" class="ft30914"></p>
<p style="position:absolute;top:379px;left:147px;white-space:nowrap" class="ft3092">A different site should be used for each new injection. Each new injection should be given at&#160;</p>
<p style="position:absolute;top:398px;left:149px;white-space:nowrap" class="ft3094">least 3&#160;cm from an old site.&#160;<b>Do NOT&#160;</b>inject into areas where the skin is tender, bruised, red, or&#160;<br/>hard. Avoid areas with scars or stretch marks. (It may be helpful to keep notes on the location of&#160;<br/>the previous injections.)</p>
<p style="position:absolute;top:454px;left:106px;white-space:nowrap" class="ft30914"></p>
<p style="position:absolute;top:456px;left:147px;white-space:nowrap" class="ft3092">If the child has psoriasis, you should try not to inject directly into any raised, thick, red, or scaly&#160;</p>
<p style="position:absolute;top:475px;left:149px;white-space:nowrap" class="ft3092">skin patches (“psoriasis skin lesions”).</p>
<p style="position:absolute;top:513px;left:106px;white-space:nowrap" class="ft3091"><b>h.</b></p>
<p style="position:absolute;top:513px;left:149px;white-space:nowrap" class="ft3091"><b>Preparing the injection site and injecting the Enbrel solution</b></p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft30914"></p>
<p style="position:absolute;top:552px;left:147px;white-space:nowrap" class="ft3092">Wipe the site where Enbrel is to be injected with a new alcohol swab, using a circular motion.&#160;</p>
<p style="position:absolute;top:571px;left:149px;white-space:nowrap" class="ft3091"><b>Do NOT&#160;</b>touch this area again before giving the injection.</p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft30914"></p>
<p style="position:absolute;top:591px;left:147px;white-space:nowrap" class="ft3092">When the cleaned area of skin has dried, pinch and hold it firmly with one hand. With the other&#160;</p>
<p style="position:absolute;top:610px;left:149px;white-space:nowrap" class="ft3092">hand, hold the syringe like a pencil.</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft30914"></p>
<p style="position:absolute;top:630px;left:147px;white-space:nowrap" class="ft3093">With a quick, short motion, push the needle all the way into the skin&#160;at an angle between 45°&#160;<br/>and 90° (see Diagram 18). With experience, you will find the angle that is most comfortable for&#160;<br/>the child. Be careful not to push the needle into the skin too slowly, or with great force.</p>
<p style="position:absolute;top:720px;left:407px;white-space:nowrap" class="ft3092">Diagram 18</p>
<p style="position:absolute;top:957px;left:106px;white-space:nowrap" class="ft30914"></p>
<p style="position:absolute;top:959px;left:149px;white-space:nowrap" class="ft3093">When the needle is completely&#160;inserted into the skin, release the skin that you are holding. With&#160;<br/>your free hand, hold the syringe near its base to stabilise it. Then push the plunger to inject all of&#160;<br/>the solution at a&#160;<b>slow</b>, steady rate (see Diagram 19).</p>
</div>
<!-- Page 310 -->
<a name="310"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page310-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3100">310</p>
<p style="position:absolute;top:108px;left:407px;white-space:nowrap" class="ft3102">Diagram 19</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft31014"></p>
<p style="position:absolute;top:356px;left:149px;white-space:nowrap" class="ft3104">When the&#160;syringe is empty, remove the needle from the skin; being careful to keep it at the same&#160;<br/>angle it was when it was inserted.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft31014"></p>
<p style="position:absolute;top:395px;left:149px;white-space:nowrap" class="ft31023">Press a cotton ball over the injection site for 10 seconds. Slight bleeding may occur.&#160;<b>Do NOT<br/></b>rub the injection site. A bandage is optional.</p>
<p style="position:absolute;top:452px;left:106px;white-space:nowrap" class="ft3101"><b>i.</b></p>
<p style="position:absolute;top:452px;left:149px;white-space:nowrap" class="ft3101"><b>Disposing of supplies</b></p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft31014"></p>
<p style="position:absolute;top:491px;left:149px;white-space:nowrap" class="ft3104">The syringe and needles should&#160;<b>NEVER&#160;</b>be re-used. Dispose of the needles and syringe as&#160;<br/>instructed by your doctor, nurse or pharmacist.</p>
<p style="position:absolute;top:548px;left:121px;white-space:nowrap" class="ft3102">If you have any questions, please talk to a doctor, nurse or pharmacist who is familiar&#160;with Enbrel.</p>
</div>
<!-- Page 311 -->
<a name="311"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page311-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3110">311</p>
<p style="position:absolute;top:108px;left:298px;white-space:nowrap" class="ft3111"><b>Package Leaflet: Information for the User</b></p>
<p style="position:absolute;top:146px;left:226px;white-space:nowrap" class="ft3111"><b>Enbrel 25&#160;mg solution for injection in dose-dispenser cartridge</b></p>
<p style="position:absolute;top:165px;left:413px;white-space:nowrap" class="ft3112">etanercept</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft31123"><b>Read all of this leaflet carefully before you start using this medicine because it contains&#160;<br/>important information for&#160;you.</b></p>
<p style="position:absolute;top:240px;left:123px;white-space:nowrap" class="ft31114"></p>
<p style="position:absolute;top:242px;left:162px;white-space:nowrap" class="ft3112">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:260px;left:123px;white-space:nowrap" class="ft31114"></p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft3112">Your doctor will also give you a Patient Card, which contains important safety information that&#160;</p>
<p style="position:absolute;top:281px;left:164px;white-space:nowrap" class="ft3112">you need to be aware of before and during treatment with Enbrel.</p>
<p style="position:absolute;top:299px;left:123px;white-space:nowrap" class="ft31114"></p>
<p style="position:absolute;top:301px;left:162px;white-space:nowrap" class="ft3112">If you&#160;have&#160;any further questions, ask&#160;your doctor,&#160;pharmacist or nurse.</p>
<p style="position:absolute;top:319px;left:123px;white-space:nowrap" class="ft31114"></p>
<p style="position:absolute;top:321px;left:162px;white-space:nowrap" class="ft3112">This medicine has been prescribed for you or a child in your care. Do not pass it on to others. It&#160;</p>
<p style="position:absolute;top:340px;left:164px;white-space:nowrap" class="ft3114">may harm them, even if their&#160;signs of illness&#160;are the same as yours or those of the child you are&#160;<br/>caring for.</p>
<p style="position:absolute;top:378px;left:123px;white-space:nowrap" class="ft31114"></p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft3112">If you&#160;get&#160;any side effects,&#160;talk to&#160;your doctor or pharmacist.&#160;This includes any possible side&#160;</p>
<p style="position:absolute;top:398px;left:164px;white-space:nowrap" class="ft3112">effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft3111"><b>What is in this leaflet</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft3112">Information in this leaflet is organised under the following&#160;6&#160;sections:</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft3112">1.</p>
<p style="position:absolute;top:512px;left:149px;white-space:nowrap" class="ft3112">What Enbrel is and&#160;what it is used for</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft3112">2.</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft3112">What you need to know before you use Enbrel</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft3112">3.</p>
<p style="position:absolute;top:550px;left:149px;white-space:nowrap" class="ft3112">How to use Enbrel</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft3112">4.</p>
<p style="position:absolute;top:569px;left:149px;white-space:nowrap" class="ft3112">Possible side effects</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft3112">5.</p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft3112">How to store Enbrel</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft3112">6.</p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft3112">Contents of the pack and other information&#160;(See Instructions for Use)</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft3111"><b>1.</b></p>
<p style="position:absolute;top:664px;left:146px;white-space:nowrap" class="ft3111"><b>What Enbrel is and what it is used for</b></p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft3114">Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in&#160;<br/>the body that causes inflammation. Enbrel works by reducing the inflammation associated with certain&#160;<br/>diseases.</p>
<p style="position:absolute;top:778px;left:106px;white-space:nowrap" class="ft3114">In adults (aged 18 and over), Enbrel can&#160;be used for moderate or severe&#160;<b>rheumatoid arthritis</b>,&#160;<br/><b>psoriatic arthritis</b>, severe&#160;<b>axial spondyloarthritis&#160;</b>including&#160;<b>ankylosing spondylitis,&#160;</b>and moderate&#160;<br/>or severe&#160;<b>psoriasis&#160;</b>–&#160;in each case usually when other widely used treatments have not worked well&#160;<br/>enough or are not suitable for you.</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft3114">For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may&#160;<br/>also be used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in&#160;<br/>combination with methotrexate, Enbrel can slow down the damage to your joints caused by the&#160;<br/>rheumatoid arthritis and improve your ability to do normal daily activities.</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft3113">For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do&#160;<br/>normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands,&#160;<br/>wrists and feet), Enbrel can slow down the structural damage to those joints&#160;caused by the disease.&#160;</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft3112">Enbrel is also prescribed for the treatment of the following diseases in children and adolescents</p>
<p style="position:absolute;top:1081px;left:133px;white-space:nowrap" class="ft31114">&#160;For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not&#160;</p>
<p style="position:absolute;top:1101px;left:147px;white-space:nowrap" class="ft3112">worked well enough or is not suitable for them:</p>
<p style="position:absolute;top:1139px;left:187px;white-space:nowrap" class="ft31114">&#160;Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in&#160;</p>
<p style="position:absolute;top:1160px;left:214px;white-space:nowrap" class="ft3112">patients from the age of 2 years</p>
</div>
<!-- Page 312 -->
<a name="312"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page312-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3120">312</p>
<p style="position:absolute;top:126px;left:187px;white-space:nowrap" class="ft31214">&#160;Psoriatic arthritis in patients from the age of 12 years</p>
<p style="position:absolute;top:165px;left:133px;white-space:nowrap" class="ft31214">&#160;For enthesitis-related arthritis in patients from the age of 12&#160;years when other widely used&#160;</p>
<p style="position:absolute;top:186px;left:160px;white-space:nowrap" class="ft3122">treatments have not worked well enough or are not suitable for them</p>
<p style="position:absolute;top:223px;left:133px;white-space:nowrap" class="ft31214">&#160;Severe psoriasis in patients from the age of 6 years who have had an inadequate response to (or&#160;</p>
<p style="position:absolute;top:244px;left:147px;white-space:nowrap" class="ft3122">are unable to take) phototherapies or other systemic therapies.</p>
<p style="position:absolute;top:301px;left:106px;white-space:nowrap" class="ft3121"><b>2.</b></p>
<p style="position:absolute;top:301px;left:146px;white-space:nowrap" class="ft3121"><b>What you need to know before you use Enbrel&#160;</b></p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft3121"><b>Do not use Enbrel</b></p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:378px;left:147px;white-space:nowrap" class="ft3123">if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of&#160;<br/>Enbrel&#160;(listed in section 6). If you or the child experience allergic reactions&#160;such as chest&#160;<br/>tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor&#160;<br/>immediately.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:455px;left:147px;white-space:nowrap" class="ft3124">if you or the child have, or are at risk of developing a serious blood infection called sepsis. If&#160;<br/>you are not sure, please contact your doctor.</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:494px;left:147px;white-space:nowrap" class="ft3122">if you&#160;or the child, have an infection of any kind. If you are not sure, please talk to your doctor.</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft3121"><b>Warnings and precautions&#160;</b></p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft3122">Talk to your doctor before taking Enbrel.</p>
<p style="position:absolute;top:608px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:609px;left:147px;white-space:nowrap" class="ft3124"><b>Allergic reactions</b>: If you or the child experience allergic reactions such as&#160;chest tightness,&#160;<br/>wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:648px;left:147px;white-space:nowrap" class="ft3124"><b>Infections/surgery</b>: If you or the child develop a new infection, or are about to have any major&#160;<br/>surgery, your doctor may wish to monitor the treatment with Enbrel.</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:688px;left:147px;white-space:nowrap" class="ft3124"><b>Infections/diabetes:&#160;</b>Tell your doctor if you or the child have a history of recurrent infections or&#160;<br/>suffer from diabetes or other conditions that increase the risk of infection.</p>
<p style="position:absolute;top:725px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:727px;left:147px;white-space:nowrap" class="ft3121"><b>Infections/monitoring:&#160;</b>Tell your doctor of any recent&#160;travel outside the European region. If you&#160;</p>
<p style="position:absolute;top:746px;left:149px;white-space:nowrap" class="ft3123">or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor&#160;<br/>immediately. Your doctor may decide to continue to monitor you or the child for the presence of&#160;<br/>infections after you&#160;or the child stop using Enbrel.</p>
<p style="position:absolute;top:802px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:804px;left:147px;white-space:nowrap" class="ft3121"><b>Tuberculosis:&#160;</b>As cases of tuberculosis have been reported in patients treated with Enbrel, your&#160;</p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft3124">doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may&#160;<br/>include a thorough medical history, a&#160;chest X-ray and a tuberculin test. The conduct of these&#160;<br/>tests should be recorded on the Patient Card. It is very important that you tell your doctor if you&#160;<br/>or the child have ever had tuberculosis, or have been in close contact with someone who has had&#160;<br/>tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:938px;left:147px;white-space:nowrap" class="ft3121"><b>Hepatitis B:&#160;</b>Tell your&#160;doctor if you&#160;or the child&#160;have or have ever had hepatitis B.&#160;Your doctor&#160;</p>
<p style="position:absolute;top:957px;left:149px;white-space:nowrap" class="ft3124">should test&#160;for the presence of hepatitis B infection before you or the child begin treatment with&#160;<br/>Enbrel.&#160;Treatment with Enbrel may result in reactivation of hepatitis B in patients who have&#160;<br/>previously been infected with the hepatitis B virus. If this occurs, you should stop using Enbrel.</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:1015px;left:147px;white-space:nowrap" class="ft3121"><b>Hepatitis C:&#160;</b>Tell your doctor if you or the child have hepatitis C. Your doctor may wish to&#160;</p>
<p style="position:absolute;top:1034px;left:149px;white-space:nowrap" class="ft3122">monitor the treatment with Enbrel in case the infection worsens.</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft31214"></p>
<p style="position:absolute;top:1054px;left:147px;white-space:nowrap" class="ft3123"><b>Blood disorders:&#160;</b>Seek medical advice immediately if you or the child have any signs or&#160;<br/>symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms&#160;<br/>may point to the existence of potentially life-threatening blood disorders, which may require&#160;<br/>discontinuation of Enbrel.</p>
</div>
<!-- Page 313 -->
<a name="313"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page313-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3130">313</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft31314"></p>
<p style="position:absolute;top:109px;left:147px;white-space:nowrap" class="ft3134"><b>Nervous system and eye disorders:&#160;</b>Tell your doctor if you or the child have multiple sclerosis,&#160;<br/>optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of&#160;<br/>the spinal cord). Your doctor will determine if Enbrel is an appropriate treatment.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft31314"></p>
<p style="position:absolute;top:167px;left:147px;white-space:nowrap" class="ft3134"><b>Congestive heart failure:&#160;</b>Tell your doctor if you or the child have a history of congestive heart&#160;<br/>failure, because Enbrel needs to be used with caution under these circumstances.</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft31314"></p>
<p style="position:absolute;top:206px;left:147px;white-space:nowrap" class="ft3134"><b>Cancer:&#160;</b>Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or&#160;<br/>any other cancer before you are given Enbrel.<br/>Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at&#160;<br/>higher than average risk of developing lymphoma.<br/>Children and&#160;adults taking Enbrel may have an increased risk of developing lymphoma or&#160;<br/>another cancer.<br/>Some children and teenage patients who have received Enbrel or other medicines that work the&#160;<br/>same way as Enbrel have developed cancers, including unusual types, which&#160;sometimes resulted&#160;<br/>in death.<br/>Some patients receiving Enbrel have developed skin cancers.&#160;Tell&#160;your doctor if you or the child&#160;<br/>develop any change in the appearance of the skin&#160;or growths on the skin.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft31314"></p>
<p style="position:absolute;top:416px;left:147px;white-space:nowrap" class="ft3134"><b>Chickenpox:&#160;</b>Tell your doctor if you or the child are exposed to chickenpox when using Enbrel.&#160;<br/>Your doctor will determine if preventive treatment for chickenpox is appropriate.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft31314"></p>
<p style="position:absolute;top:455px;left:147px;white-space:nowrap" class="ft3133"><b>Latex:&#160;</b>The needle cover is made from latex (dry natural rubber). Contact your doctor before&#160;<br/>using Enbrel if the needle cover will be handled by, or Enbrel will be given to, someone with a&#160;<br/>known or possible hypersensitivity (allergy) to latex.</p>
<p style="position:absolute;top:511px;left:106px;white-space:nowrap" class="ft31314"></p>
<p style="position:absolute;top:513px;left:147px;white-space:nowrap" class="ft3134"><b>Alcohol abuse</b>: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.&#160;<br/>Please tell your doctor if you or the child in your&#160;care have a history of alcohol abuse.</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft31314"></p>
<p style="position:absolute;top:552px;left:147px;white-space:nowrap" class="ft3133"><b>Wegener’s granulomatosis</b>: Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener’s&#160;<br/>granulomatosis, talk to your doctor.</p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft31314"></p>
<p style="position:absolute;top:611px;left:147px;white-space:nowrap" class="ft3133"><b>Anti-diabetic medicines</b>: Tell your doctor if you or the child have diabetes or are taking&#160;<br/>medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic&#160;<br/>medicine while taking Enbrel.</p>
<p style="position:absolute;top:687px;left:106px;white-space:nowrap" class="ft3131"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft3133">Vaccinations: If possible, children should be up to date with all vaccinations before using Enbrel.&#160;<br/>Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult the&#160;<br/>child’s doctor before the child receives any vaccines.</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft3133">Enbrel should not normally be used in children with polyarthritis or extended oligoarthritis below the&#160;<br/>age of 2 years, or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12&#160;<br/>years, or in children with psoriasis below the age of 6 years.</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft3131"><b>Other medicines and Enbrel</b></p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft3133">Tell the doctor or pharmacist if you or the child are taking,&#160;have recently taken&#160;or might take&#160;any other&#160;<br/>medicines (including anakinra, abatacept or sulfasalazine), even those not prescribed by the doctor.&#160;<br/>You or the child should not use Enbrel with medicines that contain the active substance anakinra or&#160;<br/>abatacept.</p>
<p style="position:absolute;top:1014px;left:106px;white-space:nowrap" class="ft3131"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft3133">Enbrel&#160;should only be used&#160;during pregnancy&#160;if clearly needed.&#160;You should consult your doctor if you<br/>become pregnant,&#160;think you may be pregnant, or are planning to have a baby.</p>
<p style="position:absolute;top:1109px;left:106px;white-space:nowrap" class="ft3134">If you received Enbrel during pregnancy,&#160;your&#160;baby may have a higher risk&#160;of&#160;getting an infection.&#160;In&#160;<br/>addition,&#160;one study&#160;found&#160;more birth defects when the mother had received&#160;Enbrel&#160;in pregnancy,&#160;<br/>compared&#160;with&#160;mothers who had not received Enbrel or other similar medicines (TNF-antagonists),&#160;</p>
</div>
<!-- Page 314 -->
<a name="314"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page314-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3140">314</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3144">but there was no&#160;particular kind of birth defect&#160;reported.&#160;Another study found no increased risk of birth&#160;<br/>defects when the mother had received Enbrel in pregnancy. Your doctor will help you to decide&#160;<br/>whether the benefits of treatment outweigh the potential risk to your baby.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft3144">Talk to your doctor if you want to breastfeed while on Enbrel treatment.&#160;It&#160;is important that you tell&#160;<br/>your&#160;baby’s doctors and other healthcare professionals about the use of Enbrel during pregnancy and&#160;<br/>breastfeeding before&#160;your&#160;baby receives any vaccine.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft3141"><b>Driving and using machines</b></p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft3142">The use of Enbrel is not expected to affect&#160;the ability to drive or use machines.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft3141"><b>Enbrel contains sodium</b></p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft3143">This medicine&#160;contains less than 1&#160;mmol sodium (23&#160;mg) per dosage unit, that is to say&#160;essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft3141"><b>3.</b></p>
<p style="position:absolute;top:450px;left:146px;white-space:nowrap" class="ft3141"><b>How to use Enbrel</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft3144">Always use&#160;this medicine&#160;exactly as the doctor has told you. Check with the doctor or pharmacist if&#160;<br/>you are not sure.</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3142">If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft3142">The dose-dispenser cartridge is available&#160;in dose strengths of 25&#160;mg and 50&#160;mg.</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft3141"><b>Dosing for adult patients (aged 18 years or over)</b></p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft3142">Rheumatoid arthritis, psoriatic arthritis,&#160;and&#160;axial spondyloarthritis including&#160;ankylosing spondylitis</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft3144">The usual dose is 25&#160;mg given twice a week or 50&#160;mg&#160;once a week as an injection under the skin.&#160;<br/>However, your doctor may determine an alternative frequency at which to inject Enbrel.&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft3142">Plaque psoriasis</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft3142">The usual dose is 25&#160;mg twice a week or 50&#160;mg once a&#160;week. &#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft3144">Alternatively, 50&#160;mg&#160;may be given twice a week for up to 12 weeks, followed by 25&#160;mg twice a week&#160;<br/>or 50&#160;mg once a week.&#160;</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft3143">Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on&#160;<br/>your response. If Enbrel has no effect on your condition after 12 weeks, your doctor may tell you to&#160;<br/>stop taking this medicine.</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft3141"><b>Use in children and adolescents</b></p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft3144">The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight&#160;<br/>and disease. Your doctor will determine the correct dose for the child and will prescribe an appropriate&#160;<br/>strength of Enbrel (10&#160;mg, 25&#160;mg or 50&#160;mg).</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft3144">For polyarthritis or extended oligoarthritis in patients from the age of 2 years, or enthesitis-related&#160;<br/>arthritis or psoriatic arthritis in patients from the age of 12 years, the usual dose is 0.4&#160;mg of Enbrel&#160;<br/>per kg bodyweight (up to a maximum of 25&#160;mg) given twice weekly, or 0.8&#160;mg of Enbrel per kg of&#160;<br/>bodyweight (up to a maximum of 50&#160;mg) given once weekly.</p>
</div>
<!-- Page 315 -->
<a name="315"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page315-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3150">315</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3154">For psoriasis in patients from the age of 6 years, the usual dose is 0.8&#160;mg of Enbrel per kg bodyweight&#160;<br/>(up to a maximum of 50&#160;mg), and should be given once weekly. If Enbrel has no effect on the child’s&#160;<br/>condition after 12 weeks, your doctor may tell you to stop using this medicine.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft3152">The doctor will provide you with detailed directions for preparing and measuring the appropriate dose.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft3151"><b>Method and route of administration</b></p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft3152">Enbrel is administered by an injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft3152">Enbrel can be taken with or without food or drink.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft3153"><b>Detailed instructions on how to inject Enbrel are provided in&#160;“Instructions for&#160;Use”.&#160;</b>Do not mix&#160;<br/>the Enbrel solution with any other medicine.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft3154">To help you remember, it may be helpful to write in&#160;a diary which day(s) of the week Enbrel should be&#160;<br/>used.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft3151"><b>If&#160;you use more Enbrel than you should</b></p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft3153">If you have used more Enbrel than you should (either by injecting too much on a single occasion or by&#160;<br/>using it too frequently), talk to a doctor or pharmacist&#160;immediately. Always have the outer carton of&#160;<br/>the medicine with you, even if it is empty.</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft3151"><b>If&#160;you forget to inject Enbrel</b></p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft3154">If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is&#160;<br/>the next day; in which case you&#160;should skip the missed dose. Then continue to inject the medicine on&#160;<br/>the usual day(s). If you do not remember until the day that the next injection is due, do not take a&#160;<br/>double dose (two doses on the same day) to make up for a forgotten dose.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft3151"><b>If&#160;you stop using Enbrel&#160;</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft3152">Your symptoms may return upon discontinuation.&#160;</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft3152">If you have any further questions on the use of this&#160;medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft3151"><b>4.</b></p>
<p style="position:absolute;top:829px;left:146px;white-space:nowrap" class="ft3151"><b>Possible side effects</b></p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft3152">Like all medicines,&#160;this medicine&#160;can cause side effects, although not everybody gets them.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft3151"><b>Allergic reactions</b></p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft3153">If any of the following happen, do not inject more Enbrel. Tell your doctor immediately, or go to the&#160;<br/>casualty department at your nearest hospital.</p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft31514"></p>
<p style="position:absolute;top:1001px;left:149px;white-space:nowrap" class="ft3152">Trouble swallowing or breathing</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft31514"></p>
<p style="position:absolute;top:1021px;left:149px;white-space:nowrap" class="ft3152">Swelling of the face, throat, hands, or feet</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft31514"></p>
<p style="position:absolute;top:1041px;left:149px;white-space:nowrap" class="ft3154">Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm&#160;<br/>feeling</p>
<p style="position:absolute;top:1078px;left:106px;white-space:nowrap" class="ft31514"></p>
<p style="position:absolute;top:1080px;left:149px;white-space:nowrap" class="ft3152">Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p>
<p style="position:absolute;top:1118px;left:106px;white-space:nowrap" class="ft3153">Serious allergic&#160;reactions are rare. However, any of the above symptoms may indicate an allergic&#160;<br/>reaction to Enbrel, so you should seek immediate medical attention.</p>
</div>
<!-- Page 316 -->
<a name="316"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page316-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3160">316</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3161"><b>Serious side effects</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3162">If you notice any of the following, you or the child may need urgent medical attention.</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft3164">Signs of&#160;<b>serious infections</b>, such as high fever that may be accompanied by cough, shortness of&#160;<br/>breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft3162">Signs of&#160;<b>blood disorders</b>, such as bleeding, bruising, or paleness</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft3164">Signs of&#160;<b>nerve disorders</b>, such as numbness or tingling, changes in vision, eye pain, or onset of&#160;<br/>weakness in an arm or leg</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft3164">Signs of&#160;<b>heart failure&#160;</b>or&#160;<b>worsening heart failure</b>, such as fatigue or shortness of breath with&#160;<br/>activity, swelling in the ankles, a feeling of fullness in the neck or abdomen, night-time&#160;<br/>shortness of breath or coughing, bluish colour of the nails or the lips</p>
<p style="position:absolute;top:340px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft3163"><b>Signs of cancers:&#160;</b>Cancers may affect any part of the body including the skin and blood, and&#160;<br/>possible signs will depend on the type and location of the cancer. These signs may include&#160;<br/>weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or&#160;<br/>growths on the skin</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:418px;left:149px;white-space:nowrap" class="ft3164">Signs of&#160;<b>autoimmune reactions&#160;</b>(where antibodies are made that may harm normal tissues in&#160;<br/>the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:458px;left:149px;white-space:nowrap" class="ft3164">Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or&#160;<br/>muscle pain, or fatigue</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:497px;left:149px;white-space:nowrap" class="ft3164">Signs of&#160;<b>inflammation of the blood vessels&#160;</b>such as&#160;pain, fever, redness or warmth of the skin,&#160;<br/>or itching.</p>
<p style="position:absolute;top:554px;left:106px;white-space:nowrap" class="ft3164">These are rare or uncommon side effects, but are serious conditions (some of which may rarely be&#160;<br/>fatal). If these signs occur, tell your doctor immediately, or visit the casualty department at your&#160;<br/>nearest hospital.</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft3162">The known side effects of Enbrel include the following in groups of decreasing frequency:</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:669px;left:149px;white-space:nowrap" class="ft3161"><b>Very common&#160;</b>(may affect more than 1 in&#160;10&#160;people):</p>
<p style="position:absolute;top:687px;left:124px;white-space:nowrap" class="ft31614">&#160;Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections);&#160;</p>
<p style="position:absolute;top:708px;left:151px;white-space:nowrap" class="ft3163">injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling) (these&#160;<br/>do not occur as often after the first month of treatment; some patients have developed a reaction&#160;<br/>at an injection site that was recently used); and headache.</p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:785px;left:149px;white-space:nowrap" class="ft3164"><b>Common&#160;</b>(may affect up to 1 in 10&#160;people):<br/>Allergic reactions; fever; rash;&#160;itching; antibodies directed against normal tissue (autoantibody&#160;<br/>formation).</p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:862px;left:149px;white-space:nowrap" class="ft3161"><b>Uncommon&#160;</b>(may affect up to 1 in 100&#160;people):</p>
<p style="position:absolute;top:880px;left:124px;white-space:nowrap" class="ft31614">&#160;Serious infections (including pneumonia, deep skin&#160;infections, joint infections, blood infection,&#160;</p>
<p style="position:absolute;top:901px;left:151px;white-space:nowrap" class="ft3163">and infections at various sites); worsening of congestive heart failure; low red blood cell count,&#160;<br/>low white blood cell count, low neutrophil (a type of white blood cell) count; low blood platelet&#160;<br/>count; skin&#160;cancer (excluding melanoma); localised swelling of the skin (angioedema); hives&#160;<br/>(elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or&#160;<br/>worsening); inflammation of the blood vessels affecting multiple organs; elevated liver blood&#160;<br/>tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood&#160;<br/>tests is common); abdominal cramps and pain, diarrhoea, weight loss or blood in the stool&#160;<br/>(signs of bowel problems).</p>
<p style="position:absolute;top:1071px;left:107px;white-space:nowrap" class="ft31614"></p>
<p style="position:absolute;top:1073px;left:151px;white-space:nowrap" class="ft3163"><b>Rare&#160;</b>(may affect up to 1 in 1,000&#160;people):<br/>Serious allergic reactions (including severe localised swelling of the skin and wheezing);&#160;<br/>lymphoma (a type of blood cancer);&#160;leukaemia (cancer affecting the blood and bone marrow);<br/>melanoma (a type of skin cancer); combined low platelet, red,&#160;and white blood cell count;&#160;<br/>nervous system disorders (with severe muscle weakness and signs and symptoms similar to&#160;</p>
</div>
<!-- Page 317 -->
<a name="317"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page317-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3170">317</p>
<p style="position:absolute;top:108px;left:152px;white-space:nowrap" class="ft3174">those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord);&#160;<br/>tuberculosis;&#160;new onset&#160;congestive heart failure; seizures; lupus or lupus-like syndrome&#160;<br/>(symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may&#160;<br/>lead to severe blistering and peeling of the skin;&#160;lichenoid reactions (itchy reddish-purple skin&#160;<br/>rash and/or threadlike white-grey lines on mucous membranes);&#160;inflammation of the liver&#160;<br/>caused by the body's own immune system (autoimmune hepatitis;&#160;in patients also receiving&#160;<br/>methotrexate treatment, the frequency is uncommon); immune disorder that can affect the&#160;<br/>lungs, skin and lymph nodes (sarcoidosis);&#160;inflammation or scarring of the lungs&#160;(in patients&#160;<br/>also receiving methotrexate treatment, the frequency&#160;of&#160;inflammation or scarring of the lungs is&#160;<br/>uncommon).</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft31714"></p>
<p style="position:absolute;top:318px;left:149px;white-space:nowrap" class="ft3174"><b>Very rare&#160;</b>(may affect up to 1 in 10,000&#160;people): failure of the bone&#160;marrow to produce crucial&#160;<br/>blood cells.</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft31714"></p>
<p style="position:absolute;top:376px;left:149px;white-space:nowrap" class="ft3174"><b>Not known&#160;</b>(frequency cannot be estimated from the available data): Merkel cell carcinoma (a&#160;<br/>type of skin cancer);&#160;Kaposi’s sarcoma (a rare cancer related to infection with human herpes&#160;<br/>virus 8. Kaposi’s sarcoma most&#160;commonly appear as purple lesions on the skin);&#160;excessive&#160;<br/>activation of white blood cells associated with inflammation (macrophage activation&#160;<br/>syndrome);&#160;recurrence of hepatitis B (a liver infection);&#160;worsening of a condition called&#160;<br/>dermatomyositis (muscle&#160;inflammation and weakness&#160;with&#160;an&#160;accompanying&#160;skin rash).</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft3171"><b>Side effects in children and adolescents</b></p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft3173">The side effects and their frequencies seen in children and adolescents are similar to those described&#160;<br/>above.</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft3171"><b>Reporting of side effects</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft3174">If you get any&#160;side effects, talk to your doctor&#160;or&#160;pharmacist.&#160;This includes any possible&#160;side effects&#160;<br/>not listed in this leaflet.&#160;You can also report side effects directly&#160;via the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>. By reporting side effects you can help provide more information on the safety of&#160;<br/>this medicine.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft3171"><b>5.</b></p>
<p style="position:absolute;top:755px;left:149px;white-space:nowrap" class="ft3171"><b>How to store Enbrel</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft3172">Keep this medicine out of the sight and reach of children.</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft3173">Do&#160;not use this medicine after the expiry date which is stated on the carton and the label after “EXP”.&#160;<br/>The expiry date refers to the last day of that month.</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft3172">Store in a refrigerator (2</p>
<p style="position:absolute;top:887px;left:267px;white-space:nowrap" class="ft31714">C&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft3172">Keep the dose-dispenser cartridge in the outer&#160;carton in order to protect from light.</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft3173">After taking a dose-dispenser cartridge from the refrigerator, wait approximately 15-30&#160;minutes to&#160;<br/>allow the Enbrel solution&#160;in the dose-dispenser cartridge to reach room temperature. Do not warm in&#160;<br/>any other way. Immediate use is then recommended.</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft3173">The dose-dispenser cartridges may be stored at room temperature (up to 25°C) for a single period of&#160;<br/>up to 4&#160;weeks with protection from light; after which they should not be refrigerated again.&#160;Enbrel&#160;<br/>should be discarded if&#160;not used within four weeks after removal from the refrigerator. It is&#160;<br/>recommended that you record the date that the Enbrel dose-dispenser is removed from the refrigerator&#160;<br/>and the date after which Enbrel should be discarded (no more than 4&#160;weeks following&#160;the removal&#160;<br/>from the refrigerator).</p>
</div>
<!-- Page 318 -->
<a name="318"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page318-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3180">318</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3183">Inspect the solution in the dose-dispenser cartridge by looking through the inspection window. The&#160;<br/>solution should be clear or slightly opalescent, colourless to pale yellow or pale brown, and may&#160;<br/>contain small white or&#160;almost transparent particles of protein.&#160;This appearance is normal for Enbrel.&#160;<br/>Do not use the solution if it is discoloured, cloudy, or if particles other than those described above are&#160;<br/>present. If you are concerned with the appearance of the solution, then contact your pharmacist for&#160;<br/>assistance.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft3183">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to&#160;<br/>throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft3181"><b>6.</b></p>
<p style="position:absolute;top:316px;left:146px;white-space:nowrap" class="ft3181"><b>Contents of the pack and other information&#160;</b></p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft3181"><b>What Enbrel contains</b></p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft3184">Enbrel 25&#160;mg&#160;solution for injection in dose-dispenser cartridge<br/>The active substance in Enbrel is etanercept. Each&#160;dose-dispenser cartridge&#160;contains 0.5&#160;ml of&#160;<br/>solution, providing 25&#160;mg of etanercept.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft3183">The other&#160;ingredients are sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate&#160;<br/>monobasic dihydrate and sodium phosphate dibasic dihydrate, and water for injections.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft3181"><b>What Enbrel looks like and contents of the pack</b></p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft3184">Enbrel is provided as a solution for injection in a ready to use dose-dispenser cartridge. The&#160;<br/>dose-dispenser cartridge is to be used with SMARTCLIC device. The device is provided separately.&#160;<br/>The solution is clear to opalescent, colourless to pale yellow or pale brown.</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft3183">Enbrel 25&#160;mg&#160;solution for injection in dose-dispenser cartridge<br/>Cartons contain 4, 8 or 24 dose-dispenser cartridges with 8, 16 or 48 alcohol swabs. Not all pack sizes&#160;<br/>may be marketed.</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft3181"><b>Marketing Authorisation Holder and Manufacturer</b></p>
<p style="position:absolute;top:753px;left:114px;white-space:nowrap" class="ft3184"><i>Marketing Authorisation Holder:<br/></i>Pfizer&#160;Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:867px;left:114px;white-space:nowrap" class="ft3184"><i>Manufacturer:<br/></i>Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
<p style="position:absolute;top:990px;left:106px;white-space:nowrap" class="ft3184">For any information about this medicinal product, please contact the local representative of the&#160;<br/>Marketing&#160;Authorisation Holder.</p>
<p style="position:absolute;top:1047px;left:114px;white-space:nowrap" class="ft3184"><b>België/Belgique/Belgien<br/>Luxembourg/Luxemburg<br/></b>Pfizer NV/SA<br/>Tél/Tel: +32 (0)2 554 62 11</p>
<p style="position:absolute;top:1047px;left:452px;white-space:nowrap" class="ft3188"><b>Kύπρος<br/></b>PFIZER EΛΛAΣ&#160;A.E. (CYPRUS BRANCH)&#160;<br/>T</p>
<p style="position:absolute;top:1085px;left:462px;white-space:nowrap" class="ft31814">: +357 22 817690</p>
</div>
<!-- Page 319 -->
<a name="319"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page319-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3190">319</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft3194"><b>Česká Republika<br/></b>Pfizer, spol.&#160;s&#160;r.o.<br/>Tel: +420-283-004-111</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft3194"><b>Magyarország<br/></b>Pfizer Kft.<br/>Tel: +36 1 488 3700</p>
<p style="position:absolute;top:184px;left:114px;white-space:nowrap" class="ft3194"><b>Danmark<br/></b>Pfizer ApS<br/>Tlf: +45 44&#160;201&#160;100</p>
<p style="position:absolute;top:184px;left:452px;white-space:nowrap" class="ft3194"><b>Malta<br/></b>Vivian Corporation Ltd.<br/>Tel: +35621 344610</p>
<p style="position:absolute;top:260px;left:114px;white-space:nowrap" class="ft3193"><b>Deutschland<br/></b>Pfizer Pharma GmbH<br/>Tel: +49 (0)30 550055-51000</p>
<p style="position:absolute;top:260px;left:452px;white-space:nowrap" class="ft3193"><b>Nederland<br/></b>Pfizer bv<br/>Tel: +31 (0)800 63 34 636</p>
<p style="position:absolute;top:337px;left:114px;white-space:nowrap" class="ft3193"><b>България<br/></b>Пфайзер Люксембург САРЛ,&#160;<br/>Клон България<br/>Teл:&#160;+359 2 970 4333</p>
<p style="position:absolute;top:337px;left:452px;white-space:nowrap" class="ft3194"><b>Norge<br/></b>Pfizer AS<br/>Tlf: +47 67&#160;52&#160;61&#160;00</p>
<p style="position:absolute;top:432px;left:114px;white-space:nowrap" class="ft3194"><b>Eesti<br/></b>Pfizer Luxembourg SARL Eesti filiaal<br/>Tel: +372 666 7500</p>
<p style="position:absolute;top:432px;left:452px;white-space:nowrap" class="ft3194"><b>Österreich<br/></b>Pfizer Corporation&#160;Austria Ges.m.b.H.<br/>Tel: +43 (0)1 521 15-0</p>
<p style="position:absolute;top:508px;left:114px;white-space:nowrap" class="ft3193"><b>Ελλάδα<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.<br/>Τηλ.: +30 210 67 85 800</p>
<p style="position:absolute;top:508px;left:452px;white-space:nowrap" class="ft3193"><b>Polska<br/></b>Pfizer Polska Sp. z o.o.<br/>Tel.: +48 22 335 61 00</p>
<p style="position:absolute;top:593px;left:114px;white-space:nowrap" class="ft3194"><b>España<br/></b>Pfizer, S.L.<br/>Télf: +34 91 490 99 00</p>
<p style="position:absolute;top:593px;left:452px;white-space:nowrap" class="ft3194"><b>Portugal<br/></b>Laboratórios Pfizer, Lda.<br/>Tel: (+351) 21 423 55 00</p>
<p style="position:absolute;top:675px;left:114px;white-space:nowrap" class="ft3193"><b>France<br/></b>Pfizer<br/>Tél&#160;+33 (0)1 58 07 34 40</p>
<p style="position:absolute;top:675px;left:452px;white-space:nowrap" class="ft3193"><b>România<br/></b>Pfizer Romania S.R.L<br/>Tel: +40 (0) 21 207 28 00</p>
<p style="position:absolute;top:751px;left:114px;white-space:nowrap" class="ft3194"><b>Hrvatska<br/></b>Pfizer Croatia d.o.o.<br/>Tel: +385 1 3908 777</p>
<p style="position:absolute;top:751px;left:452px;white-space:nowrap" class="ft3194"><b>Slovenija<br/></b>Pfizer Luxembourg SARL<i>,&#160;Pfizer, podružnica&#160;<br/>za&#160;</i>svetovanje s področja farmacevtske&#160;<br/>dejavnosti,&#160;Ljubljana<br/>Tel: +386 (0)1 52 11 400</p>
<p style="position:absolute;top:864px;left:114px;white-space:nowrap" class="ft3194"><b>Ireland<br/></b>Pfizer Healthcare Ireland<br/>Tel: +1800 633 363 (toll free)<br/>Tel: +44 (0)1304 616161</p>
<p style="position:absolute;top:864px;left:452px;white-space:nowrap" class="ft3193"><b>Slovenská Republika<br/></b>Pfizer Luxembourg SARL, organizačná zložka&#160;<br/>Tel: +421 2 3355 5500</p>
<p style="position:absolute;top:959px;left:114px;white-space:nowrap" class="ft3193"><b>Ísland<br/></b>Icepharma&#160;hf.<br/>Tel: +354&#160;540 8000</p>
<p style="position:absolute;top:959px;left:452px;white-space:nowrap" class="ft3193"><b>Suomi/Finland<br/></b>Pfizer Oy<br/>Puh/Tel: +358 (0)9&#160;430 040</p>
<p style="position:absolute;top:1039px;left:114px;white-space:nowrap" class="ft3194"><b>Italia<br/></b>Pfizer S.r.l.<br/>Tel: +39 06 33 18 21</p>
<p style="position:absolute;top:1039px;left:452px;white-space:nowrap" class="ft3194"><b>Sverige&#160;<br/></b>Pfizer AB<br/>Tel: +46 (0)8&#160;550&#160;520 00</p>
</div>
<!-- Page 320 -->
<a name="320"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page320-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3200">320</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft3204"><b>Latvija<br/></b>Pfizer Luxembourg SARL filiāle Latvijā<br/>Tel. +371 67035775</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft3204"><b>United Kingdom&#160;(Northern Ireland)<br/></b>Pfizer&#160;Limited<br/>Tel:&#160;+44 (0)1304 616161</p>
<p style="position:absolute;top:187px;left:114px;white-space:nowrap" class="ft3203"><b>Lietuva<br/></b>Pfizer Luxembourg SARL filialas Lietuvoje<br/>Tel. +3705 2514000</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft3201"><b>This leaflet was last revised in</b></p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft3204">Detailed information on this medicine is available on the European Medicines Agency web site:<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>
</div>
<!-- Page 321 -->
<a name="321"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft32138{font-size:27px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
	.ft32139{font-size:27px;font-family:PZJVUM+TimesNewRoman,BoldItalic;color:#000000;}
	.ft32140{font-size:21px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
	.ft32141{font-size:18px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
	.ft32142{font-size:18px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page321-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3210">321</p>
<p style="position:absolute;top:108px;left:332px;white-space:nowrap" class="ft32138"><b>Instructions for Use</b></p>
<p style="position:absolute;top:139px;left:398px;white-space:nowrap" class="ft32139"><i><b>Enbrel®</b></i></p>
<p style="position:absolute;top:170px;left:396px;white-space:nowrap" class="ft32140">(etanercept)</p>
<p style="position:absolute;top:194px;left:385px;white-space:nowrap" class="ft32140">25 mg / 0.5 ml</p>
<p style="position:absolute;top:218px;left:327px;white-space:nowrap" class="ft32141">For Subcutaneous Injection Only</p>
<p style="position:absolute;top:260px;left:357px;white-space:nowrap" class="ft32142"><b>Important Information</b></p>
<p style="position:absolute;top:300px;left:133px;white-space:nowrap" class="ft32114">&#160;Keep this Instructions for Use, it shows step-by-step how to prepare and&#160;give an injection.</p>
<p style="position:absolute;top:320px;left:133px;white-space:nowrap" class="ft32114">&#160;Only use Enbrel after you read and understand this Instructions for Use.</p>
<p style="position:absolute;top:341px;left:133px;white-space:nowrap" class="ft32114">&#160;Only use Enbrel after you have received training from your healthcare professional.</p>
<p style="position:absolute;top:361px;left:133px;white-space:nowrap" class="ft32114">&#160;Your Dose Dispenser Cartridge contains a single dose of Enbrel and must only be&#160;used with&#160;</p>
<p style="position:absolute;top:382px;left:160px;white-space:nowrap" class="ft3212">your SMARTCLIC Device.</p>
<p style="position:absolute;top:400px;left:133px;white-space:nowrap" class="ft32114">&#160;Dose Dispenser Cartridge and SMARTCLIC Device will be referred to as “Cartridge” and&#160;</p>
<p style="position:absolute;top:421px;left:160px;white-space:nowrap" class="ft3212">“Device” in this Instructions for Use.</p>
<p style="position:absolute;top:439px;left:133px;white-space:nowrap" class="ft32114">&#160;If this is the first time you are using your Device, make sure you follow the setup instructions&#160;</p>
<p style="position:absolute;top:460px;left:160px;white-space:nowrap" class="ft3214">in&#160;the separate User Manual. You will not be able to use your Device until you complete the&#160;<br/>setup.</p>
<p style="position:absolute;top:497px;left:133px;white-space:nowrap" class="ft32114">&#160;<b>Do not&#160;</b>attempt to use your Cartridges with any other Device.</p>
<p style="position:absolute;top:517px;left:133px;white-space:nowrap" class="ft32114">&#160;<b>Do not&#160;</b>share your Cartridges or your Device with another person.</p>
<p style="position:absolute;top:537px;left:133px;white-space:nowrap" class="ft32114">&#160;<b>Do not&#160;</b>shake your Cartridges or your Device containing a Cartridge.</p>
<p style="position:absolute;top:558px;left:133px;white-space:nowrap" class="ft32114">&#160;<b>Do not&#160;</b>reuse your Cartridge if the needle cap has been removed.</p>
<p style="position:absolute;top:578px;left:133px;white-space:nowrap" class="ft32114">&#160;Avoid spilling liquid on your Cartridges or your Device. Never rinse or put your Cartridges or&#160;</p>
<p style="position:absolute;top:598px;left:160px;white-space:nowrap" class="ft3212">your Device under water.</p>
<p style="position:absolute;top:617px;left:133px;white-space:nowrap" class="ft32114">&#160;Refer to the additional Device User Manual for accessing menus, using a Training Cartridge,&#160;</p>
<p style="position:absolute;top:638px;left:160px;white-space:nowrap" class="ft3212">advanced use and troubleshooting error messages.</p>
<p style="position:absolute;top:677px;left:417px;white-space:nowrap" class="ft32142"><b>Storage</b></p>
<p style="position:absolute;top:718px;left:133px;white-space:nowrap" class="ft32114">&#160;Store Cartridges in the refrigerator between 2 ºC to 8 ºC (36 ºF to 46 ºF).&#160;<b>Do not&#160;</b>freeze your&#160;</p>
<p style="position:absolute;top:739px;left:160px;white-space:nowrap" class="ft3212">Cartridges.&#160;<b>Do not&#160;</b>store your Cartridges in your Device.</p>
<p style="position:absolute;top:757px;left:133px;white-space:nowrap" class="ft32114">&#160;Store Cartridges in their original Carton until use to protect from direct sunlight.</p>
<p style="position:absolute;top:777px;left:133px;white-space:nowrap" class="ft32114">&#160;You may store your Cartridges at room temperature up to 25 ºC (77 ºF) for up to 4 weeks.&#160;<b>Do&#160;</b></p>
<p style="position:absolute;top:798px;left:160px;white-space:nowrap" class="ft3211"><b>not&#160;</b>return them to the refrigerator after they have reached room temperature.</p>
<p style="position:absolute;top:817px;left:133px;white-space:nowrap" class="ft32114">&#160;Keep your Cartridges and your Device out of sight and reach of children and adolescents.</p>
<p style="position:absolute;top:837px;left:133px;white-space:nowrap" class="ft32114">&#160;Refer to your Device User Manual for how to store and clean your Device.</p>
<p style="position:absolute;top:878px;left:377px;white-space:nowrap" class="ft32142"><b>Supplies you need</b></p>
<p style="position:absolute;top:919px;left:133px;white-space:nowrap" class="ft32114">&#160;<b>Gather&#160;</b>the following supplies on a clean flat surface:</p>
<p style="position:absolute;top:940px;left:187px;white-space:nowrap" class="ft3212">o</p>
<p style="position:absolute;top:940px;left:214px;white-space:nowrap" class="ft3212">Enbrel&#160;Carton containing Cartridges</p>
<p style="position:absolute;top:959px;left:187px;white-space:nowrap" class="ft3212">o</p>
<p style="position:absolute;top:959px;left:214px;white-space:nowrap" class="ft3212">your SMARTCLIC Device</p>
<p style="position:absolute;top:978px;left:187px;white-space:nowrap" class="ft3212">o</p>
<p style="position:absolute;top:978px;left:214px;white-space:nowrap" class="ft3212">alcohol wipes</p>
<p style="position:absolute;top:997px;left:187px;white-space:nowrap" class="ft3212">o</p>
<p style="position:absolute;top:997px;left:214px;white-space:nowrap" class="ft3212">clean cotton balls or gauze pads (not included)</p>
<p style="position:absolute;top:1016px;left:187px;white-space:nowrap" class="ft3212">o</p>
<p style="position:absolute;top:1016px;left:214px;white-space:nowrap" class="ft3212">a suitable sharps container (not included).</p>
<p style="position:absolute;top:1053px;left:133px;white-space:nowrap" class="ft32114">&#160;<b>Do not&#160;</b>use if the Carton is dropped or damaged.</p>
<p style="position:absolute;top:1074px;left:160px;white-space:nowrap" class="ft3211"><b>Note:&#160;</b>If you do not have everything you need, ask&#160;your healthcare professional.</p>
</div>
<!-- Page 322 -->
<a name="322"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft32243{font-size:17px;font-family:PZJVUM+TimesNewRoman;color:#323232;}
-->
</style>
<div id="page322-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3220">322</p>
<p style="position:absolute;top:108px;left:423px;white-space:nowrap" class="ft32242"><b>Your Device:</b></p>
<p style="position:absolute;top:149px;left:328px;white-space:nowrap" class="ft32243">Refer to User Manual for more information.</p>
<p style="position:absolute;top:763px;left:410px;white-space:nowrap" class="ft32242"><b>Your Cartridge:</b></p>
</div>
<!-- Page 323 -->
<a name="323"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft32344{font-size:21px;font-family:PZJVUM+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page323-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3230">323</p>
<p style="position:absolute;top:108px;left:393px;white-space:nowrap" class="ft32344"><b>Preparation Steps</b></p>
<p style="position:absolute;top:402px;left:133px;white-space:nowrap" class="ft32314">&#160;<b>Remove&#160;</b>1 Cartridge from the tray inside the Carton.</p>
<p style="position:absolute;top:422px;left:133px;white-space:nowrap" class="ft32314">&#160;<b>Put&#160;</b>the Carton and tray with any unused Cartridges back in the&#160;refrigerator.</p>
<p style="position:absolute;top:442px;left:133px;white-space:nowrap" class="ft32314">&#160;<b>Wash&#160;</b>and dry your hands.</p>
<p style="position:absolute;top:463px;left:133px;white-space:nowrap" class="ft32314">&#160;For a more comfortable injection leave your Cartridge at room temperature for approximately&#160;</p>
<p style="position:absolute;top:483px;left:160px;white-space:nowrap" class="ft3234"><b>15&#160;-&#160;30 minutes&#160;</b>away from direct sunlight.<br/><b>Do not&#160;</b>use any other methods to warm up your Cartridge.</p>
<p style="position:absolute;top:805px;left:133px;white-space:nowrap" class="ft32314">&#160;<b>Check&#160;</b>the expiration date and medication dose printed on the label.&#160;<b>Do not&#160;</b>use if the&#160;</p>
<p style="position:absolute;top:826px;left:160px;white-space:nowrap" class="ft3232">expiration date has passed or if it is not your prescribed medication dose.</p>
<p style="position:absolute;top:844px;left:133px;white-space:nowrap" class="ft32314">&#160;<b>Check&#160;</b>your Cartridge,&#160;<b>do not&#160;</b>use if:</p>
<p style="position:absolute;top:865px;left:187px;white-space:nowrap" class="ft3232">o</p>
<p style="position:absolute;top:865px;left:214px;white-space:nowrap" class="ft3232">it has been dropped even if it does not look damaged</p>
<p style="position:absolute;top:884px;left:187px;white-space:nowrap" class="ft3232">o</p>
<p style="position:absolute;top:884px;left:214px;white-space:nowrap" class="ft3232">it is damaged</p>
<p style="position:absolute;top:903px;left:187px;white-space:nowrap" class="ft3232">o</p>
<p style="position:absolute;top:903px;left:214px;white-space:nowrap" class="ft3232">the needle cap is loose</p>
<p style="position:absolute;top:922px;left:187px;white-space:nowrap" class="ft3232">o</p>
<p style="position:absolute;top:922px;left:214px;white-space:nowrap" class="ft3232">it has been frozen or exposed to heat</p>
<p style="position:absolute;top:941px;left:187px;white-space:nowrap" class="ft3232">o</p>
<p style="position:absolute;top:941px;left:214px;white-space:nowrap" class="ft3232">it has been at room temperature for more than 4 weeks</p>
<p style="position:absolute;top:960px;left:187px;white-space:nowrap" class="ft3232">o</p>
<p style="position:absolute;top:960px;left:214px;white-space:nowrap" class="ft3232">it has been returned to the refrigerator after reaching room temperature.</p>
<p style="position:absolute;top:978px;left:133px;white-space:nowrap" class="ft32314">&#160;<b>Do not&#160;</b>remove the needle cap until instructed to do so.</p>
</div>
<!-- Page 324 -->
<a name="324"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page324-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3240">324</p>
<p style="position:absolute;top:394px;left:133px;white-space:nowrap" class="ft32414">&#160;<b>Inspect&#160;</b>the medicine through the Inspection window, it should be clear or slightly opalescent,&#160;</p>
<p style="position:absolute;top:414px;left:160px;white-space:nowrap" class="ft3244">colourless to pale yellow or pale brown, and may contain small white or almost transparent&#160;<br/>particles of protein, this is normal.</p>
<p style="position:absolute;top:452px;left:133px;white-space:nowrap" class="ft32414">&#160;<b>Do not&#160;</b>use the medicine if it is&#160;discoloured, cloudy, or has particles other than those described&#160;</p>
<p style="position:absolute;top:472px;left:160px;white-space:nowrap" class="ft3242">above.</p>
<p style="position:absolute;top:491px;left:133px;white-space:nowrap" class="ft32414">&#160;<b>Do not&#160;</b>shake your Cartridge.</p>
<p style="position:absolute;top:512px;left:160px;white-space:nowrap" class="ft3241"><b>Note:&#160;</b>If you have any questions about your medicine, contact your healthcare professional.</p>
<p style="position:absolute;top:873px;left:133px;white-space:nowrap" class="ft32414">&#160;<b>Always choose&#160;</b>an area in your abdomen, upper thighs or the&#160;outer area of the upper arms&#160;</p>
<p style="position:absolute;top:894px;left:160px;white-space:nowrap" class="ft3242">(caregiver only).</p>
<p style="position:absolute;top:912px;left:133px;white-space:nowrap" class="ft32414">&#160;<b>Choose&#160;</b>an injection site at least 3 cm from where you last injected and at least 5 cm away&#160;</p>
<p style="position:absolute;top:933px;left:160px;white-space:nowrap" class="ft3242">from your belly button (navel).</p>
<p style="position:absolute;top:951px;left:133px;white-space:nowrap" class="ft32414">&#160;<b>Do not&#160;</b>inject into bony areas or areas on your skin that are broken, bruised, red, sore (tender)&#160;</p>
<p style="position:absolute;top:972px;left:160px;white-space:nowrap" class="ft3242">or hard. Avoid injecting into areas with scars or stretch marks.</p>
<p style="position:absolute;top:990px;left:133px;white-space:nowrap" class="ft32414">&#160;<b>Do not&#160;</b>inject through your clothes.</p>
<p style="position:absolute;top:1011px;left:160px;white-space:nowrap" class="ft3243"><b>Note:&#160;</b>If you have psoriasis,&#160;<b>do not&#160;</b>inject directly into any raised, thick, red, or scaly skin&#160;<br/>patches or lesions on your skin.</p>
<p style="position:absolute;top:1048px;left:133px;white-space:nowrap" class="ft32414">&#160;<b>Clean&#160;</b>your injection site with the supplied alcohol wipe and&#160;<b>allow to dry</b>.</p>
</div>
<!-- Page 325 -->
<a name="325"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page325-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3250">325</p>
<p style="position:absolute;top:394px;left:133px;white-space:nowrap" class="ft32514">&#160;<b>Clean&#160;</b>the injection end of your Device with the separate supplied alcohol wipe.</p>
<p style="position:absolute;top:414px;left:133px;white-space:nowrap" class="ft32514">&#160;<b>Allow&#160;</b>the injection end to dry before giving an injection.</p>
<p style="position:absolute;top:488px;left:407px;white-space:nowrap" class="ft32544"><b>Injection Steps</b></p>
<p style="position:absolute;top:861px;left:133px;white-space:nowrap" class="ft32514">&#160;<b>Push&#160;</b>your Cartridge firmly&#160;<b>straight&#160;</b>through the Cartridge door without twisting until you&#160;</p>
<p style="position:absolute;top:882px;left:160px;white-space:nowrap" class="ft3254">cannot push it any further. Your Device will turn on when your Cartridge has been inserted&#160;<br/>correctly.</p>
<p style="position:absolute;top:919px;left:133px;white-space:nowrap" class="ft32514">&#160;<b>Check&#160;</b>the Display shows 25 mg and the expiration date has not passed.</p>
<p style="position:absolute;top:940px;left:160px;white-space:nowrap" class="ft3254"><b>Note:&#160;</b>Your Device will turn off after 90 seconds of inactivity. Press and hold the Injection&#160;<br/>button to turn your Device back on.</p>
</div>
<!-- Page 326 -->
<a name="326"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft32645{font-size:17px;line-height:23px;font-family:PZJVUM+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page326-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3260">326</p>
<p style="position:absolute;top:418px;left:133px;white-space:nowrap" class="ft32614">&#160;<b>Remove&#160;</b>the needle cap by pulling it firmly downwards.</p>
<p style="position:absolute;top:438px;left:133px;white-space:nowrap" class="ft32614">&#160;<b>Dispose&#160;</b>of the needle cap in a suitable sharps container.</p>
<p style="position:absolute;top:458px;left:133px;white-space:nowrap" class="ft32614">&#160;<b>Inject&#160;</b>as soon as possible after removing the needle cap.</p>
<p style="position:absolute;top:478px;left:133px;white-space:nowrap" class="ft32614">&#160;<b>Do not&#160;</b>replace the needle cap.</p>
<p style="position:absolute;top:499px;left:160px;white-space:nowrap" class="ft32645"><b>Caution: Do not&#160;</b>insert your fingers into your Device after removing the needle cap to avoid a&#160;<br/>needle stick injury.<br/><b>Note:&#160;</b>To cancel the injection and eject your Cartridge, press the Cancel / Eject button&#160;</p>
<p style="position:absolute;top:542px;left:763px;white-space:nowrap" class="ft3262">for&#160;</p>
<p style="position:absolute;top:561px;left:160px;white-space:nowrap" class="ft3262">1 second.</p>
<p style="position:absolute;top:929px;left:133px;white-space:nowrap" class="ft32614">&#160;<b>Place&#160;</b>your Device with the&#160;<b>blue arrow&#160;</b>pointing at 90 degrees towards your injection site.</p>
<p style="position:absolute;top:949px;left:133px;white-space:nowrap" class="ft32614">&#160;<b>Make sure&#160;</b>you can see the Display on your Device.</p>
<p style="position:absolute;top:969px;left:133px;white-space:nowrap" class="ft32614">&#160;<b>Do not&#160;</b>pinch the skin around your injection site.</p>
<p style="position:absolute;top:990px;left:160px;white-space:nowrap" class="ft3264"><b>Caution:&#160;</b>If you drop your Device with a&#160;Cartridge inserted, eject and dispose of your&#160;<br/>Cartridge.<br/>Refer to the Troubleshooting page in the Device User Manual.</p>
</div>
<!-- Page 327 -->
<a name="327"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page327-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3270">327</p>
<p style="position:absolute;top:418px;left:133px;white-space:nowrap" class="ft32714">&#160;<b>Press &amp; hold&#160;</b>the Injection button to begin your injection when instructed by the Display.</p>
<p style="position:absolute;top:438px;left:160px;white-space:nowrap" class="ft3271"><b>Note:&#160;</b>You can release the Injection button&#160;after your injection has started.</p>
<p style="position:absolute;top:808px;left:133px;white-space:nowrap" class="ft32714">&#160;<b>Hold&#160;</b>your Device against your skin and wait while your medication is injected.</p>
<p style="position:absolute;top:828px;left:133px;white-space:nowrap" class="ft32714">&#160;<b>Watch&#160;</b>the Display on your Device.</p>
<p style="position:absolute;top:848px;left:133px;white-space:nowrap" class="ft32714">&#160;<b>Do not&#160;</b>move, tilt or remove your Device from your skin until instructed by the Display.</p>
<p style="position:absolute;top:869px;left:160px;white-space:nowrap" class="ft3274"><b>Note:&#160;</b>If you remove your Device before instructed,&#160;<b>do not&#160;</b>place it back on the injection site&#160;<br/>or inject another dose. Contact your healthcare professional for advice.</p>
</div>
<!-- Page 328 -->
<a name="328"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page328-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3280">328</p>
<p style="position:absolute;top:419px;left:133px;white-space:nowrap" class="ft32814">&#160;<b>Lift &amp; hold&#160;</b>your Device away from your skin. Your Device will display that your injection is&#160;</p>
<p style="position:absolute;top:440px;left:160px;white-space:nowrap" class="ft3282">complete.</p>
<p style="position:absolute;top:458px;left:133px;white-space:nowrap" class="ft32814">&#160;<b>Wait.&#160;</b>Your Cartridge will be partially ejected from the bottom of your Device. This may take&#160;</p>
<p style="position:absolute;top:479px;left:160px;white-space:nowrap" class="ft3284">up to 10 seconds.<br/><b>Do not&#160;</b>cover the bottom of your Device during this time.<br/><b>Do not&#160;</b>insert your fingers inside your Device as the needle will be exposed during&#160;this time.</p>
<p style="position:absolute;top:535px;left:133px;white-space:nowrap" class="ft32814">&#160;If you notice a spot of blood, press a cotton ball or gauze over the injection site until the&#160;</p>
<p style="position:absolute;top:556px;left:160px;white-space:nowrap" class="ft3282">bleeding stops.&#160;<b>Do not&#160;</b>rub.</p>
<p style="position:absolute;top:897px;left:133px;white-space:nowrap" class="ft32814">&#160;<b>Pull&#160;</b>your Cartridge straight out after your Device has partially ejected it.</p>
<p style="position:absolute;top:917px;left:133px;white-space:nowrap" class="ft32814">&#160;<b>Check&#160;</b>your Cartridge is empty of medicine with a grey bar visible in the Inspection window.&#160;</p>
<p style="position:absolute;top:938px;left:160px;white-space:nowrap" class="ft3284">If not, you may not have received your full dose. Contact your healthcare professional for&#160;<br/>advice.</p>
<p style="position:absolute;top:975px;left:133px;white-space:nowrap" class="ft32814">&#160;<b>Do not&#160;</b>reuse your Cartridge or reinsert it into your Device.</p>
<p style="position:absolute;top:995px;left:133px;white-space:nowrap" class="ft32814">&#160;<b>Dispose&#160;</b>of the used Cartridge straight away in&#160;a suitable sharps container as instructed by&#160;</p>
<p style="position:absolute;top:1016px;left:160px;white-space:nowrap" class="ft3283">your healthcare professional or pharmacist and in accordance with local health and safety&#160;<br/>laws.</p>
<p style="position:absolute;top:1096px;left:337px;white-space:nowrap" class="ft32841">--End of Instructions for Use--</p>
</div>
<!-- Page 329 -->
<a name="329"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page329-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3290">329</p>
<p style="position:absolute;top:108px;left:298px;white-space:nowrap" class="ft3291"><b>Package Leaflet: Information for the User</b></p>
<p style="position:absolute;top:146px;left:226px;white-space:nowrap" class="ft3291"><b>Enbrel 50&#160;mg&#160;solution for injection&#160;in dose-dispenser cartridge</b></p>
<p style="position:absolute;top:165px;left:413px;white-space:nowrap" class="ft3292">etanercept</p>
<p style="position:absolute;top:203px;left:123px;white-space:nowrap" class="ft32923"><b>Read all of this leaflet carefully before you start using this medicine because it contains&#160;<br/>important information for you.</b></p>
<p style="position:absolute;top:240px;left:123px;white-space:nowrap" class="ft32914"></p>
<p style="position:absolute;top:242px;left:162px;white-space:nowrap" class="ft3292">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:260px;left:123px;white-space:nowrap" class="ft32914"></p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft3292">Your doctor will also give you a Patient&#160;Card, which contains important safety information that&#160;</p>
<p style="position:absolute;top:281px;left:164px;white-space:nowrap" class="ft3292">you need to be aware of before and during treatment with Enbrel.</p>
<p style="position:absolute;top:299px;left:123px;white-space:nowrap" class="ft32914"></p>
<p style="position:absolute;top:301px;left:162px;white-space:nowrap" class="ft3292">If you&#160;have&#160;any further questions, ask your doctor,&#160;pharmacist or nurse.</p>
<p style="position:absolute;top:319px;left:123px;white-space:nowrap" class="ft32914"></p>
<p style="position:absolute;top:321px;left:162px;white-space:nowrap" class="ft3292">This medicine has been prescribed for you or a child in your care. Do not pass it on to others. It&#160;</p>
<p style="position:absolute;top:340px;left:164px;white-space:nowrap" class="ft3294">may harm them, even if their&#160;signs of illness&#160;are the same as yours or those of the child you are&#160;<br/>caring for.</p>
<p style="position:absolute;top:378px;left:123px;white-space:nowrap" class="ft32914"></p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft3292">If you&#160;get&#160;any side effects,&#160;talk to&#160;your doctor or pharmacist.&#160;This includes any possible side&#160;</p>
<p style="position:absolute;top:398px;left:164px;white-space:nowrap" class="ft3292">effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft3291"><b>What is in this leaflet</b></p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft3292">Information in this leaflet is organised under the following&#160;6&#160;sections:</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft3292">1.</p>
<p style="position:absolute;top:512px;left:149px;white-space:nowrap" class="ft3292">What Enbrel is and what it is used for</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft3292">2.</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft3292">What you need to know before you use Enbrel</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft3292">3.</p>
<p style="position:absolute;top:550px;left:149px;white-space:nowrap" class="ft3292">How to use Enbrel</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft3292">4.</p>
<p style="position:absolute;top:569px;left:149px;white-space:nowrap" class="ft3292">Possible side effects</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft3292">5.</p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft3292">How to store Enbrel</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft3292">6.</p>
<p style="position:absolute;top:607px;left:149px;white-space:nowrap" class="ft3292">Contents of the pack and other information&#160;(See Instruction for Use)</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft3291"><b>1.</b></p>
<p style="position:absolute;top:664px;left:146px;white-space:nowrap" class="ft3291"><b>What Enbrel is and what it is used for</b></p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft3294">Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in&#160;<br/>the body that causes inflammation. Enbrel works by reducing the inflammation associated with certain&#160;<br/>diseases.</p>
<p style="position:absolute;top:778px;left:106px;white-space:nowrap" class="ft3294">In adults (aged 18 and over), Enbrel can be used for moderate or severe&#160;<b>rheumatoid arthritis</b>,&#160;<br/><b>psoriatic arthritis</b>, severe&#160;<b>axial spondyloarthritis&#160;</b>including&#160;<b>ankylosing spondylitis,&#160;</b>and moderate&#160;<br/>or severe&#160;<b>psoriasis&#160;</b>–&#160;in each case usually when other widely used treatments have not worked well&#160;<br/>enough or are not suitable for you.</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft3294">For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may&#160;<br/>also be used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in&#160;<br/>combination with methotrexate, Enbrel can slow down the damage to your joints caused by the&#160;<br/>rheumatoid arthritis and improve your ability to do normal daily activities.</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft3293">For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do&#160;<br/>normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands,<br/>wrists and feet), Enbrel can slow down the structural damage to those joints caused by the disease.&#160;</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft3292">Enbrel is also prescribed for the treatment of the following diseases in children and adolescents</p>
<p style="position:absolute;top:1081px;left:133px;white-space:nowrap" class="ft32914">&#160;For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not&#160;</p>
<p style="position:absolute;top:1101px;left:147px;white-space:nowrap" class="ft3292">worked well enough or is not suitable for them:</p>
<p style="position:absolute;top:1139px;left:187px;white-space:nowrap" class="ft32914">&#160;Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in&#160;</p>
<p style="position:absolute;top:1160px;left:214px;white-space:nowrap" class="ft3292">patients from the age of 2 years</p>
</div>
<!-- Page 330 -->
<a name="330"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page330-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3300">330</p>
<p style="position:absolute;top:126px;left:187px;white-space:nowrap" class="ft33014">&#160;Psoriatic arthritis in patients from the&#160;age of 12 years</p>
<p style="position:absolute;top:165px;left:133px;white-space:nowrap" class="ft33014">&#160;For enthesitis-related arthritis in patients from the age of 12 years when other widely used&#160;</p>
<p style="position:absolute;top:186px;left:160px;white-space:nowrap" class="ft3302">treatments have not worked well enough or are not suitable for them</p>
<p style="position:absolute;top:223px;left:133px;white-space:nowrap" class="ft33014">&#160;Severe psoriasis in patients from the age of 6 years who have had an inadequate response to (or&#160;</p>
<p style="position:absolute;top:244px;left:147px;white-space:nowrap" class="ft3302">are unable to take) phototherapies or other systemic therapies.</p>
<p style="position:absolute;top:301px;left:106px;white-space:nowrap" class="ft3301"><b>2.</b></p>
<p style="position:absolute;top:301px;left:146px;white-space:nowrap" class="ft3301"><b>What you need to know before you use Enbrel&#160;</b></p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft3301"><b>Do not use Enbrel</b></p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:378px;left:147px;white-space:nowrap" class="ft3303">if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of&#160;<br/>Enbrel&#160;(listed in section 6). If you or the child experience allergic reactions such as chest&#160;<br/>tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor&#160;<br/>immediately.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:455px;left:147px;white-space:nowrap" class="ft3304">if you or the child have, or are at risk of developing a serious blood infection called sepsis. If&#160;<br/>you are not sure, please contact your doctor.</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:494px;left:147px;white-space:nowrap" class="ft3302">if you&#160;or the child, have an infection of any kind. If you are not sure, please talk to your doctor.</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft3301"><b>Warnings and precautions&#160;</b></p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft3302">Talk to your doctor before taking Enbrel.</p>
<p style="position:absolute;top:608px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:609px;left:147px;white-space:nowrap" class="ft3304"><b>Allergic reactions</b>: If you or the child experience allergic reactions such as chest tightness,&#160;<br/>wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:648px;left:147px;white-space:nowrap" class="ft3304"><b>Infections/surgery</b>: If you or the child develop a new infection,&#160;or are about to have any major&#160;<br/>surgery, your doctor may wish to monitor the treatment with Enbrel.</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:688px;left:147px;white-space:nowrap" class="ft3304"><b>Infections/diabetes:&#160;</b>Tell your doctor if you or the child have a history of recurrent infections or&#160;<br/>suffer from diabetes or other conditions that increase the risk of infection.</p>
<p style="position:absolute;top:725px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:727px;left:147px;white-space:nowrap" class="ft3301"><b>Infections/monitoring:&#160;</b>Tell your doctor of any recent travel outside the European region. If you&#160;</p>
<p style="position:absolute;top:746px;left:149px;white-space:nowrap" class="ft3303">or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor&#160;<br/>immediately. Your doctor may decide to continue to monitor you or the child for the presence of&#160;<br/>infections after you or the child stop using Enbrel.</p>
<p style="position:absolute;top:802px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:804px;left:147px;white-space:nowrap" class="ft3301"><b>Tuberculosis:&#160;</b>As cases of tuberculosis have been reported in patients treated with Enbrel, your&#160;</p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft3304">doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may&#160;<br/>include a thorough medical history, a chest X-ray and a tuberculin test. The conduct of these&#160;<br/>tests should be recorded on the Patient Card. It is very important that you tell your doctor if you&#160;<br/>or the child have ever had tuberculosis, or have been in close contact with someone who has had&#160;<br/>tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:938px;left:147px;white-space:nowrap" class="ft3301"><b>Hepatitis B:&#160;</b>Tell your&#160;doctor if you&#160;or the child&#160;have or have ever had hepatitis B.&#160;Your doctor&#160;</p>
<p style="position:absolute;top:957px;left:149px;white-space:nowrap" class="ft3304">should test&#160;for the presence of hepatitis B infection before you or the child begin treatment with&#160;<br/>Enbrel.&#160;Treatment with Enbrel may result in reactivation of hepatitis B in patients who have&#160;<br/>previously been infected with the hepatitis B virus. If this occurs, you should stop using Enbrel.</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:1015px;left:147px;white-space:nowrap" class="ft3301"><b>Hepatitis C:&#160;</b>Tell your doctor if you or the child have hepatitis C. Your doctor may wish to&#160;</p>
<p style="position:absolute;top:1034px;left:149px;white-space:nowrap" class="ft3302">monitor the treatment&#160;with Enbrel in case the infection worsens.</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft33014"></p>
<p style="position:absolute;top:1054px;left:147px;white-space:nowrap" class="ft3303"><b>Blood disorders:&#160;</b>Seek medical advice immediately if you or the child have any signs or&#160;<br/>symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms&#160;<br/>may point to the existence of potentially life-threatening blood disorders, which may require&#160;<br/>discontinuation of Enbrel.</p>
</div>
<!-- Page 331 -->
<a name="331"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page331-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3310">331</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft33114"></p>
<p style="position:absolute;top:109px;left:147px;white-space:nowrap" class="ft3314"><b>Nervous system and eye disorders:&#160;</b>Tell your doctor if you or the child have multiple sclerosis,&#160;<br/>optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of&#160;<br/>the spinal cord). Your doctor will determine if Enbrel is an appropriate treatment.</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft33114"></p>
<p style="position:absolute;top:167px;left:147px;white-space:nowrap" class="ft3314"><b>Congestive heart failure:&#160;</b>Tell your doctor if you or the child have a history of congestive heart&#160;<br/>failure, because Enbrel needs to be used with caution under these circumstances.</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft33114"></p>
<p style="position:absolute;top:206px;left:147px;white-space:nowrap" class="ft3314"><b>Cancer:&#160;</b>Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or&#160;<br/>any other cancer before you are given Enbrel.<br/>Patients with severe rheumatoid arthritis, who have had the disease for a long time,&#160;may be at&#160;<br/>higher than average risk of developing lymphoma.<br/>Children and adults taking Enbrel may have an increased risk of developing lymphoma or&#160;<br/>another cancer.<br/>Some children and teenage patients who have received Enbrel or other medicines that work the&#160;<br/>same way as Enbrel have developed cancers, including unusual types, which sometimes resulted&#160;<br/>in death.<br/>Some patients receiving Enbrel have developed skin cancers.&#160;Tell&#160;your doctor if you or the child&#160;<br/>develop any change in the appearance of the skin&#160;or growths on the skin.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft33114"></p>
<p style="position:absolute;top:416px;left:147px;white-space:nowrap" class="ft3314"><b>Chickenpox:&#160;</b>Tell your doctor if you or the child are exposed to chickenpox when using Enbrel.&#160;<br/>Your doctor will determine if preventive treatment for chickenpox is appropriate.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft33114"></p>
<p style="position:absolute;top:455px;left:147px;white-space:nowrap" class="ft3313"><b>Latex:&#160;</b>The needle cover is made from latex (dry natural rubber).&#160;Contact your doctor before&#160;<br/>using Enbrel if the needle cover will be handled by, or Enbrel will be given to, someone with a&#160;<br/>known or possible hypersensitivity (allergy) to latex.</p>
<p style="position:absolute;top:511px;left:106px;white-space:nowrap" class="ft33114"></p>
<p style="position:absolute;top:513px;left:147px;white-space:nowrap" class="ft3314"><b>Alcohol abuse</b>: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.&#160;<br/>Please tell your doctor if you or the child in your care have a history of alcohol abuse.</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft33114"></p>
<p style="position:absolute;top:552px;left:147px;white-space:nowrap" class="ft3313"><b>Wegener’s granulomatosis</b>: Enbrel is not recommended for the treatment of Wegener’s&#160;<br/>granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener’s&#160;<br/>granulomatosis, talk to your doctor.</p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft33114"></p>
<p style="position:absolute;top:611px;left:147px;white-space:nowrap" class="ft3313"><b>Anti-diabetic medicines</b>: Tell your doctor if you or the child have diabetes or are taking&#160;<br/>medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic&#160;<br/>medicine while taking Enbrel.</p>
<p style="position:absolute;top:687px;left:106px;white-space:nowrap" class="ft3311"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft3313">Vaccinations: If possible, children should be up to date with all vaccinations before using Enbrel.&#160;<br/>Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult the&#160;<br/>child’s doctor before the child receives any vaccines.</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft3313">Enbrel should not normally be used in children with polyarthritis or extended oligoarthritis below the&#160;<br/>age of 2 years, or in children with enthesitis-related arthritis or psoriatic arthritis below&#160;the age of 12&#160;<br/>years, or in children with psoriasis below the age of 6 years.</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft3311"><b>Other medicines and Enbrel</b></p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft3313">Tell the doctor or pharmacist if you or the child are taking,&#160;have recently taken&#160;or might take&#160;any other&#160;<br/>medicines (including anakinra, abatacept or&#160;sulfasalazine), even those not prescribed by the doctor.&#160;<br/>You or the child should not use Enbrel with medicines that contain the active substance anakinra or&#160;<br/>abatacept.</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft3311"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft3313">Enbrel&#160;should only be used&#160;during pregnancy&#160;if clearly&#160;needed.&#160;You should consult your doctor if you<br/>become pregnant,&#160;think you may be pregnant, or are planning to have a baby.</p>
<p style="position:absolute;top:1110px;left:106px;white-space:nowrap" class="ft3314">If you received Enbrel during pregnancy,&#160;your&#160;baby may have a higher risk&#160;of&#160;getting an infection.&#160;In&#160;<br/>addition,&#160;one study&#160;found&#160;more birth defects when the mother had received&#160;Enbrel&#160;in pregnancy,&#160;<br/>compared&#160;with&#160;mothers who had not received Enbrel or other similar medicines (TNF-antagonists),&#160;</p>
</div>
<!-- Page 332 -->
<a name="332"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page332-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3320">332</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3324">but there was no&#160;particular kind of birth defect&#160;reported.&#160;Another study found no increased&#160;risk of birth&#160;<br/>defects when the mother had received Enbrel in pregnancy. Your doctor will help you to decide&#160;<br/>whether the benefits of treatment outweigh the potential risk to your baby.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft3324">Talk to your doctor if you want to breastfeed while on Enbrel treatment.&#160;It&#160;is important that you tell&#160;<br/>your&#160;baby’s doctors and other healthcare professionals about the use of Enbrel during pregnancy and&#160;<br/>breastfeeding before&#160;your&#160;baby receives any vaccine.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft3321"><b>Driving and using&#160;machines</b></p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft3322">The use of Enbrel is not expected to affect the ability to drive or use machines.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft3321"><b>Enbrel contains sodium</b></p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft3323">This medicine&#160;contains less than 1&#160;mmol sodium (23&#160;mg) per dosage unit, that is to say&#160;essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft3321"><b>3.</b></p>
<p style="position:absolute;top:450px;left:146px;white-space:nowrap" class="ft3321"><b>How to use Enbrel</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft3324">Always use&#160;this medicine&#160;exactly as the doctor has told you. Check with the doctor or pharmacist if&#160;<br/>you are not sure.</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3322">If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft3322">The dose-dispenser cartridge is&#160;available&#160;in dose strengths of 25&#160;mg and 50&#160;mg.</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft3321"><b>Dosing for adult patients (aged 18 years or over)</b></p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft3322">Rheumatoid arthritis, psoriatic arthritis,&#160;and&#160;axial spondyloarthritis including&#160;ankylosing spondylitis</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft3324">The usual dose is 25&#160;mg given twice a week or 50&#160;mg&#160;once a week as an injection under the skin.&#160;<br/>However, your doctor may determine an alternative frequency at which to inject Enbrel.&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft3322">Plaque psoriasis</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft3322">The usual dose is 25&#160;mg twice a week or 50&#160;mg once a week. &#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft3324">Alternatively, 50&#160;mg&#160;may be given twice a&#160;week for up to 12 weeks, followed by 25&#160;mg twice a week&#160;<br/>or 50&#160;mg once a week.&#160;</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft3323">Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on&#160;<br/>your response. If Enbrel has no effect on your condition after 12 weeks, your&#160;doctor may tell you to&#160;<br/>stop taking this medicine.</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft3321"><b>Use in children and adolescents</b></p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft3324">The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight&#160;<br/>and disease. Your doctor will determine the correct dose for the child&#160;and will prescribe an appropriate&#160;<br/>strength of Enbrel (10&#160;mg, 25&#160;mg or 50&#160;mg).</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft3324">For polyarthritis or extended oligoarthritis in patients from the age of 2 years, or enthesitis-related&#160;<br/>arthritis or psoriatic arthritis in patients from the age of 12 years, the usual dose is 0.4&#160;mg of Enbrel&#160;<br/>per kg bodyweight (up to a maximum of 25&#160;mg) given twice weekly, or 0.8&#160;mg of Enbrel per kg of&#160;<br/>bodyweight (up to a maximum of 50&#160;mg) given once weekly.</p>
</div>
<!-- Page 333 -->
<a name="333"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page333-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3330">333</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3334">For psoriasis in patients from the age of 6 years, the usual dose is 0.8&#160;mg of Enbrel per kg bodyweight&#160;<br/>(up to a maximum of 50&#160;mg), and should be given once weekly. If Enbrel has no effect on the child’s&#160;<br/>condition after 12 weeks, your doctor may tell you to stop using this medicine.</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft3332">The doctor will provide you with detailed directions for preparing and measuring the appropriate dose.</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft3331"><b>Method and route of administration</b></p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft3332">Enbrel is administered by an injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft3332">Enbrel can be taken with or without food or drink.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft3333"><b>Detailed instructions on how to inject Enbrel are provided&#160;in&#160;“Instructions for&#160;Use”.&#160;</b>Do not mix&#160;<br/>the Enbrel solution with any other medicine.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft3334">To help you remember, it may be helpful to write in&#160;a diary which day(s) of the week Enbrel should be&#160;<br/>used.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft3331"><b>If&#160;you use more Enbrel than you should</b></p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft3333">If you have used more Enbrel than you should (either by injecting too much on a single occasion or by&#160;<br/>using it too frequently), talk to a doctor or pharmacist&#160;immediately. Always have the outer carton of&#160;<br/>the medicine with you, even if it is empty.</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft3331"><b>If&#160;you forget to inject Enbrel</b></p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft3334">If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is&#160;<br/>the next day; in which case you&#160;should skip the missed dose. Then continue to inject the medicine on&#160;<br/>the usual day(s). If you do not remember until the day that the next injection is due, do not take a&#160;<br/>double dose (two doses on the same day) to make up for a forgotten dose.</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft3331"><b>If&#160;you stop&#160;using Enbrel&#160;</b></p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft3332">Your symptoms may return upon discontinuation.&#160;</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft3332">If you have any further questions on the use of this&#160;medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft3331"><b>4.</b></p>
<p style="position:absolute;top:829px;left:146px;white-space:nowrap" class="ft3331"><b>Possible side effects</b></p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft3332">Like all medicines,&#160;this medicine&#160;can cause side effects, although not&#160;everybody gets them.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft3331"><b>Allergic reactions</b></p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft3333">If any of the following happen, do not inject more Enbrel. Tell your doctor immediately, or go to the&#160;<br/>casualty department at your nearest hospital.</p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft33314"></p>
<p style="position:absolute;top:1001px;left:149px;white-space:nowrap" class="ft3332">Trouble swallowing or breathing</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft33314"></p>
<p style="position:absolute;top:1021px;left:149px;white-space:nowrap" class="ft3332">Swelling of the face, throat,&#160;hands, or feet</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft33314"></p>
<p style="position:absolute;top:1041px;left:149px;white-space:nowrap" class="ft3334">Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm&#160;<br/>feeling</p>
<p style="position:absolute;top:1078px;left:106px;white-space:nowrap" class="ft33314"></p>
<p style="position:absolute;top:1080px;left:149px;white-space:nowrap" class="ft3332">Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p>
<p style="position:absolute;top:1118px;left:106px;white-space:nowrap" class="ft3333">Serious allergic reactions are rare. However, any of&#160;the above symptoms may indicate an allergic&#160;<br/>reaction to Enbrel, so you should seek immediate medical attention.</p>
</div>
<!-- Page 334 -->
<a name="334"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page334-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3340">334</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3341"><b>Serious side effects</b></p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3342">If you notice any of the following, you or the child may need urgent medical attention.</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft3344">Signs of&#160;<b>serious infections</b>, such as high fever that may be accompanied by cough, shortness of&#160;<br/>breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft3342">Signs of&#160;<b>blood disorders</b>, such as bleeding, bruising, or paleness</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft3344">Signs of&#160;<b>nerve disorders</b>, such as numbness or&#160;tingling, changes in vision, eye pain, or onset of&#160;<br/>weakness in an arm or leg</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft3344">Signs of&#160;<b>heart failure&#160;</b>or&#160;<b>worsening heart failure</b>, such as fatigue or shortness of breath with&#160;<br/>activity, swelling in the ankles, a feeling of fullness in the neck or abdomen, night-time&#160;<br/>shortness of breath or coughing, bluish colour of the nails or the lips</p>
<p style="position:absolute;top:340px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft3343"><b>Signs of cancers:&#160;</b>Cancers may affect any part of the body including the skin and blood, and&#160;<br/>possible signs will depend on the type and location of the cancer. These signs may include&#160;<br/>weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or&#160;<br/>growths on the skin</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:418px;left:149px;white-space:nowrap" class="ft3344">Signs of&#160;<b>autoimmune reactions&#160;</b>(where antibodies are made that may harm normal tissues in&#160;<br/>the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:458px;left:149px;white-space:nowrap" class="ft3344">Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or&#160;<br/>muscle pain, or fatigue</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:497px;left:149px;white-space:nowrap" class="ft3344">Signs of&#160;<b>inflammation of the blood vessels&#160;</b>such as pain, fever, redness or warmth of the skin,&#160;<br/>or itching.</p>
<p style="position:absolute;top:554px;left:106px;white-space:nowrap" class="ft3344">These are rare or uncommon side effects, but are serious conditions (some of which may rarely be&#160;<br/>fatal). If these signs occur, tell your doctor immediately, or visit the casualty department&#160;at your&#160;<br/>nearest hospital.</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft3342">The known side effects of Enbrel include the following in groups of decreasing frequency:</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:669px;left:149px;white-space:nowrap" class="ft3341"><b>Very common&#160;</b>(may affect more than 1 in&#160;10&#160;people):</p>
<p style="position:absolute;top:687px;left:124px;white-space:nowrap" class="ft33414">&#160;Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin&#160;infections);&#160;</p>
<p style="position:absolute;top:708px;left:151px;white-space:nowrap" class="ft3343">injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling) (these&#160;<br/>do not occur as often after the first month of treatment; some patients have developed a reaction&#160;<br/>at an injection site that was recently used); and headache.</p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:785px;left:149px;white-space:nowrap" class="ft3344"><b>Common&#160;</b>(may affect up to 1 in 10&#160;people):<br/>Allergic reactions; fever; rash;&#160;itching; antibodies directed against normal tissue (autoantibody&#160;<br/>formation).</p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:862px;left:149px;white-space:nowrap" class="ft3341"><b>Uncommon&#160;</b>(may affect up to 1 in 100&#160;people):</p>
<p style="position:absolute;top:880px;left:124px;white-space:nowrap" class="ft33414">&#160;Serious infections (including pneumonia,&#160;deep skin infections, joint infections, blood infection,&#160;</p>
<p style="position:absolute;top:901px;left:151px;white-space:nowrap" class="ft3343">and infections at various sites); worsening of congestive heart failure; low red blood cell count,&#160;<br/>low white blood cell count, low neutrophil (a type of white blood cell) count; low blood platelet&#160;<br/>count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives&#160;<br/>(elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or&#160;<br/>worsening); inflammation of the blood vessels affecting multiple organs; elevated liver blood&#160;<br/>tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood&#160;<br/>tests is common); abdominal cramps and pain, diarrhoea, weight loss or blood in the stool&#160;<br/>(signs of bowel problems).</p>
<p style="position:absolute;top:1071px;left:107px;white-space:nowrap" class="ft33414"></p>
<p style="position:absolute;top:1073px;left:151px;white-space:nowrap" class="ft3343"><b>Rare&#160;</b>(may affect up to&#160;1 in 1,000&#160;people):<br/>Serious allergic reactions (including severe localised swelling of the skin and wheezing);&#160;<br/>lymphoma (a type of blood cancer);&#160;leukaemia (cancer affecting the blood and bone marrow);<br/>melanoma (a type of skin cancer); combined low platelet, red, and white blood cell count;&#160;<br/>nervous system disorders (with severe muscle weakness and signs and symptoms similar to&#160;</p>
</div>
<!-- Page 335 -->
<a name="335"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page335-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3350">335</p>
<p style="position:absolute;top:108px;left:152px;white-space:nowrap" class="ft3354">those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord);&#160;<br/>tuberculosis;&#160;new onset&#160;congestive heart failure; seizures; lupus or lupus-like syndrome&#160;<br/>(symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may&#160;<br/>lead to severe blistering and peeling of the skin;&#160;lichenoid reactions (itchy reddish-purple skin&#160;<br/>rash and/or threadlike white-grey lines on mucous membranes);&#160;inflammation of the liver&#160;<br/>caused by the body's own immune system (autoimmune hepatitis;&#160;in patients also receiving&#160;<br/>methotrexate treatment, the frequency is uncommon); immune disorder that can&#160;affect the&#160;<br/>lungs, skin and lymph nodes (sarcoidosis);&#160;inflammation or scarring of the lungs&#160;(in patients&#160;<br/>also receiving methotrexate treatment, the frequency&#160;of&#160;inflammation or scarring of the lungs is&#160;<br/>uncommon).</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft33514"></p>
<p style="position:absolute;top:318px;left:149px;white-space:nowrap" class="ft3354"><b>Very rare&#160;</b>(may affect up to 1 in 10,000&#160;people): failure of the bone marrow to produce crucial&#160;<br/>blood cells.</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft33514"></p>
<p style="position:absolute;top:376px;left:149px;white-space:nowrap" class="ft3354"><b>Not known&#160;</b>(frequency cannot be estimated from the available data): Merkel cell carcinoma (a&#160;<br/>type of skin cancer);&#160;Kaposi’s sarcoma (a rare cancer related to infection with human herpes&#160;<br/>virus 8. Kaposi’s sarcoma most commonly appear as purple lesions on the skin);&#160;excessive&#160;<br/>activation of white blood cells associated with inflammation (macrophage activation&#160;<br/>syndrome);&#160;recurrence of hepatitis B (a liver infection);&#160;worsening of a condition called&#160;<br/>dermatomyositis (muscle inflammation and weakness&#160;with&#160;an&#160;accompanying&#160;skin rash).</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft3351"><b>Side effects in children and adolescents</b></p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft3353">The side effects and their frequencies seen in children and adolescents are similar to those described&#160;<br/>above.</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft3351"><b>Reporting of&#160;side effects</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft3354">If you get any side effects, talk to your doctor&#160;or&#160;pharmacist.&#160;This includes any possible&#160;side effects&#160;<br/>not listed in this leaflet.&#160;You can also report side effects directly&#160;via the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V</a>. By reporting side effects you can help provide more information on the safety of&#160;<br/>this medicine.</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft3351"><b>5.</b></p>
<p style="position:absolute;top:755px;left:149px;white-space:nowrap" class="ft3351"><b>How to store Enbrel</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft3352">Keep this medicine out of the sight&#160;and reach of children.</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft3353">Do not use this medicine after the expiry date which is stated on the carton and the label after “EXP”.&#160;<br/>The expiry date refers to the last day of that month.</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft3352">Store in a refrigerator (2</p>
<p style="position:absolute;top:887px;left:267px;white-space:nowrap" class="ft33514">C&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft3352">Keep the&#160;dose-dispenser cartridge in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft3353">After taking a dose-dispenser cartridge from the refrigerator, wait approximately 15-30&#160;minutes to&#160;<br/>allow the Enbrel solution&#160;in the dose-dispenser cartridge to reach room temperature. Do not warm in&#160;<br/>any other way. Immediate use is then recommended.</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft3353">The dose-dispenser cartridges may be stored at room temperature (up to 25°C) for a single period of&#160;<br/>up to 4&#160;weeks with protection from light; after which they should not be refrigerated again.&#160;Enbrel&#160;<br/>should be discarded if not used within four weeks after removal from the refrigerator. It is&#160;<br/>recommended that you record the date that the Enbrel dose-dispenser is removed from the refrigerator&#160;<br/>and the date after which Enbrel should be discarded (no more than 4&#160;weeks following the removal&#160;<br/>from the refrigerator).</p>
</div>
<!-- Page 336 -->
<a name="336"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page336-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3360">336</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3363">Inspect the solution in the dose-dispenser cartridge by looking through the inspection window. The&#160;<br/>solution should be clear or slightly opalescent, colourless to pale yellow or pale&#160;brown, and may&#160;<br/>contain small white or almost transparent particles of protein.&#160;This appearance is normal for Enbrel.&#160;<br/>Do not use the solution if it is discoloured, cloudy, or if particles other than those described above are&#160;<br/>present. If you are concerned with the appearance of the solution, then contact your pharmacist for&#160;<br/>assistance.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft3363">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to&#160;<br/>throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft3361"><b>6.</b></p>
<p style="position:absolute;top:316px;left:146px;white-space:nowrap" class="ft3361"><b>Contents of the pack and other information&#160;</b></p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft3361"><b>What Enbrel contains</b></p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft3364">Enbrel 50&#160;mg&#160;solution for injection in dose-dispenser cartridge<br/>The active substance in Enbrel is etanercept. Each&#160;dose-dispenser cartridge&#160;contains 1.0&#160;ml of&#160;<br/>solution, providing 50&#160;mg of etanercept.</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft3363">The other ingredients are sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate&#160;<br/>monobasic dihydrate and sodium phosphate dibasic dihydrate, and water for injections.</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft3361"><b>What Enbrel&#160;looks like and contents of the pack</b></p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft3364">Enbrel is provided as a solution for injection in a ready to use dose-dispenser cartridge. The&#160;<br/>dose-dispenser cartridge is to be used with SMARTCLIC device. The device is provided separately.&#160;<br/>The solution is clear to opalescent, colourless to pale yellow or pale brown.</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft3363">Enbrel 50&#160;mg&#160;solution for injection in dose-dispenser cartridge<br/>Cartons contain 2, 4 or 12 dose-dispenser cartridges with 4, 8 or 24 alcohol swabs. Not all pack sizes&#160;<br/>may be marketed.</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft3361"><b>Marketing Authorisation Holder and Manufacturer</b></p>
<p style="position:absolute;top:753px;left:114px;white-space:nowrap" class="ft3364"><i>Marketing Authorisation Holder:<br/></i>Pfizer Europe MA EEIG<br/>Boulevard de la Plaine 17<br/>1050 Bruxelles<br/>Belgium</p>
<p style="position:absolute;top:867px;left:114px;white-space:nowrap" class="ft3364"><i>Manufacturer:<br/></i>Pfizer Manufacturing Belgium NV<br/>Rijksweg 12,<br/>2870 Puurs<br/>Belgium</p>
<p style="position:absolute;top:990px;left:106px;white-space:nowrap" class="ft3364">For any information about this&#160;medicinal product, please contact the local representative of the&#160;<br/>Marketing Authorisation Holder.</p>
<p style="position:absolute;top:1047px;left:114px;white-space:nowrap" class="ft3364"><b>België/Belgique/Belgien<br/>Luxembourg/Luxemburg<br/></b>Pfizer&#160;NV/SA<br/>Tél/Tel: +32 (0)2 554 62 11</p>
<p style="position:absolute;top:1047px;left:452px;white-space:nowrap" class="ft3368"><b>Kύπρος<br/></b>PFIZER EΛΛAΣ&#160;A.E. (CYPRUS BRANCH)&#160;<br/>T</p>
<p style="position:absolute;top:1085px;left:462px;white-space:nowrap" class="ft33614">: +357 22 817690</p>
</div>
<!-- Page 337 -->
<a name="337"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page337-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3370">337</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft3374"><b>Česká Republika<br/></b>Pfizer, spol.&#160;s&#160;r.o.<br/>Tel: +420-283-004-111</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft3374"><b>Magyarország<br/></b>Pfizer Kft.<br/>Tel: +36 1 488 3700</p>
<p style="position:absolute;top:184px;left:114px;white-space:nowrap" class="ft3374"><b>Danmark<br/></b>Pfizer ApS<br/>Tlf: +45 44&#160;201&#160;100</p>
<p style="position:absolute;top:184px;left:452px;white-space:nowrap" class="ft3374"><b>Malta<br/></b>Vivian Corporation Ltd.<br/>Tel: +35621 344610</p>
<p style="position:absolute;top:260px;left:114px;white-space:nowrap" class="ft3373"><b>Deutschland<br/></b>Pfizer Pharma GmbH<br/>Tel: +49 (0)30 550055-51000</p>
<p style="position:absolute;top:260px;left:452px;white-space:nowrap" class="ft3373"><b>Nederland<br/></b>Pfizer bv<br/>Tel: +31 (0)800 63 34 636</p>
<p style="position:absolute;top:337px;left:114px;white-space:nowrap" class="ft3373"><b>България<br/></b>Пфайзер Люксембург САРЛ,&#160;<br/>Клон България<br/>Teл:&#160;+359 2 970 4333</p>
<p style="position:absolute;top:337px;left:452px;white-space:nowrap" class="ft3374"><b>Norge<br/></b>Pfizer AS<br/>Tlf: +47 67&#160;52&#160;61&#160;00</p>
<p style="position:absolute;top:432px;left:114px;white-space:nowrap" class="ft3374"><b>Eesti<br/></b>Pfizer Luxembourg&#160;SARL Eesti filiaal<br/>Tel: +372 666 7500</p>
<p style="position:absolute;top:432px;left:452px;white-space:nowrap" class="ft3374"><b>Österreich<br/></b>Pfizer Corporation Austria Ges.m.b.H.<br/>Tel: +43 (0)1 521 15-0</p>
<p style="position:absolute;top:508px;left:114px;white-space:nowrap" class="ft3373"><b>Ελλάδα<br/></b>PFIZER&#160;EΛΛAΣ&#160;A.E.<br/>Τηλ.: +30 210 67 85 800</p>
<p style="position:absolute;top:508px;left:452px;white-space:nowrap" class="ft3373"><b>Polska<br/></b>Pfizer Polska Sp. z o.o.<br/>Tel.: +48 22 335 61 00</p>
<p style="position:absolute;top:593px;left:114px;white-space:nowrap" class="ft3374"><b>España<br/></b>Pfizer, S.L.<br/>Télf: +34 91 490&#160;99 00</p>
<p style="position:absolute;top:593px;left:452px;white-space:nowrap" class="ft3374"><b>Portugal<br/></b>Laboratórios Pfizer, Lda.<br/>Tel: (+351) 21 423 55 00</p>
<p style="position:absolute;top:675px;left:114px;white-space:nowrap" class="ft3373"><b>France<br/></b>Pfizer<br/>Tél&#160;+33 (0)1 58 07 34 40</p>
<p style="position:absolute;top:675px;left:452px;white-space:nowrap" class="ft3373"><b>România<br/></b>Pfizer Romania S.R.L<br/>Tel: +40 (0) 21 207 28 00</p>
<p style="position:absolute;top:751px;left:114px;white-space:nowrap" class="ft3374"><b>Hrvatska<br/></b>Pfizer Croatia d.o.o.<br/>Tel: +385 1 3908 777</p>
<p style="position:absolute;top:751px;left:452px;white-space:nowrap" class="ft3374"><b>Slovenija<br/></b>Pfizer Luxembourg SARL<i>,&#160;Pfizer, podružnica&#160;<br/>za&#160;</i>svetovanje s področja farmacevtske&#160;<br/>dejavnosti, Ljubljana<br/>Tel: +386 (0)1 52 11 400</p>
<p style="position:absolute;top:864px;left:114px;white-space:nowrap" class="ft3374"><b>Ireland<br/></b>Pfizer Healthcare Ireland<br/>Tel: +1800 633 363 (toll free)<br/>Tel: +44 (0)1304 616161</p>
<p style="position:absolute;top:864px;left:452px;white-space:nowrap" class="ft3373"><b>Slovenská Republika<br/></b>Pfizer Luxembourg SARL, organizačná zložka&#160;<br/>Tel: +421 2 3355 5500</p>
<p style="position:absolute;top:959px;left:114px;white-space:nowrap" class="ft3373"><b>Ísland<br/></b>Icepharma&#160;hf.<br/>Tel: +354&#160;540 8000</p>
<p style="position:absolute;top:959px;left:452px;white-space:nowrap" class="ft3373"><b>Suomi/Finland<br/></b>Pfizer Oy<br/>Puh/Tel: +358 (0)9&#160;430 040</p>
<p style="position:absolute;top:1039px;left:114px;white-space:nowrap" class="ft3374"><b>Italia<br/></b>Pfizer S.r.l.<br/>Tel: +39 06 33 18 21</p>
<p style="position:absolute;top:1039px;left:452px;white-space:nowrap" class="ft3374"><b>Sverige&#160;<br/></b>Pfizer AB<br/>Tel: +46 (0)8&#160;550&#160;520 00</p>
</div>
<!-- Page 338 -->
<a name="338"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page338-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3380">338</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft3384"><b>Latvija<br/></b>Pfizer Luxembourg SARL filiāle Latvijā<br/>Tel. +371 67035775</p>
<p style="position:absolute;top:108px;left:452px;white-space:nowrap" class="ft3384"><b>United Kingdom&#160;(Northern Ireland)<br/></b>Pfizer Limited<br/>Tel:&#160;+44 (0)1304 616161</p>
<p style="position:absolute;top:187px;left:114px;white-space:nowrap" class="ft3383"><b>Lietuva<br/></b>Pfizer Luxembourg SARL filialas Lietuvoje<br/>Tel. +3705 2514000</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft3381"><b>This leaflet was last revised in</b></p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft3384">Detailed&#160;information on this medicine is available on the European Medicines Agency web site:<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>
</div>
<!-- Page 339 -->
<a name="339"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page339-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3390">339</p>
<p style="position:absolute;top:108px;left:332px;white-space:nowrap" class="ft33938"><b>Instructions for Use</b></p>
<p style="position:absolute;top:139px;left:398px;white-space:nowrap" class="ft33939"><i><b>Enbrel®</b></i></p>
<p style="position:absolute;top:170px;left:396px;white-space:nowrap" class="ft33940">(etanercept)</p>
<p style="position:absolute;top:194px;left:393px;white-space:nowrap" class="ft33940">50 mg / 1 ml</p>
<p style="position:absolute;top:218px;left:327px;white-space:nowrap" class="ft33941">For Subcutaneous Injection Only</p>
<p style="position:absolute;top:260px;left:357px;white-space:nowrap" class="ft33942"><b>Important&#160;Information</b></p>
<p style="position:absolute;top:300px;left:133px;white-space:nowrap" class="ft33914">&#160;Keep this Instructions for Use, it shows step-by-step how to prepare and give an injection.</p>
<p style="position:absolute;top:320px;left:133px;white-space:nowrap" class="ft33914">&#160;Only use Enbrel after you read and understand this Instructions for Use.</p>
<p style="position:absolute;top:341px;left:133px;white-space:nowrap" class="ft33914">&#160;Only use Enbrel after you have received training from your healthcare professional.</p>
<p style="position:absolute;top:361px;left:133px;white-space:nowrap" class="ft33914">&#160;Your Dose Dispenser Cartridge contains a single dose of Enbrel and must only be used with&#160;</p>
<p style="position:absolute;top:382px;left:160px;white-space:nowrap" class="ft3392">your SMARTCLIC Device.</p>
<p style="position:absolute;top:400px;left:133px;white-space:nowrap" class="ft33914">&#160;Dose Dispenser Cartridge and SMARTCLIC Device will be referred to as “Cartridge” and&#160;</p>
<p style="position:absolute;top:421px;left:160px;white-space:nowrap" class="ft3392">“Device” in this Instructions for Use.</p>
<p style="position:absolute;top:439px;left:133px;white-space:nowrap" class="ft33914">&#160;If this is the first time you are using your Device, make sure you follow the setup instructions&#160;</p>
<p style="position:absolute;top:460px;left:160px;white-space:nowrap" class="ft3394">in the separate User Manual. You will not be able to use your Device until you complete the&#160;<br/>setup.</p>
<p style="position:absolute;top:497px;left:133px;white-space:nowrap" class="ft33914">&#160;<b>Do not&#160;</b>attempt to use your Cartridges with any other Device.</p>
<p style="position:absolute;top:517px;left:133px;white-space:nowrap" class="ft33914">&#160;<b>Do not&#160;</b>share&#160;your Cartridges or your Device with another person.</p>
<p style="position:absolute;top:537px;left:133px;white-space:nowrap" class="ft33914">&#160;<b>Do not&#160;</b>shake your Cartridges or your Device containing a Cartridge.</p>
<p style="position:absolute;top:558px;left:133px;white-space:nowrap" class="ft33914">&#160;<b>Do not&#160;</b>reuse your Cartridge if the needle cap has been removed.</p>
<p style="position:absolute;top:578px;left:133px;white-space:nowrap" class="ft33914">&#160;Avoid spilling liquid on your Cartridges or your Device. Never rinse or&#160;put your Cartridges or&#160;</p>
<p style="position:absolute;top:598px;left:160px;white-space:nowrap" class="ft3392">your Device under water.</p>
<p style="position:absolute;top:617px;left:133px;white-space:nowrap" class="ft33914">&#160;Refer to the additional Device User Manual for accessing menus, using a Training Cartridge,&#160;</p>
<p style="position:absolute;top:638px;left:160px;white-space:nowrap" class="ft3392">advanced use and troubleshooting error messages.</p>
<p style="position:absolute;top:677px;left:417px;white-space:nowrap" class="ft33942"><b>Storage</b></p>
<p style="position:absolute;top:718px;left:133px;white-space:nowrap" class="ft33914">&#160;Store Cartridges in the refrigerator between 2 ºC to 8 ºC (36 ºF to 46 ºF).&#160;<b>Do not&#160;</b>freeze your&#160;</p>
<p style="position:absolute;top:739px;left:160px;white-space:nowrap" class="ft3392">Cartridges.&#160;<b>Do not&#160;</b>store your Cartridges in your Device.</p>
<p style="position:absolute;top:757px;left:133px;white-space:nowrap" class="ft33914">&#160;Store Cartridges in their original Carton until use to protect from direct sunlight.</p>
<p style="position:absolute;top:777px;left:133px;white-space:nowrap" class="ft33914">&#160;You may store your Cartridges at room temperature up to 25 ºC (77 ºF) for up to 4 weeks.&#160;<b>Do&#160;</b></p>
<p style="position:absolute;top:798px;left:160px;white-space:nowrap" class="ft3391"><b>not&#160;</b>return them to the refrigerator after they have reached room temperature.</p>
<p style="position:absolute;top:817px;left:133px;white-space:nowrap" class="ft33914">&#160;Keep your Cartridges and your Device out of sight and reach of children and adolescents.</p>
<p style="position:absolute;top:837px;left:133px;white-space:nowrap" class="ft33914">&#160;Refer to your Device User Manual for how to store and clean your Device.</p>
<p style="position:absolute;top:878px;left:377px;white-space:nowrap" class="ft33942"><b>Supplies you need</b></p>
<p style="position:absolute;top:919px;left:133px;white-space:nowrap" class="ft33914">&#160;<b>Gather&#160;</b>the following supplies on a clean flat surface:</p>
<p style="position:absolute;top:940px;left:187px;white-space:nowrap" class="ft3392">o</p>
<p style="position:absolute;top:940px;left:214px;white-space:nowrap" class="ft3392">Enbrel Carton containing Cartridges</p>
<p style="position:absolute;top:959px;left:187px;white-space:nowrap" class="ft3392">o</p>
<p style="position:absolute;top:959px;left:214px;white-space:nowrap" class="ft3392">your SMARTCLIC Device</p>
<p style="position:absolute;top:978px;left:187px;white-space:nowrap" class="ft3392">o</p>
<p style="position:absolute;top:978px;left:214px;white-space:nowrap" class="ft3392">alcohol wipes</p>
<p style="position:absolute;top:997px;left:187px;white-space:nowrap" class="ft3392">o</p>
<p style="position:absolute;top:997px;left:214px;white-space:nowrap" class="ft3392">clean cotton balls or gauze pads (not included)</p>
<p style="position:absolute;top:1016px;left:187px;white-space:nowrap" class="ft3392">o</p>
<p style="position:absolute;top:1016px;left:214px;white-space:nowrap" class="ft3392">a suitable sharps container (not included).</p>
<p style="position:absolute;top:1053px;left:133px;white-space:nowrap" class="ft33914">&#160;<b>Do not&#160;</b>use if&#160;the Carton is dropped or damaged.</p>
<p style="position:absolute;top:1074px;left:160px;white-space:nowrap" class="ft3391"><b>Note:&#160;</b>If you do not have everything you need, ask your healthcare professional.</p>
</div>
<!-- Page 340 -->
<a name="340"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page340-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3400">340</p>
<p style="position:absolute;top:108px;left:423px;white-space:nowrap" class="ft34042"><b>Your Device:</b></p>
<p style="position:absolute;top:153px;left:328px;white-space:nowrap" class="ft3402">Refer to User Manual for more information.</p>
<p style="position:absolute;top:747px;left:410px;white-space:nowrap" class="ft34042"><b>Your Cartridge:</b></p>
</div>
<!-- Page 341 -->
<a name="341"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page341-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3410">341</p>
<p style="position:absolute;top:108px;left:393px;white-space:nowrap" class="ft34144"><b>Preparation Steps</b></p>
<p style="position:absolute;top:454px;left:133px;white-space:nowrap" class="ft34114">&#160;<b>Remove&#160;</b>1 Cartridge from the tray&#160;inside the Carton.</p>
<p style="position:absolute;top:474px;left:133px;white-space:nowrap" class="ft34114">&#160;<b>Put&#160;</b>the Carton and tray with any unused Cartridges back in the refrigerator.</p>
<p style="position:absolute;top:494px;left:133px;white-space:nowrap" class="ft34114">&#160;<b>Wash&#160;</b>and dry your hands.</p>
<p style="position:absolute;top:514px;left:133px;white-space:nowrap" class="ft34114">&#160;For a more comfortable injection leave your Cartridge at room temperature for approximately&#160;</p>
<p style="position:absolute;top:535px;left:160px;white-space:nowrap" class="ft3413"><b>15&#160;-&#160;30 minutes&#160;</b>away from direct sunlight.<br/><b>Do not&#160;</b>use any other methods to warm up your Cartridge.</p>
<p style="position:absolute;top:858px;left:133px;white-space:nowrap" class="ft34114">&#160;<b>Check&#160;</b>the expiration date and medication dose printed on the label.&#160;<b>Do not&#160;</b>use if the&#160;</p>
<p style="position:absolute;top:879px;left:160px;white-space:nowrap" class="ft3412">expiration date has passed or if it is not your prescribed medication dose.</p>
<p style="position:absolute;top:898px;left:133px;white-space:nowrap" class="ft34114">&#160;<b>Check&#160;</b>your Cartridge,&#160;<b>do not&#160;</b>use if:</p>
<p style="position:absolute;top:918px;left:187px;white-space:nowrap" class="ft3412">o</p>
<p style="position:absolute;top:918px;left:214px;white-space:nowrap" class="ft3412">it has been dropped even if it does not look damaged</p>
<p style="position:absolute;top:937px;left:187px;white-space:nowrap" class="ft3412">o</p>
<p style="position:absolute;top:937px;left:214px;white-space:nowrap" class="ft3412">it is damaged</p>
<p style="position:absolute;top:956px;left:187px;white-space:nowrap" class="ft3412">o</p>
<p style="position:absolute;top:956px;left:214px;white-space:nowrap" class="ft3412">the needle cap is loose</p>
<p style="position:absolute;top:975px;left:187px;white-space:nowrap" class="ft3412">o</p>
<p style="position:absolute;top:975px;left:214px;white-space:nowrap" class="ft3412">it has been frozen or exposed to heat</p>
<p style="position:absolute;top:994px;left:187px;white-space:nowrap" class="ft3412">o</p>
<p style="position:absolute;top:994px;left:214px;white-space:nowrap" class="ft3412">it has been at room temperature for more than 4 weeks</p>
<p style="position:absolute;top:1013px;left:187px;white-space:nowrap" class="ft3412">o</p>
<p style="position:absolute;top:1013px;left:214px;white-space:nowrap" class="ft3412">it has been returned to the refrigerator after reaching room&#160;temperature.</p>
<p style="position:absolute;top:1032px;left:133px;white-space:nowrap" class="ft34114">&#160;<b>Do not&#160;</b>remove the needle cap until instructed to do so.</p>
</div>
<!-- Page 342 -->
<a name="342"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page342-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3420">342</p>
<p style="position:absolute;top:393px;left:133px;white-space:nowrap" class="ft34214">&#160;<b>Inspect&#160;</b>the medicine through the Inspection window, it should be clear or slightly opalescent,&#160;</p>
<p style="position:absolute;top:414px;left:160px;white-space:nowrap" class="ft3424">colourless to pale yellow or pale brown, and may contain small white or almost transparent&#160;<br/>particles of protein, this is normal.</p>
<p style="position:absolute;top:451px;left:133px;white-space:nowrap" class="ft34214">&#160;<b>Do not&#160;</b>use the medicine if it is discoloured, cloudy, or has particles other than those described&#160;</p>
<p style="position:absolute;top:472px;left:160px;white-space:nowrap" class="ft3422">above.</p>
<p style="position:absolute;top:490px;left:133px;white-space:nowrap" class="ft34214">&#160;<b>Do not&#160;</b>shake your Cartridge.</p>
<p style="position:absolute;top:511px;left:160px;white-space:nowrap" class="ft3421"><b>Note:&#160;</b>If you have any questions about your medicine, contact your healthcare&#160;professional.</p>
<p style="position:absolute;top:818px;left:133px;white-space:nowrap" class="ft34214">&#160;<b>Always choose&#160;</b>an area in your abdomen, upper thighs or the outer area of the upper arms&#160;</p>
<p style="position:absolute;top:839px;left:160px;white-space:nowrap" class="ft3422">(caregiver only).</p>
<p style="position:absolute;top:857px;left:133px;white-space:nowrap" class="ft34214">&#160;<b>Choose&#160;</b>an injection site at least 3 cm from where you last injected and at least 5 cm away&#160;</p>
<p style="position:absolute;top:878px;left:160px;white-space:nowrap" class="ft3422">from your belly button (navel).</p>
<p style="position:absolute;top:896px;left:133px;white-space:nowrap" class="ft34214">&#160;<b>Do not&#160;</b>inject into bony areas or areas on your skin that are broken, bruised, red, sore (tender)&#160;</p>
<p style="position:absolute;top:917px;left:160px;white-space:nowrap" class="ft3422">or hard. Avoid injecting into areas with scars or stretch marks.</p>
<p style="position:absolute;top:936px;left:133px;white-space:nowrap" class="ft34214">&#160;<b>Do not&#160;</b>inject through your clothes.</p>
<p style="position:absolute;top:956px;left:160px;white-space:nowrap" class="ft3424"><b>Note:&#160;</b>If you have psoriasis,&#160;<b>do not&#160;</b>inject directly into any raised, thick, red, or scaly skin&#160;<br/>patches or lesions on your skin.</p>
<p style="position:absolute;top:994px;left:133px;white-space:nowrap" class="ft34214">&#160;<b>Clean&#160;</b>your injection site with the supplied alcohol wipe and&#160;<b>allow to dry</b>.</p>
</div>
<!-- Page 343 -->
<a name="343"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page343-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3430">343</p>
<p style="position:absolute;top:373px;left:133px;white-space:nowrap" class="ft34314">&#160;<b>Clean&#160;</b>the injection end of your Device with the separate supplied alcohol wipe.</p>
<p style="position:absolute;top:393px;left:133px;white-space:nowrap" class="ft34314">&#160;<b>Allow&#160;</b>the injection end to dry&#160;before giving an injection.</p>
<p style="position:absolute;top:473px;left:407px;white-space:nowrap" class="ft34344"><b>Injection Steps</b></p>
<p style="position:absolute;top:843px;left:133px;white-space:nowrap" class="ft34314">&#160;<b>Push&#160;</b>your Cartridge firmly&#160;<b>straight&#160;</b>through the Cartridge door without twisting until you&#160;</p>
<p style="position:absolute;top:864px;left:160px;white-space:nowrap" class="ft3434">cannot push it any further. Your Device will turn on when your Cartridge has been inserted&#160;<br/>correctly.</p>
<p style="position:absolute;top:901px;left:133px;white-space:nowrap" class="ft34314">&#160;<b>Check&#160;</b>the&#160;Display shows 50 mg and the expiration date has not passed.</p>
<p style="position:absolute;top:922px;left:160px;white-space:nowrap" class="ft3434"><b>Note:&#160;</b>Your Device will turn off after 90 seconds of inactivity. Press and hold the Injection&#160;<br/>button to turn your Device back on.</p>
</div>
<!-- Page 344 -->
<a name="344"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page344-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3440">344</p>
<p style="position:absolute;top:397px;left:133px;white-space:nowrap" class="ft34414">&#160;<b>Remove&#160;</b>the needle cap by pulling it firmly downwards.</p>
<p style="position:absolute;top:417px;left:133px;white-space:nowrap" class="ft34414">&#160;<b>Dispose&#160;</b>of the needle cap in a suitable sharps container.</p>
<p style="position:absolute;top:438px;left:133px;white-space:nowrap" class="ft34414">&#160;<b>Inject&#160;</b>as soon as possible after removing the needle cap.</p>
<p style="position:absolute;top:458px;left:133px;white-space:nowrap" class="ft34414">&#160;<b>Do not&#160;</b>replace the needle cap.</p>
<p style="position:absolute;top:479px;left:160px;white-space:nowrap" class="ft34445"><b>Caution: Do not&#160;</b>insert your fingers into your Device after removing the needle cap to avoid a&#160;<br/>needle stick injury.<br/><b>Note:&#160;</b>To cancel the injection and eject your Cartridge, press the Cancel / Eject button&#160;</p>
<p style="position:absolute;top:521px;left:763px;white-space:nowrap" class="ft3442">for&#160;</p>
<p style="position:absolute;top:540px;left:160px;white-space:nowrap" class="ft3442">1 second.</p>
<p style="position:absolute;top:889px;left:133px;white-space:nowrap" class="ft34414">&#160;<b>Place&#160;</b>your Device with the&#160;<b>blue arrow&#160;</b>pointing at 90 degrees towards your injection site.</p>
<p style="position:absolute;top:909px;left:133px;white-space:nowrap" class="ft34414">&#160;<b>Make sure&#160;</b>you can see the Display on your Device.</p>
<p style="position:absolute;top:930px;left:133px;white-space:nowrap" class="ft34414">&#160;<b>Do&#160;not&#160;</b>pinch the skin around your injection site.</p>
<p style="position:absolute;top:950px;left:160px;white-space:nowrap" class="ft3443"><b>Caution:&#160;</b>If you drop your Device with a Cartridge inserted, eject and dispose of your&#160;<br/>Cartridge.<br/>Refer to the Troubleshooting page in the Device User Manual.</p>
</div>
<!-- Page 345 -->
<a name="345"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page345-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3450">345</p>
<p style="position:absolute;top:395px;left:133px;white-space:nowrap" class="ft34514">&#160;<b>Press &amp; hold&#160;</b>the Injection button to begin your injection when instructed by the Display.</p>
<p style="position:absolute;top:416px;left:160px;white-space:nowrap" class="ft3451"><b>Note:&#160;</b>You can release the Injection button after your injection has started.</p>
<p style="position:absolute;top:757px;left:133px;white-space:nowrap" class="ft34514">&#160;<b>Hold&#160;</b>your Device against your skin and wait while your medication is injected.</p>
<p style="position:absolute;top:777px;left:133px;white-space:nowrap" class="ft34514">&#160;<b>Watch&#160;</b>the Display on your Device.</p>
<p style="position:absolute;top:797px;left:133px;white-space:nowrap" class="ft34514">&#160;<b>Do not&#160;</b>move, tilt&#160;or remove your Device from your skin until instructed by the Display.</p>
<p style="position:absolute;top:818px;left:160px;white-space:nowrap" class="ft3453"><b>Note:&#160;</b>If you remove your Device before instructed,&#160;<b>do not&#160;</b>place it back on the injection site&#160;<br/>or inject another dose. Contact your healthcare professional for advice.</p>
</div>
<!-- Page 346 -->
<a name="346"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page346-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1194px;left:437px;white-space:nowrap" class="ft3460">346</p>
<p style="position:absolute;top:394px;left:133px;white-space:nowrap" class="ft34614">&#160;<b>Lift &amp; hold&#160;</b>your Device away from your skin. Your Device will display that your injection is&#160;</p>
<p style="position:absolute;top:415px;left:160px;white-space:nowrap" class="ft3462">complete.</p>
<p style="position:absolute;top:433px;left:133px;white-space:nowrap" class="ft34614">&#160;<b>Wait.&#160;</b>Your Cartridge will be partially ejected from the bottom of your Device. This may take&#160;</p>
<p style="position:absolute;top:454px;left:160px;white-space:nowrap" class="ft3463">up to 10 seconds.<br/><b>Do not&#160;</b>cover the bottom of your Device during this time.<br/><b>Do not&#160;</b>insert your fingers inside your Device as the needle will be exposed during this time.</p>
<p style="position:absolute;top:510px;left:133px;white-space:nowrap" class="ft34614">&#160;If you notice a spot of blood, press a cotton ball or gauze over the injection site until the&#160;</p>
<p style="position:absolute;top:531px;left:160px;white-space:nowrap" class="ft3462">bleeding stops.&#160;<b>Do not&#160;</b>rub.</p>
<p style="position:absolute;top:888px;left:133px;white-space:nowrap" class="ft34614">&#160;<b>Pull&#160;</b>your Cartridge straight out after your Device has partially ejected it.</p>
<p style="position:absolute;top:908px;left:133px;white-space:nowrap" class="ft34614">&#160;<b>Check&#160;</b>your Cartridge is empty of medicine with a grey bar visible in the Inspection window.&#160;</p>
<p style="position:absolute;top:929px;left:160px;white-space:nowrap" class="ft3464">If not, you may not have received your full dose. Contact your healthcare professional for&#160;<br/>advice.</p>
<p style="position:absolute;top:966px;left:133px;white-space:nowrap" class="ft34614">&#160;<b>Do not&#160;</b>reuse your Cartridge or reinsert it into your Device.</p>
<p style="position:absolute;top:986px;left:133px;white-space:nowrap" class="ft34614">&#160;<b>Dispose&#160;</b>of the used Cartridge straight away in a suitable sharps container as instructed by&#160;</p>
<p style="position:absolute;top:1007px;left:160px;white-space:nowrap" class="ft3464">your healthcare professional or pharmacist and in accordance with local health and safety&#160;<br/>laws.</p>
<p style="position:absolute;top:1128px;left:337px;white-space:nowrap" class="ft34641">--End of Instructions for&#160;Use--</p>
</div>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="enbrel-epar-product-information_en.html#1">SUMMARY OF PRODUCT CHARACTERISTICS</a></li>
<li><a href="enbrel-epar-product-information_en.html#179">A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</a></li>
<li><a href="enbrel-epar-product-information_en.html#179">B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</a></li>
<li><a href="enbrel-epar-product-information_en.html#179">C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</a></li>
<li><a href="enbrel-epar-product-information_en.html#179">D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</a></li>
<li><a href="enbrel-epar-product-information_en.html#182">A. LABELLING</a></li>
<li><a href="enbrel-epar-product-information_en.html#223">B. PACKAGE LEAFLET</a></li>
</ul>
<hr/>
</body>
</html>
